Clustering O 0 9.221183063345961e-06
of O 0 3.0150613383739255e-06
missense O 0 7.256367553054588e-06
mutations O 0 2.141300470270835e-08
in O 0 1.5805953879066692e-08
the O 0 6.020677574269939e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 5.21420624863822e-05
in O 0 8.511921834042369e-08
a O 0 5.886046849923332e-08
sporadic B-Disease 0 2.9509390060411533e-06
T I-Disease 1 0.6658580899238586
- I-Disease 0 0.012460404075682163
cell I-Disease 1 0.637933075428009
leukaemia I-Disease 1 0.9991357922554016
. O 0 3.0335900191857945e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999992847442627
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 7.5828566536984e-08
is O 0 2.559306988558774e-09
a O 0 1.6080480946811804e-08
recessive B-Disease 0 1.501803808423574e-06
multi I-Disease 1 1.0
- I-Disease 1 1.0
system I-Disease 1 1.0
disorder I-Disease 1 0.9999706745147705
caused O 0 4.038270517980891e-08
by O 0 7.063663542972165e-11
mutations O 0 1.0032694119921359e-10
in O 0 1.9577454934971428e-10
the O 0 1.2875173815984908e-08
ATM O 0 3.6506685319181997e-07
gene O 0 3.2626154222725745e-08
at O 0 2.662117637441952e-08
11q22 O 0 2.0241978404555994e-07
- O 0 1.5879174952715402e-07
q23 O 0 7.02129341334512e-07
( O 0 5.558134397176673e-09
ref O 0 1.4776902617086307e-06
. O 0 2.092909401341103e-09
3 O 0 1.7446408762111787e-08
) O 0 3.449108776365506e-10
. O 0 1.0664084726386136e-08

The O 0 2.0691527424787637e-06
risk O 0 1.8196204791820492e-06
of O 0 3.2057039334176807e-06
cancer B-Disease 1 0.534480094909668
, O 0 2.7981179595570893e-09
especially O 0 2.56554972821732e-08
lymphoid B-Disease 0 0.09576018154621124
neoplasias I-Disease 1 0.9972217082977295
, O 0 3.4252471969864473e-09
is O 0 8.298891573943479e-10
substantially O 0 4.1221539959224174e-08
elevated O 0 0.00033036147942766547
in O 0 1.7984127964609797e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.0026634889654815197
and O 0 2.122587261510489e-08
has O 0 4.421046306823939e-10
long O 0 1.5171802703051185e-10
been O 0 7.093717280248768e-11
associated O 0 6.440957767139821e-10
with O 0 2.3182660235931962e-09
chromosomal O 1 1.0
instability O 1 1.0
. O 0 4.526458724285476e-05

By O 0 1.8474612772934051e-07
analysing O 0 4.083702151547186e-06
tumour B-Disease 1 0.9999872446060181
DNA O 0 3.9949938468453183e-07
from O 0 1.1692340429192427e-08
patients O 0 3.1582436665900104e-09
with O 0 4.22277823819428e-10
sporadic B-Disease 0 1.020987838273868e-06
T I-Disease 0 0.009957625530660152
- I-Disease 0 0.0005778044578619301
cell I-Disease 0 0.027294065803289413
prolymphocytic I-Disease 0 2.777081863314379e-05
leukaemia I-Disease 0 0.0014596128603443503
( O 0 2.5472053355457547e-09
T B-Disease 0 2.4006695298339764e-07
- I-Disease 0 1.5197312563941523e-07
PLL I-Disease 0 1.6594116232226952e-06
) O 0 8.149886321362487e-10
, O 0 2.103196644620553e-10
a O 0 2.0275889855980722e-09
rare O 0 3.483903654455389e-08
clonal B-Disease 0 2.4988807467707375e-07
malignancy I-Disease 0 4.259887646185234e-06
with O 0 9.290630487157614e-10
similarities O 0 7.321905304280563e-09
to O 0 2.097794293831612e-08
a O 0 7.157229333643045e-07
mature B-Disease 0 1.252076572200167e-06
T I-Disease 0 8.679826714796945e-05
- I-Disease 0 1.9748942577280104e-05
cell I-Disease 0 5.062341733719222e-05
leukaemia I-Disease 0 0.00012064124166499823
seen O 0 2.5493500643847256e-08
in O 0 1.0453674370580757e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999492168426514
T I-Disease 1 1.0
, O 0 1.227578483309344e-08
we O 0 9.274748746790351e-10
demonstrate O 0 1.598439269834273e-09
a O 0 2.187984904367113e-09
high O 0 4.274056664144155e-09
frequency O 0 1.6173089534277096e-09
of O 0 2.385126984805197e-09
ATM O 0 7.270113400181799e-08
mutations O 0 1.9113306493068194e-09
in O 0 7.664222145820077e-09
T B-Disease 0 9.269340807804838e-06
- I-Disease 0 8.188571882783435e-06
PLL I-Disease 0 0.00018294062465429306
. O 0 8.919224114833924e-07

In O 0 7.541697186752572e-07
marked O 0 1.055012148754031e-06
contrast O 0 2.0572883840941358e-07
to O 0 3.245342838908982e-08
the O 0 6.56176410984699e-08
ATM O 0 6.499384994640423e-07
mutation O 0 1.7566073040597985e-09
pattern O 0 7.503492938099043e-09
in O 0 8.373146620499483e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 7.013073233252953e-09
the O 0 5.570605310367682e-09
most O 0 1.037670643855293e-10
frequent O 0 9.444135057323777e-11
nucleotide O 0 1.9373153081758687e-10
changes O 0 7.28292703922051e-11
in O 0 1.000223792679833e-10
this O 0 3.1062075134258293e-10
leukaemia B-Disease 0 9.534564924251754e-06
were O 0 3.802478332204373e-08
missense O 0 1.8322731420994387e-06
mutations O 0 6.461956303382976e-08
. O 0 1.3316299884991167e-07

These O 0 3.3534556109771074e-07
clustered O 0 8.998466682896833e-07
in O 0 4.814258325325227e-09
the O 0 9.274594425789928e-09
region O 0 2.0233161812655e-09
corresponding O 0 3.5622780281130417e-09
to O 0 2.616504879426884e-08
the O 0 9.148465096586733e-07
kinase O 0 6.026796768310305e-07
domain O 0 1.725450360368086e-08
, O 0 1.1008969430514881e-10
which O 0 5.082402554368315e-11
is O 0 5.147493195578612e-11
highly O 0 8.724810318661014e-10
conserved O 0 1.4057616182228116e-09
in O 0 7.41281758198653e-10
ATM O 0 7.052123152107015e-08
- O 0 5.390459190124375e-09
related O 0 8.233178028227428e-10
proteins O 0 6.801887525442751e-11
in O 0 1.7431656118560568e-10
mouse O 0 1.160794749210936e-08
, O 0 3.385648358888993e-11
yeast O 0 4.788983787307188e-08
and O 0 1.546742645075483e-08
Drosophila O 0 3.110224326974276e-07
. O 0 1.4741151233010896e-07

The O 0 3.975643721787492e-06
resulting O 0 1.0396367997600464e-06
amino O 0 1.6710045258605533e-07
- O 0 2.0497154196164047e-07
acid O 0 9.253094646055615e-08
substitutions O 0 6.375802996672064e-08
are O 0 1.0528466987125285e-09
predicted O 0 4.8839130073474735e-08
to O 0 1.1676316802322617e-08
interfere O 0 8.115907235151099e-08
with O 0 2.2801229793145694e-09
ATP O 0 6.806867531850003e-07
binding O 0 1.9233118209172062e-08
or O 0 1.152706285978411e-08
substrate O 0 1.4786869542149361e-06
recognition O 0 1.1355057694117932e-07
. O 0 1.384549364047416e-07

Two O 0 1.451514549444255e-06
of O 0 1.3268272596178576e-06
seventeen O 0 7.60255090881401e-07
mutated O 0 5.127971007823362e-07
T B-Disease 0 2.560195753176231e-06
- I-Disease 0 4.948647074343171e-07
PLL I-Disease 0 3.815301170106977e-06
samples O 0 2.3202845866876487e-08
had O 0 1.6060372587389793e-08
a O 0 3.0858362531915873e-09
previously O 0 1.1619597728440567e-08
reported O 0 5.0112742400187926e-08
A B-Disease 1 1.0
- I-Disease 1 0.9976346492767334
T I-Disease 1 1.0
allele O 0 4.720928700407967e-06
. O 0 4.2545025280560367e-07

In O 0 2.6520152118791884e-07
contrast O 0 1.7723642997680145e-07
, O 0 4.513141416140343e-09
no O 0 3.0057065725230814e-09
mutations O 0 6.435186272746307e-10
were O 0 1.1904154328945538e-09
detected O 0 2.3953312222602108e-08
in O 0 3.144154936407517e-09
the O 0 2.54643417463285e-08
p53 O 0 2.6545663445176615e-09
gene O 0 1.6434202887438687e-09
, O 0 8.235529619371462e-11
suggesting O 0 1.0770394576198328e-09
that O 0 2.7585583817213433e-10
this O 0 6.1781766369506386e-09
tumour B-Disease 1 1.0
suppressor O 0 1.3052446774963755e-05
is O 0 1.3068645055014372e-09
not O 0 1.2077734645732363e-10
frequently O 0 1.14688036845223e-10
altered O 0 5.741372932632771e-10
in O 0 1.1172379688062506e-10
this O 0 8.938326190310875e-10
leukaemia B-Disease 0 9.646268881624565e-05
. O 0 1.1533554555853698e-07

Occasional O 0 7.174086476879893e-06
missense O 0 1.482364496041555e-05
mutations O 0 1.4768041012303001e-07
in O 0 2.439790414143772e-08
ATM O 0 5.096426320960745e-06
were O 0 1.495023127517925e-07
also O 0 3.981154517163077e-09
found O 0 2.654612085706276e-09
in O 0 3.7444314315848715e-09
tumour B-Disease 1 0.9999974966049194
DNA O 0 3.450527685799898e-07
from O 0 9.307272286207535e-09
patients O 0 2.9453004479762512e-09
with O 0 1.2236506252705226e-09
B B-Disease 0 8.03335351520218e-05
- I-Disease 0 0.0007503961096517742
cell I-Disease 1 0.9999969005584717
non I-Disease 1 0.9950076341629028
- I-Disease 1 0.9994139671325684
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 0 0.0005646122735925019
( O 0 2.715693669941288e-09
B B-Disease 0 1.2227954471200064e-07
- I-Disease 0 1.8891611830440524e-08
NHL I-Disease 0 4.3757160028690123e-07
) O 0 4.1741862744082425e-10
and O 0 7.633989551614206e-10
a O 0 5.487662768643986e-09
B B-Disease 0 2.1664365590368106e-07
- I-Disease 0 1.6879776865152962e-07
NHL I-Disease 0 6.4717155510152224e-06
cell O 0 2.8321474019321613e-05
line O 0 7.411590559058823e-06
. O 0 1.6065773422724305e-07

The O 0 1.8306506035514758e-06
evidence O 0 9.129238947025442e-07
of O 0 6.402222538781643e-07
a O 0 1.7200845192633096e-08
significant O 0 3.4900273782056956e-09
proportion O 0 5.0890522906854585e-09
of O 0 3.7005552400160013e-08
loss O 0 1.273093062081898e-07
- O 0 1.8249401989578473e-07
of O 0 3.184894239893765e-06
- O 0 1.3099968327878742e-06
function O 0 3.359202027652941e-09
mutations O 0 9.015511670540377e-10
and O 0 8.729271194773958e-10
a O 0 5.133967473369694e-09
complete O 0 2.8919178163278048e-08
absence O 0 8.561204936086142e-07
of O 0 9.637451512389816e-07
the O 0 6.994346790634154e-08
normal O 0 3.3335247895394104e-09
copy O 0 8.204306567449748e-09
of O 0 2.0838681891177657e-08
ATM O 0 1.4481696553048096e-07
in O 0 1.3117391617356589e-09
the O 0 7.101224497318981e-09
majority O 0 6.787272410768708e-10
of O 0 3.785696378599823e-08
mutated O 0 2.828377319019637e-06
tumours B-Disease 1 0.9999998807907104
establishes O 0 3.2173224440157355e-07
somatic O 0 8.120495635921543e-07
inactivation O 0 5.4416914281318896e-06
of O 0 6.310615674465225e-08
this O 0 6.130573826368391e-10
gene O 0 8.909764037667856e-10
in O 0 2.5072349751908973e-10
the O 0 4.510155360293311e-09
pathogenesis O 0 9.8036007329938e-06
of O 0 8.901888577383943e-07
sporadic B-Disease 0 7.971373270265758e-05
T I-Disease 1 0.6863816380500793
- I-Disease 0 2.2459393221652135e-05
PLL I-Disease 0 1.0726040272857063e-05
and O 0 3.5499807538030836e-09
suggests O 0 5.150628812344848e-10
that O 0 3.204905091314103e-11
ATM O 0 1.2886376410392586e-08
acts O 0 3.0756514002305835e-10
as O 0 1.648531311460033e-09
a O 0 6.528556895091242e-08
tumour B-Disease 1 1.0
suppressor O 0 6.933817348908633e-05
. O 0 4.3941662397628534e-07

As O 0 5.608090987152536e-07
constitutional O 0 5.02684031289391e-07
DNA O 0 1.0668971839322694e-07
was O 0 1.856756881579713e-08
not O 0 3.9988217598319054e-11
available O 0 3.5966787881314133e-10
, O 0 2.290120315606714e-10
a O 0 1.3125457165585885e-08
putative O 0 0.00010629995085764676
hereditary O 1 1.0
predisposition O 1 1.0
to O 1 0.9848136305809021
T B-Disease 1 1.0
- I-Disease 1 0.9999537467956543
PLL I-Disease 0 0.0030287059489637613
will O 0 3.1885312168355995e-09
require O 0 5.520182089213677e-10
further O 0 1.3823843181270945e-09
investigation O 0 4.929440411416408e-09
. O 0 4.880388315697815e-10
. O 0 3.633070955189055e-09

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.00022919400362297893
kinase O 0 3.100574986092397e-06
is O 0 3.7888134296615306e-10
involved O 0 2.4856068592260527e-11
in O 0 3.245201676826959e-11
the O 0 2.205977622793398e-10
modulation O 0 3.3795035658812367e-09
of O 0 1.3046578262176922e-09
the O 0 4.989373802999353e-09
Ca2 O 0 7.860852235808125e-08
+ O 0 1.327053382738086e-07
homeostasis O 0 1.5343523784849822e-07
in O 0 1.2917992231464837e-09
skeletal O 0 2.676046904070972e-07
muscle O 0 2.789864694818789e-08
cells O 0 1.1198871874285032e-07
. O 0 6.995694690203891e-08

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0030752834863960743
DM B-Disease 1 1.0
) O 0 8.811817053810955e-08
, O 0 8.406523255288789e-10
the O 0 1.5157183952396736e-08
most O 0 2.839717794245189e-08
prevalent O 1 0.7423838973045349
muscular B-Disease 1 1.0
disorder I-Disease 1 0.9999998807907104
in O 0 3.903275569427933e-08
adults O 0 1.1797223642417975e-08
, O 0 2.072885474380115e-10
is O 0 6.930753193579164e-11
caused O 0 7.015080072392266e-09
by O 0 1.4502580247821584e-09
( O 0 1.1636314134477743e-09
CTG O 0 6.758103268111881e-07
) O 0 4.1931461081112786e-10
n O 0 2.32682917378213e-09
- O 0 5.492207133528382e-09
repeat O 0 1.7980238409265326e-09
expansion O 0 2.7785995726503643e-09
in O 0 9.114543841892697e-11
a O 0 4.6320391966503394e-11
gene O 0 1.1694464840950047e-11
encoding O 0 2.7086413667554154e-10
a O 0 3.6996217200879755e-09
protein O 0 1.5021111465784998e-08
kinase O 0 1.2425041973074258e-07
( O 0 2.726353809379134e-09
DM B-Disease 1 0.9999998807907104
protein O 0 1.0616533927532146e-06
kinase O 0 1.854304798598605e-07
; O 0 7.775964316891759e-10
DMPK O 0 1.3151214943718514e-06
) O 0 9.874081413618896e-11
and O 0 8.08624348036524e-11
involves O 0 1.4674168824502232e-10
changes O 0 2.7525720591725644e-10
in O 0 7.755212583226978e-10
cytoarchitecture O 0 1.0296695052147697e-07
and O 0 4.564294719955342e-09
ion O 0 1.7724095187077182e-06
homeostasis O 0 6.779212526453193e-06
. O 0 4.252964913575852e-07

To O 0 3.397641421543085e-07
obtain O 0 9.714632369650644e-07
clues O 0 4.507922767515993e-06
to O 0 1.672341554126433e-08
the O 0 2.2439349933733865e-08
normal O 0 8.375095283952305e-09
biological O 0 3.356699451728673e-08
role O 0 2.450512681662076e-08
of O 0 1.3213528404776298e-07
DMPK O 0 0.06643908470869064
in O 0 5.2215465728977506e-08
cellular O 0 1.8414613123240997e-07
ion O 0 2.372067910982878e-06
homeostasis O 0 1.102591795643093e-06
, O 0 1.2489969059004125e-09
we O 0 4.769298289630797e-10
have O 0 1.4817493065866216e-10
compared O 0 2.090164707979625e-09
the O 0 6.75836542285424e-09
resting O 0 1.6730855634250474e-07
[ O 0 1.1934214505515683e-08
Ca2 O 0 1.5181024437538326e-08
+ O 0 1.4488846566962366e-08
] O 0 5.550612858229442e-09
i O 0 4.2268899491659795e-09
, O 0 1.452023085102283e-10
the O 0 4.5741924137310264e-10
amplitude O 0 1.549443684467633e-09
and O 0 1.7737161739361795e-10
shape O 0 4.205242376542628e-09
of O 0 3.0161025676989084e-08
depolarization O 0 1.3133451659541606e-07
- O 0 1.885608611473799e-07
induced O 0 1.0434011983306846e-06
Ca2 O 0 4.3971090235572774e-07
+ O 0 7.852985106637789e-08
transients O 0 7.845289218266771e-08
, O 0 5.6356516675570845e-11
and O 0 8.153738101368546e-11
the O 0 1.5735107661285497e-09
content O 0 7.56565810000609e-10
of O 0 5.242680067851779e-09
ATP O 0 2.585578613434336e-07
- O 0 7.323976092266093e-08
driven O 0 1.3004355992052297e-07
ion O 0 7.629919309692923e-07
pumps O 0 5.279873107610911e-07
in O 0 4.550302179495702e-08
cultured O 0 2.8675581233983394e-06
skeletal O 0 7.329283562285127e-06
muscle O 0 9.87750468084414e-08
cells O 0 1.1660864629448042e-07
of O 0 5.609005029327818e-07
wild O 0 5.508870160042534e-08
- O 0 1.672016125553455e-08
type O 0 1.7041817557128525e-07
and O 0 4.382849283501855e-08
DMPK O 0 1.343837720924057e-05
[ O 0 4.176101597863635e-08
- O 0 1.8787697797506553e-07
/ O 0 1.2333047152424115e-06
- O 0 7.801908736837504e-07
] O 0 2.922945441241609e-07
knockout O 0 1.230095494975103e-05
mice O 0 8.938604310060327e-07
. O 0 9.950228729849186e-08

In O 0 4.061749223183142e-06
vitro O 0 6.807030786148971e-06
- O 0 1.104730472434312e-06
differentiated O 0 1.5503823078688583e-06
DMPK O 0 8.383183012483642e-05
[ O 0 2.462357429067197e-07
- O 0 4.04119134600478e-07
/ O 0 6.398493042070186e-07
- O 0 4.4921972630618257e-07
] O 0 9.163346703644493e-08
myotubes O 0 3.342963168506685e-07
exhibit O 0 1.5910963657717048e-09
a O 0 1.7994374879037878e-09
higher O 0 1.5944328524142293e-08
resting O 0 5.507167770701926e-07
[ O 0 5.358233678975921e-08
Ca2 O 0 9.922350585611639e-08
+ O 0 9.790249322350064e-08
] O 0 2.8014676800580673e-08
i O 0 7.96083998721997e-09
than O 0 2.41813874479746e-10
do O 0 3.935236303487244e-10
wild O 0 9.623509100720185e-09
- O 0 6.0573164262223145e-09
type O 0 2.999031067929536e-08
myotubes O 0 1.6022928548409254e-06
because O 0 7.64712382306243e-09
of O 0 1.319901432594861e-08
an O 0 3.180475327546617e-10
altered O 0 7.213919683835002e-09
open O 0 1.1407205846580837e-08
probability O 0 2.093635931288418e-09
of O 0 1.2993342402012331e-08
voltage O 0 6.07927574947098e-07
- O 0 4.4987739755697476e-08
dependent O 0 2.9774408716320977e-08
l O 0 9.811070178500358e-09
- O 0 3.748926502566974e-09
type O 0 8.053743449920603e-09
Ca2 O 0 9.413984258799246e-09
+ O 0 4.703776923520309e-09
and O 0 2.1015655882195006e-09
Na O 0 2.1003451422529906e-07
+ O 0 9.639490983204269e-09
channels O 0 1.961821993745616e-08
. O 0 5.458131280278167e-09

The O 0 0.00011476909276098013
mutant O 0 7.154833292588592e-05
myotubes O 0 1.9906965462723747e-05
exhibit O 0 6.334022373266635e-08
smaller O 0 3.4469948673176987e-08
and O 0 1.992130904682199e-08
slower O 0 5.177997763894382e-07
Ca2 O 0 5.131390707902028e-07
+ O 0 3.8038638905391053e-08
responses O 0 6.80867973112953e-10
upon O 0 2.2587440806631776e-09
triggering O 0 1.7042035338477035e-08
by O 0 2.3839569207595446e-10
acetylcholine O 0 2.866229209530502e-08
or O 0 3.169467577279761e-09
high O 0 2.2925526366179838e-08
external O 0 6.874466862427653e-08
K O 0 2.2492791629247222e-07
+ O 0 9.93462094811548e-08
. O 0 1.9694777364520633e-08

In O 0 4.4446110791795945e-07
addition O 0 1.2807650762169942e-07
, O 0 4.356476956957067e-09
we O 0 4.511624407399495e-10
observed O 0 5.159163096735142e-10
that O 0 2.1110247230837764e-11
these O 0 6.160792986875663e-10
Ca2 O 0 4.972428087057779e-07
+ O 0 7.866699434089242e-07
transients O 0 4.2302957581341616e-07
partially O 0 7.2289605412834135e-09
result O 0 7.77372499705109e-10
from O 0 3.99944966034127e-10
an O 0 3.7367504923668804e-11
influx O 0 3.904969680945669e-10
of O 0 3.2526723536818736e-09
extracellular O 0 6.902686422449733e-09
Ca2 O 0 2.9705262249990483e-08
+ O 0 5.8389910684297774e-09
through O 0 7.097524235000208e-10
the O 0 2.0368762232436666e-09
l O 0 1.227336787756883e-09
- O 0 1.5507031214667677e-09
type O 0 4.671508957443393e-09
Ca2 O 0 6.728592438776104e-08
+ O 0 1.3220487460330332e-07
channel O 0 1.7087074866140028e-07
. O 0 1.1471221306180723e-08

Neither O 0 3.927533907699399e-05
the O 0 2.1347486836020835e-06
content O 0 9.032611103521049e-08
nor O 0 1.3328433112747007e-07
the O 0 1.0733179678368288e-08
activity O 0 1.6113017586860678e-09
of O 0 1.6535391722527493e-08
Na O 0 3.5178788948542206e-07
+ O 0 1.8342570129448177e-08
/ O 0 2.5585617180468034e-08
K O 0 3.4129755022149766e-08
+ O 0 2.92063173645829e-08
ATPase O 0 3.6962241267701756e-08
and O 0 1.8542573032576115e-09
sarcoplasmic O 0 1.2393094266371918e-06
reticulum O 0 3.4193201372545445e-06
Ca2 O 0 1.5509442619077163e-07
+ O 0 2.367862883545513e-08
- O 0 6.699686139199912e-09
ATPase O 0 3.4525333703072647e-09
are O 0 4.730112568990252e-12
affected O 0 3.994293784614911e-11
by O 0 1.293124912704613e-10
DMPK O 0 1.9855999198625796e-05
absence O 0 1.4637390677307849e-06
. O 0 2.2145890454794426e-07

In O 0 2.831843630701769e-07
conclusion O 0 2.9774673748761415e-07
, O 0 1.3213070637618785e-08
our O 0 1.3113947261444991e-08
data O 0 7.692752213017684e-09
suggest O 0 2.689748646034218e-09
that O 0 5.398543834189695e-10
DMPK O 0 3.4131739084841684e-05
is O 0 1.364216739574431e-09
involved O 0 4.236912765076539e-10
in O 0 4.3916142944411263e-10
modulating O 0 6.701580446133448e-08
the O 0 9.980104742624007e-09
initial O 0 6.450882938935365e-09
events O 0 1.9608549506333617e-10
of O 0 1.521243575552944e-09
excitation O 0 1.337451323024652e-07
- O 0 9.230161168716222e-08
contraction O 0 2.208512928092432e-09
coupling O 0 4.552331400731191e-09
in O 0 1.4753908095244128e-09
skeletal O 0 7.576285270260996e-07
muscle O 0 6.796683749143995e-08
. O 0 1.1665876264999042e-08
. O 0 7.016662095793436e-08

Constitutional O 0 0.0001561088429298252
RB1 O 0 0.005146618466824293
- O 0 1.5441448340425268e-05
gene O 0 1.4536678527576896e-08
mutations O 0 1.503394408963743e-09
in O 0 2.1326408694566368e-10
patients O 0 2.259498366186108e-09
with O 0 9.860817717921577e-10
isolated O 0 1.9952851744164946e-06
unilateral B-Disease 0 0.00018756691133603454
retinoblastoma I-Disease 1 1.0
. O 0 0.012713984586298466

In O 0 1.8148081437630026e-07
most O 0 1.3350678784718184e-08
patients O 0 9.678548629210582e-09
with O 0 5.665281022082524e-10
isolated O 0 6.310976914392086e-07
unilateral B-Disease 0 8.866761163517367e-06
retinoblastoma I-Disease 1 1.0
, O 0 1.968958258657949e-07
tumor B-Disease 0 1.5836612874409184e-05
development O 0 4.067102921112564e-08
is O 0 6.03866887050053e-11
initiated O 0 2.2504478836005148e-10
by O 0 9.411043992713086e-12
somatic O 0 5.4051505493646346e-09
inactivation O 0 1.0248612625218811e-07
of O 0 1.0848306697397447e-09
both O 0 1.676849770149147e-10
alleles O 0 1.428960977323257e-10
of O 0 3.430137729409921e-09
the O 0 3.118141833624577e-08
RB1 O 0 2.586950358818285e-05
gene O 0 1.557468891633107e-07
. O 0 6.678471464738323e-08

However O 0 2.863132237962418e-07
, O 0 1.5457922719619432e-09
some O 0 5.469276767589015e-11
of O 0 9.89042958643438e-10
these O 0 2.6160182353685e-10
patients O 0 4.596303782022915e-09
can O 0 3.2831266594257613e-09
transmit O 0 1.6098699688882334e-06
retinoblastoma B-Disease 0 0.06400443613529205
predisposition O 0 0.0001262349251192063
to O 0 4.6050595869928657e-07
their O 0 3.1167442102741916e-06
offspring O 0 4.8934623919194564e-05
. O 0 8.958675721260079e-07

To O 0 1.734161401145684e-07
determine O 0 5.3397471333482827e-08
the O 0 3.3245033392859114e-08
frequency O 0 1.6734071905943892e-08
and O 0 6.041678268786654e-10
nature O 0 6.571790889253748e-10
of O 0 1.7934957963205989e-09
constitutional O 0 6.634264337890272e-08
RB1 O 0 4.1236417018808424e-05
- O 0 2.1076969858313532e-07
gene O 0 8.239996462933163e-10
mutations O 0 1.6485869613891424e-10
in O 0 4.523935739908502e-11
patients O 0 6.321994594493674e-10
with O 0 8.962191544448217e-10
isolated O 0 2.5266670036216965e-06
unilateral B-Disease 0 1.7811984434956685e-05
retinoblastoma I-Disease 1 1.0
, O 0 5.154417692665447e-08
we O 0 1.119330961252274e-09
analyzed O 0 2.3539684090856383e-10
DNA O 0 1.2353336131809556e-09
from O 0 2.2919205422411437e-10
peripheral O 0 1.1102717678568297e-07
blood O 0 2.638606133587018e-08
and O 0 1.0964512853206543e-08
from O 0 2.6130436481253128e-08
tumor B-Disease 0 0.00012175613665021956
tissue O 0 3.132877827738412e-05
. O 0 6.158049927762477e-07

The O 0 4.900658154838311e-07
analysis O 0 4.386964036484642e-08
of O 0 1.7654507473707781e-06
tumors B-Disease 1 1.0
from O 0 1.682167976468918e-06
54 O 0 1.9655998073631054e-07
( O 0 8.34769198210239e-10
71 O 0 1.6825765669636894e-08
% O 0 2.011847355376517e-10
) O 0 5.4057119891481875e-11
of O 0 8.984068600170758e-09
76 O 0 2.0986190918392822e-07
informative O 0 2.4431001666158636e-09
patients O 0 6.47530340458502e-09
showed O 0 1.8069142848631259e-09
loss O 0 1.2659953085858433e-08
of O 0 2.0513640208719153e-07
constitutional O 0 3.9631861000088975e-05
heterozygosity O 1 0.9999988079071045
( O 0 1.527238782728091e-05
LOH O 1 1.0
) O 0 7.4211685685554585e-09
at O 0 7.508349142426596e-08
intragenic O 0 1.6988994957500836e-06
loci O 0 4.086309388640075e-07
. O 0 3.050276689009479e-07

Three O 0 7.173110248004377e-07
of O 0 4.5442223495228973e-07
13 O 0 3.080833437252295e-07
uninformative O 0 0.00028092655702494085
patients O 0 1.3779396113022813e-06
had O 0 3.8697220361427753e-07
constitutional O 0 1.8174162050854648e-06
deletions O 0 2.234192106698174e-05
. O 0 2.475628434694954e-06

For O 0 1.1703383506755927e-06
39 O 0 4.3041172830271535e-06
randomly O 0 1.083876099983172e-07
selected O 0 1.7635306903684977e-06
tumors B-Disease 1 1.0
, O 0 1.0664618343980692e-07
SSCP O 1 0.9782906770706177
, O 0 9.116017452015512e-08
hetero O 0 5.094180778542068e-06
- O 0 6.743443918821868e-07
duplex O 0 2.1827690943609923e-06
analysis O 0 3.905984868879386e-09
, O 0 4.558478247651543e-11
sequencing O 0 1.8605137430682817e-09
, O 0 1.0731857763568442e-10
and O 0 4.923724761241033e-10
Southern O 0 1.602744603701467e-08
blot O 0 4.380768530154455e-07
analysis O 0 8.125037309625327e-10
were O 0 1.910105129621087e-10
used O 0 3.028146899897166e-10
to O 0 7.411362079601247e-10
identify O 0 1.2421222272962495e-08
mutations O 0 5.247044398970502e-08
. O 0 2.7130764124194684e-07

Mutations O 0 4.925740313410643e-07
were O 0 6.021470966288689e-08
detected O 0 1.0200345457178628e-07
in O 0 2.6723112611648503e-09
21 O 0 1.4977311835195906e-08
( O 0 2.2789217735130762e-10
91 O 0 1.3680999444432018e-08
% O 0 3.2059216392710255e-10
) O 0 1.2724528375418487e-10
of O 0 1.2066905696883623e-07
23 O 0 0.0002969474298879504
tumors B-Disease 1 1.0
with O 0 0.05745718628168106
LOH O 1 1.0
. O 0 0.0004622874839697033

In O 0 1.815141786210006e-06
6 O 0 7.672693413951492e-07
( O 0 1.5308081469100898e-09
38 O 0 7.411549596270106e-09
% O 0 5.428446026023437e-10
) O 0 2.291466183468316e-10
of O 0 4.922847196553448e-08
16 O 0 2.2835225536255166e-05
tumors B-Disease 1 1.0
without O 1 0.9997689127922058
LOH O 1 1.0
, O 0 8.598269651827195e-09
one O 0 8.890954639184656e-10
mutation O 0 3.1998004246247547e-10
was O 0 5.06914377140788e-09
detected O 0 1.981432351527701e-09
, O 0 4.8499950583424933e-11
and O 0 3.1186978000086185e-10
in O 0 2.527209108649231e-09
9 O 0 6.614995129439194e-08
( O 0 5.081454701461041e-10
56 O 0 4.5541899140744135e-09
% O 0 1.469217525418287e-10
) O 0 1.432530344347427e-10
of O 0 5.8353645471243e-08
the O 0 0.003565424820408225
tumors B-Disease 1 1.0
without O 1 0.9999462366104126
LOH O 1 1.0
, O 0 7.413755387375431e-09
both O 0 1.1502546692909732e-09
mutations O 0 4.386778051923557e-09
were O 0 9.275956003307329e-09
found O 0 3.1099926189881444e-08
. O 0 8.032867526708287e-08

Thus O 0 4.7125979563134024e-07
, O 0 6.3666738547851764e-09
a O 0 1.5030073852173587e-09
total O 0 9.835530306867568e-11
of O 0 6.464427881880397e-10
45 O 0 1.0398704120007096e-09
mutations O 0 1.0235138431236024e-10
were O 0 2.40076708513115e-10
identified O 0 4.109442564015353e-09
in O 0 1.138655481014439e-08
tumors B-Disease 1 1.0
of O 0 0.004743285942822695
36 O 0 1.2061113920935895e-05
patients O 0 3.979687789978925e-06
. O 0 2.8512865810625954e-06

Thirty O 0 2.7715812393580563e-05
- O 0 1.0195943787039141e-06
nine O 0 5.5612659366488515e-08
of O 0 1.140207217531497e-08
the O 0 7.243148303359703e-09
mutations O 0 1.4876943010833088e-09
- O 0 2.3198730048079597e-08
including O 0 7.118555522822589e-09
34 O 0 1.1208316408328756e-07
small O 0 9.062015493555009e-08
mutations O 0 2.075470817430869e-08
, O 0 4.483959870071885e-09
2 O 0 1.465729297933649e-07
large O 0 4.7175348072414636e-08
structural O 0 0.007781780790537596
alterations O 1 0.9999197721481323
, O 0 2.056649037740499e-07
and O 0 2.161388863441971e-07
hypermethylation O 1 0.9904963970184326
in O 0 1.7972442947211675e-05
3 O 0 0.0010349636431783438
tumors O 1 1.0
- O 0 2.630715016493923e-06
were O 0 3.144804239241239e-08
not O 0 6.532686613880401e-10
detected O 0 1.720563602702896e-08
in O 0 2.6321442248011806e-10
the O 0 1.0045835274752335e-09
corresponding O 0 4.967950939516186e-09
peripheral O 0 2.609204784675967e-06
blood O 0 5.78741378376435e-07
DNA O 0 4.966237611370161e-06
. O 0 3.2570110874985403e-07

In O 0 2.0921136183460476e-06
6 O 0 1.0439247262183926e-06
( O 0 1.124595305768139e-09
17 O 0 4.921577367866803e-09
% O 0 9.517552024274067e-11
) O 0 3.13795690820573e-11
of O 0 2.5671538228522195e-09
the O 0 4.990975810414966e-08
36 O 0 9.465571793043637e-08
patients O 0 2.8463986723181733e-08
, O 0 1.2260709114642054e-09
a O 0 1.4138129778018538e-08
mutation O 0 1.1077055717123585e-08
was O 0 3.3473878602308105e-07
detected O 0 4.861273339429317e-08
in O 0 1.0039552522655981e-09
constitutional O 0 7.457678030675652e-09
DNA O 0 6.086526838089412e-08
, O 0 1.240321734208294e-10
and O 0 9.897179603646222e-11
1 O 0 3.889035316007039e-09
of O 0 1.9686805519114614e-09
these O 0 4.343033987996847e-10
mutations O 0 8.443273302738419e-10
is O 0 9.630678893257638e-11
known O 0 5.705490524476886e-10
to O 0 2.0471536965604997e-10
be O 0 2.1849147491259657e-10
associated O 0 3.331986242471885e-09
with O 0 1.437874486143187e-09
reduced O 0 6.726590413563827e-07
expressivity O 0 0.00011428975994931534
. O 0 1.049654997586913e-06

The O 0 2.154251205865876e-06
presence O 0 1.4015033400482935e-07
of O 0 3.8300620985864953e-07
a O 0 3.385195057603596e-08
constitutional O 0 2.8593385437147845e-08
mutation O 0 2.355339479009899e-09
was O 0 1.9685679752967644e-09
not O 0 5.907911746622085e-12
associated O 0 8.780146748543771e-11
with O 0 1.1036463409830333e-11
an O 0 5.3188096288403486e-11
early O 0 1.719369357999767e-08
age O 0 1.6705275385220375e-08
at O 0 1.563349272259984e-08
treatment O 0 1.928337383105827e-07
. O 0 9.067116479855031e-08

In O 0 5.067764732302749e-07
1 O 0 1.0310102425137302e-06
patient O 0 5.267646656648139e-07
, O 0 1.1087307960622184e-08
somatic O 0 2.0564795704558492e-05
mosaicism O 1 0.9831719398498535
was O 0 1.8727873793977778e-06
demonstrated O 0 5.620703014130868e-09
by O 0 3.5626685629397414e-11
molecular O 0 6.409046071631508e-10
analysis O 0 4.017306973191914e-11
of O 0 2.342390725829091e-10
DNA O 0 1.7229369042581766e-09
and O 0 3.258594505339829e-10
RNA O 0 2.9641761045695603e-08
from O 0 1.979018948716771e-09
peripheral O 0 4.046315552841406e-06
blood O 0 8.706579706085904e-07
. O 0 2.478420242368884e-07

In O 0 1.7856107206171146e-06
2 O 0 2.6305820028937887e-06
patients O 0 1.4484673016568195e-08
without O 0 1.0643866232840082e-08
a O 0 1.1434937441379134e-08
detectable O 0 3.277016560332413e-07
mutation O 0 5.925887336388769e-09
in O 0 3.0016273910860036e-09
peripheral O 0 0.00015215091116260737
blood O 0 4.971642920281738e-05
, O 0 1.2951403505212511e-08
mosaicism O 0 0.00014519885007757694
was O 0 4.191215623450262e-07
suggested O 0 2.5501316613940617e-09
because O 0 3.3077013350535367e-10
1 O 0 3.877377086070055e-09
of O 0 2.145968514000174e-09
the O 0 3.4248440528017454e-08
patients O 0 6.723589081047976e-07
showed O 0 6.822694103902904e-06
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 2.370821903241449e-06
the O 0 4.273512956842751e-07
other O 0 1.629828827454105e-09
later O 0 3.665389769480498e-08
developed O 0 6.49881428671506e-08
bilateral B-Disease 0 9.582496204529889e-06
retinoblastoma I-Disease 1 0.976482629776001
. O 0 3.894192104780814e-06

In O 0 3.056007074064837e-07
conclusion O 0 2.751934857769811e-07
, O 0 4.612885629029506e-09
our O 0 5.472068131950891e-09
results O 0 2.557982992090757e-10
emphasize O 0 2.6557209764632717e-09
that O 0 8.237116544407286e-11
the O 0 2.2891082362974657e-09
manifestation O 0 3.613839680838282e-07
and O 0 3.0089073455030757e-09
transmissibility O 0 1.5467167031602003e-05
of O 0 2.913933201398322e-07
retinoblastoma B-Disease 0 3.805829328484833e-05
depend O 0 2.8407535523911065e-07
on O 0 2.1733957566993922e-07
the O 0 1.1645156838824278e-08
nature O 0 2.397181120272762e-09
of O 0 8.975436394109693e-09
the O 0 5.146379322695793e-09
first O 0 2.5817179505338572e-09
mutation O 0 2.2500100393951783e-10
, O 0 5.395617286296783e-11
its O 0 2.911662577709251e-10
time O 0 1.1106923158976656e-09
in O 0 3.1024532942680594e-10
development O 0 3.967684403249905e-09
, O 0 5.5849727620405076e-11
and O 0 1.225485823930228e-10
the O 0 1.4313757956685436e-09
number O 0 3.245270024931912e-11
and O 0 6.474358549279913e-11
types O 0 1.1686381862219264e-09
of O 0 5.858345808462673e-09
cells O 0 3.090984357356774e-09
that O 0 1.3095637074744815e-10
are O 0 1.1095673685401763e-10
affected O 0 3.69528430077537e-09
. O 0 5.874211783662986e-09
. O 0 1.1061943183676703e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999983310699463
the I-Disease 1 0.5209115147590637
fifth I-Disease 0 9.043823956744745e-05
component I-Disease 0 1.8739664255917887e-06
of I-Disease 0 6.416225915018003e-07
complement I-Disease 0 6.298807306848175e-07
in O 0 1.0372302767791552e-06
man O 0 0.0002792252926155925
. O 0 3.0512999273923924e-06

I O 0 0.016025017946958542
. O 0 1.6048412362579256e-05

Clinical O 0 2.0361785573186353e-05
, O 0 7.003959012763517e-08
immunochemical O 0 3.120819019386545e-05
, O 0 5.844517314557152e-09
and O 0 5.292978055848607e-09
family O 0 8.39821368003868e-08
studies O 0 1.4955872984501184e-08
. O 0 7.001874990919532e-08

The O 0 1.5129822941162274e-06
first O 0 1.4081162191814656e-07
recognized O 0 3.754517052811934e-08
human O 0 1.9054026267895097e-07
kindred O 0 0.1415254920721054
with O 0 1.1100854635515134e-07
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 1 1.0
fifth I-Disease 1 0.9999451637268066
component I-Disease 0 0.03248725086450577
of I-Disease 0 0.007495805621147156
complement I-Disease 0 0.00022786963381804526
( O 0 5.206736204854678e-06
C5 O 1 0.9999986886978149
) O 0 3.5848870538757183e-09
is O 0 1.7553212217080727e-09
described O 0 7.331453133474497e-08
. O 0 2.4761098416092864e-07

The O 0 4.2376414057798684e-05
proband O 0 0.0003150479751639068
, O 0 5.344331910350775e-08
a O 0 4.332266456685829e-08
20 O 0 9.675853007706792e-09
- O 0 7.4009833817001436e-09
year O 0 3.320230756997944e-09
- O 0 2.0008977230645542e-07
old O 0 8.274154197351891e-07
black O 0 6.7399827941017065e-09
female O 0 2.7689642245753987e-10
with O 0 6.121202988929042e-10
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 1.0
age O 1 0.9999996423721313
11 O 0 4.700089448306244e-06
, O 0 1.6121379786682155e-09
lacked O 0 6.817229518674139e-07
serum O 0 1.2032240874759736e-06
hemolytic O 0 0.11241482943296432
complement O 0 2.128762446318433e-07
activity O 0 1.2597182852402966e-08
, O 0 6.670785451801109e-11
even O 0 9.418842095154645e-11
during O 0 4.734108660642278e-09
remission O 0 5.7100361772199903e-08
. O 0 9.330057615386522e-09

C5 O 1 0.9999889135360718
was O 0 3.410170756978914e-05
undetectable O 0 2.787976654872182e-06
in O 0 2.9480655694413826e-09
her O 0 2.4633972639520607e-10
serum O 0 4.996345115415579e-09
by O 0 8.8926123409383e-11
both O 0 9.597419525775308e-10
immunodiffusion O 0 4.161557626503054e-06
and O 0 9.126368638590066e-08
hemolytic O 1 1.0
assays O 0 0.0009444309980608523
. O 0 1.6782401871751063e-05

Other O 0 7.100035759322054e-08
complement O 0 2.9891229047507295e-08
components O 0 4.368885981875792e-07
were O 0 8.396527917398089e-09
normal O 0 4.8662895935081e-09
during O 0 1.2429659079771227e-08
remission O 0 4.710333101343167e-08
of O 0 2.6740766045918463e-08
lupus O 0 0.0001322886091656983
, O 0 9.072821605116133e-09
but O 0 8.064580114819364e-09
C1 O 0 3.7862018871237524e-06
, O 0 9.541937018298086e-09
C4 O 0 4.3723557610064745e-06
, O 0 9.074305751255451e-10
C2 O 0 6.337623403851467e-08
, O 0 1.0980895082113307e-09
and O 0 1.6783104683781858e-08
C3 O 0 0.0016181182581931353
levels O 0 2.229646497653448e-06
fell O 0 8.680066821398214e-05
during O 0 1.6106470184240607e-06
exacerbations O 0 0.02954426407814026
. O 0 1.706404532342276e-06

A O 0 0.00010469782137079164
younger O 0 1.3305424545251299e-05
half O 0 1.0280343758495292e-06
- O 0 7.940665454952978e-06
sister O 0 2.6926150894723833e-05
, O 0 3.193796116462977e-09
who O 0 3.6748100118444427e-09
had O 0 3.16602530858745e-08
no O 0 1.8824888314838972e-08
underlying O 0 0.03803880512714386
disease O 1 0.8354420065879822
, O 0 9.115661558922739e-10
was O 0 1.3340132909434033e-07
also O 0 1.1056849880120012e-09
found O 0 4.11596889904331e-09
to O 0 9.39394873000765e-09
lack O 0 0.0008955405210144818
immunochemically O 1 0.9990372657775879
detectable O 1 0.9989954829216003
C5 O 1 0.9999961853027344
. O 0 5.457402039610315e-06

By O 0 5.739407811233832e-07
hemolytic O 1 1.0
assay O 0 0.41567179560661316
, O 0 1.962110758313429e-07
she O 0 4.853942581206638e-09
exhibited O 0 4.137930442738025e-09
1 O 0 1.4998381203668032e-08
- O 0 1.6727275564676347e-08
2 O 0 5.7153428656420147e-08
% O 0 7.667625423479763e-10
of O 0 7.040521943224576e-09
the O 0 2.220060935087531e-08
normal O 0 2.0579949477905757e-07
serum O 0 2.887002210627543e-06
C5 O 0 1.2694050383288413e-05
level O 0 1.5788327090149323e-08
and O 0 1.6418154336061974e-10
normal O 0 3.559973704714281e-10
concentrations O 0 3.766807421534679e-10
of O 0 3.5732730663262657e-10
other O 0 5.304059275124118e-11
complement O 0 1.987924269641894e-09
components O 0 4.3686566186806886e-07
. O 0 2.2357716034093755e-07

C5 O 1 0.9993218183517456
levels O 0 2.588919187473948e-06
of O 0 6.564217187587928e-07
other O 0 1.2749953981483486e-08
family O 0 2.0237147069224193e-08
members O 0 1.0812646611402243e-10
were O 0 9.766051300985623e-10
either O 0 3.237038637138312e-09
normal O 0 1.637404345444793e-08
or O 0 3.746660315329109e-09
approximately O 0 1.4044583551697798e-10
half O 0 2.9321283179228885e-09
- O 0 5.853185935933425e-09
normal O 0 1.7883957648123783e-09
, O 0 4.400835945661541e-11
consistent O 0 9.020740820986362e-10
with O 0 1.8851674388198347e-10
autosomal O 0 3.178477570031646e-08
codominant O 0 3.90646420100893e-07
inheritance O 0 1.4197796716075572e-08
of O 0 2.0665829936206137e-08
the O 0 3.996860797883528e-08
gene O 0 8.954408059480556e-08
determining O 0 4.053182237839792e-06
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.673168976092711e-05

Normal O 0 5.371132283471525e-05
hemolytic O 1 0.9999337196350098
titers O 0 0.0034958538599312305
were O 0 1.414146822753537e-06
restored O 0 3.2939704396994784e-05
to O 0 2.2178390679528093e-08
both O 0 7.45871986396196e-08
homozygous O 0 4.361849642009474e-05
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 1.2663688721659128e-05
C5D B-Disease 1 1.0
) O 0 3.170400830754261e-08
sera O 0 3.7638308469922777e-08
by O 0 1.5425008492719883e-11
addition O 0 3.4058841857920186e-10
of O 0 1.3210348370762404e-08
highly O 0 1.8285778935478447e-07
purified O 0 7.565749911009334e-07
human O 0 5.860924261469336e-07
C5 O 0 0.001142682507634163
. O 0 6.890987265251169e-07

In O 0 6.057514951862686e-07
specific O 0 5.336163440006203e-07
C5 O 0 0.2597810626029968
titrations O 0 2.3093421987141483e-05
, O 0 8.355214298205738e-09
however O 0 1.4915677581939235e-08
, O 0 5.971063088416884e-10
it O 0 2.3974677798577204e-10
was O 0 8.444807519936148e-09
noted O 0 2.762501893904812e-10
that O 0 5.310747501485746e-12
when O 0 1.0031814268174344e-10
limited O 0 9.489419666719456e-11
amounts O 0 1.0643779191354952e-09
of O 0 1.6029861882316254e-08
C5 O 0 6.86977409714018e-06
were O 0 1.4326984931756215e-08
assayed O 0 6.527436369196948e-08
in O 0 9.611580420454402e-10
the O 0 2.325280634707383e-09
presence O 0 1.117406833728296e-09
of O 0 1.9933548145445457e-08
low O 0 4.780423523698119e-07
dilutions O 0 2.3792817955836654e-05
of O 0 1.160466808869387e-06
either O 0 4.105620519112563e-06
C5D B-Disease 1 1.0
serum O 0 1.608592356205918e-05
, O 0 1.378621550252035e-09
curving O 0 1.4881094578811371e-08
rather O 0 8.849216914796898e-10
than O 0 9.751918023104267e-11
linear O 0 2.4392914355075845e-09
dose O 0 1.1743482275505812e-07
- O 0 2.247979047353965e-08
response O 0 2.7161963789268384e-09
plots O 0 1.5171645273426293e-08
were O 0 1.0203060618607651e-09
consistently O 0 2.744718341496366e-10
obtained O 0 7.282760505766817e-11
, O 0 5.991660726595294e-12
suggesting O 0 4.4257687792370604e-11
some O 0 4.168614758937039e-11
inhibitory O 0 1.2273021710029752e-08
effect O 0 2.7011017422751138e-08
. O 0 8.902111403585877e-08

Further O 0 2.9260749556669907e-07
studies O 0 6.95799284855525e-09
suggested O 0 2.6028699195990157e-09
that O 0 3.110232627001608e-10
low O 0 2.985647427067306e-07
dilutions O 0 0.00046466701314784586
of O 0 0.00027647349634207785
C5D B-Disease 1 1.0
serum O 0 5.014773705624975e-05
contain O 0 5.1348511220794535e-08
a O 0 1.990110476413065e-08
factor O 0 3.937520531849259e-09
( O 0 5.911972994487869e-11
or O 0 3.1392877186675605e-10
factors O 0 1.055275311578896e-09
) O 0 1.2674654381594763e-10
interfering O 0 2.048912373098233e-09
at O 0 2.2330124416214403e-09
some O 0 4.548455709296739e-11
step O 0 7.088436060342929e-09
in O 0 1.1728563675816872e-09
the O 0 1.3299947809741752e-08
hemolytic O 0 0.0009284356492571533
assay O 0 4.195496876491234e-05
of O 0 0.01643437147140503
C5 O 1 0.9999885559082031
, O 0 1.0484579870961852e-09
rather O 0 7.728235273951611e-10
than O 0 3.1644042941536554e-10
a O 0 5.894110088888738e-09
true O 0 1.0867928779134672e-07
C5 O 0 4.5164772018324584e-05
inhibitor O 0 3.087675111146382e-07
or O 0 2.2212299555235404e-08
inactivator O 0 1.7420760514141875e-06
. O 0 9.453429328232232e-08

Of O 0 5.597678409685614e-06
clinical O 0 1.7072581613319926e-05
interest O 0 1.2051265230184072e-07
are O 0 9.315153093325534e-10
( O 0 2.46123676994614e-10
a O 0 9.202607564873233e-10
) O 0 4.81625572756883e-11
the O 0 4.992265489889292e-10
documentation O 0 6.132052732255033e-08
of O 0 8.114403158288042e-07
membranous O 1 1.0
glomerulonephritis B-Disease 1 1.0
, O 0 1.5594170690746978e-05
vasculitis B-Disease 1 1.0
, O 0 4.4646372998613515e-07
and O 0 5.8993980928789824e-05
arthritis B-Disease 1 1.0
in O 0 0.006692077964544296
an O 0 6.774177307988793e-08
individual O 0 5.219611853846118e-09
lacking O 0 0.0031801171135157347
C5 O 1 0.9999659061431885
( O 0 3.182807351009842e-09
and O 0 3.0877258527794993e-09
its O 0 3.319357011477564e-09
biologic O 0 1.033007265505148e-06
functions O 0 6.529473073335623e-10
) O 0 2.284256117590644e-11
, O 0 9.737044504021242e-12
and O 0 6.24838583651588e-11
( O 0 7.591643980120466e-11
b O 0 3.932822068009045e-09
) O 0 8.975666737631727e-11
a O 0 1.7382130179655064e-09
remarkable O 0 1.5982197787423047e-09
propensity O 0 1.8325862072288146e-07
to O 0 1.6376011657825984e-08
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 1.788475145758639e-08
the O 0 8.925693606443019e-08
proband O 0 1.6929265029830276e-06
, O 0 2.942334431654814e-10
even O 0 5.004106018446919e-10
during O 0 8.087285507940578e-09
periods O 0 8.417473651434193e-08
of O 0 3.5469572168267405e-08
low O 0 8.880251556320218e-08
- O 0 3.6503318145975072e-09
dose O 0 2.074809835050928e-08
or O 0 2.6404121111767154e-09
alternate O 0 3.076317511840898e-08
- O 0 7.523917844309835e-08
day O 0 2.412005528640293e-08
corticosteroid O 0 4.059847924509086e-06
therapy O 0 2.8487615963967983e-06
. O 0 1.3411018073838932e-07

Other O 0 2.2906911567588395e-07
observations O 0 8.101909543256625e-08
indicate O 0 7.56087192854693e-09
that O 0 1.0829369623266416e-09
the O 0 1.4252827895688824e-07
C5D B-Disease 1 1.0
state O 0 2.056858328103317e-08
is O 0 3.270088089202261e-10
compatible O 0 1.571603824856993e-08
with O 0 2.2566803981050043e-10
normal O 0 1.0872091671387807e-08
coagulation O 0 5.692702487181123e-08
function O 0 3.9427794362723034e-10
and O 0 1.673478994268507e-10
the O 0 3.417362781643618e-10
capacity O 0 5.451418205737468e-10
to O 0 6.409046071631508e-10
mount O 0 2.250550323878997e-06
a O 0 2.519520023724908e-07
neutrophilic O 0 0.0004056805628351867
leukocytosis O 0 7.566699059680104e-05
during O 0 1.0036591220341506e-06
pyogenic B-Disease 0 0.00011206555791432038
infection I-Disease 0 2.639774947965634e-06
. O 0 1.798539095432261e-08
. O 0 5.8381139922403236e-08

Susceptibility O 0 0.0006424855091609061
to O 0 2.6735453502624296e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 1 0.9949609041213989
twins O 0 0.0012923681642860174
: O 0 4.2683517831321183e-10
the O 0 2.3236934598713788e-09
role O 0 7.313126548780247e-09
of O 0 2.2849915737310766e-08
genes O 0 5.957256021815738e-09
, O 0 6.97968183249742e-10
HLA O 0 3.0530125627592497e-07
, O 0 2.6102964234553383e-10
and O 0 1.649553604821108e-09
the O 0 5.369057376469755e-08
environment O 0 3.883189663156372e-07
. O 0 1.4014980820320488e-07

OBJECTIVE O 0 4.92278159072157e-05
To O 0 4.2232976227296604e-08
determine O 0 1.7677534103199832e-08
the O 0 7.593650153125964e-09
relative O 0 1.3897218309466552e-07
effects O 0 1.8784436406349414e-07
of O 0 5.8772403832563214e-08
genetic O 0 3.18632658036222e-07
and O 0 6.713600786412144e-10
environmental O 0 5.470064401436048e-09
factors O 0 3.4464653353438734e-10
in O 0 2.0217720553272756e-10
susceptibility O 0 4.789034164787154e-07
to O 0 1.394829951095744e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 1 0.9953201413154602
AS B-Disease 1 1.0
) O 0 3.961476036096201e-09
. O 0 1.5900686989311907e-08

METHODS O 0 4.500183058553375e-05
Twins O 0 0.00042882683919742703
with O 0 1.522004922094311e-08
AS B-Disease 1 0.9999998807907104
were O 0 2.2573618529975192e-09
identified O 0 2.968014445325906e-10
from O 0 2.1592207188891877e-10
the O 0 1.980733355111397e-09
Royal O 0 6.076690510781191e-07
National O 0 4.5844689822160944e-08
Hospital O 0 4.215365606796695e-06
for O 0 1.2972047436221601e-08
Rheumatic B-Disease 1 0.9999997615814209
Diseases I-Disease 1 1.0
database O 0 4.3570933485170826e-05
. O 0 5.3971180022927e-05

Clinical O 0 2.5338589694001712e-05
and O 0 1.7799715124056092e-07
radiographic O 0 5.997461994411424e-05
examinations O 0 1.5342923234129557e-06
were O 0 1.638475843890319e-08
performed O 0 1.3803502785236788e-09
to O 0 1.941910104941158e-10
establish O 0 1.3651179742169006e-08
diagnoses O 0 0.009957370348274708
, O 0 3.804173864807581e-09
and O 0 7.520141842576322e-09
disease O 0 0.00017261433822568506
severity O 0 0.36760544776916504
was O 0 2.0352208593976684e-06
assessed O 0 1.3225676553929588e-08
using O 0 1.5852681389816325e-09
a O 0 2.347656513634888e-09
combination O 0 1.1673711775017637e-08
of O 0 1.226121071340458e-07
validated O 0 2.5255607738472463e-07
scoring O 0 1.6494512067311007e-07
systems O 0 2.551672514528036e-05
. O 0 6.902886298121302e-07

HLA O 0 0.00015613964933436364
typing O 0 2.4383869003941072e-06
for O 0 5.250488399610731e-08
HLA O 0 7.108096724550705e-07
- O 0 2.707490409648017e-07
B27 O 0 1.5259601013895008e-06
, O 0 1.0058839983173584e-08
HLA O 0 9.537627221334333e-08
- O 0 3.7597768454133984e-08
B60 O 0 2.396963623141346e-07
, O 0 1.5244850937179422e-09
and O 0 2.2661277299107496e-09
HLA O 0 1.845467863859085e-06
- O 0 2.0533284441626165e-06
DR1 O 0 0.0004109444853384048
was O 0 1.0048833587461559e-07
performed O 0 8.683537777720574e-10
by O 0 5.2890875706923524e-11
polymerase O 0 1.0135067896044347e-07
chain O 0 1.2477046062997488e-08
reaction O 0 3.127169634353777e-09
with O 0 1.990078102309667e-10
sequence O 0 6.94523383248935e-10
- O 0 1.1634384566860945e-09
specific O 0 2.715298541566824e-10
primers O 0 3.4055627651241593e-08
, O 0 2.2821407263950988e-10
and O 0 2.463829418264396e-10
zygosity O 0 1.949620838104238e-07
was O 0 1.1940065824944668e-08
assessed O 0 1.535300242494486e-08
using O 0 7.50578355024345e-09
microsatellite O 0 3.4569875424494967e-06
markers O 0 2.870029334189894e-07
. O 0 2.5682945192784246e-07

Genetic O 0 7.427173841279e-05
and O 0 1.6497344290655747e-07
environmental O 0 1.3223942119111598e-07
variance O 0 2.4919049934624127e-08
components O 0 2.1987887066643452e-07
were O 0 1.6014245929341087e-08
assessed O 0 6.377785410904835e-08
with O 0 1.7836505605828279e-09
the O 0 6.997363044547456e-08
program O 0 2.1697999841308047e-08
Mx O 0 2.3198978738037113e-07
, O 0 9.168556538985406e-12
using O 0 3.413634652726927e-11
data O 0 5.081006795859544e-11
from O 0 1.2879229800699665e-11
this O 0 1.3704771692490958e-11
and O 0 1.7082528100398342e-11
previous O 0 1.5537340858351456e-10
studies O 0 4.021001934195745e-11
of O 0 6.890265580317134e-10
twins O 0 2.0169441228290452e-08
with O 0 8.177181709534409e-10
AS B-Disease 1 1.0
. O 0 1.4184798828864587e-06

RESULTS O 0 6.254982736209058e-07
Six O 0 3.00249979545697e-07
of O 0 4.0598720829621016e-07
8 O 0 8.794713721727021e-07
monozygotic O 0 6.898526044096798e-05
( O 0 1.0597399580092315e-07
MZ O 0 0.0009058438590727746
) O 0 8.198237644307937e-09
twin O 0 1.1439407217039843e-06
pairs O 0 1.384173220486673e-09
were O 0 7.64821717069708e-09
disease O 0 7.325456294893229e-07
concordant O 0 2.1482032934727613e-06
, O 0 7.131802370885509e-10
compared O 0 1.4445654672456953e-09
with O 0 1.663039816968137e-09
4 O 0 1.7084126113786624e-07
of O 0 1.7439764121718326e-07
15 O 0 4.9369234034202236e-08
B27 O 0 1.6786859191597614e-07
- O 0 4.113145379847083e-08
positive O 0 1.1425491663885623e-09
dizygotic O 0 2.3574721126351506e-06
( O 0 5.642605493960673e-09
DZ O 0 3.168700686728698e-06
) O 0 6.248174755363323e-10
twin O 0 6.017589981865967e-08
pairs O 0 1.809562222288008e-10
( O 0 1.9032790621320572e-10
27 O 0 4.972880773834731e-09
% O 0 1.813321437449389e-10
) O 0 3.6309684425805955e-11
and O 0 6.728277934797688e-10
4 O 0 6.385855755297598e-08
of O 0 1.8344745456033706e-07
32 O 0 9.113319947573473e-07
DZ O 0 0.00014476239448413253
twin O 0 4.975310730515048e-06
pairs O 0 2.4657582642362286e-09
overall O 0 1.8023476044959352e-08
( O 0 9.825035229837908e-10
12 O 0 7.93509968843864e-09
. O 0 1.1142634592786749e-09
5 O 0 8.371038973109535e-09
% O 0 9.149506152716924e-10
) O 0 9.654096411182422e-10
. O 0 3.214791277628137e-08

Nonsignificant O 0 0.0004755987029056996
increases O 0 1.8366733911534538e-07
in O 0 2.681476152233131e-09
similarity O 0 6.626762250050433e-09
with O 0 9.939554734827993e-11
regard O 0 1.9106646931277282e-08
to O 0 2.9287636760244595e-09
age O 0 4.982548418297483e-08
at O 0 2.114166619548996e-08
disease O 0 8.880031288072132e-08
onset O 0 6.679304351564497e-05
and O 0 1.9093993053331815e-09
all O 0 2.772552465390987e-10
of O 0 7.79106645865113e-09
the O 0 1.417333805875387e-08
disease O 0 4.499589323359032e-08
severity O 0 5.1778098253407734e-08
scores O 0 1.1735321603367765e-09
assessed O 0 3.795375569382031e-09
were O 0 8.31728852457303e-10
noted O 0 7.475918217814126e-10
in O 0 6.976500488420356e-10
disease O 0 2.1810036798797228e-07
- O 0 2.0488438678967213e-07
concordant O 0 4.7011439164634794e-05
MZ O 0 0.2732224464416504
twins O 0 1.2265144505363423e-05
compared O 0 3.162392303579509e-08
with O 0 1.4794578007126802e-08
concordant O 0 0.005158391781151295
DZ O 1 0.9999977350234985
twins O 0 0.020273922011256218
. O 0 4.640465704142116e-06

HLA O 0 0.0013679555850103498
- O 0 3.341727642691694e-05
B27 O 0 8.308627002406865e-06
and O 0 2.5794305358317615e-08
B60 O 0 2.657207573975029e-07
were O 0 2.1059876065265826e-09
associated O 0 3.105219636978518e-09
with O 0 2.6925089935403435e-10
the O 0 3.1378423415162615e-08
disease O 0 7.771353011776228e-06
in O 0 1.951029338087551e-09
probands O 0 5.351224444893887e-06
, O 0 2.2549034861540918e-10
and O 0 1.8224473319339296e-10
the O 0 6.938378760423802e-09
rate O 0 7.94318566477159e-09
of O 0 3.1506520059565446e-08
disease O 0 2.6823681764653884e-06
concordance O 0 1.3695367897526012e-06
was O 0 4.40332769358065e-07
significantly O 0 2.454572900489893e-08
increased O 0 1.1072049943550155e-08
among O 0 1.505110880373195e-08
DZ O 0 1.5939387594698928e-05
twin O 0 3.937846315693605e-07
pairs O 0 2.2244923958414375e-10
in O 0 2.5763643995979635e-10
which O 0 3.111176039016783e-10
the O 0 5.013451875868213e-09
co O 0 1.3396388887088051e-08
- O 0 2.6782929651858467e-08
twin O 0 3.4054662023663695e-07
was O 0 2.7889972997741097e-08
positive O 0 4.508912340717153e-11
for O 0 1.2490940226594915e-10
both O 0 1.776371383321873e-09
B27 O 0 1.3859327054888126e-06
and O 0 2.1376811787376937e-07
DR1 O 0 0.002323996974155307
. O 0 3.0371421644304064e-07

Additive O 0 3.3459978112659883e-06
genetic O 0 7.120228247003979e-07
effects O 0 1.161731972842972e-07
were O 0 3.971242890088433e-09
estimated O 0 2.5401108993960975e-10
to O 0 3.1058045024678904e-10
contribute O 0 2.1366808322653696e-09
97 O 0 7.957169856354085e-08
% O 0 3.757206767929233e-10
of O 0 7.267361712415266e-10
the O 0 5.885479881229116e-10
population O 0 9.023519778605937e-12
variance O 0 6.857436840590481e-10
. O 0 9.340456408324371e-09

CONCLUSION O 0 2.2018128220224753e-05
Susceptibility O 0 0.0011681276373565197
to O 0 2.5405602173123043e-06
AS B-Disease 1 1.0
is O 0 9.810695367207245e-09
largely O 0 1.809625338466958e-09
genetically O 0 3.1136591083225085e-09
determined O 0 4.755022153801747e-09
, O 0 3.0211891322018403e-10
and O 0 7.218843300904609e-10
the O 0 4.6459978086943465e-09
environmental O 0 2.0467457062522953e-08
trigger O 0 4.183115187572639e-09
for O 0 1.9823877261959666e-10
the O 0 5.986095619192611e-09
disease O 0 2.8396374318617745e-07
is O 0 4.322770197351389e-10
probably O 0 2.5638668077476723e-08
ubiquitous O 0 4.493388701121148e-07
. O 0 1.1695835411273947e-07

HLA O 0 0.0002074617223115638
- O 0 6.713159109494882e-06
B27 O 0 1.3208430118538672e-06
accounts O 0 1.922841441626133e-09
for O 0 5.135218361651539e-10
a O 0 1.1121932264046563e-09
minority O 0 1.9014466390299134e-10
of O 0 1.9845829424269823e-09
the O 0 3.8884269137895444e-09
overall O 0 4.944619824698293e-09
genetic O 0 5.508712774826563e-08
susceptibility O 0 5.125653501636407e-07
to O 0 9.719045834799545e-08
AS B-Disease 1 1.0
. O 0 3.369250043760985e-05

Cell O 0 4.4385960791260004e-05
cycle O 0 3.7244183204165893e-07
- O 0 1.6893045540200546e-07
dependent O 0 6.547174535853628e-08
colocalization O 0 2.0647528344852617e-06
of O 0 4.5720256025560957e-07
BARD1 O 0 0.02160709537565708
and O 0 6.2344426510208e-08
BRCA1 O 0 4.871267389461309e-09
proteins O 0 8.495365522165343e-11
in O 0 1.3227177686481184e-10
discrete O 0 1.13089821951462e-08
nuclear O 0 1.2600170293808333e-06
domains O 0 6.120852731328341e-07
. O 0 3.8637517718598247e-07

Germ O 0 0.035251908004283905
- O 0 9.543138003209606e-05
line O 0 1.979183707589982e-06
mutations O 0 1.8636685084061355e-08
of O 0 2.2201145100098074e-07
the O 0 4.087786749096267e-07
BRCA1 O 0 7.588948136572071e-08
gene O 0 4.373443829308599e-09
predispose O 0 2.1235104341599254e-08
women O 0 4.977924322746574e-11
to O 0 4.529412123144283e-10
early O 0 3.244605613872409e-05
- O 0 0.18527798354625702
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 1.5386993068577937e-10
compromising O 0 2.479209193495535e-08
the O 0 1.1374400088470793e-08
genes O 0 3.4924914071865487e-09
presumptive O 0 8.394660653721076e-06
function O 0 3.518587643469573e-09
as O 0 1.7070200808433356e-09
a O 0 1.2105676461260373e-08
tumor B-Disease 0 5.220996627031127e-06
suppressor O 0 2.578391467977781e-05
. O 0 2.9670022172467725e-07

Although O 0 5.433594196802005e-07
the O 0 1.5924854324111948e-07
biochemical O 0 3.4641027468751417e-06
properties O 0 1.0679166280169738e-06
of O 0 1.1166359854541952e-06
BRCA1 O 0 1.4326799657737865e-07
polypeptides O 0 2.297139722884367e-08
are O 0 1.2152256978481546e-10
not O 0 2.3287505257485464e-10
understood O 0 3.140237225807141e-08
, O 0 2.412035016163827e-10
their O 0 3.668155501568293e-10
expression O 0 2.8053588341236946e-09
pattern O 0 1.2667345394845597e-08
and O 0 1.7186799761148563e-09
subcellular O 0 2.441066726532881e-07
localization O 0 3.0063733902352396e-07
suggest O 0 1.933145421517679e-09
a O 0 2.4740400839107224e-09
role O 0 5.603608688176109e-09
in O 0 3.993779973399114e-09
cell O 0 7.882800332481565e-07
- O 0 2.0096140929126705e-07
cycle O 0 9.91167858899189e-09
regulation O 0 9.57875627705107e-08
. O 0 2.3719897157548075e-08

When O 0 2.170679363189265e-05
resting O 0 0.00040671208989806473
cells O 0 7.879569352553517e-07
are O 0 1.0679671591518058e-09
induced O 0 4.920810283692845e-07
to O 0 9.491112784587585e-09
proliferate O 0 1.0162128205593035e-07
, O 0 1.0439681341622986e-09
the O 0 1.5072625814127605e-08
steady O 0 2.636699392155606e-08
- O 0 5.937314195847421e-09
state O 0 1.7190068812844572e-10
levels O 0 8.420243946538619e-10
of O 0 7.097524235000208e-10
BRCA1 O 0 2.1189322518821996e-10
increase O 0 2.0192621880132933e-11
in O 0 3.3048633274468386e-10
late O 0 2.901203117744444e-07
G1 O 0 1.233649982168572e-07
and O 0 5.184673246283467e-10
reach O 0 1.877131339256266e-09
a O 0 4.6307432888248456e-10
maximum O 0 2.763625994717245e-09
during O 0 1.0596830080089603e-08
S O 0 1.2972611784789478e-06
phase O 0 1.1136412467749324e-06
. O 0 1.3543750299049861e-07

Moreover O 0 4.2745018618006725e-06
, O 0 3.244729995799389e-08
in O 0 9.744230311525826e-09
S O 0 1.8012293594438233e-06
phase O 0 1.1491277973618708e-06
cells O 0 2.012813382634704e-07
, O 0 1.1328405991051227e-09
BRCA1 O 0 1.5482678472622524e-09
polypeptides O 0 3.82295439749214e-09
are O 0 1.1774932417996098e-10
hyperphosphorylated O 0 2.3109613778160565e-07
and O 0 3.0415892027235714e-09
accumulate O 0 2.7470884234048754e-08
into O 0 2.9290779579582704e-08
discrete O 0 2.3005186733371374e-07
subnuclear O 0 1.8717660168476868e-06
foci O 0 1.157897713710554e-06
termed O 0 4.9399284307583e-07
" O 0 1.0099984848466192e-07
BRCA1 O 0 5.1490527397390906e-08
nuclear O 0 4.147500021645101e-06
dots O 0 2.7246869649388827e-06
. O 0 2.6834939603759267e-07

" O 0 2.862343899323605e-05
BRCA1 O 0 2.6347950097260764e-06
associates O 0 5.213316853769356e-07
in O 0 3.923052993570764e-09
vivo O 0 1.2180533026651119e-08
with O 0 2.3623297762398465e-10
a O 0 9.971351744297863e-09
structurally O 0 3.517050572554581e-06
related O 0 1.3350841072679032e-06
protein O 0 6.668627520411974e-06
termed O 0 2.3589864213136025e-05
BARD1 O 1 0.9208989143371582
. O 0 1.2062918131050537e-06

Here O 0 2.6954927307087928e-05
we O 0 1.653789070132916e-07
show O 0 1.4767119083103353e-08
that O 0 3.7794878338104354e-10
the O 0 1.0167980235564755e-08
steady O 0 5.817949499942188e-08
- O 0 1.2765624113342255e-08
state O 0 2.6740534786462433e-10
levels O 0 3.625822975195092e-09
of O 0 1.1027389668072374e-08
BARD1 O 0 2.7916699764318764e-05
, O 0 2.090339012994491e-10
unlike O 0 3.730699360549039e-10
those O 0 2.300948181988005e-10
of O 0 8.80022454907703e-09
BRCA1 O 0 6.453134915318515e-09
, O 0 9.650924504001068e-11
remain O 0 4.616844129223807e-10
relatively O 0 3.448201169042875e-10
constant O 0 4.437454848016387e-09
during O 0 4.765039207654809e-08
cell O 0 5.069911139798933e-07
cycle O 0 2.5842910034157285e-08
progression O 0 2.154430411849262e-08
. O 0 1.8450856842378016e-08

However O 0 2.4765965918049915e-06
, O 0 4.940342535064701e-08
immunostaining O 0 6.346106147248065e-06
revealed O 0 1.6362874077913148e-07
that O 0 4.95324758986726e-09
BARD1 O 0 0.06368492543697357
resides O 0 1.4119179923000047e-06
within O 0 1.576032246930481e-07
BRCA1 O 0 8.483298330475009e-08
nuclear O 0 1.8781206563289743e-06
dots O 0 9.666357669857462e-08
during O 0 2.420033524686005e-07
S O 0 1.2866797760580084e-06
phase O 0 5.079987772660388e-07
of O 0 5.6375089485527496e-08
the O 0 1.59867177274009e-08
cell O 0 2.062877335617941e-08
cycle O 0 2.3533042181611563e-10
, O 0 3.491453653969856e-12
but O 0 6.477282252226324e-12
not O 0 9.30172085189529e-12
during O 0 4.557057398102415e-09
the O 0 9.707908255052189e-09
G1 O 0 1.6402934477355302e-07
phase O 0 2.696186811590451e-07
. O 0 5.263242286446257e-08

Nevertheless O 0 9.139623580267653e-05
, O 0 4.584792634432233e-07
BARD1 O 0 0.0002772767620626837
polypeptides O 0 6.993579404479533e-07
are O 0 1.1582971248813578e-09
found O 0 3.1857347870811736e-09
exclusively O 0 6.437125832370327e-10
in O 0 5.985578699352345e-10
the O 0 7.954405134569242e-09
nuclear O 0 5.333049557521008e-07
fractions O 0 2.1327977606233617e-08
of O 0 3.59737519772807e-08
both O 0 4.520645635608389e-09
G1 O 0 1.1065783667163487e-07
- O 0 1.9217864632992132e-08
and O 0 3.824639716043521e-09
S O 0 6.674396217931644e-07
- O 0 6.081908310306972e-08
phase O 0 2.2684299949560227e-07
cells O 0 1.4299308759291307e-07
. O 0 4.840594769461859e-08

Therefore O 0 1.1051668025174877e-06
, O 0 1.1582159231693367e-08
progression O 0 2.2303405344814564e-08
to O 0 2.743657301351732e-09
S O 0 7.536254997830838e-07
phase O 0 4.457124020973424e-07
is O 0 6.515390449379765e-10
accompanied O 0 3.331419029528604e-10
by O 0 3.0676117895866994e-11
the O 0 1.0336650424491722e-09
aggregation O 0 4.293593036663879e-09
of O 0 4.382010754255816e-09
nuclear O 0 1.1070392247347627e-06
BARD1 O 0 4.0107730455929413e-05
polypeptides O 0 1.6697158855549787e-07
into O 0 1.9542449081200175e-07
BRCA1 O 0 4.780350693067703e-08
nuclear O 0 2.7239075279794633e-06
dots O 0 1.073933276529715e-06
. O 0 2.2764484697290754e-07

This O 0 2.4924213448684895e-07
cell O 0 2.5971814920922043e-06
cycle O 0 5.225471966241457e-08
- O 0 3.404971593568007e-08
dependent O 0 3.377204649268606e-08
colocalization O 0 1.7941969190360396e-06
of O 0 2.907338227942091e-07
BARD1 O 0 0.13386406004428864
and O 0 6.125775087184593e-08
BRCA1 O 0 7.583258465615472e-09
indicates O 0 2.2220889572821534e-09
a O 0 1.6983069395237749e-09
role O 0 3.6733942554434407e-09
for O 0 9.35491240028341e-10
BARD1 O 0 8.522231655661017e-05
in O 0 2.9206429275063783e-08
BRCA1 O 0 1.5435838918165246e-07
- O 0 5.365934043766174e-07
mediated O 0 9.491362106928136e-06
tumor B-Disease 0 0.13560369610786438
suppression O 0 0.009532924741506577
. O 0 9.702567922431626e-07

Ethnic O 0 5.14513601501676e-07
differences O 0 1.2200724768263171e-06
in O 0 7.131264823101446e-08
the O 0 2.897263016166107e-07
HFE O 0 0.0002528507320675999
codon O 0 4.373746946839674e-07
282 O 0 1.3420655022855499e-06
( O 0 3.0438485509876045e-08
Cys O 0 0.00027781896642409265
/ O 0 7.155616913223639e-06
Tyr O 0 4.248339610057883e-05
) O 0 1.446496167289979e-08
polymorphism O 0 7.929563139441598e-07
. O 0 9.777559739632125e-08

Recent O 0 9.653589216895853e-08
studies O 0 1.1101146668579531e-08
have O 0 7.697019133168226e-10
shown O 0 1.4454287544651834e-08
that O 0 9.097726660911576e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 9.543256601318717e-05
HH B-Disease 1 0.9999983310699463
) O 0 1.83466919434494e-09
is O 0 2.4473104098809983e-10
likely O 0 1.7797899820592988e-09
to O 0 1.7995266388126652e-09
be O 0 3.18096238238752e-09
caused O 0 7.822577430260935e-08
by O 0 1.0072811473804677e-09
homozygosity O 0 2.0693822477824142e-07
for O 0 7.081918940166076e-10
a O 0 3.918730229202083e-09
Cys282Tyr O 0 1.0769911540364774e-07
mutation O 0 1.0316442144997495e-09
in O 0 4.5986164876055113e-10
the O 0 8.135059736957828e-09
HFE O 0 2.1632667994708754e-05
gene O 0 9.291169789094056e-08
located O 0 1.9690163810537342e-07
4 O 0 1.5583424328724504e-07
. O 0 6.076376735109079e-08

5 O 0 5.565432002185844e-05
Mb O 0 0.00013809029769618064
telomeric O 0 0.00010607577132759616
to O 0 6.495815796370152e-07
HLA O 0 3.007041414093692e-05
- O 0 3.697497504617786e-06
A O 0 2.5176229883072665e-06
. O 0 4.894600351690315e-07

Population O 0 3.5751563931540886e-09
studies O 0 1.899946644456918e-09
of O 0 2.140980726039743e-09
this O 0 1.28531268961396e-10
polymorphism O 0 7.59857687882004e-09
are O 0 1.2970838812742524e-11
facilitated O 0 2.3179200225875718e-10
by O 0 4.186399490957449e-11
the O 0 7.109419719597554e-10
fact O 0 2.1421274476463026e-10
that O 0 5.8164983246511426e-11
the O 0 6.9004224556579175e-09
Cys282Tyr O 0 7.939430020087457e-07
mutation O 0 8.359614334096932e-09
creates O 0 1.4506238876776933e-08
a O 0 2.1526599169874316e-08
Rsal O 0 2.3447591956937686e-06
restriction O 0 1.213712437220238e-07
site O 0 4.651941196698317e-07
. O 0 4.5150461147613896e-08

We O 0 4.838877885049442e-07
have O 0 1.3184496161500192e-08
studied O 0 8.865257683510208e-08
the O 0 4.423159438715629e-08
codon O 0 4.824832089411757e-08
282 O 0 2.793139799450728e-07
( O 0 3.164334927419077e-08
Cys O 0 0.00040256103966385126
/ O 0 1.0058063708129339e-05
Tyr O 0 7.5750444921141025e-06
) O 0 6.265526431015189e-10
polymorphism O 0 5.5500199991342924e-09
in O 0 6.121304851891551e-11
different O 0 3.748357527144641e-11
ethnic O 0 1.5779007267457956e-10
groups O 0 8.696296460719566e-11
. O 0 2.5115069135495105e-08

In O 0 2.5440803597120976e-07
agreement O 0 4.899536634184187e-07
with O 0 1.3966221956707159e-08
previous O 0 2.3128134785110888e-07
observations O 0 2.953927662474598e-07
the O 0 1.3406618393219105e-07
Tyr O 0 1.651594902796205e-05
allele O 0 7.932393941700866e-08
appeared O 0 1.489750900418585e-08
to O 0 5.287364990280707e-10
be O 0 8.251052063812381e-10
rare O 0 1.833033103082471e-08
or O 0 9.685177104756804e-09
absent O 0 1.828520197477701e-07
in O 0 1.392700399449609e-09
Asiatic O 0 1.7317278278028425e-08
( O 0 5.643880154893033e-11
Indian O 0 2.3968611539970652e-09
, O 0 1.0950498841033607e-10
Chinese O 0 1.1389199583433651e-09
) O 0 1.2462288145886902e-10
populations O 0 2.0798407440736355e-09
. O 0 4.9588653183718634e-08

The O 0 2.961183781735599e-06
highest O 0 5.619955345537164e-07
allele O 0 8.41124325745568e-09
frequency O 0 5.8519580292681894e-09
( O 0 8.181359062442439e-11
7 O 0 9.73029656847757e-10
. O 0 5.5286299843748665e-11
5 O 0 6.492316684258981e-10
% O 0 4.725921737280814e-11
) O 0 2.0294129224329716e-11
was O 0 1.79353687457251e-09
found O 0 7.247857869430163e-10
in O 0 3.3066556159866423e-09
Swedes O 0 3.3027733934432035e-06
. O 0 5.309492507876712e-07

Saamis O 0 0.000787240918725729
( O 0 2.715763400829019e-07
2 O 0 5.289085152071493e-07
% O 0 3.526172687173812e-09
) O 0 5.188441898340557e-10
and O 0 2.547302369038107e-09
Mordvinians O 0 7.507269856432686e-06
( O 0 3.878272369917113e-09
1 O 0 3.1471806494209886e-08
. O 0 6.252705020415306e-10
8 O 0 5.772120559299765e-09
% O 0 1.3150301680919796e-10
) O 0 2.3552292061079783e-11
had O 0 4.541626796861209e-10
significantly O 0 5.159913829544394e-09
lower O 0 5.984762196931115e-08
frequencies O 0 1.543792294000923e-08
of O 0 1.1476517514097395e-08
the O 0 1.978668784374804e-08
Tyr O 0 3.968658802477876e-06
allele O 0 1.185969935590947e-07
. O 0 5.4206712007953683e-08

Comparisons O 0 1.7925959809872438e-06
with O 0 2.0080157980828517e-08
allele O 0 5.964250249235192e-08
frequencies O 0 4.762622296539121e-08
based O 0 5.751767062633917e-09
on O 0 4.02785316211407e-09
prevalence O 0 2.7107101008283507e-09
estimates O 0 9.51171363894332e-10
of O 0 2.8773762039691064e-08
HH B-Disease 1 0.9999961853027344
showed O 0 1.5376951978396391e-07
some O 0 9.75408198655714e-10
disagreements O 0 7.179399830192779e-08
with O 0 6.934723906226736e-10
the O 0 1.0868359545668227e-08
RFLP O 0 2.219591550556288e-07
data O 0 5.486113785480029e-09
, O 0 1.573687014033709e-10
particularly O 0 1.1535062904854954e-09
in O 0 5.1066217920947565e-09
Finns O 0 1.899558355944464e-06
. O 0 1.8030873150109983e-07

The O 0 2.071002199954819e-05
newly O 0 3.016010668943636e-05
described O 0 7.290752364497166e-06
HFE O 0 0.02365393005311489
marker O 0 1.6611040337011218e-05
provides O 0 3.050881502986158e-08
a O 0 1.1439846403504816e-08
new O 0 2.8334998791734733e-09
approach O 0 1.2041518893113334e-08
to O 0 5.234364608419639e-10
the O 0 1.7291295062449308e-09
screening O 0 4.591309998858151e-09
of O 0 6.68852662144559e-09
HH B-Disease 0 0.018404493108391762
as O 0 9.052079086302456e-09
well O 0 4.362128713797375e-10
as O 0 3.75759909299056e-11
studies O 0 1.1084224683932664e-11
of O 0 1.0410963063867129e-10
the O 0 1.2024063689164421e-10
relationship O 0 1.3857125169547402e-10
between O 0 9.530199962526353e-10
the O 0 1.6110567102600726e-08
HFE O 0 9.772481280378997e-05
Tyr O 0 5.930932729825145e-06
allele O 0 1.600887067354506e-08
and O 0 8.757689018423775e-10
different O 0 3.256844127719205e-09
disorders O 0 0.0005318227922543883
including O 0 3.2207944400397537e-07
cancer B-Disease 1 1.0

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999992847442627
associated O 0 1.9862422959704418e-06
with O 0 1.3768406859071547e-08
a O 0 2.185075800298364e-07
missense O 0 5.319761271493917e-07
mutation O 0 2.4011816535107755e-08
encoding O 0 2.3406742855058837e-07
Gly23 O 0 3.255304181948304e-05
- O 0 1.677090153862082e-06
- O 0 1.9698213691299316e-06
> O 0 1.9333565433043987e-06
Val O 0 1.2876961363872397e-06
in O 0 5.932446534018254e-09
neurophysin O 0 6.5523181547177956e-06
II O 1 0.9999998807907104
. O 0 1.776760541361e-06

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 9.980733466363745e-07
ADNDI B-Disease 1 0.9947263598442078
) O 0 1.3967174083973077e-09
is O 0 1.6335750807616733e-10
an O 0 3.475577048384082e-10
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.09041082859039307
by O 0 2.8689967734862876e-08
progressive O 1 0.9978004097938538
degeneration O 1 1.0
of O 0 0.00030817583319731057
the O 0 1.776907629391644e-05
magnocellular O 0 0.0011960326228290796
neurons O 0 6.239313847800076e-07
of O 0 9.570343308951124e-07
the O 0 6.310540811682586e-06
hypothalamus O 0 6.702323389617959e-06
leading O 0 4.812268912246509e-07
to O 0 8.592138556196005e-09
decreased O 0 7.307301785886011e-08
ability O 0 1.728741239048759e-08
to O 0 1.0550121665175993e-08
produce O 0 5.1597098149613885e-08
the O 0 2.217568777496126e-07
hormone O 0 4.5779678714552574e-08
arginine O 0 1.6308285921695642e-07
vasopressin O 0 1.9704083342730883e-07
( O 0 2.866107573495924e-09
AVP O 0 4.6672454345753067e-07
) O 0 6.279979869461272e-10
. O 0 1.0793988813873057e-08

Affected O 0 3.5162085509909957e-07
individuals O 0 9.374202525336273e-10
are O 0 2.3212648470050112e-10
not O 0 8.804080797730762e-10
symptomatic O 0 3.276423376519233e-05
at O 0 1.585892128730393e-08
birth O 0 5.908618927463749e-09
, O 0 5.758940546662927e-11
but O 0 1.671893318233586e-10
usually O 0 1.5546843812330735e-08
develop O 0 4.709264430857729e-06
diabetes B-Disease 1 1.0
insipidus I-Disease 1 0.9990720748901367
at O 0 5.1369070206419565e-06
1 O 0 1.6865275256350287e-06
- O 0 9.649351113694138e-07
6 O 0 2.104317900375463e-06
yr O 0 9.148438039119355e-06
of O 0 4.220093074991382e-08
age O 0 4.8089102477888446e-08
. O 0 1.1601940741456929e-07

The O 0 1.5612477000104263e-06
genetic O 0 1.4818182307863026e-06
locus O 0 3.643750119408651e-07
of O 0 2.819350868321635e-07
the O 0 5.927799975324888e-07
disease O 0 0.007119736168533564
is O 0 1.781319092231115e-08
the O 0 8.647273261885857e-07
AVP O 0 0.00037259861710481346
- O 0 2.7372787371859886e-05
neurophysin O 0 0.02095026895403862
II O 1 1.0
( O 0 1.549507118170368e-07
NPII O 0 9.446909825783223e-05
) O 0 3.4616970401302183e-10
gene O 0 6.768527405220937e-10
, O 0 6.414448833202968e-11
and O 0 3.1349436935279584e-10
mutations O 0 1.1842576919107728e-09
that O 0 3.413649363182003e-10
cause O 0 2.6342020191805204e-06
ADNDI B-Disease 0 0.3825954794883728
have O 0 6.056773749207878e-09
been O 0 1.7105628025149144e-09
found O 0 2.3751431377228016e-10
in O 0 3.725087252548498e-11
both O 0 5.3395145943602174e-11
the O 0 2.747836402861026e-09
signal O 0 1.0738179412328464e-07
peptide O 0 3.560853301110001e-08
of O 0 4.819911509912345e-07
the O 0 1.415857923348085e-06
prepro O 0 0.00010341986489947885
- O 0 2.5765675673028454e-05
AVP O 0 0.0002656863653101027
- O 0 7.225927220133599e-06
NPII O 0 0.00017803227819968015
precursor O 0 2.136999455615296e-06
and O 0 2.1593216104065505e-08
within O 0 4.6659099695034456e-08
NPII O 0 0.00015693924797233194
itself O 0 2.1788000026390364e-07
. O 0 7.901498833007281e-08

An O 0 2.2280939049323933e-07
affected O 0 1.7799206375457288e-07
girl O 0 5.36650759386248e-07
who O 0 1.4312755425294199e-08
presented O 0 6.357357307251732e-08
at O 0 7.494127629570357e-08
9 O 0 1.2562965778784019e-08
months O 0 2.8989080025354497e-09
of O 0 8.329501532955419e-09
age O 0 1.41527536356989e-08
and O 0 3.340685283959033e-09
her O 0 5.882337394957915e-10
similarly O 0 6.453771961290045e-10
affected O 0 1.1511742670222702e-09
younger O 0 1.2936546056607767e-07
brother O 0 2.707991370698437e-06
and O 0 1.2645908320507715e-08
father O 0 1.2491772167777526e-06
were O 0 3.1019123269970805e-08
all O 0 3.159446593237192e-10
found O 0 6.834598442750917e-10
to O 0 5.461784358118393e-10
have O 0 5.630088617536444e-10
a O 0 9.134480727368555e-09
novel O 0 3.679630466990602e-08
missense O 0 1.0979040609981894e-07
mutation O 0 5.9852962586148806e-09
( O 0 3.1865537986064396e-10
G1758 O 0 4.476288850696619e-08
- O 0 8.016459673854115e-08
- O 0 3.527672163272655e-07
> O 0 2.299990171650279e-07
T O 0 3.676003501595915e-08
) O 0 4.893239285985729e-11
encoding O 0 7.897468790041273e-10
the O 0 2.301129287118897e-09
amino O 0 2.902607598720408e-10
acid O 0 5.010676873418163e-10
substitution O 0 5.720433016165316e-09
Gly23 O 0 1.3715169870920363e-06
- O 0 4.1408031847822713e-07
- O 0 1.1648733106994769e-06
> O 0 2.0459747247514315e-06
Val O 0 2.525621312088333e-06
within O 0 9.707096637612267e-08
NPII O 0 0.00015993356646504253
. O 0 2.63639606146171e-07

The O 0 2.265481953145354e-06
mutation O 0 1.1093742813272911e-07
was O 0 1.0905181113685103e-07
confirmed O 0 4.078722692923975e-09
by O 0 1.4774259593508532e-10
restriction O 0 3.2683316053550016e-09
endonuclease O 0 2.591960424069839e-07
analysis O 0 1.4930220615383405e-08
. O 0 4.570098610656714e-08

A O 0 0.00011949904728680849
T1 O 0 0.0004085749969817698
- O 0 1.1246933127040393e-06
weighted O 0 4.5857635910806493e-08
magnetic O 0 6.454467182948065e-08
resonance O 0 1.233940594147498e-07
imaging O 0 2.167617822124157e-06
of O 0 1.2384858791847364e-06
the O 0 1.7018564903992228e-05
fathers O 0 0.00014912259939592332
pituitary O 0 0.00013443808711599559
gland O 0 4.440541033545742e-06
demonstrates O 0 2.7059281038077643e-08
an O 0 9.935390288262624e-10
attenuated O 0 4.779940354637802e-07
posterior O 0 1.0646767805155832e-06
pituitary O 0 5.7670287787914276e-05
bright O 0 2.6257888748659752e-05
spot O 0 7.765154441585764e-05
. O 0 7.154438321776979e-07

This O 0 8.287177877264185e-08
mutation O 0 3.3001740007421176e-08
may O 0 6.276629882506768e-09
be O 0 7.452029548993266e-10
valuable O 0 1.1844074165878737e-08
for O 0 9.867773959060244e-11
developing O 0 3.453053620816604e-09
models O 0 1.3498857143190435e-08
of O 0 7.524677698711457e-07
dominantly B-Disease 1 0.9999997615814209
inherited I-Disease 1 1.0
neurodegeneration I-Disease 1 1.0
, O 0 1.900215984562692e-08
as O 0 3.920148650138344e-10
the O 0 4.4546930033639853e-10
early O 0 2.904087859079141e-09
age O 0 2.934734122383986e-10
of O 0 7.318355366159324e-10
onset O 0 0.00023221342416945845
of O 0 2.6183576551375154e-07
symptoms O 0 9.491787750448566e-06
suggests O 0 2.058336612265066e-09
that O 0 3.495693318145143e-11
this O 0 1.329689136575496e-10
mutation O 0 4.752490623260996e-10
may O 0 3.8491537734941517e-10
be O 0 1.2825454587250817e-10
particularly O 0 1.3213491412145117e-09
deleterious O 0 1.8404811896743922e-08
to O 0 5.9461764401191886e-09
the O 0 2.0352894125608145e-07
magnocellular O 0 2.5765897589735687e-05
neuron O 0 1.0961230145767331e-06
. O 0 7.881657104746864e-09
. O 0 4.4069572879834595e-08

Frequent O 0 3.026746526302304e-06
inactivation O 0 0.0003654907050076872
of O 0 3.166820897604339e-05
PTEN O 1 0.9999979734420776
/ O 1 0.5583076477050781
MMAC1 O 1 0.9999488592147827
in O 0 4.6312246126944956e-07
primary O 1 0.9999797344207764
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.467322474331013e-06

Sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 0.0005199023871682584
the O 0 9.493389370618388e-06
most O 0 7.816161051721338e-09
common O 0 2.1732475943281315e-06
male B-Disease 0 1.3118931008193613e-07
cancer I-Disease 0 2.8045209546689875e-05
in O 0 3.4490714728718785e-09
the O 0 7.029802873148583e-07
Western O 0 0.00013751242659054697
world O 0 4.905479045191896e-08
, O 0 6.406110364398643e-11
yet O 0 1.6275944481058957e-10
many O 0 2.3190199760492192e-11
of O 0 6.439851985007294e-10
the O 0 1.8581128857775298e-09
major O 0 2.280488464734276e-09
genetic O 0 2.9163826908984447e-09
events O 0 1.6794544921427956e-11
involved O 0 3.7186701634661645e-11
in O 0 1.3479625748935575e-10
the O 0 3.3263984899889465e-09
progression O 0 7.767681609038846e-09
of O 0 4.96242957837012e-09
this O 0 1.9284829289034633e-09
often O 0 4.0087098085450634e-08
fatal O 0 0.00023654480173718184
cancer B-Disease 0 0.001459079678170383
remain O 0 2.8182378741803404e-07
to O 0 2.83369043785342e-08
be O 0 2.340687643709316e-07
elucidated O 0 0.05072224512696266
. O 0 2.764663804555312e-06

Numerous O 0 4.871400051342789e-06
cytogenetic O 0 0.0007337657734751701
and O 0 4.908296205030638e-07
allelotype O 0 8.134121344482992e-06
studies O 0 6.209198488704715e-09
have O 0 5.390435875440858e-10
reported O 0 3.1154177015935147e-09
frequent O 0 4.9568007476352705e-09
loss O 0 4.099673844848439e-08
of O 0 8.855859050527215e-07
heterozygosity O 1 0.9999557733535767
on O 0 0.00029660394648090005
chromosomal O 0 0.0004895604215562344
arm O 0 0.0002520194393582642
10q O 0 1.2398364560795017e-05
in O 0 2.1350366807837418e-07
sporadic B-Disease 1 0.9999995231628418
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.7861911803483963e-05

Deletion O 0 1.4841043594060466e-05
mapping O 0 6.339279821077071e-07
studies O 0 2.3006652583035248e-08
have O 0 2.8540187990699906e-09
unambiguously O 0 3.2785852255301506e-08
identified O 0 1.6575810946051206e-08
a O 0 1.0345038603531975e-08
region O 0 3.552102612047747e-08
of O 0 3.94605677911386e-07
chromosome O 0 1.8107937194145052e-07
10q23 O 0 3.371252148554049e-07
to O 0 2.238812468746687e-09
be O 0 1.6816197323521465e-09
the O 0 7.112149980059712e-09
minimal O 0 1.7128924412190827e-07
area O 0 4.783451856837928e-08
of O 0 1.7030760801617362e-08
loss O 0 1.0685874940463691e-07
. O 0 2.191210910496011e-07

A O 0 1.1055441973439883e-05
new O 0 4.0726655470280093e-07
tumor B-Disease 0 8.496817827108316e-07
suppressor O 0 1.0649804380591377e-06
gene O 0 1.792156290036928e-08
, O 0 3.69632080499116e-09
PTEN O 0 0.0010239161783829331
/ O 0 6.410840433090925e-05
MMAC1 O 1 0.9988818764686584
, O 0 1.8272803714580732e-08
was O 0 1.0395217486802721e-06
isolated O 0 4.882413691120746e-07
recently O 0 4.690305033250297e-08
at O 0 4.739836967360134e-09
this O 0 1.053746256918231e-10
region O 0 2.407518406855047e-09
of O 0 1.3505604634644897e-08
chromosome O 0 7.332499052381536e-09
10q23 O 0 2.6656234553001923e-08
and O 0 4.3936840277147837e-10
found O 0 1.444867836486452e-10
to O 0 6.86299350682873e-11
be O 0 2.580179299382923e-11
inactivated O 0 1.3125299735960994e-09
by O 0 1.3742543561456877e-11
mutation O 0 6.270688135412428e-11
in O 0 2.4127713715849097e-10
three O 0 1.307202097677873e-07
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.3165973126888275
lines O 0 6.628433197874983e-07
. O 0 1.2389261883072322e-07

We O 0 2.128402229573112e-06
screened O 0 4.590928801917471e-05
80 O 0 1.3656483133672737e-05
prostate B-Disease 1 1.0
tumors I-Disease 1 1.0
by O 0 1.9841296605704883e-08
microsatellite O 0 9.209714335156605e-06
analysis O 0 1.8491229880623905e-08
and O 0 3.0286220198405545e-09
found O 0 3.2270766059383504e-09
chromosome O 0 4.6522670160698e-09
10q23 O 0 2.3340755106460165e-08
to O 0 8.805794426969271e-10
be O 0 1.6228091093140051e-09
deleted O 0 6.881206715547705e-09
in O 0 4.426817801217453e-10
23 O 0 1.9177759380539783e-09
cases O 0 8.011254992723593e-10
. O 0 2.6419197496352353e-08

We O 0 2.678023065527668e-07
then O 0 2.8451935918383242e-08
proceeded O 0 1.4704301776191642e-08
with O 0 1.2248611847009983e-11
sequence O 0 2.3917893707259275e-11
analysis O 0 5.373761852167647e-11
of O 0 1.0156500085400921e-09
the O 0 7.66492380677164e-09
entire O 0 1.2284261856621015e-06
PTEN O 0 0.006136992014944553
/ O 0 1.1598092896747403e-05
MMAC1 O 0 9.931444947142154e-05
coding O 0 8.335296115546953e-07
region O 0 3.838234263753293e-08
and O 0 2.7796438484273267e-09
tested O 0 6.948695396857829e-09
for O 0 1.3877101689985238e-09
homozygous O 0 4.126486263800189e-09
deletion O 0 1.5282649812320415e-08
with O 0 2.1342848322003505e-10
new O 0 1.0203415889975531e-08
intragenic O 0 1.507861384197895e-06
markers O 0 7.2919141835825485e-09
in O 0 1.1513120318218384e-10
these O 0 2.1250466664124446e-11
23 O 0 2.989353486970714e-10
cases O 0 3.004803697526093e-11
with O 0 8.161813586093913e-11
10q23 O 0 1.7469126589730877e-07
loss O 0 1.9235508830206527e-07
of O 0 7.74186719354475e-06
heterozygosity O 1 0.9999886751174927
. O 0 5.366796540329233e-05

The O 0 3.3267878052356537e-07
identification O 0 1.4335969922285585e-07
of O 0 2.826482443651912e-07
the O 0 2.374398491156171e-07
second O 0 6.832023018432665e-07
mutational O 0 8.375261131732259e-06
event O 0 3.5573027190594075e-08
in O 0 4.0515848453992476e-09
10 O 0 6.999028911991445e-09
( O 0 4.082814641925836e-10
43 O 0 3.645699564458482e-08
% O 0 2.4192022607394392e-08
) O 0 1.2739822352614283e-07
tumors B-Disease 1 1.0
establishes O 0 0.0004990607849322259
PTEN O 1 0.9999997615814209
/ O 0 0.17612586915493011
MMAC1 O 0 0.020941302180290222
as O 0 1.936489724130297e-08
a O 0 4.2265031474642e-09
main O 0 2.225436723790608e-08
inactivation O 0 3.5445228974140264e-08
target O 0 1.1731964288941299e-09
of O 0 2.1619168677489142e-09
10q O 0 1.1348507911179695e-07
loss O 0 1.5434567401939603e-08
in O 0 7.913441457674253e-09
sporadic B-Disease 1 0.975417971611023
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.2333524068708357e-07
. O 0 6.549247899556576e-08

Risk O 0 1.0966711670334917e-05
reversals O 0 4.900452040601522e-06
in O 0 9.147330004566356e-09
predictive O 0 2.980191027290857e-08
testing O 0 2.892094386197641e-08
for O 0 4.3162902585436314e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.2481448266044026e-06

The O 0 6.061005706214928e-07
first O 0 2.986541147720345e-08
predictive O 0 2.7978632743952403e-08
testing O 0 1.9990279653825382e-08
for O 0 3.638266932171064e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.496180779270162e-08
HD B-Disease 0 4.299222564441152e-05
) O 0 5.001147829197805e-10
was O 0 3.359599265451152e-09
based O 0 1.6077091047339565e-10
on O 0 6.322694034999188e-10
analysis O 0 3.731553399610732e-10
of O 0 1.405801808296303e-09
linked O 0 1.538686156266067e-08
polymorphic O 0 4.027562994224354e-08
DNA O 0 2.0577731163484714e-07
markers O 0 8.90305784650991e-09
to O 0 3.200764930877398e-10
estimate O 0 2.801765486282193e-09
the O 0 6.192250712189207e-09
likelihood O 0 7.655591360844483e-08
of O 0 7.36904013365347e-08
inheriting O 0 1.8280897506883775e-07
the O 0 1.0123302018882896e-07
mutation O 0 4.830888578055692e-09
for O 0 1.1677006916954724e-08
HD B-Disease 0 4.5607714127982035e-05
. O 0 6.631360065512126e-07

Limits O 0 7.537052510997455e-07
to O 0 2.0281506252217696e-08
accuracy O 0 5.982924733416439e-08
included O 0 6.91288404297552e-09
recombination O 0 6.556832410353763e-09
between O 0 2.0760915209194764e-09
the O 0 2.9004787460706893e-09
DNA O 0 5.502779387711598e-08
markers O 0 1.467314714176382e-08
and O 0 2.1831618735035363e-09
the O 0 1.543297756256834e-08
mutation O 0 5.730654617508435e-09
, O 0 4.561385436030463e-10
pedigree O 0 7.731291162826892e-09
structure O 0 2.8841949273328282e-08
, O 0 3.471522513898151e-10
and O 0 8.115198096847465e-11
whether O 0 1.0561265750830273e-10
DNA O 0 3.024633210557681e-09
samples O 0 1.671440624795295e-10
were O 0 8.788674649151673e-11
available O 0 2.601022452974888e-10
from O 0 3.1340960937598084e-09
family O 0 1.8918372290954721e-07
members O 0 8.509596582939594e-09
. O 0 1.2635256041448883e-07

With O 0 2.3532033210926784e-08
direct O 0 3.045399310508401e-08
tests O 0 1.271546778980337e-08
for O 0 3.45105211074781e-09
the O 0 4.775165507453494e-08
HD B-Disease 0 5.6350014347117394e-05
mutation O 0 5.523515866912021e-08
, O 0 5.38096456281778e-10
we O 0 2.2265723986780728e-10
have O 0 6.189575935122704e-11
assessed O 0 5.9059490631341305e-09
the O 0 1.9479355906071305e-09
accuracy O 0 7.788065303770964e-09
of O 0 1.6643917355452231e-09
results O 0 1.870090332589669e-10
obtained O 0 9.66666191537513e-10
by O 0 1.5942244746547374e-10
linkage O 0 1.0127334526544018e-08
approaches O 0 1.7575933597413496e-08
when O 0 1.8742836171981025e-09
requested O 0 8.712508936525865e-09
to O 0 1.183993458830912e-09
do O 0 2.075765809239627e-10
so O 0 9.226557712294081e-11
by O 0 2.7591829862561035e-11
the O 0 8.715994592733978e-10
test O 0 2.305021062909418e-09
individuals O 0 7.440777161082934e-11
. O 0 2.1249933368494567e-08

For O 0 1.2975020524663705e-07
six O 0 1.6204932506980185e-08
such O 0 1.0474585643294176e-09
individuals O 0 1.9238749482397566e-10
, O 0 3.6606212505674307e-10
there O 0 2.1860567522846708e-10
was O 0 1.0654488846739696e-08
significant O 0 1.4779594215141856e-09
disparity O 0 4.564642885895864e-09
between O 0 1.5581121948216037e-09
the O 0 1.0317529941517023e-08
tests O 0 1.2765575263529172e-08
. O 0 3.0557675501086123e-08

Three O 0 5.20889170729788e-06
went O 0 7.782884381413169e-07
from O 0 8.289909203540446e-09
a O 0 5.589709584086222e-09
decreased O 0 7.417121139496885e-09
risk O 0 2.384294761625938e-09
to O 0 4.13043710345562e-10
an O 0 1.0037996128753335e-10
increased O 0 2.9585978111867917e-10
risk O 0 5.5694791001315025e-09
, O 0 8.523313999031501e-11
while O 0 6.038288619114596e-11
in O 0 1.341586008951623e-10
another O 0 4.793182517559558e-10
three O 0 1.9629353698036311e-10
the O 0 7.307280336377175e-10
risk O 0 1.2953693673267708e-09
was O 0 3.102870849147621e-08
decreased O 0 2.9507054577493363e-08
. O 0 4.950058141162117e-08

Knowledge O 0 4.3588097469182685e-05
of O 0 2.237814805994276e-05
the O 0 3.3613835626056243e-07
potential O 0 4.1701319730691466e-08
reasons O 0 2.5162043559845415e-09
for O 0 1.7072439295606756e-10
these O 0 4.4161899831474116e-11
changes O 0 4.2395806310047135e-10
in O 0 4.880676418572705e-10
results O 0 4.870410741375508e-10
and O 0 5.610321651694505e-10
impact O 0 8.350976798965348e-09
of O 0 7.518822897623068e-09
these O 0 5.372719491525402e-10
risk O 0 4.621798055381987e-09
reversals O 0 4.549017873500816e-08
on O 0 3.54156277637685e-08
both O 0 8.914116111924386e-10
patients O 0 4.996745239793654e-09
and O 0 8.555034014534613e-09
the O 0 1.2194182374969387e-07
counseling O 0 3.7278010012187224e-08
team O 0 3.500327139249748e-09
can O 0 8.776149806877243e-10
assist O 0 1.7382237871288453e-08
in O 0 3.27898375118707e-09
the O 0 2.0566739422633873e-08
development O 0 7.170351423724242e-09
of O 0 2.9241642440780424e-09
strategies O 0 3.951424520920455e-09
for O 0 1.8034289339663445e-10
the O 0 1.9399712947176795e-09
prevention O 0 1.1089231755079254e-08
and O 0 6.679137798393242e-11
, O 0 1.1300858686336124e-11
where O 0 5.6680018317711856e-11
necessary O 0 2.517932751189278e-09
, O 0 7.511017502404016e-11
management O 0 1.3910916862869271e-09
of O 0 2.2106709796076984e-09
a O 0 3.928713798728722e-09
risk O 0 5.697783134195333e-09
reversal O 0 1.1652133480311022e-08
in O 0 6.095908222647495e-10
any O 0 9.98008009567286e-10
predictive O 0 5.816703563255032e-09
testing O 0 5.4784177194733275e-09
program O 0 5.694697602365295e-09
. O 0 1.243997016509013e-09
. O 0 1.123493831300948e-08

A O 0 1.3207548363425303e-05
novel O 0 1.381920583298779e-06
common O 0 1.177119429485174e-06
missense O 0 3.308630539322621e-06
mutation O 0 8.231819492721115e-08
G301C O 0 6.349238219627296e-07
in O 0 1.0607487332947585e-08
the O 0 5.596092123028029e-08
N O 0 2.2363174423389864e-07
- O 0 8.584443378367723e-08
acetylgalactosamine O 0 2.2155466012918623e-06
- O 0 1.9112447091629292e-07
6 O 0 1.426648168489919e-07
- O 0 3.928565917021842e-08
sulfate O 0 7.407170983242395e-07
sulfatase O 0 5.621731361316051e-06
gene O 0 4.5356582489830544e-08
in O 0 2.0698175617894776e-08
mucopolysaccharidosis B-Disease 0 7.003774226177484e-05
IVA I-Disease 1 0.9996429681777954
. O 0 7.1000736170390155e-06

Mucopolysaccharidosis B-Disease 1 0.9840116500854492
IVA I-Disease 1 1.0
( O 0 4.72010942758061e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 2.657085573787299e-08
is O 0 2.7546056546867703e-09
an O 0 5.158309779318415e-09
autosomal B-Disease 1 0.9999996423721313
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 1.0
by O 0 6.226471305126324e-05
a O 1 0.9995098114013672
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 3.380784983164631e-05
N O 0 6.3080979089136235e-06
- O 0 8.547287393412262e-07
acetylgalactosamine O 0 1.4646182535216212e-05
- O 0 7.774190180498408e-07
6 O 0 5.275051648823137e-07
- O 0 1.259478494830546e-07
sulfate O 0 4.074447588209296e-06
sulfatase O 0 4.5677050366066396e-05
( O 0 9.422318925089712e-09
GALNS O 0 2.975903043989092e-05
) O 0 4.7908819134079295e-09
. O 0 2.6305107425628194e-08

In O 0 4.008755922768614e-07
previous O 0 8.56772572888076e-08
studies O 0 4.681079079915662e-09
, O 0 2.5856983221217433e-10
we O 0 1.1785605824599088e-10
have O 0 4.0979480225855625e-11
found O 0 4.1903558400946395e-10
two O 0 2.541026833391413e-10
common O 0 3.2453475462546066e-09
mutations O 0 1.5490357885283856e-09
in O 0 5.011556170053666e-10
Caucasians O 0 2.2939040889013995e-08
and O 0 6.990317213961816e-09
Japanese O 0 1.7484308045823127e-05
, O 0 7.43635775179996e-09
respectively O 0 5.6387566615967444e-08
. O 0 1.99425102209716e-07

To O 0 5.831041676174209e-07
characterize O 0 6.148019110696623e-06
the O 0 2.060926590274903e-06
mutational O 0 0.0011268315138295293
spectrum O 0 1.0449713045090903e-05
in O 0 7.048485684002515e-10
various O 0 1.7500649540647117e-10
ethnic O 0 3.6540482445390765e-11
groups O 0 7.923744993476589e-12
, O 0 1.3087040132142569e-11
mutations O 0 5.536185399002136e-11
in O 0 2.721219638512906e-10
the O 0 4.8556185738846125e-09
GALNS O 0 1.2343659818725428e-06
gene O 0 2.8150390907200062e-09
in O 0 2.049862501962707e-09
Colombian O 0 4.4419834011932835e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 1 0.6988485455513
were O 0 2.7524811230250634e-07
investigated O 0 3.6927539781572705e-07
, O 0 7.224614795298123e-10
and O 0 8.795454364829425e-10
genetic O 0 3.198412557026131e-08
backgrounds O 0 3.6297256311712545e-09
were O 0 7.035581894854204e-09
extensively O 0 7.248178501839675e-09
analyzed O 0 6.645115124825907e-09
to O 0 8.424371755744176e-10
identify O 0 4.682186638405028e-09
racial O 0 5.972407568499705e-10
origin O 0 4.4828715739519964e-10
, O 0 8.146602836767158e-11
based O 0 2.3206095378647262e-10
on O 0 3.570529427676661e-09
mitochondrial O 0 1.0461788102489322e-09
DNA O 0 3.282437655016679e-09
( O 0 8.831137210396633e-11
mtDNA O 0 7.828659942532568e-10
) O 0 2.1020898910428798e-10
lineages O 0 8.636006576523414e-09
. O 0 5.447671824754252e-08

Three O 0 1.086689849216782e-06
novel O 0 1.8104706214217003e-06
missense O 0 2.825069486789289e-06
mutations O 0 4.654079788224408e-08
never O 0 7.530263701482909e-08
identified O 0 2.473786508971898e-08
previously O 0 1.1666744903493509e-08
in O 0 4.735867809024796e-10
other O 0 1.597999510494219e-10
populations O 0 1.46023290681363e-10
and O 0 1.7660597984026083e-10
found O 0 3.751463584222847e-10
in O 0 1.027810392351114e-09
16 O 0 3.7969032362639155e-09
out O 0 2.057539916222595e-09
of O 0 2.6964638522031237e-08
19 O 0 1.9331137934841536e-07
Colombian O 0 2.164775287383236e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
unrelated O 0 7.621875965924119e-07
alleles O 0 2.3243273972184397e-09
account O 0 2.750477900992365e-10
for O 0 9.228304787001207e-10
84 O 0 2.250315560559102e-07
. O 0 3.3146079658763483e-07

2 O 0 3.043279093617457e-06
% O 0 3.841901907719603e-09
of O 0 8.582998312078871e-09
the O 0 3.686519978174374e-09
alleles O 0 2.5490701216490663e-10
in O 0 3.5004654730386164e-10
this O 0 1.7923663941932233e-10
study O 0 1.6423704618517831e-09
. O 0 1.67838098974471e-08

The O 0 8.141920261550695e-06
G301C O 0 1.2309169505897444e-05
and O 0 3.99057604738573e-08
S162F O 0 1.9794732963873685e-07
mutations O 0 6.467967272882902e-10
account O 0 7.549782327087584e-11
for O 0 3.870045950371548e-10
68 O 0 1.8732450257630262e-07
. O 0 1.3454751979224966e-07

4 O 0 4.83458325106767e-06
% O 0 4.1103064063463535e-08
and O 0 1.3657899700092457e-08
10 O 0 6.338614610967852e-08
. O 0 1.0270842665249802e-07

5 O 0 1.531197881377011e-06
% O 0 9.996068861539698e-09
of O 0 6.28222274201562e-09
mutations O 0 1.2304048890854347e-09
, O 0 1.7021521692139885e-10
respectively O 0 9.335785478015168e-10
, O 0 4.3695064233517655e-10
whereas O 0 5.421619597711924e-09
the O 0 1.531954438860339e-07
remaining O 0 1.1052184163418133e-06
F69V O 0 1.665167474129703e-05
is O 0 7.672028567995426e-10
limited O 0 3.8642483657369553e-10
to O 0 5.546906267639429e-10
a O 0 5.61874191618017e-09
single O 0 1.6246463729885363e-08
allele O 0 4.6323730629183046e-08
. O 0 8.14697216355853e-08

The O 0 3.909798579115886e-06
skewed O 0 8.499816885887412e-07
prevalence O 0 3.6585174711945e-07
of O 0 5.3589694459788006e-08
G301C O 0 2.54327488846684e-07
in O 0 5.988707307835739e-10
only O 0 3.25667437461874e-10
Colombian O 0 3.810297144468677e-08
patients O 0 1.1221831464069965e-08
and O 0 1.4965053640736414e-09
haplotype O 0 2.8356964776321547e-08
analysis O 0 1.6727290386153726e-10
by O 0 1.1413718060959699e-11
restriction O 0 8.358744946201924e-11
fragment O 0 1.0599027211455336e-09
length O 0 6.975263144859412e-10
polymorphisms O 0 1.6362110555334652e-09
in O 0 3.0180216659125847e-10
the O 0 1.1323098902948914e-08
GALNS O 0 2.871088327083271e-06
gene O 0 3.1657219068392806e-09
suggest O 0 7.023725490107324e-10
that O 0 1.269260530012417e-10
G301C O 0 3.3402919541458687e-08
originated O 0 2.048994529602055e-09
from O 0 1.79884607209857e-10
a O 0 8.076552759916922e-10
common O 0 7.788124811725083e-09
ancestor O 0 1.8541929875937058e-06
. O 0 1.5662898533719272e-07

Investigation O 0 5.789323950011749e-06
of O 0 9.892736443362082e-07
the O 0 7.205643726138078e-08
genetic O 0 2.742350702078511e-08
background O 0 2.960688361142161e-09
by O 0 1.8323320638558016e-10
means O 0 1.878306932212581e-08
of O 0 1.6870312435912638e-07
mtDNA O 0 1.674237282145441e-08
lineages O 0 1.726358056508559e-09
indicate O 0 2.1687221463118078e-10
that O 0 1.3296028167353313e-10
all O 0 6.293577325955368e-10
our O 0 1.3290463840576194e-08
patients O 0 1.7865376955583656e-09
are O 0 2.4270833606787612e-11
probably O 0 2.5441171391804573e-09
of O 0 7.688600867084006e-09
native O 0 9.560117142370927e-09
American O 0 9.851764559698495e-08
descent O 0 6.802404186601052e-06

Low O 0 3.766923100556596e-06
frequency O 0 1.5054618529575237e-07
of O 0 9.726816330157817e-08
BRCA1 O 0 4.295200639603536e-08
germline O 0 9.300247683086127e-08
mutations O 0 2.859564252055691e-10
in O 0 1.4721011909468729e-10
45 O 0 3.513128898902096e-09
German O 1 0.7639217376708984
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.297101210999244e-07
. O 0 1.412005303791375e-07

In O 0 1.871698600552918e-07
this O 0 2.9861750849846658e-09
study O 0 6.508583672015789e-10
we O 0 4.359398259046188e-11
investigated O 0 5.585614748504497e-10
45 O 0 8.536187312557786e-10
German O 0 0.00019828607037197798
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.363323118956487e-09
for O 0 3.4290631445443864e-10
germline O 0 1.54005146413283e-08
mutations O 0 2.349693495329319e-10
in O 0 1.8069237772699864e-10
the O 0 1.4613182663936186e-08
BRCA1 O 0 7.2230337266887545e-09
gene O 0 1.9813009899394274e-08
. O 0 2.8397611373520704e-08

We O 0 2.422915486022248e-07
identified O 0 1.1036799918429097e-07
four O 0 3.4642564372688867e-08
germline O 0 1.049528805197042e-06
mutations O 0 2.1201836730710966e-08
in O 0 1.2324958831300137e-08
three O 0 1.7720584821745433e-07
breast B-Disease 1 0.999815046787262
cancer I-Disease 1 0.9965901374816895
families O 0 4.511155538011735e-08
and O 0 1.7261449158922915e-08
in O 0 2.1313830700364633e-07
one O 1 0.9734894037246704
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 5.191002128412947e-05
. O 0 1.2717978059573198e-10
among O 0 5.98439700572051e-12
these O 0 5.694764972086208e-12
were O 0 3.525411074178919e-10
one O 0 6.105042582582598e-10
frameshift O 0 6.656608153576826e-09
mutation O 0 1.5357437543883634e-10
, O 0 6.13279288463886e-11
one O 0 1.7928929174626518e-10
nonsense O 0 8.653005423298055e-09
mutation O 0 1.1547521827637297e-09
, O 0 1.30402022513465e-10
one O 0 1.4000292591909158e-10
novel O 0 5.549564807694196e-09
splice O 0 4.102811601569556e-07
site O 0 5.246404199965582e-08
mutation O 0 8.111659122178594e-10
, O 0 6.766768395616296e-11
and O 0 5.412173487151506e-10
one O 0 3.4893616884801304e-09
missense O 0 1.114298925131152e-06
mutation O 0 2.3229773660204955e-07
. O 0 3.902055425442086e-07

The O 0 6.20050650468329e-06
missense O 0 5.882656751055038e-06
mutation O 0 8.083895863819635e-08
was O 0 2.64789605353144e-07
also O 0 1.0070813072360352e-09
found O 0 2.0715862358855475e-09
in O 0 3.1676123946056123e-09
2 O 0 4.0929631950348266e-07
. O 0 2.2576907099391974e-07

8 O 0 6.081234005250735e-06
% O 0 1.095845014731367e-08
of O 0 1.4788258617670635e-08
the O 0 5.8832494431726445e-09
general O 0 6.564865984159951e-09
population O 0 3.310792265343032e-11
, O 0 9.365310610354172e-12
suggesting O 0 7.654894079722752e-11
that O 0 3.5906499128157687e-12
it O 0 1.3019395457558591e-11
is O 0 1.2954743180970674e-11
not O 0 1.9886654822887095e-11
disease O 0 2.8667910267898833e-09
associated O 0 2.025865697419249e-08
. O 0 1.5516424411998742e-07

The O 0 1.197532355945441e-06
average O 0 2.1505998759607792e-08
age O 0 4.460774416514823e-09
of O 0 1.2276557548318578e-08
disease O 0 1.321349486715917e-06
onset O 1 0.5010154843330383
in O 0 9.82661418902353e-09
those O 0 2.638876450689054e-09
families O 0 1.283965600507031e-09
harbouring O 0 4.9892623366076805e-08
causative O 0 3.0472698142602894e-08
mutations O 0 4.669264086487601e-09
was O 0 6.546000719254153e-08
between O 0 2.157699796612178e-08
32 O 0 8.435053473476728e-07
. O 0 6.59153727156081e-07

3 O 0 4.251044629199896e-06
and O 0 9.300779879595211e-08
37 O 0 1.2623250995602575e-06
. O 0 6.481199648078473e-07

4 O 0 5.601096290774876e-06
years O 0 7.694942638636348e-08
, O 0 6.837793109504275e-10
whereas O 0 6.15062845099601e-09
the O 0 2.122753173239289e-08
family O 0 1.1191398385790308e-07
harbouring O 0 6.521040631923825e-07
the O 0 6.336076552315717e-08
missense O 0 9.237858478172711e-08
mutation O 0 4.1029730724062574e-09
had O 0 5.79482284379651e-09
an O 0 4.738313907903802e-11
average O 0 1.760896706226589e-10
age O 0 4.731353087095158e-10
of O 0 5.926508617193349e-09
onset O 0 0.1742021143436432
of O 0 8.656383579364046e-05
51 O 0 2.717263214435661e-06
. O 0 3.151445753246662e-07

2 O 0 1.780271304596681e-05
years O 0 5.742085136262176e-07
. O 0 5.275534817883454e-07

These O 0 1.7895710868742754e-07
findings O 0 1.239980491618553e-07
show O 0 1.208560540533199e-08
that O 0 5.347915998932251e-10
BRCA1 O 0 1.1677987465930073e-08
is O 0 4.263535080539782e-10
implicated O 0 1.1295745672157409e-08
in O 0 7.021046521948904e-10
a O 0 9.917555665595046e-10
small O 0 1.816298084156287e-10
fraction O 0 1.0150109641671179e-09
of O 0 2.989564336530748e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.497350378888768e-09
suggesting O 0 6.968348675862046e-10
the O 0 1.0763372415567574e-09
involvement O 0 1.6924054380140774e-09
of O 0 2.8555762199289347e-09
another O 0 1.4935653824821316e-09
susceptibility O 0 1.1054007487132367e-08
gene O 0 2.9022051428739815e-09
( O 0 1.2245845448788373e-09
s O 0 1.4765028026886284e-06
) O 0 2.7651890377455857e-07

Paternal O 0 0.00044756216811947525
transmission O 0 0.0010475795716047287
of O 0 0.0001676111714914441
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9998401403427124

We O 0 1.7366174631661124e-07
report O 0 5.091042254434797e-09
a O 0 1.7283349196262066e-09
rare O 0 1.6708676664478617e-09
case O 0 3.985576757514764e-09
of O 0 7.697085635527401e-08
paternally O 1 0.9999966621398926
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.010885972529649734
DM B-Disease 1 1.0
) O 0 9.365078312839614e-08
. O 0 1.0232225378103976e-07

The O 0 1.683568552834913e-05
proband O 0 4.742271630675532e-05
is O 0 8.438399312638012e-09
a O 0 7.044040462034218e-09
23 O 0 6.827214349414135e-09
year O 0 1.879610689314859e-09
old O 0 4.173962679487886e-06
, O 0 9.81010046530173e-08
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 1.4041809663467575e-05
who O 0 1.2457363141038513e-07
suffers O 0 0.18261714279651642
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 1 0.9999998807907104

He O 0 2.40323061007075e-07
presented O 0 2.0096504727007414e-07
with O 0 1.619170930666769e-08
respiratory O 1 1.0
and O 0 4.844173417950515e-07
feeding O 0 4.333016931923339e-06
difficulties O 0 5.728554242523387e-06
at O 0 1.9202238945581485e-06
birth O 0 7.701835784246214e-06
. O 0 1.2237770761203137e-06

His O 0 4.409695611684583e-05
two O 0 2.8016897886118386e-06
sibs O 0 0.1296871304512024
suffer O 0 8.784696206021181e-07
from O 0 2.15330942410219e-07
childhood O 1 0.5261569023132324
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 0.0024880925193428993

Their O 0 7.40262350973353e-07
late O 0 0.0002628130023367703
father O 0 1.0048082913272083e-05
had O 0 6.336390612204923e-08
the O 0 4.3250980574782716e-09
adult O 0 3.732656683741453e-10
type O 0 9.48844669501625e-10
of O 0 2.38385933215568e-08
DM B-Disease 1 1.0
, O 0 1.6374316347267381e-09
with O 0 3.6970804195846085e-10
onset O 1 0.9966095685958862
around O 0 4.7309519857208215e-08
30 O 0 1.7606264890446255e-08
years O 0 8.944827989409987e-09
. O 0 3.083719235519311e-08

Only O 0 4.588667934513069e-08
six O 0 4.5323522712692466e-09
other O 0 2.468089621565639e-11
cases O 0 3.5961622568692064e-11
of O 0 9.546755608269564e-10
paternal O 0 9.757268344401382e-07
transmission O 0 0.0008387918351218104
of O 0 0.0005221476894803345
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.00027306406991556287
been O 0 1.7597342605313315e-07
reported O 0 1.1229068341833681e-08
recently O 0 3.2660896209790735e-08
. O 0 3.106044843548261e-08

We O 0 5.431764975583064e-07
review O 0 1.073705391263502e-07
the O 0 8.172913901205447e-09
sex O 0 2.0675154643878813e-10
related O 0 4.12670453364683e-10
effects O 0 6.443221955976242e-09
on O 0 7.409118207846177e-09
transmission O 0 3.316507957151771e-07
of O 0 9.417180990567431e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9543086886405945

Decreased O 0 3.1044421575643355e-06
fertility O 0 7.25603115370177e-07
of O 0 4.301831335595807e-09
males O 0 2.3293535503232654e-11
with O 0 3.1719075282987674e-11
adult O 0 6.313611411457032e-09
onset O 0 0.46134597063064575
DM B-Disease 1 1.0
and O 0 6.848058120567657e-08
contraction O 0 1.5968128153076577e-08
of O 0 1.4095479450304538e-08
the O 0 9.931813593766492e-09
repeat O 0 1.3348991911854569e-09
upon O 0 1.0855861765080022e-09
male O 0 9.791468330577757e-11
transmission O 0 6.596263119051926e-11
contribute O 0 5.0792404136801306e-12
to O 0 1.1427948171105484e-10
the O 0 3.3375582297878736e-09
almost O 0 3.42070816117257e-10
absent O 0 1.4359834432653429e-09
occurrence O 0 3.6259181768194537e-10
of O 0 5.262915658832412e-10
paternal O 0 6.406497732314165e-08
transmission O 0 5.777134219897562e-07
of O 0 1.7669109411144746e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.6086005568504333

Also O 0 9.338666586700128e-07
the O 0 1.9871146150762797e-07
fathers O 0 2.4017091959649406e-07
of O 0 6.977118971462914e-08
the O 0 1.0233825520344908e-07
reported O 0 1.935947580022912e-07
congenitally O 0 0.008559090085327625
affected O 0 1.9521772287589556e-07
children O 0 2.0167902903267532e-08
showed O 0 1.2305909180554409e-08
, O 0 8.064761081172378e-10
on O 0 1.8342012353400605e-08
average O 0 4.973487843784596e-09
, O 0 8.292704301027243e-10
shorter O 0 1.0921099828919978e-06
CTG O 0 0.0007064315141178668
repeat O 0 7.909895884949947e-07
lengths O 0 1.7064600115190842e-06
and O 0 8.793944461515935e-10
hence O 0 2.7852800066341388e-09
less O 0 5.713952644370579e-10
severe O 0 1.0554131790740939e-07
clinical O 0 4.277566034716074e-08
symptoms O 0 7.018844172534955e-08
than O 0 1.0155759566643496e-10
the O 0 2.967257328734263e-09
mothers O 0 1.0878761086408062e-10
of O 0 9.50771752994406e-11
children O 0 8.728284761616578e-11
with O 0 1.9929886629910243e-09
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9994339346885681

We O 0 6.581718992038077e-08
conclude O 0 6.001668850785791e-08
that O 0 2.7049756878838593e-10
paternal O 0 9.551724815537455e-07
transmission O 0 1.2154676369391382e-05
of O 0 9.158589818980545e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 3.862834273604676e-05
rare O 0 1.3036056145665498e-07
and O 0 8.38804026237483e-10
preferentially O 0 1.2376046854001288e-09
occurs O 0 2.3273873106521847e-10
with O 0 2.2357164730646417e-11
onset O 0 2.200228118454106e-05
of O 0 2.3329028408625163e-05
DM B-Disease 1 1.0
past O 0 1.0031442343461094e-06
30 O 0 3.918535718128169e-09
years O 0 1.6205967123816833e-10
in O 0 4.068524336875434e-11
the O 0 4.5573853024727384e-10
father O 0 7.861074458048734e-09
. O 0 1.3393852693610597e-09
. O 0 1.64831206461713e-08

The O 0 3.2262341846944764e-06
RB1 O 0 7.743384048808366e-05
gene O 0 2.3931850279268474e-08
mutation O 0 5.661654700617191e-09
in O 0 5.63816993093269e-10
a O 0 3.90144272444104e-09
child O 0 7.2970507858372e-08
with O 0 1.0787344706386648e-07
ectopic B-Disease 1 0.9999624490737915
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.00014931011537555605

The O 0 1.178154161607381e-05
RB1 O 0 0.00012015527317998931
gene O 0 6.859640677703283e-08
mutation O 0 6.7465166786462305e-09
was O 0 1.0184749932307113e-08
investigated O 0 5.8721396634098255e-09
in O 0 1.0841068043276891e-09
a O 0 2.6635854410983484e-08
child O 0 1.0138176094187656e-06
with O 0 1.0107963532846043e-07
ectopic B-Disease 0 0.4971410930156708
intracranial I-Disease 1 0.9999890327453613
retinoblastoma I-Disease 0 6.265161937335506e-05
using O 0 4.941735021191107e-09
DNA O 0 8.515230298655752e-09
obtained O 0 1.371558644436277e-09
from O 0 9.905947173649565e-10
both O 0 4.6219542082504006e-10
the O 0 4.399466035920341e-08
pineal B-Disease 1 0.8029228448867798
and I-Disease 0 2.011614128605288e-07
retinal I-Disease 1 0.9995619654655457
tumours I-Disease 1 1.0
of O 0 0.0003908737562596798
the O 0 1.827161031542346e-05
patient O 0 7.891099085099995e-05
. O 0 4.792003664988442e-07

A O 0 3.487434150883928e-05
nonsense O 0 6.063686669222079e-06
mutation O 0 7.655722811250598e-08
in O 0 1.2830482454262437e-08
exon O 0 3.126491776583862e-07
17 O 0 3.034151063729951e-08
( O 0 2.3453949893337267e-10
codon O 0 2.018644362777877e-09
556 O 0 1.0769353409045834e-08
) O 0 3.179893015570201e-10
of O 0 1.4717208784986724e-08
the O 0 5.58234944492142e-07
RB1 O 0 0.0002508041507098824
gene O 0 6.98193787229684e-08
was O 0 1.6350394105302257e-07
found O 0 1.0146334883387453e-09
to O 0 2.310760055523886e-10
be O 0 2.709638902143041e-10
present O 0 3.3859555159665433e-09
homozygously O 0 1.736971512400487e-06
in O 0 1.3736163317901173e-09
both O 0 7.360014819823846e-10
the O 0 1.0591757693134696e-08
retinal B-Disease 0 5.140749181009596e-06
and I-Disease 0 2.432370820315555e-07
the I-Disease 0 2.0591704014805146e-05
pineal I-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 4.9980739277089015e-05

The O 0 2.6606917344906833e-06
same O 0 8.047942401390173e-08
mutation O 0 3.6311263329480425e-08
was O 0 3.757446975782841e-08
present O 0 5.073109488051841e-09
heterozygously O 0 1.493163722443569e-06
in O 0 3.2502909252940526e-09
the O 0 6.5390728387626496e-09
DNA O 0 3.5285495414427714e-08
from O 0 3.2985549847097673e-09
the O 0 7.472158003452023e-09
constitutional O 0 4.188665769788713e-08
cells O 0 2.1771585423380202e-08
of O 0 4.366594552607239e-08
the O 0 2.7407976332938233e-08
patient O 0 5.655818569039184e-08
, O 0 2.437401946941975e-10
proving O 0 1.1692296020271442e-08
it O 0 1.2468089061190568e-10
to O 0 2.1692930785022213e-10
be O 0 3.1197508465474755e-10
of O 0 1.0064443500823472e-08
germline O 0 2.0164333136563073e-07
origin O 0 2.170983925964265e-08
. O 0 1.0755070434242953e-07

The O 0 9.835165428739856e-07
initial O 0 1.6399805247147015e-07
mutation O 0 2.2090828721843536e-08
was O 0 3.868706244247733e-08
shown O 0 7.236516386122105e-10
to O 0 3.841906792700911e-10
have O 0 2.0585123883254397e-10
occurred O 0 1.1554644352429477e-08
in O 0 3.295874129172205e-10
the O 0 2.707000623658473e-09
paternally O 0 1.4976316720094474e-07
derived O 0 1.6909163491618528e-07
RB1 O 0 0.00016103028610814363
allele O 0 1.1432754263296374e-06
. O 0 2.488476695816644e-07

The O 0 2.9656630431418307e-06
mutation O 0 7.312851124652298e-08
is O 0 1.4298013883973226e-09
in O 0 5.683605253103963e-10
an O 0 7.203269924982436e-11
area O 0 2.5416144744383473e-09
of O 0 4.251275331768056e-09
the O 0 5.304843675446591e-09
gene O 0 3.531319681115974e-10
that O 0 1.5161677469066603e-10
encodes O 0 6.489295767408976e-10
the O 0 3.1807561029495446e-09
protein O 0 3.932799863548553e-09
- O 0 9.342826068348131e-09
binding O 0 2.6296980593087937e-08
region O 0 6.854793923594116e-07
known O 0 5.563765171245905e-06
as O 0 1.3363816719902388e-07
the O 0 8.94430201014984e-08
pocket O 0 5.9963702369714156e-05
region O 0 4.194922382794175e-07
and O 0 4.0457795336124036e-08
has O 0 5.699693494953806e-10
been O 0 4.078938298235357e-10
detected O 0 1.1191858551029554e-09
in O 0 1.9082979987872228e-11
other O 0 1.0177005939360217e-11
cases O 0 9.679479440194427e-11
of O 0 1.715445208105848e-08
retinoblastoma B-Disease 0 3.13025557261426e-05
. O 0 9.725276584049425e-08
. O 0 5.156965130481694e-07

Low O 0 4.945097680320032e-05
levels O 0 3.8880921238160226e-07
of O 0 1.5415626819503814e-07
beta O 0 9.344465752292308e-07
hexosaminidase O 0 1.677870955063554e-06
A O 0 4.160836297728565e-08
in O 0 6.776743610714675e-10
healthy O 0 2.755371764084913e-10
individuals O 0 1.1085318860765137e-12
with O 0 3.423846275940612e-11
apparent O 0 2.526452362872078e-06
deficiency O 1 0.9624723792076111
of O 0 5.450849494081922e-05
this O 0 1.032700396308428e-07
enzyme O 0 8.467034149362007e-07
. O 0 7.099155396872447e-08

Appreciable O 0 0.00011573158553801477
beta O 0 3.2785766961751506e-05
hexosaminidase O 0 6.481531454483047e-05
A O 0 1.3458154171530623e-05
( O 0 2.865627912740365e-08
hex O 0 2.182065600209171e-06
A O 0 2.5452845875406638e-06
) O 0 3.089216216167756e-09
activity O 0 2.5332997921623246e-09
has O 0 8.150120023309171e-10
been O 0 1.47751688661657e-09
detected O 0 3.863817354954335e-08
in O 0 3.573588314154108e-09
cultured O 0 3.762359881420707e-07
skin O 0 5.279322067508474e-06
fibroblasts O 0 3.7724018397966574e-07
and O 0 1.4796758307511482e-07
melanoma B-Disease 1 0.9999998807907104
tissue O 0 0.0001367034128634259
from O 0 2.424138187961944e-07
healthy O 0 2.5602799880175553e-08
individuals O 0 2.7884984252213307e-11
previously O 0 1.131446225599575e-08
reported O 0 5.019737958633641e-09
as O 0 8.090617953371293e-09
having O 0 1.8625905795488507e-07
deficiency B-Disease 1 0.9999566078186035
of I-Disease 1 0.5259971022605896
hex I-Disease 0 0.00044922399683855474
A I-Disease 0 2.48918195211445e-06
activity O 0 4.768200501104047e-09
indistinguishable O 0 1.5557215515826783e-09
from O 0 4.6091516020529966e-11
that O 0 1.1461509909563294e-12
of O 0 1.0818258094902333e-10
patients O 0 2.2878107741597375e-10
with O 0 5.123082758018427e-08
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 4.082874056621222e-07
TSD B-Disease 1 0.9981583952903748
) O 0 1.1474421057755535e-07
. O 0 3.782355406656279e-07

Identification O 0 2.0239638161001494e-06
and O 0 3.979836549206084e-07
quantitation O 0 0.46056655049324036
of O 0 0.0007713583181612194
hex O 0 0.00017786397074814886
A O 0 4.628161605069181e-06
, O 0 1.8469156204403703e-09
amounting O 0 9.863117433894786e-09
to O 0 2.497253070998795e-08
3 O 0 1.0553421816439368e-06
. O 0 1.798731830149336e-07

5 O 0 4.719110620499123e-06
% O 0 1.4706915862916503e-07
- O 0 7.504426093873917e-07
6 O 0 1.1893196187884314e-06
. O 0 3.354389832566085e-07

9 O 0 3.2498887776455376e-06
% O 0 9.074898166261391e-09
of O 0 2.3975800900188915e-08
total O 0 2.1933166394205728e-09
beta O 0 8.594830092079064e-08
hexosaminidase O 0 1.1451741102064261e-06
activity O 0 8.998199518828187e-09
, O 0 2.731208592621215e-10
has O 0 4.337551845479126e-11
been O 0 1.0077168960398453e-10
obtained O 0 3.76366188215016e-10
by O 0 3.3476554861522345e-10
cellulose O 0 2.8597719392564613e-06
acetate O 0 1.5241856772263418e-06
gel O 0 5.472811608342454e-07
electrophoresis O 0 3.1188383786684426e-07
, O 0 9.127688826993108e-09
DEAE O 0 1.9935348973376676e-05
- O 0 4.50744039426354e-07
cellulose O 0 8.657663784106262e-06
ion O 0 5.936761908742483e-07
- O 0 2.2429514956456842e-07
exchange O 0 6.813271369310314e-08
chromatography O 0 4.217997116029437e-07
, O 0 1.0635763381117158e-09
radial O 0 1.0413599227376835e-07
immunodiffusion O 0 1.7939555618795566e-06
, O 0 1.4763787969940267e-09
and O 0 8.281059393766554e-09
radioimmunoassay O 0 1.8199352780357003e-05
. O 0 6.726025958414539e-07

Previous O 0 0.00030905293533578515
family O 0 3.0258229344326537e-06
studies O 0 7.398752721599067e-09
suggested O 0 2.0566610636763016e-09
that O 0 2.935931012193471e-11
these O 0 3.131559248026328e-11
individuals O 0 4.026709955057273e-12
may O 0 3.0028571296192297e-10
be O 0 5.620218179736014e-10
compound O 0 6.91204320446559e-08
heterozygotes O 0 1.3075408311635783e-08
for O 0 1.0602222433320208e-09
the O 0 1.0341190126439415e-08
common O 0 9.19519322906126e-08
mutant O 0 3.5311018109496217e-07
TSD B-Disease 0 2.3406839773087995e-06
gene O 0 8.613042723482067e-09
and O 0 2.3025910067531186e-09
a O 0 1.2108724689596784e-08
rare O 0 2.3584965092027232e-08
( O 0 7.104892230103133e-10
allelic O 0 1.0794013149961756e-07
) O 0 1.401111893173379e-09
mutant O 0 5.590000995425726e-08
gene O 0 2.1596141763779997e-08
. O 0 5.383824230875689e-08

Thus O 0 1.2532066193671199e-06
, O 0 1.479144540184052e-08
the O 0 1.691964079952868e-08
postulated O 0 4.413148815274326e-07
rate O 0 2.3014418815137105e-08
mutant O 0 3.9266254248104815e-08
gene O 0 1.6156656013066595e-09
appears O 0 2.349914263177766e-09
to O 0 2.8902111259831997e-10
code O 0 4.941657638646291e-10
for O 0 9.730254102446878e-11
the O 0 5.321521556744813e-10
expression O 0 1.595553827948848e-10
of O 0 6.053605394740202e-10
low O 0 6.11884809487151e-09
amounts O 0 1.1011768163982083e-09
of O 0 6.8347971726723245e-09
hex O 0 7.252869522744732e-07
A O 0 1.349715262222162e-06
. O 0 4.171839123046084e-07

Heterozygotes O 0 0.0002526786702219397
for O 0 1.276396460525575e-06
the O 0 3.983162059739698e-06
rare O 0 2.4144694634742336e-06
mutant O 0 4.6864283831382636e-07
may O 0 5.673556291441173e-09
be O 0 6.015806186532302e-10
indistinguishable O 0 6.790824347291391e-09
from O 0 3.193556807890019e-10
heterozygotes O 0 1.475611011159117e-08
for O 0 8.5075635425369e-10
the O 0 4.479328907791569e-08
common O 0 4.686286501964787e-06
TSD B-Disease 0 0.002247026888653636
mutant O 0 5.40728524356382e-06
. O 0 2.436461556953873e-07

However O 0 5.509568836714607e-07
, O 0 3.386213753842071e-09
direct O 0 1.3183365510371914e-08
visualization O 0 2.580740101620904e-06
and O 0 8.283621610871705e-08
quantitation O 1 0.9994983673095703
of O 0 0.28591153025627136
hex O 0 0.00019928609253838658
A O 0 1.9095789411949227e-06
by O 0 1.2271237359584575e-09
the O 0 3.6591221164172794e-09
methods O 0 1.2789387326961332e-08
described O 0 2.1717283527067366e-09
may O 0 6.461407520141904e-10
prevent O 0 3.4741340915189767e-09
false O 0 2.0007442813607668e-08
- O 0 1.4901599953986988e-08
positive O 0 1.180148756496635e-10
prenatal O 0 1.4220297828160255e-07
diagnosis O 0 1.5996255342543009e-06
of O 0 1.9431092823651852e-07
TSD B-Disease 0 0.002094473224133253
in O 0 8.419576857932043e-08
fetuses O 0 2.956438720502774e-07
having O 0 8.65630678248408e-09
the O 0 1.5405413478219998e-07
incomplete O 0 4.166545841144398e-05
hex B-Disease 0 0.0007569232257083058
A I-Disease 0 7.055054447846487e-05
deficiency I-Disease 1 0.9999405145645142
of O 0 0.3525502681732178
the O 0 1.1478758096927777e-05
type O 0 9.217525985150132e-06
described O 0 1.3879390792226332e-07
in O 0 2.769821039194653e-09
the O 0 4.123286245771851e-08
four O 0 2.8714932653883807e-08
healthy O 0 5.308337946985375e-08
individuals O 0 1.5615194470797178e-08

The O 0 1.3285834938869812e-05
tumor B-Disease 0 6.442844460252672e-05
suppressor O 0 2.2802389139542356e-05
gene O 0 2.885772119043395e-07
Smad4 O 0 4.792763866134919e-05
/ O 0 7.366520094365114e-06
Dpc4 O 0 3.679339670270565e-06
is O 0 4.724823865487338e-10
required O 0 3.748874266573665e-10
for O 0 1.950388323068708e-10
gastrulation O 0 1.729117968807259e-07
and O 0 1.4862676644966655e-09
later O 0 1.1969389035471067e-08
for O 0 3.240941404136777e-10
anterior O 0 2.6558983901026068e-09
development O 0 1.281492689741981e-08
of O 0 1.6655070211868406e-08
the O 0 6.921845852048136e-08
mouse O 0 7.839879572202335e-07
embryo O 0 1.979216648351212e-07
. O 0 6.714977018873469e-08

Mutations O 0 9.234183266926266e-07
in O 0 8.965378839320692e-08
the O 0 4.2230405483678624e-07
SMAD4 O 1 0.5361570715904236
/ O 0 0.00017900798411574215
DPC4 O 0 0.0007480503991246223
tumor B-Disease 0 5.446130217023892e-06
suppressor O 0 8.145851211338595e-07
gene O 0 4.700153599657142e-09
, O 0 4.4397385767780406e-10
a O 0 9.707944670367397e-09
key O 0 5.711637641070411e-06
signal O 0 8.036318467929959e-05
transducer O 0 1.919304850162007e-06
in O 0 3.1985834425540816e-08
most O 0 8.925842287510477e-09
TGFbeta O 0 4.3852087401319295e-06
- O 0 9.635873965407882e-08
related O 0 2.045052127641611e-08
pathways O 0 2.3809603177937788e-08
, O 0 1.3724966475836542e-11
are O 0 6.860879594484948e-13
involved O 0 1.2032569385311831e-11
in O 0 8.41539060658647e-11
50 O 0 2.839297963408427e-10
% O 0 1.036027708067877e-09
of O 0 5.756027121606166e-07
pancreatic B-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 3.465318513917737e-05

Homozygous O 0 0.00028349633794277906
Smad4 O 0 0.003071863204240799
mutant O 0 2.9337799787754193e-05
mice O 0 1.4462858644037624e-06
die O 0 3.194931537109369e-07
before O 0 8.783140970081149e-08
day O 0 2.779052579171548e-07
7 O 0 5.260041007204563e-07
. O 0 1.0577730336081004e-07

5 O 0 2.3247998797160108e-06
of O 0 6.641518552896741e-07
embryogenesis O 0 3.3350388548569754e-05
. O 0 1.648059537728841e-06

Mutant O 0 2.6954952772939578e-05
embryos O 0 8.397843203056254e-07
have O 0 4.1219552215920885e-09
reduced O 0 1.5697255051350112e-08
size O 0 2.5483437582352053e-08
, O 0 7.274684188374181e-10
fail O 0 2.5925308122509705e-08
to O 0 1.1109068331904837e-08
gastrulate O 0 1.0075852515001316e-05
or O 0 1.9542182982945633e-08
express O 0 4.046595947215792e-09
a O 0 1.50272927434969e-09
mesodermal O 0 2.8825130016230105e-07
marker O 0 3.0720786980964476e-07
, O 0 1.92516047547997e-09
and O 0 4.1999759226030164e-09
show O 0 1.5584488366471305e-08
abnormal O 0 1.3270503806950273e-08
visceral O 0 1.1969705155934207e-06
endoderm O 0 0.0023410075809806585
development O 0 4.434751645021606e-06
. O 0 1.7941233920737432e-07

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 1 0.7146614193916321
the O 0 0.0002237595763290301
Smad4 O 1 0.9997521042823792
- O 0 0.0008586342446506023
deficient O 0 0.00017471134196966887
embryos O 0 1.4453604535447084e-07
results O 0 7.192235695896443e-10
from O 0 1.1301861668755464e-09
reduced O 0 1.5035098499538435e-08
cell O 0 1.804577038910793e-07
proliferation O 0 6.966863530522005e-09
rather O 0 2.0262348743305125e-10
than O 0 7.363563231388426e-11
increased O 0 1.6786714240879519e-09
apoptosis O 0 3.220131077341648e-07
. O 0 4.981322376806929e-08

Aggregation O 0 1.1887042091984767e-05
of O 0 7.068133072607452e-06
mutant O 0 6.1592045312863775e-06
Smad4 O 0 7.065867248456925e-05
ES O 0 4.780045401275856e-06
cells O 0 1.1492902629584023e-08
with O 0 5.592437068990819e-10
wild O 0 3.202514875511042e-08
- O 0 8.392269101875627e-09
type O 0 1.4697647543471248e-07
tetraploid O 0 2.7560674425330944e-05
morulae O 0 3.788462345255539e-05
rescues O 0 2.344602535231388e-06
the O 0 1.0526829896662093e-07
gastrulation B-Disease 0 8.474644710076973e-05
defect I-Disease 0 4.145480852457695e-05
. O 0 4.616078399521939e-07

These O 0 1.2275474148282228e-07
results O 0 4.716410373362123e-08
indicate O 0 3.778281154609431e-08
that O 0 1.799650206635306e-09
Smad4 O 0 3.887460934492992e-06
is O 0 1.0065590583252515e-09
initially O 0 1.0913452364036402e-09
required O 0 3.027361417107244e-10
for O 0 1.8062656925721399e-10
the O 0 1.0004571615596092e-09
differentiation O 0 2.3319339792493565e-09
of O 0 1.7607204583214298e-08
the O 0 1.9519756477848205e-08
visceral O 0 7.20695595646248e-07
endoderm O 0 0.00011188371718162671
and O 0 7.635478915801741e-09
that O 0 2.581893865372109e-10
the O 0 9.767937569904461e-09
gastrulation B-Disease 0 1.3016058346693171e-06
defect I-Disease 0 4.769540282723028e-07
in O 0 4.2111656384236085e-09
the O 0 6.763577431456724e-08
epiblast O 0 3.908772487193346e-05
is O 0 1.626986989577972e-09
secondary O 0 3.803914339073344e-08
and O 0 3.712571805536413e-09
non O 0 6.287092446655151e-08
- O 0 2.496651632100111e-06
cell O 0 9.73715286818333e-05
autonomous O 0 3.839680857709027e-07
. O 0 2.405032830665732e-07

Rescued O 0 0.0022619436495006084
embryos O 0 1.7555150407133624e-05
show O 0 3.448402878802881e-07
severe O 0 4.469414307095576e-06
anterior O 0 9.215495083481073e-06
truncations O 1 0.9997730851173401
, O 0 5.3652286169381114e-08
indicating O 0 8.818879138061675e-08
a O 0 1.4632489353516576e-07
second O 0 8.78953187566367e-07
important O 0 1.0029589248006232e-07
role O 0 7.195782814051199e-08
for O 0 2.1770961922129572e-08
Smad4 O 0 0.0010162488324567676
in O 0 1.6382485057420126e-07
anterior O 0 1.4867843674437609e-05
patterning O 0 0.0002546495234128088
during O 0 4.636518860934302e-05
embryogenesis O 0 7.715052197454497e-05
. O 0 7.561811798950657e-07

Prevalence O 0 1.5935585906845517e-05
of O 0 8.476228572362743e-07
p16 O 0 7.142365348045132e-07
and O 0 8.461321243657949e-08
CDK4 O 0 0.008177426643669605
germline O 0 3.8077429053373635e-05
mutations O 0 4.634653549828727e-08
in O 0 1.1311916736644889e-08
48 O 0 5.110054530632624e-07
melanoma B-Disease 1 1.0
- O 0 0.0008575529209338129
prone O 0 0.00021670020942110568
families O 0 4.231796779663455e-08
in O 0 1.498574064839886e-08
France O 0 2.096874567314444e-07
. O 0 5.577688284574833e-07

The O 0 1.1388571692805272e-05
French O 0 5.0475769967306405e-05
Familial B-Disease 1 0.9942494630813599
Melanoma I-Disease 1 1.0
Study O 0 3.6787815815841896e-07
Group O 0 1.9675704621135992e-08
. O 0 4.738357262112913e-08

Germline O 0 0.0004788234073203057
mutations O 0 6.918676831446646e-07
in O 0 4.522199859025022e-08
the O 0 1.308030164182128e-07
p16 O 0 2.515544110792689e-07
and O 0 6.328455270931954e-08
CDK4 O 0 0.000640942482277751
genes O 0 2.9176030480471127e-08
have O 0 1.2756125045143563e-09
been O 0 1.8561363557267896e-09
reported O 0 1.3519541042228411e-09
in O 0 3.4124905679000506e-10
a O 0 5.4947637551094886e-09
subset O 0 3.194900699554637e-08
of O 0 1.6477784470225743e-07
melanoma B-Disease 1 0.9999898672103882
pedigrees O 0 1.379337163598393e-06
, O 0 6.098176408286804e-10
but O 0 1.3684796351665085e-10
their O 0 3.9502615067910085e-10
prevalence O 0 9.673121859066214e-09
is O 0 6.66661378878608e-11
not O 0 4.9314295702540534e-11
well O 0 8.486235603122338e-10
known O 0 2.694330092367636e-08
. O 0 6.313553768677593e-08

We O 0 4.291302957426524e-07
searched O 0 5.135243554832414e-07
for O 0 2.9523197220271413e-09
such O 0 7.900244902714348e-09
germline O 0 5.467351911647711e-06
mutations O 0 9.028855885162557e-08
in O 0 2.7545967284936523e-08
48 O 0 8.759273555369873e-07
French O 0 3.6004021239932626e-05
melanoma B-Disease 1 1.0
- O 1 0.9934116005897522
prone O 0 0.00012555619468912482
families O 0 5.120061707941659e-09
selected O 0 3.232545342513049e-10
according O 0 2.366605245107678e-10
to O 0 1.3007468435688452e-09
two O 0 1.4275615134451414e-09
major O 0 6.309291933348504e-08
criteria O 0 7.346949359998689e-08
families O 0 5.266252323110621e-09
with O 0 1.942689120681962e-09
at O 0 4.0250563415611396e-07
least O 0 2.6409159303852903e-09
three O 0 6.904806504337557e-09
affected O 0 6.56469101301127e-09
members O 0 1.3080315719449231e-09
( O 0 1.0003368133837398e-09
n O 0 1.3406536325533125e-08
= O 0 2.0384307575227467e-09
20 O 0 3.450267016535946e-10
) O 0 1.5551089929677353e-11
or O 0 1.1059141796776473e-10
families O 0 9.423405805675245e-11
with O 0 5.871159114434477e-11
two O 0 4.22538865008093e-10
affected O 0 1.5338826875321843e-09
members O 0 3.4840860752005653e-10
, O 0 1.1180736197990981e-10
one O 0 9.026932673572574e-11
of O 0 1.536090254994349e-09
them O 0 1.1933086463411513e-10
affected O 0 2.9490540565113577e-10
before O 0 8.154446007324623e-09
the O 0 3.927544955928397e-09
age O 0 1.0290933660783708e-09
of O 0 5.837298200361829e-09
50 O 0 6.452983702942561e-10
( O 0 1.146106196059371e-10
n O 0 1.9011865415308193e-09
= O 0 1.3182100966346866e-09
28 O 0 4.393375885314299e-09
) O 0 5.959432253233032e-11
, O 0 5.0691003478098295e-11
and O 0 2.1158023943979032e-10
one O 0 2.393177878090569e-10
additional O 0 2.0137143064147267e-09
minor O 0 1.9493121783398237e-07
criterion O 0 2.5758772608241998e-05
. O 0 5.388774866332824e-07

Sixteen O 0 4.332776825322071e-06
different O 0 6.267325147746305e-08
p16 O 0 4.708437870704074e-07
germline O 0 6.896582362969639e-07
mutations O 0 1.417305939277469e-09
were O 0 1.274819583230169e-09
found O 0 4.368389816544749e-10
in O 0 5.754628440435283e-10
21 O 0 5.447626794108373e-09
families O 0 9.177208437627371e-10
, O 0 2.0256166188836744e-10
while O 0 9.928760036359563e-10
one O 0 1.108394043214389e-09
germline O 0 8.037035570396256e-08
mutation O 0 2.0136143863425104e-09
, O 0 3.468835496622802e-10
Arg24His O 0 7.719402219663607e-07
, O 0 9.31190180519792e-10
was O 0 3.1092692864831406e-08
detected O 0 7.256063305760563e-09
in O 0 9.57790735611752e-10
the O 0 2.8096659221432674e-08
CDK4 O 0 6.36702316114679e-05
gene O 0 2.7352211873221677e-07
. O 0 2.3606844479218125e-07

The O 0 4.3382991066209797e-07
frequency O 0 1.0414035500616592e-07
of O 0 4.865530911501992e-08
p16 O 0 2.165913315366197e-08
gene O 0 2.8004831786887507e-09
mutation O 0 1.2339347321699279e-09
in O 0 7.743860552800186e-10
our O 0 4.977995793353784e-09
sample O 0 8.963524367189279e-10
( O 0 2.1671672789658203e-10
44 O 0 1.9200854239898035e-09
% O 0 4.173828227482801e-10
) O 0 1.6365378496807637e-10
is O 0 9.491302188635586e-11
among O 0 1.2205404742449133e-10
the O 0 2.327472659047203e-09
highest O 0 2.4671942711051997e-08
rates O 0 5.552007742437581e-10
yet O 0 1.3086798311690018e-10
reported O 0 3.733069686706614e-10
and O 0 3.0196109501723356e-10
the O 0 4.0644332344186296e-09
CDK4 O 0 9.428611633666151e-07
mutation O 0 1.2005690885885656e-09
is O 0 7.167035021016233e-11
the O 0 4.522937024908913e-10
second O 0 2.728429482345973e-09
mutation O 0 2.846699820313603e-10
detected O 0 2.486747474605977e-09
in O 0 7.955368308554256e-11
this O 0 3.0982783005839565e-10
gene O 0 3.483044963559223e-09
worldwide O 0 4.7707295891541435e-09
. O 0 5.8460255303316444e-08

In O 0 4.330457556989131e-07
summary O 0 1.5656999039492803e-06
, O 0 1.3361479034301738e-08
our O 0 1.9776045689923194e-08
results O 0 1.5719539003811178e-09
show O 0 5.831597982286496e-10
frequent O 0 3.2229352520118937e-10
involvement O 0 2.1476638245587765e-09
of O 0 5.010659887005886e-09
the O 0 1.0164296071479839e-08
p16 O 0 1.0108383463602877e-08
gene O 0 2.974294810442757e-09
in O 0 1.7835211085781566e-09
familial B-Disease 0 9.718165529193357e-06
melanoma I-Disease 1 0.9999998807907104
and O 0 9.638814901791193e-08
confirm O 0 5.5520665398489655e-08
the O 0 6.533502272532132e-08
role O 0 7.708956673013745e-08
of O 0 7.457424544554669e-07
the O 0 1.2505240647442406e-06
CDK4 O 0 0.0004934868775308132
gene O 0 2.766506845830463e-08
as O 0 9.868668549017912e-09
a O 0 5.418438320248242e-08
melanoma B-Disease 0 0.01572839729487896
- O 0 1.8024151131612598e-06
predisposing O 0 1.5745164319014293e-06
gene O 0 2.84596435307094e-08
. O 0 2.3200721344096564e-08
. O 0 1.0973262476454693e-07

Progression O 0 6.469836080214009e-05
of O 0 1.6724932720535435e-05
somatic O 0 0.0008032144978642464
CTG O 0 9.914128895616159e-05
repeat O 0 1.1854068304728571e-07
length O 0 9.10437147894072e-09
heterogeneity O 0 3.44001307439612e-08
in O 0 3.5907632423004543e-10
the O 0 9.184878968504506e-10
blood O 0 3.419659444503509e-09
cells O 0 2.2785242137501882e-08
of O 0 1.0416797380230491e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.011316405609250069
. O 0 1.2501770925155142e-06

The O 0 4.93593461214914e-07
genetic O 0 1.8995569917024113e-07
basis O 0 6.304432531578641e-08
of O 0 5.476411388372071e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 8.655856072437018e-05
DM B-Disease 1 1.0
) O 0 1.0311686615693816e-08
is O 0 4.707939038617326e-10
the O 0 2.8048665612345758e-09
expansion O 0 1.674435878840086e-07
of O 0 7.117119338317934e-08
an O 0 3.869354170404904e-09
unstable O 0 2.3925199457153212e-06
CTG O 0 4.090687070856802e-06
repeat O 0 2.464447845795803e-08
in O 0 2.639818141858541e-09
the O 0 8.152952979401107e-09
34 O 0 8.050011324201023e-09
UTR O 0 1.3705748642678373e-05
of O 0 4.608736503541877e-08
the O 0 2.2388057629996183e-07
DM B-Disease 1 0.999997615814209
protein O 0 1.3926339192948944e-07
kinase O 0 1.1198167015891158e-07
gene O 0 8.325780620488388e-10
on O 0 3.1214248963351565e-09
chromosome O 0 1.0369632263973472e-08
19 O 0 2.2184861947494028e-08
. O 0 5.7032444544802274e-08

One O 0 4.997719997845707e-07
of O 0 2.1846778963663382e-07
the O 0 3.411608773262742e-08
principal O 0 5.0282782382282676e-08
features O 0 2.8373343674559237e-09
of O 0 4.924669028127937e-08
the O 0 2.3926088488224195e-06
DM B-Disease 1 1.0
mutation O 0 8.973836429504445e-07
is O 0 2.4477924132071394e-09
an O 0 1.3235758322682756e-10
extraordinarily O 0 1.5348961213135226e-08
high O 0 3.71506665430843e-08
level O 0 5.555530435685796e-08
of O 0 3.773671863882555e-08
somatic O 0 4.7836938392720185e-06
mosaicism O 0 6.311570177786052e-05
, O 0 4.126562702655434e-10
due O 0 1.6173068217995024e-08
to O 0 1.4594067065942795e-09
an O 0 2.7465357765876774e-10
extremely O 0 4.3620973499969296e-09
high O 0 5.945155923114953e-09
degree O 0 1.6889590170876545e-08
of O 0 1.1745001415874867e-08
somatic O 0 3.428380637160444e-07
instability O 0 4.84242299592097e-08
both O 0 2.0051281468536075e-10
within O 0 7.307169314074713e-10
and O 0 2.500324669529874e-10
between O 0 2.4280938371035177e-10
different O 0 6.072976566073862e-10
tissues O 0 5.942936240899144e-07
. O 0 1.1172374314583067e-07

This O 0 2.1463315533765126e-06
instability O 0 6.797698006266728e-05
appears O 0 6.314408551588713e-07
to O 0 5.08587927328108e-09
be O 0 1.016723927271812e-09
biased O 0 5.388382628979116e-09
towards O 0 9.397855826875912e-09
further O 0 8.909288307101804e-10
expansion O 0 1.3588754121940383e-08
and O 0 4.706502965134973e-10
continuous O 0 4.717217727545631e-09
throughout O 0 4.697838784650799e-10
the O 0 1.6351532350356024e-09
life O 0 7.776527755076756e-10
of O 0 5.397390867578622e-10
an O 0 9.621769526957369e-12
individual O 0 1.3614722413693436e-12
, O 0 5.8426809397549295e-12
features O 0 7.277539681993517e-11
that O 0 1.8379665844836524e-11
could O 0 4.822968691087226e-10
be O 0 3.1995320282085515e-10
associated O 0 5.346837195219223e-09
with O 0 5.232238531327482e-10
the O 0 1.1001070987504136e-07
progressive O 0 1.5790335510246223e-06
nature O 0 6.951174746916422e-09
of O 0 2.338857285621998e-08
the O 0 1.9563071873562876e-07
disease O 0 1.254556354979286e-05
. O 0 2.225874453642973e-07

Although O 0 3.930439902433136e-07
increasing O 0 7.00720619306594e-08
measured O 0 1.0720089704818747e-07
allele O 0 4.920235330274636e-09
size O 0 1.70646663466556e-09
between O 0 1.4323781050151752e-09
patients O 0 8.964965658719848e-09
clearly O 0 4.035781486777523e-09
correlates O 0 1.2573705632235033e-08
with O 0 3.8516488609641186e-11
an O 0 1.0654350665606493e-11
increased O 0 2.716597606589044e-11
severity O 0 2.419807287878939e-07
of O 0 4.878540948993759e-08
symptoms O 0 9.333636512565135e-07
and O 0 1.7913009964232174e-09
an O 0 8.838737380889583e-11
earlier O 0 7.374727495346178e-10
age O 0 5.078422127269278e-10
of O 0 3.2998197507794202e-09
onset O 0 2.2355932287609903e-06
, O 0 1.5764448080268778e-10
this O 0 2.0909123391033013e-11
correlation O 0 1.3654785635530686e-10
is O 0 2.2049794282108515e-11
not O 0 1.3762688905183396e-11
precise O 0 5.6525584213318325e-09
and O 0 1.9785131311067516e-09
measured O 0 8.46293080059013e-09
allele O 0 1.1406243727307697e-09
length O 0 2.650805963622105e-10
cannot O 0 2.3835569629149234e-10
be O 0 1.062991639155797e-10
used O 0 8.154846797836512e-10
as O 0 3.08708253404788e-10
an O 0 2.068966178936371e-11
accurate O 0 7.561737902506138e-09
predictor O 0 9.282880597538679e-08
of O 0 4.48539694275496e-09
age O 0 9.206386764049057e-09
of O 0 1.2607932831087965e-07
onset O 0 0.22754473984241486
. O 0 1.5738949059596052e-06

In O 0 1.1779757613794573e-07
order O 0 4.307284839910608e-08
to O 0 2.610516691703424e-09
further O 0 3.4202203291755495e-09
characterize O 0 6.837081656385635e-08
the O 0 2.3224362877272142e-08
dynamics O 0 3.5154710076312767e-07
of O 0 4.536074811767321e-06
DM B-Disease 1 1.0
CTG O 0 0.17897704243659973
repeat O 0 1.3526379234463093e-06
somatic O 0 1.9411738321650773e-05
instability O 0 1.3906103504268685e-06
, O 0 9.102804066074555e-10
we O 0 1.5721089707820823e-10
have O 0 7.317710326582016e-11
studied O 0 1.203444122133135e-09
repeat O 0 6.171377853192439e-10
length O 0 2.1128584992702315e-10
changes O 0 5.298265298714355e-11
over O 0 1.477011846162668e-10
time O 0 1.0976847902854914e-10
in O 0 3.538250525902953e-10
111 O 0 2.3404197690979345e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 8.460143163802059e-08
with O 0 1.1177601899614587e-10
varying O 0 4.288461585844061e-09
clinical O 0 8.36044534935354e-07
severity O 0 0.3513930141925812
and O 0 9.21528567232599e-07
CTG O 0 9.043218597071245e-06
repeat O 0 9.627363795061683e-09
size O 0 1.455823017693092e-09
over O 0 2.3990734399070845e-10
time O 0 1.1157111345916348e-10
intervals O 0 9.095892095078995e-11
of O 0 4.974851086636534e-10
1 O 0 7.2742025736260985e-09
- O 0 1.0283560669677172e-08
7 O 0 2.1945522732380596e-08
years O 0 8.397712747409969e-09
. O 0 3.016482352791172e-08

We O 0 9.952248092304217e-07
have O 0 6.352966597233944e-09
found O 0 3.2449514186794204e-09
a O 0 2.6197592983834284e-09
direct O 0 4.549692622646262e-09
progression O 0 3.126038095047079e-08
of O 0 2.964905299052134e-08
the O 0 2.1202726685487505e-08
size O 0 2.8702666909907748e-08
heterogeneity O 0 7.806182367176007e-08
over O 0 3.0719533583578595e-09
time O 0 9.676217604948079e-10
related O 0 1.2449844488671147e-09
to O 0 2.5006312576181244e-09
initial O 0 1.5781951390181348e-07
CTG O 0 7.515400739066536e-06
repeat O 0 2.7570461469395013e-08
size O 0 4.034296008370575e-09
and O 0 7.348904818016422e-10
the O 0 1.027095075656348e-09
time O 0 1.7653761785751954e-10
interval O 0 9.594491867659372e-10
and O 0 1.0678973677569203e-10
always O 0 2.195508774782695e-10
biased O 0 5.287708049195317e-10
towards O 0 1.4709118367761675e-09
further O 0 1.5971044486917663e-09
expansion O 0 6.003180175184752e-08
. O 0 3.269343196166119e-08

Attempts O 0 1.3933162335888483e-05
to O 0 7.008583224887843e-08
mathematically O 0 2.3903365331534587e-07
model O 0 7.891332387544026e-08
the O 0 1.1885923356658168e-07
dynamics O 0 5.824622348882258e-07
have O 0 9.822922919511257e-09
proved O 0 1.03356103409169e-06
only O 0 3.7520311302330356e-09
partially O 0 3.432534612102245e-08
successful O 0 5.3401416622023135e-09
suggesting O 0 7.579350480568792e-10
that O 0 8.510248929172182e-12
individual O 0 1.7633787225551645e-12
specific O 0 4.2550189066625776e-11
genetic O 0 1.2791947945345328e-08
and O 0 3.882187460391151e-09
/ O 0 2.335170165679301e-06
or O 0 6.152015430416213e-08
environmental O 0 2.1913425030106737e-07
factors O 0 4.652613405653483e-09
also O 0 7.272727975404791e-10
play O 0 2.0353927432381624e-09
a O 0 2.563210310668751e-09
role O 0 7.279156832851186e-09
in O 0 2.320265313215941e-09
somatic O 0 4.799609882866207e-07
mosaicism O 0 1.8570066458778456e-05
. O 0 2.2223868967330418e-08
. O 0 7.175566452133353e-08

Aspartylglucosaminuria B-Disease 1 1.0
among O 0 1.4422722642848385e-06
Palestinian O 0 1.117728061217349e-05
Arabs O 0 3.5221391954110004e-06
. O 0 7.494469969060447e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 0 0.23705093562602997
AGU B-Disease 1 1.0
) O 0 7.732768381174537e-08
is O 0 4.227454386551699e-09
a O 0 3.5949060617213036e-08
rare O 0 5.396762935561128e-05
disorder B-Disease 1 1.0
of I-Disease 1 1.0
glycoprotein I-Disease 1 1.0
metabolism I-Disease 1 0.9999990463256836
caused O 0 1.5935579540382605e-06
by O 0 1.047494646577718e-09
the O 0 9.40546897254535e-07
deficiency B-Disease 1 0.9429160952568054
of I-Disease 0 0.0029270281083881855
the I-Disease 0 5.029332896810956e-05
lysosomal I-Disease 0 0.00015075589180923998
enzyme I-Disease 0 1.5296900812700187e-07
aspartylglucosaminidase I-Disease 0 1.2578786936501274e-06
( O 0 1.8601233886528235e-09
AGA O 0 4.382856059237383e-05
) O 0 6.35271257820591e-09
. O 0 5.068837083399558e-08

AGU B-Disease 1 1.0
is O 0 2.1235687199805398e-06
inherited O 1 0.8790102005004883
as O 0 5.788152748209541e-07
an O 0 1.1145296241465985e-08
autosomal O 0 0.0003983311471529305
recessive O 0 0.000475849024951458
trait O 0 0.00012480549048632383
and O 0 5.649962986353785e-07
occurs O 0 1.0145880224854409e-07
with O 0 1.065724730686668e-09
a O 0 5.2753126311699816e-08
high O 0 1.6831082803037134e-06
frequency O 0 1.1863126303524041e-07
in O 0 1.3618223215772218e-09
Finland O 0 1.6615939735231677e-09
because O 0 3.730727948791923e-10
of O 0 1.0674829908907668e-08
a O 0 2.0805241973675948e-08
founder O 0 2.0169062509012292e-07
effect O 0 1.869475241278451e-08
. O 0 6.984348743799274e-08

While O 0 4.3496129364939407e-07
very O 0 2.9643739907214695e-08
few O 0 2.2250970843629148e-08
patients O 0 3.905420342675825e-08
with O 0 5.2602317168748414e-08
AGU B-Disease 1 1.0
have O 0 1.4731327837580466e-06
been O 0 6.474343194895482e-08
reported O 0 5.871590769146451e-09
from O 0 1.999591381363075e-09
non O 0 1.7738532420707998e-08
- O 0 1.3961266809303652e-08
Finnish O 0 3.874060894304421e-07
origin O 0 2.60574246624401e-08
, O 0 2.1413075756981925e-09
we O 0 2.1415442752470426e-09
diagnosed O 0 3.5532557376427576e-05
the O 0 3.1435246228284086e-07
disorder O 0 1.3781505003862549e-05
in O 0 1.0333462086009604e-08
8 O 0 2.5312870022276002e-08
patients O 0 2.1326702626112137e-09
originating O 0 5.535325087180354e-09
from O 0 4.5288896188822036e-08
3 O 0 2.570080539499031e-07
unrelated O 0 5.75534784275078e-08
families O 0 1.4120712377163613e-09
, O 0 1.5753236215498845e-10
all O 0 1.078800937470703e-10
Palestinian O 0 2.2492658402484267e-08
Arabs O 0 6.509456529357749e-09
from O 0 9.73857772201825e-10
the O 0 1.1986448500422853e-09
region O 0 9.739896666971504e-10
of O 0 5.2414206308526445e-09
Jerusalem O 0 9.24998573736957e-07
. O 0 1.0309408793318653e-07

The O 0 9.35832531467895e-07
clinical O 0 1.3141901945346035e-05
diagnosis O 1 1.0
of O 1 1.0
AGU B-Disease 1 1.0
is O 0 1.1610131878114771e-05
often O 0 1.0681224793529509e-08
difficult O 0 8.396852280156963e-08
, O 0 3.4311303798162385e-10
in O 0 2.7304689065310583e-10
particular O 0 4.427191946376752e-09
early O 0 8.465499945486954e-07
in O 0 1.564917639917951e-09
the O 0 2.2350024053707784e-09
course O 0 4.557648480840726e-09
of O 0 1.750974143455153e-09
the O 0 2.1870087962838625e-09
disease O 0 1.192886998069298e-07
, O 0 3.057932032590749e-11
and O 0 1.8626646058894636e-10
most O 0 6.974438249152115e-10
of O 0 4.7367397115749554e-08
the O 0 2.22170513097808e-07
patients O 0 1.803334548355906e-08
are O 0 1.7926399253909153e-10
diagnosed O 0 2.3765258561070368e-07
after O 0 6.076098912899397e-08
the O 0 3.4980864427325287e-08
age O 0 6.408560793147444e-09
of O 0 5.4691287942887357e-08
5 O 0 4.436289202658372e-08
years O 0 2.1176699505076613e-08
. O 0 6.449199929647875e-08

However O 0 6.717333462802344e-07
, O 0 6.049084344539324e-09
since O 0 3.1594726834782705e-09
these O 0 5.216861942436424e-10
patients O 0 5.977606853946327e-09
excrete O 0 1.723934559549889e-07
early O 0 5.933139846092672e-08
large O 0 1.0049016063717886e-09
amounts O 0 1.6619395859507335e-09
of O 0 3.245002488938553e-08
aspartylglucosamine O 0 3.2514014947082615e-06
in O 0 7.769964227577475e-09
urine O 0 1.0534176198007117e-08
, O 0 1.6057570551009093e-10
biochemical O 0 1.2568047935701543e-08
screening O 0 5.2702542774341055e-08
is O 0 5.5006749155595e-10
easy O 0 3.0650824101030594e-09
by O 0 1.4440522388969868e-10
urine O 0 5.970861138848704e-09
chromatography O 0 1.0323753940610914e-07
. O 0 1.546795758144981e-08
. O 0 7.441752813974745e-08

Detection O 0 6.364084401866421e-05
of O 0 2.074404392260476e-06
heterozygous O 0 1.660891335575343e-08
carriers O 0 2.125401632468993e-09
of O 0 2.616819294587458e-08
the O 0 5.243930900178384e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 8.018613470994751e-07
ATM O 0 3.001812046932173e-06
) O 0 4.258016994551639e-10
gene O 0 3.3449684688768855e-10
by O 0 2.7466037777479357e-10
G2 O 0 9.224104928762245e-07
phase O 0 3.7129814245417947e-07
chromosomal O 0 6.595970489797764e-07
radiosensitivity O 0 8.789137382336776e-07
of O 0 1.04101829379033e-07
peripheral O 0 0.00045848285662941635
blood O 0 1.041840914695058e-05
lymphocytes O 0 2.5636670670792228e-06
. O 0 2.906478755448916e-07

In O 0 0.00011430327867856249
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999927282333374
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.5357334720865765e-07
patients O 0 1.0610572189762024e-06
, O 0 7.785357913903113e-10
mutations O 0 3.678707338750087e-10
in O 0 7.040705796157454e-10
a O 0 4.569817413369037e-09
single O 0 1.8246464339455315e-09
gene O 0 4.1719735999201646e-10
, O 0 2.860975865937032e-11
ATM O 0 6.203575431129593e-09
, O 0 3.3964935898522786e-12
result O 0 1.0271376804649179e-10
in O 0 1.7303303234683653e-09
an O 0 5.4276132033237445e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 9.502634270575072e-07
embraces O 0 5.369532800614252e-07
a O 0 7.822425374115483e-09
variety O 0 1.0192406918463348e-08
of O 0 1.0603465483427499e-07
clinical O 0 2.784511480058427e-06
features O 0 2.0189320366625907e-06
and O 0 3.1143829914981325e-07
manifests O 0 1.371527332594269e-06
extreme O 0 0.0008962246938608587
radiosensitivity O 0 0.00063446129206568
and O 0 1.2962466655608296e-07
a O 0 9.182014792941118e-08
strong O 0 1.0375909198501176e-07
pre O 0 0.0003000067954417318
- O 0 5.440715540316887e-06
disposition O 0 3.286555875092745e-05
to O 0 1.9060607314713707e-07
malignancy B-Disease 1 0.9740476012229919
. O 0 6.581066145372461e-07

Heterozygotes O 0 3.088172888965346e-05
for O 0 2.1470100364240352e-07
the O 0 5.136585059517529e-07
ATM O 0 4.579715550789842e-06
gene O 0 2.965651901831734e-08
have O 0 8.114629523880978e-10
no O 0 8.096139869628871e-10
clinical O 0 6.6545515764460106e-09
expression O 0 2.3645532198912633e-09
of O 0 6.177926366035535e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 1.390026049818971e-08
may O 0 9.141434276216387e-09
be O 0 3.3662443943427434e-09
cancer B-Disease 0 2.1534297047764994e-06
prone O 0 3.578528406933401e-08
with O 0 2.549264688234132e-10
a O 0 2.4089526817760998e-08
moderate O 0 5.444699695544841e-07
increase O 0 2.0378243537066965e-09
in O 0 1.7188645173860095e-08
in O 0 3.241525803332479e-08
vitro O 0 2.290799102411256e-06
radiosensitivity O 0 1.2028456694679335e-05
. O 0 2.5151388172162115e-07

We O 0 2.240485400761827e-06
performed O 0 1.4357290183397708e-06
a O 0 2.004014163503598e-07
blind O 0 5.75461683638423e-07
chromosomal O 0 3.050631676160265e-07
analysis O 0 4.3514795322607824e-08
on O 0 1.2900743229238287e-07
G2 O 0 7.113718538676039e-07
- O 0 3.548303695311006e-08
phase O 0 1.1327553295359394e-07
lymphocytes O 0 9.309758297604276e-09
from O 0 3.6762122235245442e-09
7 O 0 1.6745532960271703e-08
unrelated O 0 4.816465093426814e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 3.379916051926557e-06
, O 0 1.8599745077452212e-09
13 O 0 8.89642048917949e-09
obligate O 0 6.964806686937663e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 4.938938218401745e-05
( O 0 5.937653924092956e-09
parents O 0 1.1495835394725873e-09
of O 0 7.100628529599362e-09
the O 0 9.556161195689583e-09
patients O 0 5.504600664174575e-10
) O 0 4.2624598295404326e-11
, O 0 4.507966222533355e-11
and O 0 7.736892793097638e-10
14 O 0 8.500073533923569e-09
normal O 0 2.4717680346952875e-08
controls O 0 3.566753292716385e-08
following O 0 9.425823677133849e-09
X O 0 2.5011390789586585e-06
- O 0 7.092090470450785e-08
irradiation O 0 2.849533586868347e-07
with O 0 1.673840399618598e-09
1 O 0 8.059448219910337e-08
Gy O 0 4.889728643320268e-06
in O 0 2.443182600675442e-10
order O 0 1.2277628913537342e-09
to O 0 5.844826844736417e-10
evaluate O 0 4.754668658790706e-09
this O 0 2.732928050530603e-10
cytogenetic O 0 1.3532580567243713e-07
method O 0 7.928745660024106e-09
as O 0 2.143717425795444e-10
a O 0 3.335144937999246e-10
tool O 0 2.279123112458592e-09
for O 0 6.979092304071344e-11
detection O 0 2.911933449922799e-07
of O 0 1.0451924481458263e-07
ATM O 0 6.3513793975289445e-06
carriers O 0 1.344867115449233e-07
. O 0 2.5486627919235616e-07

Both O 0 7.542644743807614e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 1 0.9988555908203125
and O 0 3.0919889582037285e-07
heterozygotes O 0 1.3556521025748225e-06
showed O 0 5.7643529949302774e-09
significantly O 0 2.6649713547044485e-09
increased O 0 1.1577868663792401e-09
levels O 0 3.3020672862704714e-09
of O 0 7.315708039357105e-09
radiation O 1 0.999880313873291
- O 0 1.038921982399188e-05
induced O 0 2.5546332835801877e-05
chromatid O 0 5.6674285588087514e-05
damage O 0 1.4916259715391789e-05
relative O 0 1.91132500049207e-07
to O 0 7.105732668932774e-10
that O 0 1.6945170266957632e-10
of O 0 7.759626718950585e-09
normal O 0 5.280054082845709e-08
controls O 0 3.2733555599406827e-07
. O 0 6.366251881217977e-08

These O 0 2.4051772129496385e-07
results O 0 8.521652006265867e-08
show O 0 2.034982315990419e-08
that O 0 1.8539106916293235e-09
the O 0 3.3926607301282274e-08
G2 O 0 1.9993454770883545e-05
- O 0 1.0950927844532998e-06
phase O 0 4.944603915646439e-06
chromosomal O 0 7.4568797572283074e-06
radiosensitivity O 0 4.726780844066525e-06
assay O 0 2.0556625202061696e-07
can O 0 3.9318148736811054e-10
be O 0 1.1792981868818941e-10
used O 0 1.6341424047272568e-10
for O 0 4.743748449609342e-11
the O 0 4.714534873606624e-10
detection O 0 4.4081852479394e-07
of O 0 1.9988988242403138e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
heterozygotes O 0 1.2266946214367636e-05
. O 0 7.073946335367509e-07

In O 0 2.8038579102940275e-07
combination O 0 5.742670623476442e-07
with O 0 3.4008094118576082e-09
molecular O 0 5.877576541024609e-07
genetic O 0 1.2795199211268482e-07
analyses O 0 4.038732726030503e-08
, O 0 3.488049016286965e-10
this O 0 1.9153222063916786e-10
test O 0 8.433764797644017e-09
may O 0 1.057683385319308e-09
be O 0 9.211822277199744e-11
of O 0 2.589686243226197e-10
value O 0 9.921712756932877e-11
in O 0 7.995722139941819e-12
studies O 0 1.4300099299147107e-11
of O 0 5.179879303263135e-10
familial B-Disease 0 6.5583606101427e-08
and I-Disease 0 1.2212868050198722e-08
sporadic I-Disease 0 1.2805040796592948e-06
cancers I-Disease 0 0.0024724092800170183
aimed O 0 1.5977975920122844e-07
at O 0 3.7796649365873236e-08
determination O 0 1.2104661273326656e-08
of O 0 1.611271827073324e-08
the O 0 3.291672934224721e-09
potential O 0 2.0745754003570482e-09
involvement O 0 4.191468949699129e-09
of O 0 1.3327017711617373e-08
ATM O 0 9.41229700401891e-07
mutations O 0 2.4394728459498083e-09
in O 0 6.328594315263558e-10
tumor B-Disease 0 6.650594741586247e-07
risk O 0 9.783973631272147e-09
or O 0 6.752232550866211e-09
development O 0 3.777214274691687e-08
. O 0 6.823985376769315e-09
. O 0 7.126165968429632e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 2.1418237849957222e-07
identification O 0 1.6701140737040987e-07
and O 0 1.0515146087186622e-08
detection O 0 0.00482640927657485
of O 0 0.00013591731840278953
founder O 0 0.40491774678230286
- O 0 2.509305204512202e-06
effect O 0 7.927478407054878e-08
mutations O 0 3.991731389874076e-09
in O 0 1.2126931681066822e-09
the O 0 1.9751581703530974e-08
ATM O 0 7.975829419137881e-08
gene O 0 7.693892745130881e-10
in O 0 1.5285460397418404e-10
ethnic O 0 1.863876414320842e-10
populations O 0 2.6073716519192658e-09
. O 0 5.1018737678987236e-08

To O 0 2.0252522858754674e-07
facilitate O 0 2.0442766412998026e-07
the O 0 3.998309239250375e-08
evaluation O 0 1.095427393238424e-07
of O 0 2.459034647017688e-07
ATM O 0 5.603163572232006e-06
heterozygotes O 0 1.9308400567297213e-07
for O 0 2.1189938692600663e-09
susceptibility O 0 4.861236675424152e-07
to O 0 3.9480041458261894e-09
other O 0 2.3038564389565863e-09
diseases O 1 0.9977849125862122
, O 0 2.981574986904434e-10
such O 0 6.936737850793406e-09
as O 0 5.149428761797026e-05
breast B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999051094055176
, O 0 3.2393117077589295e-09
we O 0 1.6778136657791265e-09
have O 0 5.926923951626861e-10
attempted O 0 5.327569851942826e-08
to O 0 2.3000761295577377e-09
define O 0 4.473742709620865e-09
the O 0 8.074508173194772e-09
most O 0 1.9092237513174126e-10
common O 0 3.674850146406783e-10
mutations O 0 6.660995366392086e-11
and O 0 6.48147507886776e-11
their O 0 3.380771773642266e-10
frequencies O 0 2.5901437439301844e-08
in O 0 4.813067278064409e-08
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.0027682168874889612
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.544410821452402e-08
homozygotes O 0 5.39410166311427e-07
from O 0 9.117892219023815e-09
10 O 0 8.036786347531688e-09
ethnic O 0 5.133103386789628e-10
populations O 0 3.4281490979282125e-09
. O 0 5.8921912682308175e-08

Both O 0 1.3740472581957874e-07
genomic O 0 7.346836810029345e-07
mutations O 0 2.531036003006193e-08
and O 0 8.485653291145923e-10
their O 0 9.770466657954557e-10
effects O 0 1.0017697604780551e-07
on O 0 1.241888298864069e-07
cDNA O 0 1.9717994348411594e-07
were O 0 1.203871669019918e-08
characterized O 0 1.1015853829121625e-07
. O 0 1.0560091112665759e-07

Protein O 0 2.0471320567594375e-06
- O 0 5.651709216181189e-07
truncation O 0 1.2320421092226752e-06
testing O 0 1.0334017730428968e-07
of O 0 7.472048224599348e-08
the O 0 4.317072566095703e-08
entire O 0 1.4475482146281138e-07
ATM O 0 1.7997203372033255e-07
cDNA O 0 6.652155093433976e-08
detected O 0 4.3972512742129766e-08
92 O 0 2.788694075661624e-08
( O 0 2.855395087042467e-10
66 O 0 8.230387038565823e-09
% O 0 1.9768976733391952e-10
) O 0 6.613938563493349e-11
truncating O 0 1.2400533044854e-08
mutations O 0 1.343128053221676e-09
in O 0 1.3435226264846278e-09
140 O 0 1.3185100122825588e-08
mutant O 0 6.83645566823543e-08
alleles O 0 6.534534247037982e-09
screened O 0 1.3638381801683863e-07
. O 0 5.4706724483821745e-08

The O 0 8.037914994929451e-06
haplotyping O 0 0.0003110674733761698
of O 0 3.2948266834864626e-06
patients O 0 4.355988778570463e-07
with O 0 3.871613252215411e-09
identical O 0 2.245388031951734e-06
mutations O 0 1.1523615484065886e-07
indicates O 0 5.056323004737351e-08
that O 0 7.180584460364514e-10
almost O 0 1.6449317463695934e-09
all O 0 1.5296164335154572e-10
of O 0 5.409201420114584e-10
these O 0 3.653267618974887e-11
represent O 0 1.4236499132347369e-11
common O 0 6.222580783976639e-10
ancestry O 0 1.7558492160230088e-10
and O 0 4.217616533797042e-11
that O 0 5.257352279214311e-12
very O 0 1.4718036511762733e-10
few O 0 1.3717469382612535e-09
spontaneously O 0 3.759961231253328e-09
recurring O 0 2.67624535865707e-08
ATM O 0 2.6241950763505884e-06
mutations O 0 3.550097460447432e-08
exist O 0 8.25360970679867e-08
. O 0 5.347712317416153e-07

Assays O 0 1.171404255728703e-05
requiring O 0 1.5674957865030592e-07
minimal O 0 1.7576512334471772e-07
amounts O 0 1.081956835236042e-08
of O 0 5.668407965231381e-09
genomic O 0 5.294644278563965e-09
DNA O 0 1.1149867695792182e-08
were O 0 4.1016956497941237e-10
designed O 0 3.5251910279754384e-09
to O 0 4.778166751151502e-10
allow O 0 1.3224813466550245e-09
rapid O 0 1.1048022052762008e-08
screening O 0 9.989340910010469e-09
for O 0 1.4126040615014546e-10
common O 0 1.5974883638136816e-09
ethnic O 0 5.817544224129279e-10
mutations O 0 6.388301887483294e-09
. O 0 3.1824328061702545e-08

These O 0 3.3012133826559875e-07
rapid O 0 1.4741657423655852e-06
assays O 0 1.4014060525369132e-06
detected O 0 5.199245833864552e-07
mutations O 0 2.9904498877186825e-09
in O 0 9.40979738572878e-10
76 O 0 1.9520351557389404e-08
% O 0 5.42776268375178e-10
of O 0 1.3032757095743364e-08
Costa O 0 3.624338944518968e-07
Rican O 0 1.1198673064427567e-06
patients O 0 6.526266815853887e-08
( O 0 6.318329748289386e-10
3 O 0 7.284684855335399e-09
) O 0 2.1501207064789085e-11
, O 0 1.5678321488299396e-11
50 O 0 1.2978912389272068e-10
% O 0 4.194007988123083e-11
of O 0 1.8695205383778557e-09
Norwegian O 0 6.475305553976796e-07
patients O 0 1.8028153192517493e-08
( O 0 5.171152950289581e-10
1 O 0 1.3516737062957418e-08
) O 0 1.410665334544703e-10
, O 0 6.042228523073234e-11
25 O 0 6.361426940770798e-10
% O 0 1.17847745451094e-10
of O 0 2.839348089977989e-09
Polish O 0 4.847083619097248e-05
patients O 0 3.8452799344668165e-07
( O 0 2.391107534194248e-09
4 O 0 4.008571963254326e-08
) O 0 1.8962167946945385e-10
, O 0 1.2035168694968235e-10
and O 0 5.43565747967989e-10
14 O 0 4.34388125469809e-09
% O 0 4.226791139316788e-10
of O 0 1.8259912692997204e-08
Italian O 0 6.116002623457462e-06
patients O 0 1.444667248051701e-07
( O 0 2.428873324689107e-09
1 O 0 7.456173989339732e-08
) O 0 1.866939935979417e-10
, O 0 8.75302538783096e-11
as O 0 6.418564013621619e-10
well O 0 1.7262229423664621e-09
as O 0 9.560824354437614e-10
in O 0 5.562989513485661e-10
patients O 0 1.764491774913779e-09
of O 0 5.2246150517021306e-08
Amish O 0 1.4054145367481397e-06
/ O 0 1.3905759033150389e-06
Mennonite O 0 8.860826028467272e-07
and O 0 2.2095001384059287e-08
Irish O 0 1.0437780417760223e-07
English O 0 8.55552713119323e-08
backgrounds O 0 1.236138444937751e-07
. O 0 1.9014854046872642e-07

Additional O 0 2.7398473889661545e-07
mutations O 0 2.426429723811907e-08
were O 0 6.627722815011339e-09
observed O 0 5.2088111601733544e-09
in O 0 1.8657411171574267e-09
Japanese O 0 1.0692883734009229e-06
, O 0 2.0825599023055474e-09
Utah O 0 1.8611824259551213e-07
Mormon O 0 3.230693579325816e-08
, O 0 7.257827672191297e-11
and O 0 6.752766401607602e-11
African O 0 4.125665920007293e-10
American O 0 1.8191976813852762e-09
patients O 0 7.5375030661462e-09
. O 0 5.472321618071874e-08

These O 0 1.346982543282138e-07
assays O 0 3.356744855409488e-07
should O 0 4.343351012181529e-09
facilitate O 0 7.178917904582249e-09
screening O 0 4.5220012623303774e-08
for O 0 2.5091559052725643e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
heterozygotes O 0 2.9523212106141727e-06
in O 0 4.115576324181802e-09
the O 0 3.0901061709442956e-09
populations O 0 7.002853852355884e-11
studied O 0 6.41882103025182e-10
. O 0 4.269247733112991e-10
. O 0 1.2243562608205139e-08

The O 0 2.904280881921295e-05
von B-Disease 1 0.9999967813491821
Hippel I-Disease 1 1.0
- I-Disease 1 0.999992847442627
Lindau I-Disease 1 0.999854326248169
tumor I-Disease 0 0.0014805736718699336
suppressor O 0 4.252666713000508e-06
gene O 0 2.226900441826274e-09
is O 0 4.488182048234535e-11
required O 0 6.221106269022059e-11
for O 0 2.2836210700205584e-10
cell O 0 4.189728386450042e-08
cycle O 0 2.524472630938135e-09
exit O 0 1.983235797808902e-09
upon O 0 1.296634910552541e-09
serum O 0 3.0466946299156916e-08
withdrawal O 0 2.4702314860292063e-08
. O 0 5.416268678004599e-08

The O 0 3.604154926506453e-06
inactivation O 0 7.327154162339866e-05
of O 0 7.700930950704787e-07
the O 0 3.9085284697648603e-07
von B-Disease 1 0.9999903440475464
Hippel I-Disease 1 1.0
- I-Disease 1 0.9999974966049194
Lindau I-Disease 1 0.9999998807907104
( I-Disease 0 2.658434368640883e-06
VHL I-Disease 1 1.0
) I-Disease 0 2.067795549010043e-06
tumor I-Disease 1 0.9996687173843384
suppressor O 0 0.12556429207324982
gene O 0 8.880520567799977e-07
predisposes O 0 5.807671641377965e-07
affected O 0 1.1640443053906324e-09
individuals O 0 4.081525915855533e-12
to O 0 1.8246454347448093e-10
the O 0 4.323533175920602e-08
human O 0 0.04099195450544357
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 5.225346821902122e-10
is O 0 3.8991327527826414e-11
associated O 0 2.5204782705401385e-10
with O 0 1.0380466625159457e-10
sporadic B-Disease 0 0.002495294902473688
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 1.0899545088705054e-07
RCC B-Disease 1 0.9998801946640015
) O 0 2.0456528915246963e-08
and O 0 1.3755631016465486e-06
brain B-Disease 1 0.9999935626983643
hemangioblastomas I-Disease 0 0.009082161821424961
. O 0 2.697384843486361e-06

VHL O 1 0.5257412791252136
- O 0 6.508791557280347e-05
negative O 0 9.794206334845512e-07
786 O 0 3.7365229218266904e-05
- O 0 8.997562690638006e-05
0 O 0 1.1295810509182047e-06
RCC B-Disease 0 0.02491569146513939
cells O 0 9.080042218556628e-06
are O 0 1.6698871618814337e-08
tumorigenic O 0 0.001792444265447557
in O 0 1.6853589102083788e-07
nude O 0 1.7164735766073136e-07
mice O 0 1.0622144941407896e-08
which O 0 9.171797349383226e-11
is O 0 6.295651500121124e-11
suppressed O 0 1.5104679729205372e-09
by O 0 1.3047417313227783e-10
the O 0 9.440992876363907e-09
reintroduction O 0 6.799879770369444e-07
of O 0 1.1207932715251445e-07
VHL B-Disease 0 0.03224904462695122
. O 0 1.0220828698948026e-06

Remarkably O 0 0.00013776151172351092
, O 0 7.295043680244362e-09
this O 0 3.5987304802809206e-10
occurs O 0 1.7052660394867303e-09
without O 0 7.690254544279185e-10
affecting O 0 1.7469835300598646e-10
the O 0 3.4350070010624734e-10
growth O 0 9.544166151842504e-11
rate O 0 5.31217125843142e-10
and O 0 4.776298800912571e-10
cell O 0 7.883449626433503e-08
cycle O 0 1.6139777292423219e-09
profile O 0 3.174717710940911e-10
of O 0 1.099701218976179e-09
these O 0 1.0366379282755744e-10
cells O 0 2.4697779377191864e-09
in O 0 8.849993515802623e-10
culture O 0 1.6366017874247518e-08
. O 0 1.0352834145521683e-08

The O 0 6.605824637517799e-06
786 O 0 8.464890015602577e-06
- O 0 1.7725632233123179e-06
0 O 0 7.872014862186916e-08
cell O 0 2.582929141681234e-07
line O 0 1.8131522665498778e-06
, O 0 2.2293951129626066e-09
like O 0 4.059412805901275e-09
many O 0 1.960833495573411e-09
cancer B-Disease 0 6.282504728005733e-06
cells O 0 1.3133374920926144e-07
, O 0 6.726648127397539e-10
fails O 0 1.377825853410286e-08
to O 0 3.7580258904768016e-09
exit O 0 1.3118203412432194e-07
the O 0 6.745075165071057e-09
cell O 0 1.0604026989824433e-08
cycle O 0 2.360870388073977e-10
upon O 0 2.088378359133003e-10
serum O 0 8.087054581551456e-09
withdrawal O 0 9.616573315440746e-09
. O 0 7.005990454445055e-08

Here O 0 1.383195581183827e-06
, O 0 8.108537841167163e-09
it O 0 4.722932045453376e-10
is O 0 1.849219943839131e-10
shown O 0 1.0380071802096325e-10
that O 0 2.340112131848926e-11
reintroduction O 0 5.52832233324807e-08
of O 0 1.3441820101434132e-08
the O 0 2.077597649474683e-08
wild O 0 4.3583241904343595e-08
- O 0 1.7093537252321767e-08
type O 0 1.9246444082909875e-07
VHL B-Disease 1 0.9565728306770325
gene O 0 3.6089900845581724e-07
restores O 0 6.454216872953111e-06
the O 0 6.751642445124162e-08
ability O 0 6.604442859270421e-08
of O 0 2.0034651697642403e-06
VHL O 1 1.0
- O 1 0.8604469299316406
negative O 0 7.824784802323848e-07
RCC B-Disease 1 0.9999994039535522
cancer I-Disease 0 0.0005010405438952148
cells O 0 9.634495512500507e-08
to O 0 1.164144869392203e-08
exit O 0 1.8882394670072244e-07
the O 0 2.0693084579193055e-08
cell O 0 4.973831835286546e-08
cycle O 0 1.764427715045258e-09
and O 0 3.7803027375105103e-10
enter O 0 2.7174309025213006e-08
G0 O 0 6.287924043135718e-05
/ O 0 1.389113890581939e-06
quiescence O 0 1.3850461755282595e-06
in O 0 2.5180193485851987e-09
low O 0 1.733780976564958e-07
serum O 0 2.5413160642528965e-07
. O 0 3.888303012899996e-08

Both O 0 1.992155193875078e-05
VHL O 1 0.9999951124191284
- O 0 0.009912131354212761
positive O 0 1.0819981071108487e-06
and O 0 1.4610822063332307e-06
VHL O 1 1.0
- O 1 0.9886821508407593
negative O 0 1.9035951481782831e-06
RCC B-Disease 1 0.9999434947967529
cells O 0 2.314742914677481e-06
exit O 0 2.839599630988232e-07
the O 0 3.6624945298768807e-09
cell O 0 5.9016249664978204e-09
cycle O 0 7.003882890321833e-11
by O 0 1.0318714632751025e-11
contact O 0 2.793702602588155e-09
inhibition O 0 2.408967247902183e-07
. O 0 1.6637298472232942e-07

The O 0 2.5970799470087513e-05
cyclin O 0 2.4571674657636322e-05
- O 0 3.060363269469235e-06
dependent O 0 8.050250812630111e-07
kinase O 0 1.3532339835364837e-06
inhibitor O 0 1.8772330179217533e-07
, O 0 1.3418656186203748e-09
p27 O 0 3.0687402841067524e-07
, O 0 3.5531289022117107e-10
accumulates O 0 6.976490496413135e-09
upon O 0 1.0975178543759512e-09
serum O 0 1.0987080578672703e-08
withdrawal O 0 6.373769956269371e-09
, O 0 1.055641199454449e-10
only O 0 3.0053997485124384e-11
in O 0 6.752019776623541e-11
the O 0 3.3208372163251454e-10
presence O 0 1.1301063418400759e-09
of O 0 3.9415052555114016e-08
VHL B-Disease 1 0.9999648332595825
, O 0 8.764577508202365e-09
as O 0 1.8437689153216752e-09
a O 0 6.861806123303893e-10
result O 0 3.604541942703321e-10
of O 0 5.1189581462551814e-09
the O 0 5.197854591187934e-09
stabilization O 0 2.940346632840374e-07
of O 0 7.04331739598274e-07
the O 0 4.884136615146417e-07
protein O 0 7.846663834243373e-07
. O 0 1.5705107614394365e-07

We O 0 3.5727387626138807e-07
propose O 0 7.711309280011847e-08
that O 0 1.4341003939932762e-09
the O 0 2.155309886120449e-08
loss O 0 7.34134673052722e-08
of O 0 3.278948668139492e-07
wild O 0 6.275973305491789e-07
- O 0 1.5990842427981988e-07
type O 0 8.444680474894994e-07
VHL B-Disease 1 0.9999688863754272
gene O 0 6.60230128346484e-08
results O 0 5.313937290196691e-09
in O 0 2.2642436814379607e-09
a O 0 5.482975407034019e-09
specific O 0 5.6763301614637385e-08
cellular O 0 8.812178748485167e-06
defect O 0 2.575616235844791e-06
in O 0 8.980573618089238e-09
serum O 0 4.400097168399952e-06
- O 0 1.937851493494236e-06
dependent O 0 3.839303275299244e-08
growth O 0 1.7300927357410956e-09
control O 0 5.546657533272992e-08
, O 0 1.0461603111577844e-10
which O 0 6.776196964652925e-11
may O 0 9.371056153284485e-10
initiate O 0 1.3245520236182529e-08
tumor B-Disease 0 6.151417437649798e-07
formation O 0 6.267002277127176e-07
. O 0 2.152096101326606e-07

This O 0 9.402305778394293e-08
is O 0 2.13666462300921e-09
corrected O 0 9.63122204211686e-09
by O 0 3.4647290592104696e-10
the O 0 1.0341151046588948e-08
reintroduction O 0 4.7018329496495426e-07
of O 0 4.4688835743045274e-08
wild O 0 7.83243052637772e-08
- O 0 3.618308497266298e-08
type O 0 9.653862207414932e-07
VHL B-Disease 1 1.0
, O 0 1.2111546254800487e-07
implicating O 0 7.640199328307062e-05
VHL B-Disease 1 1.0
as O 0 4.686675310949795e-06
the O 0 2.2420369987230515e-06
first O 0 1.7131407048509573e-07
tumor B-Disease 0 4.769167389895301e-06
suppressor O 0 5.188908289710525e-07
involved O 0 5.091139509971754e-09
in O 0 2.9072468876734092e-09
the O 0 5.3654947151926535e-08
regulation O 0 1.068677164539622e-07
of O 0 5.343924414091816e-08
cell O 0 8.708788641342835e-07
cycle O 0 1.1058436832911411e-08
exit O 0 1.3908032059362085e-08
, O 0 4.514480109185648e-11
which O 0 9.359453316537536e-12
is O 0 3.380112509332456e-11
consistent O 0 6.292257270779089e-10
with O 0 6.894284448888399e-11
its O 0 3.802091974591804e-09
gatekeeper O 0 1.787967676136759e-07
function O 0 6.498536153642931e-10
in O 0 3.0184935106980504e-10
the O 0 5.68612357199072e-09
kidney O 0 1.6409753698098939e-06
. O 0 5.081767895376288e-09
. O 0 2.9726971106924793e-08

Piebaldism B-Disease 1 1.0
with O 1 0.9598994255065918
deafness B-Disease 1 1.0
: O 0 2.6592200441655223e-08
molecular O 0 6.927049156502108e-08
evidence O 0 3.848944629680773e-08
for O 0 1.8001307111603637e-09
an O 0 1.249668923897218e-09
expanded O 0 1.8421128515910823e-06
syndrome O 1 1.0
. O 0 2.201116558353533e-06

In O 0 1.1419361953812768e-06
a O 0 3.680487168367108e-07
South O 0 1.2060175436090503e-07
African O 0 8.936421380667525e-09
girl O 0 1.4827659100546953e-08
of O 0 9.180066484759664e-09
Xhosa O 0 8.453781447315123e-06
stock O 0 1.315518183275799e-08
with O 0 1.770208007956242e-10
severe O 0 1.0232346539851278e-05
piebaldism B-Disease 0 0.1849454939365387
and O 0 3.1416743695444893e-06
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 0.00033060566056519747
identified O 0 2.18210569613575e-08
a O 0 3.0713676046900673e-09
novel O 0 4.9652419953361004e-09
missense O 0 3.254845992728406e-08
substitution O 0 1.3913582108671108e-07
at O 0 4.545141223388782e-07
a O 0 2.623175809901568e-08
highly O 0 2.6619652260251314e-08
conserved O 0 1.2444248298493221e-08
residue O 0 1.3324684289273137e-07
in O 0 1.0832799102189483e-09
the O 0 5.491379795330431e-09
intracellular O 0 1.0583034004696401e-08
kinase O 0 1.8001934165567945e-08
domain O 0 1.4567508310747712e-09
of O 0 3.6411114123779953e-09
the O 0 1.632433566101099e-08
KIT O 0 1.3884880900150165e-05
proto O 0 2.7818210583063774e-05
- O 0 1.7507430811747327e-06
oncogene O 0 6.471036158472998e-06
, O 0 3.3123244147503783e-09
R796G O 0 7.698457125115965e-07
. O 0 1.1113629483361365e-07

Though O 0 4.4852336031908635e-06
auditory B-Disease 0 0.08751169592142105
anomalies I-Disease 0 0.00011515047663124278
have O 0 1.3273642629485494e-08
been O 0 8.987565358609118e-09
observed O 0 1.92069435911435e-08
in O 0 2.894327888469661e-09
mice O 0 8.946383900365618e-08
with O 0 3.541452686661728e-09
dominant O 1 0.6237278580665588
white O 0 0.0008252256666310132
spotting O 0 7.881315104896203e-05
( O 0 8.891183256309887e-08
W O 0 3.5941634450864512e-06
) O 0 1.5951430454297366e-10
due O 0 2.982033109333315e-08
to O 0 1.26840991043764e-08
KIT O 1 0.9999547004699707
mutations O 0 1.029423492582282e-05
, O 0 3.002222115355835e-07
deafness B-Disease 1 1.0
is O 0 1.057644971602656e-09
not O 0 7.440351112997234e-11
typical O 0 1.8308552451884452e-09
in O 0 4.1341891021673405e-10
human O 0 8.220722769181066e-09
piebaldism B-Disease 0 4.0399340832664166e-06
. O 0 2.66427207407105e-07

Thus O 0 2.3523647030287975e-07
, O 0 2.4367849960071908e-09
the O 0 1.8946848534540095e-09
occurrence O 0 2.769833251647924e-08
of O 0 9.652526387071703e-07
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 5.507501100510126e-06
this O 0 5.341662046021156e-08
patient O 0 1.6333669918822125e-06
extends O 0 5.895946131317942e-08
considerably O 0 2.770983087430068e-07
the O 0 4.9538741109245166e-08
phenotypic O 0 7.688149850082482e-08
range O 0 7.367999899088318e-08
of O 0 8.34897377899324e-08
piebaldism B-Disease 0 6.996642127887753e-07
due O 0 1.4025168582065817e-07
to O 0 8.088334446654244e-09
KIT O 0 4.765202902490273e-06
gene O 0 5.914685630159511e-09
mutation O 0 4.1934020145184547e-10
in O 0 6.056258966546935e-11
humans O 0 3.150037564125796e-09
and O 0 7.583138561528813e-10
tightens O 0 3.748413490711755e-08
the O 0 1.4291743344330143e-09
clinical O 0 9.495875197274017e-09
similarity O 0 3.554196581490032e-08
between O 0 1.2478474253896366e-08
piebaldism B-Disease 0 2.9733489554928383e-06
and O 0 7.569266879947634e-10
the O 0 2.4796181774533466e-10
various O 0 3.099092510394641e-11
forms O 0 1.8660151201999042e-09
of O 0 2.7420770720709697e-07
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.7987011819163854e-08
. O 0 1.014469859228484e-07

Cycloheximide O 0 0.00027598810265772045
facilitates O 0 1.0298535926267505e-06
the O 0 9.546727852693948e-08
identification O 0 1.6658032109262422e-07
of O 0 4.707903826783877e-07
aberrant O 0 7.577520477752842e-07
transcripts O 0 3.2184945553126454e-07
resulting O 0 6.458900259076472e-08
from O 0 1.8306501203824155e-08
a O 0 1.7841786714711816e-08
novel O 0 6.762894599887659e-08
splice O 0 5.17180751558044e-06
- O 0 5.568705887526448e-07
site O 0 3.1287342494579207e-08
mutation O 0 6.197682922426395e-10
in O 0 3.129805581369993e-10
COL17A1 O 0 5.70352176509914e-06
in O 0 1.2801557591757273e-09
a O 0 5.1896718034072364e-09
patient O 0 3.1656270493840566e-08
with O 0 3.209318810704076e-09
generalized O 0 0.002438499592244625
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
. O 0 6.793978536734357e-05

Patients O 0 4.3503614506335e-06
with O 0 8.999130329812033e-08
generalized O 1 0.9997119307518005
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
often O 0 2.559719632699853e-06
show O 0 7.458460515863408e-09
decreased O 0 1.7548792419219694e-09
expression O 0 4.887719673440927e-10
of O 0 1.386659786994926e-09
type O 0 8.855489852521714e-08
XVII O 0 0.0006608236581087112
collagen O 0 3.68475434697757e-06
, O 0 5.6315738738987875e-09
a O 0 8.980162391480917e-09
transmembrane O 0 4.041720735870058e-09
hemidesmosomal O 0 1.4815389803857215e-08
protein O 0 4.091436633935075e-10
encoded O 0 2.0536651545999263e-10
by O 0 2.382629649133605e-10
COL17A1 O 0 1.4651631317974534e-05
. O 0 1.8258734257869946e-07

This O 0 1.7341844227303227e-07
report O 0 2.0154443447495396e-08
documents O 0 7.485770936455083e-08
a O 0 4.225650940270498e-08
novel O 0 1.7628451587370364e-07
splice O 0 1.878548391687218e-05
- O 0 2.2789517970522866e-06
site O 0 7.712780814017606e-08
mutation O 0 1.4832119976659897e-09
in O 0 4.902078742929916e-10
COL17A1 O 0 5.8866076869890094e-05
in O 0 5.39207389849139e-09
a O 0 1.381578496051361e-08
patient O 0 9.299006364926754e-08
with O 0 1.2996564713319003e-08
generalized O 1 0.9995887875556946
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 2.2483013140117691e-07
and O 0 1.0477148926213431e-08
applies O 0 7.603041751735873e-09
a O 0 4.737170655744194e-09
new O 0 2.1583819176385077e-09
methodology O 0 5.5266746734616845e-09
to O 0 3.3557681633489267e-10
define O 0 9.173883319668619e-10
and O 0 7.299173487851363e-10
characterize O 0 1.3340954119200887e-08
the O 0 5.071445485782533e-09
resulting O 0 1.5511892215158696e-08
mRNA O 0 1.736252208672795e-08
splice O 0 3.3904103702298016e-07
variants O 0 4.3106382463520276e-08
. O 0 4.415101528820742e-08

Mutational O 0 0.0006405754247680306
analysis O 0 8.479220241497387e-07
of O 0 2.0951745227648644e-06
COL17A1 O 0 0.0031895602587610483
identified O 0 1.233741045325587e-06
a O 0 2.940271031093289e-07
maternally O 0 6.196010531311913e-07
inherited O 0 2.733731162152253e-05
G O 0 2.848114127118606e-05
- O 0 1.388104101351928e-05
to O 0 7.688353775847645e-07
- O 0 0.00015553114644717425
T O 0 3.281235331087373e-05
transversion O 0 1.3151980965631083e-05
at O 0 3.180169372285491e-08
the O 0 2.9456375116865274e-09
- O 0 2.8436948351640012e-09
1 O 0 3.0638431791629728e-09
position O 0 8.207468482623881e-09
of O 0 1.9333713296987298e-08
exon O 0 3.041028833195014e-07
32 O 0 8.461336875598136e-08
. O 0 4.8003236940985516e-08

This O 0 1.7694577536531142e-07
acceptor O 0 1.84467037200875e-08
splice O 0 1.2580522707139608e-05
- O 0 8.424409543295042e-07
site O 0 6.950315878384572e-08
mutation O 0 2.0508910125727198e-09
led O 0 3.517923286011637e-09
to O 0 9.627212360641124e-10
the O 0 1.2368078117219738e-08
formation O 0 1.1234578778385185e-07
of O 0 2.098740196743165e-06
aberrant O 0 4.094341363725107e-07
transcripts O 0 2.2843298097541265e-07
present O 0 7.376352328947178e-08
at O 0 5.889393506208762e-08
extremely O 0 3.297084560927033e-08
low O 0 1.0300972235199879e-06
levels O 0 1.7506918936760485e-07
. O 0 2.165889156913181e-07

Based O 0 1.4844007409919868e-06
on O 0 1.28449016756349e-06
our O 0 2.8762732640075228e-08
recent O 0 4.839705969317265e-09
finding O 0 1.1682955047831456e-08
that O 0 1.7317698386420943e-09
cycloheximide O 0 8.087656169664115e-06
stabilized O 0 4.7653687943238765e-05
mutant O 0 2.941183765869937e-06
COL17A1 O 0 2.6799678380484693e-05
transcripts O 0 1.4897656797074887e-07
in O 0 1.823411310830636e-09
keratinocytes O 0 1.8286999647898483e-07
homozygous O 0 1.597842569367458e-08
for O 0 2.217520611580426e-09
a O 0 2.1536290972790084e-08
frameshift O 0 9.136659286923532e-07
mutation O 0 1.8518337085993153e-08
, O 0 7.42360006800169e-10
the O 0 2.817800215382249e-09
effects O 0 1.78616630819306e-07
of O 0 7.14266434442834e-07
the O 0 5.229819066698838e-07
splice O 0 8.614541911811102e-06
- O 0 3.221547046905471e-07
site O 0 4.4990912329012644e-08
mutation O 0 8.134527496039823e-10
on O 0 2.1311212794472567e-09
splicing O 0 1.644835379011056e-08
of O 0 1.5168231115580966e-08
COL17A1 O 0 2.45352402998833e-05
transcripts O 0 2.2798052157213533e-07
were O 0 7.288423642393127e-09
determined O 0 8.425853792459748e-09
using O 0 8.079114266479337e-09
reverse O 0 1.3447544233713415e-07
transcriptase O 0 1.0228126967604112e-07
polymerase O 0 2.563153600476653e-07
chain O 0 2.200143178754388e-08
reaction O 0 2.3877624322210522e-09
of O 0 3.4127396464356252e-09
total O 0 3.9356472941731724e-11
RNA O 0 5.783777345946817e-10
from O 0 4.640909531672399e-11
keratinocytes O 0 3.796526648613963e-09
incubated O 0 3.8685055159248805e-09
for O 0 1.1689028911465726e-10
2 O 0 2.422864220363863e-08
. O 0 2.448027203172387e-08

5 O 0 6.037748789822217e-06
h O 0 5.929304052187945e-07
in O 0 4.1779162351929244e-09
the O 0 7.011708991200294e-09
presence O 0 1.94593785529662e-09
or O 0 4.5407198001612414e-09
absence O 0 1.7445584887809673e-07
of O 0 2.1771631963929394e-07
10 O 0 2.871936999326863e-08
microg O 0 1.5408527360705193e-06
cycloheximide O 0 1.1185310313521768e-06
per O 0 4.346013682265948e-08
ml O 0 5.704864634026308e-07
. O 0 1.7714670264012966e-07

Using O 0 3.4899898082585423e-07
this O 0 1.004078331590108e-08
approach O 0 1.1472539540591242e-07
, O 0 1.162903773277435e-09
an O 0 4.4253997688592506e-10
abnormally O 0 2.6400005737059473e-08
spliced O 0 6.003696029210914e-08
transcript O 0 3.187675758908881e-07
was O 0 8.067384271726041e-08
identified O 0 4.634259920255346e-10
that O 0 2.82770942078292e-11
contains O 0 8.607646539982028e-11
an O 0 5.428029206666629e-11
extra O 0 2.062962689564074e-09
264 O 0 5.3702633451280235e-09
bases O 0 1.1564963209309553e-08
upstream O 0 2.985937541666317e-08
from O 0 3.3649607544816718e-09
exon O 0 3.237781598386391e-08
32 O 0 3.061775277757306e-09
, O 0 2.0199441078116998e-11
resulting O 0 6.563335430698203e-10
in O 0 4.989209601014011e-10
a O 0 4.767818584383576e-09
premature O 0 2.9125098777171843e-08
termination O 0 3.56306856019728e-07
codon O 0 9.81433032620771e-08
27 O 0 3.2821208151290193e-07
bp O 0 8.354404030797014e-07
downstream O 0 5.1021462610378876e-08
from O 0 4.440096290636575e-09
the O 0 3.159251349416081e-08
cryptic O 0 8.305024721266818e-07
splice O 0 1.8569162421044894e-05
site O 0 1.7313500393356662e-06
. O 0 9.318305416172734e-08

Three O 0 1.0629379403326311e-06
other O 0 2.5625372046533812e-08
splice O 0 2.724492105699028e-06
variants O 0 9.18155862450476e-08
, O 0 6.457391288350323e-10
including O 0 2.2873614113905205e-10
one O 0 2.7188071238803957e-10
derived O 0 4.075021209359875e-09
from O 0 1.520287185030611e-08
the O 0 4.438896183955876e-08
skipping O 0 3.516925417557104e-08
of O 0 5.371269651277544e-08
exon O 0 4.6430415068243747e-08
32 O 0 8.356234815209973e-09
, O 0 1.1528766136192914e-10
were O 0 5.300683780795623e-10
also O 0 1.0875736977666861e-09
identified O 0 4.247087659337012e-08
. O 0 8.548252594664518e-08

These O 0 5.894135668427225e-08
results O 0 2.0237532538658343e-08
indicate O 0 2.3248206915127412e-08
the O 0 2.880896055046378e-08
usefulness O 0 3.9911708427098347e-07
of O 0 9.296222458488046e-08
cycloheximide O 0 1.7077232996598468e-06
treatment O 0 4.1873002487591293e-07
in O 0 3.50365358947613e-09
evaluating O 0 1.0699780617073884e-08
the O 0 5.9846803068808185e-09
abnormal O 0 2.8187785439115487e-09
processing O 0 5.0746219670827486e-08
of O 0 4.5274212823187554e-08
mRNA O 0 5.624813681492924e-08
due O 0 3.2229144153461675e-07
to O 0 2.5185297403140794e-08
splice O 0 1.3556322301155888e-05
- O 0 1.3627281987282913e-06
site O 0 5.305038541791873e-08
mutations O 0 3.119250968630638e-10
, O 0 4.8468694335834783e-11
because O 0 2.025191542243121e-10
( O 0 4.970147071681197e-10
i O 0 3.408389304127013e-08
) O 0 9.774232534454086e-10
aberrant O 0 2.5742354026192515e-08
splicing O 0 5.233531297221816e-08
often O 0 7.609334273794843e-10
generates O 0 6.573320221470169e-10
a O 0 2.575786028913285e-09
premature O 0 1.815531014415228e-08
termination O 0 3.298270883078658e-07
codon O 0 3.070303122854057e-08
, O 0 1.2255798598204137e-09
( O 0 2.451323311003506e-10
ii O 0 7.740653381915763e-05
) O 0 1.0994621879589772e-09
transcripts O 0 1.7274622621243907e-08
with O 0 3.778810597765414e-10
premature O 0 4.763021976827986e-08
termination O 0 4.37574954048614e-07
codons O 0 5.8157972659955703e-08
can O 0 3.439420748208022e-09
occur O 0 1.0017330964728899e-08
at O 0 2.9442572824223134e-08
low O 0 4.990737920707033e-07
or O 0 2.363725037923814e-08
undetectable O 0 2.81415026393006e-07
levels O 0 8.464997591772772e-09
due O 0 4.1995697586116876e-08
to O 0 3.6976322004278472e-09
nonsense O 0 6.705697330744442e-08
- O 0 3.039259866000066e-08
mediated O 0 1.5619967541624646e-07
mRNA O 0 2.175477220589528e-08
decay O 0 1.956687896154108e-07
, O 0 7.687698394542863e-11
and O 0 1.0710305559102906e-10
( O 0 1.9895923797363935e-10
iii O 0 0.0015423651784658432
) O 0 1.0339371581125079e-09
the O 0 6.673337438201088e-09
levels O 0 3.3242928410004424e-09
of O 0 2.4828563649492708e-09
these O 0 2.210475830155545e-10
transcripts O 0 3.381934510215956e-09
can O 0 2.662885363602374e-11
be O 0 2.9939398182854404e-11
increased O 0 8.132894357970599e-11
by O 0 4.838780487403938e-10
cycloheximide O 0 2.3380534912575968e-06
. O 0 2.889707673148223e-07

A O 0 2.033287273661699e-05
deletion O 0 2.0303084511397174e-06
mutation O 0 3.38697745405625e-08
in O 0 5.910558265043164e-09
COL17A1 O 0 2.781502735160757e-05
in O 0 4.810605247485e-09
five O 0 2.6973625555370973e-09
Austrian O 0 2.9832509085281345e-07
families O 0 3.110014912266479e-09
with O 0 4.241362372425783e-09
generalized O 1 0.8537229895591736
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999998807907104
represents O 0 2.3635722357084887e-07
propagation O 0 1.2623298744074418e-06
of O 0 4.5739007248357666e-08
an O 0 1.2722133346798614e-09
ancestral O 0 2.2134108235150052e-07
allele O 0 7.983941685552054e-08
. O 0 5.520482559973061e-08

Patients O 0 7.636174814251717e-06
with O 0 1.3905649609569082e-07
generalized O 1 0.9629388451576233
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 1.3917522778683633e-07
a O 0 8.016058039572727e-09
usually O 0 2.0204700135195708e-09
nonlethal O 0 8.444366130788694e-07
form O 0 9.679438051080069e-08
of O 0 0.0009269516449421644
junctional B-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999675750732422
, O 0 5.761418453431588e-09
have O 0 6.605028746164976e-10
generalized O 0 1.461628329479936e-07
blistering B-Disease 0 1.951992635440547e-05
, O 0 2.3867892551265868e-08
nail B-Disease 1 0.9999815225601196
dystrophy I-Disease 1 0.9999996423721313
, O 0 2.492134001386148e-07
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 1.5614217829806876e-07
and O 0 3.1826259601075435e-06
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 0 0.0020169022027403116

Skin B-Disease 1 1.0
fragility I-Disease 1 1.0
in O 0 3.0281150031896686e-08
most O 0 5.119473178716305e-10
cases O 0 1.1014598955139121e-10
is O 0 2.5458329888650155e-11
due O 0 2.2384707420997074e-09
to O 0 5.484625531515519e-10
mutations O 0 4.3865247545404884e-10
in O 0 4.413901466548964e-10
the O 0 4.891097749037954e-09
gene O 0 2.17783435729757e-09
encoding O 0 1.99226395380947e-08
type O 0 9.209443305735476e-07
XVII O 0 0.003264766652137041
collagen O 0 2.163134740840178e-05
( O 0 2.8534651974609915e-08
COL17A1 O 0 2.68909425358288e-05
) O 0 3.408680226968386e-09
. O 0 2.2880007222170207e-08

Recently O 0 1.062882711266866e-05
, O 0 1.1711223990573671e-08
we O 0 8.81951012221549e-10
reported O 0 1.6127221780237733e-09
five O 0 4.5722037267381666e-10
Austrian O 0 7.663699364002241e-08
families O 0 2.7286533033077376e-09
with O 0 3.2569931196491098e-09
generalized O 0 0.02345571108162403
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
who O 0 0.0001629573671380058
share O 0 3.770744001485582e-07
the O 0 5.130549425302888e-07
same O 0 1.4711321227878216e-07
COL17A1 O 0 0.0011095743393525481
mutation O 0 7.841913429729175e-07
. O 0 1.6405937230956624e-07

Affected O 0 3.724468342625187e-07
individuals O 0 2.880201077637423e-10
in O 0 2.359660689066345e-09
three O 0 2.301559387518637e-09
families O 0 1.0491901791809255e-09
are O 0 2.537989540751795e-10
homozygous O 0 5.438646422106785e-09
for O 0 1.0740955902477367e-09
4003delTC O 0 7.743543051219604e-08
, O 0 1.2274414817881052e-10
whereas O 0 3.5744249227143143e-10
those O 0 2.6763904981130793e-10
in O 0 7.060339535236437e-10
two O 0 4.4972336965543036e-10
others O 0 2.4173224533186044e-10
are O 0 5.043071862886883e-11
compound O 0 1.7338504676445154e-07
heterozygotes O 0 6.295492198660213e-07
. O 0 2.5870286890494754e-07

To O 0 2.687363576114876e-07
determine O 0 8.845091059583865e-08
if O 0 5.0533888185100295e-09
the O 0 4.953512267036331e-09
occurrence O 0 4.778816453665513e-09
of O 0 3.032124773483247e-09
4003delTC O 0 1.5848035772592084e-08
in O 0 1.0132077121749461e-10
these O 0 5.580798670412612e-11
unrelated O 0 2.4178448132516905e-09
families O 0 8.012870922335935e-11
signifies O 0 9.477300888516282e-11
propagation O 0 1.9522511607306114e-08
of O 0 6.37661523583688e-09
an O 0 3.572503126658688e-10
ancestral O 0 8.761139014268338e-08
allele O 0 2.9815991897663707e-09
or O 0 6.348533698741221e-09
a O 0 6.947306729898628e-08
mutational O 0 3.8984868297120556e-05
hot O 0 7.497272599721327e-05
spot O 0 1.1717902452801354e-06
, O 0 2.8045762934247875e-10
haplotypes O 0 5.066263408792793e-09
were O 0 1.3617963423584456e-09
determined O 0 3.828244832249084e-09
for O 0 1.2951074657152617e-09
polymorphisms O 0 1.986864006653377e-08
both O 0 2.2461263959883127e-09
within O 0 4.772807216113506e-08
and O 0 5.336733366334556e-08
flanking O 0 0.0013750087236985564
COL17A1 O 1 0.9999327659606934
. O 0 5.931910891376901e-06

Five O 0 8.554769010515884e-06
intragenic O 0 2.025456888077315e-05
polymorphisms O 0 4.2550584566924954e-07
were O 0 1.9233853620903574e-08
chosen O 0 1.414330874638381e-08
based O 0 3.396390368948232e-08
on O 0 3.0954410590311454e-07
their O 0 4.872552139545405e-08
informativeness O 0 5.476546357385814e-05
. O 0 3.228904290608625e-07

One O 0 5.202380748414726e-07
of O 0 1.4313961571588152e-07
these O 0 1.9247714533321414e-09
, O 0 2.267328269578428e-10
not O 0 1.4900961020636316e-10
previously O 0 3.969371942247335e-09
reported O 0 2.5477593368350426e-09
, O 0 3.4080155364435427e-10
was O 0 2.6789775731117516e-08
2988 O 0 4.0012048430071445e-07
A O 0 2.2123134613138973e-07
or O 0 2.127175058319608e-08
C O 0 1.084103132598102e-06
that O 0 1.3199008552788882e-09
introduces O 0 3.707703255528827e-09
a O 0 1.9325405720138633e-09
new O 0 2.3364707946171848e-09
restriction O 0 3.579509577633644e-09
site O 0 1.01645873940015e-08
for O 0 2.6850521805954486e-10
Eco0109 O 0 2.671841912160744e-07
I O 0 1.8332065110371332e-06
. O 0 1.3675473553576012e-07

All O 0 7.607207521687087e-07
the O 0 2.72548248858584e-07
4003delTC O 0 6.482782168859558e-07
alleles O 0 1.9897603564800193e-09
showed O 0 1.4403064296786283e-09
the O 0 6.541789332459302e-10
same O 0 5.790930512894477e-10
haplotype O 0 1.0193733146479644e-07
for O 0 6.573320221470169e-10
these O 0 4.248144891416672e-10
five O 0 3.1755913454389884e-09
polymorphic O 0 1.3897390260808606e-07
markers O 0 3.535816119892843e-07
. O 0 3.131445396320487e-07

Fourteen O 0 3.742799526662566e-05
microsatellite O 0 4.27765044150874e-05
polymorphisms O 0 1.106052422983339e-06
were O 0 3.312970164870421e-08
selected O 0 4.428390987243347e-09
based O 0 7.289327363935172e-09
on O 0 7.993511275117271e-08
their O 0 2.490715855785197e-09
high O 0 1.1220016915558517e-07
heterozygosity O 0 5.25263931194786e-06
and O 0 2.137781729416588e-09
their O 0 3.2941789296359048e-09
location O 0 8.346632540678911e-08
within O 0 1.0483866219601623e-08
10q23 O 0 3.839776070435619e-07
- O 0 1.920596162108268e-07
q25 O 0 2.001030452447594e-06
near O 0 2.9513357731048018e-06
COL17A1 O 0 0.00036104783066548407
. O 0 8.678899803271634e-07

Three O 0 1.3638892824019422e-06
families O 0 1.800511739702415e-07
shared O 0 3.6326716212897736e-07
microsatellite O 0 1.880661875475198e-05
polymorphisms O 0 3.8125476748973597e-06
covering O 0 1.2297788316573133e-06
at O 0 3.1179698112282495e-07
most O 0 7.762971598879176e-09
19 O 0 1.216154288385951e-08
cM O 0 2.152388844933739e-08
, O 0 3.5324515534895795e-10
whereas O 0 7.162724635634277e-09
the O 0 8.502419746037049e-07
others O 0 1.1796159782306859e-07
shared O 0 8.803821316405447e-08
smaller O 0 2.0488002405727457e-08
regions O 0 2.295194034829251e-09
consistent O 0 2.7349333464599113e-08
with O 0 1.5038045253490395e-09
cross O 0 9.1205912156056e-08
- O 0 1.632165123055529e-07
over O 0 2.8457349809940524e-09
events O 0 1.9532325756799196e-10
during O 0 6.950123809801312e-10
passage O 0 6.552353659650123e-10
of O 0 1.1420213386070799e-10
this O 0 6.525556570796676e-12
mutation O 0 4.004782963584752e-11
through O 0 1.187559495186008e-10
several O 0 4.99561836342366e-10
generations O 0 8.192863276690332e-08
. O 0 1.4314029783690785e-07

These O 0 3.674846738022097e-08
results O 0 1.3668479681427925e-08
indicate O 0 9.048679139311844e-09
that O 0 4.713356926977497e-10
4003delTC O 0 1.0441104336678109e-07
occurs O 0 2.3392396908406e-09
on O 0 3.466449571831731e-09
a O 0 5.100642130884125e-10
single O 0 1.185213593934975e-09
ancestral O 0 4.980420342803882e-08
allele O 0 8.196470169252734e-09
. O 0 3.020954597587888e-09
. O 0 3.1727356741839685e-08

The O 0 1.1185214134457055e-05
haptoglobin O 0 0.000271056400379166
- O 0 3.1635222512704786e-06
gene O 0 4.235810280306396e-08
deletion O 0 8.1846167176991e-08
responsible O 0 1.1161847446317097e-08
for O 0 1.8803142154411034e-08
anhaptoglobinemia B-Disease 0 0.0001971729943761602
. O 0 1.78638038050849e-06

We O 0 6.631208293583768e-07
have O 0 1.3832660350487913e-08
found O 0 8.21404633200018e-09
an O 0 4.1653741567060365e-10
allelic O 0 1.2388693448883714e-07
deletion O 0 1.990786842043235e-07
of O 0 3.770804823943763e-07
the O 0 8.246369134212728e-07
haptoglobin O 0 7.142255344660953e-05
( O 0 2.0859600269318435e-08
Hp O 0 3.6568081895893556e-07
) O 0 4.302239398068508e-10
gene O 0 7.339155949637188e-10
from O 0 8.04147526345389e-10
an O 0 1.0907681702310157e-10
individual O 0 1.0433028052592164e-10
with O 0 5.746895181957257e-10
anhaptoglobinemia B-Disease 0 1.0417366866022348e-05
. O 0 5.892977696930757e-07

The O 0 6.83083817420993e-06
Hp O 0 3.097779199379147e-06
gene O 0 4.058594171851837e-08
cluster O 0 4.008571963254326e-08
consists O 0 6.685032527542489e-09
of O 0 3.384594648991879e-08
coding O 0 6.487160817414406e-07
regions O 0 7.182605088473792e-08
of O 0 3.674416075227782e-05
the O 0 9.157299064099789e-05
alpha O 0 8.306133736368793e-07
chain O 0 9.10991282410123e-09
and O 0 5.728006957639309e-10
beta O 0 7.923272704601914e-09
chain O 0 1.0158113461500307e-08
of O 0 8.261811679233233e-09
the O 0 3.1774895603575715e-08
haptoglobin O 0 5.227834662946407e-07
gene O 0 3.283251670538334e-09
( O 0 1.535579857714353e-10
Hp O 0 1.147211836638462e-08
) O 0 1.1408456818129409e-10
and O 0 4.1798908778645227e-10
of O 0 1.9476246393423935e-08
the O 0 1.0037378217475634e-07
alpha O 0 1.237376920926181e-07
chain O 0 1.2378532865398029e-08
and O 0 1.9539192486206503e-09
beta O 0 2.6768017136191702e-08
chain O 0 6.090437487671352e-09
of O 0 6.637539851084284e-09
the O 0 1.520588810421941e-08
haptoglobin O 0 1.693296326266136e-06
- O 0 8.88587692315923e-08
related O 0 2.0700191782907496e-08
gene O 0 1.4300802320121875e-08
( O 0 7.696446813199032e-10
Hpr O 0 5.8007191228171e-07
) O 0 8.05010003102069e-10
, O 0 2.8677135666121956e-10
in O 0 1.8593004913469713e-09
tandem O 0 1.9829386133096705e-07
from O 0 5.778005629508698e-08
the O 0 2.8064340540367994e-07
5 O 0 2.3292065520763572e-07
side O 0 8.437193628196837e-07
. O 0 5.404894523053372e-07

Southern O 0 0.00018303869001101702
blot O 0 0.0003858351265080273
and O 0 2.735288830990612e-07
PCR O 0 2.4017051600822015e-06
analyses O 0 5.9381321193541226e-08
have O 0 8.609062907005693e-10
indicated O 0 3.267296877496051e-09
that O 0 4.281656973414982e-11
the O 0 4.137912512636177e-10
individual O 0 3.2623476402954266e-12
with O 0 1.0438517238087197e-11
anhaptoglobinemia B-Disease 0 3.6520191315503325e-08
was O 0 2.0204941719725866e-08
homozygous O 0 1.3693942646497703e-09
for O 0 5.679811621028819e-10
the O 0 4.054615310167264e-09
gene O 0 1.0143723638833535e-09
deletion O 0 1.1802129940008399e-08
and O 0 4.985319379535724e-10
that O 0 7.310232280621776e-11
the O 0 3.9488776693019645e-09
gene O 0 8.345399926668051e-10
deletion O 0 5.772186284502823e-09
was O 0 1.864159138165178e-08
included O 0 8.623968761334311e-10
at O 0 3.906118539731551e-09
least O 0 1.9114827776167687e-10
from O 0 7.949486624525548e-10
the O 0 8.467452516924823e-09
promoter O 0 6.015605436004989e-07
region O 0 1.5842994116610498e-07
of O 0 1.56856356170465e-06
Hp O 0 2.5359040591865778e-05
to O 0 2.609271803066804e-07
Hpr O 0 1.9174285625922494e-05
alpha O 0 4.6098006123429514e-07
but O 0 1.5784585860600941e-09
not O 0 4.842695133788766e-10
to O 0 2.3024813167182856e-09
Hpr O 0 2.397322987235384e-06
beta O 0 4.094158043699281e-07
( O 0 1.299983010127903e-09
Hpdel O 0 4.7553604076711053e-07
) O 0 3.4761691303231146e-09
. O 0 5.71123450754385e-08

In O 0 2.841826471922104e-07
addition O 0 2.6493124138937674e-08
, O 0 4.435187328510892e-09
we O 0 4.0128211864498553e-10
found O 0 6.195448598589337e-10
seven O 0 5.034760941491356e-10
individuals O 0 3.082584318012116e-12
with O 0 7.960073572510495e-11
hypohaptoglobinemia B-Disease 0 8.81742289493559e-06
in O 0 1.539643079695452e-08
three O 0 1.509728342341532e-08
families O 0 3.672834036905215e-09
, O 0 3.170590734402623e-10
and O 0 7.536248292083769e-10
the O 0 1.0834271257920136e-08
genotypes O 0 6.065572932811847e-08
of O 0 2.498678384199593e-07
six O 0 5.903620348135519e-08
of O 0 4.1261037608819606e-07
the O 0 1.8121636458090506e-07
seven O 0 2.491266970494621e-09
individuals O 0 8.235368116615849e-12
were O 0 8.517987981626618e-10
found O 0 9.422259639180197e-10
to O 0 1.1920989750890953e-09
be O 0 2.0052983273899372e-08
Hp2 O 0 0.0011431206949055195
/ O 0 0.0002120478602591902
Hpdel O 0 0.0004324215988162905
. O 0 1.3507700487025431e-06

The O 0 1.3488284821505658e-05
phenotypes O 0 8.77183902048273e-06
and O 0 7.272679170000629e-08
genotypes O 0 7.212229320430197e-07
in O 0 6.678303687834841e-09
one O 0 8.049884092642401e-10
of O 0 4.264838704415297e-09
these O 0 4.901574146565224e-10
three O 0 1.5511084638930583e-09
families O 0 4.779069362470523e-10
showed O 0 8.611953372650305e-10
the O 0 3.483901833689629e-09
father O 0 1.1774051245083683e-07
to O 0 4.184966595488504e-09
be O 0 2.1862799570726565e-08
hypohaptoglobinemic B-Disease 0 4.772461124957772e-06
( O 0 3.769252909791021e-09
Hp2 O 0 1.3819837931805523e-06
) O 0 1.4795982217208348e-09
and O 0 1.070876454178915e-08
Hp2 O 0 9.024440805660561e-05
/ O 0 1.6693635188858025e-05
Hpdel O 0 0.00010592838953016326
, O 0 6.899737670096329e-09
the O 0 4.883307624936606e-08
mother O 0 3.306581675133202e-08
to O 0 3.372986334682082e-09
be O 0 3.911076351670317e-09
Hp2 O 0 2.660861809999915e-06
- O 0 2.332360509171849e-07
1 O 0 9.642363352213579e-08
and O 0 6.1542895224420135e-09
Hp1 O 0 1.434023943147622e-05
/ O 0 9.950681487680413e-07
Hp2 O 0 3.4938268527184846e-06
, O 0 4.436893907833195e-10
one O 0 9.656374311273197e-11
of O 0 3.1126674571169133e-09
the O 0 9.418132940197665e-09
two O 0 6.676058594834444e-10
children O 0 9.55112239298117e-11
to O 0 5.585422679921237e-10
be O 0 1.5911366446630382e-08
hypohaptoglobinemic B-Disease 0 7.800177627359517e-06
( O 0 9.277300705434754e-09
Hp2 O 0 6.707246939186007e-06
) O 0 2.706411983410817e-09
and O 0 2.7836881244525102e-08
Hp2 O 0 0.0008202517637982965
/ O 0 0.00012280767259653658
Hpdel O 0 0.00044943083776161075
, O 0 4.635075434578084e-09
and O 0 1.1811807087980242e-09
the O 0 8.824158292952688e-09
other O 0 6.021637632969146e-10
child O 0 2.0111885490337045e-09
to O 0 3.751391974837759e-10
be O 0 3.321092290065053e-09
Hp1 O 0 7.890097549534403e-06
and O 0 3.187863839571037e-08
Hp1 O 0 0.00013256326201371849
/ O 0 3.7727688322775066e-05
Hpdel O 0 8.331175922648981e-05
, O 0 1.1376694031284273e-09
showing O 0 1.2072995936307507e-09
an O 0 9.986187571309202e-11
anomalous O 0 2.7934961011055748e-08
inheritance O 0 2.3729053282295354e-06
of O 0 0.00021180738986004144
Hp O 0 0.00031503476202487946
phenotypes O 0 2.8375768579280702e-06
in O 0 1.51481653887231e-08
the O 0 1.1344526029688495e-07
child O 0 7.424059589311582e-08
with O 0 1.4209663667941186e-08
Hp1 O 0 0.0001794047566363588
. O 0 2.9465884381352225e-06

The O 0 8.082006388576701e-05
Hp2 O 0 0.018317079171538353
/ O 0 0.0005447373841889203
Hpdel O 0 0.0001011867425404489
individuals O 0 2.3322630493538554e-09
had O 0 6.362791538094825e-08
an O 0 6.155390086526324e-10
extremely O 0 1.6434837490919563e-08
low O 0 4.128047805807e-07
level O 0 1.251260783874386e-07
of O 0 7.006136826248621e-08
Hp O 0 2.0627324204269826e-07
( O 0 4.6235237860514644e-10
mean O 0 4.832141797805889e-09
+ O 0 3.8226266596552705e-09
/ O 0 6.239877059499577e-09
- O 0 1.0958428831031597e-08
SD O 0 1.6513337186552235e-07
= O 0 5.6311653118257254e-09
0 O 0 1.0514499271252475e-09
. O 0 1.4873899334411078e-10
049 O 0 4.6753175553249093e-08
+ O 0 1.70392655540752e-09
/ O 0 7.343401886572565e-09
- O 0 1.2274660399214099e-08
0 O 0 6.007025987742054e-09
. O 0 8.748706203931533e-10
043 O 0 4.6212099391595984e-07
mg O 0 7.445685668017177e-08
/ O 0 7.985202721272344e-09
ml O 0 5.868545205345299e-09
; O 0 3.385611513362363e-10
n O 0 2.8468425394834185e-09
= O 0 2.561900469544298e-09
6 O 0 1.9948676044379e-09
) O 0 1.2629738400937729e-11
, O 0 6.49404401781295e-12
compared O 0 1.2472084476300438e-10
with O 0 8.670227730211977e-11
the O 0 4.773824002768379e-09
level O 0 2.7180114159364166e-08
( O 0 1.9215644353476335e-10
1 O 0 3.3172558033811583e-09
. O 0 1.989770709309724e-10
64 O 0 4.707717327079308e-09
+ O 0 2.557662526214699e-09
/ O 0 4.0816408031219e-09
- O 0 5.122112511912746e-09
1 O 0 7.581117955623995e-09
. O 0 3.167689166527765e-10
07 O 0 1.2441020658116031e-08
mg O 0 2.2007936806289763e-08
/ O 0 4.595734459655887e-09
ml O 0 9.646916598882171e-10
) O 0 4.704343685435486e-12
obtained O 0 1.0574851411204733e-10
from O 0 2.1176929099198105e-09
52 O 0 2.860669390258863e-08
healthy O 0 6.276725361686886e-09
volunteers O 0 5.587748486135524e-09
having O 0 1.3629533945902494e-08
phenotype O 0 5.809643539578246e-07
Hp2 O 0 5.118324679642683e-06
, O 0 1.3032700474369108e-09
whereas O 0 4.529811636899694e-09
the O 0 2.3400621884661632e-08
serum O 0 7.124751277842734e-07
Hp O 0 1.584106001928376e-07
level O 0 1.3319850999948812e-08
of O 0 3.608836784962932e-09
an O 0 3.510955068342092e-11
individual O 0 2.782419043431683e-12
with O 0 4.679128612350425e-11
Hp1 O 0 9.515892998024356e-07
/ O 0 1.8291500225586788e-07
Hpdel O 0 2.178383283535368e-06
was O 0 3.122093801266601e-07
0 O 0 5.623977372692934e-08
. O 0 1.953286599132298e-08

50 O 0 2.8694566935882904e-06
mg O 0 8.370869181817397e-06
/ O 0 8.945613103605865e-07
ml O 0 2.1146794892956677e-07
, O 0 3.4637642754020703e-10
which O 0 1.3422565836584965e-10
was O 0 8.288944641776652e-09
approximately O 0 6.754802273079008e-11
half O 0 2.2333181137756952e-10
the O 0 3.2004107697325423e-10
level O 0 3.2201044053437045e-09
of O 0 3.578567664419552e-09
Hp O 0 9.520470456436669e-08
in O 0 2.5255515456734656e-09
control O 0 2.5073958909160865e-07
sera O 0 3.6355621091388457e-07
from O 0 7.480228880751838e-09
the O 0 3.66407562069071e-08
Hp1 O 0 1.0358374993302277e-06
phenotype O 0 4.276407494785417e-08
( O 0 3.032181172812898e-10
1 O 0 4.440824596940729e-09
. O 0 4.097605865727161e-10
26 O 0 4.605711367844378e-09
+ O 0 2.2548314326797936e-09
/ O 0 5.4325712817160365e-09
- O 0 6.3911294034824095e-09
0 O 0 2.961117351318876e-09
. O 0 3.1309518866429187e-10
33 O 0 6.766943005942494e-09
mg O 0 1.6447570416744384e-08
/ O 0 4.336844661168016e-09
ml O 0 5.134799696548953e-09
; O 0 2.648804509064462e-10
n O 0 6.692687293252675e-09
= O 0 4.62418769942019e-09
9 O 0 4.027837618991725e-09
) O 0 6.004179098351159e-11
, O 0 1.9453494370935687e-11
showing O 0 5.027046001693236e-10
a O 0 3.290398620237056e-09
gene O 0 4.942187548095944e-09
- O 0 2.348266647800301e-08
dosage O 0 3.9207176882882777e-07
effect O 0 4.378525488846208e-07
. O 0 3.95950678466761e-07

The O 0 8.727481144887861e-06
other O 0 1.0508333048164786e-07
allele O 0 4.8111491679492246e-08
( O 0 1.2079882649729257e-09
Hp2 O 0 1.079913545254385e-06
) O 0 5.757559429220294e-10
of O 0 4.111355256242177e-09
individuals O 0 1.8811410762431535e-10
with O 0 4.484524307457605e-09
Hp2 O 0 0.4478518068790436
/ O 0 0.0006133450078777969
Hpdel O 0 0.00024587861844338477
was O 0 8.639121347187029e-07
found O 0 1.722053166730575e-09
to O 0 2.5767085687355973e-10
have O 0 1.1030765884045834e-10
, O 0 3.1388669441412276e-11
in O 0 1.190555570795837e-10
all O 0 2.841850088586284e-10
exons O 0 2.530461529204331e-08
, O 0 5.574564421184647e-11
no O 0 5.32711444400924e-11
mutation O 0 2.6932881272423437e-11
, O 0 7.383206893085692e-12
by O 0 2.7409241543097096e-11
DNA O 0 3.512246493642124e-08
sequencing O 0 5.972424332867377e-07
. O 0 3.2866969945644087e-07

On O 0 2.7459052489575697e-06
the O 0 4.3306638275453224e-08
basis O 0 5.467644559331575e-09
of O 0 1.6533910240923433e-08
the O 0 4.808183629023688e-09
present O 0 1.2329631760010784e-09
study O 0 6.351364434387108e-10
, O 0 4.142632764603249e-11
the O 0 5.512890699499451e-10
mechanism O 0 5.500680799741531e-08
of O 0 9.738548811810688e-08
anhaptoglobinemia B-Disease 0 8.021237590583041e-06
and O 0 9.130421751990525e-09
the O 0 1.582924369358807e-08
mechanism O 0 7.677012803242178e-08
of O 0 2.3914648039635722e-08
anomalous O 0 1.8379454047590116e-07
inheritance O 0 4.1089668911808985e-07
of O 0 8.64841979364428e-07
Hp O 0 2.1322787233657436e-06
phenotypes O 0 1.281377137729578e-07
were O 0 1.34025226472545e-08
well O 0 7.70354358081704e-09
explained O 0 5.712215056519199e-08
. O 0 7.553135361604291e-08

However O 0 2.6026560817626887e-07
, O 0 2.6704261024690368e-09
the O 0 2.9986746419297106e-09
mechanism O 0 4.76880295252613e-08
of O 0 1.386629264743533e-07
hypohaptoglobinemia B-Disease 0 0.00015270266158040613
remains O 0 4.7262943553505465e-05
unknown O 0 3.8700276490999386e-05

ATM O 0 0.00013057069736532867
mutations O 0 3.5167718692719063e-07
and O 0 4.7634941324758984e-08
phenotypes O 0 4.730762611870887e-06
in O 0 1.3140007695255917e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 1 0.9976574182510376
in O 0 3.087309892180201e-07
the O 0 8.495781003148295e-07
British O 0 5.710623440791096e-07
Isles O 0 2.524051524233073e-06
: O 0 5.540434777628889e-10
expression O 0 1.6966751337221808e-09
of O 0 2.4163846035207825e-08
mutant O 0 2.6856950441356275e-08
ATM O 0 5.5263189580045946e-08
and O 0 2.8129551465916336e-10
the O 0 8.529286166236716e-10
risk O 0 1.3634831041997586e-09
of O 0 1.0989888998835795e-08
leukemia B-Disease 1 1.0
, O 0 2.9322138743737014e-06
lymphoma B-Disease 1 1.0
, O 0 1.0404024806121015e-06
and O 0 0.00012884374882560223
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999983310699463
. O 0 4.9646419029159006e-06

We O 0 1.519870380661814e-07
report O 0 6.7883378918054404e-09
the O 0 7.2625150338012645e-09
spectrum O 0 1.0553587515005347e-07
of O 0 2.402794585520951e-08
59 O 0 3.330113429456105e-08
ATM O 0 9.51763823309193e-08
mutations O 0 2.537623000620215e-09
observed O 0 6.346160930092992e-09
in O 0 5.6981559026780815e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999996423721313
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.4372036005738664e-08
patients O 0 1.5007708853431723e-08
in O 0 1.4446893681352435e-09
the O 0 5.967231686554442e-08
British O 0 4.561807713798771e-07
Isles O 0 1.0022577953350265e-05
. O 0 2.520856412502326e-07

Of O 0 3.0168392186169513e-05
51 O 0 4.135450126341311e-06
ATM O 0 6.671712071693037e-06
mutations O 0 2.631951190323889e-08
identified O 0 1.5600280178773573e-08
in O 0 2.42029019048573e-09
families O 0 1.621395240292145e-09
native O 0 3.4911260549108647e-09
to O 0 1.2342713517909942e-09
the O 0 8.71896261855909e-08
British O 0 4.6019118826734484e-07
Isles O 0 5.0416165322531015e-06
, O 0 1.3831227274607727e-09
11 O 0 3.855121999407629e-09
were O 0 7.083016839715128e-09
founder O 0 1.5224946992020705e-07
mutations O 0 9.25744647606308e-10
, O 0 1.792701403990904e-10
and O 0 1.0858740573382875e-09
2 O 0 7.730571383035567e-08
of O 0 2.1817685436076317e-08
these O 0 1.0247415360709056e-08
11 O 0 3.412005966652032e-08
conferred O 0 8.049369881746316e-08
a O 0 9.927098254536304e-09
milder O 0 1.1537485988810658e-06
clinical O 0 5.028221039538039e-08
phenotype O 0 1.929138804257491e-08
with O 0 4.959179247809864e-11
respect O 0 1.2429107743017198e-09
to O 0 3.0613138690682717e-09
both O 0 4.964410749153103e-08
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 9.048085485119373e-05
cellular O 0 1.560385726406821e-06
features O 0 8.301019960299527e-08
. O 0 8.580301624760978e-08

We O 0 4.3236363467258343e-07
report O 0 3.5876315251925917e-08
, O 0 2.518125041817143e-09
in O 0 2.0567747505140233e-09
two O 0 8.939284867892638e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999979734420776
T I-Disease 1 1.0
families O 0 8.958231774158776e-07
, O 0 4.847114265515984e-09
an O 0 1.5317631607558724e-09
ATM O 0 1.9364718184533558e-07
mutation O 0 5.395972557664663e-09
( O 0 6.372429806056346e-10
7271T O 0 1.650200260883139e-07
- O 0 5.352350740395195e-07
- O 0 1.8740397536021192e-06
> O 0 2.249526914965827e-06
G O 0 7.234907570818905e-07
) O 0 1.1718988279785236e-10
that O 0 6.783564161783051e-12
may O 0 2.030281359699515e-10
be O 0 4.264053346525465e-11
associated O 0 2.4552024302515463e-10
with O 0 9.786646319731584e-12
an O 0 3.6232596783980497e-12
increased O 0 3.619793700893048e-11
risk O 0 1.9459303057800525e-09
of O 0 1.7964792675684293e-07
breast B-Disease 1 0.9837443232536316
cancer I-Disease 0 0.00016499384946655482
in O 0 9.643132514725039e-09
both O 0 1.513866187963231e-08
homozygotes O 0 6.663965450570686e-07
and O 0 8.182552413416033e-09
heterozygotes O 0 8.84323512195806e-08
( O 0 5.438841044203002e-10
relative O 0 4.472815007261488e-08
risk O 0 2.2519699882650457e-08
12 O 0 5.392331026143893e-09
. O 0 6.9394606727613e-10
7 O 0 1.3245267105332914e-08
; O 0 1.108721670028956e-09
P O 0 7.608316536789062e-07
= O 0 1.3216775229807354e-08
. O 0 6.596757584631519e-10
0025 O 0 2.0720186455491785e-07
) O 0 3.871712325742571e-11
, O 0 6.212707431840769e-12
although O 0 7.246097472046742e-11
there O 0 5.479917214445962e-11
is O 0 5.627788512985177e-11
a O 0 3.369531875740961e-10
less O 0 2.0149359958310242e-09
severe O 0 0.0001741895393934101
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 1.519348700185219e-07
in O 0 7.655244493864899e-11
terms O 0 8.46337513960016e-11
of O 0 5.001262182169341e-10
the O 0 1.519033371311096e-10
degree O 0 4.379562934531123e-09
of O 0 1.3104844320821485e-08
cerebellar B-Disease 1 0.9999828338623047
degeneration I-Disease 1 1.0
. O 0 6.689685505989473e-06

This O 0 6.737620310559578e-07
mutation O 0 7.75986634948822e-08
( O 0 2.7075117703390106e-09
7271T O 0 1.4231449085855274e-07
- O 0 9.010997814584698e-08
- O 0 2.03435405410346e-07
> O 0 3.918620450349408e-07
G O 0 2.5234419354092097e-07
) O 0 2.9823202241097135e-10
also O 0 2.33110142300319e-10
allows O 0 1.6160191240732757e-10
expression O 0 3.643276791365224e-10
of O 0 4.063270608867242e-09
full O 0 9.40707334251556e-09
- O 0 1.3526847197908864e-08
length O 0 3.84629350591581e-09
ATM O 0 8.962916808741284e-08
protein O 0 9.301380110571245e-09
at O 0 9.09704200857675e-10
a O 0 1.1321381332418667e-10
level O 0 4.364308914261983e-10
comparable O 0 2.6853812506999475e-09
with O 0 1.7186453649120637e-11
that O 0 1.9784127461286438e-11
in O 0 3.4604297205476087e-10
unaffected O 0 5.016323711970472e-08
individuals O 0 1.016137868292688e-10
. O 0 1.8921651800951622e-08

In O 0 2.88042429019697e-07
addition O 0 9.475525075686164e-08
, O 0 4.968804034888308e-09
we O 0 6.584852663138463e-10
have O 0 1.8087410735834197e-10
studied O 0 1.3528524966943678e-08
18 O 0 3.801513770440579e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 5.210754807194462e-06
, O 0 2.915792052249344e-10
in O 0 3.7621689097377953e-10
15 O 0 9.790744881499336e-10
families O 0 1.8736856510770394e-10
, O 0 4.891391458539118e-11
who O 0 3.071084775374544e-10
developed O 0 1.1065314538427629e-05
leukemia B-Disease 1 1.0
, O 0 0.06460661441087723
lymphoma B-Disease 1 1.0
, O 0 0.00017674917762633413
preleukemic O 1 0.9993958473205566
T O 1 0.9982958436012268
- O 0 0.01695222035050392
cell O 0 0.000500527152325958
proliferation O 0 2.7724641768145375e-05
, O 0 5.572494132799477e-10
or O 0 7.497715728277399e-07
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 4.5469923293239844e-07
mostly O 0 6.005536956621427e-09
in O 0 8.489996261573651e-09
childhood O 0 2.1761512471130118e-05
. O 0 7.831025072846387e-07

A O 0 2.9938477382529527e-05
wide O 0 1.1531941481734975e-06
variety O 0 3.7811791031572284e-08
of O 0 1.0905596070642787e-07
ATM O 0 5.760832664236659e-07
mutation O 0 2.7633728638676303e-09
types O 0 6.601481139512089e-09
, O 0 2.395831588675179e-10
including O 0 8.334423706735095e-10
missense O 0 7.42815984722256e-07
mutations O 0 4.712903489689779e-08
and O 0 5.452754692214512e-08
in O 0 2.48437839189819e-08
- O 0 4.3076468614344776e-07
frame O 0 1.920652493936359e-06
deletions O 0 1.3696592304768274e-07
, O 0 2.9734650852653033e-10
were O 0 7.733026996525894e-10
seen O 0 1.4162170325349166e-09
in O 0 1.7614476544025592e-10
these O 0 8.96051677301557e-10
patients O 0 2.622165240495633e-08
. O 0 1.0065042488349718e-07

We O 0 5.731040801038034e-06
also O 0 5.870384001127604e-08
show O 0 2.5577795437214945e-09
that O 0 6.250901185556046e-11
25 O 0 6.160323362536246e-10
% O 0 6.246813483157254e-11
of O 0 1.7449263145508098e-09
all O 0 1.3980987922934673e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 7.083208402036689e-07
carried O 0 3.721336128137409e-08
in O 0 1.240533542556932e-08
- O 0 1.0631736557797922e-07
frame O 0 6.009274784446461e-07
deletions O 0 2.3106396440653043e-07
or O 0 1.0801880989674828e-07
missense O 0 7.654611522411869e-07
mutations O 0 1.2649525871211154e-08
, O 0 1.4315990060076444e-10
many O 0 6.855210149536717e-11
of O 0 5.076148834604055e-09
which O 0 5.3047494175118e-10
were O 0 1.2472686217179785e-09
also O 0 7.040326654994544e-11
associated O 0 1.8963833281482323e-10
with O 0 4.2394331101203164e-11
expression O 0 1.462084231462768e-09
of O 0 9.668533351714359e-08
mutant O 0 1.2968439477845095e-07
ATM O 0 8.93690014436288e-07
protein O 0 7.251195910384922e-08
. O 0 2.2901138763131712e-08

The O 0 3.8110645164124435e-06
DMPK O 0 0.00037594896275550127
gene O 0 3.010085833921039e-07
of O 0 1.3227295880824386e-07
severely O 0 0.000288971554255113
affected O 0 8.754122973186895e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9996015429496765
is O 0 2.060006920601154e-08
hypermethylated O 0 1.046815896188491e-06
proximal O 0 0.00011761576752178371
to O 0 1.0313067377865082e-07
the O 0 8.877608706825413e-06
largely O 0 5.498403652381967e-07
expanded O 0 4.203841115213436e-07
CTG O 0 1.3182042494008783e-05
repeat O 0 4.7460275709454436e-07
. O 0 1.0427889662878442e-07

Using O 0 2.7840417260449613e-06
methylation O 0 2.977690655825427e-06
- O 0 4.600981810654048e-06
sensitive O 0 3.8557454900001176e-06
restriction O 0 1.6057247975709288e-08
enzymes O 0 7.466829821112242e-09
, O 0 1.6368469080152437e-10
we O 0 1.7562377940816276e-10
characterized O 0 1.55538348867168e-09
the O 0 4.64341054495776e-09
methylation O 0 4.712712442511702e-09
pattern O 0 5.4646211999909156e-09
on O 0 2.0171055936657467e-08
the O 0 1.3309083612966788e-08
5 O 0 5.759747789824132e-09
side O 0 2.0040749504346422e-08
of O 0 7.343278696225752e-08
the O 0 3.2792550541671517e-07
CTG O 0 1.2679810424742755e-05
repeat O 0 2.9634920295507072e-08
in O 0 2.424531686529008e-09
the O 0 9.103885645345144e-09
DMPK O 0 2.0530032998067327e-06
gene O 0 2.180668978724043e-09
of O 0 1.3820441457923494e-09
normal O 0 1.2105669799922225e-09
individuals O 0 2.319439128609102e-12
and O 0 7.265057305749778e-11
of O 0 1.843811103796611e-09
patients O 0 2.6634570104988597e-09
affected O 0 2.3233566182057075e-09
with O 0 2.091090856026767e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 3.6528391422763207e-09
showing O 0 4.518005414233528e-10
expansions O 0 1.4142931270555437e-08
of O 0 6.837420585270593e-08
the O 0 9.32246564389061e-08
repetitive O 0 1.6604137442755018e-07
sequence O 0 3.157401806674898e-08
. O 0 5.92949689348643e-08

The O 0 7.812071999069303e-06
gene O 0 9.790081634264425e-08
segment O 0 5.7708245293497384e-08
analyzed O 0 5.5286886180283545e-09
corresponds O 0 4.111802454076496e-09
to O 0 4.448013513069782e-09
the O 0 8.252476391135133e-08
genomic O 0 7.605292466905667e-07
SacI O 0 1.3170860256650485e-05
- O 0 1.236855382558133e-07
HindIII O 0 5.79753361762414e-07
fragment O 0 2.562312317877513e-08
carrying O 0 1.0210151835110537e-08
exons O 0 1.2249383019025117e-07
11 O 0 4.7261540458976015e-08
- O 0 1.1445928294051555e-07
15 O 0 5.2830763763722643e-08
. O 0 1.097476953759724e-07

There O 0 1.3188387981699634e-07
is O 0 1.1291072077312947e-08
constitutive O 0 7.560333870060276e-07
methylation O 0 7.204406529126572e-07
in O 0 1.1039348635222268e-07
intron O 0 1.9397341020521708e-05
12 O 0 5.217131615609105e-07
at O 0 3.8210032471397426e-08
restriction O 0 1.9240595783287517e-09
sites O 0 2.4074311433253115e-09
of O 0 1.5115782403540834e-08
SacII O 0 1.8616631223267177e-06
and O 0 1.9463135103592322e-08
HhaI O 0 2.170563448089524e-06
, O 0 8.794783235011039e-10
localized O 0 3.896045797091574e-08
1 O 0 2.6382590334605993e-08
, O 0 1.758282408559353e-10
159 O 0 3.4104881141416854e-09
- O 0 2.788587849522628e-08
1 O 0 3.470062992505518e-08
, O 0 1.0287989349322402e-09
232 O 0 9.312386417548169e-09
bp O 0 1.46116008181707e-07
upstream O 0 3.843398488356797e-08
of O 0 2.487944250617602e-08
the O 0 6.838568822331581e-08
CTG O 0 7.884809747338295e-06
repeat O 0 2.2011924727394216e-08
, O 0 1.38517600167809e-10
whereas O 0 1.1238662223078677e-09
most O 0 3.694261008213573e-10
, O 0 4.2016543022604935e-11
if O 0 3.55981563671115e-11
not O 0 4.234890910170819e-11
all O 0 6.745531910823388e-11
, O 0 2.9931175593578274e-11
of O 0 6.901313409635179e-10
the O 0 1.2744014732390951e-09
other O 0 4.437543735247296e-11
sites O 0 6.613096736884927e-10
of O 0 6.429889509718123e-09
SacII O 0 1.6444014363514725e-06
, O 0 1.7226543524984095e-09
HhaI O 0 5.073473403172102e-06
, O 0 2.8266067264581807e-09
and O 0 2.303605750597626e-09
HpaII O 0 1.7869284420157783e-05
in O 0 3.830450623354409e-09
this O 0 2.0911696818615155e-09
region O 0 5.065184183195015e-08
are O 0 2.9821796143636448e-09
unmethylated O 0 8.801225703791715e-06
, O 0 1.1248698639221288e-09
in O 0 2.565992418546159e-10
normal O 0 2.2263357823959495e-09
individuals O 0 8.81812158015638e-12
and O 0 1.399297760995566e-10
most O 0 1.8342483087963046e-10
of O 0 4.028544609013807e-09
the O 0 1.495088142178247e-08
patients O 0 1.966546214760001e-08
. O 0 6.958977394333488e-08

In O 0 2.7802215640804206e-07
a O 0 1.4909845802435484e-08
number O 0 2.747541638647988e-10
of O 0 1.1951755141126341e-08
young O 0 6.400437513320867e-09
and O 0 9.549419921484059e-09
severely O 0 0.00020922911062370986
affected O 0 1.0358429136658742e-07
patients O 0 2.2182203451848181e-07
, O 0 3.4491878797560105e-10
however O 0 1.237916325003141e-09
, O 0 1.1820409928642306e-10
complete O 0 4.666727004831728e-09
methylation O 0 5.010612369460432e-09
of O 0 2.8413309482999694e-09
these O 0 3.165611384137179e-10
restriction O 0 2.0117563170884978e-09
sites O 0 1.1300740343500593e-09
was O 0 2.7991267081972637e-09
found O 0 1.0581852755153776e-10
in O 0 6.103351157804582e-11
the O 0 1.513501768357628e-09
mutated O 0 2.230042639439489e-08
allele O 0 9.33787660528651e-08
. O 0 8.388704486606002e-08

In O 0 6.193138801791065e-08
most O 0 1.6606436226140886e-09
of O 0 1.5931856944817469e-09
these O 0 6.346928538292218e-11
patients O 0 3.9672051754813253e-10
, O 0 7.209176398209616e-12
the O 0 1.3563235257141315e-10
onset O 0 2.5952625946956687e-05
of O 0 8.513529081710658e-08
the O 0 3.045762468900648e-07
disease O 1 0.7594171762466431
was O 0 0.0007602557307109237
congenital O 1 1.0
. O 0 8.660901585244574e-06

Preliminary O 0 6.513273092423333e-06
in O 0 1.4116526472207624e-06
vivo O 0 2.5986755645135418e-05
footprinting O 0 0.0007221144041977823
data O 0 4.0389838318333204e-07
gave O 0 7.616398534082691e-08
evidence O 0 7.137673918578002e-08
for O 0 4.169732115144598e-09
protein O 0 1.32588144907686e-08
- O 0 2.4164997114439757e-08
DNA O 0 4.118923868645652e-08
contact O 0 6.542356345562439e-08
in O 0 2.999052339802688e-09
normal O 0 3.956139238425749e-08
genes O 0 5.816437553818332e-09
at O 0 7.199733698115551e-09
an O 0 3.904284395783719e-10
Sp1 O 0 6.067141384846764e-07
consensus O 0 1.5098817129910458e-07
binding O 0 2.2129337651222158e-07
site O 0 1.7045927052095067e-06
upstream O 0 7.261576939754377e-08
of O 0 1.9206835233376296e-08
the O 0 2.5802275871456004e-08
CTG O 0 2.361549604756874e-06
repeat O 0 1.2999142207092973e-08
and O 0 4.113824003670885e-10
for O 0 4.835281480763953e-11
a O 0 1.3747740446046208e-10
significant O 0 7.04420827224439e-11
reduction O 0 3.3698162038575674e-09
of O 0 3.5016294308576335e-09
this O 0 6.049770406857391e-11
interaction O 0 2.571072799106844e-10
in O 0 1.0062226746265779e-10
cells O 0 1.328148008239438e-10
with O 0 4.070402348510527e-11
a O 0 1.1083860940175327e-08
hypermethylated O 0 1.1581097396629048e-06
DMPK O 0 1.2758835509885103e-05
gene O 0 2.1793811200154778e-08
. O 0 5.821698678687426e-09
. O 0 2.6194310720484282e-08

The O 0 0.0008371673175133765
hemochromatosis B-Disease 1 1.0
gene O 0 2.3003607907412515e-07
product O 0 1.622150769264863e-08
complexes O 0 1.9679346152656763e-08
with O 0 8.28560553500779e-10
the O 0 4.7405990244442364e-08
transferrin O 0 4.583854752127081e-05
receptor O 0 1.1480835127031241e-07
and O 0 1.4918144497499952e-09
lowers O 0 2.1882701872755206e-08
its O 0 1.9378844362538672e-10
affinity O 0 6.29043317434963e-10
for O 0 5.311459605472635e-11
ligand O 0 2.6633415473042987e-08
binding O 0 4.1790979565803354e-08
. O 0 1.0272958661516896e-07

We O 0 4.785267719853437e-07
recently O 0 9.500480047108795e-08
reported O 0 8.90975204725919e-09
the O 0 1.6214942721859416e-09
positional O 0 2.328189339095843e-07
cloning O 0 2.6721799883944186e-08
of O 0 4.26456203683756e-09
a O 0 1.8352641628638366e-09
candidate O 0 3.7874134939386295e-09
gene O 0 1.4005382631410157e-08
for O 0 4.38328413565614e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9999998807907104
HFE O 1 0.9999996423721313
. O 0 3.5884299904864747e-06

The O 0 1.926373897731537e-06
gene O 0 1.1947150824198616e-08
product O 0 1.1358962659357985e-08
, O 0 7.249115197005551e-10
a O 0 3.0681004403732004e-09
member O 0 4.477063164642914e-09
of O 0 2.3591944398049236e-07
the O 0 1.4190372894518077e-06
major O 0 5.037589744461002e-06
histocompatibility O 1 0.9941798448562622
complex O 0 0.004623490385711193
class O 0 3.0843551712678163e-07
I O 0 7.950728104333393e-06
- O 0 4.7276688519559684e-07
like O 0 5.239841005533208e-09
family O 0 2.7173635785970873e-08
, O 0 1.2937810545121664e-10
was O 0 2.607083438022073e-09
found O 0 2.851764657751943e-10
to O 0 5.212366649409717e-10
have O 0 1.8211139263257792e-09
a O 0 3.468918308158209e-08
mutation O 0 4.459089986141862e-09
, O 0 1.1408854971861615e-09
Cys O 0 1.536323111395177e-06
- O 0 9.189125194097869e-07
282 O 0 6.879358807054814e-07
- O 0 2.154382627850282e-06
- O 0 4.694817107520066e-06
> O 0 2.645021368152811e-06
Tyr O 0 1.1842076673929114e-05
( O 0 1.0371091763161644e-09
C282Y O 0 8.557694108901615e-09
) O 0 2.312999097808799e-11
, O 0 5.57391285904707e-12
in O 0 3.5506476231406126e-11
85 O 0 1.3409062749047962e-09
% O 0 2.9641897270060724e-10
of O 0 3.284341687503911e-09
patient O 0 3.7649005690809645e-08
chromosomes O 0 7.380306499271683e-08
. O 0 2.639711738083861e-07

This O 0 1.9966317665875977e-07
mutation O 0 1.5300825850772526e-07
eliminates O 0 3.7774853467453795e-07
the O 0 4.122413699292338e-08
ability O 0 2.122255260417205e-08
of O 0 2.610508715861215e-07
HFE O 1 0.896719753742218
to O 0 2.750177259258635e-07
associate O 0 1.161317072728707e-06
with O 0 1.715131148216642e-08
beta2 O 0 6.684089748887345e-05
- O 0 1.5706000340287574e-05
microglobulin O 0 0.0001392061385558918
( O 0 2.502545726201788e-08
beta2m O 0 2.61703962678439e-06
) O 0 8.697428333093171e-10
and O 0 9.124394018122928e-10
prevents O 0 3.608795262621811e-09
cell O 0 1.05594529031805e-06
- O 0 5.216429954657542e-08
surface O 0 5.297607117427106e-07
expression O 0 1.09351525168222e-07
. O 0 9.140130430296267e-08

A O 0 9.177002357318997e-05
second O 0 3.7369636629591696e-06
mutation O 0 1.1966535318208571e-08
that O 0 5.365059507767e-10
has O 0 4.205119863431861e-10
no O 0 7.96120114276988e-10
effect O 0 8.468954426632536e-09
on O 0 6.445596767434836e-08
beta2m O 0 2.2248821096582105e-06
association O 0 9.373438025761516e-09
, O 0 1.3777515794899386e-09
H63D O 0 1.8267377527081408e-05
, O 0 2.379324737233901e-09
was O 0 2.778002183845274e-08
found O 0 3.74435066285983e-10
in O 0 1.8680011704130806e-10
eight O 0 3.158639183542533e-10
out O 0 2.753196559623916e-10
of O 0 5.3792641452332646e-09
nine O 0 1.1885986417325967e-08
patients O 0 2.8784008510029935e-09
heterozygous O 0 1.3717442737259944e-09
for O 0 2.7826037030109774e-09
the O 0 5.799137170470203e-07
C282Y O 0 2.8646678401855752e-05
mutant O 0 1.8464219465386122e-05
. O 0 1.2699442777375225e-06

In O 0 2.2530234389250836e-07
this O 0 3.5552865096377673e-09
report O 0 4.074943049658941e-09
, O 0 1.0171952169457654e-09
we O 0 2.795326747850879e-10
demonstrate O 0 3.4232880974371938e-09
in O 0 7.586614891863519e-09
cultured O 0 3.0716918786311e-07
293 O 0 6.493016257991258e-08
cells O 0 6.977318633971663e-08
overexpressing O 0 2.0863712961727288e-06
wild O 0 1.9940854656397278e-07
- O 0 1.198273338332001e-07
type O 0 2.2314864054351347e-06
or O 0 1.1022910939573194e-06
mutant O 0 9.88869828688621e-07
HFE O 0 7.594951966893859e-06
proteins O 0 4.4717957115025797e-10
that O 0 4.8938832153400114e-11
both O 0 1.726880721752977e-10
the O 0 6.803646535047392e-09
wild O 0 2.2830660029171668e-08
- O 0 1.724654019596983e-08
type O 0 1.5433882083470962e-07
and O 0 9.766730357796405e-08
H63D O 0 0.00019478380272630602
HFE O 0 3.208212729077786e-05
proteins O 0 1.4812330251245953e-09
form O 0 7.453507810950555e-10
stable O 0 2.0350986673633997e-08
complexes O 0 4.226486716163436e-09
with O 0 3.067467113648803e-10
the O 0 5.438981531824538e-08
transferrin O 0 7.026664661680115e-06
receptor O 0 6.076493264117744e-08
( O 0 2.4993090930180983e-10
TfR O 0 1.0603262978747807e-07
) O 0 2.1294217777967361e-10
. O 0 7.069640872714444e-09

The O 0 2.6783120119944215e-05
C282Y O 0 4.130993693252094e-05
mutation O 0 2.837612385064858e-07
nearly O 0 6.562212551131097e-09
completely O 0 2.1105647007857442e-08
prevents O 0 4.00113764342791e-09
the O 0 5.171056915997951e-09
association O 0 6.452097189857398e-10
of O 0 1.34803572748865e-08
the O 0 4.0041779669763855e-08
mutant O 0 3.450508074820391e-07
HFE O 0 5.019021955376957e-06
protein O 0 1.7167314680932577e-08
with O 0 4.932673713931024e-10
the O 0 4.0024602299126855e-08
TfR O 0 3.1814444810152054e-05
. O 0 4.834753326576902e-07

Studies O 0 5.344984970179212e-07
on O 0 3.158745585096767e-07
cell O 0 2.6297391286789207e-07
- O 0 7.461351714255215e-08
associated O 0 5.6834263517657746e-08
transferrin O 0 0.0003193423617631197
at O 0 4.1969110498030204e-07
37 O 0 1.90267481769979e-08
degrees O 0 3.6901664657307265e-07
C O 0 2.433507688692771e-07
suggest O 0 3.880366250541556e-09
that O 0 3.11837056177211e-10
the O 0 1.4018156413442284e-08
overexpressed O 0 6.195780315465527e-07
wild O 0 5.316859841286714e-08
- O 0 3.561980932431652e-08
type O 0 2.2951520861624886e-07
HFE O 0 0.00018902530428022146
protein O 0 3.743776133546817e-08
decreases O 0 1.2842644725452601e-09
the O 0 2.999119563806829e-10
affinity O 0 5.863484697776755e-10
of O 0 2.961128675593727e-09
the O 0 8.876285484404889e-09
TfR O 0 3.462979236701358e-07
for O 0 2.392928077910028e-09
transferrin O 0 8.842593160807155e-06
. O 0 1.807098328754364e-07

The O 0 0.0004353267140686512
overexpressed O 0 0.0042658294551074505
H63D O 1 0.7406920194625854
protein O 0 1.1066559864048031e-06
does O 0 2.905162777011583e-09
not O 0 1.8636736598409698e-10
have O 0 5.633910005187204e-11
this O 0 3.337955953308658e-11
effect O 0 1.7212969938285028e-10
, O 0 8.002785933935996e-12
providing O 0 2.938070967073436e-11
the O 0 1.170299412933673e-10
first O 0 6.084591164245978e-11
direct O 0 5.8173861561261475e-11
evidence O 0 6.029775012628136e-10
for O 0 1.5142689879787952e-10
a O 0 8.854771360589098e-10
functional O 0 2.9925171673994555e-08
consequence O 0 6.480420466914438e-08
of O 0 1.0792840043905017e-07
the O 0 2.766911393337068e-07
H63D O 0 0.0001543056860100478
mutation O 0 1.916190655038008e-07
. O 0 1.1389361986857693e-07

Addition O 0 8.542219234186632e-07
of O 0 3.049693987122737e-06
soluble O 0 4.253536098985933e-05
wild O 0 3.099235982517712e-06
- O 0 5.764717911915795e-07
type O 0 1.1986808203801047e-05
HFE O 1 1.0
/ O 1 0.990444004535675
beta2m O 0 0.00010571083112154156
heterodimers O 0 1.020217860059347e-05
to O 0 4.470563297331864e-08
cultured O 0 6.774952225896413e-07
cells O 0 5.636971422973147e-08
also O 0 2.808114574204268e-10
decreased O 0 6.480711522982574e-10
the O 0 1.3262552167603303e-09
apparent O 0 3.81201274990417e-08
affinity O 0 1.3964223555262834e-08
of O 0 3.7808472796996284e-08
the O 0 1.1748675809997167e-08
TfR O 0 9.27507599612909e-08
for O 0 1.049942355280109e-10
its O 0 3.9455230749219083e-11
ligand O 0 7.255177347786912e-09
under O 0 2.5885235288569675e-08
steady O 0 6.805894514627653e-08
- O 0 6.495788351656984e-09
state O 0 1.4202089504422588e-10
conditions O 0 6.643454675270277e-09
, O 0 5.559295385149099e-11
both O 0 6.677557812251322e-11
in O 0 1.6518605927551278e-10
293 O 0 6.652898232317739e-10
cells O 0 6.331479784904559e-10
and O 0 1.0400309502500704e-09
in O 0 4.6800527897516986e-09
HeLa O 0 5.5205523494805675e-06
cells O 0 5.186696512282651e-07
. O 0 3.1169651037998847e-07

Furthermore O 0 1.5948868394843885e-06
, O 0 2.840985580121469e-08
at O 0 3.271470205845617e-08
4 O 0 8.816285479440467e-09
degrees O 0 5.623290633138822e-08
C O 0 2.7832322757603833e-07
, O 0 5.425423998950407e-10
the O 0 4.717577883894819e-09
added O 0 4.679686416153572e-09
soluble O 0 1.0698029484501603e-07
complex O 0 3.198504430201865e-07
of O 0 3.383966031833552e-07
HFE O 0 0.330456018447876
/ O 0 1.2798614079656545e-05
beta2m O 0 1.6188487279578112e-06
inhibited O 0 3.194065811840119e-08
binding O 0 8.094322545559862e-09
of O 0 5.501352262626824e-08
transferrin O 0 1.0504127203603275e-05
to O 0 1.2252233716480987e-07
HeLa O 0 2.5560859285178594e-05
cell O 0 4.467111409667268e-07
TfR O 0 2.0503331654708745e-07
in O 0 3.764968614650144e-10
a O 0 1.2590066766904329e-09
concentration O 0 1.5264768649103644e-07
- O 0 5.8715709627676915e-08
dependent O 0 1.6280370829235835e-08
manner O 0 7.253921552319298e-08
. O 0 9.797684441537058e-08

Scatchard O 0 0.0013811428798362613
plots O 0 1.440247524442384e-05
of O 0 2.980000317620579e-06
these O 0 1.629786261503341e-08
data O 0 2.051858416507457e-08
indicate O 0 6.5938046134306205e-09
that O 0 6.195697288546853e-10
the O 0 6.371074334765581e-08
added O 0 8.464271061825457e-09
heterodimer O 0 3.340939258578146e-07
substantially O 0 1.5466630642890777e-08
reduced O 0 7.567090953841671e-09
the O 0 3.7001368635714016e-09
affinity O 0 6.163146437643263e-09
of O 0 4.6515573615124595e-09
TfR O 0 3.323296482449223e-07
for O 0 2.6016391263539163e-09
transferrin O 0 1.2633290680241771e-05
. O 0 3.316422976240574e-07

These O 0 9.255724364720663e-08
results O 0 3.0961786023908644e-08
establish O 0 1.0848027187648768e-07
a O 0 1.4572850481897603e-08
molecular O 0 6.94304134185586e-08
link O 0 1.0203400790942396e-07
between O 0 4.2558859547625616e-08
HFE O 1 0.9999979734420776
and O 0 3.4044178391923197e-06
a O 0 5.94937773712445e-07
key O 0 6.926480637048371e-06
protein O 0 5.143516546013416e-08
involved O 0 2.3422623840474444e-09
in O 0 2.7491262599710353e-09
iron O 1 0.692749559879303
transport O 0 2.8971905976504786e-06
, O 0 1.0110653425599025e-09
the O 0 9.462896244372132e-09
TfR O 0 2.77304775408993e-06
, O 0 5.885041898245902e-10
and O 0 6.832239218823588e-10
raise O 0 1.1430461022143845e-09
the O 0 3.514811330873613e-09
possibility O 0 4.313267965017076e-09
that O 0 1.597968979361042e-10
alterations O 0 2.6353117021926664e-08
in O 0 4.279503695858722e-10
this O 0 5.48443408743271e-11
regulatory O 0 6.260309604044778e-09
mechanism O 0 1.6099846789074945e-08
may O 0 4.165646494413977e-09
play O 0 8.889924352217804e-09
a O 0 3.951574623073384e-09
role O 0 4.724186819515808e-09
in O 0 4.3331052634876244e-10
the O 0 5.788238777171273e-09
pathogenesis O 1 0.6375217437744141
of O 0 0.4393776059150696
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0010436663869768381
. O 0 9.963862339645857e-07

Genomic O 0 7.366814770648489e-06
organization O 0 1.4627410394041362e-07
of O 0 1.123688775805931e-06
the O 0 1.7364297946187435e-06
UBE3A O 1 0.6022902131080627
/ O 0 0.00028066232334822416
E6 O 0 0.00041739290463738143
- O 0 1.3859882983524585e-06
AP O 0 1.7713770148475305e-06
gene O 0 5.9355023118712325e-09
and O 0 9.670148015672453e-10
related O 0 6.325715418142863e-08
pseudogenes O 0 2.850247074093204e-05
. O 0 9.671139196143486e-07

The O 0 3.601535354391672e-05
UBE3A O 0 0.0005161421140655875
gene O 0 5.691333626600681e-07
encodes O 0 1.1188730297817528e-07
the O 0 2.608955753657938e-07
E6 O 0 2.526013122405857e-05
- O 0 2.8290301088418346e-06
AP O 0 5.2075323765166104e-05
ubiquitin O 0 5.359958322515013e-06
- O 0 6.015639542056306e-07
protein O 0 1.6003284031285148e-08
ligase O 0 1.8712162486167472e-08
and O 0 2.3066397680793216e-09
has O 0 3.7027542143519554e-10
recently O 0 4.387980534481528e-10
been O 0 8.225781167325863e-11
shown O 0 3.922854402427234e-11
to O 0 1.0123340533907399e-11
be O 0 7.971103638260146e-11
mutated O 0 3.581703467148145e-08
in O 0 1.9257350913903792e-07
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.47681406140327454
who O 0 1.8549869196249347e-08
lack O 0 1.6565733176321373e-06
15q11 O 0 5.741122549807187e-06
- O 0 9.789275736693526e-07
q13 O 0 6.897858497723064e-07
deletions O 0 1.0781997161757317e-07
or O 0 4.0729872807787615e-08
chromosome O 0 8.816777352649297e-08
15 O 0 1.2469509158563596e-07
paternal O 0 5.749331467086449e-05
uniparental B-Disease 1 0.9999545812606812
disomy I-Disease 1 0.8836792707443237
. O 0 1.9749300918192603e-05

Previous O 0 3.177363032591529e-05
UBE3A O 0 0.0006029572105035186
cDNA O 0 2.5418300992896548e-06
analysis O 0 3.2753600720525355e-08
has O 0 8.362815440143834e-10
shown O 0 3.0531893679963673e-10
a O 0 5.939531089182992e-10
coding O 0 1.6156418425339325e-08
region O 0 2.024435730163532e-09
of O 0 1.2030178631050603e-08
approximately O 0 1.0490180946121086e-09
2 O 0 3.612364452010297e-08
. O 0 2.9309669358212886e-08

6 O 0 4.833881394006312e-05
kb O 0 2.727699938986916e-05
and O 0 7.709118676757498e-08
a O 0 2.8582323352566164e-07
3 O 0 1.3381765029407688e-06
- O 0 1.0587999668132397e-06
untranslated O 1 0.9999874830245972
region O 0 2.776241672108881e-06
( O 0 1.180861453065063e-08
UTR O 0 0.07340525835752487
) O 0 3.529759151632561e-09
of O 0 5.460779206600819e-08
< O 0 4.955868462275248e-07
50 O 0 2.0138459788654473e-08
bp O 0 6.160245646924523e-08
, O 0 1.6628422250253294e-10
whereas O 0 7.135803059554746e-10
Northern O 0 6.823933418331762e-09
analysis O 0 1.383191450265997e-09
has O 0 1.3194621784062832e-10
indicated O 0 5.548649040232334e-11
mRNA O 0 2.1278140360792008e-10
sizes O 0 1.168328433998056e-09
of O 0 1.0851458398519753e-08
5 O 0 4.891585447808211e-08
- O 0 1.8410364077681152e-07
8 O 0 4.0748838614490523e-07
kb O 0 1.4460623788181692e-05
. O 0 4.900550720776664e-07

We O 0 1.6124558896990493e-06
have O 0 2.2958300149866773e-08
analyzed O 0 1.7177042010985133e-08
additional O 0 4.717271906429232e-09
cDNA O 0 5.622421213047346e-07
clones O 0 4.217425839669886e-07
and O 0 1.4801994074886693e-09
provide O 0 2.3452653707956017e-10
evidence O 0 2.3858093278761316e-09
for O 0 1.5265212705006803e-10
an O 0 1.8999520706719508e-11
additional O 0 1.664232085474282e-10
0 O 0 1.4620849420055038e-08
. O 0 1.4028694650392026e-08

5 O 0 1.423885169060668e-05
kb O 0 1.050190348905744e-05
of O 0 2.480676585037145e-06
5 O 0 6.72301155191235e-07
- O 0 4.296167901429726e-07
UTR O 0 0.009280639700591564
and O 0 7.311832916911953e-08
> O 0 2.855003913282417e-07
2 O 0 1.0901479186031793e-07
kb O 0 1.2977348262666055e-07
of O 0 1.0173706499472246e-07
3 O 0 1.696207277745998e-06
- O 0 2.0599106846930226e-06
UTR O 1 0.9998940229415894
. O 0 1.3645891385749565e-06

We O 0 4.236521817801986e-07
have O 0 8.256078487534069e-09
established O 0 2.179397817769768e-08
the O 0 1.1360653751069094e-08
genomic O 0 2.3102600721358613e-08
organization O 0 1.499385282599519e-09
of O 0 1.2903568880062721e-08
UBE3A O 0 2.088758446916472e-05
and O 0 1.3083316652284793e-08
the O 0 7.1062515871744836e-09
sequence O 0 1.9286154895326035e-09
of O 0 1.792997395000384e-08
intron O 0 1.2870541468146257e-06
- O 0 9.30308374336164e-07
exon O 0 1.30129183162353e-06
borders O 0 7.230300980154425e-08
. O 0 1.1160915391883464e-07

We O 0 3.220872713427525e-06
have O 0 6.658642348611465e-08
also O 0 9.801475187032338e-09
mapped O 0 1.0719925569446787e-07
two O 0 4.787027219066431e-09
highly O 0 1.494777279731352e-08
homologous O 0 4.380133233894412e-08
processed O 0 2.3211570976400253e-07
pseudogenes O 0 1.642876327423437e-06
, O 0 3.2405846894789647e-09
UBE3AP1 O 0 6.101431790739298e-05
and O 0 5.084329401938703e-08
UBE3AP2 O 0 0.0014343890361487865
, O 0 2.8612243685444128e-09
to O 0 1.1542722333501843e-09
chromosomes O 0 1.8094077347541315e-09
2 O 0 8.916398286373806e-09
and O 0 5.740760089523178e-10
21 O 0 6.695240362120103e-09
, O 0 7.10030992334687e-11
respectively O 0 3.781709112526954e-10
, O 0 9.812407136822188e-11
and O 0 1.5865680991211661e-10
determined O 0 1.2702662255392738e-09
their O 0 2.2616024608623775e-09
genomic O 0 7.865622109193282e-08
organization O 0 5.872318631361395e-09
. O 0 5.815397940978073e-08

These O 0 7.78965798531317e-08
results O 0 1.4176257501219425e-08
will O 0 2.9988908578637563e-10
form O 0 3.953427307745727e-10
the O 0 8.861225642142756e-10
basis O 0 1.5523594909527816e-10
for O 0 6.61248486522048e-12
studies O 0 1.2031950089030907e-11
of O 0 1.8441055626983172e-10
mutation O 0 6.54922643894551e-11
and O 0 2.1013321638285731e-10
imprinting O 0 2.4414435983999283e-07
of O 0 9.968975973606575e-07
UBE3A O 0 0.4036531448364258
. O 0 3.937684141419595e-06

Mutation O 0 5.114440682518762e-06
spectrum O 0 1.4118443687038962e-05
and O 0 7.953558878170952e-08
genotype O 0 1.4492405853161472e-06
- O 0 1.1534984167838047e-07
phenotype O 0 1.1254498666346535e-08
analyses O 0 1.61133251186385e-09
in O 0 2.5511520673759946e-10
Cowden B-Disease 0 0.00013709868653677404
disease I-Disease 0 1.566724677104503e-06
and O 0 1.36538620409965e-08
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 9.81488845752665e-09
two O 0 6.067424607181238e-08
hamartoma B-Disease 1 0.9999998807907104
syndromes I-Disease 1 0.9999996423721313
with O 0 6.482465687440708e-05
germline O 1 0.9999994039535522
PTEN O 1 1.0
mutation O 0 3.013077912328299e-05
. O 0 1.4674709518658346e-06

The O 0 0.00017229696095455438
tumour B-Disease 1 1.0
suppressor O 0 0.0007281426223926246
gene O 0 1.8364384004598833e-06
PTEN O 0 0.00014493671187665313
, O 0 1.940233973485306e-09
which O 0 3.1967259395138115e-10
maps O 0 9.472954864975236e-09
to O 0 1.3763654216347732e-08
10q23 O 0 6.2270542002806906e-06
. O 0 3.846845970656432e-07

3 O 0 2.5381482373632025e-06
and O 0 2.8177373323501342e-08
encodes O 0 8.068919754578019e-09
a O 0 2.7890969533928e-09
403 O 0 1.101943647441317e-09
amino O 0 7.027530779524227e-10
acid O 0 2.2939423693912886e-09
dual O 0 2.3313123875823294e-08
specificity O 0 6.392393743226421e-07
phosphatase O 0 0.0001366507785860449
( O 0 5.398917313215179e-09
protein O 0 1.4667662640022172e-08
tyrosine O 0 5.333894037562459e-08
phosphatase O 0 2.900314939324744e-07
; O 0 2.6308191736212905e-10
PTPase O 0 8.353401881322498e-08
) O 0 3.806020776320196e-11
, O 0 6.94616716576113e-12
was O 0 3.509470491991351e-10
shown O 0 7.908951271673459e-11
recently O 0 5.982325745890194e-10
to O 0 1.7429328813545197e-10
play O 0 2.2684716327603383e-09
a O 0 2.4039392698682605e-09
broad O 0 1.3230268436359438e-08
role O 0 7.3474928363737035e-09
in O 0 1.655949710688276e-09
human O 0 2.103459451063827e-08
malignancy B-Disease 0 0.00489208847284317
. O 0 3.965190273902408e-07

Somatic O 0 0.0018897600239142776
PTEN O 0 0.005794032476842403
deletions O 0 3.2851064588612644e-06
and O 0 1.0993033150441534e-08
mutations O 0 2.2125818954776832e-09
were O 0 4.825655430806819e-10
observed O 0 8.136669116254325e-10
in O 0 4.799559083501492e-10
sporadic B-Disease 0 2.8768054107786156e-06
breast I-Disease 1 0.9999994039535522
, I-Disease 0 5.4572907970396045e-08
brain I-Disease 1 0.9907708168029785
, I-Disease 0 2.9145883928549665e-08
prostate I-Disease 1 1.0
and I-Disease 1 0.9625656008720398
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9999319314956665
lines O 0 9.899059705276159e-07
and O 0 3.418318073045157e-08
in O 0 8.819547758776025e-09
several O 0 6.091776327821208e-08
primary O 0 0.0001800020836526528
tumours B-Disease 1 1.0
such O 0 1.797932114300238e-08
as O 0 2.8177428248454817e-05
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 0.0007915051537565887
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 1 0.9993163347244263

In O 0 2.3241960889208713e-07
addition O 0 5.182869244890753e-08
, O 0 9.854241866946722e-09
PTEN O 0 9.731379395816475e-05
was O 0 2.4938077558545046e-07
identified O 0 7.756696618343994e-09
as O 0 5.490444765499092e-10
the O 0 7.144900227018525e-10
susceptibility O 0 1.0629401359096846e-08
gene O 0 9.295061942360405e-10
for O 0 4.975952427876962e-10
two O 0 1.0698396835095991e-07
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 2.2398683796609475e-08
CD B-Disease 0 7.679482223466039e-05
; O 0 5.464393666443357e-07
MIM O 0 0.004128979053348303
158350 O 0 3.792833695115405e-06
) O 0 1.2999730181206814e-09
and O 0 6.964286036748035e-09
Bannayan B-Disease 0 0.00012173443246865645
- I-Disease 0 0.00012308445002418011
Zonana I-Disease 0 0.12027320265769958
( I-Disease 0 9.036315162802566e-08
BZS I-Disease 0 8.506049925927073e-05
) I-Disease 0 2.5284965232685863e-09
or I-Disease 0 5.016416615433172e-09
Ruvalcaba I-Disease 0 1.0142837709281594e-05
- I-Disease 0 2.268227490276331e-06
Riley I-Disease 0 2.2005388018442318e-05
- I-Disease 0 0.04287155717611313
Smith I-Disease 1 0.8288093209266663
syndrome I-Disease 1 1.0
( O 0 1.1169262847943173e-07
MIM O 0 0.001263078534975648
153480 O 0 1.9587991118896753e-05
) O 0 2.0782914944561526e-08
. O 0 1.9918807936392113e-07

Constitutive O 0 6.24010954197729e-06
DNA O 0 2.035636271102703e-06
from O 0 1.108731098042881e-07
37 O 0 9.025274749774326e-08
CD B-Disease 0 7.523515250795754e-07
families O 0 1.1891451379142381e-08
and O 0 5.200829544804719e-09
seven O 0 1.9450517640962062e-08
BZS B-Disease 0 0.0002078168763546273
families O 0 8.230889747551373e-09
was O 0 3.956146699124474e-08
screened O 0 1.7826412346266807e-08
for O 0 3.449387220300082e-09
germline O 0 3.874809863191331e-06
PTEN O 0 0.0003442563465796411
mutations O 0 3.2196612664847635e-07
. O 0 3.76905404664285e-07

PTEN O 0 0.002168472856283188
mutations O 0 3.6373688772073365e-07
were O 0 2.895483319775849e-08
identified O 0 1.577574515465585e-08
in O 0 3.0159861275080857e-09
30 O 0 9.248838139797044e-09
of O 0 3.80714446635011e-08
37 O 0 5.5327316061948295e-08
( O 0 6.485014747426021e-10
81 O 0 2.0329958161369177e-08
% O 0 2.117086089770126e-10
) O 0 6.310835881651045e-11
CD B-Disease 0 1.3974886314827017e-07
families O 0 9.9072516857035e-10
, O 0 3.7033828781396494e-10
including O 0 1.0845617737231805e-09
missense O 0 2.4502796236447466e-07
and O 0 4.6016921828595514e-08
nonsense O 0 2.0927491561906209e-07
point O 0 1.7755803582986118e-07
mutations O 0 8.811305018951998e-10
, O 0 8.060850598123892e-11
deletions O 0 1.2678559535572731e-08
, O 0 9.93944593297158e-10
insertions O 0 7.704884552595104e-08
, O 0 2.8298974275031696e-09
a O 0 1.4985168661496573e-08
deletion O 0 1.6958468052052922e-07
/ O 0 2.248905985879901e-07
insertion O 0 4.297241318340639e-08
and O 0 4.247273821533781e-08
splice O 0 7.437748718075454e-05
site O 0 1.1963086308242055e-06
mutations O 0 1.045810549271664e-07
. O 0 1.0053165766521488e-07

These O 0 1.6319550866228383e-07
mutations O 0 9.102934228621962e-08
were O 0 5.391850166347467e-08
scattered O 0 1.2277675409677613e-07
over O 0 1.595576826218803e-08
the O 0 2.6480948989160424e-08
entire O 0 2.2427029122695785e-08
length O 0 5.0879651602997455e-09
of O 0 2.0517722632007462e-08
PTEN O 0 3.338399210406351e-06
, O 0 2.673110344186824e-10
with O 0 3.076664964463127e-11
the O 0 2.4756354743971087e-09
exception O 0 1.8124992617885027e-09
of O 0 1.085810374945595e-08
the O 0 6.871501589955642e-09
first O 0 3.1614015849612542e-09
, O 0 1.8434796744681847e-10
fourth O 0 3.978985674280011e-08
and O 0 3.1778211173616455e-09
last O 0 1.6065848740254296e-07
exons O 0 1.0133410796697717e-05
. O 0 6.398694267772953e-07

A O 0 0.0001760441082296893
hot O 0 0.00041062262607738376
spot O 0 6.207701517269015e-06
for O 0 2.4866395165190625e-08
PTEN O 0 1.668535878707189e-05
mutation O 0 9.379393262065605e-09
in O 0 2.645665020395427e-09
CD B-Disease 0 6.034285320311028e-07
was O 0 3.1470310091208376e-07
identified O 0 1.2703879725961542e-08
in O 0 3.4041842678078638e-09
exon O 0 2.2450224790304674e-08
5 O 0 3.1843496728356513e-09
that O 0 5.8164983246511426e-11
contains O 0 3.346353194544349e-10
the O 0 9.110555865277092e-09
PTPase O 0 1.5706410749771749e-06
core O 0 8.945545459937421e-07
motif O 0 4.324671110111922e-08
, O 0 1.171876345962275e-10
with O 0 5.591815552263846e-11
13 O 0 2.9712103888357433e-09
of O 0 1.9581209542707256e-08
30 O 0 1.2632022539094123e-08
( O 0 3.5227087913369814e-10
43 O 0 9.40657063353001e-09
% O 0 2.7962013260385277e-10
) O 0 1.3701720313896715e-10
CD B-Disease 0 3.9988581335137496e-08
mutations O 0 1.1265747223987432e-09
identified O 0 1.938147864422035e-09
in O 0 1.2861323117618895e-09
this O 0 4.782044094042703e-09
exon O 0 1.6433416476502316e-06
. O 0 1.7801191631861002e-07

Seven O 0 9.907531421049498e-06
of O 0 1.9041597170144087e-06
30 O 0 2.1759426260814507e-07
( O 0 2.306943303054254e-09
23 O 0 1.5263422525890746e-08
% O 0 7.503374033213106e-10
) O 0 1.6835027816242132e-10
were O 0 3.930782366268204e-09
within O 0 1.604335153615466e-08
the O 0 1.0399724459375648e-07
core O 0 9.158800935438194e-07
motif O 0 4.61326585821098e-08
, O 0 1.5297739464070759e-10
the O 0 2.2283110912013626e-09
majority O 0 1.2804261817489504e-10
( O 0 5.150203527537478e-11
five O 0 2.4570623313735496e-10
of O 0 2.567516199647457e-09
seven O 0 6.902762250682315e-10
) O 0 2.8743984623047503e-11
of O 0 6.217526493657033e-10
which O 0 2.855716496608096e-10
were O 0 1.4707695505933316e-08
missense O 0 3.790418645621685e-07
mutations O 0 1.095320456556692e-08
, O 0 2.6290736254708236e-10
possibly O 0 1.6804310831730618e-08
pointing O 0 4.044151680204777e-08
to O 0 1.7921144568333602e-09
the O 0 1.6248819179054408e-08
functional O 0 4.501675121559856e-08
significance O 0 2.861673564780176e-08
of O 0 2.885108152383964e-08
this O 0 1.8158834436121651e-09
region O 0 4.6080600668574334e-08
. O 0 7.776267807457771e-08

Germline O 0 0.00388735206797719
PTEN O 0 0.0013066409155726433
mutations O 0 1.2106326607863593e-07
were O 0 1.0101906866566424e-08
identified O 0 5.881510389826872e-09
in O 0 6.407555042109436e-10
four O 0 1.2038664509717023e-09
of O 0 3.2668747707020884e-08
seven O 0 1.2282905359484175e-08
( O 0 5.527399093985252e-10
57 O 0 2.6711761691444735e-08
% O 0 5.358660626342271e-09
) O 0 1.1210151917850908e-08
BZS B-Disease 0 0.41106516122817993
families O 0 4.969232918483613e-07
studied O 0 2.900353365475894e-06
. O 0 9.349003562419966e-07

Interestingly O 0 2.1969158296997193e-06
, O 0 4.9616253328110815e-09
none O 0 7.298787796372608e-09
of O 0 2.9579223514986097e-09
these O 0 2.437690049816865e-10
mutations O 0 1.1811807087980242e-09
was O 0 7.617717123764578e-09
observed O 0 1.6914696310266208e-09
in O 0 7.15032644205138e-10
the O 0 4.0433956627339285e-08
PTPase O 0 1.933289058797527e-05
core O 0 2.1057949197711423e-05
motif O 0 1.3214375940151513e-06
. O 0 1.3104212825965078e-07

It O 0 7.229266429931158e-08
is O 0 4.5725028208210006e-09
also O 0 5.565186089739882e-10
worthy O 0 8.414066776651907e-09
of O 0 8.316959565490833e-09
note O 0 3.494136979753648e-09
that O 0 2.068777649189002e-10
a O 0 5.967491389924362e-09
single O 0 1.2330743537347644e-08
nonsense O 0 7.869147822248124e-08
point O 0 2.6280934761757635e-08
mutation O 0 4.1562636665659625e-10
, O 0 9.123118926979146e-11
R233X O 0 3.0516321913864886e-08
, O 0 1.8858579975411516e-10
was O 0 4.148266619097285e-09
observed O 0 8.186483158034719e-10
in O 0 2.1763880975189664e-10
the O 0 1.506316404942254e-09
germline O 0 1.3451797009622624e-08
DNA O 0 1.5103216455258917e-08
from O 0 1.8975783167007876e-09
two O 0 3.9870495793792315e-10
unrelated O 0 1.6739690522626915e-08
CD B-Disease 0 3.0907792734069517e-06
families O 0 3.4482308564065534e-08
and O 0 5.7932780350711255e-08
one O 0 2.290538247962104e-07
BZS B-Disease 1 0.994631290435791
family O 0 2.5264203941333108e-05
. O 0 1.1997419733233983e-06

Genotype O 0 0.00012858967238571495
- O 0 6.12758003626368e-06
phenotype O 0 1.9022689912162605e-07
studies O 0 1.058932830311221e-09
were O 0 8.77363848239554e-10
not O 0 9.100403763895315e-11
performed O 0 4.98471097731823e-10
on O 0 1.3906353846238062e-09
this O 0 5.006576056509893e-11
small O 0 2.408316046587089e-10
group O 0 6.213279196698451e-11
of O 0 1.071587529821727e-08
BZS B-Disease 1 0.9998383522033691
families O 0 2.9895102215959923e-06
. O 0 2.356997811148176e-06

However O 0 1.083765027942718e-06
, O 0 3.862027142531588e-08
genotype O 0 7.747449899397907e-07
- O 0 2.6767924055093317e-07
phenotype O 0 1.0759502089285888e-07
analysis O 0 4.645642981415676e-09
inthe O 0 7.028810387055273e-07
group O 0 5.395661695217768e-10
of O 0 1.9280058438653214e-08
CD B-Disease 0 0.0007523390231654048
families O 0 5.190348062455996e-08
revealed O 0 4.9337135266114274e-08
two O 0 2.405598498178563e-10
possible O 0 1.1298196822551176e-09
associations O 0 1.9444119925271508e-10
worthy O 0 6.069461733204662e-08
of O 0 2.425786682636044e-08
follow O 0 9.476731399615801e-09
- O 0 7.383066247257375e-08
up O 0 6.275157282686905e-09
in O 0 1.0196329336409349e-09
independent O 0 2.6988549173267984e-09
analyses O 0 2.3704883389541465e-08
. O 0 8.604376233734001e-08

The O 0 9.26439133763779e-06
first O 0 1.0634651061991462e-06
was O 0 4.54740870736714e-07
an O 0 6.594832457906818e-10
association O 0 3.1029862013198795e-10
noted O 0 2.7506824595846524e-10
in O 0 1.0606707179228181e-10
the O 0 1.5221259808129162e-09
group O 0 3.641343823690413e-11
of O 0 1.4206620324586083e-09
CD B-Disease 0 6.10847127973102e-05
families O 0 3.488464983547601e-08
with O 0 4.4591775605340445e-08
breast B-Disease 1 0.9999988079071045
disease I-Disease 1 0.9995267391204834
. O 0 4.183830242254771e-06

A O 0 7.721545443928335e-06
correlation O 0 1.5610048365033435e-07
was O 0 1.0214149170906239e-07
observed O 0 2.9685025548786825e-09
between O 0 1.4353263022570673e-09
the O 0 5.688943538473268e-09
presence O 0 1.4454039742872737e-08
/ O 0 6.614679364247422e-07
absence O 0 4.5099170620233053e-07
of O 0 4.2374105646558746e-07
a O 0 1.5222580884710624e-07
PTEN O 0 6.143353857623879e-06
mutation O 0 2.581437286153232e-09
and O 0 5.906971023428298e-10
the O 0 7.588202288744128e-10
type O 0 4.560381228202459e-08
of O 0 2.3236886192989914e-07
breast O 0 1.6278483599307947e-05
involvement O 0 4.2070735162269557e-07
( O 0 1.753504896839786e-08
unaffected O 0 6.572074653377058e-06
versus O 0 0.00016427111404482275
benign O 1 0.9908451437950134
versus O 0 0.03409678116440773
malignant O 1 0.9983978867530823
) O 0 8.518592942152736e-09
. O 0 2.348284766640063e-08

Specifically O 0 5.611011602013605e-07
and O 0 2.6947260423071384e-08
more O 0 3.0420635455108425e-10
directly O 0 1.7002516061737083e-09
, O 0 1.3340736848554968e-10
an O 0 3.4469500170830614e-11
association O 0 2.0335369499413503e-10
was O 0 1.968291130083344e-08
also O 0 5.945830633402593e-11
observed O 0 9.398527095472176e-11
between O 0 4.3947880057348954e-11
the O 0 1.9647333759920116e-10
presence O 0 3.4933886339238995e-10
of O 0 4.017372212672399e-09
a O 0 3.849098817454433e-08
PTEN O 0 0.025733383372426033
mutation O 0 7.47513979604264e-07
and O 0 1.2761603329636273e-06
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.999882698059082
. O 0 1.2733763696815004e-06

Secondly O 0 0.00031319932895712554
, O 0 1.1708547020816695e-07
there O 0 6.5197944820738485e-09
appeared O 0 4.981978207752036e-08
to O 0 1.128906412795061e-09
be O 0 1.973891938789052e-09
an O 0 7.733263474030139e-10
interdependent O 0 2.0573963865899714e-07
association O 0 4.023199995373261e-09
between O 0 2.444947355684235e-08
mutations O 0 3.5681075871707435e-08
upstream O 0 1.1737392213717612e-07
and O 0 7.367237486732847e-09
within O 0 1.7576873290181538e-08
the O 0 3.3710273328324547e-07
PTPase O 0 1.2687998605542816e-05
core O 0 3.925704277207842e-06
motif O 0 9.694089442291443e-08
, O 0 5.715718454091245e-10
the O 0 3.698746642299966e-09
core O 0 8.64321094695697e-08
motif O 0 3.095480316517296e-09
containing O 0 3.103749479649309e-10
the O 0 3.3267983923224165e-09
majority O 0 4.284485821681727e-10
of O 0 3.27080265094537e-08
missense O 0 2.8063567469871487e-07
mutations O 0 3.104420054356183e-09
, O 0 1.7284229603120593e-10
and O 0 2.1669317729067217e-10
the O 0 3.2056419740911224e-09
involvement O 0 1.0523552695929084e-08
of O 0 2.1075397427239295e-08
all O 0 1.3993198821893316e-09
major O 0 2.950564770287656e-08
organ O 0 1.327472818957176e-05
systems O 1 0.9999433755874634
( O 0 1.1008098681486445e-06
central O 1 0.9998703002929688
nervous O 1 0.9999001026153564
system O 1 1.0
, O 0 5.2916791901225224e-05
thyroid O 1 1.0
, O 0 4.2789515646290965e-06
breast O 1 1.0
, O 0 3.763859979244444e-07
skin O 1 1.0
and O 1 0.9858318567276001
gastrointestinal O 1 1.0
tract O 1 0.9999996423721313
) O 0 8.116293770399352e-08
. O 0 1.41854218327353e-06

However O 0 2.711575689318124e-06
, O 0 1.2737654486727479e-08
these O 0 6.238576877315438e-10
observations O 0 1.2433713614257158e-08
would O 0 9.396095013158856e-10
need O 0 1.8794994449677915e-09
to O 0 7.592458883820541e-10
be O 0 3.4457423025990863e-10
confirmed O 0 3.5912289808592845e-10
by O 0 1.512014298488129e-11
studying O 0 2.88770396483784e-10
a O 0 7.109619837297743e-11
larger O 0 6.524166623611549e-11
number O 0 1.6054315862823465e-11
of O 0 1.6318664197711996e-09
CD B-Disease 0 9.769559028427466e-07
families O 0 2.0147219004229555e-08
. O 0 1.2490838230405643e-07

Molecular O 1 0.9877349734306335
defects O 1 1.0
leading O 0 1.710003925836645e-05
to O 0 6.060716373212927e-08
human O 0 1.9401186364120804e-06
complement B-Disease 1 0.9999843835830688
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.084815082208479e-07
an O 0 7.242274557839323e-10
African O 0 1.4202503617610773e-09
- O 0 4.6655075358614795e-09
American O 0 6.3981548947822375e-09
family O 0 8.531865347549683e-08
. O 0 3.511188140237209e-08

Complement B-Disease 0 0.00047303701285272837
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 2.2015206013747957e-07
C6D B-Disease 0 0.0003622434742283076
) O 0 5.700805161268363e-09
was O 0 7.218607720460568e-07
diagnosed O 0 2.1687383195967413e-06
in O 0 8.144731111769943e-09
a O 0 3.803355852483037e-08
16 O 0 2.8700039678142275e-08
- O 0 9.371542653013876e-09
year O 0 5.2659507865371324e-09
- O 0 3.5825848954118555e-08
old O 0 5.839038408339547e-07
African O 0 2.230149043214169e-08
- O 0 2.8526271123041624e-08
American O 0 1.3994105874104434e-09
male O 0 4.040053847020886e-10
with O 0 5.884615572604446e-10
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.6243577192653902e-05

The O 0 4.904931302007753e-06
patients O 0 6.507950729428558e-07
father O 0 7.649798135389574e-06
and O 0 7.677189017840647e-08
two O 0 8.771070270086057e-08
brothers O 0 0.000134563772007823
also O 0 4.9365564080972035e-08
had O 0 6.320240117929643e-07
C6D B-Disease 1 0.9996033310890198
, O 0 1.9375308024649485e-09
but O 0 5.86304893523959e-10
gave O 0 1.5260794850036064e-09
no O 0 5.345404327505854e-11
history O 0 5.415022874544206e-10
of O 0 2.0463308825213744e-09
meningitis B-Disease 1 0.9992257356643677
or O 0 4.339003822906307e-09
other O 0 2.115363662014147e-09
neisserial B-Disease 0 1.7463546100771055e-05
infection I-Disease 0 0.000799074477981776
. O 0 2.033232249232242e-06

By O 0 5.6193560027395506e-08
using O 0 4.919073859355194e-08
exon O 0 1.7777254868178716e-07
- O 0 1.4078553434160312e-08
specific O 0 1.4296213102227284e-09
polymerase O 0 4.5087645617059025e-07
chain O 0 4.764039474025594e-08
reaction O 0 3.757760769218521e-09
( O 0 1.729791726523544e-10
PCR O 0 1.5649005646878322e-08
) O 0 3.136091941691177e-10
/ O 0 3.0673632522848493e-09
single O 0 3.4746709953736854e-09
- O 0 8.153668851207385e-09
strand O 0 6.952527442649625e-09
conformation O 0 2.041519175932649e-10
polymorphism O 0 5.904087774233346e-10
as O 0 4.1627354341322587e-11
a O 0 6.427761795047005e-11
screening O 0 4.5049086683235373e-10
step O 0 2.5440007878074766e-09
and O 0 1.0798714006332588e-10
nucleotide O 0 2.1156825180668193e-09
sequencing O 0 3.140912419041797e-09
of O 0 7.465647655635621e-09
target O 0 1.9761417391350733e-08
exons O 0 2.513081653887639e-07
, O 0 1.7478042346752432e-09
we O 0 3.40570210921598e-10
determined O 0 7.674956226111362e-10
that O 0 4.643636516976635e-11
the O 0 1.96317606615537e-09
proband O 0 1.625969332508248e-07
was O 0 1.9593986877453062e-08
a O 0 1.322198683872955e-09
compound O 0 3.651392077586024e-08
heterozygote O 0 2.490891404249851e-07
for O 0 3.2622031742590707e-09
two O 0 1.021979656457006e-08
C6 O 0 3.007583654834889e-05
gene O 0 9.039780479724868e-08
mutations O 0 2.665582954364254e-08
. O 0 4.6573212841849454e-08

The O 0 4.996360985387582e-06
first O 0 3.467112890120916e-07
, O 0 3.188920461028033e-09
1195delC O 0 1.9986357813195355e-07
located O 0 1.3445538016298997e-08
in O 0 1.0128025085265335e-09
exon O 0 3.9657038541918155e-08
7 O 0 2.3846871144428405e-08
, O 0 1.1707460001453285e-10
is O 0 6.256280909999745e-11
a O 0 3.034182627370541e-10
novel O 0 1.6043587569569695e-09
mutation O 0 4.391145225213222e-10
, O 0 7.606471702503725e-11
while O 0 1.8760742959145205e-10
the O 0 5.13877784769079e-09
second O 0 9.461744809868833e-08
, O 0 5.374789502354815e-10
1936delG O 0 7.586111649970917e-08
in O 0 5.5818474287150366e-09
exon O 0 9.830929315057801e-08
12 O 0 3.7589593659959064e-08
, O 0 7.776572163997741e-10
has O 0 1.626362516882196e-10
been O 0 1.0096933289460708e-09
described O 0 3.1692379831582684e-09
before O 0 9.34353927561915e-09
to O 0 6.742169045281798e-09
cause O 0 1.2086870810890105e-06
C6D B-Disease 1 0.7931320071220398
in O 0 3.8554766490506154e-08
an O 0 9.442914228330324e-10
unrelated O 0 1.5970625710792774e-08
African O 0 7.860653461477796e-09
- O 0 7.605061114190903e-08
American O 0 2.0037461467836692e-08
individual O 0 3.960750838416516e-09
. O 0 1.4968493644573755e-07

Both O 0 1.1685143874728965e-07
mutations O 0 2.765441031726823e-08
result O 0 1.0716487253148443e-08
in O 0 9.657121324835316e-09
premature O 0 1.1344785377787048e-07
termination O 0 3.983937403972959e-06
codons O 0 3.436911697463074e-07
and O 0 1.527601085626884e-07
C6 O 0 0.00011006364366039634
null O 0 9.387525096826721e-06
alleles O 0 1.576296710936731e-07
. O 0 1.9293418063170975e-07

Allele O 0 1.0420060334581649e-06
- O 0 1.5461917257653113e-07
specific O 0 4.338350567678617e-09
PCR O 0 2.918093855441839e-07
indicated O 0 2.1589428911283903e-08
that O 0 3.7211336789688687e-10
the O 0 1.022835682817913e-08
probands O 0 2.0109152956138132e-06
two O 0 2.826694434077126e-08
brothers O 0 1.0407796935396618e-06
also O 0 2.819950939425553e-09
inherited O 0 3.142693003610475e-06
the O 0 6.067587037250632e-07
1195delC O 0 2.9132135637155443e-07
mutation O 0 8.107235438536975e-10
from O 0 1.037303021256264e-09
their O 0 2.5020385763241393e-09
heterozygous O 0 1.4066225961784085e-09
mother O 0 2.291441036916808e-09
and O 0 9.028073288952498e-10
the O 0 7.358909481780529e-09
1936delG O 0 5.008216419355449e-08
mutation O 0 4.4841375057558253e-10
from O 0 4.724562963076551e-10
their O 0 6.42097652825413e-10
homozygous O 0 1.2861330667135462e-08
father O 0 7.792213807533699e-08
. O 0 1.0220127855120609e-08
. O 0 8.048019140005636e-08

PAX6 O 0 0.020381396636366844
mutations O 0 9.358188435726333e-06
reviewed O 0 5.8646651268645655e-06
. O 0 2.5545982680341695e-06

Mutations O 0 6.122673312347615e-06
in O 0 2.600123139018251e-07
PAX6 O 0 0.008575762622058392
are O 0 8.575078425110405e-09
responsible O 0 4.3011937123083044e-08
for O 0 5.724209550805881e-09
human O 0 7.004586223047227e-06
aniridia B-Disease 1 1.0
and O 0 6.465545993705746e-06
have O 0 9.188492633427359e-09
also O 0 8.138267282298273e-10
been O 0 2.1963547647274595e-10
found O 0 7.987327466096872e-11
in O 0 1.438526034402976e-11
patients O 0 3.3499213819565554e-11
with O 0 5.168379613174068e-11
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 6.161855736763755e-08
with O 0 9.890822184388526e-06
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 1 0.8731076717376709
with O 0 0.29074281454086304
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
keratitis I-Disease 1 1.0
, O 0 1.4972262363244226e-07
and O 0 3.2781976244677935e-08
with O 0 1.521340777799196e-07
isolated B-Disease 1 1.0
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.007127317599952221

No O 0 3.750573569050175e-06
locus O 0 1.4473097280642833e-06
other O 0 5.377345679846712e-09
than O 0 1.0855966126044336e-09
chromosome O 0 2.3835136531147327e-08
11p13 O 0 2.1587169385384186e-07
has O 0 1.8216350650135382e-09
been O 0 1.3889652761278626e-09
implicated O 0 3.0454920363354177e-08
in O 0 1.9932864248062288e-08
aniridia B-Disease 1 1.0
, O 0 2.5572296280529372e-08
and O 0 4.0696171765830513e-08
PAX6 O 1 0.9094045162200928
is O 0 1.1520776332929472e-08
clearly O 0 5.7524580654444435e-09
the O 0 1.284691375502689e-08
major O 0 7.456557682417042e-08
, O 0 7.943905255825001e-11
if O 0 1.7614836672619205e-11
not O 0 1.3828602325738348e-11
only O 0 3.26793557492433e-11
, O 0 1.4479016943735878e-11
gene O 0 3.580730156826917e-10
responsible O 0 1.975286245681218e-08
. O 0 1.4930569136595295e-07

Twenty O 0 3.887409093294991e-06
- O 0 1.2082663261026028e-06
eight O 0 3.642530188585624e-08
percent O 0 4.014438559352129e-09
of O 0 7.349357566965864e-09
identified O 0 4.726875246774398e-08
PAX6 O 0 2.0992221834603697e-05
mutations O 0 2.0770272612935514e-08
are O 0 1.6411710879182806e-09
C O 0 1.648507713980507e-05
- O 0 3.9533566450700164e-05
T O 0 7.314298727578716e-06
changes O 0 6.601622004609453e-08
at O 0 1.8060406148379116e-07
CpG O 0 3.155249999053922e-07
dinucleotides O 0 1.8892913544732437e-07
, O 0 3.4619085376164094e-10
20 O 0 4.865507996498764e-10
% O 0 6.034028138257597e-11
are O 0 1.1775444334893859e-11
splicing O 0 2.2754017336978904e-08
errors O 0 6.11938730799011e-08
, O 0 5.396639246590951e-10
and O 0 5.510010225862061e-10
more O 0 4.530515546052882e-11
than O 0 1.7091010551251173e-10
30 O 0 2.2993653647773726e-09
% O 0 3.2291930240901934e-10
are O 0 3.9528900985796867e-11
deletion O 0 1.0188772492369935e-08
or O 0 1.4509330403811305e-09
insertion O 0 6.662186535777437e-08
events O 0 3.4523686132104103e-09
. O 0 2.0749602924752253e-08

There O 0 2.786687787192932e-07
is O 0 2.4720367974850888e-08
a O 0 5.1452829552545154e-08
noticeably O 0 3.406899395486107e-06
elevated O 0 0.00014607426419388503
level O 0 2.4176483748306055e-07
of O 0 3.362081812952056e-08
mutation O 0 1.5857399837670982e-09
in O 0 5.414960702054827e-10
the O 0 2.983203684081559e-09
paired O 0 6.817295616912133e-10
domain O 0 2.4309670942912476e-10
compared O 0 5.0341057711289494e-11
with O 0 9.888191827844839e-12
the O 0 5.709932526798411e-10
rest O 0 4.375964035574498e-09
of O 0 6.552206777143965e-09
the O 0 1.9598697775791152e-08
gene O 0 9.011492885235839e-09
. O 0 2.4924089458977505e-08

Increased O 0 1.5123548280371324e-07
mutation O 0 2.616230254659513e-08
in O 0 2.3625923439851704e-09
the O 0 1.81790120734604e-08
homeodomain O 0 4.6779666718066437e-07
is O 0 3.9176820121333833e-10
accounted O 0 2.0984564086390378e-10
for O 0 1.6010189701765043e-11
by O 0 1.204929489517781e-10
the O 0 5.989935658590184e-08
hypermutable O 0 1.3232410310592968e-05
CpG O 0 2.1730465959990397e-06
dinucleotide O 0 9.73972532847256e-07
in O 0 1.0627920765671206e-08
codon O 0 1.929440607284505e-08
240 O 0 4.6123069807890715e-08
. O 0 4.920143581443881e-08

Very O 0 9.947996204573428e-07
nearly O 0 3.449336105632028e-08
all O 0 1.7298551480138258e-09
mutations O 0 2.73360734048822e-09
appear O 0 4.45512826630079e-09
to O 0 1.084797585093611e-09
cause O 0 5.403044838203641e-07
loss O 0 4.013526222479413e-07
of O 0 1.1166999911438324e-06
function O 0 2.8811818708618375e-08
of O 0 2.1844152797712013e-07
the O 0 2.7472037089637524e-08
mutant O 0 7.271275581643977e-09
allele O 0 5.521108570327726e-10
, O 0 3.329512013316993e-11
and O 0 3.60070619154218e-11
more O 0 1.3385410835287104e-11
than O 0 7.467235163538533e-11
80 O 0 5.15951781299151e-10
% O 0 1.5942214215414197e-10
of O 0 3.1841309588998e-09
exonic O 0 1.034295138424568e-07
substitutions O 0 1.8046076633027042e-08
result O 0 5.149875192955733e-09
in O 0 3.588820574051965e-09
nonsense O 0 2.3335731214046973e-07
codons O 0 1.7455636225349735e-07
. O 0 2.006519537189888e-07

In O 0 4.081468318872794e-07
a O 0 6.169206301365193e-08
gene O 0 5.456247453849983e-09
with O 0 1.442741898172173e-10
such O 0 2.872510673768147e-09
extraordinarily O 0 8.783676094026305e-06
high O 0 4.668884230341064e-06
sequence O 0 4.650627971614085e-08
conservation O 0 1.1257633047989657e-08
throughout O 0 7.445220828738996e-11
evolution O 0 4.5978798546286725e-10
, O 0 9.55479792508207e-12
there O 0 1.2980640000381793e-11
are O 0 2.483516864382196e-11
presumed O 0 6.931377356522717e-07
undiscovered O 0 8.640566375106573e-05
missense O 0 7.506845349780633e-07
mutations O 0 8.296331621693298e-09
, O 0 1.8134768686728364e-10
these O 0 8.576100246626694e-11
are O 0 8.208619201033329e-11
hypothesized O 0 2.5021067884267723e-08
to O 0 5.757185839172507e-10
exist O 0 1.7422757681018197e-09
in O 0 7.736601581598279e-09
as O 0 1.683170403055101e-08
- O 0 3.6689428384306666e-08
yet O 0 3.782691937459504e-09
unidentified O 0 2.5124077041027704e-08
phenotypes O 0 3.220265654135801e-08
. O 0 2.4826432021285427e-09
. O 0 7.831519610590476e-08

Genetic O 0 2.0855259208474308e-05
heterogeneity O 0 6.088987447583349e-06
and O 0 2.2812638889035952e-08
penetrance O 0 1.3699744840778294e-06
analysis O 0 7.42385841689952e-09
of O 0 1.4398874270682427e-07
the O 0 1.516175842652956e-07
BRCA1 O 0 8.2966202796797e-08
and O 0 1.0215878809560763e-08
BRCA2 O 0 2.6053944779391713e-08
genes O 0 3.5890945770944427e-09
in O 0 1.2448141184506767e-08
breast B-Disease 1 0.9539822340011597
cancer I-Disease 1 0.9237877726554871
families O 0 4.3397264448685746e-07
. O 0 1.1844286973428098e-06

The O 0 0.00469035841524601
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 5.620516458293423e-05
Consortium O 0 1.6618822655800614e-06
. O 0 2.024807912448523e-07

The O 0 1.7625760051487305e-07
contribution O 0 4.4071590821204154e-08
of O 0 1.1945297728743753e-07
BRCA1 O 0 1.34559329012518e-07
and O 0 2.3866890686008446e-08
BRCA2 O 0 1.0421323395348736e-06
to O 0 2.243230483145453e-06
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 1 0.9917113780975342
assessed O 0 1.755349643417503e-07
by O 0 1.1228934448936911e-09
linkage O 0 9.954898416708602e-08
and O 0 1.740299571117987e-09
mutation O 0 3.35857258670913e-10
analysis O 0 2.84349821466634e-10
in O 0 1.6366689947755475e-10
237 O 0 7.007935343139593e-10
families O 0 6.616399095271674e-11
, O 0 8.063706820327088e-12
each O 0 4.621596941950523e-12
with O 0 4.3307562397343347e-11
at O 0 3.0941580408949676e-09
least O 0 3.407201257243919e-11
four O 0 6.958144477264838e-11
cases O 0 1.5825031562943792e-10
of O 0 1.0442638398444615e-07
breast B-Disease 0 0.01600027270615101
cancer I-Disease 0 8.316216053572134e-07
, O 0 1.2093980331084886e-11
collected O 0 1.6077575035189362e-11
by O 0 4.37772075534415e-11
the O 0 1.4422158756133285e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 4.08106234317529e-06
Consortium O 0 2.0743713946558273e-07
. O 0 5.169284733597124e-08

Families O 0 3.343160983604321e-07
were O 0 1.731140031324685e-08
included O 0 1.478596578508018e-09
without O 0 5.449404039126193e-09
regard O 0 1.7775246163864722e-08
to O 0 1.0932847960276604e-09
the O 0 3.071765952711303e-09
occurrence O 0 3.0847900234221015e-08
of O 0 3.2724803986639017e-06
ovarian B-Disease 1 0.9999806880950928
or I-Disease 0 5.880974640604109e-07
other I-Disease 0 2.3633717205484572e-07
cancers I-Disease 1 0.9998440742492676
. O 0 4.7774615268281195e-06

Overall O 0 8.087347850960214e-06
, O 0 1.0853656107201459e-07
disease O 0 8.547844481654465e-05
was O 0 4.538238499662839e-06
linked O 0 2.938680381703307e-06
to O 0 7.676558766434027e-08
BRCA1 O 0 1.74462172708445e-07
in O 0 6.462298696163771e-09
an O 0 1.9805583562071405e-10
estimated O 0 9.892348051820932e-11
52 O 0 6.860157442112325e-10
% O 0 6.913220690352162e-11
of O 0 3.613768173593712e-09
families O 0 1.4107576218336249e-09
, O 0 3.214040145138597e-10
to O 0 1.573318586522987e-09
BRCA2 O 0 1.613264544175763e-08
in O 0 3.0148703533683374e-09
32 O 0 6.981522471249946e-09
% O 0 2.252698166893552e-10
of O 0 2.1770867331127874e-09
families O 0 2.2943874578018608e-10
, O 0 5.944719022599187e-11
and O 0 9.161918446132233e-11
to O 0 2.8290325637669866e-10
neither O 0 7.0083663317177525e-09
gene O 0 1.694844375954574e-09
in O 0 1.3023953027158086e-09
16 O 0 4.7847450446170114e-09
% O 0 2.552680289369391e-10
( O 0 1.3843336199581557e-10
95 O 0 5.046649320661345e-08
% O 0 1.6166959326824326e-08
confidence O 0 9.013505177790648e-07
interval O 0 4.051614439504192e-07
[ O 0 2.6699137833929854e-07
CI O 0 4.214115051581757e-06
] O 0 1.6197949648244503e-08
6 O 0 7.343696317718695e-09
% O 0 2.1216864376505384e-10
- O 0 1.5846212120251835e-09
28 O 0 3.979803597786713e-09
% O 0 2.7604107888379303e-10
) O 0 3.995878974927258e-11
, O 0 1.7484425365865697e-11
suggesting O 0 6.503098615162628e-10
other O 0 9.559948388471184e-10
predisposition O 0 2.4678049612703035e-06
genes O 0 4.931375769956503e-07
. O 0 5.974292776045331e-07

The O 0 7.403269592032302e-06
majority O 0 4.040867196408726e-08
( O 0 2.606416860118088e-09
81 O 0 1.8436503879115662e-08
% O 0 3.0496041802940965e-10
) O 0 4.0477801666050084e-11
of O 0 5.679338332953421e-09
the O 0 0.0010015740990638733
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.4005863963338925e-08
were O 0 2.2111854569573097e-09
due O 0 1.1039011127422782e-07
to O 0 3.748547694470972e-09
BRCA1 O 0 6.607779212686182e-09
, O 0 1.0793978211243171e-10
with O 0 3.166902157181184e-11
most O 0 1.5263502683993124e-09
others O 0 2.011403266166667e-09
( O 0 2.6735794134147284e-10
14 O 0 1.669402283077659e-09
% O 0 2.3606092081074337e-10
) O 0 3.8134471275208526e-11
due O 0 5.05711419407362e-08
to O 0 2.2279218114817922e-07
BRCA2 O 0 4.117390744795557e-06
. O 0 6.437352908506e-07

Conversely O 0 7.558967354270862e-06
, O 0 1.423071083195282e-08
the O 0 1.2369280710800012e-08
majority O 0 5.577906470044525e-10
of O 0 6.188012324770398e-09
families O 0 6.233200067207179e-10
with O 0 9.196197969796316e-11
male B-Disease 0 3.2575027120174127e-09
and I-Disease 0 6.3879368461527974e-09
female I-Disease 0 4.052220248240701e-08
breast I-Disease 0 0.00015401566633954644
cancer I-Disease 0 0.0011701073963195086
were O 0 5.520650958601436e-08
due O 0 0.00010970455332426354
to O 0 1.921090699852357e-07
BRCA2 O 0 1.9124078676213685e-07
( O 0 1.1695993062943444e-09
76 O 0 4.877759351984423e-08
% O 0 7.159142167978416e-10
) O 0 5.356429744196589e-10
. O 0 1.70810547928113e-08

The O 0 5.500974293681793e-05
largest O 0 1.3555693385569612e-06
proportion O 0 2.9275028623487742e-08
( O 0 1.0620315737952524e-09
67 O 0 1.5536468112031798e-08
% O 0 4.730514313600054e-10
) O 0 4.382407978176239e-11
of O 0 1.7311952982268508e-09
families O 0 2.9006168578149527e-09
due O 0 4.652353595702152e-07
to O 0 8.138256291090329e-09
other O 0 2.2611668093475146e-09
genes O 0 1.6358864263210648e-09
was O 0 1.790447967664477e-08
found O 0 2.158590667322713e-10
in O 0 6.142509417772501e-11
families O 0 4.003202283553442e-11
with O 0 9.052790635177832e-12
four O 0 2.221202388685839e-10
or O 0 5.333410380004011e-10
five O 0 3.367315315472297e-10
cases O 0 2.9931304657004887e-10
of O 0 4.838453264710552e-07
female O 0 1.8844486930902349e-06
breast B-Disease 1 0.5199940800666809
cancer I-Disease 0 0.0010717230616137385
only O 0 1.6117674306315166e-07
. O 0 2.003040890485863e-06

These O 0 6.812972941361295e-08
estimates O 0 5.44114975298271e-08
were O 0 6.110043138107812e-09
not O 0 3.424899530646286e-10
substantially O 0 1.4783887003488871e-08
affected O 0 2.4010982091482447e-09
either O 0 1.0229170843700786e-09
by O 0 1.847760278117505e-10
changing O 0 2.313314650947973e-09
the O 0 7.1600059214915746e-09
assumed O 0 4.4616445649126035e-08
penetrance O 0 2.335525692842566e-07
model O 0 3.453205277281768e-09
for O 0 3.0995372934938814e-10
BRCA1 O 0 4.8723985957011e-10
or O 0 3.291211053690901e-11
by O 0 2.7277399089475907e-11
including O 0 2.996574932634388e-10
or O 0 8.229916304003382e-09
excluding O 0 4.0530398592864e-08
BRCA1 O 0 7.616950625788377e-08
mutation O 0 1.0577625886298847e-08
data O 0 4.722009450119913e-08
. O 0 8.99988492619741e-08

Among O 0 1.8799489964749228e-07
those O 0 1.2103459567924801e-08
families O 0 2.781775920723817e-09
with O 0 6.714266365115407e-10
disease O 0 4.614727458829293e-06
due O 0 8.562218863517046e-05
to O 0 2.4720418423385127e-07
BRCA1 O 0 1.197928298779516e-07
that O 0 1.1218401763102293e-09
were O 0 2.6732644986537935e-09
tested O 0 6.571979072056422e-10
by O 0 3.603330481216638e-11
one O 0 2.603295634617808e-10
of O 0 9.25735765822111e-10
the O 0 2.7300433025345683e-09
standard O 0 3.815575411181271e-09
screening O 0 7.917980715532735e-10
methods O 0 8.884309954382275e-10
, O 0 4.938442016433342e-11
mutations O 0 4.889003785146784e-11
were O 0 7.118918232684734e-10
detected O 0 1.1582910630636434e-08
in O 0 4.800969066742766e-10
the O 0 4.746314452575007e-09
coding O 0 3.702644946201872e-08
sequence O 0 6.928566165242955e-09
or O 0 1.272648386674291e-08
splice O 0 1.0153424909731257e-06
sites O 0 8.869904810637763e-09
in O 0 6.909492977769105e-10
an O 0 6.472567620763314e-11
estimated O 0 1.5331302893883958e-10
63 O 0 3.928848357759307e-09
% O 0 5.909450706553798e-10
( O 0 5.688235438228162e-10
95 O 0 1.1805398258957212e-07
% O 0 2.0201975203804068e-08
CI O 0 7.807827387296129e-06
51 O 0 5.985801010410796e-08
% O 0 5.612293740853147e-09
- O 0 4.387248608850314e-08
77 O 0 3.541022408626304e-08
% O 0 2.2747237427012124e-09
) O 0 5.801122915372048e-10
. O 0 1.5492789273707785e-08

The O 0 1.0666169600881403e-06
estimated O 0 8.974511800374785e-09
sensitivity O 0 1.2306571761655505e-07
was O 0 1.9470562051537854e-08
identical O 0 1.1114467124428984e-09
for O 0 1.154914636147808e-10
direct O 0 1.049986986245699e-09
sequencing O 0 9.66250102152344e-09
and O 0 3.568342010762393e-10
other O 0 1.4387352420541788e-10
techniques O 0 1.4595751451906835e-07
. O 0 8.767792536445995e-08

The O 0 6.997254786256235e-06
penetrance O 0 0.0003266455896664411
of O 0 1.6058180335676298e-05
BRCA2 O 0 2.0373104234749917e-06
was O 0 2.928173898908426e-07
estimated O 0 2.1181646714385494e-10
by O 0 1.1806665367597446e-10
maximizing O 0 2.688919131799139e-08
the O 0 7.240471688874095e-08
LOD O 0 0.026422027498483658
score O 0 8.599582770330017e-07
in O 0 3.2674105199248515e-08
BRCA2 O 0 8.310683341505865e-08
- O 0 4.4961229406226266e-08
mutation O 0 6.256617446354085e-10
families O 0 2.828093870199666e-10
, O 0 3.1816750623026024e-11
over O 0 1.3369676199470604e-10
all O 0 8.277592500327557e-11
possible O 0 1.8247343192001608e-08
penetrance O 0 4.317198090575403e-06
functions O 0 6.794454776581915e-08
. O 0 8.174460219834145e-08

The O 0 4.20492767716496e-07
estimated O 0 2.0957136026567014e-09
cumulative O 0 1.0404343164793772e-08
risk O 0 3.9146680563817426e-08
of O 0 3.7696077015425544e-07
breast B-Disease 0 0.20652464032173157
cancer I-Disease 0 0.0013280356070026755
reached O 0 1.1393472050258424e-06
28 O 0 9.586981519760229e-08
% O 0 1.1899046192809237e-09
( O 0 1.1137699096330778e-10
95 O 0 2.3549183936211193e-08
% O 0 4.679936882467928e-09
CI O 0 2.4606113129266305e-06
9 O 0 5.774545996928282e-08
% O 0 9.420283442196364e-10
- O 0 3.972765671989009e-09
44 O 0 1.1984802039677334e-09
% O 0 4.136521680742078e-11
) O 0 2.630997416458447e-12
by O 0 2.653787996645396e-12
age O 0 2.4334212422871815e-10
50 O 0 2.729187986716397e-10
years O 0 4.014490129211623e-10
and O 0 3.2314109721376383e-10
84 O 0 5.9932934171058605e-09
% O 0 2.524221109911906e-10
( O 0 1.1228329377388491e-10
95 O 0 1.8126245393546014e-08
% O 0 5.0999933165485345e-09
CI O 0 1.9562901343306294e-06
43 O 0 5.342467090940772e-08
% O 0 2.1155774909686897e-09
- O 0 7.157889392317429e-09
95 O 0 9.772819886677553e-09
% O 0 1.1742211369902833e-10
) O 0 4.668286156944701e-12
by O 0 1.1440526477557444e-11
age O 0 1.0873331124372498e-09
70 O 0 5.727310625758264e-09
years O 0 5.8244866707468645e-09
. O 0 4.231490180472974e-08

The O 0 7.175037808337947e-06
corresponding O 1 0.9987057447433472
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 1.4863131809761398e-06
were O 0 1.1123744769747645e-07
0 O 0 1.1281250067440851e-07
. O 0 6.028147225833891e-08

4 O 0 8.848144716466777e-06
% O 0 4.4057724579715796e-08
( O 0 2.9052844574550818e-09
95 O 0 1.233335922279366e-07
% O 0 1.4106506185385115e-08
CI O 0 2.404276528977789e-06
0 O 0 2.2918486664025295e-08
% O 0 4.816919085826044e-10
- O 0 3.043515883760506e-09
1 O 0 3.280335114652644e-09
% O 0 3.934844117203795e-11
) O 0 2.6077458335077575e-12
by O 0 6.3928025199888605e-12
age O 0 3.422652994355957e-10
50 O 0 2.349855032779402e-10
years O 0 2.7783172984463533e-10
and O 0 2.486997552342274e-10
27 O 0 1.3208627525074235e-09
% O 0 9.616801799339214e-11
( O 0 2.4342599116988772e-11
95 O 0 5.034974659423597e-09
% O 0 2.6022395349656335e-09
CI O 0 4.810515861208842e-07
0 O 0 1.2511791602776157e-08
% O 0 8.03931254900192e-10
- O 0 6.778737571266902e-09
47 O 0 7.977864591168782e-09
% O 0 1.164216917315386e-10
) O 0 1.1069287847442766e-11
by O 0 2.5787231724971882e-11
age O 0 2.3291113482315495e-09
70 O 0 6.892161508176287e-09
years O 0 1.0431724817294707e-08
. O 0 2.861629688766243e-08

The O 0 4.2946399503307475e-07
lifetime O 0 4.497010763770959e-07
risk O 0 5.309436801326228e-07
of O 0 7.310909040825209e-06
breast B-Disease 1 0.9999995231628418
cancer I-Disease 1 0.6593850255012512
appears O 0 6.296765064917054e-08
similar O 0 6.073083813618041e-09
to O 0 1.5029078426209708e-08
the O 0 1.4310046481114114e-06
risk O 0 2.2644917407887988e-07
in O 0 2.858104641845216e-09
BRCA1 O 0 1.497219126456173e-09
carriers O 0 1.4218758115358554e-10
, O 0 3.048555852203094e-11
but O 0 4.060020375451501e-11
there O 0 5.362396637842437e-11
was O 0 2.8227382653511768e-09
some O 0 1.6015626325138754e-11
suggestion O 0 3.0893341218529713e-09
of O 0 1.7274713881576531e-09
a O 0 9.469252049143506e-09
lower O 0 1.1564019075649412e-07
risk O 0 9.872527684251509e-09
in O 0 2.0417461055188824e-09
BRCA2 O 0 6.290879817072437e-09
carriers O 0 3.58200935579589e-09
< O 0 6.390851581272727e-08
50 O 0 2.5529836022997188e-09
years O 0 1.0180627452172075e-09
of O 0 6.73751499036257e-09
age O 0 2.7105306443786503e-08
. O 0 7.754776021329235e-08

Eye B-Disease 1 0.9999998807907104
movement I-Disease 0 6.81643869029358e-05
abnormalities I-Disease 0 0.00034410375519655645
correlate O 0 9.123618127659938e-08
with O 0 1.8350225783336782e-09
genotype O 0 5.9971252994728275e-06
in O 0 7.96406354197643e-08
autosomal O 1 0.9407665133476257
dominant O 1 0.9999984502792358
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 1.0
. O 0 2.531603240640834e-05

We O 0 1.138905076913943e-06
compared O 0 7.682849059165164e-07
horizontal O 0 8.325498129124753e-06
eye O 0 0.007975542917847633
movements O 0 2.2279856182194635e-07
( O 0 9.035312942273777e-09
visually O 0 2.973071211442857e-08
guided O 0 4.3089451651212585e-07
saccades O 0 8.272087870864198e-05
, O 0 1.4862656882996816e-08
antisaccades O 0 1.8241709085486946e-06
, O 0 1.3871861437309008e-09
and O 0 1.5665662100872169e-09
smooth O 0 2.689816724910088e-08
pursuit O 0 4.2865174521011795e-08
) O 0 1.4313560059431296e-10
in O 0 2.515128383340226e-10
control O 0 3.1923605092742946e-08
subjects O 0 5.925121726590987e-08
( O 0 5.406879943770093e-10
n O 0 4.4566244028487745e-09
= O 0 2.708405277829229e-09
14 O 0 4.380580065355133e-10
) O 0 1.0901520137995835e-11
and O 0 7.449198202724716e-11
patients O 0 1.755929568414416e-10
with O 0 8.844235066529649e-11
three O 0 4.266658970575321e-10
forms O 0 1.525055992601665e-08
of O 0 5.461931777972495e-06
autosomal O 0 0.006356419529765844
dominant O 0 0.4423770010471344
cerebellar B-Disease 1 1.0
ataxias I-Disease 0 0.21827273070812225
type I-Disease 1 0.9006662964820862
I I-Disease 1 0.9990490078926086
spinocerebellar B-Disease 1 0.9996844530105591
ataxias I-Disease 0 0.00011683598131639883
1 I-Disease 0 8.769746386860788e-07
and I-Disease 0 2.3072745491958813e-08
2 I-Disease 0 3.389883431736962e-07
( O 0 3.177772489593167e-09
SCA1 B-Disease 0 2.745760139077902e-05
, O 0 3.784438096232634e-09
n O 0 8.426272124495426e-09
= O 0 4.938258246767191e-09
11 O 0 1.920059888860237e-09
; O 0 3.500365275410644e-10
SCA2 B-Disease 0 1.5770140180393355e-06
, O 0 1.0214626922078196e-09
n O 0 1.971175445092399e-09
= O 0 1.4584076168944193e-09
10 O 0 2.381139452278802e-10
) O 0 8.657172895221166e-11
and O 0 3.667744552515728e-09
SCA3 B-Disease 1 1.0
/ O 0 3.533993731252849e-05
Machado B-Disease 0 5.711643098038621e-06
- I-Disease 0 1.5801151675987057e-06
Joseph I-Disease 0 0.0001237329706782475
disease I-Disease 1 0.9067467451095581
( O 0 2.023286249652756e-08
MJD B-Disease 1 1.0
) O 0 5.269648273298344e-09
( O 0 1.0505177838737723e-09
n O 0 1.0783576698258912e-08
= O 0 2.2424119450192848e-08
16 O 0 1.4118350932790236e-08
) O 0 1.5774201944651622e-09
. O 0 6.102033012211905e-08

In O 0 1.5687774066464044e-06
SCA1 B-Disease 0 0.0003471612581051886
, O 0 1.475898159242206e-08
saccade O 0 1.800587142497534e-06
amplitude O 0 8.446857435728816e-08
was O 0 7.668755408474226e-09
significantly O 0 7.502315435559126e-10
increased O 0 1.1418797157825011e-10
, O 0 1.3096178655414015e-11
resulting O 0 5.6288107508351e-10
in O 0 9.540003231833794e-10
hypermetria B-Disease 0 1.8890693809225922e-06
. O 0 7.344651464791241e-08

The O 0 1.4363521586346906e-05
smooth O 0 7.791374628141057e-06
pursuit O 0 2.4738678803259972e-06
gain O 0 6.741315701219719e-07
was O 0 4.909110771222913e-07
decreased O 0 1.042528410266641e-07
. O 0 7.235171040065325e-08

In O 0 1.355071617581416e-06
SCA2 B-Disease 0 0.0002528266631998122
, O 0 2.3386254710544563e-08
saccade O 0 6.135908279247815e-07
velocity O 0 2.1447488052217523e-07
was O 0 1.2788976277988695e-07
markedly O 0 2.592173302673473e-07
decreased O 0 1.2292777284983458e-07
. O 0 8.302540521754054e-08

The O 0 3.938585450669052e-06
percentage O 0 4.7477072939727805e-07
of O 0 1.4136087145288911e-07
errors O 0 6.11807945460896e-06
in O 0 2.0705667225229263e-07
antisaccades O 0 0.004353818483650684
was O 0 4.341094609117135e-06
greatly O 0 4.825053068202578e-08
increased O 0 4.306855760916051e-09
and O 0 6.07681183151243e-10
was O 0 4.198606351479839e-09
significantly O 0 3.0460986510938426e-10
correlated O 0 4.803047959356377e-10
with O 0 1.3281879068793856e-11
age O 0 2.601847404193336e-09
at O 0 2.1257068993918438e-08
disease O 0 8.808120810499531e-08
onset O 0 6.284705159487203e-05
. O 0 5.158505018698634e-07

In O 0 1.9928192784846033e-07
addition O 0 1.78322956401189e-08
, O 0 8.985384103432636e-10
a O 0 1.8708690152635654e-09
correlation O 0 3.5118830066238615e-09
between O 0 1.0309464393287726e-08
smooth O 0 1.7281237774113833e-07
pursuit O 0 2.055082433116695e-07
gain O 0 2.491116291025719e-08
and O 0 2.5181620677550143e-10
the O 0 7.978043781164956e-10
number O 0 8.292778963525649e-11
of O 0 2.0207784334758117e-09
trinucleotide O 0 1.2927508805660182e-06
repeats O 0 1.3786986663433254e-08
was O 0 2.5921599089429037e-08
found O 0 3.5291263245085247e-09
. O 0 2.3593422326939617e-08

In O 0 4.715290924650617e-05
SCA3 B-Disease 1 1.0
, O 0 1.5434117131007952e-06
gaze B-Disease 0 0.00013619285891763866
- I-Disease 0 2.6441020963829942e-05
evoked I-Disease 0 3.938087320420891e-05
nystagmus I-Disease 0 0.00046081209438852966
was O 0 5.728973633267742e-07
often O 0 7.553085379363722e-10
present O 0 1.530521820392039e-09
as O 0 3.461414932459661e-09
was O 0 5.681573256310912e-08
saccade O 0 7.870871741033625e-07
hypometria O 0 3.0081714612606447e-06
and O 0 2.708354962521753e-08
smooth O 0 1.0046437637356576e-07
pursuit O 0 5.08896732753783e-07
gain O 0 2.4448269186905236e-07
was O 0 3.378326312031277e-07
markedly O 0 4.706799074938317e-07
decreased O 0 1.3535576215417677e-07
. O 0 3.638114165482875e-08

Three O 0 1.7485489252067055e-06
major O 0 8.105562869786809e-07
criteria O 0 1.926164969745514e-07
, O 0 1.1372251584873538e-08
saccade O 0 2.146741053365986e-06
amplitude O 0 1.912324165687096e-07
, O 0 8.596313105790898e-10
saccade O 0 1.396385727048255e-07
velocity O 0 4.973452760737018e-08
, O 0 4.2848205539236517e-10
and O 0 2.5332985709169975e-10
presence O 0 2.7206239483490435e-09
of O 0 3.1658748866902897e-07
gaze B-Disease 0 4.0490842366125435e-05
- I-Disease 0 5.639150458591757e-06
evoked I-Disease 0 4.618104867404327e-06
nystagmus I-Disease 0 2.9701607218157733e-06
, O 0 4.392360086757918e-10
permitted O 0 7.47511996745942e-10
the O 0 1.655924508625617e-09
correct O 0 4.422305188711562e-09
assignment O 0 1.147060935124955e-08
of O 0 1.6806041003292194e-08
90 O 0 4.196957004154456e-09
% O 0 3.3337327343119227e-10
of O 0 2.5987922924741724e-09
the O 0 2.996594972159983e-08
SCA1 B-Disease 0 2.8196565835969523e-05
, O 0 2.0351829110865083e-09
90 O 0 3.0519100580050917e-09
% O 0 3.0848751331191693e-10
of O 0 5.970952621225933e-09
the O 0 1.1095367291602543e-08
SCA2 B-Disease 0 9.871317161014304e-06
, O 0 5.188758867014087e-10
and O 0 4.357288696521522e-10
93 O 0 2.5611381904155905e-09
% O 0 8.682490143518962e-11
of O 0 2.96574098612723e-09
the O 0 1.1426346979703794e-08
patients O 0 9.558002389553621e-09
with O 0 1.54002215424498e-08
SCA3 B-Disease 1 1.0
to O 0 1.4801274517139973e-07
their O 0 3.024351613589715e-08
genetically O 0 1.1227788121459525e-07
confirmed O 0 3.6538445158385e-08
patient O 0 4.1946583451135666e-07
group O 0 5.515488621377074e-10
and O 0 6.098292426592877e-10
, O 0 1.3042840418808765e-10
therefore O 0 1.8555522673935343e-09
, O 0 3.1691033131053814e-10
may O 0 7.544133318049262e-09
help O 0 7.981977745430413e-08
orient O 0 6.980479270168871e-07
diagnoses O 0 2.435326223348966e-06
of O 0 4.68009602627717e-06
SCA1 B-Disease 1 0.9990299940109253
, O 0 8.590401279207072e-09
SCA2 B-Disease 0 0.0004987435531802475
, O 0 4.506844231144669e-09
and O 0 6.69988082790951e-08
SCA3 B-Disease 1 1.0
at O 0 3.3709241620272223e-07
early O 0 1.8569622284303477e-08
clinical O 0 3.0170792530981316e-09
stages O 0 9.27183485543992e-09
of O 0 1.3876102045173866e-08
the O 0 1.070578576900516e-07
diseases O 0 0.021079853177070618
. O 0 1.8560097458930613e-08
. O 0 3.1392974619848246e-07

Genetic O 0 4.3575221297942335e-07
basis O 0 2.314600244801568e-08
and O 0 5.209682685247685e-10
molecular O 0 1.4324061936576982e-08
mechanism O 0 1.5606521230893122e-07
for O 0 3.943698061448231e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.9999160766601562

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 1.0
causes O 0 3.674433901323937e-05
more O 0 6.666133756105808e-10
than O 0 1.6527997026560826e-10
300 O 0 3.7993641566202996e-10
, O 0 3.660702990737619e-11
000 O 0 4.851199997268907e-10
sudden O 0 1.8012091818064846e-09
deaths O 0 2.856217484747958e-10
each O 0 9.358042986351567e-12
year O 0 2.3938628856967625e-10
in O 0 4.83551421126549e-10
the O 0 1.7839575150446763e-08
USA O 0 3.092094758017083e-08
alone O 0 1.4404336390327899e-08
. O 0 3.9633523130078174e-08

In O 0 6.206998932611896e-07
approximately O 0 1.5859525248629325e-08
5 O 0 4.0283083535541664e-08
- O 0 1.231419677338863e-08
12 O 0 1.8837917892255973e-09
% O 0 4.283830234985686e-11
of O 0 1.1706431657376726e-10
these O 0 1.4428346538364334e-11
cases O 0 1.715374647881518e-10
, O 0 1.317133121320202e-11
there O 0 8.330696375791202e-12
are O 0 6.961035480673727e-12
no O 0 9.451798232973374e-10
demonstrable O 0 9.027341729961336e-05
cardiac O 1 0.9999998807907104
or O 0 0.00035465165274217725
non O 1 0.9999995231628418
- O 1 1.0
cardiac O 1 1.0
causes O 0 7.786412425048184e-06
to O 0 7.72987540642589e-09
account O 0 8.130494610902872e-10
for O 0 3.0031852560341576e-09
the O 0 4.83217718283413e-07
episode O 0 2.2190243953446043e-07
, O 0 3.5259607733539866e-11
which O 0 4.566987413245904e-12
is O 0 9.520775010388172e-13
therefore O 0 3.5475927750994174e-12
classified O 0 1.0638070979673842e-10
as O 0 7.878726115961854e-09
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 0.18821030855178833
IVF B-Disease 1 1.0
) O 0 6.545239727984153e-08
. O 0 2.300547237155115e-07

A O 0 4.459991487237858e-06
distinct O 0 7.715561167742635e-08
group O 0 1.0320777121819447e-08
of O 0 1.6628176808808348e-06
IVF B-Disease 1 1.0
patients O 0 0.00013759428111370653
has O 0 1.0505397662896598e-09
been O 0 2.0515979193280742e-10
found O 0 7.245876815220598e-11
to O 0 3.841787998837276e-11
present O 0 6.203619840050578e-10
with O 0 5.624485877042673e-10
a O 0 1.9474757806392518e-08
characteristic O 0 5.337730613064195e-07
electrocardiographic O 0 1.3088831110508181e-05
pattern O 0 4.268835255061276e-06
. O 0 1.2242019238328794e-06

Because O 0 6.839554316684371e-06
of O 0 1.8707860363065265e-05
the O 0 1.2819042467526742e-06
small O 0 2.226065021204704e-08
size O 0 1.568971086385318e-08
of O 0 3.888176891564399e-08
most O 0 3.0403597417461015e-09
pedigrees O 0 4.4830645862248275e-08
and O 0 7.97033217203591e-10
the O 0 1.8038152083121872e-09
high O 0 8.650447469449318e-09
incidence O 0 2.338036608762195e-08
of O 0 9.664491429361988e-09
sudden B-Disease 0 1.1820460343869854e-07
death I-Disease 0 4.474329671211308e-07
, O 0 3.05515834853054e-10
however O 0 4.547087428807828e-10
, O 0 7.183512812369841e-11
molecular O 0 2.9867446293962985e-09
genetic O 0 2.473063531738262e-09
studies O 0 5.063053865050904e-10
of O 0 1.3440774182527093e-07
IVF B-Disease 1 1.0
have O 0 1.4682161264545357e-08
not O 0 1.3318015579244502e-09
yet O 0 5.29391686043823e-09
been O 0 7.3447887771749265e-09
done O 0 1.1357512263998615e-08
. O 0 1.7095461046778837e-08

Because O 0 6.713320908602327e-05
IVF B-Disease 1 1.0
causes O 1 0.999645471572876
cardiac O 1 1.0
rhythm O 1 0.9999998807907104
disturbance O 1 0.9999991655349731
, O 0 6.143733966013087e-09
we O 0 1.4679019111341063e-09
investigated O 0 2.0983664583695827e-08
whether O 0 7.3853301252313486e-09
malfunction O 0 0.00011428724974393845
of O 0 1.0723933741019209e-07
ion O 0 9.087144462682772e-06
channels O 0 6.958798053346982e-07
could O 0 2.226731687926531e-08
cause O 0 1.5623660942765127e-07
the O 0 1.0271524075733396e-08
disorder O 0 6.820290554543362e-09
by O 0 1.0440945850953565e-11
studying O 0 2.1530355276411228e-10
mutations O 0 4.141550644098935e-11
in O 0 1.1468781480061807e-10
the O 0 1.2080995759333746e-08
cardiac O 0 1.0144608495465945e-05
sodium O 0 2.038888624156243e-06
channel O 0 1.2958046227140585e-06
gene O 0 9.694145575167568e-08
SCN5A O 0 1.9866170987370424e-05
. O 0 2.131809964112108e-07

We O 0 7.287619609996909e-07
have O 0 1.6899742050213717e-08
now O 0 3.5586922297881074e-09
identified O 0 4.73250150179183e-09
a O 0 1.2512508362760855e-08
missense O 0 1.5227618632707163e-07
mutation O 0 4.671678599521556e-09
, O 0 1.0140202011399424e-09
a O 0 6.70807454028477e-09
splice O 0 2.565105205576401e-06
- O 0 1.427844580348392e-07
donor O 0 1.3579117386086637e-08
mutation O 0 4.972757761123603e-09
, O 0 2.1345941680905867e-10
and O 0 8.800018491683659e-10
a O 0 2.0023822600023777e-08
frameshift O 0 2.121784206110533e-07
mutation O 0 3.0956397445436323e-09
in O 0 1.013258477122747e-09
the O 0 8.328039591276593e-09
coding O 0 4.8381945561004613e-08
region O 0 6.058830326338693e-09
of O 0 4.4438941415592126e-08
SCN5A O 0 0.0006986034568399191
in O 0 5.820155024593987e-09
three O 0 1.492398560287711e-08
IVF B-Disease 1 1.0
families O 0 1.0128145433441205e-08
. O 0 5.2056360999586104e-08

We O 0 5.012574320062413e-07
show O 0 1.1344889472297837e-08
that O 0 1.7285746445327987e-10
sodium O 0 1.4230683298421809e-08
channels O 0 2.7615603137576272e-09
with O 0 1.1107298414358979e-10
the O 0 7.527833467690925e-09
missense O 0 2.474853886269557e-07
mutation O 0 1.633047119753428e-08
recover O 0 9.109149345931655e-07
from O 0 6.058577639578289e-08
inactivation O 0 2.971927278849762e-05
more O 0 2.3062160514619734e-10
rapidly O 0 2.679589439225083e-09
than O 0 1.9246814211837382e-11
normal O 0 1.6258165647098366e-10
and O 0 4.41444623910936e-11
that O 0 1.4416242505310706e-11
the O 0 1.7613377423231213e-09
frameshift O 0 3.9581394162269135e-08
mutation O 0 6.74129085886932e-10
causes O 0 1.319201081706467e-09
the O 0 3.220405275783378e-09
sodium O 0 4.749722393171396e-08
channel O 0 3.926827574218805e-08
to O 0 2.3174294427885656e-10
be O 0 8.061177281248888e-10
non O 0 2.473116822443444e-08
- O 0 8.19242629290784e-08
functional O 0 3.145158871120657e-07
. O 0 1.0916230763768908e-07

Our O 0 7.16178874426987e-06
results O 0 2.48616061071516e-08
indicate O 0 7.148897918085595e-09
that O 0 4.901330452611319e-10
mutations O 0 1.4639929268867036e-09
in O 0 7.856917338955327e-10
cardiac O 0 1.1005653277607053e-06
ion O 0 5.5089089983084705e-06
- O 0 4.7637015086365864e-05
channel O 0 2.3223725520438165e-07
genes O 0 3.368162970751598e-10
contribute O 0 2.019154461685435e-11
to O 0 7.462323814433347e-11
the O 0 1.1652749876134294e-09
risk O 0 2.1355728296867937e-09
of O 0 9.389900412770658e-09
developing O 0 6.231078373275523e-07
IVF B-Disease 1 1.0
. O 0 1.4589482510984908e-08
. O 0 2.5745201526206074e-08

Molecular O 0 2.601918822620064e-05
heterogeneity O 0 2.743402001215145e-05
in O 0 4.863211984229565e-07
mucopolysaccharidosis B-Disease 0 0.0005539247649721801
IVA I-Disease 1 0.999992847442627
in O 0 1.1557425949604294e-07
Australia O 0 5.0176511834365556e-09
and O 0 1.9436230402902765e-09
Northern O 0 4.512575202397784e-08
Ireland O 0 1.7006543728825818e-08
: O 0 2.2986539061076172e-10
nine O 0 1.0781473491761062e-09
novel O 0 2.1397317251370396e-09
mutations O 0 5.240757827706943e-10
including O 0 2.142025307128037e-10
T312S O 0 1.7106820848766802e-07
, O 0 4.035156098147752e-10
a O 0 6.499824567463008e-10
common O 0 1.0291566709952349e-08
allele O 0 2.4228119510638635e-09
that O 0 1.4191393893359106e-10
confers O 0 2.011205069152311e-08
a O 0 2.3169764773456336e-08
mild O 0 9.522151231067255e-06
phenotype O 0 2.9009288482484408e-05
. O 0 5.325314305082429e-07

Mucopolysaccharidosis B-Disease 1 0.9854581356048584
IVA I-Disease 1 1.0
( O 0 5.7319884945172817e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 2.6272916286984582e-08
is O 0 2.1973447505985177e-09
an O 0 3.6140923587169027e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 1.0
by O 0 1.4242233191907872e-05
a O 1 0.5859485864639282
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 2.2596499547944404e-05
N O 0 5.689744284609333e-06
- O 0 7.727799129497726e-07
acetylgalactosamine O 0 8.390226867049932e-06
- O 0 9.074449280888075e-07
6 O 0 1.1576581755434745e-06
- O 0 6.50775803023862e-07
sulfate O 0 1.7170747014461085e-05
sulfatase O 0 8.65135807543993e-05
( O 0 1.5901203909152173e-08
GALNS O 0 2.6156323656323366e-05
) O 0 4.317745716519994e-09
. O 0 3.1837561920156077e-08

Previous O 0 6.589230565623438e-07
studies O 0 1.743875799320449e-08
of O 0 3.2750225642530495e-08
patients O 0 1.0951596962627264e-08
from O 0 7.263374790511534e-09
a O 0 3.316086960580833e-08
British O 0 8.977868333204242e-07
- O 0 3.9754845602146816e-06
Irish O 0 9.195962888952636e-07
population O 0 1.269626070943275e-10
showed O 0 4.145907506192259e-10
that O 0 7.794536543981323e-11
the O 0 5.178498518887409e-09
I113F O 0 9.59762971319833e-08
mutation O 0 5.361867616571203e-10
is O 0 7.063326312728435e-11
the O 0 3.5785521768083584e-10
most O 0 5.845660067116398e-11
common O 0 8.38244251788467e-10
single O 0 1.5927906771295852e-09
mutation O 0 1.3396944664734178e-09
among O 0 2.8252915562632097e-09
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 0.0010417067678645253
and O 0 1.506627356206991e-08
produces O 0 1.2578904584614747e-09
a O 0 2.1352062340440625e-09
severe O 0 4.808277935808292e-07
clinical O 0 9.525062978354981e-07
phenotype O 0 1.1045798601116985e-05
. O 0 1.103635867139019e-07

We O 0 3.9673156493336137e-07
studied O 0 1.4668508185877727e-07
mutations O 0 4.864934677328847e-09
in O 0 7.968158910465206e-10
the O 0 5.713475914603805e-09
GALNS O 0 2.146898623323068e-06
gene O 0 1.0215932544355155e-09
from O 0 1.6354715359767624e-09
23 O 0 1.2691407036413693e-08
additional O 0 4.65215386213913e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 2.5220777388312854e-05
( O 0 1.7113657158063234e-09
15 O 0 1.89533544414644e-09
from O 0 1.6228061117118386e-09
Australia O 0 8.926978600776181e-10
, O 0 8.715691363070377e-11
8 O 0 1.0278927708995411e-09
from O 0 7.075600105821422e-10
Northern O 0 2.2565620483305793e-08
Ireland O 0 6.715703992909994e-09
) O 0 6.763284376987144e-11
, O 0 1.311040078583181e-11
with O 0 6.289779027474074e-12
various O 0 8.601939160968186e-10
clinical O 0 1.0736679314504727e-06
phenotypes O 0 0.00037380505818873644
( O 0 3.671897275125957e-08
severe O 1 0.9985038042068481
, O 0 2.181161029568557e-08
16 O 0 2.0911546272373016e-08
cases O 0 1.37491895646491e-09
; O 0 1.3473565596555659e-09
intermediate O 0 7.705530151724815e-07
, O 0 2.2127621956968824e-10
4 O 0 4.639851614030022e-09
cases O 0 7.41943784188237e-10
; O 0 1.1188037163378795e-09
mild O 0 2.9697797799599357e-05
, O 0 2.5056012820101614e-09
3 O 0 1.4206844589637058e-08
cases O 0 5.817654691320229e-10
) O 0 1.140593952619895e-09
. O 0 4.289919885991367e-08

We O 0 5.139858672009723e-07
found O 0 1.797126358837886e-08
two O 0 1.0667069449965538e-09
common O 0 5.733890695580612e-09
mutations O 0 4.534494446595261e-10
that O 0 6.125918522448259e-11
together O 0 3.180766483534825e-10
accounted O 0 2.376190799679989e-09
for O 0 4.293680688771673e-10
32 O 0 7.884469077623635e-09
% O 0 3.5326133684954186e-10
of O 0 3.6859433283353837e-09
the O 0 1.1242891950757894e-08
44 O 0 3.769180967339025e-09
unrelated O 0 1.389277914931597e-09
alleles O 0 4.294301372831377e-11
in O 0 2.1105776848440172e-11
these O 0 1.0791426086065314e-10
patients O 0 9.545231272056753e-09
. O 0 4.441724854586937e-08

One O 0 9.353221344099438e-07
is O 0 1.4483845234281034e-08
the O 0 1.4626567512721067e-08
T312S O 0 1.048412983095659e-07
mutation O 0 8.348455815543332e-10
, O 0 3.0580486060083345e-11
a O 0 2.4524646202728206e-10
novel O 0 1.9274166707106133e-09
mutation O 0 3.359514333389768e-10
found O 0 1.0065777378276408e-10
exclusively O 0 5.233795619119519e-10
in O 0 3.47777889819767e-10
milder O 0 0.0022483530919998884
patients O 0 0.0004081639344803989
. O 0 3.558861408237135e-06

The O 0 7.386597189906752e-06
other O 0 1.7029364585141593e-08
is O 0 1.0751286527721504e-09
the O 0 2.9835107717701703e-09
previously O 0 1.9937642647960274e-09
described O 0 5.8369531430457755e-09
I113F O 0 7.445685668017177e-08
that O 0 2.2361311413643392e-10
produces O 0 1.3095468043289316e-09
a O 0 4.011101673029316e-09
severe O 0 4.263175469532143e-06
phenotype O 0 2.28773587878095e-05
. O 0 4.804738864550018e-07

The O 0 1.009582047117874e-05
I113F O 0 1.7114671209128574e-05
and O 0 1.1906026031738293e-07
T312S O 0 5.89328692512936e-07
mutations O 0 3.773921619654175e-09
accounted O 0 2.5657831415060173e-09
for O 0 9.46220546360621e-10
8 O 0 2.2908828611889476e-08
( O 0 1.6061398044886488e-10
18 O 0 2.288876865819134e-09
% O 0 1.4981839380201478e-10
) O 0 6.336163538289696e-11
and O 0 1.2542561433903643e-09
6 O 0 3.3114289976765576e-08
( O 0 3.346768140399803e-10
14 O 0 1.0716767473439859e-09
% O 0 6.921347522892418e-11
) O 0 2.279294461504655e-11
of O 0 1.7415083819471988e-09
44 O 0 5.444043438274093e-09
unrelated O 0 1.53011114889523e-08
alleles O 0 9.749356877364335e-10
, O 0 4.1135653217061474e-10
respectively O 0 9.97473748043376e-09
. O 0 9.790902311124228e-08

The O 0 1.4440626728173811e-05
relatively O 0 2.930114533228334e-06
high O 0 3.996170107711805e-06
residual O 0 3.7429388612508774e-05
GALNS O 0 8.672173134982586e-05
activity O 0 2.345325889052674e-08
seen O 0 8.335270251791371e-09
when O 0 2.0769153064037482e-09
the O 0 7.207867636083165e-09
T312S O 0 1.016633532913147e-07
mutant O 0 3.857948271956957e-08
cDNA O 0 5.6468717701818605e-08
is O 0 1.0108032189037885e-09
overexpressed O 0 2.0717320126095728e-07
in O 0 2.868415505119515e-09
mutant O 0 2.0495349417615216e-08
cells O 0 3.220325339725605e-09
provides O 0 1.9945013696176517e-10
an O 0 3.238423418316927e-12
explanation O 0 9.6585114905956e-11
for O 0 4.8749435044292966e-11
the O 0 1.4086281030500913e-09
mild O 0 1.6734813357288658e-07
phenotype O 0 6.21986941951036e-08
in O 0 3.1980310066792583e-10
patients O 0 5.973042199736156e-11
with O 0 6.817522241187035e-12
this O 0 2.468156790058629e-10
mutation O 0 1.0268585981521028e-08
. O 0 3.448507257530764e-08

The O 0 3.0942484841034457e-07
distribution O 0 7.933238954649369e-09
and O 0 1.5579606493787423e-09
relative O 0 1.8714338523295737e-08
frequencies O 0 1.5885500914691875e-08
of O 0 2.5203508613458325e-08
the O 0 3.65597792040262e-08
I113F O 0 2.6395480290375417e-07
and O 0 4.7019734772391075e-09
T312S O 0 1.2540203897515312e-07
mutations O 0 1.2379517411176266e-09
in O 0 2.405066146238255e-10
Australia O 0 1.3675506560506534e-10
corresponded O 0 2.142352129030911e-10
to O 0 2.3616675282056576e-10
those O 0 1.7521424588995416e-10
observed O 0 1.678271299709877e-09
in O 0 1.0667762229132904e-09
Northern O 0 3.4817112748442014e-08
Ireland O 0 2.325920434032014e-08
and O 0 1.7671525354145956e-09
are O 0 3.7828035842624175e-11
unique O 0 3.0964350528073226e-10
to O 0 1.9857594735217532e-10
these O 0 1.5829801358613338e-10
two O 0 3.3408112387611766e-10
populations O 0 1.8611659435840977e-10
, O 0 1.608502740724216e-11
suggesting O 0 1.187509812705656e-10
that O 0 1.9055274025348012e-10
both O 0 1.966706575373678e-09
mutations O 0 1.5435619449277738e-09
were O 0 5.0491117953299636e-09
probably O 0 1.3888918459770139e-08
introduced O 0 6.103951122327089e-09
to O 0 4.442584633501667e-10
Australia O 0 1.082267470087217e-10
by O 0 1.4703389894510366e-10
Irish O 0 1.9381525717676595e-08
migrants O 0 7.67068297768958e-10
during O 0 3.9303778009980306e-09
the O 0 6.867007407151959e-09
19th O 0 3.4054139064210176e-07
century O 0 2.239282594018732e-06
. O 0 1.9974848441961512e-07

Haplotype O 0 4.2041796405101195e-05
analysis O 0 1.259629840433263e-07
using O 0 9.188987348807132e-08
6 O 0 3.3439067692597746e-07
RFLPs O 0 1.4765098512725672e-06
provides O 0 1.1742710137596646e-09
additional O 0 2.42837167041543e-10
data O 0 4.774241002536428e-10
that O 0 3.846795798567726e-11
the O 0 2.2952071354609416e-09
I113F O 0 3.174757168267206e-08
mutation O 0 3.819432548013424e-10
originated O 0 5.411099901486693e-10
from O 0 5.951253378988497e-11
a O 0 6.429297649823695e-10
common O 0 5.676154213318796e-09
ancestor O 0 1.5335346006395412e-06
. O 0 1.7149780262570857e-07

The O 0 3.849209406325826e-06
other O 0 2.4125853315126733e-08
9 O 0 3.813365623273057e-08
novel O 0 7.816071345700948e-09
mutations O 0 4.544729315103524e-10
identified O 0 7.457575113001269e-10
in O 0 1.4674420012461553e-10
these O 0 2.9755131691899805e-10
23 O 0 1.9203282519697495e-08
patients O 0 2.3744328725427977e-09
were O 0 3.7901739524670575e-09
each O 0 1.1739749450345727e-10
limited O 0 6.629717330675078e-10
to O 0 1.2552205941318562e-09
a O 0 2.09415631502452e-08
single O 0 8.661479711236098e-08
family O 0 1.6283358661439706e-07
. O 0 9.988658433712772e-08

These O 0 4.2559509694228836e-08
data O 0 3.060083741956987e-08
provide O 0 9.291925007204327e-10
further O 0 5.525301882691735e-10
evidence O 0 9.815149581982041e-09
for O 0 1.4619335741983264e-09
extensive O 0 9.330559436193653e-08
allelic O 0 1.0791734439408174e-06
heterogeneity O 0 3.190265715602436e-06
in O 0 3.0344929768943985e-07
MPS B-Disease 1 0.9999974966049194
IVA I-Disease 1 1.0
in O 0 1.1793031973184043e-07
British O 0 3.732828190550208e-06
- O 0 1.4847723832644988e-05
Irish O 0 3.4913120998680824e-06
patients O 0 8.936629569689103e-08
and O 0 1.6558360238505543e-09
provide O 0 4.1785674920191695e-10
evidence O 0 2.2900003671111335e-08
for O 0 7.31659732799983e-10
their O 0 3.588888963790282e-09
transmission O 0 9.710374371252328e-08
to O 0 3.1770091002414347e-09
Australia O 0 3.018764127560303e-10
by O 0 2.1662002747113718e-10
British O 0 9.610672435655943e-08
- O 0 1.701060909908847e-07
Irish O 0 4.978577550218688e-08
migrants O 0 1.1474672323430468e-09
. O 0 6.139303510011018e-10
. O 0 1.2809967309124204e-08

Identification O 0 1.2228554169269046e-06
of O 0 3.5885018405679148e-06
constitutional O 0 3.0371029424713925e-05
WT1 O 1 0.9481571316719055
mutations O 0 1.2725942610813945e-07
, O 0 4.469083991764933e-10
in O 0 2.6940910613504343e-10
patients O 0 1.6518865164627528e-09
with O 0 1.0741694200788743e-09
isolated O 0 0.49162572622299194
diffuse B-Disease 1 1.0
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 1.5465980496287557e-08
and O 0 5.695824367712987e-10
analysis O 0 8.504221216121266e-10
of O 0 5.240183398314002e-08
genotype O 0 3.341679757795646e-06
/ O 0 3.956887439926504e-07
phenotype O 0 1.5077889159442748e-08
correlations O 0 4.92949459030001e-10
by O 0 2.9072882989922277e-11
use O 0 1.0417761098224787e-09
of O 0 2.8107967509072296e-08
a O 0 3.724020203321743e-08
computerized O 0 4.358689977834729e-07
mutation O 0 1.1625627571731911e-08
database O 0 1.993792153598406e-08
. O 0 4.3799243343300986e-08

Constitutional O 0 1.4534909496433102e-05
mutations O 0 2.762089366115106e-07
of O 0 7.963346888573142e-07
the O 0 2.579669740043755e-07
WT1 O 0 1.5818211977602914e-05
gene O 0 1.5253149854288495e-08
, O 0 4.044387047485998e-10
encoding O 0 1.5036706102478092e-08
a O 0 5.613774334278787e-08
zinc O 0 8.508824248565361e-05
- O 0 0.00010096131882164627
finger O 0 0.0006925574853084981
transcription O 0 0.00012954026169609278
factor O 0 1.1664435106695237e-07
involved O 0 9.527514777118995e-09
in O 0 3.173268225964421e-08
renal O 1 1.0
and O 0 2.735987663982087e-06
gonadal O 1 0.9919251799583435
development O 0 4.339354200055823e-05
, O 0 2.7811061786842117e-10
are O 0 7.689351759487817e-12
found O 0 7.852613698178246e-11
in O 0 2.6041882192351373e-11
most O 0 6.153508952388975e-11
patients O 0 6.340612757060882e-11
with O 0 4.224083027803971e-10
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.3563835636887234e-05
DDS B-Disease 1 1.0
) O 0 1.701627816430573e-08
, O 0 5.19418452693543e-10
or O 0 2.780340651042934e-07
diffuse B-Disease 1 1.0
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 4.944594365952071e-06
DMS B-Disease 0 0.027979429811239243
) O 0 2.303446600127046e-10
associated O 0 3.017723848586229e-09
with O 0 2.278331967531244e-09
pseudohermaphroditism B-Disease 1 1.0
and O 0 7.74111831560731e-05
/ O 1 0.9982985854148865
or O 0 0.00012826868623960763
Wilms B-Disease 1 1.0
tumor I-Disease 0 0.005301991011947393
( O 0 1.8659376266327854e-08
WT B-Disease 1 0.9999910593032837
) O 0 3.809030868495711e-09
. O 0 2.2628118045986412e-08

Most O 0 3.468832971975644e-07
mutations O 0 2.0017222368551302e-07
in O 0 1.6469142849473428e-07
DDS B-Disease 1 1.0
patients O 1 0.8920824527740479
lie O 0 1.9415772840147838e-05
in O 0 5.484923804033315e-08
exon O 0 2.70501033128312e-07
8 O 0 2.2957379997023963e-08
or O 0 2.183790925869289e-09
exon O 0 5.015357373849838e-08
9 O 0 1.2875517541033332e-08
, O 0 2.892643069518641e-10
encoding O 0 9.995900285275638e-08
zinc O 0 0.00046978367026895285
finger O 0 0.006546440068632364
2 O 0 0.00012768295709975064
or O 0 2.404930000921013e-06
zinc O 0 0.05392145738005638
finger O 0 0.0005547415930777788
3 O 0 1.8904030412159045e-06
, O 0 1.0049783227827902e-09
respectively O 0 1.6573337147107736e-09
, O 0 2.6706281630595186e-10
with O 0 3.8719949468912773e-10
a O 0 1.6114600498440268e-07
hot O 0 2.1472329535754398e-05
spot O 0 7.781830504427489e-07
( O 0 2.51408754925464e-10
R394W O 0 8.053328670598603e-09
) O 0 5.023631163836306e-11
in O 0 2.778380858714513e-10
exon O 0 7.654189460026828e-08
9 O 0 1.7835840537827607e-07
. O 0 8.246324512128922e-08

We O 0 3.724247790160007e-07
analyzed O 0 4.293882227557333e-08
a O 0 1.014365036411391e-08
series O 0 3.1440949843641874e-09
of O 0 4.246542673058684e-09
24 O 0 1.501257607117168e-08
patients O 0 7.897834386483282e-09
, O 0 6.819453890472005e-10
10 O 0 4.517783480650905e-09
with O 0 7.89301513037799e-09
isolated B-Disease 0 0.034870345145463943
DMS I-Disease 1 1.0
( O 0 2.585489710327238e-06
IDMS B-Disease 1 0.9998898506164551
) O 0 8.119278582796596e-09
, O 0 7.499797449739276e-10
10 O 0 1.1766565499726767e-09
with O 0 9.139478063246997e-10
DDS B-Disease 1 1.0
, O 0 1.5916009843408574e-08
and O 0 4.15331724568091e-09
4 O 0 4.072816395250811e-08
with O 0 2.8432933785182968e-09
urogenital B-Disease 1 0.9999544620513916
abnormalities I-Disease 1 0.9999998807907104
and O 0 6.96624701959081e-05
/ O 1 0.9999990463256836
or O 1 0.971609890460968
WT B-Disease 1 1.0
. O 0 4.952450581185985e-06

We O 0 2.342517063880223e-06
report O 0 7.470101195394818e-07
WT1 O 0 0.0001390912220813334
heterozygous O 0 6.78771883144691e-08
mutations O 0 1.5376497852770399e-09
in O 0 1.3435020873586723e-09
16 O 0 5.277594361530191e-09
patients O 0 7.069371754653275e-09
, O 0 3.5762184880105963e-10
4 O 0 2.818285516070773e-08
of O 0 1.4891145205808698e-08
whom O 0 4.308945023012711e-08
presented O 0 1.564889373639744e-07
with O 0 9.93973898744116e-08
IDMS B-Disease 1 0.9999998807907104
. O 0 2.367762863286771e-05

One O 0 2.7568998461902083e-07
male O 0 3.810297144468677e-08
and O 0 3.341437349035914e-09
two O 0 1.2343397415293111e-09
female O 0 7.57574003529271e-09
IDMS B-Disease 1 0.9843674302101135
patients O 0 6.074349130358314e-07
with O 0 2.411921116163285e-07
WT1 O 1 1.0
mutations O 0 0.0001088055651052855
underwent O 1 0.9573165774345398
normal O 0 1.093888386094477e-05
puberty O 0 1.5733990949229337e-05
. O 0 8.128610318181018e-08

Two O 0 4.423051905177999e-06
mutations O 0 8.041112096179859e-07
associated O 0 3.868449311994482e-07
with O 0 2.109357311042004e-08
IDMS B-Disease 1 0.9999890327453613
are O 0 5.916002687733624e-10
different O 0 1.812460320715914e-10
from O 0 6.653862461014626e-10
those O 0 2.1957599627420166e-10
described O 0 1.0784666493179884e-08
in O 0 1.6631135579814327e-08
DDS B-Disease 1 1.0
patients O 0 0.00021717697381973267
. O 0 5.598835173259431e-07

No O 0 2.849516022251919e-05
WT1 O 0 0.002792139770463109
mutations O 0 2.2557838974535116e-07
were O 0 1.7672375562938214e-08
detected O 0 4.438489753511021e-08
in O 0 8.888258462569354e-10
the O 0 8.353334024491232e-09
six O 0 6.088509252322183e-09
other O 0 6.565291865712197e-09
IDMS B-Disease 1 1.0
patients O 0 0.00011743713548639789
, O 0 1.2068851473756581e-09
suggesting O 0 4.353702287573924e-09
genetic O 0 7.438659110903245e-08
heterogeneity O 0 2.0127673394654266e-07
of O 0 5.455053155856149e-07
this O 0 1.6723963369713601e-07
disease O 1 0.989099383354187
. O 0 1.4205104434950044e-06

We O 0 7.76628326093487e-07
analyzed O 0 6.027785843798483e-07
genotype O 0 5.620573574560694e-06
/ O 0 7.316589289985131e-07
phenotype O 0 7.586734085407443e-08
correlations O 0 1.6673283198542777e-08
, O 0 2.8749591596266555e-10
on O 0 2.4115902608201623e-09
the O 0 7.963448789283234e-10
basis O 0 1.0362154467813411e-09
of O 0 2.539172205828777e-09
the O 0 2.2454837989016596e-09
constitution O 0 3.5665048692123946e-10
of O 0 9.77501990462315e-09
a O 0 2.66824820016609e-08
WT1 O 0 5.491373940458288e-06
mutation O 0 1.7476116553893917e-08
database O 0 9.518324795010358e-09
of O 0 9.803272860153811e-08
84 O 0 8.520398182554345e-07
germ O 1 0.9998666048049927
- O 1 0.7604314088821411
line O 0 0.00046778598334640265
mutations O 0 5.2324136134984656e-08
, O 0 3.3809008370688787e-10
to O 0 4.017891297447562e-10
compare O 0 5.520869095221315e-09
the O 0 9.18052212028897e-09
distribution O 0 1.0098550884407587e-09
and O 0 1.0527136107274515e-10
type O 0 4.749610926779724e-09
of O 0 5.820655069044278e-09
mutations O 0 1.6534934532685952e-10
, O 0 6.904124407597356e-12
according O 0 8.656046365795866e-12
to O 0 5.5981011493067e-11
the O 0 1.3721394021004585e-09
different O 0 2.421693956478066e-09
symptoms O 0 3.417928155613481e-06
. O 0 4.779507207786082e-07

This O 0 2.691490692541265e-07
demonstrated O 0 3.8401057622650114e-07
( O 0 3.6642275880183206e-09
1 O 0 2.181098679443494e-08
) O 0 1.1688672252319066e-10
the O 0 1.1114849041149455e-09
association O 0 1.57858712213077e-10
between O 0 6.112569339578044e-10
mutations O 0 4.6291359634409446e-10
in O 0 2.9298363735108524e-09
exons O 0 3.0739658996026265e-07
8 O 0 9.49975529351832e-08
and O 0 5.870425923149014e-09
9 O 0 1.0319324417196185e-07
and O 0 3.1483093465567435e-08
DMS B-Disease 0 0.002943072933703661
; O 0 2.1151670637209463e-08
( O 0 3.6443976725308858e-09
2 O 0 2.138641548299347e-07
) O 0 2.0910967402087977e-10
among O 0 2.8790472783590815e-10
patients O 0 2.4860313807550938e-09
with O 0 2.4950093102660276e-09
DMS B-Disease 0 0.4447972774505615
, O 0 8.163000830840872e-10
a O 0 2.1996553467573676e-09
higher O 0 3.0388407346038093e-09
frequency O 0 8.631494630151337e-09
of O 0 5.038010453262132e-09
exon O 0 8.298673748186047e-09
8 O 0 1.2595878784438241e-09
mutations O 0 4.7534122471493134e-11
among O 0 6.252845463627921e-11
46 O 0 3.768361622746852e-09
, O 0 1.5497687577692432e-09
XY O 0 0.0013690300984308124
patients O 0 1.2914063063362846e-07
with O 0 1.5640165829111652e-09
female O 0 3.4299021400840957e-09
phenotype O 0 1.1289241541589945e-08
than O 0 8.662590783581336e-11
among O 0 2.6928889673705214e-10
46 O 0 2.0235333408891165e-08
, O 0 6.169639021891271e-09
XY O 1 0.9666162729263306
patients O 0 8.904098081075063e-08
with O 0 8.903988102382243e-10
sexual O 0 3.3403158017364376e-09
ambiguity O 0 3.8330906448891255e-08
or O 0 3.948922966401369e-09
male O 0 3.778060919668036e-10
phenotype O 0 5.020894255913788e-10
; O 0 5.106305309143799e-11
and O 0 3.2309302455679756e-10
( O 0 3.461842479346444e-10
3 O 0 1.4379356372273833e-08
) O 0 3.3351175987572645e-11
statistically O 0 1.4245896996778473e-11
significant O 0 1.6206398723017656e-10
evidence O 0 4.791658625435957e-09
that O 0 1.9040669041459068e-10
mutations O 0 4.396273900475478e-10
in O 0 1.103439117855487e-09
exons O 0 1.4819691784850875e-07
8 O 0 2.821254163620779e-08
and O 0 2.1721842102806477e-09
9 O 0 6.712400413277919e-09
preferentially O 0 1.0096855573848984e-09
affect O 0 1.6666248381369542e-09
amino O 0 6.585857414975749e-10
acids O 0 1.1266579336144389e-10
with O 0 6.2172593462417325e-12
different O 0 1.2465140031281408e-10
functions O 0 7.745545316240054e-10
. O 0 8.717790378476309e-10
. O 0 6.904227412007913e-09

The O 0 1.9186925783287734e-05
185delAG O 0 4.3566869862843305e-05
BRCA1 O 0 4.440692009666236e-07
mutation O 0 9.11622244359478e-09
originated O 0 8.817059082844025e-09
before O 0 3.912650647919236e-09
the O 0 1.109366931650868e-09
dispersion O 0 2.7842085970064545e-08
of O 0 1.3969499335075852e-08
Jews O 0 1.473985111744014e-08
in O 0 1.4636578615778717e-09
the O 0 4.802097830491903e-09
diaspora O 0 4.388719165859811e-09
and O 0 4.6294007516323177e-10
is O 0 6.99020286099028e-11
not O 0 4.073796855408318e-11
limited O 0 8.594953082585732e-10
to O 0 8.794250661026126e-09
Ashkenazim O 0 2.8883659979328513e-05
. O 0 6.405581416402129e-07

The O 0 2.661148755578324e-06
185delAG O 0 3.14286990032997e-06
mutation O 0 4.272616394018769e-08
in O 0 1.3103695906124813e-08
BRCA1 O 0 2.0078473994544765e-08
is O 0 3.2497993185387486e-10
detected O 0 4.34080016376015e-09
in O 0 1.5388343377331637e-10
Ashkenazi O 0 1.283832062881629e-07
Jews O 0 1.8709377158643292e-08
both O 0 1.2753108569185656e-09
in O 0 6.4146998823844115e-09
familial B-Disease 1 0.9999370574951172
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.1220136520460073e-07
in O 0 1.3358721906442383e-09
the O 0 3.3355679107671676e-08
general O 0 4.213128335095462e-08
population O 0 3.040218909955428e-10
. O 0 1.6032460692372297e-08

All O 0 3.8619762676717073e-07
tested O 0 2.359450945732533e-07
Ashkenazi O 0 2.2637066194874933e-06
mutation O 0 1.7146208008966823e-08
carriers O 0 4.830741584527232e-09
share O 0 2.8774678195730985e-09
the O 0 6.2499894148970725e-09
same O 0 3.895152644872724e-09
allelic O 0 4.1584092969060293e-07
pattern O 0 1.2132957749599882e-07
at O 0 7.525942180564016e-08
the O 0 2.510036622993539e-08
BRCA1 O 0 5.0489791902919023e-08
locus O 0 2.999580601681373e-07
. O 0 4.737760761486243e-08

Our O 0 4.9625868996372446e-05
previous O 0 1.9965204955951776e-06
study O 0 1.4171932072315485e-08
showed O 0 2.750489613845275e-09
that O 0 5.46676350021702e-11
this O 0 1.6459478224817303e-10
Ashkenazi O 0 4.479666699808149e-07
mutation O 0 3.78287934310606e-09
also O 0 1.1049190729028879e-10
occurs O 0 6.018465587009914e-11
in O 0 4.222413391152813e-11
Iraqi O 0 7.356369291500187e-09
Jews O 0 9.93774484925325e-09
with O 0 4.289702759674441e-10
a O 0 2.22643770086961e-09
similar O 0 2.5134703207640996e-09
allelic O 0 4.6028776523598935e-07
pattern O 0 4.0809274537423335e-07
. O 0 1.9374878945654928e-07

We O 0 1.2992570646019885e-06
extended O 0 8.506287940690527e-07
our O 0 5.206231890042545e-08
analysis O 0 3.2316098685925e-09
to O 0 7.364017173827619e-10
other O 0 2.8938459961658225e-10
non O 0 1.2328110088333233e-08
- O 0 2.606179982933554e-08
Ashkenazi O 0 4.6834620093250123e-07
subsets O 0 7.317832029229976e-08
354 O 0 6.563439125528703e-09
of O 0 1.9779697879585e-09
Moroccan O 0 9.03355523718119e-09
origin O 0 7.472183427559287e-10
, O 0 1.629234247513267e-10
200 O 0 3.2015953776998174e-10
Yemenites O 0 2.955167417439952e-07
and O 0 4.471609749145955e-09
150 O 0 4.489282723341148e-09
Iranian O 0 5.358601384841677e-08
Jews O 0 1.6250190526534425e-07
. O 0 2.501615767869225e-07

Heteroduplex O 0 4.7736335545778275e-05
analysis O 0 6.696163268316013e-08
complemented O 0 2.3848597763276302e-08
by O 0 3.421471717057756e-10
direct O 0 1.3076524307820137e-09
DNA O 0 1.3820898203675824e-08
sequencing O 0 1.3663473907854495e-08
of O 0 5.828520333039933e-09
abnormally O 0 3.429459027870507e-08
migrating O 0 3.16095549734996e-09
bands O 0 7.584358030499061e-09
were O 0 2.7585858042300515e-09
employed O 0 4.2369656227947416e-08
. O 0 4.8031996158215406e-08

Four O 0 7.710926297477272e-07
of O 0 3.2002191119318013e-07
Moroccan O 0 1.5991008694982156e-06
origin O 0 5.345341236306922e-08
( O 0 8.140860208172285e-10
1 O 0 5.873024289115847e-09
. O 0 3.9365122272982944e-10
1 O 0 1.0805400130209364e-08
% O 0 3.996414588147701e-10
) O 0 6.699846233360063e-11
and O 0 3.6374719902809716e-10
none O 0 3.189347808074672e-08
of O 0 3.59900212743014e-07
the O 0 5.472044222187833e-07
Yemenites O 0 3.4249403597641503e-06
or O 0 1.5331522718042834e-08
Iranians O 0 7.093575948857733e-09
was O 0 1.5762960714482688e-08
a O 0 6.228232374283493e-10
carrier O 0 9.792201494107644e-10
of O 0 2.972627477504375e-09
the O 0 9.306917014839655e-09
185delAG O 0 2.43685889245171e-07
mutation O 0 2.316711267269511e-08
. O 0 4.1842422859872386e-08

BRCA1 O 0 2.5548866688041016e-05
allelic O 0 8.478334166284185e-06
patterns O 0 1.2533401161363145e-07
were O 0 2.9062393380741014e-08
determined O 0 1.5914856987819803e-08
for O 0 3.4709350948958217e-09
four O 0 2.1268857786083117e-09
of O 0 2.5362199007616937e-09
these O 0 6.890629733469211e-11
individuals O 0 7.866702081416044e-12
and O 0 2.475100957521903e-10
for O 0 2.965739320792693e-10
12 O 0 1.5015145793384477e-09
additional O 0 1.8022813241813651e-09
non O 0 4.998234715003491e-08
- O 0 1.0618077794788405e-07
Ashkenazi O 0 2.8756758752024325e-07
185delAG O 0 1.0982513565238605e-08
mutation O 0 9.749909213319086e-11
carriers O 0 1.5900884775543744e-10
who O 0 1.6249308565363663e-09
had O 0 3.904490029071894e-07
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.568704803707078e-05

Six O 0 1.3437058441923e-05
non O 0 1.1905250175914261e-05
- O 0 5.15381179866381e-06
Ashkenazi O 0 1.1248810551478527e-05
individuals O 0 7.296389603617115e-10
shared O 0 2.0650620768947192e-08
the O 0 9.281761137458489e-09
common O 0 7.336671359325919e-08
Ashkenazi O 0 1.1420655027905013e-05
haplotype O 0 1.748989598127082e-05
, O 0 1.3943624033174729e-08
four O 0 1.659004489340532e-08
had O 0 6.174396816049921e-08
a O 0 1.2630335888275113e-08
closely O 0 2.494386031060003e-09
related O 0 1.8485659225575546e-08
pattern O 0 8.496437544636137e-07
, O 0 1.9687032004611638e-09
and O 0 5.9460405488209744e-09
the O 0 2.4921530439314665e-07
rest O 0 8.913075930649939e-07
( O 0 3.2385085724229157e-09
n O 0 1.7393613660487972e-08
= O 0 1.712228581141062e-08
6 O 0 6.066322999487284e-09
) O 0 3.860842895386796e-11
displayed O 0 6.560607057615186e-10
a O 0 8.797606199095753e-09
distinct O 0 1.2503203805636076e-08
BRCA1 O 0 4.448507340271135e-08
allelic O 0 3.138860336093785e-07
pattern O 0 2.102693770211772e-07
. O 0 8.207487667277746e-08

We O 0 5.639938649437681e-07
conclude O 0 5.983678192933439e-07
that O 0 7.007724622809519e-09
the O 0 1.199313715005701e-07
185delAG O 0 2.0382722141221166e-06
BRCA1 O 0 1.016408646137279e-07
mutation O 0 1.8390731160167206e-09
occurs O 0 3.224761568887402e-10
in O 0 7.038097882272609e-11
some O 0 9.575546605633534e-11
non O 0 2.2282909739601564e-08
- O 0 2.0197511219066655e-07
Ashkenazi O 0 7.656081834284123e-06
populations O 0 6.458589663083103e-09
at O 0 6.897050708332131e-10
rates O 0 1.607085818589038e-11
comparable O 0 2.1119560267290893e-10
with O 0 1.3551953829959995e-11
that O 0 1.2647342895188984e-10
of O 0 7.447148675510107e-08
Ashkenazim O 0 2.425213278911542e-05
. O 0 2.5606786380194535e-07

The O 0 1.1270050208622706e-06
majority O 0 2.286430245135307e-08
of O 0 1.3332564208212716e-07
Jewish O 0 1.3095379358674109e-07
185delAG O 0 2.3151569905621727e-07
mutation O 0 8.018138153431664e-09
carriers O 0 2.427872791699315e-09
have O 0 1.7191847945241534e-09
a O 0 9.188632965617671e-09
common O 0 5.623955345868126e-08
allelic O 0 4.7446607709389355e-07
pattern O 0 9.493379593550344e-08
, O 0 7.570103432996689e-10
supporting O 0 3.6278151593904795e-09
the O 0 4.1780859305617923e-07
founder O 0 3.687820026243571e-06
effect O 0 3.201164844313098e-08
notion O 0 1.4851950425054383e-07
, O 0 3.5753999760856914e-10
but O 0 3.637810538914543e-11
dating O 0 1.573789765174638e-09
the O 0 8.265101936189012e-10
mutations O 0 1.1988974049637058e-11
origin O 0 3.360006023411799e-11
to O 0 5.934862323808687e-11
an O 0 2.235814658413382e-11
earlier O 0 9.641067943988446e-10
date O 0 2.7435330451908158e-08
than O 0 7.047409877891653e-10
currently O 0 2.340836691150372e-10
estimated O 0 4.701810052409883e-10
. O 0 3.98247834709764e-08

However O 0 5.475233706420113e-07
, O 0 6.515604944468123e-09
the O 0 3.167497597544866e-09
different O 0 6.878868030746332e-10
allelic O 0 3.374204879946774e-07
pattern O 0 2.627044466407824e-07
at O 0 1.5915379947273323e-07
the O 0 5.741674868886548e-08
BRCA1 O 0 2.9536842305333266e-08
locus O 0 2.318085989827523e-08
even O 0 7.908683707924524e-10
in O 0 2.0387602717164555e-10
some O 0 3.1687874546548755e-11
Jewish O 0 2.0598802663585047e-09
mutation O 0 4.924946006568121e-10
carriers O 0 6.463096169362359e-10
, O 0 1.655917347687108e-10
might O 0 6.349111791870143e-10
suggest O 0 1.7066456026171295e-09
that O 0 1.3773251983373314e-10
the O 0 3.892241196012947e-09
mutation O 0 7.120982692399025e-10
arose O 0 8.287533437290051e-10
independently O 0 5.569953942519135e-10
. O 0 7.772301691133521e-10
. O 0 1.4382538715551618e-08

Crystal O 0 0.0002648658992256969
structure O 0 3.782026396947913e-05
of O 0 0.005554413888603449
the O 0 0.052990689873695374
hemochromatosis B-Disease 1 1.0
protein O 0 0.0001859035692177713
HFE O 0 0.07400393486022949
and O 0 2.5289367044933897e-08
characterization O 0 1.6371676281323744e-07
of O 0 7.639036425644008e-08
its O 0 3.6713772022523017e-09
interaction O 0 3.5454943425605734e-09
with O 0 6.99554136840419e-10
transferrin O 0 8.332543075084686e-06
receptor O 0 5.313768269843422e-07
. O 0 5.887371656854157e-08

HFE O 1 0.998236894607544
is O 0 3.7548900309047895e-06
an O 0 4.604835268651186e-08
MHC O 0 2.092897739203181e-05
- O 0 1.5163656826189253e-05
related O 0 1.5026563460196485e-06
protein O 0 1.0120136550995085e-07
that O 0 1.8547870184182358e-10
is O 0 5.4344514999193905e-11
mutated O 0 2.4790565156251887e-09
in O 0 3.978602169940615e-10
the O 0 8.09446447647133e-08
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.005406305193901062

HFE O 0 0.00267963157966733
binds O 0 2.9330976758501492e-06
to O 0 3.206818348644447e-07
transferrin O 0 9.444838360650465e-05
receptor O 0 8.601780905337364e-07
( O 0 1.159758289404067e-09
TfR O 0 1.879052859976582e-07
) O 0 6.650090894622096e-11
and O 0 1.0720831167265743e-10
reduces O 0 2.8502544768826965e-09
its O 0 1.038126362651326e-09
affinity O 0 8.469940304678403e-09
for O 0 2.114149522114417e-09
iron O 0 4.705843821284361e-05
- O 0 4.411894565237162e-07
loaded O 0 5.593135483650258e-07
transferrin O 0 6.155000392027432e-06
, O 0 2.6826476595687154e-09
implicating O 0 6.927874665052514e-07
HFE O 1 0.9953579306602478
in O 0 1.092641241484671e-06
iron O 1 0.9999994039535522
metabolism O 0 0.00058638775954023
. O 0 5.356170049708453e-07

The O 0 2.0764089640579186e-05
2 O 0 1.3173282241041306e-05
. O 0 6.782515811210033e-07

6 O 0 0.0001881546195363626
A O 0 1.1800478205259424e-05
crystal O 0 1.9108971173409373e-05
structure O 0 9.35327261686325e-06
of O 0 3.59863079211209e-05
HFE O 1 0.9999998807907104
reveals O 0 1.8588796137919417e-06
the O 0 2.218207129089933e-08
locations O 0 1.5947128062521188e-08
of O 0 7.284436946974893e-07
hemochromatosis B-Disease 1 1.0
mutations O 0 2.7680857783707324e-06
and O 0 2.87909500684691e-07
a O 0 7.667090358154383e-07
patch O 1 0.999998927116394
of O 1 0.9999897480010986
histidines O 1 0.9997355341911316
that O 0 3.0331442246733786e-08
could O 0 6.52798419764622e-08
be O 0 3.758032995904159e-09
involved O 0 3.3985725345075934e-09
in O 0 2.7077853292922782e-09
pH O 0 1.687357666924072e-06
- O 0 2.4704300471967144e-07
dependent O 0 2.6725112789449668e-08
interactions O 0 1.6598526997313456e-08
. O 0 7.525741096969796e-08

We O 0 2.69054089585552e-06
also O 0 5.04874826390278e-08
demonstrate O 0 3.627097555636283e-08
that O 0 5.052001483818458e-09
soluble O 0 9.977297850127798e-06
TfR O 0 5.284115832182579e-05
and O 0 4.463355551820314e-08
HFE O 0 0.00023819509078748524
bind O 0 3.315110461699078e-07
tightly O 0 5.724708103116427e-07
at O 0 3.503387802084035e-08
the O 0 4.3723926701488836e-09
basic O 0 8.661793771125303e-08
pH O 0 2.2389252762877732e-07
of O 0 1.0127106975232891e-07
the O 0 5.3259746835010446e-08
cell O 0 1.7768950044683152e-07
surface O 0 4.9530424206523094e-08
, O 0 8.501168519137181e-11
but O 0 8.195180645209632e-11
not O 0 2.4530447118031873e-10
at O 0 4.67406691129213e-09
the O 0 9.198483086336751e-10
acidic O 0 6.11157275898222e-08
pH O 0 7.979235761013115e-07
of O 0 2.507783563032717e-07
intracellular O 0 3.825776673238579e-07
vesicles O 0 5.547415184992133e-06
. O 0 5.173180852580117e-07

TfR O 0 0.004730009939521551
HFE O 0 0.0036578960716724396
stoichiometry O 0 3.520643076626584e-05
( O 0 1.3588008584974887e-07
2 O 0 2.953947273454105e-07
1 O 0 3.083743038700959e-08
) O 0 9.075097617827765e-11
differs O 0 2.6824837906502808e-09
from O 0 5.736450869875398e-09
TfR O 0 2.4391868009843165e-06
transferrin O 0 7.487378752557561e-06
stoichiometry O 0 6.659378755102807e-07
( O 0 4.106386342073165e-09
2 O 0 3.176404916871434e-08
2 O 0 6.568773969206632e-09
) O 0 2.852873146053092e-11
, O 0 9.559938778103128e-12
implying O 0 5.056443042050773e-10
a O 0 6.602346447337482e-10
different O 0 9.882767521007807e-11
mode O 0 7.191773399028989e-09
of O 0 4.0747549778785697e-10
binding O 0 9.714089532764092e-10
for O 0 1.5971775013667866e-09
HFE O 0 7.988937431946397e-05
and O 0 3.406692883345386e-08
transferrin O 0 3.3647750115051167e-06
to O 0 1.0647500658933495e-08
TfR O 0 2.266104274895042e-06
, O 0 6.89991896951625e-10
consistent O 0 7.423405001816263e-09
with O 0 6.844134148309422e-10
our O 0 2.896383399786373e-08
demonstration O 0 7.26318027943762e-09
that O 0 3.8068356800202707e-10
HFE O 0 2.0585322999977507e-05
, O 0 1.968068596980288e-09
transferrin O 0 2.354861180720036e-06
, O 0 1.0736941336020323e-09
and O 0 1.2394046899899536e-09
TfR O 0 1.8499419240924908e-07
form O 0 7.488223374707559e-09
a O 0 3.6382321155770114e-08
ternary O 0 2.738726152529125e-06
complex O 0 7.525502587668598e-05
. O 0 1.7009746215990162e-06

Identification O 0 1.271488144993782e-06
of O 0 2.4994221803353867e-06
three O 0 2.5236172263021217e-08
novel O 0 1.0478372303168726e-07
mutations O 0 6.697999488380901e-09
and O 0 2.460144532534514e-09
a O 0 1.0271621775359563e-08
high O 0 1.0861836585718265e-07
frequency O 0 1.1019022139180379e-08
of O 0 1.145191852458538e-08
the O 0 5.520732315744681e-09
Arg778Leu O 0 7.786048428215508e-08
mutation O 0 2.1288004692365803e-10
in O 0 7.515172512073676e-11
Korean O 0 1.3535236043082932e-08
patients O 0 1.829768558891942e-10
with O 0 2.3591598119487855e-10
Wilson B-Disease 0 1.3937687981524505e-06
disease I-Disease 0 4.120901576243341e-05
. O 0 6.17821456216916e-07

Four O 0 3.0482285637845052e-06
mutations O 0 4.072645509722861e-08
- O 0 2.7831023885482864e-07
- O 0 2.876109306271246e-07
R778L O 0 1.7415311504009878e-06
, O 0 4.842946932370751e-09
A874V O 0 2.229464826086769e-07
, O 0 1.196908572254074e-09
L1083F O 0 1.5307715273138456e-07
, O 0 8.126742057079639e-10
and O 0 3.1356628404921594e-09
2304delC O 0 1.2213456557219615e-07
- O 0 5.808414371699655e-08
- O 0 6.873798241713303e-08
in O 0 4.648142759577922e-09
the O 0 4.9390802558946234e-08
copper O 0 5.219778813625453e-07
- O 0 1.119880863598155e-07
transporting O 0 1.1007934830331578e-07
enzyme O 0 5.79858472349315e-08
, O 0 4.7293524652047836e-09
P O 0 3.622013991844142e-06
- O 0 8.967377311819291e-07
type O 0 3.993529389845207e-06
ATPase O 0 1.2822368944398477e-06
( O 0 1.9499653003407502e-09
ATP7B O 0 1.0166980928261182e-06
) O 0 6.711765865308195e-11
, O 0 3.52608003559296e-12
were O 0 2.992072908880594e-11
identified O 0 1.2200609966761533e-10
in O 0 7.148549807656224e-11
Korean O 0 6.405581132185034e-08
Patients O 0 9.731484507113919e-10
with O 0 5.118125923075922e-10
Wilson B-Disease 0 4.6725504034839105e-06
disease I-Disease 0 0.0006102607003413141
. O 0 1.5030074109745328e-06

Arg778Leu O 0 0.011071387678384781
, O 0 9.544943679884454e-08
the O 0 5.961441473800733e-08
most O 0 1.7380771266672923e-09
frequently O 0 4.694256094950333e-10
reported O 0 2.0659109145615417e-10
mutation O 0 1.3701720313896715e-10
of O 0 2.104064256158722e-09
this O 0 3.7086772541883306e-10
enzyme O 0 4.188512203739947e-09
, O 0 1.3587730940400888e-10
was O 0 7.829067172338e-09
found O 0 4.875355119615676e-10
in O 0 1.9935884887356536e-10
six O 0 6.766772142619004e-10
of O 0 3.2885163481211066e-09
eight O 0 2.7903952481977967e-09
unrelated O 0 8.877978352472837e-09
patients O 0 3.3159638923585533e-10
studied O 0 2.6256621321607554e-09
, O 0 2.8369633031655184e-11
an O 0 1.90546467493391e-11
allele O 0 2.3066693000117766e-10
frequency O 0 5.5599795878436e-09
of O 0 4.6782613338791634e-08
37 O 0 3.1813044643058674e-07
. O 0 2.9576372639894544e-07

5 O 0 3.968030341638951e-06
% O 0 1.9020651720325077e-08
, O 0 5.431201044459044e-10
which O 0 1.4442175233497778e-10
is O 0 3.7404732089463266e-11
considerably O 0 5.5913198515611384e-09
higher O 0 1.966211415904695e-09
than O 0 2.8797270124059082e-11
those O 0 1.0416525281220501e-10
in O 0 1.1010523048859966e-10
other O 0 3.5966582490054577e-10
Asian O 0 1.7234595972581701e-09
populations O 0 1.0086808055476126e-09
. O 0 2.393052511706628e-08

The O 0 3.877833478327375e-06
novel O 0 4.717683736998879e-07
single O 0 3.857197938827994e-08
nucleotide O 0 2.9461224571036837e-08
deletion O 0 2.757856165658268e-08
, O 0 2.954582967173991e-10
2304delC O 0 4.2865501370670245e-08
, O 0 1.4718540275460157e-10
was O 0 6.4533813848299815e-09
found O 0 2.2518732711862555e-10
in O 0 2.127619191938379e-10
one O 0 6.844786959447902e-10
patient O 0 3.442842100298549e-08
. O 0 6.302688859705086e-08

Since O 0 1.4365562037710333e-06
a O 0 1.1450305947846573e-07
mutation O 0 1.3545307986362332e-08
at O 0 2.1276173711726187e-08
cDNA O 0 1.844955903607115e-07
nucleotide O 0 4.3032943608523055e-07
2302 O 0 1.9596473066485487e-05
( O 0 3.915876067850377e-09
2302insC O 0 9.396694622409996e-08
) O 0 4.696844579932247e-10
had O 0 2.308004010131981e-09
been O 0 1.3859855485520711e-09
previously O 0 2.067248372483732e-09
described O 0 2.3932704706908225e-09
, O 0 1.2385078206056388e-11
this O 0 1.379338310236733e-11
region O 0 9.412453039203683e-10
of O 0 1.0690722973549782e-08
the O 0 8.244688842751202e-08
ATP7B O 0 0.00015249632997438312
gene O 0 1.233069735206982e-08
may O 0 2.0123858135434602e-09
be O 0 7.035632076934917e-10
susceptible O 0 2.4607680870758486e-07
to O 0 1.042555908270515e-08
gene O 0 2.0217200926708756e-06
rearrangements O 0 0.0015730282757431269
causing O 0 0.00013006928202230483
Wilson B-Disease 0 0.0002726771926973015
disease I-Disease 0 0.04923658072948456
. O 0 8.173866490324144e-07

Disruption O 0 0.00014669695519842207
of O 0 2.3006336959952023e-06
splicing O 0 1.2788077583536506e-06
regulated O 0 1.3594821268725354e-08
by O 0 6.27255747343014e-10
a O 0 1.4487491206693903e-08
CUG O 0 7.791969437676016e-06
- O 0 4.500224193293434e-08
binding O 0 7.4261530258468156e-09
protein O 0 1.2359144818674395e-07
in O 0 1.0943452366518613e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 1.964606053661555e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.001378015847876668
DM B-Disease 1 1.0
) O 0 1.4136274728571152e-07
is O 0 4.284537169496616e-09
caused O 0 7.386573486201087e-08
by O 0 3.1240574571711477e-09
a O 0 1.589654061717738e-07
CTG O 0 3.9592191569681745e-06
expansion O 0 1.8849002003662463e-07
in O 0 3.101768619728773e-09
the O 0 1.3944156052048129e-08
3 O 0 2.4667663467425882e-08
untranslated O 0 7.311564331757836e-06
region O 0 8.187173605733733e-09
of O 0 2.2340488570193884e-08
the O 0 2.3066567678142746e-07
DM B-Disease 1 1.0
gene O 0 6.418619022952043e-07
. O 0 1.923094146150106e-07

One O 0 8.245333305012537e-08
model O 0 7.787994604768755e-08
of O 0 8.318659183714772e-07
DM B-Disease 1 1.0
pathogenesis O 1 0.9999450445175171
suggests O 0 1.2087937761862122e-07
that O 0 1.7229928594986177e-09
RNAs O 0 9.748789153718462e-08
from O 0 3.18318371661519e-09
the O 0 9.376853071785263e-09
expanded O 0 1.073936406470466e-08
allele O 0 2.9488753661155442e-09
create O 0 1.823060147287947e-09
a O 0 4.753498927811961e-09
gain O 0 2.107668350959102e-08
- O 0 4.0790823163661116e-08
of O 0 5.602542785254627e-08
- O 0 3.6102015599226434e-08
function O 0 3.542038606862974e-10
mutation O 0 5.643740336180869e-11
by O 0 5.77239818444486e-12
the O 0 1.3567995338359395e-10
inappropriate O 0 1.3917436647581383e-10
binding O 0 3.398356596129304e-10
of O 0 1.9750368007720454e-09
proteins O 0 8.641945492549041e-11
to O 0 6.497048454789933e-10
the O 0 5.5415604549580166e-08
CUG O 0 0.0005997645203024149
repeats O 0 1.6933836377575062e-06
. O 0 2.441350659410091e-07

Data O 0 2.6887657895713346e-06
presented O 0 1.1795996215369087e-06
here O 0 5.119165891187549e-08
indicate O 0 1.1562161894573819e-08
that O 0 1.5331514946481661e-09
the O 0 4.7259376856345625e-08
conserved O 0 9.347267848625052e-08
heterogeneous O 0 1.9404776594456052e-06
nuclear O 0 0.003338039852678776
ribonucleoprotein O 0 0.00169204396661371
, O 0 4.12200442667654e-08
CUG O 0 4.176284346613102e-05
- O 0 2.948495421151165e-07
binding O 0 5.6521734848047345e-08
protein O 0 1.0304415809514467e-07
( O 0 9.349114815648818e-10
CUG O 0 1.6830405002110638e-05
- O 0 1.1224090030736988e-06
BP O 0 1.865243939391803e-05
) O 0 2.8487108227892577e-09
, O 0 6.697510879227764e-10
may O 0 1.236229962842117e-08
mediate O 0 5.661818818225584e-07
the O 0 1.5578863212795113e-06
trans O 0 9.714465249999193e-07
- O 0 4.948132641402481e-07
dominant O 0 1.2391814152579173e-07
effect O 0 1.8381166810854666e-08
of O 0 3.4801178827592594e-08
the O 0 7.195644968760462e-08
RNA O 0 5.543526526707865e-07
. O 0 3.757518740599153e-08

CUG O 1 0.9987916350364685
- O 0 0.01617307960987091
BP O 0 0.00045081600546836853
was O 0 1.1856978971991339e-06
found O 0 6.461214230313317e-09
to O 0 7.767085308252319e-10
bind O 0 2.4973472179112832e-09
to O 0 7.2130941219938904e-09
the O 0 1.9825603203571518e-07
human O 0 3.00901797345432e-06
cardiac O 1 0.9999785423278809
troponin O 0 0.002743807155638933
T O 0 5.768744813394733e-05
( O 0 3.3758764672597863e-09
cTNT O 0 7.135945168101898e-08
) O 0 1.0629835900388684e-10
pre O 0 2.1587786136478826e-07
- O 0 5.188091378727222e-08
messenger O 0 3.8380218114753006e-08
RNA O 0 2.818392985659557e-08
and O 0 2.0497088748516745e-10
regulate O 0 2.942860538590608e-11
its O 0 1.187444031991447e-10
alternative O 0 2.6088855520356447e-08
splicing O 0 2.332787687464588e-07
. O 0 3.4052899167136275e-08

Splicing O 0 9.517231774225365e-06
of O 0 3.142123659927165e-06
cTNT O 0 4.414492650539614e-05
was O 0 4.095753411093028e-06
disrupted O 0 7.067176284181187e-06
in O 0 2.244783416927021e-07
DM B-Disease 1 1.0
striated O 0 0.05879563093185425
muscle O 0 1.9306320609757677e-05
and O 0 1.5460294378044637e-07
in O 0 2.8736175661236985e-09
normal O 0 2.383868391575561e-08
cells O 0 1.3759612116359676e-08
expressing O 0 2.5061748232246828e-09
transcripts O 0 8.985061583643983e-09
that O 0 2.07685091346832e-10
contain O 0 2.4137543519486826e-08
CUG O 0 0.00013802792818751186
repeats O 0 6.881550120851898e-07
. O 0 1.6722337647934182e-07

Altered O 0 1.979242188099306e-05
expression O 0 1.020576974042342e-06
of O 0 9.142708563558699e-07
genes O 0 5.754183973749605e-08
regulated O 0 1.552660222614577e-08
posttranscriptionally O 0 4.816134264729044e-07
by O 0 3.973841256055266e-09
CUG O 1 0.9873880743980408
- O 0 5.23369453730993e-05
BP O 0 1.03668126030243e-05
therefore O 0 4.087374438910274e-09
may O 0 1.160081364304233e-09
contribute O 0 3.217364430430081e-10
to O 0 7.80244224785065e-09
DM B-Disease 1 1.0
pathogenesis O 1 0.7333309650421143
. O 0 4.428663302746827e-08
. O 0 8.658077632617278e-08

Identification O 0 1.1104693840024993e-06
of O 0 7.423705596920627e-07
a O 0 5.929180346697649e-08
novel O 0 7.527090417625004e-08
nonsense O 0 1.529951276779684e-07
mutation O 0 4.982507739725861e-09
and O 0 5.154746629543183e-10
a O 0 3.5377396567781716e-09
missense O 0 3.6797356273154946e-08
substitution O 0 1.1860084470072252e-07
in O 0 1.4121528835175923e-08
the O 0 7.210633867771321e-08
vasopressin O 0 4.894610015071521e-07
- O 0 1.6779912925812823e-07
neurophysin O 0 6.274591441979283e-07
II O 1 0.5666442513465881
gene O 0 2.1663417726358603e-09
in O 0 1.4728904207395033e-10
two O 0 1.74209882630727e-10
Spanish O 0 3.982294050075552e-09
kindreds O 0 1.9178504828687437e-07
with O 0 2.3627997336461704e-09
familial B-Disease 1 0.6658393740653992
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
. O 0 6.477566057583317e-05

Familial B-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 5.193012111703865e-05
FNDI B-Disease 1 1.0
) O 0 1.0341388190227008e-08
is O 0 7.071606633601846e-10
an O 0 8.582208277374548e-10
autosomal B-Disease 1 0.9999994039535522
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.8836166858673096
by O 0 1.6130806557157484e-07
deficiency O 1 1.0
in O 0 4.790395450982032e-06
the O 0 0.013649745844304562
antidiuretic O 0 3.0882671126164496e-05
hormone O 0 1.2750128064453747e-07
arginine O 0 1.0512723491729048e-07
vasopressin O 0 1.554533639591682e-07
( O 0 1.273507299615062e-09
AVP O 0 1.0118900206634862e-07
) O 0 2.450779856832952e-11
encoded O 0 5.2722166909990875e-11
by O 0 1.0456775029199505e-10
the O 0 2.8500819482246698e-08
AVP O 0 2.419362999717123e-06
- O 0 3.479113104276621e-07
neurophysin O 0 1.168134440376889e-05
II O 1 1.0
( O 0 1.5306370926282398e-07
AVP O 0 1.0976860721712e-05
- O 0 4.4378217012308596e-07
NPII O 0 5.072520707471995e-06
) O 0 7.498696108498848e-10
gene O 0 2.7386644063653875e-09
on O 0 2.9013321523052582e-08
chromosome O 0 4.574563661208231e-08
20p13 O 0 1.4627692053181818e-06
. O 0 4.029169815567002e-07

In O 0 2.3912784286039823e-07
this O 0 6.610401115381137e-09
study O 0 1.8959465108991935e-09
, O 0 1.885922806810214e-10
we O 0 1.3593225156594002e-10
analyzed O 0 9.164841108244559e-10
two O 0 4.251062835081143e-10
families O 0 5.937979552506079e-10
with O 0 1.0762817304055261e-09
FNDI B-Disease 1 1.0
using O 0 1.6983344153231883e-07
direct O 0 7.848447580727225e-08
automated O 0 5.926872859163268e-07
fluorescent O 0 1.4034775119853293e-07
, O 0 9.7048113989473e-10
solid O 0 3.9624602266030706e-08
phase O 0 1.8247730793063965e-07
, O 0 7.287127012922667e-10
single O 0 1.8522989808644752e-09
- O 0 6.0253286804368145e-09
stranded O 0 5.462161833946766e-09
DNA O 0 6.777053362938545e-10
sequencing O 0 1.6439658523381695e-09
of O 0 3.8257486068005164e-09
PCR O 0 4.3616839207061275e-07
- O 0 3.967300017393427e-06
amplified O 0 7.144727078411961e-06
AVP O 0 3.725705755641684e-05
- O 0 1.1890315363416448e-06
NPII O 0 2.240984031232074e-05
DNA O 0 1.2373384379316121e-06
. O 0 1.221585534949554e-07

In O 0 4.077970459093194e-07
one O 0 1.4325865826947393e-08
of O 0 2.0314377735530798e-08
the O 0 7.629757270422033e-09
families O 0 1.104418223540904e-09
, O 0 5.5470406046254084e-11
affected O 0 1.2210527033928997e-10
individuals O 0 2.4718867577822046e-11
presented O 0 1.0897087676653427e-08
a O 0 1.240358482590409e-08
novel O 0 2.9388933953100604e-08
nonsense O 0 3.68414561080499e-08
mutation O 0 1.0585208265467827e-09
in O 0 5.662202373635239e-10
exon O 0 7.070773744288772e-09
3 O 0 3.943225301838993e-09
of O 0 1.7245348482575196e-09
the O 0 3.389599934067178e-09
gene O 0 5.852758833135852e-10
, O 0 3.6799407271415063e-11
consisting O 0 1.0039125780680891e-10
in O 0 3.095401990282909e-10
a O 0 1.0152012563935386e-08
G O 0 2.886171444060892e-07
to O 0 8.844517651596107e-08
T O 0 5.383004463510588e-06
transition O 0 6.3487759689451195e-06
at O 0 1.624442660386194e-07
nucleotide O 0 8.417296726292989e-08
2101 O 0 1.4291689467427204e-06
, O 0 9.588888710831966e-11
which O 0 1.6253630386042772e-11
produces O 0 1.3569058376905474e-10
a O 0 9.278942614265873e-10
stop O 0 4.134853348602974e-09
signal O 0 6.432038190951062e-08
in O 0 2.221178130312751e-09
codon O 0 4.434620226589914e-09
82 O 0 1.1125420940061304e-07
( O 0 2.5165212136357695e-09
Glu O 0 2.97934661830368e-06
) O 0 2.0563275526797042e-09
of O 0 1.0145202367084494e-07
NPII O 0 0.004599933512508869
. O 0 1.2676017604462686e-06

The O 0 1.4121204003458843e-05
premature O 0 8.798733688308857e-06
termination O 0 1.199484813696472e-05
eliminates O 0 1.7782472241378855e-06
part O 0 3.7955729226268886e-08
of O 0 5.429901150932892e-08
the O 0 2.7106494826512062e-08
C O 0 9.471636985836085e-07
- O 0 6.71857662837283e-08
terminal O 0 1.3405085041995335e-07
domain O 0 4.2945678124794995e-09
of O 0 7.68254615479691e-09
NPII O 0 8.96098390512634e-06
, O 0 6.508111827230323e-10
including O 0 5.294893967722203e-10
a O 0 7.029572479666513e-09
cysteine O 0 1.0860568444570617e-08
residue O 0 8.777815452276627e-08
in O 0 1.7137632424280014e-09
position O 0 3.4087339173538567e-08
85 O 0 4.023662469876399e-08
, O 0 4.727753744049323e-10
which O 0 8.45350178746429e-11
could O 0 1.3416890931594594e-09
be O 0 7.507210963986211e-10
involved O 0 1.164461860270194e-09
in O 0 4.653134544341242e-10
the O 0 2.0835611014291544e-09
correct O 0 1.709503827385106e-08
folding O 0 1.476083184570598e-07
of O 0 5.301821914827087e-08
the O 0 2.2319369463730254e-07
prohormone O 0 0.0010183549020439386
. O 0 2.2881245058670174e-06

In O 0 8.831518130136828e-07
the O 0 8.300060585497704e-07
second O 0 1.0975624036291265e-06
family O 0 8.508431648124315e-08
, O 0 4.179619705890758e-10
a O 0 1.7013349618011375e-09
G279A O 0 2.5765933386878714e-08
substitution O 0 2.607184157454867e-08
at O 0 4.0908084031343606e-08
position O 0 5.637788547119271e-08
- O 0 4.144433063402175e-08
1 O 0 1.6424809956561148e-08
of O 0 4.727846558694182e-09
the O 0 9.83499592877024e-09
signal O 0 1.4281890514666884e-07
peptide O 0 1.3850876001697543e-08
was O 0 1.2498292178975134e-08
observed O 0 5.305751948903037e-10
in O 0 1.3903535267534295e-10
all O 0 1.0646880599374242e-10
affected O 0 7.766773890693912e-10
individuals O 0 2.4776375395774153e-10
. O 0 4.630103234148919e-08

This O 0 4.178460528692085e-07
missense O 0 5.8564492064761e-06
mutation O 0 8.453417166265353e-08
, O 0 2.2782538078303105e-09
which O 0 3.2338420830058112e-09
replaces O 0 5.296369272400625e-05
Ala O 0 0.0014281056355684996
with O 0 3.35362138059736e-08
Thr O 1 0.9033265113830566
, O 0 1.9472150558641488e-09
is O 0 1.7951103103985844e-10
frequent O 0 2.704193313718406e-09
among O 0 2.1873020727980474e-08
FNDI B-Disease 1 1.0
patients O 0 0.0014652620302513242
and O 0 5.500093180899057e-08
is O 0 1.1159585477926726e-09
thought O 0 1.9968089404187594e-09
to O 0 4.045598300805864e-10
reduce O 0 3.2832392360404583e-09
the O 0 3.205006260387222e-09
efficiency O 0 1.725601705970803e-08
of O 0 2.849906532986779e-09
cleavage O 0 1.9266749973212427e-08
by O 0 9.464714567641863e-10
signal O 0 7.773500101393438e-07
peptidases O 0 1.0239990615446004e-06
. O 0 7.07984249004312e-09
. O 0 3.61748035970777e-08

Genetic O 0 3.145031223539263e-05
heterogeneity O 0 8.046110451687127e-05
of O 0 0.0002893210912588984
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 6.463445334503604e-09
due O 0 1.1227247114220518e-06
to O 0 5.463289909357627e-08
TWIST O 0 0.013428318314254284
and O 0 2.8133822524978314e-06
FGFR O 1 0.9851831793785095
mutations O 0 7.255601985889371e-07
. O 0 3.0525728789143614e-07

Thirty O 0 8.869508747011423e-05
- O 0 1.7982129065785557e-05
two O 0 1.7250224360054744e-08
unrelated O 0 1.1432324953375428e-07
patients O 0 3.7006380182447174e-09
with O 0 1.0256126503627172e-10
features O 0 1.0034943542791552e-08
of O 0 6.085219411033904e-06
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.9976554571931047e-10
a O 0 8.73926708777617e-10
common O 0 1.9480798982840497e-06
autosomal B-Disease 1 0.7716687917709351
dominant I-Disease 1 0.9999111890792847
condition I-Disease 1 1.0
of O 1 1.0
craniosynostosis B-Disease 1 1.0
and O 1 0.9999152421951294
limb B-Disease 1 1.0
anomalies I-Disease 1 0.9879651069641113
, O 0 1.5729144209331025e-08
were O 0 2.625858819271798e-08
screened O 0 1.7997203372033255e-07
for O 0 3.935628711815298e-09
mutations O 0 4.3436245711347965e-09
in O 0 1.0250934323607908e-08
TWIST O 0 0.0001897523325169459
, O 0 1.6923385359746135e-08
FGFR2 O 0 0.0002019822277361527
, O 0 2.7080746534124955e-09
and O 0 2.8314321554034905e-08
FGFR3 O 0 0.0026726729702204466
. O 0 1.4132825754131773e-06

Nine O 0 2.3596810478920816e-06
novel O 0 5.716415785173012e-07
and O 0 3.30775513646131e-08
three O 0 1.1153121981521963e-08
recurrent O 0 1.3866414292351692e-06
TWIST O 0 1.8500406440580264e-05
mutations O 0 1.0303625508356618e-08
were O 0 2.619499728240271e-09
found O 0 1.2650097636068836e-09
in O 0 1.8901478160415763e-09
12 O 0 2.626279638207052e-08
families O 0 2.17475957242641e-08
. O 0 1.4677380022476427e-07

Seven O 0 6.462969849962974e-06
families O 0 5.908520961384056e-08
were O 0 8.281928032261021e-09
found O 0 2.751917138610338e-09
to O 0 1.7153983788986693e-09
have O 0 2.9512614574400686e-09
the O 0 8.299912224174477e-08
FGFR3 O 0 0.00018471320800017565
P250R O 0 1.4289972796177608e-06
mutation O 0 9.110312504390095e-09
, O 0 4.989562096824329e-10
and O 0 1.0634221281335954e-09
one O 0 7.129599133293141e-10
individual O 0 1.1886971962304926e-10
was O 0 2.2329283311250947e-08
found O 0 1.5800126762499644e-09
to O 0 9.389753419242197e-10
have O 0 1.6605991026708011e-09
an O 0 2.3248991620761217e-09
FGFR2 O 0 1.9992845409433357e-05
VV269 O 0 3.177506641804939e-06
- O 0 7.973158062668517e-07
270 O 0 9.701322056798745e-08
deletion O 0 2.897230046983168e-07
. O 0 1.0527110561042718e-07

To O 0 3.815876254975592e-07
date O 0 3.1446359116671374e-06
, O 0 5.221922005915758e-09
our O 0 2.6802131625203174e-09
detection O 0 1.7611445457532682e-07
rate O 0 1.7477308489333154e-09
for O 0 1.4456894015246746e-10
TWIST O 0 6.80310336065304e-07
or O 0 1.487047427417565e-07
FGFR O 0 0.00015068231732584536
mutations O 0 7.073418295533429e-09
is O 0 4.989390567367025e-10
68 O 0 2.183665692712111e-09
% O 0 9.460215943946082e-11
in O 0 4.3154052553617817e-10
our O 0 4.8148486087029596e-08
Saethre B-Disease 1 0.9250401258468628
- I-Disease 1 0.934698760509491
Chotzen I-Disease 1 0.9999997615814209
syndrome I-Disease 1 1.0
patients O 0 4.125890029627044e-08
, O 0 1.889710748992357e-10
including O 0 7.375192123681984e-10
our O 0 5.735140007345763e-07
five O 0 3.380014490517169e-08
patients O 0 5.469334762864264e-09
elsewhere O 0 3.903675604988166e-09
reported O 0 3.382869984136505e-09
with O 0 6.255388984577337e-10
TWIST O 0 1.715307189442683e-05
mutations O 0 1.64224047694006e-07
. O 0 1.0177277687262176e-07

More O 0 5.457353680071719e-08
than O 0 3.749391463969687e-09
35 O 0 5.7852367341126865e-09
different O 0 4.190092162126291e-10
TWIST O 0 5.496705171026406e-07
mutations O 0 1.4017347282901937e-09
are O 0 1.9233861031642263e-11
now O 0 1.655576231662792e-10
known O 0 7.069529961434284e-10
in O 0 1.2501880086723816e-10
the O 0 2.3102677548791917e-09
literature O 0 5.359028332208027e-09
. O 0 1.519991421616851e-08

The O 0 1.7277021470363252e-05
most O 0 6.913796823937446e-08
common O 0 7.8753188859082e-08
phenotypic O 0 1.1884528561267871e-07
features O 0 1.646932545895652e-08
, O 0 1.5242662687597885e-10
present O 0 1.0485500245849266e-09
in O 0 1.5644402440173621e-09
more O 0 5.932644653316999e-11
than O 0 3.0337010681336096e-11
a O 0 7.350615116585857e-10
third O 0 9.962853653178172e-09
of O 0 3.045908636423178e-09
our O 0 3.9988257150014306e-09
patients O 0 2.410269206443161e-10
with O 0 4.314242713077121e-11
TWIST O 0 4.227638328302419e-07
mutations O 0 3.7231091543077355e-09
, O 0 3.434967588145099e-10
are O 0 2.4048646407592855e-10
coronal B-Disease 0 0.00156977993901819
synostosis I-Disease 0 0.0006902019376866519
, O 0 2.1132878558205448e-08
brachycephaly B-Disease 0 0.00010162895341636613
, O 0 8.175224053275087e-08
low B-Disease 1 0.9997401833534241
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 9.406697358826932e-07
facial B-Disease 1 0.973116397857666
asymmetry I-Disease 1 0.6756319999694824
, O 0 9.242528875574862e-08
ptosis B-Disease 1 0.9997255206108093
, O 0 1.2737926624595275e-07
hypertelorism B-Disease 1 0.9872058629989624
, O 0 6.209047000993451e-07
broad B-Disease 1 0.9876043796539307
great I-Disease 1 1.0
toes I-Disease 1 0.999998927116394
, O 0 2.815190924820854e-08
and O 0 2.2837330959646351e-07
clinodactyly B-Disease 0 0.0006173250149004161
. O 0 7.1907179517438635e-06

Significant O 0 7.677372923353687e-05
intra O 1 0.6012224555015564
- O 0 0.0038330242969095707
and O 0 1.8352952224631736e-07
interfamilial O 0 1.1764317605411634e-05
phenotypic O 0 5.039560164732393e-07
variability O 0 3.549333484897943e-07
is O 0 1.9578501320172137e-10
present O 0 5.251124535199381e-10
for O 0 1.8707324578315365e-10
either O 0 8.170077059332925e-09
TWIST O 0 2.126982872141525e-05
mutations O 0 8.214833258080034e-08
or O 0 6.590072842982408e-08
FGFR O 0 6.552640843437985e-05
mutations O 0 4.2999548810485066e-08
. O 0 4.584189383649573e-08

The O 0 3.478291091596475e-06
overlap O 0 2.1367844738051645e-07
in O 0 5.443804518279194e-09
clinical O 0 4.411961640471418e-08
features O 0 1.1781213338224461e-08
and O 0 4.634721939567044e-09
the O 0 2.003776700121307e-08
presence O 0 4.1679348861123344e-09
, O 0 7.19539150484394e-10
in O 0 2.1471997790900588e-10
the O 0 2.1310031517174366e-09
same O 0 3.06308201025729e-10
genes O 0 2.479292049439863e-10
, O 0 4.9151464148744495e-11
of O 0 1.19217402616556e-09
mutations O 0 3.6787495272250226e-10
for O 0 8.608865842418822e-10
more O 0 3.721190577898881e-10
than O 0 6.024693521844426e-10
one O 0 3.149593030826736e-09
craniosynostotic B-Disease 0 4.4586292347048584e-07
condition I-Disease 0 6.787679467379348e-07
- O 0 9.728987038215564e-08
such O 0 7.896087339531732e-09
as O 0 3.569925155488818e-08
Saethre B-Disease 0 1.2436934412107803e-05
- I-Disease 0 7.677758731006179e-07
Chotzen I-Disease 0 1.8464870663592592e-05
, I-Disease 0 5.390099477864396e-09
Crouzon I-Disease 0 4.161423566984013e-05
, I-Disease 0 1.3377417396043256e-08
and I-Disease 0 8.244563076686973e-08
Pfeiffer I-Disease 1 0.8990619778633118
syndromes I-Disease 1 1.0
- O 1 0.9999765157699585
support O 1 0.8436516523361206
the O 0 0.036917440593242645
hypothesis O 0 5.346199941413943e-06
that O 0 1.1055942827908893e-09
TWIST O 0 7.428109825013962e-07
and O 0 3.740262766172009e-09
FGFRs O 0 1.3675682453140325e-07
are O 0 1.755721089347073e-11
components O 0 6.144531106144768e-09
of O 0 4.7255142021640495e-08
the O 0 1.1882472783497633e-08
same O 0 1.1141975120310121e-09
molecular O 0 4.031250000480213e-09
pathway O 0 1.5775133421769283e-09
involved O 0 9.178634415019093e-12
in O 0 1.03707259793695e-11
the O 0 1.629946178027808e-10
modulation O 0 2.4920476349166165e-08
of O 0 1.2592810350042782e-08
craniofacial O 1 0.9999732971191406
and O 0 2.521222313589533e-06
limb O 1 0.9999998807907104
development O 0 1.9094233721261844e-05
in O 0 8.09702438431259e-09
humans O 0 1.4813524629175845e-08
. O 0 2.4211626037384804e-09
. O 0 2.6244318718227078e-08

Mutation O 0 2.7727615758976754e-08
analysis O 0 1.7186209122499463e-09
of O 0 3.030264394965343e-08
UBE3A O 1 0.9999608993530273
in O 0 7.22529657650739e-05
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9997329115867615
. O 0 1.6017581856431207e-06

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.18086163699626923
AS B-Disease 1 1.0
) O 0 6.578528832790198e-09
is O 0 1.0877562184319345e-09
caused O 0 2.7562155224813978e-08
by O 0 2.660603515280968e-09
chromosome O 0 8.912491722412597e-08
15q11 O 0 4.655833549804811e-07
- O 0 1.0751582379953106e-07
q13 O 0 3.53010193521186e-07
deletions O 0 3.489875766149453e-08
of O 0 5.235525346591885e-09
maternal O 0 7.113465816388498e-09
origin O 0 1.0946453743443385e-09
, O 0 5.368332167687839e-11
by O 0 1.7850450284573327e-10
paternal O 0 2.1095736883580685e-05
uniparental B-Disease 1 0.9999973773956299
disomy I-Disease 1 0.9999924898147583
( O 0 6.123654202383477e-06
UPD B-Disease 1 1.0
) O 0 1.4557349103938577e-08
15 O 0 8.394174244585884e-09
, O 0 4.77453909741854e-11
by O 0 2.3993892983575904e-10
imprinting O 0 0.00018563187040854245
defects O 1 0.9864736795425415
, O 0 3.40170308588128e-10
and O 0 2.477070493167588e-10
by O 0 9.392219640913524e-11
mutations O 0 6.209065483986365e-10
in O 0 7.829018544569522e-10
the O 0 1.1444193148690829e-07
UBE3A O 0 5.888735904591158e-05
gene O 0 1.9126704842165054e-07
. O 0 1.2435806695521023e-07

UBE3A O 0 0.005706508178263903
encodes O 0 4.215449735056609e-06
a O 0 6.521513569168746e-07
ubiquitin O 0 3.26683652929205e-06
- O 0 7.825560714991298e-07
protein O 0 4.1622808311103654e-08
ligase O 0 8.070077228694572e-08
and O 0 6.275457042903554e-09
shows O 0 1.3745290239342012e-08
brain O 0 1.3826113445247756e-06
- O 0 5.6029062278639685e-08
specific O 0 3.281118665654503e-08
imprinting O 0 9.15549935598392e-06
. O 0 3.105284065441083e-07

Here O 0 2.4856733489286853e-06
we O 0 3.917670809983065e-08
describe O 0 1.4439592632697895e-07
UBE3A O 0 0.00026133927167393267
coding O 0 1.2437195437087212e-05
- O 0 2.765141061900067e-06
region O 0 3.8713636740794755e-08
mutations O 0 3.741033260951099e-09
detected O 0 9.61760004969392e-09
by O 0 2.81150686065601e-10
SSCP O 0 1.5828962887098896e-06
analysis O 0 3.01804625735258e-09
in O 0 9.428228198160582e-10
13 O 0 2.8547335162443233e-08
AS B-Disease 1 0.9999905824661255
individuals O 0 9.805971312726314e-11
or O 0 8.158910880240455e-09
families O 0 8.93901219711779e-09
. O 0 4.408084208762375e-08

Two O 0 1.3095171880195267e-06
identical O 0 1.2098910247004824e-06
de O 0 1.4932129488443024e-05
novo O 0 4.286973489797674e-05
5 O 0 3.2266493690258358e-06
- O 0 2.985624178108992e-06
bp O 0 1.8731856243903167e-06
duplications O 0 1.4799059044889873e-06
in O 0 1.4836570194631804e-08
exon O 0 1.2596827048128034e-07
16 O 0 1.3644255503209024e-08
were O 0 3.060595776815944e-09
found O 0 2.9105109433658072e-08
. O 0 1.3908793050632084e-07

Among O 0 7.3150340540451e-07
the O 0 3.261306460444757e-07
other O 0 7.952341896100279e-09
11 O 0 7.182245909120866e-09
unique O 0 1.0802468919379749e-09
mutations O 0 2.5929003388824867e-09
, O 0 7.227701770418093e-10
8 O 0 2.2273008326578747e-08
were O 0 3.280086247059444e-08
small O 0 3.2811623640327525e-08
deletions O 0 3.151310750126868e-07
or O 0 2.549899988935067e-07
insertions O 0 2.6248933409078745e-06
predicted O 0 9.438184065402311e-07
to O 0 4.017880073092783e-08
cause O 0 4.028690091217868e-05
frameshifts O 0 0.0023639074061065912
, O 0 1.561900653257453e-08
1 O 0 8.340060730915866e-08
was O 0 3.570306006395185e-08
a O 0 1.8040181570810887e-09
mutation O 0 1.178385305999896e-10
to O 0 2.3784657576797485e-10
a O 0 1.3881760185796566e-09
stop O 0 2.146181454776297e-09
codon O 0 7.146808700397855e-10
, O 0 6.456676859833976e-10
1 O 0 9.40298328089284e-09
was O 0 3.046618957114333e-08
a O 0 3.687708360899933e-09
missense O 0 1.528189130794999e-08
mutation O 0 8.213462132644622e-10
, O 0 1.9776970339169253e-10
and O 0 9.167411829658079e-10
1 O 0 7.788290901089567e-08
was O 0 3.005181099524634e-07
predicted O 0 2.4217598593168077e-08
to O 0 4.060852987208818e-09
cause O 0 6.617531767005858e-08
insertion O 0 1.930121982240962e-07
of O 0 1.8031579429589328e-07
an O 0 2.179987079742318e-09
isoleucine O 0 7.997308415497173e-08
in O 0 1.1373526564995018e-09
the O 0 4.319584689937983e-08
hect O 0 1.2000429023828474e-06
domain O 0 2.772507734505325e-08
of O 0 5.9084307224566146e-08
the O 0 1.4729907604760228e-07
UBE3A O 0 1.3359755030251108e-05
protein O 0 2.53240735048621e-08
, O 0 1.1144881545410712e-10
which O 0 2.1984870521296607e-11
functions O 0 6.498659943510177e-10
in O 0 1.1976369895805306e-09
E2 O 0 2.2205760785709572e-07
binding O 0 9.578405624210973e-09
and O 0 4.997088076663658e-09
ubiquitin O 0 3.9947502727955e-07
transfer O 0 1.5397891957036336e-06
. O 0 3.5028276101911615e-07

Eight O 0 3.2327081953553716e-06
of O 0 2.1968016028495185e-07
the O 0 1.5021655030977854e-08
cases O 0 1.4530294745185302e-09
were O 0 3.739078824338549e-09
familial O 0 3.767623866224312e-07
, O 0 8.969151532589592e-10
and O 0 3.0532025796503603e-09
five O 0 3.864677466935973e-09
were O 0 2.5017822480322138e-08
sporadic O 0 9.651978871261235e-06
. O 0 2.750780367932748e-06

In O 0 4.4995033476880053e-07
two O 0 1.5993549595805234e-08
familial O 0 3.427171009207086e-07
cases O 0 9.380734411479352e-09
and O 0 5.919245094077041e-09
one O 0 1.3005930776799346e-09
sporadic O 0 5.4894240264502514e-08
case O 0 9.466148753745074e-08
, O 0 1.7203001245746918e-09
mosaicism O 0 3.213010495528579e-05
for O 0 4.3017678308387985e-08
UBE3A O 0 0.0024472845252603292
mutations O 0 1.17404141519728e-07
was O 0 2.2114188880095753e-07
detected O 0 2.1460106580661886e-08
in O 0 2.5971358397214317e-10
the O 0 2.6454380908091935e-09
mother O 0 1.07337934096563e-08
of O 0 4.273839238067012e-08
three O 0 3.407225790397206e-08
AS B-Disease 1 1.0
sons O 0 0.0002183240430895239
, O 0 3.082410993116014e-10
in O 0 4.32570618214001e-10
the O 0 3.634741396751906e-09
maternal O 0 1.4154485938888683e-07
grandfather O 0 2.0209496142342687e-05
of O 0 6.406695774785476e-06
two O 0 1.0776193448691629e-06
AS B-Disease 1 1.0
first O 0 6.340409868244024e-07
cousins O 0 2.5279483452322893e-05
, O 0 1.3150710520548614e-09
and O 0 2.514659591668078e-09
in O 0 6.1148353047713044e-09
the O 0 2.882881062760134e-07
mother O 0 1.4210807819381444e-07
of O 0 1.32069018832226e-07
an O 0 8.500998127658477e-09
AS B-Disease 1 1.0
daughter O 0 0.00039413050399161875
. O 0 5.058858732809313e-06

The O 0 1.6839046566019533e-06
frequencies O 0 9.248877574918879e-08
with O 0 6.550691655782259e-10
which O 0 5.092001265083468e-10
we O 0 3.822099858830086e-10
detected O 0 4.464468794651566e-09
mutations O 0 1.7788930051221286e-10
were O 0 4.1631026403976534e-10
5 O 0 2.096209206214894e-09
( O 0 5.1734685979631934e-11
14 O 0 3.961436179089617e-10
% O 0 5.7452483742670424e-11
) O 0 1.9853682933779204e-11
of O 0 2.7231472632394116e-09
35 O 0 4.83681716900719e-09
in O 0 4.009011456140854e-10
sporadic O 0 5.03641572890956e-09
cases O 0 1.3849495994477934e-09
and O 0 2.3872706034211433e-09
8 O 0 1.253281034507836e-08
( O 0 5.202174108154267e-11
80 O 0 3.2532848637245593e-10
% O 0 4.186000157613279e-11
) O 0 2.811087473908458e-11
of O 0 9.936887979122844e-10
10 O 0 8.346338620235372e-10
in O 0 2.3764570866724455e-10
familial O 0 9.324933714083272e-09
cases O 0 1.3643312035682698e-09
. O 0 1.4953925875360596e-09
. O 0 2.145953281740276e-08

The O 0 0.00029466478736139834
hemochromatosis B-Disease 1 1.0
845 O 0 2.0734863937832415e-05
G O 0 2.037605554505717e-06
- O 0 3.470196077159926e-07
- O 0 2.084821204562104e-07
> O 0 1.2022888995488756e-07
A O 0 9.047525395544653e-08
and O 0 1.6886747555844295e-09
187 O 0 1.3321979075442414e-09
C O 0 1.8651265420999152e-08
- O 0 2.3229059564755516e-08
- O 0 1.0425026175653329e-07
> O 0 4.289862829409685e-07
G O 0 6.720011924699065e-07
mutations O 0 2.829033896034616e-09
: O 0 5.020757420926003e-11
prevalence O 0 1.7626012871474472e-09
in O 0 4.1033310083093966e-10
non O 0 9.445801474328164e-09
- O 0 5.382715428936535e-08
Caucasian O 0 1.1290537571539971e-07
populations O 0 3.48507320779845e-08
. O 0 5.995776319878132e-08

Hemochromatosis B-Disease 1 1.0
, O 0 2.86679863847894e-07
the O 0 1.2811740816687234e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 1.0
, O 0 4.156286195211578e-06
leads O 0 0.0002066321758320555
, O 0 4.8029981769559527e-08
if O 0 6.442096491809934e-06
untreated O 1 1.0
, O 0 2.377053220925518e-08
to O 0 3.6358116517476446e-07
progressive O 1 1.0
iron B-Disease 1 1.0
overload I-Disease 1 0.999998927116394
and O 0 2.5606712483750016e-07
premature B-Disease 0 8.837711220621713e-07
death I-Disease 0 2.567207275205874e-06
. O 0 2.2915061492767563e-07

The O 0 0.0008607644122093916
hemochromatosis B-Disease 1 1.0
gene O 0 1.4382997505890671e-05
, O 0 6.651977457750036e-08
HFE O 1 0.9998998641967773
, O 0 3.0185432819962443e-07
recently O 0 2.2972412239141704e-07
has O 0 8.267356799152026e-10
been O 0 3.275056892348971e-10
identified O 0 2.4866467218664923e-10
, O 0 1.79512290449102e-11
and O 0 5.254367427265372e-11
characterization O 0 2.718249980659948e-08
of O 0 1.1124530630013396e-07
this O 0 6.68046906682207e-09
gene O 0 1.0550222917515839e-08
has O 0 4.486669646919239e-10
shown O 0 1.2881547217791223e-10
that O 0 3.235035503368344e-11
it O 0 5.777688397157199e-11
contains O 0 1.552347694833145e-10
two O 0 2.1185242449206498e-10
mutations O 0 4.768450218017861e-11
that O 0 3.3755512274247224e-11
result O 0 1.4267802495027126e-09
in O 0 4.713764045760627e-09
amino O 0 4.122584496002446e-09
acid O 0 1.0705026198820633e-08
substitutions O 0 1.6991954510103824e-08
- O 0 4.41707257436974e-08
cDNA O 0 7.257145995254177e-08
nucleotides O 0 7.92520804537844e-09
845 O 0 2.6738012692817392e-08
G O 0 2.513634633771744e-08
- O 0 4.769021444417376e-08
- O 0 1.0199022426604643e-07
> O 0 1.1276656408654162e-07
A O 0 1.0434933273018032e-07
( O 0 2.948356836451893e-10
C282Y O 0 6.1607257073603705e-09
) O 0 3.090733918797994e-11
and O 0 9.267882988828191e-11
187 O 0 6.080591585799766e-10
C O 0 2.2157713885917474e-08
- O 0 3.50865079212781e-08
- O 0 9.286333835234473e-08
> O 0 2.8136912533227587e-07
G O 0 5.86868168284127e-07
( O 0 3.3123244147503783e-09
H63D O 0 9.774315003596712e-06
) O 0 4.422938015835598e-09
. O 0 2.176490099259354e-08

Although O 0 0.00038431386929005384
hemochromatosis B-Disease 1 1.0
is O 0 6.164242449813173e-08
common O 0 9.735539663324744e-08
in O 0 1.4240152390598837e-09
Caucasians O 0 8.983968768916384e-08
, O 0 9.600349404337294e-10
affecting O 0 3.5069964710032764e-09
> O 0 3.0279016982603935e-07
= O 0 4.515175788810666e-08
1 O 0 5.278342030123895e-08
/ O 0 1.0843017150818923e-08
300 O 0 1.5148554632915534e-10
individuals O 0 3.3096921470826546e-12
of O 0 8.854501576394114e-10
northern O 0 1.9145267593501103e-09
European O 0 1.3860753655947633e-09
origin O 0 1.8362340536981492e-09
, O 0 5.470956326858456e-11
it O 0 1.9280396723608817e-11
has O 0 3.15305052032977e-12
not O 0 3.368230390779492e-12
been O 0 4.0621814939578726e-11
recognized O 0 7.147977348909151e-11
in O 0 1.4403057913003892e-10
other O 0 2.373476415407083e-10
populations O 0 2.4901078976569124e-09
. O 0 2.7880558306492276e-08

The O 0 1.1777660802181344e-06
present O 0 3.7934881902401685e-08
study O 0 1.045566411228549e-09
used O 0 1.1712870673363796e-09
PCR O 0 8.55379767017439e-08
and O 0 3.856445385252982e-09
restriction O 0 1.506716529320329e-08
- O 0 3.154343986011554e-08
enzyme O 0 4.381626173000086e-09
digestion O 0 3.5281050969615535e-08
to O 0 2.8190352829859933e-10
analyze O 0 2.2727417725576515e-09
the O 0 1.6964388782625406e-09
frequency O 0 3.792068437036278e-09
of O 0 2.4300688128420234e-09
the O 0 4.649170826098725e-09
845 O 0 7.20403292575611e-09
G O 0 4.118481555792641e-09
- O 0 7.622382725003263e-09
- O 0 1.8620482933329185e-08
> O 0 2.309502278308173e-08
A O 0 2.4253376196270438e-08
and O 0 1.263905202719684e-09
187 O 0 3.3468830484828516e-10
C O 0 6.312888878312606e-09
- O 0 1.301745378157193e-08
- O 0 4.803089836968866e-08
> O 0 1.5439447054177435e-07
G O 0 1.9717919030881603e-07
mutations O 0 1.6137868819043888e-09
in O 0 1.5963522725925827e-09
HLA O 0 3.243702906274848e-08
- O 0 7.9888886617141e-09
typed O 0 4.0075454066368366e-09
samples O 0 6.663209983770457e-10
from O 0 1.4569564443789318e-09
non O 0 4.709272971581413e-08
- O 0 2.8753908054568456e-07
Caucasian O 0 1.000227712211199e-06
populations O 0 1.8821944891556086e-08
, O 0 6.795692342187465e-10
comprising O 0 3.137456128232685e-10
Australian O 0 4.834059819103231e-09
Aboriginal O 0 1.162500762319496e-08
, O 0 3.0425145042256574e-11
Chinese O 0 2.0312110327047606e-10
, O 0 1.202617311291121e-10
and O 0 1.898454282667217e-09
Pacific O 0 4.378454718789726e-07
Islanders O 0 5.249134119367227e-06
. O 0 3.642892068000947e-07

Results O 0 3.0160995265759993e-06
showed O 0 5.53805193703738e-07
that O 0 4.855692292693448e-09
the O 0 5.187794371863674e-08
845 O 0 2.7002266733688884e-07
G O 0 5.34741161573038e-07
- O 0 6.21910999143438e-07
- O 0 7.624377076353994e-07
> O 0 1.54825457343577e-07
A O 0 3.7250575957159526e-08
mutation O 0 2.926550668469474e-10
was O 0 8.783299643155829e-10
present O 0 7.765081633248627e-11
in O 0 2.309798359523274e-11
these O 0 1.6949849510061732e-11
populations O 0 1.1710892672267548e-11
( O 0 5.624094506079258e-12
allele O 0 6.996445089946235e-11
frequency O 0 9.256175270699885e-10
0 O 0 8.694907016604247e-10
. O 0 5.887924175995707e-11
32 O 0 3.6812763948290694e-10
% O 0 4.6267149833578713e-11
) O 0 2.8683139197127616e-11
, O 0 2.9520014904749203e-11
and O 0 1.0912843545485273e-10
, O 0 4.26598964486935e-11
furthermore O 0 8.337540102765217e-10
, O 0 6.775628669242195e-11
it O 0 9.244596060886678e-11
was O 0 1.7915240846377856e-08
always O 0 1.0334146871571193e-09
seen O 0 7.809228264044066e-10
in O 0 1.0876934075643163e-10
conjunction O 0 4.835698508287578e-10
with O 0 3.701991768689794e-10
HLA O 0 9.268246685678605e-07
haplotypes O 0 1.564379061846921e-07
common O 0 7.075511803122936e-07
in O 0 2.0864375116502742e-08
Caucasians O 0 1.799274116365268e-07
, O 0 6.638903871092339e-10
suggesting O 0 2.202228621683844e-09
that O 0 6.488651838054693e-10
845 O 0 6.008976782823083e-08
G O 0 2.8882638503091584e-07
- O 0 1.136320861405693e-06
- O 0 5.32599187863525e-06
> O 0 5.6681842579564545e-06
A O 0 1.0631832765284344e-06
may O 0 4.758515359526427e-09
have O 0 1.0367032232672102e-10
been O 0 2.5871882414207903e-10
introduced O 0 1.0305266362475862e-10
into O 0 1.0891217788744356e-10
these O 0 4.6878360568380906e-12
populations O 0 1.8691478920196403e-11
by O 0 2.7836627100596978e-11
Caucasian O 0 1.7030695076414304e-08
admixture O 0 6.456652386077621e-07
. O 0 4.287997512619768e-07

187 O 0 1.0404947943243315e-06
C O 0 8.059707283791795e-07
- O 0 1.0906615699468603e-07
- O 0 8.87681395056461e-08
> O 0 8.424990483035799e-08
G O 0 7.886457353833976e-08
was O 0 6.134857954975814e-09
present O 0 1.730725562865132e-10
at O 0 3.0239796777742356e-10
an O 0 1.1675781869113777e-12
allele O 0 8.03977977942294e-12
frequency O 0 3.493615396976679e-10
of O 0 3.097122114326112e-09
2 O 0 1.2999841203509277e-07
. O 0 6.149269893285236e-08

68 O 0 1.4449305126618128e-05
% O 0 4.314521007131589e-08
in O 0 1.023499240915271e-08
the O 0 1.8731729056753466e-08
two O 0 1.3782929242367459e-09
populations O 0 2.1056210941505782e-10
analyzed O 0 2.6598627744789383e-09
( O 0 3.21554838311755e-10
Australian O 0 1.30504185236191e-08
Aboriginal O 0 4.082966498231144e-08
and O 0 1.1282348388874652e-09
Chinese O 0 3.44418027431459e-09
) O 0 8.523383110414784e-10
. O 0 1.7620038761378964e-08

In O 0 1.52310747125739e-06
the O 0 1.0184340908381273e-06
Australian O 0 2.6819000709110696e-07
Aboriginal O 0 3.9632009674051005e-08
samples O 0 7.507698351894021e-10
, O 0 1.6557089033142347e-10
187 O 0 4.842196088539197e-10
C O 0 3.8189629236740075e-08
- O 0 8.819030483664392e-08
- O 0 2.7513473810358846e-07
> O 0 4.4958230205338623e-07
G O 0 5.267852429824416e-07
was O 0 2.7474500896573772e-08
found O 0 2.181500119435853e-10
to O 0 3.065769166310517e-11
be O 0 4.1299307723674517e-11
associated O 0 1.088742207500104e-09
with O 0 8.145208951759741e-10
HLA O 0 2.8752585876645753e-06
haplotypes O 0 2.0927691934957693e-07
common O 0 3.5336384485162853e-07
in O 0 1.8669737755772076e-08
Caucasians O 0 3.3363320994794776e-07
, O 0 3.475630339089264e-10
suggesting O 0 1.0365791558442083e-09
that O 0 6.698375881741825e-11
it O 0 1.4511482293588784e-10
was O 0 1.7566272880742417e-09
introduced O 0 1.0717579601582372e-10
by O 0 2.5252600358016686e-11
recent O 0 1.1336230842928785e-09
admixture O 0 1.8014168290392263e-07
. O 0 8.77774795071673e-08

In O 0 1.8637628045325982e-06
the O 0 5.036956167714379e-07
Chinese O 0 4.6576587919844314e-08
samples O 0 3.4612896993024833e-09
analyzed O 0 4.310554135855682e-09
, O 0 2.5274007886544325e-10
187 O 0 1.027216534055242e-09
C O 0 2.357552020271214e-08
- O 0 4.137648090818402e-08
- O 0 5.980323436460822e-08
> O 0 1.6768521504673117e-07
G O 0 2.047394644932865e-07
was O 0 1.6928098034441064e-08
present O 0 6.23367579777323e-10
in O 0 2.6593438562372285e-10
association O 0 8.482897717598803e-11
with O 0 9.76330821744753e-11
a O 0 2.4200454973311025e-09
wide O 0 1.1011248801651163e-08
variety O 0 6.210916225768415e-09
of O 0 7.254364220443676e-08
HLA O 0 6.446540282922797e-06
haplotypes O 0 4.0644280829837953e-07
, O 0 6.695773935305738e-10
showing O 0 9.091890018630977e-10
this O 0 4.057522096090338e-10
mutation O 0 1.7736087043473958e-09
to O 0 8.14657674652608e-10
be O 0 2.3621418154817775e-09
widespread O 0 5.6184234153988655e-08
and O 0 6.815842557017504e-09
likely O 0 5.949806869409713e-09
to O 0 2.366967510880613e-09
predate O 0 1.0823922593772295e-06
the O 0 1.3250375729967345e-07
more O 0 2.9162758319323245e-10
genetically O 0 5.164817018510348e-09
restricted O 0 2.054159953246426e-09
845 O 0 1.9614889268382285e-08
G O 0 1.153577642298842e-07
- O 0 5.149789217284706e-07
- O 0 9.454903988626029e-07
> O 0 4.528302213202551e-07
A O 0 3.144154163692292e-07
mutation O 0 3.471334153459793e-08
. O 0 3.113257207587594e-08

Genotype O 0 0.00013900823250878602
- O 0 6.5393892327847425e-06
phenotype O 0 8.522251278009207e-07
correlations O 0 3.801608556841529e-07
in O 0 1.1850134740143403e-07
attenuated B-Disease 1 0.9999964237213135
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
. O 0 0.0013170713791623712

Germ O 0 0.07366404682397842
- O 0 9.719008085085079e-05
line O 0 1.0318335625925101e-06
mutations O 0 9.317716376244789e-09
of O 0 2.2960096046631406e-08
the O 0 4.9645812794096855e-08
tumor B-Disease 0 4.853694463236025e-06
suppressor O 0 4.465992788027506e-06
APC O 0 3.6409602444109623e-08
are O 0 9.358030322870192e-11
implicated O 0 1.3313679048110316e-08
in O 0 3.836404260937343e-08
attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 1.9572717064875178e-05
AAPC B-Disease 1 1.0
) O 0 7.877219432295135e-10
, O 0 2.182955725904545e-11
a O 0 1.6886127218729285e-10
variant O 0 1.8316476371182944e-06
of O 1 0.999500036239624
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 2.931704784714384e-06
FAP B-Disease 0 9.838871847023256e-06
) O 0 6.356397186380036e-09
. O 0 1.2565631379857223e-07

AAPC B-Disease 1 1.0
is O 0 1.5964937460921647e-07
recognized O 0 9.329951033976158e-09
by O 0 2.419827394017915e-10
the O 0 2.3617949818088846e-09
occurrence O 0 6.669774510470461e-09
of O 0 2.055563896874446e-08
< O 0 8.041280921133875e-07
100 O 0 1.982703423664134e-08
colonic B-Disease 0 7.655672561668325e-06
adenomas I-Disease 0 6.949254611754441e-07
and O 0 3.680174220921373e-10
a O 0 6.127838236835714e-10
later O 0 1.4273797255270892e-08
onset O 1 0.9932361245155334
of O 1 0.9995912909507751
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 3.276443838462484e-10
age O 0 9.087919861094917e-10
> O 0 9.899907560395604e-09
40 O 0 7.269357893413542e-10
years O 0 4.1124981198237265e-10
) O 0 1.893253470663936e-10
. O 0 5.822808901712051e-09

The O 0 3.1149077130976366e-06
aim O 0 5.459539238472644e-07
of O 0 2.1165350361229684e-08
this O 0 4.729034386308228e-10
study O 0 3.0182861765482016e-10
was O 0 3.3738356552959203e-09
to O 0 2.7905217026003015e-10
assess O 0 3.4945117022289196e-08
genotype O 0 2.368927880525007e-06
- O 0 8.953405767897493e-07
phenotype O 0 1.7838902977018734e-07
correlations O 0 1.954144295268634e-07
in O 0 7.815940961108936e-08
AAPC B-Disease 1 1.0
families O 0 9.900475106405793e-07
. O 0 7.37576044684829e-07

By O 0 1.5798634933616995e-07
protein O 0 2.2805923549640283e-07
- O 0 2.194220058981955e-07
truncation O 0 1.7672598460194422e-06
test O 0 5.924397896706068e-07
( O 0 1.36102062953114e-08
PTT O 0 2.74092940344417e-07
) O 0 9.734189843069174e-11
assay O 0 2.4874175608147198e-08
, O 0 3.247587199162183e-10
the O 0 2.7319497775124546e-09
entire O 0 1.5422296328893026e-08
coding O 0 3.2755348655655325e-08
region O 0 6.28719787343357e-09
of O 0 1.976435726191994e-08
the O 0 3.35697478703878e-08
APC B-Disease 0 4.342077630781205e-08
gene O 0 4.0901273479221345e-09
was O 0 2.6323176527398573e-08
screened O 0 4.718576640527772e-09
in O 0 5.290711618810562e-11
affected O 0 1.0075822814981095e-10
individuals O 0 1.2564480705856695e-11
from O 0 2.2732370652533973e-08
11 O 0 8.193493158614729e-06
AAPC B-Disease 1 1.0
kindreds O 0 0.2534821331501007
, O 0 7.094306475607937e-09
and O 0 9.866462091778772e-10
their O 0 2.8306315069670518e-09
phenotypic O 0 1.4970520112456143e-07
differences O 0 5.8098436284126365e-08
were O 0 1.9573113263504638e-07
examined O 0 3.1583529107592767e-06
. O 0 8.636897064207005e-07

Five O 0 6.399531002898584e-07
novel O 0 2.7962235549239267e-07
germ O 0 0.00021175628353375942
- O 0 6.1555638239951804e-06
line O 0 1.6162709925993113e-06
APC B-Disease 0 2.6133034225495066e-07
mutations O 0 1.8604179308212565e-09
were O 0 1.0167199304689234e-09
identified O 0 2.990558467530491e-09
in O 0 4.745590587162951e-09
seven O 0 7.401833101994271e-08
kindreds O 0 2.899371611420065e-05
. O 0 4.90530169372505e-07

Mutations O 0 8.729310820854153e-07
were O 0 1.2076253597115283e-07
located O 0 4.1363382052850284e-08
in O 0 9.411520451862998e-10
three O 0 1.78457512656216e-10
different O 0 5.646130785130765e-11
regions O 0 1.3250617270088583e-09
of O 0 2.1588981269360374e-07
the O 0 3.499665410799935e-07
APC B-Disease 0 5.236407218944805e-08
gene O 0 1.6891709142541345e-09
( O 0 2.3524648895545397e-10
1 O 0 7.837179794023541e-09
) O 0 2.770369211813062e-10
at O 0 6.7863443753424235e-09
the O 0 2.1371549863147266e-08
5 O 0 1.727719478594736e-08
end O 0 5.71798146609126e-08
spanning O 0 5.8528314639261225e-08
exons O 0 6.589733203554715e-08
4 O 0 1.0395832639176206e-08
and O 0 3.894704558859985e-10
5 O 0 2.382826158608964e-09
, O 0 9.32364463412938e-11
( O 0 2.0017462687427212e-10
2 O 0 1.4423690686271584e-08
) O 0 2.876472948720732e-10
within O 0 2.531213239009844e-09
exon O 0 2.788380193408102e-08
9 O 0 9.522646671200619e-09
, O 0 5.847745898623913e-11
and O 0 1.9638153603285247e-10
( O 0 2.528625364650594e-10
3 O 0 1.135610361302497e-08
) O 0 3.0104613246706435e-10
at O 0 5.5753139882597225e-09
the O 0 1.0190035482082749e-08
3 O 0 3.873136478205197e-08
distal O 0 1.7811227337460878e-07
end O 0 1.2047819097915635e-07
of O 0 6.698551402450903e-08
the O 0 5.90391344701402e-08
gene O 0 4.349172755269137e-08
. O 0 4.588773094837961e-08

Variability O 0 3.273100082878955e-05
in O 0 2.443054825107538e-08
the O 0 1.3360052619759699e-08
number O 0 1.5248428075764764e-09
of O 0 4.525159965851344e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 1 1.0
most O 0 4.427464261880232e-08
apparent O 0 1.3459709862218006e-06
in O 0 9.167341330496015e-10
individuals O 0 1.9525015285126734e-11
with O 0 2.5616939125505667e-10
mutations O 0 4.614416404535859e-09
in O 0 2.098386531201868e-08
region O 0 1.6087871699710377e-05
1 O 0 0.1488751322031021
, O 0 2.292412659699039e-08
and O 0 8.596516636316665e-07
upper O 1 1.0
- O 1 0.999988317489624
gastrointestinal O 1 0.9983136653900146
manifestations O 0 9.933765250025317e-05
were O 0 2.3964691564515306e-08
more O 0 1.2621365064191536e-10
severe O 0 7.907813710517075e-07
in O 0 7.194901563423173e-09
them O 0 9.4237746495196e-09
. O 0 1.263253324168545e-07

In O 0 8.83701432030648e-08
individuals O 0 7.162720416786783e-10
with O 0 4.407490761249022e-10
mutations O 0 1.710739105931225e-09
in O 0 2.930998777017635e-09
either O 0 5.730471741571819e-08
region O 0 1.0194836477239733e-06
2 O 0 4.794623237103224e-06
or O 0 8.240507298751254e-08
region O 0 9.587311211589622e-08
3 O 0 4.560302784284431e-07
, O 0 4.4880132943347917e-10
the O 0 5.133614866537073e-09
average O 0 5.3680717648774134e-09
number O 0 8.201533341356537e-10
of O 0 5.232463351489969e-08
adenomas B-Disease 0 0.000191161161637865
tended O 0 5.443521331471857e-07
to O 0 2.1544016348684636e-08
be O 0 1.8802818857466264e-08
lower O 0 1.0275540489601553e-06
than O 0 1.1327990628862139e-10
those O 0 5.2971946273849824e-11
in O 0 2.962221787305985e-11
individuals O 0 1.282930576010366e-12
with O 0 1.220763334169872e-11
mutations O 0 6.631559884562321e-11
in O 0 1.6307484529409777e-10
region O 0 4.4412908906110715e-09
1 O 0 4.859919755517694e-08
, O 0 3.9254589162540654e-11
although O 0 1.2151583905772867e-10
age O 0 1.2595903209344783e-09
at O 0 1.3127804399104548e-09
diagnosis O 0 3.144546667499526e-08
was O 0 5.86827653137334e-09
similar O 0 3.675854731710615e-09
. O 0 5.5408207799700904e-08

In O 0 1.3644924365507904e-05
all O 0 4.546061518340139e-06
AAPC B-Disease 1 1.0
kindreds O 0 0.0010683962609618902
, O 0 1.4000200110331207e-08
a O 0 9.611769158368588e-09
predominance O 0 1.4819396483289893e-06
of O 0 0.00041675561806187034
right O 1 1.0
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 1.0
rectal B-Disease 1 1.0
polyp I-Disease 1 0.9999995231628418
sparing O 0 1.7462813048041426e-05
was O 0 2.2919746243132977e-06
observed O 0 2.3316104602599808e-08
. O 0 3.099274792361939e-08

No O 0 0.00210804701782763
desmoid B-Disease 1 0.9999998807907104
tumors I-Disease 1 1.0
were O 0 3.1282573331736785e-07
found O 0 1.2451466524510124e-08
in O 0 2.624215289515064e-09
these O 0 1.0319950227710706e-08
kindreds O 0 7.070168067002669e-05
. O 0 4.892602873951546e-07

Our O 0 2.106899773934856e-05
data O 0 3.023787087386154e-07
suggest O 0 1.0924787297028615e-08
that O 0 5.306015071759873e-10
, O 0 1.573789765174638e-09
in O 0 1.251012182734712e-08
AAPC B-Disease 1 1.0
families O 0 2.9645718768733786e-08
, O 0 1.34575059429487e-10
the O 0 3.724741348687388e-10
location O 0 6.934806506819768e-09
of O 0 1.4968257744385483e-08
the O 0 6.854983780613111e-08
APC B-Disease 0 4.276330400898587e-07
mutation O 0 1.4918635216076837e-08
may O 0 9.43082412163676e-09
partially O 0 1.4474461806912586e-07
predict O 0 2.0863977212570717e-08
specific O 0 4.585690938085918e-09
phenotypic O 0 3.984070531259931e-07
expression O 0 3.2138478900378686e-07
. O 0 1.675049219329594e-07

This O 0 5.073316060588695e-07
should O 0 9.111549559293053e-08
help O 0 1.4446129625866888e-08
in O 0 3.86015441833365e-09
the O 0 7.742299246160655e-09
design O 0 5.9155457421411484e-08
of O 0 7.425246195680302e-09
tailored O 0 1.0442594344794998e-08
clinical O 0 8.127571504701336e-08
- O 0 1.586420665944388e-07
management O 0 1.2373622126915507e-08
protocols O 0 2.4698456968508253e-07
in O 0 4.303675749106617e-10
this O 0 4.8317870537939456e-11
subset O 0 9.533853706500395e-10
of O 0 1.4911090140401484e-09
FAP B-Disease 0 1.0114057857890657e-07
patients O 0 6.703316568490436e-09
. O 0 1.1603763283574153e-08
. O 0 1.1288201307024792e-07

Wilms B-Disease 1 0.9999995231628418
' I-Disease 0 0.29652902483940125
tumor I-Disease 0 0.00017651962116360664
1 O 0 1.5392283785331529e-06
and O 0 6.326874313344888e-08
Dax O 0 0.0001090133810066618
- O 0 9.539735401631333e-07
1 O 0 9.408169034941238e-07
modulate O 0 5.101844635646557e-07
the O 0 8.846134846862697e-07
orphan O 0 3.5661998936120654e-06
nuclear O 0 1.7061562175513245e-05
receptor O 0 9.428270573152986e-07
SF O 0 5.820899968966842e-05
- O 0 1.3505790263934614e-07
1 O 0 7.540521984594761e-09
in O 0 5.3991588977453375e-11
sex O 0 1.6491459239875716e-11
- O 0 9.151160385023616e-11
specific O 0 7.614557595569948e-11
gene O 0 1.2058750664678541e-09
expression O 0 6.902186377999442e-09
. O 0 2.2206114280720612e-08

Products O 0 5.838008291902952e-06
of O 0 1.8145647118217312e-05
steroidogenic O 1 0.6163182854652405
factor O 0 2.497749392205151e-06
1 O 0 3.203593621492473e-07
( O 0 6.791468498690278e-10
SF O 0 3.4212196624139324e-05
- O 0 2.1518189896596596e-07
1 O 0 6.891573178791077e-08
) O 0 3.2538868821596623e-10
and O 0 7.1032157933359485e-09
Wilms B-Disease 1 0.9987257122993469
tumor I-Disease 0 0.00014267352526076138
1 O 0 2.869397235372162e-07
( O 0 6.185660317292729e-10
WT1 O 0 1.2668670024140738e-06
) O 0 1.0251374055192386e-10
genes O 0 6.018902043436469e-11
are O 0 6.119889317535154e-12
essential O 0 2.954550604172823e-09
for O 0 3.5853431334942343e-10
mammalian O 0 7.97920506556693e-07
gonadogenesis O 0 3.609324323861074e-07
prior O 0 1.5474922676617098e-08
to O 0 7.879293328905135e-10
sexual O 0 3.7633890448418583e-10
differentiation O 0 1.1367762731140374e-08
. O 0 9.409836465579247e-09

In O 0 3.6280806625654805e-07
males O 0 1.1152016199389436e-08
, O 0 1.2468054144676444e-08
SF O 1 0.5215895175933838
- O 0 2.70787495537661e-05
1 O 0 2.6161237087762856e-07
participates O 0 1.2037287833166488e-09
in O 0 7.938815577146485e-11
sexual O 0 3.345949212141264e-11
development O 0 1.0695525715087584e-10
by O 0 1.0008415970985673e-11
regulating O 0 3.5854250124423004e-10
expression O 0 2.7649268985463493e-10
of O 0 7.2922756721993665e-09
the O 0 5.5504251861293596e-08
polypeptide O 0 9.328457508672727e-07
hormone O 0 3.288292305114737e-08
Mullerian O 0 3.922642918041674e-06
inhibiting O 0 7.948038671656832e-08
substance O 0 8.327900502536068e-08
( O 0 3.5919023311237197e-09
MIS O 0 8.393059943045955e-06
) O 0 2.2179182934678465e-09
. O 0 2.8140098251583368e-08

Here O 0 9.953274457075167e-06
, O 0 7.524592859908807e-08
we O 0 1.2142861827157958e-08
show O 0 4.570811285020682e-09
that O 0 1.73922443114094e-09
WT1 O 0 8.545480523025617e-05
- O 0 7.166469004005194e-06
KTS O 0 0.0005328260012902319
isoforms O 0 2.430557515253895e-07
associate O 0 1.4903199030413816e-07
and O 0 3.443549667636603e-09
synergize O 0 3.585948888940038e-07
with O 0 1.2301755170085471e-08
SF O 1 0.9998761415481567
- O 0 3.512389594106935e-05
1 O 0 1.000925294647459e-06
to O 0 1.9105298676436178e-08
promote O 0 1.0125233274038692e-07
MIS O 0 0.0007826529908925295
expression O 0 1.1733094140709e-07
. O 0 7.563500759033559e-08

In O 0 3.8881142927493784e-07
contrast O 0 9.150192568085913e-07
, O 0 1.307743247025428e-07
WT1 O 0 0.0034398064017295837
missense O 0 1.7780554117052816e-05
mutations O 0 8.607741364130561e-08
, O 0 7.675570734555492e-10
associated O 0 8.670070883454173e-09
with O 0 2.973625568003513e-09
male B-Disease 0 9.469604833611811e-07
pseudohermaphroditism I-Disease 1 1.0
in O 0 1.0565244110694039e-06
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.87962791389873e-07
fail O 0 1.937631395776407e-06
to O 0 1.5448533474682336e-07
synergize O 0 0.0002674726420082152
with O 0 4.652518327930011e-06
SF O 1 1.0
- O 1 0.696076512336731
1 O 0 1.6470037735416554e-05
. O 0 3.823821259629767e-07

Additionally O 0 1.7564893823873717e-06
, O 0 1.3112446239915698e-08
the O 0 4.123624464114073e-08
X O 0 1.5883608284639195e-05
- O 0 1.6294975466735195e-06
linked O 0 1.8485201280782348e-06
, O 0 1.0896376023694643e-09
candidate O 0 1.0224806779035589e-08
dosage O 0 6.313613880593039e-07
- O 0 2.7578570893638243e-07
sensitive O 0 1.5807903537279344e-06
sex O 0 2.9860840466966465e-09
- O 0 1.3192621217683609e-08
reversal O 0 1.27360504365015e-08
gene O 0 2.4375705898194155e-09
, O 0 5.529349755839519e-10
Dax O 0 6.077471425669501e-06
- O 0 2.649618977557111e-07
1 O 0 4.972997658114764e-07
, O 0 6.225112425539692e-09
antagonizes O 0 6.477943088611937e-07
synergy O 0 1.6381250134145375e-07
between O 0 1.1385821352405401e-07
SF O 0 0.0474514365196228
- O 0 7.918077358226583e-07
1 O 0 5.5796999021140437e-08
and O 0 3.804006887264677e-09
WT1 O 0 5.566556865232997e-06
, O 0 3.3492966733383867e-10
most O 0 2.4489679728567637e-10
likely O 0 8.373908788605888e-10
through O 0 3.503504708568528e-10
a O 0 4.3976494668029886e-10
direct O 0 1.2842564511839072e-10
interaction O 0 8.165773057733361e-10
with O 0 5.683865045291725e-10
SF O 0 0.24989105761051178
- O 0 9.991932529374026e-06
1 O 0 1.3632467243951396e-06
. O 0 1.2152180772773136e-07

We O 0 7.821054168744013e-07
propose O 0 2.341647729053875e-07
that O 0 2.2651391873296234e-08
WT1 O 0 0.0001131678800447844
and O 0 7.728668833806296e-07
Dax O 0 0.005493730306625366
- O 0 8.075748155533802e-06
1 O 0 6.063081059437536e-07
functionally O 0 1.1028067348206605e-07
oppose O 0 1.3543757226841535e-08
each O 0 5.761888188793307e-10
other O 0 6.564975785217086e-10
in O 0 1.8475285745722658e-09
testis O 0 1.6145519055044133e-07
development O 0 2.3190709352860495e-09
by O 0 4.6245998697180823e-10
modulating O 0 2.802743210850167e-07
SF O 0 0.0003796590317506343
- O 0 1.2352162457318627e-06
1 O 0 2.7781911171587126e-07
- O 0 7.136013380204531e-08
mediated O 0 6.839102866251778e-07
transactivation O 0 6.02724958298495e-06
. O 0 1.0066363742566864e-08
. O 0 2.0238884346213126e-08

A O 0 1.4945948350941762e-05
mouse O 0 1.5551341903119464e-06
model O 0 2.876097582316106e-08
for O 0 4.301603695466838e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 1.0
- O 1 1.0
centre O 0 0.0004024326626677066
mutations O 0 1.0646367343269958e-07
. O 0 7.301728999209445e-08

Imprinting O 0 6.97171562933363e-05
in O 0 2.69745726200199e-07
the O 0 5.026323037782277e-07
15q11 O 0 5.442179372039391e-06
- O 0 4.434157858668186e-07
q13 O 0 1.2195524732305785e-06
region O 0 2.3860701858779976e-08
involves O 0 9.025563407760728e-09
an O 0 1.7240974203858173e-09
imprinting O 0 4.413502097122546e-07
centre O 0 9.629137593947235e-07
( O 0 1.1706526859001087e-09
IC O 0 9.56325493461918e-07
) O 0 9.501994746585751e-10
, O 0 2.562930423444243e-10
mapping O 0 2.6510447170835505e-09
in O 0 4.983836121574825e-10
part O 0 3.330715703242504e-09
to O 0 1.2180155772867352e-09
the O 0 1.4427652850201866e-08
promoter O 0 2.0078134355117072e-07
and O 0 3.79623710244914e-09
first O 0 7.9867561453284e-09
exon O 0 7.978659510854413e-08
of O 0 9.694385738612254e-08
SNRPN O 0 0.0005102715222164989
. O 0 1.1639837111943052e-06

Deletion O 0 3.812736622421653e-06
of O 0 4.946537615069246e-07
this O 0 1.87052027200707e-08
IC O 0 3.084793934249319e-05
abolishes O 0 5.846510248375125e-06
local O 0 4.810717868508618e-08
paternally O 0 8.857145417096035e-08
derived O 0 1.644019032021049e-09
gene O 0 2.943524313181456e-10
expression O 0 1.1358258084070982e-10
and O 0 3.0000561063170395e-11
results O 0 9.385861532429374e-11
in O 0 4.7191432983595405e-09
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.4306515157222748
PWS B-Disease 1 1.0
) O 0 1.3522625295081525e-06
. O 0 1.723982109069766e-06

We O 0 4.2729385540951625e-07
have O 0 8.987393940174115e-09
created O 0 4.733695746494959e-08
two O 0 9.232905107126044e-09
deletion O 0 1.0560373198131856e-07
mutations O 0 1.3120150299528177e-08
in O 0 3.5393863395682956e-09
mice O 0 1.2651824476961337e-07
to O 0 1.5763502503318705e-08
understand O 0 7.66929497331148e-06
PWS B-Disease 1 1.0
and O 0 2.209581452916609e-06
the O 0 4.933111341642871e-08
mechanism O 0 3.527984304696474e-08
of O 0 4.964787247985214e-09
this O 0 1.7110916017415434e-09
IC O 0 4.7935991460690275e-06
. O 0 1.876320254723396e-07

Mice O 0 0.0002931402123067528
harbouring O 0 0.00016342684102710336
an O 0 9.310807769224994e-08
intragenic O 0 2.8256485165911727e-05
deletion O 0 3.0615017294621794e-06
in O 0 2.3135850568678507e-08
Snrpn O 0 0.00020502606639638543
are O 0 5.12322673174026e-09
phenotypically O 0 0.00042426938307471573
normal O 0 2.340255377930589e-06
, O 0 6.895103377146938e-10
suggesting O 0 1.1332685900811157e-09
that O 0 1.3871589987779487e-10
mutations O 0 2.1580361941886395e-09
of O 0 2.857059655525518e-08
SNRPN O 0 0.000169950959389098
are O 0 1.3688189470784096e-10
not O 0 1.226128781839364e-10
sufficient O 0 1.5855381008123004e-08
to O 0 2.010422583964555e-08
induce O 0 1.4439249753195327e-05
PWS B-Disease 1 1.0
. O 0 5.270628025755286e-05

Mice O 0 1.545286431792192e-05
with O 0 1.0257759974763303e-08
a O 0 3.1760475138753463e-08
larger O 0 1.0584269460878204e-07
deletion O 0 1.1977500946613873e-07
involving O 0 8.682598640064043e-09
both O 0 6.837431065775945e-09
Snrpn O 0 1.3686052625416778e-05
and O 0 3.070127618798324e-08
the O 0 1.6707002714611008e-07
putative O 0 0.00048449449241161346
PWS O 1 1.0
- O 0 0.00043442711466923356
IC O 0 9.568652603775263e-05
lack O 0 9.405190439792932e-07
expression O 0 1.5071389469767382e-08
of O 0 1.7633150051210578e-08
the O 0 1.5829666466515846e-08
imprinted O 0 2.8509029803558406e-08
genes O 0 1.487760226126511e-08
Zfp127 O 0 1.8791741922541405e-06
( O 0 4.130691344528259e-09
mouse O 0 4.124097188196174e-07
homologue O 0 3.7887557482463308e-06
of O 0 8.327176033162687e-07
ZNF127 O 1 0.5428438186645508
) O 0 1.891180012592031e-08
, O 0 8.657644379184148e-09
Ndn O 0 1.7283184206462465e-05
and O 0 2.7757460330235517e-08
Ipw O 0 1.5384505331894616e-06
, O 0 8.54640191949585e-10
and O 0 7.561734016725552e-10
manifest O 0 5.634732680448451e-09
several O 0 4.3426034990190487e-10
phenotypes O 0 2.981379054745048e-08
common O 0 1.425891866801976e-07
to O 0 1.1664540124911582e-06
PWS B-Disease 1 1.0
infants O 1 1.0
. O 0 3.2098283554660156e-05

These O 0 1.37550514978102e-07
data O 0 9.070922146747762e-08
demonstrate O 0 8.8769622763607e-09
that O 0 3.334197085091972e-10
both O 0 9.18649045722475e-10
the O 0 4.627319860617263e-09
position O 0 6.576035360694732e-08
of O 0 1.4690733962652303e-08
the O 0 1.1588347170743418e-08
IC O 0 5.502290605363669e-07
and O 0 1.9668640049985697e-09
its O 0 7.441802729601932e-10
role O 0 3.769504264283796e-09
in O 0 1.8907563015257978e-10
the O 0 1.049054176860409e-09
coordinate O 0 7.486192221684007e-10
expression O 0 1.7629846471578503e-09
of O 0 1.0447376297406663e-08
genes O 0 2.165821300081916e-09
is O 0 5.896929611282076e-10
conserved O 0 2.969363421811977e-09
between O 0 2.5798572167445855e-09
mouse O 0 1.1873386256411322e-06
and O 0 2.5381363677468016e-09
human O 0 1.4420335148201957e-08
, O 0 2.0548092394268025e-10
and O 0 4.209453341452729e-10
indicate O 0 1.377993386064702e-09
that O 0 1.1633118912612872e-09
the O 0 8.597912426466792e-08
mouse O 0 2.494045361345343e-07
is O 0 2.746388949592671e-10
a O 0 7.486991582261737e-10
suitable O 0 2.8596000234415442e-08
model O 0 4.336894399159519e-09
system O 0 3.2378927983245376e-08
in O 0 6.444632050239818e-10
which O 0 8.344536173154893e-11
to O 0 2.8170893395795815e-10
investigate O 0 1.7149012210282422e-09
the O 0 2.359152206921067e-09
molecular O 0 1.4121555480528514e-08
mechanisms O 0 6.502509819483748e-08
of O 0 2.45503173346151e-08
imprinting O 0 1.6022043780594686e-07
in O 0 8.279855134851744e-10
this O 0 6.890880227539142e-11
region O 0 7.66357532988593e-10
of O 0 4.2873495864625966e-09
the O 0 5.686751958222658e-09
genome O 0 4.411185194896916e-09
. O 0 1.324068854557936e-09
. O 0 2.6096916627693645e-08

Mutations O 0 3.6654392943091807e-07
of O 0 6.861654924250615e-07
the O 0 2.9255613753775833e-07
ATM O 0 2.0249713088560384e-06
gene O 0 1.2855541520195857e-08
detected O 0 3.096651113310145e-08
in O 0 6.122350626469597e-09
Japanese O 1 0.9967837333679199
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 1.0
: O 0 6.131418928134735e-09
possible O 0 3.38469163807531e-08
preponderance O 0 3.7807534681633115e-05
of O 0 8.376798632525606e-07
the O 0 1.6395489410570008e-07
two O 0 1.812116501298533e-08
founder O 0 6.820955604780465e-07
mutations O 0 9.278345203256322e-09
4612del165 O 0 2.459578638536186e-07
and O 0 2.227347550842751e-08
7883del5 O 0 4.953013103659032e-06
. O 0 3.938559700600308e-07

The O 0 1.5175995940808207e-05
ATM O 0 3.13205600832589e-05
( O 0 2.1314887987955444e-07
A O 1 1.0
- O 1 0.9999954700469971
T O 1 1.0
, O 0 2.6749018555705106e-09
mutated O 0 5.393338664561043e-09
) O 0 1.3892613448529545e-10
gene O 0 7.893793951829764e-10
on O 0 6.554256692936633e-09
human O 0 3.588779495800054e-09
chromosome O 0 7.721479988731517e-08
11q22 O 0 3.4270606192876585e-06
. O 0 2.626337902711384e-07

3 O 0 2.5369590730406344e-05
has O 0 9.33915611511793e-09
recently O 0 3.315219210264786e-09
been O 0 2.850709668322793e-10
identified O 0 1.8026140302662697e-10
as O 0 2.5726460892161462e-11
the O 0 5.6207729443036314e-11
gene O 0 2.081013486532335e-11
responsible O 0 3.036184151317123e-11
for O 0 3.9831710846316426e-11
the O 0 2.2764641283146148e-09
human O 0 6.334759063975071e-07
recessive B-Disease 1 0.9998366832733154
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999974966049194
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 5.246929504210129e-07
. O 0 9.50944297528622e-07

In O 0 2.9664337830581644e-07
order O 0 1.4801923953200458e-07
to O 0 1.2545893213200543e-08
define O 0 2.1515845105568587e-08
the O 0 3.7976999323063865e-09
types O 0 6.641870609058742e-09
of O 0 4.388570928881563e-08
disease O 0 3.535861105774529e-05
- O 0 2.582350475677231e-07
causing O 0 1.583103141911124e-07
ATM O 0 6.19123795786436e-07
mutations O 0 8.795454364829425e-10
in O 0 2.671740384485588e-09
Japanese O 0 0.020004669204354286
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.014125023037195206
as O 0 7.046489258755173e-08
well O 0 2.0275734424757275e-09
as O 0 6.119043605146146e-10
to O 0 3.0381902549336814e-10
look O 0 4.866622105303975e-10
for O 0 4.963667254997972e-10
possible O 0 5.0729575207242306e-08
mutational O 0 2.2133053789730184e-05
hotspots O 0 1.1458437256806064e-06
, O 0 5.746084164037768e-10
reverse O 0 6.744805602920678e-09
- O 0 8.462770040296164e-09
transcribed O 0 6.909140815025694e-09
RNA O 0 1.2001208915535244e-08
derived O 0 1.1296387159021037e-09
from O 0 1.3989408520487245e-09
ten O 0 3.930550107611452e-09
patients O 0 5.204180975049155e-10
belonging O 0 6.600523683175652e-09
to O 0 4.29592805772927e-09
eight O 0 1.3774684504141987e-08
unrelated O 0 3.58748167172962e-07
Japanese O 0 0.04729461669921875
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 1.0716122744724998e-07
was O 0 3.160697659154721e-08
analyzed O 0 8.164387499398629e-10
for O 0 2.7351692091781565e-11
mutations O 0 5.7498089622853854e-11
by O 0 4.736886230483073e-11
the O 0 3.902454803750288e-09
restriction O 0 1.5738445213742125e-08
endonuclease O 0 2.1090421853386943e-07
fingerprinting O 0 1.042910326987112e-07
method O 0 8.849833221802328e-08
. O 0 8.08796727369554e-08

As O 0 2.2383326268027304e-06
has O 0 7.0401320328983275e-09
been O 0 5.998321839228993e-10
reported O 0 1.2951563432839208e-10
by O 0 2.6773796721335508e-11
others O 0 8.337269763458721e-10
, O 0 1.0549205953225282e-10
mutations O 0 2.6670957109509175e-10
that O 0 3.9629399761764716e-10
lead O 0 8.624733993656264e-08
to O 0 2.903912132978803e-08
exon O 0 4.130983597860904e-06
skipping O 0 5.682504138349032e-07
or O 0 2.7581506856222404e-08
premature O 0 5.04246386867635e-08
protein O 0 8.969036180417334e-09
truncation O 0 1.676535532624257e-07
were O 0 2.1138683692356608e-08
also O 0 3.344446719566463e-09
predominant O 0 3.0486017976727453e-07
in O 0 6.199979640797437e-09
our O 0 1.6506960776041524e-07
mutants O 0 1.1096298067059251e-06
. O 0 9.393092881282428e-08

Six O 0 2.502651454960869e-07
different O 0 7.085242947901804e-10
mutations O 0 8.755434155460762e-10
were O 0 9.998352146212142e-10
identified O 0 6.082821801811633e-09
on O 0 1.4282430349510378e-08
12 O 0 4.444451473517574e-09
of O 0 1.080733813552115e-08
the O 0 7.824591818916815e-08
16 O 0 4.907940365228569e-08
alleles O 0 6.686141862388695e-09
examined O 0 3.997982105374831e-07
. O 0 3.9447624544663995e-07

Four O 0 1.242663415723655e-06
were O 0 8.954970809327278e-08
deletions O 0 2.090872186499837e-07
involving O 0 1.5496217642407828e-08
a O 0 3.477172327848166e-08
loss O 0 4.079627728970081e-07
of O 0 1.3919230696046725e-05
a O 0 2.0970376226614462e-06
single O 0 5.070984343547025e-07
exon O 0 2.4190273961721687e-07
exon O 0 1.198894068465961e-07
7 O 0 4.083441851321368e-08
, O 0 4.1009992624019276e-10
exon O 0 2.039131885567258e-08
16 O 0 1.965121221303434e-08
, O 0 1.1751941642046404e-09
exon O 0 8.604130385947428e-08
33 O 0 1.4407171988750633e-07
or O 0 4.190655644720209e-08
exon O 0 4.082736268173903e-06
35 O 0 1.2370434205877245e-06
. O 0 7.12782366463216e-07

The O 0 5.431141289591324e-06
others O 0 3.842823730337841e-07
were O 0 8.001824625125664e-08
minute O 0 4.669996940265264e-07
deletions O 0 2.865814394681365e-07
, O 0 4.6460155722627405e-09
4649delA O 0 3.3121366982413747e-07
in O 0 5.799754454471895e-09
exon O 0 1.6080335285550973e-07
33 O 0 4.5882565302690637e-08
and O 0 1.7459383938600581e-09
7883del5 O 0 3.677119195799605e-07
in O 0 1.425401841004259e-08
exon O 0 3.744037485375884e-06
55 O 0 4.7594531338290835e-07
. O 0 2.321059611176679e-07

The O 0 1.81408195203403e-05
mutations O 0 7.266882562362298e-07
4612del165 O 0 2.260332621517591e-06
and O 0 1.9883348301164006e-08
7883del5 O 0 3.829733827842574e-07
were O 0 4.610334780608127e-09
found O 0 1.048654052482334e-09
in O 0 7.133622165200748e-11
more O 0 3.8122816535535176e-12
than O 0 1.3088013312012592e-11
two O 0 5.0723984040823566e-11
unrelated O 0 1.790406045643067e-09
families O 0 1.6530141144777133e-10
; O 0 1.7264789597959407e-10
44 O 0 1.4450117769015947e-09
% O 0 2.1011156703387712e-10
( O 0 9.738591183472423e-11
7 O 0 1.5484340920579598e-08
of O 0 3.59888510104156e-08
16 O 0 3.295676265224756e-08
) O 0 2.5351737376055894e-10
of O 0 1.3763339801187158e-08
the O 0 3.2812689454431165e-08
mutant O 0 1.071039790190298e-08
alleles O 0 1.3514739327646907e-10
had O 0 1.1293586066329908e-09
one O 0 8.180079530406559e-11
of O 0 1.3001293375225487e-09
the O 0 8.141330276600911e-09
two O 0 2.9453677274915435e-09
mutations O 0 8.921434258013505e-09
. O 0 6.94535913225991e-08

The O 0 2.0690635210485198e-05
4612del165 O 0 3.224801184842363e-05
mutations O 0 7.226399389992366e-08
in O 0 5.058693020032479e-09
three O 0 9.331121431088718e-10
different O 0 2.074384414241237e-10
families O 0 1.8503850673923239e-09
were O 0 3.0798501526874134e-09
all O 0 2.0021395652491947e-10
ascribed O 0 1.3119500152924957e-08
to O 0 3.6796916624837195e-09
the O 0 6.102777660998981e-08
same O 0 1.3468330450905341e-08
T O 0 9.224212504932439e-08
- O 0 5.217484755348778e-08
- O 0 2.7265684821031755e-08
> O 0 1.6725648421811457e-08
A O 0 1.090498891187508e-08
substitution O 0 3.918393609581017e-09
at O 0 5.903932898121411e-09
the O 0 1.7449695022264677e-09
splice O 0 1.1443996328353023e-07
donor O 0 3.6184653051662963e-09
site O 0 1.130850790787008e-08
in O 0 3.3469866878022003e-09
intron O 0 2.1316016045602737e-06
33 O 0 1.3318018545760424e-06
. O 0 3.434231530263787e-07

Microsatellite O 0 0.0015452171210199594
genotyping O 0 0.0001574161578901112
around O 0 3.290560925961472e-07
the O 0 5.026351459491707e-07
ATM O 0 4.208741756883683e-06
locus O 0 1.327414196339305e-07
also O 0 4.960941657472517e-10
indicated O 0 2.2165469459878295e-10
that O 0 1.9471906725909705e-11
a O 0 2.542553945161785e-10
common O 0 1.8960804037959633e-09
haplotype O 0 1.7350711800645513e-07
was O 0 4.1377745674253674e-08
shared O 0 1.6159984461694421e-09
by O 0 5.89982923626664e-11
the O 0 1.9465429268450407e-09
mutant O 0 5.125279312068187e-09
alleles O 0 1.8004045476693875e-10
in O 0 2.0580803727909824e-10
both O 0 1.6225739640773895e-09
mutations O 0 6.892190640428453e-08
. O 0 3.0466108569271455e-07

This O 0 5.685453530190898e-08
suggests O 0 9.405997758449303e-09
that O 0 5.209799952554661e-11
these O 0 1.336666610729509e-10
two O 0 2.1432975394475307e-09
founder O 0 2.35490787758863e-07
mutations O 0 2.2013384448626994e-09
may O 0 3.6576845996449947e-09
be O 0 2.2794186538277472e-09
predominant O 0 6.880539444864553e-07
among O 0 3.839469631117254e-09
Japanese O 0 3.3525665799061244e-07
ATM O 0 1.9029199620490544e-06
mutant O 0 1.696158875574838e-07
alleles O 0 1.6122923440775594e-08
. O 0 1.0661282345836298e-07

W474C O 0 6.650112482020631e-05
amino O 0 7.683149192416749e-07
acid O 0 4.9108148658660866e-08
substitution O 0 2.3591983477899703e-08
affects O 0 4.0957015556841725e-09
early O 0 1.0106456116432128e-08
processing O 0 2.3189437925452694e-08
of O 0 1.520409043109794e-08
the O 0 1.3426164180430078e-08
alpha O 0 1.2222655776383817e-08
- O 0 1.0218251800253597e-09
subunit O 0 1.7690510167867046e-09
of O 0 2.558618872328111e-09
beta O 0 1.0476749245924566e-08
- O 0 1.3720510949610798e-08
hexosaminidase O 0 6.073329217315404e-08
A O 0 6.993824630541212e-09
and O 0 2.7397184521049667e-10
is O 0 2.5139185871880798e-11
associated O 0 4.2968267832677043e-10
with O 0 3.457117925265152e-10
subacute O 0 0.002232904313132167
G B-Disease 0 0.00020217571000102907
( I-Disease 0 2.211658767237168e-08
M2 I-Disease 0 6.209145794855431e-06
) I-Disease 0 1.563349272259984e-08
gangliosidosis I-Disease 0 7.833079507690854e-06
. O 0 3.3784391462177155e-07

Mutations O 0 1.1679724138957681e-06
in O 0 1.733939711812127e-07
the O 0 2.265632303988241e-07
HEXA O 0 2.5044017093023285e-05
gene O 0 8.964400777244919e-09
, O 0 3.59988372444775e-10
encoding O 0 2.8307827193430057e-09
the O 0 3.913772061991949e-08
alpha O 0 1.6161102678324824e-08
- O 0 2.8124256257200386e-09
subunit O 0 6.217174330913622e-09
of O 0 1.0559523033748519e-08
beta O 0 1.0441463160759668e-07
- O 0 1.0837355546300387e-07
hexosaminidase O 0 1.3114768080413342e-06
A O 0 7.097008847267716e-07
( O 0 4.305549694549882e-09
Hex O 0 2.9475987162186357e-07
A O 0 8.295163667071392e-08
) O 0 1.2230105816968262e-10
, O 0 3.519819158359638e-11
that O 0 8.785222549434479e-11
abolish O 0 5.6183697694223156e-08
Hex O 0 6.003638191032223e-07
A O 0 7.1218039465748e-08
enzyme O 0 6.802102436864743e-09
activity O 0 1.8807042589941148e-09
cause O 0 1.2134825738030486e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 7.035155391577064e-08
TSD B-Disease 1 0.9889863729476929
) O 0 7.931060252985844e-09
, O 0 7.701748128141617e-10
the O 0 4.0587643468370516e-08
fatal O 0 4.418966454977635e-06
infantile B-Disease 0 3.49308010072491e-07
form I-Disease 0 1.497368451452985e-08
of I-Disease 0 0.0002713566063903272
G I-Disease 0 6.95957278367132e-05
( I-Disease 0 4.391516039703447e-09
M2 I-Disease 0 6.989865255491168e-07
) I-Disease 0 1.0714642506570726e-09
gangliosidosis I-Disease 0 1.8417212288568408e-07
, I-Disease 0 4.879457393691666e-10
Type I-Disease 0 1.856219284945837e-07
1 I-Disease 0 1.077899014489958e-06
. O 0 1.347239475535389e-07

Less O 0 5.1222314141341485e-06
severe O 1 0.7045401930809021
, O 0 1.0783168846728586e-07
subacute O 1 0.9999998807907104
( O 0 4.3403395011409884e-07
juvenile O 1 0.9989585876464844
- O 0 0.00035394469159655273
onset O 1 1.0
) O 0 1.736777562655334e-06
and O 0 3.2768962228146847e-06
chronic O 1 1.0
( O 0 7.19311969987757e-08
adult O 0 1.3409602388492203e-06
- O 0 2.254273113067029e-06
onset O 1 0.738266110420227
) O 0 2.3356808154240127e-10
variants O 0 1.6884751374846019e-09
are O 0 1.341695331225079e-11
characterized O 0 4.4297740475762737e-10
by O 0 5.590301485614013e-11
a O 0 1.7406515118167931e-09
broad O 0 1.187232356869572e-08
spectrum O 0 3.0036082421247556e-07
of O 0 4.11801037714099e-09
clinical O 0 2.3327270781692278e-08
manifestations O 0 2.6272823561157566e-07
and O 0 5.935227309628033e-10
are O 0 6.624805738708606e-12
associated O 0 1.4657300373421833e-10
with O 0 1.9691442920688473e-11
residual O 0 5.940958658356976e-07
levels O 0 5.340928410646484e-08
of O 0 2.512017829303659e-07
Hex O 0 1.566631908644922e-06
A O 0 3.213685602077021e-07
enzyme O 0 4.547490917161667e-08
activity O 0 3.452561614381011e-08
. O 0 3.5771769546499854e-08

We O 0 7.327217304009537e-07
identified O 0 9.864061922826295e-08
a O 0 6.954426368110944e-08
1422 O 0 4.0824870666256174e-06
G O 0 7.731853770565067e-07
- O 0 4.403252376050659e-07
- O 0 2.931750486823148e-07
> O 0 2.1702187780192617e-07
C O 0 2.230122078117347e-07
( O 0 3.01069696950762e-10
amino O 0 3.4800748394125947e-10
acid O 0 3.060693365419809e-10
W474C O 0 2.5924651314568337e-09
) O 0 1.6480289355413902e-12
substitution O 0 2.0916153531391757e-10
in O 0 1.7685611308770888e-10
the O 0 1.8591514994170666e-09
first O 0 3.265415493558521e-09
position O 0 9.102079978617894e-09
of O 0 1.1724364590293135e-08
exon O 0 8.271101847867612e-08
13 O 0 1.010795891431826e-08
of O 0 2.7133289393077575e-08
HEXA O 0 5.245316424407065e-05
of O 0 5.067871029496018e-07
a O 0 1.1973914126883756e-07
non O 0 3.0871626677253516e-07
- O 0 8.853469353198307e-07
Jewish O 0 5.507640707946848e-07
proband O 0 0.00023771141422912478
who O 0 2.177685942683638e-08
manifested O 0 4.285994137376292e-08
a O 0 4.601551495397871e-08
subacute O 0 8.416368655161932e-05
variant O 0 6.45305190118961e-05
of O 1 0.998046875
G B-Disease 1 0.9796053171157837
( I-Disease 0 5.0156636177689506e-08
M2 I-Disease 0 5.1116853683197405e-06
) I-Disease 0 9.871172323983046e-09
gangliosidosis I-Disease 0 3.972100785176735e-06
. O 0 3.5572358569879725e-07

On O 0 2.8761840439983644e-05
the O 0 1.1036142950615613e-06
second O 0 1.1790270946221426e-06
maternally O 0 7.339441481235554e-07
inherited O 0 5.487882390298182e-06
allele O 0 1.6279973635846545e-07
, O 0 1.3544215748950705e-09
we O 0 1.9030393927366163e-10
identified O 0 1.0573383280032544e-09
the O 0 3.611404952863495e-09
common O 0 2.193018417528947e-06
infantile O 0 0.30681514739990234
disease O 0 0.049715764820575714
- O 0 1.1700761888278066e-06
causing O 0 5.0298126552661415e-06
4 O 0 5.850319666933501e-06
- O 0 1.8010456415140652e-06
bp O 0 2.477140014889301e-06
insertion O 0 3.7228133464850544e-07
, O 0 4.322731061989771e-09
+ O 0 3.197857267878135e-08
TATC O 0 9.715682608657517e-06
1278 O 0 1.308355149376439e-05
, O 0 1.1025785839891e-09
in O 0 1.2428065243597075e-09
exon O 0 1.8861265971281682e-07
11 O 0 4.5632351231006396e-08
. O 0 7.19295556450561e-08

Pulse O 0 0.00022033076675143093
- O 0 1.7232327081728727e-05
chase O 0 3.3629385143285617e-07
analysis O 0 7.005947377791699e-09
using O 0 1.2498387214066042e-08
proband O 0 1.9377441731194267e-06
fibroblasts O 0 9.165076875206069e-08
revealed O 0 1.0693174345988155e-07
that O 0 4.697749411697316e-10
the O 0 1.3532628351242693e-08
W474C O 0 5.0373213156262864e-08
- O 0 6.860422008259093e-09
containing O 0 2.8374858018764826e-09
alpha O 0 2.887646211036099e-08
- O 0 1.2058435139294943e-08
subunit O 0 1.4339725851186813e-08
precursor O 0 3.2208799183308656e-08
was O 0 1.558906603804644e-08
normally O 0 1.1420735884781763e-10
synthesized O 0 8.967560582995304e-10
, O 0 2.952023694935413e-11
but O 0 4.638705738968518e-11
not O 0 5.076705375528512e-11
phosphorylated O 0 8.999469613968358e-09
or O 0 3.4454943342865363e-09
secreted O 0 1.488829726170593e-09
, O 0 1.601050264588011e-10
and O 0 7.696739912077533e-10
the O 0 1.8877312157883352e-08
mature O 0 1.9716651422641007e-08
lysosomal O 0 9.763524531081202e-07
alpha O 0 1.2436908036761452e-07
- O 0 2.8295156440094615e-08
subunit O 0 2.443842461730128e-08
was O 0 2.8690298137235004e-08
not O 0 3.3366592822048347e-10
detected O 0 1.0062892386031308e-07
. O 0 2.509864138744433e-08

When O 0 4.645921308110701e-06
the O 0 8.288535582323675e-07
W474C O 0 4.026576618798572e-07
- O 0 3.125573044826524e-08
containing O 0 8.338657764284108e-09
alpha O 0 1.9318710187121724e-08
- O 0 6.964206544779472e-09
subunit O 0 3.123236780311345e-08
was O 0 6.425980814128707e-08
transiently O 0 2.41808599810156e-08
co O 0 1.1350690165556898e-08
- O 0 5.109272116499142e-09
expressed O 0 6.904342098046357e-10
with O 0 3.042011365028685e-10
the O 0 7.43099848321549e-09
beta O 0 1.0036302455773694e-08
- O 0 5.717116557946156e-09
subunit O 0 3.740576737243373e-09
to O 0 1.4030614448046208e-09
produce O 0 3.4797860593016594e-08
Hex O 0 1.119619696510199e-06
A O 0 8.227579542108288e-07
( O 0 6.709008459893084e-09
alphabeta O 0 5.629718202726508e-07
) O 0 8.241818894028086e-10
in O 0 2.5182977925197747e-09
COS O 0 6.370129540300695e-06
- O 0 5.533881335395563e-07
7 O 0 8.566598097559108e-08
cells O 0 7.200145812902292e-09
, O 0 2.8444419042372715e-10
the O 0 2.819133593234824e-09
mature O 0 2.3560313699988455e-09
alpha O 0 9.878103668370386e-09
- O 0 4.206413439789003e-09
subunit O 0 4.478335924318344e-09
was O 0 1.0966855867877712e-08
present O 0 7.821540637387159e-10
, O 0 5.0918338989625056e-11
but O 0 3.546079402338975e-11
its O 0 1.4489687227836612e-10
level O 0 8.2289748348785e-09
was O 0 1.2291552664578376e-08
much O 0 6.346810854651608e-10
lower O 0 4.8959143406079875e-09
than O 0 2.7064918015073935e-11
that O 0 2.405762394852573e-11
from O 0 4.454123736508109e-10
normal O 0 4.0397170053552145e-09
alpha O 0 3.151216887431474e-08
- O 0 1.6319948059617673e-08
subunit O 0 2.9443697258102475e-08
transfections O 0 1.8118042532933032e-07
, O 0 8.201794798878836e-11
although O 0 1.4881704202274193e-10
higher O 0 3.13928905093519e-09
than O 0 3.692758598905499e-11
in O 0 2.425279976847605e-10
those O 0 6.809897090676031e-11
cells O 0 7.506437693649559e-10
transfected O 0 3.983382157457527e-08
with O 0 1.0737325611964721e-10
an O 0 1.322253556645947e-10
alpha O 0 5.9691989129362355e-09
- O 0 3.76573172644612e-09
subunit O 0 3.861303277119532e-09
associated O 0 5.5470357196441e-09
with O 0 3.3591764925233747e-09
infantile O 0 1.565775710332673e-05
TSD B-Disease 0 0.0005246898508630693
. O 0 9.132704690273385e-07

Furthermore O 0 6.812635547248647e-06
, O 0 4.790006968846683e-08
the O 0 3.187693664585822e-08
precursor O 0 4.3866879195775255e-07
level O 0 3.76850067596024e-07
of O 0 1.353229635014941e-07
the O 0 5.7997791458319625e-08
W474C O 0 2.551057889377262e-07
alpha O 0 4.116654039876266e-08
- O 0 1.7473317015515022e-08
subunit O 0 1.1726466908612565e-08
was O 0 1.222312295823258e-08
found O 0 5.952936477093829e-10
to O 0 2.3129208270855628e-10
accumulate O 0 2.528482090369266e-09
in O 0 2.0914159293283774e-10
comparison O 0 3.272017767841362e-09
to O 0 2.552632993868542e-09
the O 0 1.6877740094400906e-08
normal O 0 2.5920513735400164e-08
alpha O 0 6.353963755145742e-08
- O 0 1.2131471827103724e-08
subunit O 0 1.0869521283041195e-08
precursor O 0 3.038564244661757e-08
levels O 0 1.691234885470294e-08
. O 0 1.353038303619769e-08

We O 0 6.581806815120217e-07
conclude O 0 2.555801472681196e-07
that O 0 7.528408119128471e-09
the O 0 5.034141992155128e-08
1422 O 0 3.872076831612503e-06
G O 0 8.358715604117606e-07
- O 0 3.446910170623596e-07
- O 0 1.7341844227303227e-07
> O 0 5.742518638385263e-08
C O 0 5.61346382710326e-08
mutation O 0 1.3140924459698056e-10
is O 0 1.1204661330699306e-11
the O 0 1.2249062875113736e-10
cause O 0 4.561075073183929e-09
of O 0 5.179587958537013e-08
Hex B-Disease 0 4.283414455130696e-05
A I-Disease 0 0.0011649061925709248
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.637967178031886e-08
the O 0 1.9939143669489567e-07
proband O 0 1.5056074516905937e-05
. O 0 2.987555944855558e-07

The O 0 4.707670996140223e-06
resulting O 0 2.3097238681657473e-06
W474C O 0 1.7106295899793622e-06
substitution O 0 9.356971730767327e-08
clearly O 0 2.3799431758675382e-08
interferes O 0 1.8074047147820238e-08
with O 0 1.1650016507047667e-09
alpha O 0 2.370474661006483e-08
- O 0 7.1414976154926535e-09
subunit O 0 2.2044475134208597e-09
processing O 0 9.786100818587329e-09
, O 0 1.737763752340804e-11
but O 0 6.487408700517339e-12
because O 0 3.7767618893402854e-11
the O 0 3.150023852871442e-10
base O 0 1.9285833374738104e-08
substitution O 0 1.0433913288920849e-08
falls O 0 3.1153541613093694e-07
at O 0 8.280838237340049e-09
the O 0 2.581816316293839e-09
first O 0 3.0184721389048264e-09
position O 0 2.563847267822439e-08
of O 0 2.7909504041190303e-08
exon O 0 6.604191327141962e-08
13 O 0 1.2303162932880696e-08
, O 0 2.633826767795e-10
aberrant O 0 8.284692931681548e-09
splicing O 0 3.197272349098057e-07
may O 0 1.654040637788512e-08
also O 0 3.3290070700076058e-09
contribute O 0 4.623632143818668e-09
to O 0 1.4991321961588255e-07
Hex B-Disease 0 0.12812501192092896
A I-Disease 0 0.006503792013972998
deficiency I-Disease 1 0.9999852180480957
in O 0 2.7919353939864777e-08
this O 0 6.602361768415221e-09
proband O 0 2.1843266040377785e-06
. O 0 9.042071091869275e-09
. O 0 3.67177115379036e-08

Two O 0 2.018703639805608e-07
frequent O 0 2.2100907415278925e-07
missense O 0 5.1334300223970786e-06
mutations O 0 3.5115436958221835e-07
in O 0 4.730654268314538e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0002648303343448788

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 2.4189719738387794e-07
an O 0 7.427458399433817e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.015320146456360817
by O 0 4.022494337618809e-09
early O 1 0.9993076324462891
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 1.0
goiter B-Disease 1 1.0
. O 1 0.999993085861206

A O 0 2.349307123949984e-06
century O 0 1.99694500224723e-06
after O 0 3.606897891472727e-08
its O 0 4.6083981075639713e-10
recognition O 0 8.195079281847484e-09
as O 0 2.388728326252476e-09
a O 0 8.823518804490504e-09
syndrome O 0 4.224744429848215e-07
by O 0 2.040141250381211e-10
Vaughan O 0 5.33651984824246e-07
Pendred O 0 4.6479981392621994e-05
, O 0 8.779866278452175e-10
the O 0 1.3629742667831124e-08
disease O 0 2.3282002814539737e-07
gene O 0 2.5031938744035642e-09
( O 0 8.64359916974422e-10
PDS O 0 8.851992788549978e-06
) O 0 2.3023847273151432e-09
was O 0 2.3789205272350955e-07
mapped O 0 1.78075936219102e-07
to O 0 3.47644260045854e-08
chromosome O 0 4.950152288074605e-07
7q22 O 0 1.1222976354474667e-05
- O 0 6.677747023786651e-06
q31 O 0 2.586264417914208e-05
. O 0 5.711239055017359e-07

1 O 0 1.0045294402516447e-05
and O 0 6.272144759122966e-08
, O 0 3.1939362266086846e-09
recently O 0 8.573900700525883e-09
, O 0 1.264145732537969e-10
found O 0 3.488514754845795e-10
to O 0 3.365292766677186e-10
encode O 0 5.223197430126447e-09
a O 0 3.304740658904848e-08
putative O 0 7.574726168968482e-06
sulfate O 0 0.00027511094231158495
transporter O 0 0.08745944499969482
. O 0 2.2753424673283007e-06

We O 0 6.661169322796923e-07
performed O 0 3.187511055102732e-08
mutation O 0 8.831529396680082e-10
analysis O 0 4.761545602249839e-10
of O 0 5.566537009116246e-09
the O 0 2.8602658019849514e-08
PDS B-Disease 0 7.3079536377917975e-06
gene O 0 2.772252649663187e-09
in O 0 4.683872734112526e-10
patients O 0 2.048236469320841e-09
from O 0 7.850225358652096e-09
14 O 0 2.5349299548338422e-08
Pendred B-Disease 0 2.152243041564361e-06
families O 0 1.4405263648598066e-09
originating O 0 3.712954166346094e-09
from O 0 1.2966769880051743e-09
seven O 0 6.236577920759601e-10
countries O 0 7.365259444003236e-12
and O 0 6.928060347632936e-10
identified O 0 1.0651481474610591e-08
all O 0 3.842597795511438e-09
mutations O 0 2.8320803480141876e-08
. O 0 6.064578172981783e-08

The O 0 2.327029051230056e-06
mutations O 0 6.079066139363931e-08
include O 0 7.2869088540983284e-09
three O 0 1.0604654931967161e-08
single O 0 1.9158648001393885e-08
base O 0 1.949048055394087e-06
deletions O 0 7.989240771166806e-07
, O 0 4.062960634598767e-09
one O 0 3.2470066635426065e-09
splice O 0 2.366103444728651e-06
site O 0 1.2332111509749666e-07
mutation O 0 2.0527106681100804e-09
and O 0 2.4479511750996608e-09
10 O 0 2.4276657129007617e-08
missense O 0 1.721632656881411e-06
mutations O 0 2.7832510340886074e-07
. O 0 4.46658788177956e-07

One O 0 4.0724735299590975e-06
missense O 0 4.21205413658754e-06
mutation O 0 6.333200985864096e-08
( O 0 1.946494743165772e-09
L236P O 0 2.9182942284933233e-07
) O 0 5.946332315431846e-10
was O 0 1.3179568547627696e-08
found O 0 8.493133973885847e-10
in O 0 5.794653645807557e-10
a O 0 2.4057189573767346e-09
homozygous O 0 8.975226117868829e-10
state O 0 2.072498145322399e-10
in O 0 5.897615729111294e-10
two O 0 2.175447155750021e-09
consanguineous O 0 2.119542386935791e-06
families O 0 1.4193790143224305e-08
and O 0 5.212130727016984e-09
in O 0 1.5805040609606635e-09
a O 0 9.992217719911878e-09
heterozygous O 0 2.467196724698084e-10
state O 0 1.139927804927332e-10
in O 0 1.4144399540505503e-10
five O 0 9.906779840918034e-10
additional O 0 3.074626331311947e-09
non O 0 3.792823122239497e-07
- O 0 4.760188403452048e-06
consanguineous O 0 0.00019126691040582955
families O 0 5.3503396202359e-07
. O 0 2.90962361759739e-07

Another O 0 1.1905352948815562e-05
missense O 0 2.079425030387938e-05
mutation O 0 2.563698728863528e-07
( O 0 3.5097535988626305e-09
T416P O 0 3.2189825560635654e-07
) O 0 8.044451216271398e-10
was O 0 3.6822207505338156e-08
found O 0 1.3541063825783795e-09
in O 0 4.991960733669032e-10
a O 0 1.6993632057094032e-09
homozygous O 0 9.782588072937415e-10
state O 0 1.9590605526698113e-10
in O 0 9.533981382148227e-10
one O 0 2.3018973394073328e-09
family O 0 8.215894631291576e-09
and O 0 1.0157934493548737e-09
in O 0 1.4094101441486373e-09
a O 0 7.1032157933359485e-09
heterozygous O 0 4.6240530848784545e-10
state O 0 7.061710244338215e-11
in O 0 2.142392929727066e-10
four O 0 3.2518288062277634e-09
families O 0 2.3518871294925248e-09
. O 0 7.156403825092639e-08

Pendred B-Disease 0 0.09882748126983643
patients O 0 3.754614226636477e-05
in O 0 1.8606890250794095e-07
three O 0 7.482316277673817e-08
non O 0 2.8193690013722517e-06
- O 0 6.612398919969564e-06
consanguineous O 0 0.0007958508795127273
families O 0 1.0229044278275978e-07
were O 0 4.176131440658537e-09
shown O 0 4.5975118156960093e-10
to O 0 3.717203767017452e-10
be O 0 1.0723434362702733e-09
compound O 0 1.2723914721846086e-07
heterozygotes O 0 3.7073725422942516e-08
for O 0 1.5530267072350057e-09
L236P O 0 2.9107366117386846e-07
and O 0 1.605804555993018e-08
T416P O 0 2.0034879071317846e-06
. O 0 1.8617186015035259e-07

In O 0 4.0326909811483347e-07
total O 0 8.623907810090259e-09
, O 0 3.350210386887653e-10
one O 0 2.5421853511176096e-10
or O 0 7.222162312636726e-10
both O 0 2.2303638103071677e-10
of O 0 4.68318717139482e-09
these O 0 2.2629302598442536e-10
mutations O 0 2.520439690290033e-10
were O 0 3.186316488434926e-10
found O 0 4.82941242552215e-10
in O 0 2.8145866193263203e-10
nine O 0 1.38732902943417e-09
of O 0 1.552749040456547e-08
the O 0 7.212298669401207e-08
14 O 0 3.652506563867064e-08
families O 0 4.801181674451982e-09
analyzed O 0 7.67260672773773e-08
. O 0 1.2388434811327897e-07

The O 0 2.499074014394864e-07
identification O 0 8.904981285695612e-08
of O 0 2.8148025421614875e-07
two O 0 2.2015242961970216e-08
frequent O 0 8.92787213047086e-08
PDS B-Disease 0 1.1861630810017232e-05
mutations O 0 2.0762100927385063e-09
will O 0 2.1938260930109976e-10
facilitate O 0 2.048041292113112e-09
the O 0 5.202813735394329e-09
molecular O 0 2.325874675079831e-07
diagnosis O 1 0.5784238576889038
of O 0 0.23960678279399872
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.387366955896141e-05

Insertional O 0 0.00017614098032936454
mutation O 0 1.5922969964776712e-07
by O 0 4.7856394402856495e-09
transposable O 0 1.1071479093516245e-05
element O 0 2.641890432641958e-06
, O 0 1.5384426177433852e-08
L1 O 0 7.228628874145215e-06
, O 0 1.4341550169660877e-09
in O 0 2.3312936026087527e-09
the O 0 1.7291375797867659e-07
DMD B-Disease 1 1.0
gene O 0 1.4263537906344936e-08
results O 0 1.0654808146881578e-09
in O 0 4.05421296534314e-09
X B-Disease 1 0.999996542930603
- I-Disease 1 0.9860549569129944
linked I-Disease 1 0.9983823299407959
dilated I-Disease 1 0.9999978542327881
cardiomyopathy I-Disease 1 1.0
. O 0 3.5421351640252396e-05

X B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
linked I-Disease 1 0.999998927116394
dilated I-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
( O 0 3.719449296113453e-06
XLDCM B-Disease 1 0.9997106194496155
) O 0 1.5677319442630733e-09
is O 0 1.185968268035964e-10
a O 0 5.670048319750265e-10
clinical O 0 1.933625526362448e-08
phenotype O 0 4.856464101976599e-07
of O 0 4.0164403003473126e-07
dystrophinopathy B-Disease 0 3.061240931856446e-05
which O 0 9.357534747067575e-10
is O 0 1.1276145989169706e-10
characterized O 0 2.181500119435853e-10
by O 0 1.9390740749192226e-11
preferential O 0 2.0264725009155882e-08
myocardial B-Disease 0 0.00026423283270560205
involvement I-Disease 0 1.2071690314030548e-08
without O 0 1.7706073274226242e-09
any O 0 6.927439177850658e-10
overt O 0 2.838438595276216e-09
clinical O 0 1.6827755189297022e-08
signs O 0 3.591753028331368e-08
of O 0 1.0058620318886824e-05
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 1 0.999990701675415

To O 0 3.7998319157850347e-08
date O 0 3.7575730971184385e-07
, O 0 1.0073848422109677e-09
several O 0 1.5459594715494518e-10
mutations O 0 7.814636715508527e-10
in O 0 1.3438454793401888e-09
the O 0 2.54006096156445e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 1 0.9985511898994446
, O 0 2.522886461520102e-06
DMD O 1 1.0
, O 0 4.189608659999067e-08
have O 0 8.157802766639577e-10
been O 0 2.1847907927252663e-09
identified O 0 3.0495941327757237e-09
in O 0 3.8219394316030275e-10
patients O 0 2.900965467844685e-09
with O 0 9.48403244827034e-10
XLDCM B-Disease 1 0.9999916553497314
, O 0 5.891558796378149e-09
but O 0 6.203809133076277e-10
a O 0 1.7506234240016738e-09
pathogenic O 0 6.459365931021921e-09
correlation O 0 1.332431609490925e-09
of O 0 3.920718860683792e-09
these O 0 2.3652164671261744e-09
cardiospecific O 0 1.290932459596661e-06
mutations O 0 4.96731633603531e-09
in O 0 2.725776715450934e-09
DMD O 1 1.0
with O 0 2.6136369513096724e-08
the O 0 1.4571915016858838e-06
XLDCM B-Disease 0 0.0053569963201880455
phenotype O 0 1.0759681572380941e-06
has O 0 1.6691030779725224e-09
remained O 0 8.086282754504737e-09
to O 0 1.196202720210593e-10
be O 0 8.278749907830729e-10
elucidated O 0 7.505823759856867e-06
. O 0 2.2679238043110672e-07

We O 0 3.3206984539901896e-07
report O 0 1.064947063866839e-08
here O 0 1.4603395159795696e-09
the O 0 1.3282246413837129e-09
identification O 0 5.311120432338612e-09
of O 0 1.0237882541730414e-08
a O 0 1.02568806781278e-08
unique O 0 2.441713320422423e-08
de O 0 1.52137999975821e-06
novo O 0 8.744577826291788e-06
L1 O 0 1.0374606063123792e-05
insertion O 0 5.104716365167405e-07
in O 0 1.7809318464401258e-08
the O 0 3.9788186967371075e-08
muscle O 0 3.745261523135923e-08
exon O 0 2.0074726592156367e-07
1 O 0 4.5199836762321866e-08
in O 0 4.807724884869913e-09
DMD O 1 1.0
in O 0 6.544253494666918e-08
three O 0 2.6317955814647576e-08
XLDCM B-Disease 0 0.00024216354358941317
patients O 0 1.6938789926257414e-08
from O 0 6.611359903985203e-09
two O 0 1.3861494174705058e-09
unrelated O 0 4.282333421201656e-08
Japanese O 0 1.2113712273276178e-06
families O 0 3.574094620262258e-08
. O 0 2.771567437775957e-07

The O 0 6.558838322234806e-06
insertion O 0 2.1805428787047276e-06
was O 0 3.7017346130596707e-06
a O 0 4.3673278327105436e-08
5 O 0 1.2737363164205817e-08
- O 0 2.6740549774473266e-09
truncated O 0 1.1232560659379942e-08
form O 0 6.0141682745040725e-09
of O 0 6.558398268907695e-08
human O 0 2.1248718340416417e-08
L1 O 0 9.34037700517365e-07
inversely O 0 9.435847658778584e-08
integrated O 0 5.628644430544227e-07
in O 0 5.33855271100947e-09
the O 0 5.453025053725469e-08
5 O 0 4.3552407902325285e-08
- O 0 5.947517678350778e-08
untranslated O 0 0.0030412827618420124
region O 0 9.004623535702194e-08
in O 0 1.1087455398239854e-08
the O 0 2.6791818541482826e-08
muscle O 0 4.439201006789517e-08
exon O 0 5.684304582587174e-08
1 O 0 1.39649163344302e-08
, O 0 3.4953599042930605e-11
which O 0 2.11040056957712e-11
affected O 0 9.465779271522479e-10
the O 0 3.313538954330397e-08
transcription O 0 3.9953408759174636e-07
or O 0 6.256778561919418e-08
the O 0 1.3762216610757605e-07
stability O 0 6.807744739489863e-06
of O 0 9.087170838029124e-07
the O 0 2.2652174891391041e-07
muscle O 0 1.1956223566755853e-08
form O 0 1.626178125491151e-08
of O 0 4.925984171677555e-07
dystrophin O 0 1.2631945764951524e-06
transcripts O 0 6.551409370558758e-08
but O 0 1.0671038497278573e-09
not O 0 1.0017282142671391e-10
that O 0 7.666378643023108e-11
of O 0 1.4289079253160253e-08
the O 0 1.3358682338093786e-07
brain O 0 8.737641110201366e-06
or O 0 5.4373632707438446e-08
Purkinje O 0 0.001110755605623126
cell O 0 0.00028336228569969535
form O 0 1.8510397126192402e-07
, O 0 4.088505090038552e-09
probably O 0 4.4145963329356164e-08
due O 0 2.3868383323133457e-06
to O 0 6.349235803781994e-09
its O 0 4.478438508925819e-09
unique O 0 2.5417115079306996e-09
site O 0 1.4588786179103863e-08
of O 0 3.4867604359334337e-09
integration O 0 8.542254192889231e-08
. O 0 9.942773004922856e-08

We O 0 6.415198186005e-07
speculate O 0 6.61945023239241e-08
that O 0 2.1705594266396844e-10
this O 0 1.2875553401237028e-10
insertion O 0 1.0500035507732264e-08
of O 0 1.2435421581358241e-08
an O 0 7.601994034267534e-10
L1 O 0 2.3987243480405596e-07
sequence O 0 6.94531676614929e-09
in O 0 6.180498335339735e-09
DMD O 1 1.0
is O 0 3.779597967934478e-09
responsible O 0 9.780946053083994e-10
for O 0 9.258536298739628e-11
some O 0 2.103929877539379e-11
of O 0 8.035433984865392e-10
the O 0 7.560609360801607e-10
population O 0 1.3428851130051211e-12
of O 0 1.437939767257035e-10
Japanese O 0 1.1412189415693774e-08
patients O 0 7.508098587294398e-10
with O 0 5.099669575514554e-10
XLDCM B-Disease 0 9.259649232262745e-05
. O 0 8.486082236913717e-08
. O 0 2.2177106018261838e-07

Severe O 1 0.7863962054252625
early O 1 0.9999768733978271
- O 1 0.9999971389770508
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 9.54099050431978e-07
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 4.247853212291375e-05
red O 1 0.999259889125824
hair O 0 0.00013751386723015457
pigmentation O 1 0.629206657409668
caused O 0 2.805901203828398e-06
by O 0 1.5182008539227354e-08
POMC O 1 0.9992341995239258
mutations O 0 7.639400223524717e-08
in O 0 4.712937151651886e-09
humans O 0 3.262908592205349e-07
. O 0 1.3759512285105302e-07

Sequential O 0 1.5302610336220823e-05
cleavage O 0 2.5796631234697998e-05
of O 0 1.182896266982425e-05
the O 0 7.608099394929013e-07
precursor O 0 7.954315037750348e-07
protein O 0 6.22264622052171e-08
pre O 0 6.1856112552050035e-06
- O 0 2.896174009947572e-06
pro O 0 1.8735319827101193e-05
- O 0 1.0913615369645413e-05
opiomelanocortin O 0 5.520597187569365e-05
( O 0 1.7693489340331325e-08
POMC O 0 2.786039658531081e-05
) O 0 1.3426977307773313e-09
generates O 0 1.7029647692012873e-09
the O 0 1.567063101504118e-08
melanocortin O 0 5.844497991347453e-06
peptides O 0 6.798472895752639e-08
adrenocorticotrophin O 0 1.0227244047200656e-06
( O 0 1.9491062097642953e-09
ACTH O 0 4.429838043051859e-07
) O 0 1.8880652596919845e-09
, O 0 3.5696712252786256e-09
melanocyte O 0 1.9959319615736604e-05
- O 0 6.8531016950146295e-06
stimulating O 0 7.480775110479954e-08
hormones O 0 9.342951301505309e-09
( O 0 3.988860075576639e-10
MSH O 0 3.597698423618567e-07
) O 0 2.488805550537876e-10
alpha O 0 2.8784776784362975e-09
, O 0 4.1311044862712976e-11
beta O 0 1.0950254036856677e-09
and O 0 2.0664507605072657e-10
gamma O 0 2.9484987784655914e-09
as O 0 3.6473443709716946e-10
well O 0 1.9702722786618665e-10
as O 0 2.3019093575715743e-10
the O 0 7.648972566443035e-10
opioid O 0 2.0709588710587923e-08
- O 0 1.337198440864995e-08
receptor O 0 5.83788839492172e-09
ligand O 0 9.728078254056527e-08
beta O 0 2.971139281271462e-07
- O 0 5.704940804207581e-07
endorphin O 0 3.388419281691313e-05
. O 0 2.2664146115403128e-07

While O 0 4.959366606271942e-07
a O 0 2.457730374771927e-08
few O 0 4.277449505707409e-09
cases O 0 2.770793594564225e-09
of O 0 1.2541758565021155e-07
isolated O 0 0.004479074850678444
ACTH B-Disease 1 0.9999994039535522
deficiency I-Disease 1 1.0
have O 0 1.2306453811561369e-07
been O 0 4.6609287096543994e-08
reported O 0 2.2479104799799643e-08
( O 0 5.880310016692647e-09
OMIM O 0 5.688165401807055e-05
201400 O 0 1.766420723470219e-06
) O 0 1.363982482516235e-09
, O 0 2.8860300260724614e-10
an O 0 1.4398175984808859e-09
inherited O 1 0.9997434020042419
POMC O 1 1.0
defect O 1 1.0
has O 0 3.7483280834749166e-07
not O 0 1.4401388970242124e-09
been O 0 2.4674613463560036e-09
described O 0 3.6531806468786954e-09
so O 0 1.2151381012515117e-09
far O 0 9.395382249977047e-09
. O 0 2.4578897139804212e-08

Recent O 0 4.801541990673286e-07
studies O 0 5.4098773460964367e-08
in O 0 4.234661066249146e-09
animal O 0 8.109868332439873e-09
models O 0 4.194507852162133e-09
elucidated O 0 2.341088020330062e-06
a O 0 1.1236550534476919e-07
central O 0 2.1413417528037826e-07
role O 0 8.365615400407478e-08
of O 0 5.292080004437594e-06
alpha O 0 9.733877959661186e-06
- O 0 1.9345425243955106e-06
MSH O 0 5.6142012908821926e-05
in O 0 1.0873834277447259e-08
the O 0 1.1832333335348721e-08
regulation O 0 1.0276894002458903e-08
of O 0 1.4891762267765785e-09
food O 0 5.475531694720814e-10
intake O 0 2.9105398646755987e-11
by O 0 3.434125596737947e-12
activation O 0 3.4129610249067355e-09
of O 0 4.977514223014623e-08
the O 0 4.0279093127537635e-07
brain O 0 4.431677552929614e-06
melanocortin O 0 1.4509135326079559e-05
- O 0 4.3362555857129337e-07
4 O 0 1.6685920911641006e-07
- O 0 5.1052417404662265e-08
receptor O 0 4.0905742793029276e-08
( O 0 2.2784014674925857e-09
MC4 O 0 4.954401447321288e-05
- O 0 7.084727826622839e-07
R O 0 5.096845256957749e-07
; O 0 4.8360142557157815e-09
refs O 0 7.527592060796451e-07
3 O 0 4.129527653162768e-08
- O 0 4.049691693097657e-09
5 O 0 9.004221257491452e-10
) O 0 1.047709401874597e-11
and O 0 2.923625924688977e-11
the O 0 2.5699942174384205e-10
linkage O 0 3.236101875359054e-08
of O 0 4.2407897637986025e-08
human O 0 6.593303965019004e-07
obesity B-Disease 1 0.999996542930603
to O 0 7.138611035628628e-09
chromosome O 0 3.018266525600666e-08
2 O 0 2.3621502975856856e-07
in O 0 6.000132835026761e-09
close O 0 2.3692052764090477e-07
proximity O 0 3.6682858990388922e-06
to O 0 4.672072506650693e-08
the O 0 5.713456516787119e-07
POMC O 0 0.00040983071085065603
locus O 0 2.437400326016359e-07
, O 0 3.5108496665436917e-10
led O 0 4.0426745284705135e-10
to O 0 2.462598458485843e-10
the O 0 3.488702660092713e-09
proposal O 0 4.181886392728984e-09
of O 0 7.4321748755323824e-09
an O 0 2.1970797403625397e-10
association O 0 4.69225103216786e-10
of O 0 1.1060081739344696e-08
POMC O 0 0.0036076647229492664
with O 0 5.318726437053556e-08
human O 0 0.00013255214435048401
obesity B-Disease 1 1.0
. O 0 1.1286205108262948e-06

The O 0 2.2623944460065104e-06
dual O 0 8.83906011495128e-07
role O 0 9.689446187621797e-07
of O 0 1.8092252503265627e-05
alpha O 0 0.0002487958990968764
- O 0 8.438678196398541e-05
MSH O 0 0.29243913292884827
in O 0 4.162471611834917e-08
regulating O 0 6.485181103244031e-08
food O 0 1.0214631807059504e-08
intake O 0 3.933947834156015e-09
and O 0 7.258481593552801e-10
influencing O 0 4.805288966736043e-08
hair O 0 3.0829025376988284e-07
pigmentation O 0 1.2003819392703008e-05
predicts O 0 7.775359911477153e-09
that O 0 5.527090590762285e-11
the O 0 1.1586417381082015e-09
phenotype O 0 7.546263169899703e-09
associated O 0 3.5780745033520134e-10
with O 0 4.872897918506425e-11
a O 0 5.98121108197347e-09
defect O 0 7.5628681770467665e-06
in O 0 1.4232630007882108e-07
POMC O 1 0.9999620914459229
function O 0 4.9362547827058734e-08
would O 0 6.176397615575979e-09
include O 0 1.0651689308360801e-07
obesity B-Disease 1 1.0
, O 0 5.942511482892598e-10
alteration O 0 1.1828676633740542e-06
in O 0 1.7731158763467647e-08
pigmentation O 1 0.8018040657043457
and O 0 3.991185906215833e-07
ACTH B-Disease 0 0.006505838129669428
deficiency I-Disease 1 0.9998553991317749
. O 0 1.344791826340952e-06

The O 0 4.317741513659712e-06
observation O 0 4.618078310159035e-05
of O 0 5.38832296115288e-07
these O 0 6.1792491123924265e-09
symptoms O 0 1.5836189049878158e-05
in O 0 1.5561765209781697e-08
two O 0 8.048138155913875e-09
probands O 0 2.3368966139969416e-06
prompted O 0 2.4996834824264624e-08
us O 0 4.493754701684338e-09
to O 0 1.6641440447884293e-09
search O 0 1.0662375871106633e-08
for O 0 6.241218653002534e-10
mutations O 0 5.231220456813901e-10
within O 0 1.046180697628074e-09
their O 0 2.5937426428868093e-08
POMC O 0 0.00026779077597893775
genes O 0 2.4051334435171157e-07
. O 0 9.701507508452778e-08

Patient O 0 0.00024933781241998076
1 O 0 4.787267243955284e-06
was O 0 1.6794224677596503e-07
found O 0 1.341786237674114e-09
to O 0 3.7565045518661577e-10
be O 0 6.931312190872063e-10
a O 0 3.78684994473133e-09
compound O 0 1.6566305305332207e-07
heterozygote O 0 2.0268403488898912e-07
for O 0 9.940736012126195e-10
two O 0 8.53367987385667e-10
mutations O 0 6.957272535856873e-10
in O 0 3.8574161642657145e-09
exon O 0 2.6028894239971123e-07
3 O 0 1.2170829677415895e-07
( O 0 1.2747417565961427e-09
G7013T O 0 2.0731057759348914e-07
, O 0 3.747303356504972e-09
C7133delta O 0 2.044784878307837e-06
) O 0 4.081739946037999e-10
which O 0 1.441971542170961e-10
interfere O 0 6.891185400093036e-10
with O 0 2.434654561289662e-11
appropriate O 0 1.444554365015449e-09
synthesis O 0 1.3687289524000334e-08
of O 0 8.94174068122311e-09
ACTH O 0 5.178349056222942e-07
and O 0 1.0610222744844577e-07
alpha O 0 4.042130512971198e-06
- O 0 2.131811015715357e-06
MSH O 0 8.760135096963495e-05
. O 0 2.531538711991743e-07

Patient O 0 8.564236486563459e-05
2 O 0 5.7105648920696694e-06
was O 0 3.4380917668386246e-07
homozygous O 0 1.3386018515859632e-08
for O 0 9.339561346521918e-10
a O 0 4.889549654052416e-09
mutation O 0 2.1543840045268325e-09
in O 0 5.469710462335797e-09
exon O 0 1.4739913467565202e-07
2 O 0 1.0137929251641253e-07
( O 0 2.395223741569197e-10
C3804A O 0 3.268033665904113e-08
) O 0 2.9094865405809855e-10
which O 0 9.506018194826993e-10
abolishes O 0 3.8036862406443106e-06
POMC O 0 0.00036716312752105296
translation O 0 2.488068957973155e-06
. O 0 7.423506644954614e-07

These O 0 4.183563717674588e-08
findings O 0 1.7532308049794665e-08
represent O 0 6.381308259584273e-10
the O 0 2.5598585473574076e-09
first O 0 4.827735988754966e-10
examples O 0 2.6442121825454024e-09
of O 0 3.399228987177594e-08
a O 0 2.628535469284543e-07
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
within O 0 5.181085498406901e-07
the O 0 3.058508752928901e-07
POMC O 0 5.211924872128293e-05
gene O 0 7.853789618650353e-09
and O 0 7.044090866159536e-10
define O 0 7.611036245691594e-09
a O 0 4.426298971793585e-08
new O 0 7.641842785233166e-06
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.9986944794654846
resulting O 0 1.042422582031577e-06
in O 0 1.7924776329891756e-08
early O 0 0.08164895325899124
- O 1 0.7981892824172974
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 2.424837248327094e-06
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 3.9420472603524104e-05
red O 0 0.006645769812166691
hair O 0 2.184533059335081e-06
pigmentation O 0 0.00014451293100137264
. O 0 8.361994474626044e-08
. O 0 1.656619446066543e-07

A O 0 6.926467904122546e-06
European O 0 6.804232270951616e-07
multicenter O 0 0.00016830992535687983
study O 0 8.87117550973926e-07
of O 1 0.9998319149017334
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 4.456830637877829e-08
classification O 0 1.461926615320408e-07
of O 0 5.1830802476615645e-06
105 O 0 5.487873977472191e-07
mutations O 0 1.8692603021008836e-09
and O 0 1.935148485898708e-09
a O 0 7.3348487283908526e-09
general O 0 3.1527438437706223e-08
system O 0 1.9757503366690798e-07
for O 0 8.673871065845162e-10
genotype O 0 8.687965902254291e-09
- O 0 1.7158827692043133e-09
based O 0 2.0548170109879749e-10
prediction O 0 6.13298851703803e-08
of O 0 5.2588269738862436e-08
metabolic O 0 0.0005922748241573572
phenotype O 0 1.3874920341550023e-06
. O 0 4.6226467986798525e-08

Phenylketonuria B-Disease 1 0.9945171475410461
( O 0 9.594241419108585e-07
PKU B-Disease 0 0.0024804635904729366
) O 0 1.684005290769619e-08
and O 0 3.7980786515845466e-08
mild B-Disease 1 1.0
hyperphenylalaninemia I-Disease 1 1.0
( O 1 1.0
MHP B-Disease 1 1.0
) O 0 1.0010827509177034e-06
are O 0 1.9177074150888984e-08
allelic B-Disease 1 0.9893476963043213
disorders I-Disease 1 0.9997305274009705
caused O 0 1.405400951171032e-07
by O 0 2.750950023333587e-10
mutations O 0 4.950581611318228e-10
in O 0 3.6633310274147846e-10
the O 0 8.677019103231487e-09
gene O 0 2.0931299360427147e-08
encoding O 0 7.824859267202555e-07
phenylalanine O 0 1.0224738616670948e-05
hydroxylase O 0 0.00016857621085364372
( O 0 1.6582079354066082e-07
PAH O 1 1.0
) O 0 6.944975439182599e-08
. O 0 9.349264473712537e-08

Previous O 0 3.1419438073498895e-06
studies O 0 1.0205011946595732e-08
have O 0 5.233126709747182e-10
suggested O 0 6.517180128895461e-10
that O 0 2.7590726578430314e-11
the O 0 4.711496193188225e-10
highly O 0 1.1446786629676353e-08
variable O 0 3.189527717495366e-07
metabolic O 1 0.9994837045669556
phenotypes O 0 0.00012179701298009604
of O 1 0.9999788999557495
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.00041569952736608684
with O 0 5.944386430201121e-06
PAH O 1 1.0
genotypes O 1 0.9998989105224609
. O 0 1.0341947017877828e-05

We O 0 1.6835758742672624e-07
identified O 0 2.9804297696500726e-08
both O 0 1.035867613907726e-09
causative O 0 1.4531111958149268e-07
mutations O 0 1.2664542303753024e-08
in O 0 2.4187303271361316e-09
686 O 0 1.3137550922692753e-06
patients O 0 3.8418014014496293e-07
from O 0 2.8781781225006853e-07
seven O 0 2.51967861686353e-07
European O 0 9.340406137425816e-08
centers O 0 6.81256949519593e-07
. O 0 2.8347886882329476e-07

On O 0 1.3568834447141853e-06
the O 0 1.352535150545009e-08
basis O 0 5.724973384246823e-09
of O 0 1.2028227303062522e-08
the O 0 6.6945511356664156e-09
phenotypic O 0 4.170163592220888e-08
characteristics O 0 3.8022967885353864e-08
of O 0 1.4828060557192657e-07
297 O 0 8.200743195629911e-08
functionally O 0 1.3316240483618458e-06
hemizygous O 0 1.4082565030548722e-05
patients O 0 7.810620417103564e-08
, O 0 5.120879276176993e-10
105 O 0 1.453903486492436e-08
of O 0 7.139740798578487e-09
the O 0 1.2943771388052028e-08
mutations O 0 2.588397551850363e-10
were O 0 2.9051833161375384e-10
assigned O 0 3.562943939883212e-09
to O 0 8.666363182641135e-10
one O 0 1.1782915754210421e-09
of O 0 9.284045532353957e-09
four O 0 1.5197472169603543e-09
arbitrary O 0 6.189794454769526e-09
phenotype O 0 8.39366549598708e-08
categories O 0 2.1532347460606616e-08
. O 0 4.381729112878929e-08

We O 0 5.136105301062344e-07
proposed O 0 2.431816596981662e-07
and O 0 1.3288842026781822e-08
tested O 0 1.0043158304995359e-08
a O 0 1.3608875137904874e-09
simple O 0 2.9166999926388826e-09
model O 0 4.179523949154884e-10
for O 0 2.5984228657627284e-11
correlation O 0 2.5308546924840414e-10
between O 0 4.19577012022998e-10
genotype O 0 3.7922585960359356e-08
and O 0 1.7454289125140576e-09
phenotypic O 0 5.381688339411994e-08
outcome O 0 2.1105492464812414e-07
. O 0 1.262706490479104e-07

The O 0 2.488011887180619e-06
observed O 0 3.5865988934347115e-07
phenotype O 0 7.812391800143814e-07
matched O 0 2.4164080514310626e-07
the O 0 1.7645473349148233e-07
predicted O 0 2.6507484562898753e-07
phenotype O 0 5.413277222032775e-07
in O 0 5.0268185169954904e-09
79 O 0 2.7227748944369523e-08
% O 0 2.4481741633941567e-10
of O 0 6.439778155176157e-10
the O 0 8.766011250216366e-10
cases O 0 5.129432989470217e-10
, O 0 6.225569365581052e-11
and O 0 1.0718704396284195e-10
in O 0 4.2683984818880916e-11
only O 0 3.759771313727178e-11
5 O 0 2.584736868982418e-10
of O 0 5.134023761677042e-10
184 O 0 3.911412083112964e-09
patients O 0 2.7165278915219915e-09
was O 0 1.57098710928949e-07
the O 0 1.7043628730561977e-08
observed O 0 7.297409343465233e-09
phenotype O 0 8.67807870008619e-09
more O 0 4.4065643495239115e-11
than O 0 4.5055164460405805e-11
one O 0 1.9304030596245525e-10
category O 0 6.855252476789531e-10
away O 0 1.389956483244248e-09
from O 0 2.3551585681680365e-10
that O 0 1.1889421391853006e-10
expected O 0 2.0939566525157716e-08
. O 0 1.1824847234720437e-07

Among O 0 1.3418839444057085e-06
the O 0 5.86434055094287e-07
seven O 0 2.4773560980406728e-08
contributing O 0 3.4781983959675244e-09
centers O 0 6.157671261775022e-09
, O 0 6.43432390701193e-11
the O 0 2.1987943410461952e-10
proportion O 0 3.818150517975738e-10
of O 0 1.7198177326704922e-09
patients O 0 2.8322733047758675e-09
for O 0 7.679114566450096e-10
whom O 0 5.6406928905516907e-08
the O 0 1.9521512228948268e-07
observed O 0 1.9733130685040123e-08
phenotype O 0 1.0463608646205103e-08
did O 0 1.9119941185863354e-09
not O 0 3.5806549392169984e-10
match O 0 1.0654082949201893e-08
the O 0 2.480088845402406e-08
predicted O 0 1.9273219464821523e-08
phenotype O 0 2.0765597241734213e-08
was O 0 4.639146311546938e-08
4 O 0 4.678696097215607e-09
% O 0 1.5658424556974637e-10
- O 0 2.3019894879183767e-09
23 O 0 6.802699292762782e-09
% O 0 2.1504920066917066e-09
( O 0 1.631197288354258e-09
P O 0 6.990424935793271e-06
< O 0 1.2901755326311104e-06
. O 0 7.119071554484435e-09
0001 O 0 5.738127129006898e-07
) O 0 1.4151199656531332e-10
, O 0 2.8715654853961325e-11
suggesting O 0 3.1929661692409184e-10
that O 0 2.204529440941183e-11
differences O 0 8.231890169518863e-10
in O 0 5.293901775282883e-11
methods O 0 1.0222540591797724e-09
used O 0 6.299558652500536e-10
for O 0 1.6658135981728606e-10
mutation O 0 1.023352402818034e-09
detection O 0 6.923727141838754e-06
or O 0 1.4088383792909553e-08
phenotype O 0 4.5917936120076774e-08
classification O 0 2.2801056598353853e-09
may O 0 2.289700928859162e-10
account O 0 6.54548013012679e-11
for O 0 2.62419391772184e-10
a O 0 1.2580416708374287e-09
considerable O 0 2.5571160744419785e-09
proportion O 0 1.5517652718344266e-09
of O 0 2.660909359519792e-08
genotype O 0 1.0982009825966088e-06
- O 0 1.9821607111225603e-06
phenotype O 0 1.01354794423969e-06
inconsistencies O 0 4.696383371083357e-07
. O 0 2.5809666226450645e-07

Our O 0 3.6087069020140916e-05
data O 0 4.2678925638028886e-07
indicate O 0 1.6956018811242757e-08
that O 0 5.0374722171397934e-09
the O 0 3.819014580130897e-07
PAH O 1 1.0
- O 0 6.005974228173727e-06
mutation O 0 6.013491482548261e-09
genotype O 0 1.9072638579586965e-08
is O 0 8.773869131228906e-11
the O 0 2.6526467133969334e-10
main O 0 6.382943507077243e-09
determinant O 0 2.6889138027286208e-08
of O 0 2.848772062691296e-08
metabolic O 1 0.9929105639457703
phenotype O 0 1.585243921908841e-06
in O 0 1.0455902810235784e-09
most O 0 1.614581246478508e-09
patients O 0 6.757117887445929e-08
with O 0 1.0314400924471556e-06
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.0010077389888465405

In O 0 6.551571800628153e-07
the O 0 5.0221828473695496e-08
present O 0 4.503381667575468e-09
study O 0 4.811299691986903e-10
, O 0 4.1533689681960695e-11
the O 0 4.156786859166317e-10
classification O 0 2.615302463482294e-08
of O 0 1.027122948471515e-06
105 O 0 0.00027864318690262735
PAH O 1 1.0
mutations O 0 3.5491032690515567e-07
may O 0 1.104022739895072e-08
allow O 0 3.786026603336268e-09
the O 0 1.8496381315458166e-08
prediction O 0 3.793355176640034e-07
of O 0 3.513546076305829e-08
the O 0 1.1140535605136392e-08
biochemical O 0 2.697786385397194e-07
phenotype O 0 1.2642054514344636e-07
in O 0 1.7060793888745707e-09
> O 0 6.665783303105854e-08
10 O 0 4.0172190018950005e-09
, O 0 1.6648669942664895e-10
000 O 0 2.077525484978082e-09
genotypes O 0 3.2399931626514444e-08
, O 0 1.658199272336347e-10
which O 0 8.033422538300528e-11
may O 0 4.815284282422283e-10
be O 0 6.88886933608579e-11
useful O 0 4.375561302172315e-10
for O 0 3.3768390861332875e-11
the O 0 1.0941234585004622e-09
management O 0 4.807633402492684e-09
of O 0 3.716505503348344e-08
hyperphenylalaninemia B-Disease 1 1.0
in O 0 8.543900520407988e-08
newborns O 0 4.778974016517168e-07
. O 0 2.0762476538038754e-07

Somatic O 0 0.0007064462988637388
instability O 0 0.0003690501907840371
of O 0 4.9319674872094765e-05
the O 0 1.7739463146426715e-05
CTG O 0 0.0021684139501303434
repeat O 0 1.0918849966401467e-06
in O 0 3.093409972620975e-08
mice O 0 1.1779622610674778e-07
transgenic O 0 1.2724764530958055e-07
for O 0 2.7289084325587964e-09
the O 0 3.4212131140520796e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.005100454669445753
is O 0 5.4491549050794674e-09
age O 0 9.63294333189424e-10
dependent O 0 7.876107543935973e-10
but O 0 1.746003168434651e-11
not O 0 5.715406880407725e-12
correlated O 0 3.7078992654038245e-10
to O 0 1.8499254905712803e-10
the O 0 7.2019310515258894e-09
relative O 0 7.696709758420184e-07
intertissue O 0 5.174737907509552e-06
transcription O 0 2.1267334204821964e-07
levels O 0 3.543306092979037e-08
and O 0 1.1345689721053986e-08
proliferative O 0 0.00035919982474297285
capacities O 0 2.7999803933198564e-06
. O 0 2.776440624074894e-07

A O 0 0.00036050236667506397
( O 0 3.5558110766942264e-07
CTG O 0 2.1565208953688852e-05
) O 0 4.647610740704522e-09
nexpansion O 0 1.1070508207922103e-06
in O 0 5.220448517917475e-09
the O 0 5.008464754041597e-08
3 O 0 3.6381877066560264e-07
- O 0 3.002322443990124e-07
untranslated O 1 0.9824486374855042
region O 0 3.623029272148415e-07
( O 0 3.3582410186028255e-09
UTR O 0 0.005073880311101675
) O 0 6.954088416222248e-10
of O 0 9.397442823910751e-09
the O 0 3.4419301186972007e-07
DM O 1 1.0
protein O 0 1.6239483784374897e-06
kinase O 0 1.9071261192493694e-07
gene O 0 1.7822493481034485e-09
( O 0 8.092754244515277e-11
DMPK O 0 2.525881086512527e-07
) O 0 4.145241094821728e-11
is O 0 8.251342317744381e-12
responsible O 0 2.348878036517732e-10
for O 0 4.135166931096279e-10
causing O 0 1.0984408618242014e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 4.155886017542798e-06
DM B-Disease 1 1.0
) O 0 7.576206684234421e-08
. O 0 2.616610288441734e-07

Major O 0 0.0019748536869883537
instability O 1 0.9820480346679688
, O 0 2.670330445653235e-08
with O 0 1.0064247213392719e-09
very O 0 4.357989080716607e-09
large O 0 2.726546322051604e-09
expansions O 0 7.995905093594047e-08
between O 0 2.1078411904795757e-08
generations O 0 3.741299678949872e-07
and O 0 1.1737223415408948e-09
high O 0 7.1945174262566525e-09
levels O 0 7.155183112672603e-10
of O 0 2.0208439366342645e-09
somatic O 0 1.4071953557959205e-07
mosaicism O 0 1.918799625855172e-06
, O 0 4.6459752711669466e-11
is O 0 5.9188973167145775e-12
observed O 0 6.126152363172821e-11
in O 0 1.172636571178387e-10
patients O 0 4.77610129223649e-09
. O 0 2.5938911463185832e-08

There O 0 2.1380053283337475e-07
is O 0 2.0616500506775992e-08
a O 0 8.940308049432133e-09
good O 0 1.0596687971542451e-08
correlation O 0 2.382994468419497e-09
between O 0 4.731147917880207e-09
repeat O 0 1.5258590835287578e-08
size O 0 2.3013761563106527e-08
( O 0 5.577980854987175e-10
at O 0 8.571607312823915e-10
least O 0 3.8342183594775037e-11
in O 0 1.0229595642785583e-10
leucocytes O 0 5.299304461914289e-08
) O 0 5.875752662198863e-11
, O 0 1.4108961395031816e-11
clinical O 0 1.0254410653942614e-09
severity O 0 2.4546579879825003e-07
and O 0 1.6487576859347541e-09
age O 0 7.843819815889219e-09
of O 0 9.336167039464272e-08
onset O 0 0.4702996015548706
. O 0 1.2359987522359006e-06

The O 0 0.00017492986808065325
trinucleotide O 1 0.9996697902679443
repeat O 0 3.5833574656862766e-05
instability O 0 1.580506250320468e-05
mechanisms O 0 1.0076449825646705e-06
involved O 0 7.890651687603167e-09
in O 0 1.901303470219773e-08
DM B-Disease 1 1.0
and O 0 2.6376332584732154e-07
other O 0 6.081522396783612e-09
human O 0 7.004666713328334e-07
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 1.170043284481892e-09
unknown O 0 4.782421001436887e-07
. O 0 2.241880139308705e-07

We O 0 7.128829224711808e-07
studied O 0 1.418801957697724e-06
somatic O 0 2.5669389287941158e-05
instability O 0 2.6174739105044864e-06
by O 0 1.1053839621411043e-08
measuring O 0 2.6458562842890387e-06
the O 0 4.441348266936984e-07
CTG O 0 1.2309226804063655e-05
repeat O 0 4.217180205046134e-08
length O 0 5.131686631187904e-09
at O 0 3.5327496483716914e-09
several O 0 2.4876083831726348e-11
ages O 0 2.4013627197838616e-10
in O 0 3.675198687047576e-11
various O 0 2.725011050142001e-10
tissues O 0 6.560387788567823e-08
of O 0 1.0641454650794913e-07
transgenic O 0 5.975272756586492e-07
mice O 0 1.8732123407971812e-08
carrying O 0 5.0520592154157384e-09
a O 0 8.355792147085594e-08
( O 0 1.4586171381836266e-08
CTG O 0 1.4982167158450466e-05
) O 0 6.477798297765958e-09
55expansion O 0 9.574370096743223e-07
surrounded O 0 2.7891150011782884e-07
by O 0 2.1419774842712513e-09
45 O 0 1.513866187963231e-08
kb O 0 4.5267867676557216e-07
of O 0 8.546295759970235e-08
the O 0 2.1910354064402782e-07
human O 0 9.016136459649715e-07
DM B-Disease 1 1.0
region O 0 4.793772632183391e-07
, O 0 7.200787188743618e-10
using O 0 3.4074452148757928e-09
small O 0 3.1977780423630975e-08
- O 0 7.480004171611654e-08
pool O 0 7.805765278590115e-08
PCR O 0 7.302389803953702e-07
. O 0 1.2757256229178893e-07

These O 0 5.086454279989994e-07
mice O 0 5.300275347508432e-07
have O 0 9.622805885456387e-10
been O 0 1.4980018336885337e-09
shown O 0 9.222146379883611e-10
to O 0 4.758549665417888e-10
reproduce O 0 1.4781631030302833e-08
the O 0 3.311352969603831e-08
intergenerational O 0 1.4842859741293069e-07
and O 0 9.550912949407575e-09
somatic O 0 1.2045525181747507e-06
instability O 0 4.5502761736315733e-07
of O 0 1.8192997686128365e-07
the O 0 7.812600415491033e-07
55 O 0 3.196559248408448e-07
CTG O 0 3.0374917514564004e-06
repeat O 0 3.548323945778975e-08
suggesting O 0 6.950538367078707e-09
that O 0 1.301873053805025e-10
surrounding O 0 1.0143302198173387e-08
sequences O 0 1.0069430844694693e-09
and O 0 5.445099926504327e-10
the O 0 1.0805518702028394e-09
chromatin O 0 1.519472547784062e-08
environment O 0 1.7842357591391078e-09
are O 0 9.649612706108535e-12
involved O 0 1.6193112128970455e-10
in O 0 3.3747221683810835e-10
instability O 0 1.2410262684170448e-07
mechanisms O 0 2.5994042971433373e-06
. O 0 4.4580721692000225e-07

As O 0 4.1496701896903687e-07
observed O 0 4.747421655793005e-08
in O 0 1.504068425361993e-09
some O 0 1.1049528653162e-10
of O 0 1.8354145980836734e-09
the O 0 2.227924511544188e-09
tissues O 0 1.3176884294807678e-07
of O 0 9.897529480440426e-07
DM B-Disease 1 1.0
patients O 0 0.00576659943908453
, O 0 2.184382452696809e-09
there O 0 5.472169384290737e-10
is O 0 4.736210867939405e-10
a O 0 1.453129283568444e-09
tendency O 0 4.217626248248507e-10
for O 0 2.866931414491347e-10
repeat O 0 3.1988258708537387e-09
length O 0 8.592400568829817e-09
and O 0 4.213246640460966e-09
somatic O 0 1.228534642905288e-07
mosaicism O 0 7.125349839043338e-07
to O 0 3.75117742423825e-10
increase O 0 2.764340145677835e-11
with O 0 2.4435078960216572e-11
the O 0 1.274046645960425e-09
age O 0 1.7519730111104082e-09
of O 0 4.614038484618277e-09
the O 0 2.9041281379704742e-08
mouse O 0 7.512975912504771e-07
. O 0 2.4837339296368555e-08

Furthermore O 0 3.3225687730009668e-06
, O 0 2.955386158021156e-08
we O 0 1.9071209056420457e-09
observed O 0 8.742634949321371e-10
no O 0 1.7526037565662733e-10
correlation O 0 3.6392971969334553e-10
between O 0 5.118028223449755e-10
the O 0 4.308671641695128e-09
somatic O 0 5.012340693610895e-07
mutation O 0 2.001347354507743e-08
rate O 0 5.813121095599172e-09
and O 0 1.1662222298980396e-09
tissue O 0 8.74389414207144e-08
proliferation O 0 2.8432307885850605e-07
capacity O 0 2.690642730840409e-08
. O 0 4.37748575166097e-08

The O 0 5.4320107665262185e-06
somatic O 0 2.726545062614605e-05
mutation O 0 8.976124377113592e-08
rates O 0 2.8725981593424876e-09
in O 0 8.309784110815954e-11
different O 0 7.172477889394457e-11
tissues O 0 1.605918669156381e-07
were O 0 1.5013291942977958e-08
also O 0 4.5567422057857243e-10
not O 0 9.571912013006667e-11
correlated O 0 1.6273750125250785e-09
to O 0 2.2847639336021075e-09
the O 0 6.102265359686498e-08
relative O 0 1.872170832939446e-05
inter O 0 0.00043019320582970977
- O 0 6.986559583310736e-06
tissue O 0 4.0015601143750246e-07
difference O 0 1.1297276003574552e-08
in O 0 2.0452997628872538e-10
transcriptional O 0 5.155240678789141e-09
levels O 0 9.425370484095197e-10
of O 0 1.872614951992091e-09
the O 0 3.774547785440063e-09
three O 0 8.841911647294864e-10
genes O 0 1.299031215928892e-09
( O 0 5.05782249415887e-10
DMAHP O 0 4.159193849773146e-05
, O 0 9.265311184947223e-09
DMPK O 0 0.0003591063432395458
and O 0 2.0669425282449083e-07
59 O 0 1.2638329849323782e-07
) O 0 5.182409501536256e-10
surrounding O 0 4.3493553647522276e-08
the O 0 3.158064387775994e-08
repeat O 0 2.6046592438433436e-08
. O 0 5.856200857579097e-09
. O 0 4.603114334145175e-08

A O 0 4.909709787170868e-06
novel O 0 5.507714035957179e-07
missense O 0 8.215121169996564e-07
mutation O 0 6.682253417267248e-09
in O 0 7.245051780735423e-10
patients O 0 6.502705929278818e-09
from O 0 1.7474850011467424e-08
a O 0 2.703091581679473e-07
retinoblastoma B-Disease 1 0.9991282820701599
pedigree O 0 2.8027350708725862e-05
showing O 0 8.41493701386753e-08
only O 0 5.833102445507166e-09
mild O 0 1.886088284663856e-06
expression O 0 1.5655812646286904e-08
of O 0 1.5196297908914858e-07
the O 0 7.436701565666226e-08
tumor B-Disease 0 2.1040268620708957e-06
phenotype O 0 4.663210120270378e-07
. O 0 2.900612905420985e-08

We O 0 5.702177645616757e-07
have O 0 9.49746858935896e-09
used O 0 2.594999415350685e-08
single O 0 3.3712193925339307e-08
strand O 0 3.086408284502795e-08
conformation O 0 2.5976225614954274e-09
polymorphism O 0 2.0235633169107814e-09
analysis O 0 1.165914725875794e-10
to O 0 6.533231594607614e-11
study O 0 9.268430467557209e-11
the O 0 1.0035187125723155e-09
27 O 0 9.312065785138657e-09
exons O 0 7.745611441123401e-08
of O 0 1.2437081586824661e-08
the O 0 1.1404313049467873e-08
RB1 O 0 2.2810324935562676e-06
gene O 0 1.0049839849202158e-09
in O 0 5.992669555032748e-11
individuals O 0 2.766765115624903e-12
from O 0 1.1784804243575309e-09
a O 0 3.29721068226263e-08
family O 0 1.2377616087633214e-07
showing O 0 5.802919034181286e-09
mild O 0 5.628939447888115e-07
expression O 0 5.588454854432712e-08
of O 0 1.4066775975152268e-06
the O 0 1.0189023669227026e-06
retinoblastoma B-Disease 0 9.372158092446625e-05
phenotype O 0 5.146890998730669e-06
. O 0 1.363877117910306e-07

In O 0 1.5286154564364551e-07
this O 0 1.2647210390070995e-08
family O 0 2.5724144592231823e-08
affected O 0 3.458792974253555e-10
individuals O 0 2.551720119925438e-11
developed O 0 6.736303248544573e-07
unilateral B-Disease 1 0.9926067590713501
tumors I-Disease 1 1.0
and O 1 0.7410464882850647
, O 0 3.149599026031069e-09
as O 0 5.319816809290501e-10
a O 0 6.256283824335185e-10
result O 0 8.672282891808436e-10
of O 0 4.866438363393399e-09
linkage O 0 3.475534171570871e-08
analysis O 0 1.6063336216731727e-09
, O 0 1.0749538065235598e-10
unaffected O 0 1.4827028493868966e-09
mutation O 0 7.077297081714562e-11
carriers O 0 1.254324838440013e-10
were O 0 5.652210366413613e-10
also O 0 2.9899693831936247e-10
identified O 0 5.438975381188982e-10
within O 0 2.764279471989539e-09
the O 0 4.495745997701306e-08
pedigree O 0 1.0175041325055645e-06
. O 0 9.957025781659468e-08

A O 0 1.784088453860022e-05
single O 0 3.7887815551584936e-07
band O 0 3.724244095337781e-07
shift O 0 9.447120419281418e-08
using O 0 1.0038600173345458e-08
SSCP O 0 1.2317153959884308e-05
was O 0 8.342288282392474e-08
identified O 0 4.9024926340734964e-09
in O 0 1.1631343665996496e-09
exon O 0 2.0852995774589544e-08
21 O 0 2.8225768389233963e-09
which O 0 4.419593857551973e-11
resulted O 0 4.728838653988987e-09
in O 0 1.9417962793255583e-09
a O 0 2.5334218278771914e-08
missense O 0 1.3572169166309322e-07
mutation O 0 8.481741531340958e-09
converting O 0 2.6499344585317886e-07
a O 0 1.0249198822975814e-07
cys O 0 9.158441571344156e-06
- O 0 2.258802851429209e-06
- O 0 2.2094677660788875e-06
> O 0 1.366434389638016e-06
arg O 0 7.58948260681791e-07
at O 0 9.77084457787214e-09
nucleotide O 0 2.176820945720692e-09
position O 0 6.150980169650211e-09
28 O 0 3.86302723143217e-09
in O 0 1.0360019508937057e-09
the O 0 3.57577185639002e-08
exon O 0 1.2984072554900195e-06
. O 0 1.1055404058879503e-07

The O 0 3.607067583288881e-06
mutation O 0 4.4738135329680517e-07
destroyed O 0 9.816847523325123e-06
an O 0 9.83212622429619e-09
NdeI O 0 3.6208673463988816e-06
restriction O 0 6.90303210149068e-08
enzyme O 0 2.2259722243234137e-07
site O 0 5.961816782473761e-07
. O 0 8.538035700667024e-08

Analysis O 0 2.165238583984319e-07
of O 0 2.7136504741065437e-06
all O 0 1.6122246648819782e-08
family O 0 7.750843167286803e-08
members O 0 1.5907010431082114e-10
demonstrated O 0 2.7566346982865753e-09
that O 0 2.1910911973677116e-10
the O 0 1.3892786476787933e-08
missense O 0 1.6614782794022176e-07
mutation O 0 6.022114007464552e-08
co O 0 1.4748295598110417e-06
- O 0 4.149078449700028e-06
segregated O 0 1.0088702140365058e-07
with O 0 2.239478602561462e-09
patients O 0 1.3524572750611696e-06
with O 0 4.324050678405911e-06
tumors B-Disease 1 1.0
or O 1 1.0
who O 0 0.011628382839262486
, O 0 6.516201356276952e-09
as O 0 3.662816050464812e-09
a O 0 3.590313379930876e-09
result O 0 2.5675652715051456e-09
of O 0 2.271884724791562e-08
linkage O 0 3.1781382858753204e-08
analysis O 0 1.663242876759341e-09
had O 0 4.8059276558376496e-09
been O 0 5.600923613791053e-10
predicted O 0 1.4243629609111963e-09
to O 0 1.3923331931842142e-10
carry O 0 9.957966673468377e-10
the O 0 2.134022558664128e-08
predisposing O 0 1.8278349216416245e-06
mutation O 0 1.2995378995128704e-07
. O 0 2.1678977191186277e-07

These O 0 1.1692033297094895e-07
observations O 0 3.6170669659441046e-07
point O 0 1.6693687143742864e-07
to O 0 2.2298543012055916e-09
another O 0 1.2865788434623937e-09
region O 0 4.594147728909093e-09
of O 0 7.719064853972668e-08
the O 0 4.6295997435663594e-07
RB1 O 0 3.832383663393557e-05
gene O 0 1.3568786094708685e-08
where O 0 2.139025623293378e-09
mutations O 0 1.304274049873655e-10
only O 0 2.621351052889409e-11
modify O 0 1.6087375875883936e-09
the O 0 3.880218368834676e-09
function O 0 4.85252338311426e-10
of O 0 3.4399783022109887e-09
the O 0 1.7921690798061718e-09
gene O 0 6.857174827956669e-10
and O 0 1.8501124243730516e-10
raise O 0 3.401164350158581e-10
important O 0 5.606684561065833e-10
questions O 0 1.175010422294065e-09
for O 0 1.1137635952396252e-10
genetic O 0 4.959032740003977e-09
counseling O 0 7.321873662924361e-10
in O 0 9.405987100308266e-11
families O 0 1.9215122548654762e-11
with O 0 6.651267644292025e-12
these O 0 7.246291067186661e-11
distinctive O 0 2.217733374720865e-08
phenotypes O 0 1.4371410372859827e-07
. O 0 7.081193409419484e-09
. O 0 5.817128467811017e-08

Maternal B-Disease 0 0.0006729287561029196
disomy I-Disease 0 0.003910407889634371
and O 0 9.383730503031984e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 1 0.9998394250869751
with O 0 3.385528373200941e-07
gamete O 0 8.948942195274867e-06
complementation O 0 1.2116925063310191e-05
in O 0 7.294000514690424e-09
a O 0 7.5226385121141e-09
case O 0 4.3313740150097146e-08
of O 0 1.9289554131773912e-07
familial O 0 1.637779746488377e-06
translocation O 0 8.66237826357974e-07
( O 0 1.5061555336259858e-09
3 O 0 1.2330743537347644e-08
; O 0 5.371039168977632e-10
15 O 0 7.150520620058387e-09
) O 0 3.118656166645195e-10
( O 0 4.875614911803439e-10
p25 O 0 1.4673180714908085e-07
; O 0 6.167282795566109e-10
q11 O 0 3.1679704193265934e-08
. O 0 8.343457591486469e-10
2 O 0 1.4607329568150362e-08
) O 0 6.013500253310156e-10
. O 0 1.728273169021577e-08

Maternal B-Disease 1 0.9595733880996704
uniparental I-Disease 1 0.9999995231628418
disomy I-Disease 1 0.9999953508377075
( I-Disease 0 2.7333533580531366e-05
UPD I-Disease 1 1.0
) I-Disease 0 5.4502386603871855e-08
for I-Disease 0 1.0926663129851022e-08
chromosome I-Disease 0 7.381348865465043e-08
15 I-Disease 0 1.9726432043398745e-08
is O 0 5.460606966600778e-10
responsible O 0 1.8101568022288461e-09
for O 0 5.402540081966833e-10
an O 0 7.183238726060637e-11
estimated O 0 7.012691122243453e-11
30 O 0 3.4892400080366315e-10
% O 0 2.133754631317153e-11
of O 0 8.143837687546451e-11
cases O 0 1.3634382511895637e-10
of O 0 3.3201663995896524e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.8971664905548096
PWS B-Disease 1 1.0
) O 0 9.067891824088292e-07
. O 0 5.48281036572007e-07

We O 0 3.8552934711333364e-07
report O 0 2.3215239508544983e-08
on O 0 1.9403422868435882e-08
an O 0 7.207558161415051e-11
unusual O 0 3.9455930189724597e-10
case O 0 2.531251652726496e-09
of O 0 1.4623247501788228e-08
maternal B-Disease 0 4.917919795843773e-06
disomy I-Disease 0 0.0009245903929695487
15 I-Disease 0 4.22927143972629e-07
in O 0 1.6315628670326987e-07
PWS B-Disease 1 1.0
that O 0 1.9294265030112e-07
is O 0 3.6668492686686704e-09
most O 0 2.2221770257235818e-10
consistent O 0 1.3948884269865403e-09
with O 0 1.468814098126714e-10
adjacent O 0 6.973512967078932e-08
- O 0 1.1109093378536272e-07
1 O 0 3.985510232951128e-08
segregation O 0 4.779964868362185e-09
of O 0 8.855211008906849e-10
a O 0 2.5353104060599208e-09
paternal O 0 2.885966665644446e-08
t O 0 1.2709017838119507e-08
( O 0 3.159338346492291e-10
3 O 0 6.124522666794974e-09
; O 0 3.6308317463706885e-10
15 O 0 3.865429754057459e-09
) O 0 1.8537896218084882e-10
( O 0 3.730635522725123e-10
p25 O 0 1.442588342115414e-07
; O 0 6.247054540331476e-10
q11 O 0 3.270640291930249e-08
. O 0 2.4045893054491785e-10
2 O 0 7.55127016471846e-10
) O 0 2.261590220653531e-12
with O 0 4.008449388387403e-12
simultaneous O 0 3.0612847812250266e-09
maternal O 0 1.3523073505439243e-07
meiotic O 0 4.52354697699775e-06
nondisjunction O 0 4.028995135740843e-06
for O 0 6.4921961140385065e-09
chromosome O 0 4.481448456772341e-08
15 O 0 2.7201171093338417e-08
. O 0 6.325426227249409e-08

The O 0 1.1306176020298153e-05
patient O 0 3.079501766478643e-06
( O 0 4.4121613029801665e-09
J O 0 4.977922571924864e-07
. O 0 2.31658181526484e-09
B O 0 3.537039461321001e-08
. O 0 2.1948305672925272e-10
) O 0 1.7089111375989674e-11
, O 0 1.984535452637104e-11
a O 0 7.591416384400418e-10
17 O 0 1.7727971313163948e-09
- O 0 4.856516966356139e-09
year O 0 7.324000961261845e-09
- O 0 3.187025185980019e-07
old O 0 3.0662761218991363e-06
white O 0 2.1118074755577254e-07
male O 0 2.2565609381075546e-09
with O 0 7.772019694485266e-10
PWS B-Disease 1 1.0
, O 0 2.7875881158934135e-08
was O 0 6.970581125642639e-07
found O 0 5.714325901351458e-09
to O 0 2.6404625153020334e-09
have O 0 2.7856308371099203e-09
47 O 0 2.6398344843414634e-08
chromosomes O 0 1.3261741704795327e-09
with O 0 1.0528186100700054e-09
a O 0 7.33987576495565e-07
supernumerary O 0 0.001742514199577272
, O 0 1.4405544312978691e-08
paternal O 0 2.580686214059824e-06
der O 0 7.379605813184753e-05
( O 0 2.872937887588023e-09
15 O 0 5.360050625569102e-09
) O 0 5.550268231124811e-11
consisting O 0 5.564538829716525e-10
of O 0 4.954752341745916e-08
the O 0 2.3378723312816874e-07
short O 0 1.4535271475324407e-07
arm O 0 6.367089895320532e-07
and O 0 1.0234563418975995e-08
the O 0 1.5664690522498859e-07
proximal O 0 0.00035134784411638975
long O 0 5.751512617280241e-06
arm O 0 2.0202262476232136e-06
of O 0 3.1568782787871896e-07
chromosome O 0 4.297699973676572e-08
15 O 0 2.7424031046052733e-08
, O 0 5.368007705008893e-10
and O 0 1.7870839030820207e-08
distal O 0 0.022128941491246223
chromosome O 0 0.00010442122584208846
arm O 1 0.9960466027259827
3p O 1 0.9999983310699463
. O 0 7.462388020940125e-05

The O 0 6.177312752697617e-05
t O 0 2.1718492462241556e-06
( O 0 7.2567689635150145e-09
3 O 0 3.9945284413533955e-08
; O 0 5.692479820851304e-10
15 O 0 2.584082503531704e-09
) O 0 1.659635762152334e-10
was O 0 8.845796095613423e-09
present O 0 1.2160283890949586e-09
in O 0 9.921377053245806e-10
the O 0 1.82562109873885e-09
balanced O 0 4.94652319105171e-10
state O 0 3.348030533367741e-11
in O 0 2.5568210743065478e-11
the O 0 2.255079734059251e-10
patients O 0 2.7686261616644003e-10
father O 0 2.2026624080240254e-08
and O 0 3.402444548328276e-09
a O 0 2.2906671404143708e-07
sister O 0 1.5310799426515587e-05
. O 0 1.4297360166892759e-06

Fluorescent O 0 2.5520570488879457e-05
in O 0 1.6458984930523002e-07
situ O 0 3.7328140933823306e-06
hybridization O 0 3.325581587887427e-08
analysis O 0 2.433343304630853e-09
demonstrated O 0 5.811292336233009e-09
that O 0 2.2600833704533585e-10
the O 0 1.8101509624557366e-08
PWS B-Disease 1 1.0
critical O 0 2.9778422685922123e-05
region O 0 2.075261846812282e-07
resided O 0 4.2264528588020767e-07
on O 0 4.563444022664953e-08
the O 0 2.106276708602195e-09
derivative O 0 4.491963245811803e-09
chromosome O 0 2.619049865870693e-09
3 O 0 2.544825683514773e-09
and O 0 7.43586858753531e-11
that O 0 3.438899165431053e-11
there O 0 3.33693905840704e-10
was O 0 2.7383261880231657e-08
no O 0 6.872625246678865e-10
deletion O 0 4.120446206457018e-09
of O 0 2.8176712074667876e-09
the O 0 5.5215355843074576e-08
PWS B-Disease 1 1.0
region O 0 2.560906295911991e-06
on O 0 1.5483580000363872e-06
the O 0 3.082225674688743e-08
normal O 0 1.0963509211592282e-08
pair O 0 2.819198208214857e-09
of O 0 1.6257988288970182e-09
15s O 0 1.8854539973744977e-07
present O 0 4.37289564558796e-08
in O 0 5.443028783247428e-08
J O 0 7.052975706756115e-05
. O 0 3.7835820876352955e-07

B O 0 0.0007227743626572192
. O 0 6.2502463151759e-06

Methylation O 0 1.6229388393185218e-06
analysis O 0 5.091161483505857e-07
at O 0 5.262770628178259e-07
exon O 0 5.649004037877603e-07
alpha O 0 2.748003851138492e-07
of O 0 8.144595398107413e-08
the O 0 6.269919339274566e-08
small O 0 3.2946708472536557e-08
nuclear O 0 3.5677444429893512e-06
ribonucleoprotein O 0 8.663529115437996e-06
- O 0 3.392493397313956e-07
associated O 0 8.548985874767823e-08
polypeptide O 0 4.124077577216667e-07
N O 0 1.20200226660927e-07
( O 0 7.298129323096703e-10
SNRPN O 0 1.0521756621528766e-06
) O 0 3.178637908440862e-10
gene O 0 8.7134843784753e-10
showed O 0 5.819808523988002e-10
a O 0 7.562801496163729e-10
pattern O 0 3.1762454888450975e-09
characteristic O 0 7.259053358410483e-09
of O 0 1.9189295485944058e-08
only O 0 5.583676299103502e-10
the O 0 2.7381994449626745e-09
maternal O 0 1.230400759055783e-08
chromosome O 0 1.5808718778487219e-09
15 O 0 2.002171095583094e-09
in O 0 2.7001523239533753e-09
J O 0 2.9436052500386722e-05
. O 0 9.247797834177618e-07

B O 0 0.0002677165321074426
. O 0 3.934388587367721e-06

Maternal B-Disease 0 0.00032922360696829855
disomy I-Disease 0 8.532850915798917e-05
was O 0 4.2622716023288376e-07
confirmed O 0 1.3094625828102835e-08
by O 0 4.0168188220057743e-10
polymerase O 0 2.1197233479597344e-07
chain O 0 2.0575253500965118e-08
reaction O 0 3.514429414153142e-09
analysis O 0 2.9365274656356632e-09
of O 0 5.7763749339301285e-08
microsatellite O 0 2.004877387662418e-06
repeats O 0 9.523540001055153e-08
at O 0 1.1174138947467327e-08
the O 0 2.951621613789257e-09
gamma O 0 7.088642206554141e-08
- O 0 4.0318209215683964e-08
aminobutyric O 0 4.5460689079845906e-07
acid O 0 4.202341585823888e-08
receptor O 0 3.334212905770073e-08
beta3 O 0 3.6619729826270486e-07
subunit O 0 2.9417988045565835e-08
( O 0 5.674700709334957e-10
GABRB3 O 0 6.129831717771594e-07
) O 0 1.125565307624754e-09
locus O 0 8.443119980938718e-08
. O 0 2.2515406428169626e-08

A O 0 7.538768841186538e-05
niece O 0 5.708276148652658e-05
( O 0 5.293301352793378e-09
B O 0 1.447832715939512e-07
. O 0 4.4606018878567966e-10
B O 0 6.938074559315055e-09
. O 0 3.629694114715143e-11
) O 0 4.314034806468525e-12
with O 0 1.5360594740609912e-11
45 O 0 8.509251636645843e-10
chromosomes O 0 4.292223521051852e-10
and O 0 5.449609097318842e-10
the O 0 1.4607907106167772e-09
derivative O 0 1.9325453237684087e-08
3 O 0 6.547584252558636e-09
but O 0 1.942173089020116e-10
without O 0 9.113261811855011e-10
the O 0 1.2419445027944676e-08
der O 0 3.4643466051420546e-07
( O 0 2.3918364511210655e-10
15 O 0 2.407192223330412e-09
) O 0 2.0981963388955194e-10
demonstrated O 0 1.08032782719647e-08
a O 0 2.0078090301467455e-08
phenotype O 0 4.1046344989581485e-08
consistent O 0 5.660520940864444e-09
with O 0 6.55940232685559e-11
that O 0 4.8877263347790745e-11
reported O 0 5.29889465639144e-10
for O 0 1.5483084259138025e-10
haploinsufficiency O 0 2.2332037019623385e-07
of O 0 4.401816511290235e-08
distal O 0 8.306329982588068e-05
3 O 0 2.2885671569383703e-05
p O 0 3.806381209869869e-05
. O 0 5.65826724141516e-07

Uniparental B-Disease 1 1.0
disomy I-Disease 1 1.0
associated O 0 9.586883243173361e-05
with O 0 2.048136735766093e-07
unbalanced O 0 3.2475094485562295e-05
segregation O 0 1.2981427062186413e-05
of O 0 9.724105893837987e-07
non O 0 8.621519555163104e-06
- O 0 1.1671378160826862e-05
Robertsonian O 0 0.0007186383591033518
translocations O 0 2.487250094418414e-05
has O 0 6.857272438764994e-08
been O 0 5.037443795430363e-09
reported O 0 3.738822140775255e-09
previously O 0 4.719305835010346e-09
but O 0 3.347048749269277e-10
has O 0 1.009423170050816e-10
not O 0 5.886677950650565e-11
, O 0 4.5982721103010604e-11
to O 0 2.6134050479242887e-10
our O 0 5.701033867211436e-09
knowledge O 0 3.0005530504695344e-08
, O 0 1.3608790483399247e-10
been O 0 1.1172145153448554e-10
observed O 0 1.1517865133869876e-10
in O 0 4.741514125772284e-11
a O 0 6.755372372602153e-10
case O 0 1.2373056357262158e-08
of O 0 3.600018487759371e-07
PWS B-Disease 1 1.0
. O 0 0.00016109018179122359

Furthermore O 0 9.847282854025252e-06
, O 0 4.3088792978096535e-08
our O 0 3.178040941520521e-08
findings O 0 2.374935581528348e-09
are O 0 9.398975348018368e-11
best O 0 1.5343801784695188e-09
interpreted O 0 3.1442870529474476e-09
as O 0 2.0133954503620544e-09
true O 0 2.971886381430977e-08
gamete O 0 4.2587771531543694e-07
complementation O 0 8.252474685832567e-07
resulting O 0 3.101083834167184e-08
in O 0 4.7892761756429536e-08
maternal B-Disease 0 0.0001508815767010674
UPD I-Disease 1 1.0
15 I-Disease 0 1.145084297604626e-05
and O 0 5.298079486237839e-06
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9999957084655762
- I-Disease 1 0.9999998807907104
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
type I-Disease 0 0.009881366975605488
2 I-Disease 0 4.894816083833575e-05
and O 0 1.0789464965910156e-07
Stuve B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999995231628418
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 8.556971242690281e-10
a O 0 2.3544142191411765e-09
case O 0 3.1600029259948315e-09
for O 0 5.329434671352828e-10
" O 0 5.083512277792579e-09
lumping O 0 4.8420353948586126e-08
" O 0 1.7175732835994495e-08
. O 0 2.3293834416904247e-08

Recent O 0 4.292367066227598e-07
studies O 0 4.915978735198223e-08
demonstrated O 0 8.437791620963253e-08
the O 0 2.0445567017191024e-08
existence O 0 4.666533115482707e-08
of O 0 1.267426199547117e-07
a O 0 3.311732044153359e-08
genetically O 0 1.3204252802268002e-08
distinct O 0 5.978644690429746e-09
, O 0 2.3625371103896953e-10
usually O 0 3.846401530616106e-10
lethal O 0 4.313918111620296e-09
form O 0 2.3929600523331374e-09
of O 0 3.611951342463726e-07
the O 0 1.0476958323124563e-06
Schwartz B-Disease 1 0.9468682408332825
- I-Disease 1 0.9962007403373718
Jampel I-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
( O 0 8.719794664102665e-08
SJS B-Disease 1 0.8420822620391846
) O 0 4.250691798546313e-09
of O 0 5.488701049216616e-07
myotonia B-Disease 1 1.0
and O 1 0.6789213418960571
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 1.6076776887530286e-07
which O 0 2.419253064545046e-08
we O 0 1.0003663675206553e-07
called O 0 4.2785309233295266e-06
SJS B-Disease 0 0.03494838625192642
type I-Disease 0 3.600151467253454e-05
2 I-Disease 0 8.62534398038406e-06
. O 0 2.2996961490662216e-07

This O 0 1.0349557442168589e-06
disorder O 1 0.9573662877082825
is O 0 1.0808781425453162e-08
reminiscent O 0 1.2465293366403785e-06
of O 0 3.506815176024247e-07
another O 0 4.364177907945077e-09
rare O 0 2.2883236638904236e-08
condition O 0 6.283618859015405e-06
, O 0 1.0358597313242512e-09
the O 0 1.9089404190708592e-07
Stuve B-Disease 1 0.9999994039535522
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 4.2018429667223245e-05
SWS B-Disease 1 0.999799907207489
) O 0 9.16501652348245e-10
, O 0 1.0178138193372988e-10
which O 0 1.0152659962736621e-10
comprises O 0 1.0340239775530335e-09
campomelia B-Disease 0 2.825018327712314e-06
at O 0 3.455281927244869e-08
birth O 0 2.3784305369645153e-07
with O 0 2.85952364009745e-08
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 3.1978578363123233e-07
contractures B-Disease 1 0.9997915625572205
, O 0 8.744440727070923e-09
and O 0 8.217368119289858e-09
early B-Disease 0 5.500320639839629e-06
death I-Disease 0 3.4575608879094943e-05
. O 0 1.6872513697308023e-06

To O 0 3.9257159301087086e-07
test O 0 9.284332236347836e-08
for O 0 3.072346155263972e-09
possible O 0 9.022176783446412e-08
nosologic O 0 5.979678826406598e-05
identity O 0 1.1399021815350352e-07
between O 0 1.5644888051724593e-08
these O 0 1.7922998196695517e-08
disorders O 0 0.0014354794984683394
, O 0 4.4680270594454896e-10
we O 0 2.831116174828452e-10
reviewed O 0 2.3380712921294844e-09
the O 0 8.831293474287349e-10
literature O 0 1.9399629125338436e-10
and O 0 4.56037395346609e-11
obtained O 0 2.4604576709386095e-10
a O 0 3.2602606725440353e-10
follow O 0 3.2112704162479133e-10
- O 0 2.975384161274519e-09
up O 0 8.258751460488156e-10
of O 0 9.985621218788765e-10
the O 0 4.616069193552619e-10
only O 0 4.180917417828667e-11
two O 0 1.219967876719963e-10
surviving O 0 1.4377866364156944e-07
patients O 0 9.72028502133071e-09
, O 0 5.220247012438506e-10
one O 0 3.5405274267930054e-09
with O 0 9.521120780675574e-09
SJS B-Disease 1 0.5937482118606567
type I-Disease 1 0.8022449016571045
2 I-Disease 0 0.0007094073807820678
at O 0 4.5037531037905865e-08
age O 0 9.747050944142188e-10
10 O 0 1.7962165088647453e-10
years O 0 1.9970976261607376e-10
and O 0 1.1766985996697343e-10
another O 0 7.394460044274354e-10
with O 0 9.999725492093603e-10
SWS B-Disease 0 2.0213141397107393e-05
at O 0 2.7621570808378237e-08
age O 0 2.888884242935319e-09
7 O 0 2.6733729896477598e-08
years O 0 6.502308469436002e-09
. O 0 5.471820330171795e-08

Patients O 0 9.103564480028581e-06
reported O 0 8.520417082991116e-08
as O 0 4.7365293909251704e-09
having O 0 1.1751543738114378e-08
either O 0 1.4217004036254366e-06
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 1 0.9257588386535645
SWS B-Disease 1 0.9637259244918823
presented O 0 4.438125955630312e-08
a O 0 1.683805428420726e-09
combination O 0 1.4252712787765631e-08
of O 0 2.2501582819245414e-08
a O 0 2.984132763117486e-08
severe O 0 1.8123699192074127e-05
, O 0 7.503293097954611e-09
prenatal O 0 0.030998453497886658
- O 0 0.02781757339835167
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 1.4832919781326837e-08
with O 0 1.25280593010757e-07
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 1.0
respiratory O 1 1.0
and O 1 1.0
feeding O 1 0.9961161613464355
difficulties O 0 0.011976898647844791
, O 0 7.702045223823006e-09
tendency O 0 2.773047214077451e-08
to O 0 8.821083241628003e-08
hyperthermia B-Disease 1 1.0
, O 0 5.099672684139023e-09
and O 0 8.774040383130455e-10
frequent O 0 2.1245463166508216e-09
death O 0 3.412397120428068e-07
in O 0 5.902885735764585e-09
infancy O 0 8.848294896779407e-07
) O 0 6.280791164936517e-11
with O 0 2.916240859907049e-11
a O 0 2.853235425703815e-09
distinct O 0 9.665859579399694e-08
campomelic B-Disease 1 0.962361752986908
- I-Disease 1 0.9994919300079346
metaphyseal I-Disease 1 0.9999887943267822
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.0035261735320091248

The O 0 8.44952978695801e-07
similarity O 0 5.845924988534534e-07
of O 0 1.655670075706439e-06
the O 0 1.65730668300057e-07
clinical O 0 9.527025213174056e-07
and O 0 9.976031556391263e-09
radiographic O 0 0.014111516997218132
findings O 0 4.128388354729395e-06
is O 0 2.0612883844250973e-08
so O 0 7.12064296415349e-10
extensive O 0 2.5074097464994338e-08
that O 0 2.3799270887359114e-10
these O 0 1.5684885612543553e-09
disorders O 0 6.78925914598949e-07
appear O 0 8.307320165101828e-09
to O 0 2.1377122294552464e-09
be O 0 1.987196629471555e-09
a O 0 2.1721312748468335e-08
single O 0 1.5154871135791836e-08
entity O 0 5.680619352688154e-08
. O 0 3.30836115836064e-07

The O 0 4.360150796856033e-06
follow O 0 3.265838017796341e-07
- O 0 7.678036695324408e-07
up O 0 1.9230331105291043e-08
observation O 0 1.3751851213328337e-07
of O 0 7.273203816993146e-09
an O 0 1.5326361013645595e-10
identical O 0 1.3701936252275004e-09
and O 0 1.2243975833214904e-09
unique O 0 5.246141299153351e-09
pattern O 0 4.018290553631232e-07
of O 1 0.7924386262893677
progressive O 1 1.0
bone B-Disease 1 1.0
dysplasia I-Disease 1 1.0
in O 0 6.31965895081521e-06
the O 0 0.01538520772010088
two O 0 3.1268643851944944e-07
patients O 0 8.565846343344674e-08
( O 0 2.402151810798614e-09
one O 0 9.678400303414492e-09
with O 0 6.39874064845003e-09
SJS B-Disease 0 0.0027029968332499266
type I-Disease 0 0.0003659610520116985
2 I-Disease 0 1.3822309483657591e-05
, O 0 7.962840942177252e-10
one O 0 8.212318602929258e-10
with O 0 2.2709825131528305e-09
SWS B-Disease 0 2.428314292046707e-05
) O 0 1.7505467075906722e-09
surviving O 0 3.832364200206939e-06
beyond O 0 4.300096406950615e-06
infancy O 0 5.807743491459405e-06
adds O 0 3.5997069769422296e-09
to O 0 3.66404406815235e-10
the O 0 7.084675068824708e-10
evidence O 0 1.8821362246512763e-09
in O 0 1.6085864584791665e-10
favor O 0 4.618880833362482e-09
of O 0 3.7150793552598316e-09
identity O 0 1.6877867992093343e-08
. O 0 5.695699911711927e-08

The O 0 9.102592230192386e-06
hypothesis O 0 1.2325344869168475e-05
that O 0 8.865325185070105e-08
SWS B-Disease 1 0.5097219944000244
and O 0 6.987000347180583e-07
SJS B-Disease 1 0.9967693090438843
type I-Disease 0 2.6674330001696944e-05
2 I-Disease 0 6.475490863522282e-07
are O 0 9.024797575918342e-11
the O 0 3.1585687398916207e-09
same O 0 3.7124583407432965e-09
disorder O 0 5.493361641129013e-07
should O 0 2.41305225801014e-10
be O 0 2.3133089888105474e-10
testable O 0 2.2113288977720913e-09
by O 0 2.8716844440584977e-12
molecular O 0 4.837543698954505e-10
methods O 0 2.5296058581147918e-09
. O 0 1.2785501546375144e-09
. O 0 2.3291969242222876e-08

A O 0 2.8334095532045467e-06
mouse O 0 2.990911127653817e-07
model O 0 2.0708394998791846e-09
of O 0 3.4746643340355376e-09
severe O 0 0.12126396596431732
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.9999874830245972
defects O 1 1.0
in O 0 2.3351467461907305e-05
hemostasis O 1 1.0
and O 0 0.0005119232810102403
thrombosis B-Disease 1 1.0
. O 0 0.0003596586175262928

von B-Disease 1 0.9999992847442627
Willebrand I-Disease 1 1.0
factor I-Disease 0 0.0377953015267849
( I-Disease 0 1.021897674036154e-06
vWf I-Disease 1 0.7830321192741394
) I-Disease 0 6.829430390098423e-07
deficiency I-Disease 1 1.0
causes O 0 0.08159294724464417
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 1 0.9999984502792358
humans O 1 0.9885382652282715
. O 0 2.937845238193404e-06

We O 0 8.970251315076894e-07
generated O 0 2.807501608970142e-08
a O 0 1.157575457710891e-08
mouse O 0 3.492606381882979e-08
model O 0 5.995279273030008e-10
for O 0 2.4848010801714615e-11
this O 0 1.3550661460970392e-11
disease O 0 3.5073824400377873e-10
by O 0 7.785498808143831e-12
using O 0 3.7174449629695516e-10
gene O 0 1.6690521187356921e-09
targeting O 0 3.5570653977856637e-08
. O 0 8.420090580329997e-08

vWf B-Disease 1 0.9967225193977356
- I-Disease 1 1.0
deficient I-Disease 1 1.0
mice O 0 0.00015302200336009264
appeared O 0 2.2855064685245452e-07
normal O 0 5.1199176454019835e-08
at O 0 8.79062778125217e-09
birth O 0 1.6034592542624182e-09
; O 0 6.019888754149605e-11
they O 0 1.2884127098544695e-10
were O 0 3.5483695981497476e-09
viable O 0 2.986983247410535e-07
and O 0 2.0330384487010633e-08
fertile O 0 9.122849405684974e-06
. O 0 1.803080493800735e-07

Neither O 0 0.00032422866206616163
vWf O 0 0.0039346725679934025
nor O 0 0.0001523754035588354
vWf O 0 0.0005563507438637316
propolypeptide O 0 0.0002936190867330879
( O 0 7.84570843848087e-08
von B-Disease 1 0.8444714546203613
Willebrand I-Disease 1 0.9999997615814209
antigen O 0 0.01064867153763771
II O 1 1.0
) O 0 6.601722901677931e-08
were O 0 7.162163750962236e-09
detectable O 0 6.941161956319775e-08
in O 0 1.3675045540395558e-09
plasma O 0 3.276809579233486e-08
, O 0 1.602229460218041e-10
platelets O 0 2.846257629585125e-08
, O 0 1.8691095893252907e-10
or O 0 6.10634653952502e-10
endothelial O 0 6.203717539676745e-09
cells O 0 2.6309108225319733e-09
of O 0 1.8291180126084328e-08
the O 0 1.7018007270053204e-07
homozygous O 0 2.7468536245578434e-07
mutant O 0 1.5960781638568733e-06
mice O 0 8.380258122997475e-07
. O 0 1.621528156192653e-07

The O 0 0.00018668212578631938
mutant O 0 0.00124540482647717
mice O 0 5.593718924501445e-06
exhibited O 0 8.359889136499987e-08
defects O 0 0.02117645926773548
in O 0 3.378113078156275e-08
hemostasis O 0 0.01239553652703762
with O 0 6.023467058469123e-09
a O 0 4.2776312625392166e-07
highly O 0 0.0001031738065648824
prolonged O 1 0.9999995231628418
bleeding O 1 0.9999948740005493
time O 0 1.9702572444657562e-06
and O 0 8.839306531172042e-08
spontaneous O 0 6.498157745227218e-08
bleeding O 0 2.1869936972507276e-07
events O 0 1.0970568897761268e-10
in O 0 2.5324565361417584e-11
approximately O 0 1.0572687690613147e-11
10 O 0 3.238282905715373e-11
% O 0 2.3608151891729712e-11
of O 0 1.6622025977852672e-09
neonates O 0 1.052337211149279e-06
. O 0 4.502417993990093e-07

As O 0 5.967436891296529e-07
in O 0 1.8991217487496215e-08
the O 0 2.8332149071275126e-08
human O 0 2.7508059829983722e-08
disease O 0 8.642615512144403e-07
, O 0 2.5246160717529165e-10
the O 0 6.832294729974819e-09
factor O 0 3.4308591523313225e-08
VIII O 1 1.0
level O 0 0.018093740567564964
in O 0 1.8639493504224447e-08
these O 0 3.169914997158685e-09
mice O 0 1.8381236088771402e-08
was O 0 5.1571684700491005e-09
reduced O 0 5.1559099212283854e-09
strongly O 0 1.29279498217727e-09
as O 0 8.627736303168376e-10
a O 0 8.311912824687795e-10
result O 0 7.593212170142749e-10
of O 0 5.118010903970571e-09
the O 0 2.4533359788136977e-09
lack O 0 1.601003063456119e-08
of O 0 1.4745468179810928e-09
protection O 0 7.87838061455659e-09
provided O 0 1.607746824561218e-09
by O 0 7.088405973298961e-10
vWf O 0 5.355967459763633e-06
. O 0 4.493456913223781e-07

Defective O 1 0.9999868869781494
thrombosis B-Disease 1 1.0
in O 0 0.000867075752466917
mutant O 0 0.001417196705006063
mice O 0 3.952831775677623e-06
was O 0 3.2701669283596857e-07
also O 0 9.398406497496126e-10
evident O 0 8.627346836931338e-09
in O 0 4.48074327641379e-10
an O 0 4.541312811912057e-11
in O 0 3.4679006194471285e-11
vivo O 0 2.424511980070321e-10
model O 0 3.4047151209470883e-10
of O 0 2.9612488461339126e-08
vascular B-Disease 1 1.0
injury I-Disease 1 0.9999998807907104
. O 0 4.883798465016298e-05

In O 0 4.2696188984336914e-07
this O 0 7.612356967001688e-09
model O 0 2.034081880708527e-08
, O 0 9.977777493119788e-10
the O 0 1.3927543562886058e-08
exteriorized O 0 7.229649327200605e-06
mesentery O 0 3.971418482251465e-05
was O 0 1.5992137605280732e-06
superfused O 0 8.527340469299816e-07
with O 0 1.6603807218018574e-09
ferric O 0 0.00010003462375607342
chloride O 0 1.2308441000641324e-05
and O 0 3.462355095962266e-07
the O 0 1.6535966551600723e-07
accumulation O 0 1.5493757246076711e-06
of O 0 1.1516182212290005e-06
fluorescently O 0 6.53492461424321e-05
labeled O 0 2.969246963857586e-07
platelets O 0 3.663552092803002e-07
was O 0 1.0466846589451961e-07
observed O 0 1.2046842412516412e-09
by O 0 2.865745141189535e-10
intravital O 0 2.2948587741211668e-07
microscopy O 0 7.746673986730457e-07
. O 0 4.4924158260073455e-07

We O 0 6.838711783530016e-07
conclude O 0 5.079667744212202e-07
that O 0 7.575462479536554e-10
these O 0 2.0716335313863965e-09
mice O 0 6.205673486192609e-08
very O 0 6.3360217072983e-10
closely O 0 7.737383178607615e-09
mimic O 0 1.5866203284531366e-06
severe O 1 0.9976643323898315
human O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 1 0.9999992847442627
will O 0 6.407426411669803e-08
be O 0 3.1675699840860716e-09
very O 0 2.9873586937512187e-10
useful O 0 2.7145374836834435e-10
for O 0 1.6113707590470483e-11
investigating O 0 2.83882695129023e-10
the O 0 8.03558719564279e-10
role O 0 5.755004028884514e-09
of O 0 7.508017318968996e-09
vWf O 0 2.746497216321586e-07
in O 0 1.0728773425228155e-09
normal O 0 9.942294987297373e-09
physiology O 0 6.95494106750516e-09
and O 0 2.2323300152837788e-10
in O 0 1.1013191053566018e-10
disease O 0 5.253100177071701e-09
models O 0 3.511923196697353e-09
. O 0 1.553021533595711e-08
. O 0 4.3833591689690365e-07

Oral O 0 0.0003656576154753566
contraceptives O 0 0.00021256603940855712
and O 0 3.5215148574962996e-09
the O 0 2.4167103873651286e-09
risk O 0 1.307346320089664e-08
of O 0 1.3626068721350748e-05
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.773560769739561e-05

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999997615814209
Clinical O 0 1.5197881111816969e-05
Study O 0 5.0539899376644826e-08
Group O 0 1.2915017499892656e-08
. O 0 9.67432498555354e-08

BACKGROUND O 0 1.840128970798105e-05
Women O 0 3.6364127264931767e-09
with O 0 2.5106805523478215e-10
mutations O 0 1.1345575590127055e-09
in O 0 4.802965802852555e-10
either O 0 9.081200680327584e-09
the O 0 5.916036798225832e-07
BRCA1 O 0 4.7955467152860365e-08
or O 0 8.167178933149444e-09
the O 0 3.347256338770421e-08
BRCA2 O 0 6.5264882387339185e-09
gene O 0 4.689280630465475e-10
have O 0 9.52732337466955e-11
a O 0 9.19550158240412e-10
high O 0 2.270628485234738e-08
lifetime O 0 2.3870988741236943e-08
risk O 0 8.708442322813426e-08
of O 0 0.021559465676546097
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.9495995477191173e-06

Oral O 1 0.9617618322372437
contraceptives O 1 1.0
protect O 1 0.9999998807907104
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.0153637504117796e-06
general O 0 3.4325198612350505e-06
, O 0 1.1245737674414613e-09
but O 0 5.882875853124858e-10
it O 0 8.590326366908485e-11
is O 0 9.597099157043765e-12
not O 0 7.54852690770802e-12
known O 0 1.716896763648279e-10
whether O 0 9.862543420835479e-11
they O 0 1.4399047232327433e-10
also O 0 1.6510290357096835e-10
protect O 0 1.709219210610513e-09
against O 0 9.596820227386615e-09
hereditary B-Disease 1 0.9984094500541687
forms I-Disease 0 0.09848538786172867
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.952590309883817e-06

METHODS O 0 1.9646622604341246e-05
We O 0 1.2991017683816608e-07
enrolled O 0 5.5423427625100885e-08
207 O 0 1.1225471219233896e-08
women O 0 4.759254795816403e-11
with O 0 3.5696441358368247e-09
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.934155981572985e-07
161 O 0 5.797677715690952e-08
of O 0 4.654489202948753e-06
their O 0 5.957935718470253e-05
sisters O 1 0.9673375487327576
as O 0 1.2004904874629574e-06
controls O 0 2.084235802612966e-06
in O 0 2.8436529575515124e-08
a O 0 8.591896261123111e-08
case O 0 4.6460974090223317e-07
- O 0 2.004778849595823e-07
control O 0 7.895773990185262e-08
study O 0 3.100041556791666e-09
. O 0 1.2112190361790454e-08

All O 0 1.0443554998573745e-07
the O 0 8.096672132751337e-08
patients O 0 1.2003705585073021e-08
carried O 0 1.4158146877107924e-09
a O 0 1.9858552580132027e-09
pathogenic O 0 2.20292726282878e-08
mutation O 0 5.253450563458273e-09
in O 0 4.147696852641047e-09
either O 0 1.6334334773659975e-08
BRCA1 O 0 2.5424691685316247e-08
( O 0 4.408735321259627e-10
179 O 0 4.606379278015993e-09
women O 0 6.465152718737599e-11
) O 0 3.191054365192514e-10
or O 0 1.2475665833733274e-08
BRCA2 O 0 1.1892318241280009e-07
( O 0 1.7893204695695886e-09
28 O 0 2.8927892969932145e-08
women O 0 1.5425545563108045e-10
) O 0 6.611671765632821e-10
. O 0 2.7547439884756386e-08

The O 0 7.415284926537424e-05
control O 0 2.2231824914342724e-05
women O 0 2.216104189045609e-09
were O 0 1.2030815232932923e-09
enrolled O 0 3.5575251633446214e-09
regardless O 0 5.915768763742335e-09
of O 0 4.526926833392508e-09
whether O 0 8.403925888522679e-10
or O 0 9.474558915201214e-10
not O 0 1.5141535247842342e-10
they O 0 2.1595336630042539e-10
had O 0 1.0262354299683807e-09
either O 0 9.919446375405983e-10
mutation O 0 1.332284949029372e-08
. O 0 4.104337136823233e-08

Lifetime O 0 3.533898279783898e-06
histories O 0 1.6574362007304444e-06
of O 0 9.915054306475213e-07
oral O 0 0.00010564563854131848
- O 0 8.494322969454515e-07
contraceptive O 0 3.425844568027969e-07
use O 0 2.3089417044985794e-09
were O 0 1.1402414568095764e-09
obtained O 0 1.2826634199214482e-09
by O 0 1.926820092368331e-10
interview O 0 2.588670389158665e-09
or O 0 1.7187119782935412e-10
by O 0 2.022635010867635e-11
written O 0 4.933649322413913e-11
questionnaire O 0 3.627534730932247e-11
and O 0 1.925694846638404e-11
were O 0 1.0513812737089623e-10
compared O 0 2.653745001524044e-10
between O 0 1.1693807033807957e-09
patients O 0 1.916497183174215e-08
and O 0 6.607829394766895e-09
control O 0 5.32778869910544e-07
women O 0 7.203297680558052e-11
, O 0 1.9194097700125923e-11
after O 0 1.906203667134676e-10
adjustment O 0 9.898581954104202e-10
for O 0 3.0058296129897855e-11
year O 0 9.996611177731651e-11
of O 0 3.3322724579676333e-09
birth O 0 4.537354314493314e-08
and O 0 1.652423087250554e-08
parity O 0 1.110906850954052e-06
. O 0 3.3568059620847635e-07

RESULTS O 0 4.837982487515546e-06
The O 0 7.008261491137091e-07
adjusted O 0 3.385283093848557e-07
odds O 0 1.899136123029166e-06
ratio O 0 2.3947609406604897e-07
for O 0 4.868891664955299e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 2.067427402607791e-07
with O 0 3.1695507329843053e-10
any O 0 5.276427295086705e-09
past O 0 4.611046655611517e-09
use O 0 1.1447609526982205e-09
of O 0 6.564754073679069e-09
oral O 0 3.119843654530996e-07
contraceptives O 0 1.3149609685569885e-06
was O 0 1.3201122328609927e-07
0 O 0 2.707673196766791e-08
. O 0 1.4399583747604083e-08

5 O 0 2.0600994048436405e-06
( O 0 9.542209689072934e-09
95 O 0 3.6078338894185435e-07
percent O 0 4.115476315291744e-08
confidence O 0 6.56731131698507e-08
interval O 0 1.750240308240336e-08
, O 0 3.472396536974287e-10
0 O 0 6.249819550774305e-10
. O 0 6.731779716995234e-11
3 O 0 1.1866884142008871e-09
to O 0 3.549044669259871e-10
0 O 0 2.675279331398883e-09
. O 0 3.189344621734591e-10
8 O 0 1.4354147204187484e-08
) O 0 9.508304144034696e-10
. O 0 1.3220935457525229e-08

The O 0 6.046634098311188e-06
risk O 0 5.309269681674778e-07
decreased O 0 1.1458539006525825e-08
with O 0 1.1803738542148778e-10
increasing O 0 4.807080289381815e-10
duration O 0 2.0630817942901558e-08
of O 0 4.730642544359398e-09
use O 0 3.4262797043993487e-09
( O 0 4.149340593340156e-10
P O 0 1.0592832211386849e-07
for O 0 5.856689022643025e-10
trend O 0 2.153328404475019e-09
, O 0 1.310463126902306e-10
< O 0 3.852578256413608e-09
0 O 0 1.519851577924669e-09
. O 0 6.925758577747132e-11
001 O 0 5.634474664617528e-09
) O 0 6.0535994619859146e-12
; O 0 3.7834943511505514e-12
use O 0 2.5728977282035714e-10
for O 0 2.644695018538812e-10
six O 0 8.552402119832436e-10
or O 0 6.677077224459538e-10
more O 0 3.892964769991458e-11
years O 0 3.825848804428489e-10
was O 0 1.5162177069427685e-09
associated O 0 1.7889716097396757e-10
with O 0 2.320338539363309e-11
a O 0 9.846290449644357e-10
60 O 0 9.435137116042824e-10
percent O 0 1.3741187354643358e-10
reduction O 0 2.3115327429934496e-09
in O 0 3.4089273626136674e-09
risk O 0 1.4652317759100697e-07
. O 0 2.1569945829469361e-07

Oral O 0 0.003101387294009328
- O 0 3.1905045034363866e-05
contraceptive O 0 3.501916353343404e-06
use O 0 4.920819307585589e-08
protected O 1 0.6532877683639526
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 5.689114734863665e-10
for O 0 7.140864288768256e-11
carriers O 0 2.55719279085298e-10
of O 0 4.1550627827291464e-08
the O 0 1.7503712967936735e-07
BRCA1 O 0 2.1788730819594093e-09
mutation O 0 1.6238022038095323e-10
( O 0 7.752809678962524e-12
odds O 0 1.0815127682306525e-09
ratio O 0 8.452501892852737e-11
, O 0 3.298501402571041e-11
0 O 0 1.3166413792564668e-10
. O 0 1.5910401468532953e-11
5 O 0 4.3074613320648325e-10
; O 0 9.990245436464207e-11
95 O 0 2.07638564120316e-08
percent O 0 3.64075725123314e-09
confidence O 0 1.1076527250963863e-08
interval O 0 4.6540242770731766e-09
, O 0 1.824342760192721e-10
0 O 0 6.10730188643771e-10
. O 0 4.3495644586055704e-11
3 O 0 1.1709162528461547e-09
to O 0 2.9356636566113536e-10
0 O 0 1.8863084427778176e-09
. O 0 9.637973752418816e-11
9 O 0 6.57043752738673e-10
) O 0 5.197251917027357e-12
and O 0 7.736472053265775e-12
for O 0 4.6475327926398524e-12
carriers O 0 1.825031792357379e-10
of O 0 2.3095815038232104e-08
the O 0 1.0453558729750512e-07
BRCA2 O 0 1.571349095286223e-08
mutation O 0 1.2370595658950378e-09
( O 0 8.183168725972578e-11
odds O 0 1.2742173538526913e-08
ratio O 0 9.942858758549278e-10
, O 0 1.2575755714561154e-10
0 O 0 5.62950908111759e-10
. O 0 9.517298060757184e-11
4 O 0 5.876565012385981e-09
; O 0 4.022691624250285e-10
95 O 0 1.0391020310862586e-07
percent O 0 1.7208588332096042e-08
confidence O 0 4.846100409849896e-08
interval O 0 7.942792201731663e-09
, O 0 2.159509099319834e-10
0 O 0 5.680180215072994e-10
. O 0 8.876514107081235e-11
2 O 0 1.6239517508509493e-09
to O 0 2.4184432234619635e-10
1 O 0 4.905673200994443e-09
. O 0 2.2367711849380356e-10
1 O 0 1.0341960177129295e-08
) O 0 4.287346866416186e-10
. O 0 2.0447009418944617e-08

CONCLUSIONS O 0 7.34182758606039e-05
Oral O 0 0.34991922974586487
- O 0 5.292633068165742e-05
contraceptive O 0 4.157408056926215e-06
use O 0 5.4023163720273715e-09
may O 0 9.227337227635246e-10
reduce O 0 1.8979076088498914e-09
the O 0 3.723137798061771e-09
risk O 0 3.354748230322002e-07
of O 1 0.9999932050704956
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.131490844410223e-09
women O 0 3.792431646498784e-12
with O 0 4.180540462417337e-12
pathogenic O 0 4.707546352733516e-09
mutations O 0 4.848869084028706e-10
in O 0 6.501214011578327e-10
the O 0 4.683921872583596e-08
BRCA1 O 0 6.771658433990524e-08
or O 0 8.853783839413154e-08
BRCA2 O 0 9.151178801403148e-07
gene O 0 2.1018568077124655e-06

A O 0 3.946941433241591e-05
Japanese O 0 6.169764674268663e-05
family O 0 1.3615551779366797e-06
with O 0 2.865912307470353e-08
adrenoleukodystrophy B-Disease 1 1.0
with O 0 6.293618781683108e-08
a O 0 2.5510652790217136e-07
codon O 0 1.1731415128224398e-07
291 O 0 2.9948811430813294e-08
deletion O 0 4.381202600711731e-08
: O 0 1.6191320506564466e-10
a O 0 4.870299163961533e-10
clinical O 0 2.333884019378729e-08
, O 0 3.2674571381896556e-10
biochemical O 0 2.6499699288251577e-06
, O 0 3.772878010011027e-09
pathological O 0 2.420024247840047e-05
, O 0 2.0054276017589245e-09
and O 0 2.706432633559075e-09
genetic O 0 3.255312321925885e-07
report O 0 3.8632425258811054e-08
. O 0 8.971406373348145e-07

We O 0 1.2578483676861651e-07
report O 0 3.706062567943036e-09
a O 0 8.831567477329827e-09
Japanese O 0 2.9360649023146834e-07
family O 0 1.3985233238145156e-07
with O 0 4.31396109945581e-08
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.00011056160292355344
ALD B-Disease 1 1.0
) O 0 8.616722446674885e-09
with O 0 2.473096394339791e-09
a O 0 5.938539970884449e-08
three O 0 4.2936854072195274e-08
base O 0 1.0440450751048047e-05
pair O 0 4.0524375322092965e-07
deletion O 0 1.7690224751731876e-07
( O 0 1.0385403648172087e-09
delGAG O 0 6.107237737751348e-08
291 O 0 1.2223023704294178e-09
) O 0 3.209480944899035e-11
in O 0 6.799556473424673e-10
the O 0 2.3444766839020303e-07
ALD B-Disease 1 1.0
gene O 0 6.758097697456833e-06
. O 0 9.710279300634284e-07

A O 0 2.8801655389543157e-06
variety O 0 4.9178169092556345e-08
of O 0 3.7898864491126005e-08
phenotypes O 0 6.714093103710184e-08
were O 0 1.3315907265720739e-09
observed O 0 7.769248022704289e-10
within O 0 4.0461692329962773e-10
this O 0 3.553562444302827e-10
family O 0 3.2779848169184334e-08
. O 0 2.8127864482030418e-08

While O 0 1.0841320090548834e-06
the O 0 7.823710461707378e-07
proband O 0 3.1722491257824004e-05
( O 0 1.4969886663607213e-08
patient O 0 5.470150199471391e-07
1 O 0 3.4104320434380497e-07
) O 0 8.536268358838583e-10
was O 0 3.6655574575661376e-08
classified O 0 1.4608918519343206e-08
as O 0 2.3530493109547024e-09
having O 0 5.145554649033102e-09
a O 0 5.259094937315467e-09
rare O 0 6.138685559875512e-09
intermediate O 0 3.8575141303454075e-08
type O 0 3.2536021876694576e-07
of O 0 1.6629476249363506e-06
adult O 0 1.7330647779090214e-06
cerebral O 0 2.6947498554363847e-05
and O 0 1.6214508491430024e-07
cerebello O 0 0.0016424106433987617
- O 0 0.0004429194377735257
brain O 0 1.3885251973988488e-05
stem O 0 1.3956023003913742e-08
forms O 0 4.033203548914344e-09
, O 0 1.8874449225769752e-10
his O 0 6.36402752718368e-09
younger O 0 7.595087225809039e-08
brother O 0 3.669094212455093e-06
( O 0 1.1721430492883655e-09
patient O 0 1.907138909018613e-07
2 O 0 2.1208920486515126e-07
) O 0 3.3134409105350926e-10
and O 0 3.6681855331011093e-09
nephew O 0 0.0008694817079231143
( O 0 8.77320882608501e-09
patient O 0 3.6378894492372638e-06
3 O 0 9.96539256448159e-07
) O 0 6.072061742301571e-10
had O 0 2.013112343490775e-08
a O 0 2.2551041922724835e-07
childhood O 0 0.002605027984827757
ALD B-Disease 1 1.0
type O 1 0.9998699426651001
. O 0 1.1314093171677087e-05

Another O 0 7.376459961960791e-06
nephew O 0 0.001365219708532095
( O 0 2.6457875890173455e-08
patient O 0 7.828613206584123e-07
4 O 0 4.4534064613799274e-07
) O 0 4.4303063995165815e-10
of O 0 3.6838084582768715e-08
patient O 0 7.563422968814848e-06
1 O 0 2.1677810764231253e-06
was O 0 5.383494681154843e-07
classified O 0 1.124728843393541e-08
as O 0 1.2344150146503807e-09
having O 0 1.16493281687724e-09
an O 0 2.2082928541333757e-10
adolescent O 0 2.158040190991528e-09
form O 0 2.8523536865776578e-09
. O 0 9.028046576986526e-08

The O 0 7.28824088582769e-05
tau O 0 1.3594476513389964e-05
level O 0 5.340398843145522e-07
in O 0 6.240555183723018e-09
the O 0 1.829780948980897e-08
cerebrospinal O 0 8.080612445837687e-08
fluid O 0 1.1869724403368309e-07
( O 0 9.20726428432772e-09
CSF O 0 3.424820533837192e-05
) O 0 2.8174080846099514e-09
in O 0 1.2024213624783897e-08
patient O 0 3.4619890357134864e-05
1 O 0 9.585657608113252e-06
was O 0 1.2757619515468832e-05
as O 0 8.14651812675038e-09
high O 0 4.8029981769559527e-08
as O 0 2.3600238430177e-10
that O 0 1.5406367154247036e-11
of O 0 1.3837455625775874e-09
patients O 0 2.6219988402687022e-09
with O 0 2.7055242490803266e-09
Alzheimers B-Disease 1 1.0
disease I-Disease 0 7.032076246105134e-05
( O 0 6.613777858710534e-10
AD B-Disease 0 1.9740534185075376e-07
) O 0 3.5096732187156476e-09
. O 0 3.2780349101813044e-08

His O 0 7.142568938434124e-05
brain O 0 0.0012037428095936775
magnetic O 0 2.1620644474751316e-05
resonance O 0 8.056694241531659e-06
image O 0 2.502350980648771e-06
( O 0 1.750113476362003e-08
MRI O 0 0.00011128912592539564
) O 0 5.6770854683918515e-09
showed O 0 9.93827597994823e-09
abnormalities B-Disease 0 1.3166487633498036e-06
in I-Disease 0 1.9003745244106085e-09
the I-Disease 0 3.3638777097166894e-08
bilateral I-Disease 0 0.0015294024487957358
cerebellar I-Disease 1 1.0
hemispheres I-Disease 1 1.0
and O 0 0.025174947455525398
brain O 1 0.5431667566299438
stem O 0 1.4419009630728397e-06
, O 0 5.130245117612731e-10
but O 0 5.864267960120628e-10
not O 0 1.3375701657381e-09
in O 0 8.666334316842494e-09
the O 0 2.3255664416410582e-07
cerebral O 0 1.4383326742972713e-05
white O 0 1.326423415548561e-07
matter O 0 8.393549855156834e-09
, O 0 3.762992348277372e-11
where O 0 7.993423284391454e-11
marked O 0 3.4103433965704255e-10
reductions O 0 2.9209269669649984e-08
of O 0 3.435594351230975e-07
the O 0 9.763989510247484e-07
cerebral O 0 2.43507183768088e-05
blood O 0 3.28295357121533e-07
flow O 0 2.3889572986490748e-08
and O 0 3.4367650947331185e-09
oxygen O 0 1.3974006662920146e-07
metabolism O 0 3.250937652410357e-08
were O 0 1.4549014215603506e-09
clearly O 0 4.1405809336758637e-10
demonstrated O 0 1.8247334754306621e-09
by O 0 2.4605234516528185e-10
positron O 0 7.630968923422188e-08
emission O 0 2.7274632330431814e-08
tomography O 0 2.384655886089604e-07
( O 0 4.157882926847378e-09
PET O 0 6.556259677381604e-07
) O 0 1.2382777025976566e-09
. O 0 4.5525940350898964e-08

In O 0 4.828418127544865e-07
patients O 0 3.170086415593687e-07
2 O 0 5.776043963123811e-07
and O 0 1.0036494302312349e-08
3 O 0 1.1973480695814942e-07
, O 0 7.190589790262436e-10
the O 0 1.086230838609481e-08
autopsy O 0 5.788119779026601e-07
findings O 0 3.8632574472785564e-08
showed O 0 4.2920561327264295e-08
massive O 0 9.062256140168756e-06
demyelination B-Disease 1 1.0
of I-Disease 1 0.9999992847442627
the I-Disease 1 0.9931880235671997
cerebral I-Disease 1 0.9998527765274048
white I-Disease 0 1.8375122863290017e-06
matter I-Disease 0 2.6778435469054784e-08
with O 0 4.1480113788239237e-10
sparing O 0 8.712745369621189e-08
of O 0 6.7771247813652735e-06
the O 0 8.089740003924817e-05
U O 0 0.03711804002523422
- O 0 1.4879106856824365e-05
fibers O 0 1.661108967709879e-06
, O 0 1.25052967980821e-09
compatible O 0 1.7847206379428826e-07
with O 0 4.923039198523327e-10
the O 0 9.954590929339702e-09
findings O 0 3.3969844714931696e-09
of O 0 7.525970602273446e-08
childhood O 0 0.0005734222941100597
ALD B-Disease 1 1.0
. O 0 5.797981884825276e-06

Oleic O 1 0.973269522190094
and O 0 3.589993139030412e-05
erucic O 1 0.9999698400497437
acids O 0 1.673017868597526e-05
( O 0 2.827470879651628e-08
Lorenzos O 0 4.328783234086586e-06
Oil O 0 5.351411118681426e-07
) O 0 2.2073748384698888e-10
were O 0 4.60866178553232e-10
administered O 0 1.2314520514422611e-09
to O 0 1.5814871634489691e-09
patients O 0 6.401353225271578e-09
1 O 0 9.015140989276915e-08
and O 0 4.714645118752969e-09
4 O 0 3.632095868510987e-08
, O 0 6.968743637703056e-11
but O 0 2.192034748160765e-11
sufficient O 0 1.5301949707335893e-09
effectiveness O 0 1.098247182085288e-08
was O 0 8.07350719611577e-09
not O 0 8.986681537814789e-11
obtained O 0 6.398435559162863e-09
. O 0 2.527528586426797e-08

The O 0 4.963534138369141e-06
findings O 0 2.557447373874311e-07
in O 0 1.0762575719525103e-08
this O 0 2.8246234240469903e-09
family O 0 7.73787078856003e-09
suggest O 0 9.079810792123055e-10
that O 0 9.917285048732793e-11
delGAG291 O 0 3.1338586836682225e-08
is O 0 8.558011937997989e-11
part O 0 2.8360883086442357e-10
of O 0 4.465703362654949e-09
the O 0 3.261568570778195e-09
cause O 0 4.614858895024554e-08
of O 0 2.2384639919437177e-07
Japanese O 0 0.0002255431900266558
ALD B-Disease 1 1.0
with O 0 2.60281268538165e-07
phenotypic O 0 4.161787728662603e-06
variations O 0 2.2717733827448683e-06
. O 0 1.554410687276686e-06

Moreover O 0 9.003625564218964e-06
, O 0 2.6039636225050344e-08
although O 0 9.61081525474583e-09
the O 0 1.1534738497687158e-08
scale O 0 1.2427543083504133e-07
of O 0 1.0417845253130054e-08
the O 0 1.4772492118453329e-09
study O 0 7.20057763414772e-11
is O 0 1.2386921349749613e-11
limited O 0 8.2039854076843e-11
, O 0 2.689756230245255e-11
there O 0 5.2179840309696246e-11
is O 0 1.1630184315603032e-10
a O 0 1.2848132557863323e-09
possibility O 0 1.346463207596571e-08
that O 0 7.202535456940495e-09
PET O 0 4.522701055975631e-05
can O 0 4.463100111706808e-08
detect O 0 8.052445991779678e-06
an O 0 2.8840629440196608e-08
insidious B-Disease 0 9.91478082141839e-05
lesion I-Disease 1 0.9486358165740967
which O 0 7.309375771313853e-09
is O 0 4.66144900457266e-10
undetectable O 0 5.116624901546629e-09
by O 0 1.3205624094236867e-10
computed O 0 1.5796912222754145e-08
tomogram O 0 3.323199280202971e-06
( O 0 5.4672275595635256e-09
CT O 0 1.9080562196904793e-05
) O 0 2.608058213837694e-09
or O 0 3.0785816118594767e-09
MRI O 0 2.2811775579612004e-07
analysis O 0 2.543738775173665e-09
, O 0 5.949755271794643e-11
and O 0 4.770415312771448e-11
that O 0 1.116219269792218e-11
the O 0 5.240977651865819e-10
higher O 0 2.740289328784229e-09
level O 0 8.60755644538358e-09
of O 0 2.9386117983420945e-09
tau O 0 1.8550780911397169e-09
reflects O 0 8.581352989311952e-11
the O 0 5.04565070280627e-11
process O 0 2.175284258276733e-10
of O 0 1.861188092533439e-09
neuronal B-Disease 0 4.556166004476836e-06
degeneration I-Disease 1 0.9947406649589539
in O 0 6.441854338845587e-07
ALD B-Disease 1 1.0
. O 0 1.91978870134335e-05

Lorenzos O 0 0.001415345468558371
Oil O 0 5.5900763982208446e-06
should O 0 5.825652849011931e-09
be O 0 3.8531719481760263e-10
given O 0 3.8464237350765984e-10
in O 0 1.7162812837590025e-10
the O 0 6.37289165883459e-10
early O 0 6.290508558493002e-09
stage O 0 7.413783364995652e-09
. O 0 1.2722399800324524e-09
. O 0 1.1748809924938541e-08

Nonsense O 0 2.458409835526254e-05
mutation O 0 2.2090392803875147e-07
in O 0 1.4746937893050927e-08
exon O 0 2.797767990614375e-07
4 O 0 5.497943078580647e-08
of O 0 5.515070622408302e-09
human O 0 4.970150069283363e-09
complement O 0 6.885922942956313e-08
C9 O 1 0.7886727452278137
gene O 0 4.8089930260175606e-08
is O 0 3.476969823168474e-10
the O 0 8.288798536426611e-10
major O 0 4.711184331540608e-09
cause O 0 1.1940840316526646e-08
of O 0 3.2892899071157444e-08
Japanese O 0 2.8212973575136857e-06
complement B-Disease 0 1.64868361025583e-05
C9 I-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
. O 0 4.759670900966739e-06

Deficiency B-Disease 1 0.9999971389770508
of I-Disease 0 0.348987340927124
the I-Disease 0 0.0005355211324058473
ninth I-Disease 1 0.975364089012146
component I-Disease 0 4.378511221148074e-05
of I-Disease 0 2.5727072170411702e-06
human I-Disease 0 2.9159349423935055e-07
complement I-Disease 0 8.27355393084872e-07
( O 0 2.607955877920176e-07
C9 O 1 0.9999998807907104
) O 0 5.301091121623358e-09
is O 0 1.8378973343224914e-10
the O 0 4.904632255886554e-10
most O 0 1.2800281667946223e-10
common O 0 7.199626139708926e-08
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 9.14293440956726e-09
Japan O 0 1.3372392082544593e-08
but O 0 3.2876867894771067e-10
is O 0 1.6115836443120202e-10
rare O 0 4.09142109081273e-10
in O 0 6.956923925827141e-11
other O 0 1.1803152899503289e-10
countries O 0 2.1442898845425162e-10
. O 0 9.980774251516777e-08

We O 0 2.050448557611162e-07
studied O 0 1.1906809760375836e-07
the O 0 3.634512912853438e-09
molecular O 0 1.2881412381204882e-08
basis O 0 1.8182895189511328e-08
of O 0 5.318183866620529e-07
C9 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.436020369283142e-07
four O 0 7.409841629169023e-08
Japanese O 0 1.6909831174416468e-05
C9 B-Disease 1 1.0
- I-Disease 1 0.9999982118606567
deficient I-Disease 1 0.9999961853027344
patients O 0 8.597318083047867e-05
who O 0 9.875169126871697e-08
had O 0 1.8830064618668985e-07
suffered O 0 9.627889085095376e-05
from O 0 1.5861421616136795e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 6.210649644344812e-06

Direct O 0 5.05963726027403e-07
sequencing O 0 4.772338684233546e-07
of O 0 2.681688044958719e-07
amplified O 0 3.7041395444248337e-06
C9 O 0 0.00045650952961295843
cDNA O 0 3.162294888170436e-06
and O 0 4.278267695667637e-08
DNA O 0 3.5156082844878256e-07
revealed O 0 5.030024397001398e-08
a O 0 4.189998570325315e-09
nonsense O 0 1.4361157596454177e-08
substitution O 0 1.0913603354367751e-08
( O 0 5.172809958153834e-10
CGA O 0 1.887742655526381e-07
- O 0 5.905805267047981e-08
- O 0 1.2325257614520524e-07
> O 0 1.8649775768153631e-07
TGA O 0 1.050005380420771e-06
) O 0 2.103136415021467e-10
at O 0 1.7338521729470813e-09
codon O 0 2.353124639586923e-10
95 O 0 5.5775264407031955e-09
in O 0 9.252433263995385e-10
exon O 0 2.1261934435301555e-08
4 O 0 6.39805763924528e-09
in O 0 3.317203456365547e-10
the O 0 6.182101941476503e-09
four O 0 1.6992149909356158e-08
C9 B-Disease 1 0.9996771812438965
- I-Disease 0 0.0001465447130613029
deficient I-Disease 0 3.341753108543344e-05
individuals O 0 4.1915968473915655e-09
. O 0 2.647857968440803e-07

An O 0 8.406514950820565e-08
allele O 0 5.660610113977782e-08
- O 0 4.226142635843644e-08
specific O 0 7.681697056227677e-09
polymerase O 0 4.924546828988241e-06
chain O 0 3.89786379173529e-07
reaction O 0 5.9237201810447004e-08
system O 0 9.99319127004128e-07
designed O 0 2.874974143196596e-07
to O 0 1.0771961989064494e-08
detect O 0 1.490700753947749e-07
exclusively O 0 2.2592827608747257e-09
only O 0 1.636803054205771e-10
one O 0 1.4537911152689986e-10
of O 0 6.817347242282779e-10
the O 0 1.384051762087779e-09
normal O 0 2.649124031250949e-09
and O 0 3.324754083156023e-10
mutant O 0 7.387130351865778e-10
alleles O 0 2.4481916494067946e-11
indicated O 0 1.8342692642558944e-10
that O 0 2.283079801601584e-11
all O 0 9.037613019069468e-11
the O 0 1.3469249049435916e-09
four O 0 3.549945060132842e-10
patients O 0 2.341560001450915e-10
were O 0 4.013946397485313e-10
homozygous O 0 5.900687716220432e-10
for O 0 3.317209840147939e-10
the O 0 4.621163451901111e-09
mutation O 0 1.6249184220384905e-09
in O 0 4.731581348949021e-09
exon O 0 5.9471663149679443e-08
4 O 0 1.308581243364415e-08
and O 0 2.6889676596475454e-10
that O 0 1.7389043330262588e-11
the O 0 2.026629974949401e-09
parents O 0 1.950507394488099e-10
of O 0 2.4948618726483573e-09
patient O 0 2.997304093810271e-08
2 O 0 7.967755522031439e-08
were O 0 1.4342186993587802e-08
heterozygous O 0 1.030118923495138e-08
. O 0 4.235753792158903e-08

The O 0 1.6152000625879737e-06
common O 0 1.9542373763670184e-07
mutation O 0 2.8751870218002296e-08
at O 0 1.4593991792821726e-08
codon O 0 3.0053568522703245e-09
95 O 0 9.851539317651259e-08
in O 0 1.038998576063932e-08
exon O 0 1.2335746646385815e-07
4 O 0 2.4344494420347473e-08
might O 0 2.962166623099449e-10
be O 0 8.923739525101837e-11
responsible O 0 4.3447906383775603e-10
for O 0 1.110687444794145e-10
most O 0 1.6098149480114898e-09
Japanese O 0 2.0562774807331152e-06
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9999129772186279
. O 0 8.667925754934913e-08
. O 0 1.1288373968909582e-07

BRCA1 O 0 8.758279363973998e-07
required O 0 2.4242279295094704e-08
for O 0 1.494703205651149e-08
transcription O 0 1.0673587667042739e-06
- O 0 2.356426875849138e-06
coupled O 0 4.8162814891838934e-06
repair O 0 0.3300396203994751
of O 0 9.766746416062233e-07
oxidative O 0 6.056168331269873e-06
DNA O 0 1.702389795354975e-06
damage O 0 7.900216587586328e-05
. O 0 1.7784817885058146e-07

The O 0 9.122515621129423e-05
breast B-Disease 1 1.0
and I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 8.20968398329569e-06
gene O 0 8.341218382668103e-09
BRCA1 O 0 1.247480230226472e-09
encodes O 0 4.928516483815315e-10
a O 0 1.0787110094057084e-09
zinc O 0 4.2505200781306485e-07
finger O 0 1.6602554353539745e-07
protein O 0 9.50798195731295e-09
of O 0 1.8631922671374923e-08
unknown O 0 4.057696401105204e-08
function O 0 1.663322812817114e-08
. O 0 2.7104116284704105e-08

Association O 0 1.8083705981553067e-06
of O 0 2.6037857878691284e-06
the O 0 2.96486120987538e-07
BRCA1 O 0 9.209056628378676e-09
protein O 0 2.7855775464047383e-09
with O 0 1.3463642700717315e-10
the O 0 9.56173984434372e-09
DNA O 0 1.4896705806677346e-06
repair O 0 0.32458919286727905
protein O 0 2.9922798603365663e-06
Rad51 O 0 2.726519596762955e-06
and O 0 1.741448429903869e-09
changes O 0 1.0414661355540034e-09
in O 0 7.385552169836274e-10
the O 0 1.7492116644035605e-09
phosphorylation O 0 3.987005836592061e-09
and O 0 9.227407171685797e-10
cellular O 0 5.623588261727264e-09
localization O 0 2.7590090212470386e-07
of O 0 2.6992063695274737e-08
the O 0 2.5992298091637167e-08
protein O 0 1.8989622319054433e-08
after O 0 6.783161143886218e-09
exposure O 0 6.588388856698657e-08
to O 0 3.1630422725470453e-09
DNA O 0 8.080024258561025e-07
- O 0 2.8768087645403284e-07
damaging O 0 3.027099353403173e-07
agents O 0 2.0307548975750933e-09
are O 0 1.2924263222136023e-11
consistent O 0 4.4677034294338114e-10
with O 0 3.674946458254169e-11
a O 0 1.5439653999749225e-09
role O 0 5.360684340871558e-09
for O 0 3.554825545037943e-09
BRCA1 O 0 1.1188682869089916e-08
in O 0 4.5805945703136786e-09
DNA O 0 1.883711888694961e-06
repair O 0 0.06029914319515228
. O 0 2.8633251076826127e-06

Here O 0 3.1989914077712456e-06
, O 0 4.962439348332737e-09
it O 0 1.8868186180132085e-10
is O 0 6.196285151638392e-11
shown O 0 3.524617542272068e-10
that O 0 4.2715608827847973e-10
mouse O 0 2.791872191210132e-07
embryonic O 0 6.726218089170288e-07
stem O 0 4.552411780878174e-07
cells O 0 2.4949713406385854e-06
deficient B-Disease 0 0.00088821433018893
in I-Disease 0 3.8454739836879526e-08
BRCA1 I-Disease 0 2.6848397283174563e-08
are O 0 1.907040081405853e-10
defective O 0 5.385671784097212e-07
in O 0 6.552394182790522e-09
the O 0 3.316327479296888e-08
ability O 0 4.8047730238920394e-09
to O 0 1.277195016413657e-09
carry O 0 9.786916832510428e-10
out O 0 5.925367307924034e-09
transcription O 0 2.374772378743728e-07
- O 0 7.470450782420812e-07
coupled O 0 2.7614096325123683e-06
repair O 0 0.002407881896942854
of O 0 5.838013521497487e-07
oxidative O 0 5.045204488851596e-06
DNA O 0 1.1953316061408259e-05
damage O 0 0.04596732184290886
, O 0 2.157999112739617e-09
and O 0 2.0449184567894463e-09
are O 0 5.56676760243846e-10
hypersensitive O 0 4.669543159252498e-06
to O 0 2.5076392518030843e-08
ionizing O 0 0.40320536494255066
radiation O 1 0.9999655485153198
and O 0 2.7128839619194878e-08
hydrogen O 0 1.9713876042715128e-07
peroxide O 0 2.1121873032825533e-06
. O 0 2.3075698152297264e-07

These O 0 1.513384688678343e-07
results O 0 5.0451287592068184e-08
suggest O 0 3.6347433507444293e-08
that O 0 5.146929105137588e-09
BRCA1 O 0 8.625080027968579e-08
participates O 0 3.83474185738919e-09
, O 0 6.971269395084079e-11
directly O 0 1.0904811775791501e-10
or O 0 3.997253084087049e-10
indirectly O 0 6.228042526146282e-10
, O 0 8.305917759132697e-11
in O 0 4.88648899121813e-10
transcription O 0 8.316041544276231e-07
- O 0 2.8973784083063947e-06
coupled O 0 5.165183210920077e-06
repair O 0 0.006113219074904919
of O 0 4.2469255845389853e-07
oxidative O 0 1.080565766642394e-06
DNA O 0 6.016867359903699e-07
damage O 0 6.789960025344044e-06
. O 0 7.047965322470873e-09
. O 0 3.344378285419225e-08

Truncation O 0 7.568136061308905e-05
mutations O 0 6.940643970665406e-07
in O 0 1.2136748495095162e-08
the O 0 8.130579942644545e-08
transactivation O 0 2.034323006228078e-05
region O 0 2.8821830255765235e-07
of O 0 2.399930963292718e-06
PAX6 O 1 0.9894517064094543
result O 0 9.668198117651627e-07
in O 0 5.645040701551807e-08
dominant O 0 1.3563524589699227e-05
- O 0 7.238828061417735e-07
negative O 0 6.349686287876466e-08
mutants O 0 1.231840087712044e-06
. O 0 1.0359535451698321e-07

PAX6 O 0 0.02323571778833866
is O 0 6.022585239406908e-07
a O 0 1.2341571675733576e-07
transcription O 0 8.100472825844918e-08
factor O 0 6.240912675536947e-09
with O 0 1.9116833116505916e-10
two O 0 8.88129403353588e-10
DNA O 0 3.5578388235535385e-08
- O 0 6.92617732056533e-08
binding O 0 4.987530743960633e-08
domains O 0 6.210137115658654e-08
( O 0 6.519367823365485e-10
paired O 0 4.33854907555542e-09
box O 0 1.7342954095056484e-07
and O 0 7.825021519636266e-09
homeobox O 0 6.823493094998412e-07
) O 0 4.8333009816659e-10
and O 0 2.7562139237602423e-09
a O 0 6.652054196365498e-08
proline O 0 6.191296506585786e-07
- O 0 7.061005362629658e-07
serine O 0 7.976025244715856e-07
- O 0 1.012413008538715e-06
threonine O 0 2.3047944353038474e-07
( O 0 2.5216624344182037e-09
PST O 0 1.2197398064017761e-05
) O 0 1.3269130239024207e-09
- O 0 1.511647340635136e-08
rich O 0 2.591863257350724e-08
transactivation O 0 1.2857750334660523e-05
domain O 0 4.307724736918317e-07
. O 0 7.790728062673224e-08

PAX6 O 1 0.9999994039535522
regulates O 0 7.398495654342696e-05
eye O 0 0.0556672103703022
development O 0 3.2360316026824876e-07
in O 0 2.1856825238586453e-09
animals O 0 4.5623949063156033e-10
ranging O 0 5.562653004886897e-09
from O 0 5.6034159534590344e-09
jellyfish O 0 1.4048455732051934e-08
to O 0 4.594848945771446e-09
Drosophila O 0 5.558328552979219e-08
to O 0 4.1275884932190365e-09
humans O 0 1.7791026607483218e-07
. O 0 1.8551715186276851e-07

Heterozygous O 0 1.0530981171541498e-06
mutations O 0 1.9762660841138313e-08
in O 0 1.9756585256658354e-09
the O 0 1.1801184918169838e-08
human O 0 8.089232039765193e-08
PAX6 O 0 0.0005280075711198151
gene O 0 2.668823562146372e-08
result O 0 4.55671811394609e-09
in O 0 4.0357717168149065e-10
various O 0 9.007141144046216e-10
phenotypes O 0 2.5374113477028004e-08
, O 0 9.199268430348795e-11
including O 0 6.992686985007879e-10
aniridia B-Disease 1 1.0
, O 0 1.097363835356191e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 1.726573017890587e-08
autosomal B-Disease 0 5.59136151423445e-06
dominant I-Disease 0 0.05030500516295433
keratitis I-Disease 1 1.0
, O 0 1.5909097328403732e-07
and O 0 1.3981488109493512e-06
familial B-Disease 1 1.0
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 1 0.9999939203262329

It O 0 9.92049535852857e-08
is O 0 2.0470414252571345e-09
believed O 0 4.501269135204211e-09
that O 0 1.4210976839734712e-10
the O 0 1.969356677733458e-09
mutated O 0 1.2230119139644557e-08
allele O 0 2.5463322117502685e-08
of O 0 1.3905304285799502e-07
PAX6 O 0 0.00018082470342051238
produces O 0 6.4278293798736286e-09
an O 0 1.8726853401318522e-10
inactive O 0 7.527244605398664e-09
protein O 0 2.0724922222825626e-08
and O 0 1.2200622734326316e-08
aniridia B-Disease 1 1.0
is O 0 1.1255529841491807e-08
caused O 0 3.271750870226242e-08
due O 0 1.743973001566701e-07
to O 0 1.7472784108463202e-08
genetic O 0 8.22205720396596e-07
haploinsufficiency O 0 1.0157735232496634e-05
. O 0 3.1820476920074725e-07

However O 0 1.9909987258870387e-06
, O 0 2.4000600618023782e-08
several O 0 6.7257155400568536e-09
truncation O 0 5.865090315637644e-07
mutations O 0 1.7623332126959212e-08
have O 0 2.0697534797164963e-09
been O 0 2.1668542515840272e-09
found O 0 8.979867405223274e-10
to O 0 1.9972117015765178e-10
occur O 0 1.9349150059966291e-10
in O 0 1.249380598977723e-09
the O 0 1.3879781768366684e-08
C O 0 3.9163901988104044e-07
- O 0 1.2098939805582631e-07
terminal O 0 4.831333626498235e-07
half O 0 7.640053034663197e-09
of O 0 5.661395352518639e-09
PAX6 O 0 7.206758164102212e-05
in O 0 3.2699400964730785e-09
patients O 0 7.310072547284108e-09
with O 0 2.5989903562617656e-09
Aniridia B-Disease 1 1.0
resulting O 0 1.3138430404069368e-05
in O 0 4.800012476380289e-08
mutant O 0 1.8945124580227457e-08
proteins O 0 1.4190093544641513e-10
that O 0 5.776068165430637e-11
retain O 0 4.707151113336749e-09
the O 0 3.511991764071354e-08
DNA O 0 1.4051033758732956e-07
- O 0 3.479825849694862e-08
binding O 0 5.518384860181413e-09
domains O 0 8.369729798118897e-09
but O 0 1.284494621778265e-09
have O 0 1.5716360435291676e-09
lost O 0 3.9036180510265694e-08
most O 0 5.512879597269205e-10
of O 0 4.64391547438936e-09
the O 0 1.9160109943072712e-08
transactivation O 0 1.6896765373530798e-06
domain O 0 4.388696481782972e-07
. O 0 1.0121603111201694e-07

It O 0 1.0988530618760706e-07
is O 0 2.779023677845771e-09
not O 0 2.3835430851271155e-10
clear O 0 5.858010521109236e-09
whether O 0 1.153391937513959e-09
such O 0 1.233561341962286e-08
mutants O 0 8.341748980456032e-06
really O 0 1.9227549330480542e-07
behave O 0 7.344312713541967e-09
as O 0 3.680211024814639e-09
loss O 0 1.5750998727526166e-08
- O 0 6.347845982190847e-08
of O 0 1.51445465235156e-06
- O 0 1.8576974980533123e-06
function O 0 1.131502447293542e-08
mutants O 0 2.6461510316266867e-08
as O 0 7.951033720310363e-10
predicted O 0 8.91697649052503e-09
by O 0 2.394987319576103e-09
haploinsufficiency O 0 3.216262848582119e-05
. O 0 7.11352242888097e-07

Contrary O 0 1.045766839524731e-05
to O 0 6.209710790017198e-08
this O 0 3.313657570558348e-09
theory O 0 1.1492424789594224e-07
, O 0 9.54300527489238e-10
our O 0 6.057258694625034e-09
data O 0 1.0585173626509459e-08
showed O 0 1.7986687694815373e-09
that O 0 1.0047095100329528e-10
these O 0 4.4233322560316424e-10
mutants O 0 5.003481007292976e-08
are O 0 3.295176631556984e-10
dominant O 0 5.439064665324622e-08
- O 0 3.049770214147429e-08
negative O 0 2.611143967712337e-09
in O 0 1.7718944089750721e-09
transient O 0 7.22695006061258e-08
transfection O 0 7.372370305347431e-07
assays O 0 1.978864894169874e-08
when O 0 3.3130698184891116e-09
they O 0 3.744915211267852e-10
are O 0 1.396250476348726e-10
coexpressed O 0 3.435640110183158e-07
with O 0 1.752457623460657e-09
wild O 0 3.155349475036928e-07
- O 0 3.461833273377124e-07
type O 0 1.3795865015708841e-05
PAX6 O 1 0.994111955165863
. O 0 4.393672952573979e-06

We O 0 1.109321942749375e-06
found O 0 4.7648029521951685e-08
that O 0 1.708182928439328e-09
the O 0 6.0796814693731e-08
dominant O 0 2.49882873504248e-06
- O 0 1.4855605456887133e-07
negative O 0 4.989657020892935e-10
effects O 0 1.637054580783115e-08
result O 0 3.3135374444270838e-09
from O 0 3.773496626280348e-09
the O 0 4.426060407070054e-09
enhanced O 0 1.793527637516945e-08
DNA O 0 8.614553514973977e-09
binding O 0 2.3184076880511384e-09
ability O 0 1.34943967111667e-09
of O 0 7.343724295338916e-09
these O 0 1.510332525711533e-09
mutants O 0 1.6367650346182927e-07
. O 0 2.937010812331664e-08

Kinetic O 0 1.6715892343199812e-05
studies O 0 5.747975606595901e-08
of O 0 3.1831611124744086e-08
binding O 0 2.613582061883335e-08
and O 0 5.804977831758151e-09
dissociation O 0 1.18938380921918e-07
revealed O 0 2.864076265041149e-08
that O 0 6.636646787683276e-11
various O 0 1.1490617346510135e-09
truncation O 0 2.2136745769785193e-07
mutants O 0 7.837512328023877e-08
have O 0 2.304942015030065e-09
3 O 0 2.5705654493890506e-08
- O 0 2.5109034851311662e-08
5 O 0 5.067406405601105e-08
- O 0 7.311832916911953e-08
fold O 0 8.853783839413154e-08
higher O 0 4.802558351002517e-08
affinity O 0 7.143922786667645e-09
to O 0 1.217253631224935e-09
various O 0 5.660302226928593e-10
DNA O 0 7.789981992800676e-09
- O 0 8.619315261526594e-10
binding O 0 4.901218320085832e-10
sites O 0 6.330549418009923e-10
when O 0 4.698026967453472e-10
compared O 0 3.062941844600431e-10
with O 0 2.09085249114338e-11
the O 0 4.034611755798778e-09
wild O 0 4.252169816254536e-08
- O 0 3.9587735756185793e-08
type O 0 1.428129394298594e-06
PAX6 O 0 0.4798717200756073
. O 0 1.3557373677031137e-06

These O 0 7.89444882798307e-08
results O 0 1.9518751059877104e-08
provide O 0 6.636210692079203e-09
a O 0 8.799418971250361e-09
new O 0 8.494741798870109e-09
insight O 0 5.850596007661579e-09
into O 0 5.544388836931091e-10
the O 0 5.392369328838242e-10
role O 0 1.3613340454909917e-09
of O 0 1.1407771616234186e-08
mutant O 0 5.023140943194448e-07
PAX6 O 0 0.00024538818979635835
in O 0 3.4764095602213274e-08
causing O 0 2.7468192911328515e-06
aniridia B-Disease 1 1.0
. O 0 1.826249587111306e-07
. O 0 2.2725137682755303e-07

Reversal O 0 2.540294917707797e-05
of O 0 9.12925497686956e-06
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 1 1.0
excellent O 1 0.9982159733772278
neuropsychologic O 1 0.6388140320777893
outcome O 0 8.903208799893036e-05
in O 0 4.033375375911419e-07
very B-Disease 0 5.991272189476149e-08
- I-Disease 0 1.0895471547200941e-07
long I-Disease 0 9.286812030495639e-08
- I-Disease 0 1.2743163324557827e-07
chain I-Disease 0 6.538638785968942e-08
acyl I-Disease 0 3.318599084423113e-08
- I-Disease 0 1.0715489651147436e-07
coenzyme I-Disease 0 1.0306538911208918e-07
A I-Disease 0 9.475401384406723e-06
dehydrogenase I-Disease 0 2.0653496903833002e-05
deficiency I-Disease 0 4.3366238969611004e-05
. O 0 2.0207993145504588e-07

Very B-Disease 0 2.073407586067333e-06
- I-Disease 0 1.2516265996964648e-06
long I-Disease 0 1.9735057321668137e-07
- I-Disease 0 1.0937155536794307e-07
chain I-Disease 0 2.3409370442095678e-08
acyl I-Disease 0 1.5944085163255295e-08
- I-Disease 0 1.769554813790819e-08
coenzyme I-Disease 0 6.6081575766929745e-09
A I-Disease 0 5.371981615098775e-07
dehydrogenase I-Disease 0 8.137807299135602e-07
( I-Disease 0 2.80888201587004e-09
VLCAD I-Disease 0 0.2973591983318329
) I-Disease 0 4.059554115087849e-08
deficiency I-Disease 0 0.043679844588041306
is O 0 4.931020036735845e-09
a O 0 1.2475051391902525e-07
disorder O 1 0.9531211256980896
of O 0 0.06333998590707779
fatty O 0 0.0009820627747103572
acid O 0 3.85683415515814e-06
beta O 0 7.163395707721065e-07
oxidation O 0 1.0008358941604456e-07
that O 0 1.269147453797359e-09
reportedly O 0 6.673619878938553e-08
has O 0 2.1371525382729573e-10
high O 0 4.343682302732077e-09
rates O 0 1.9768446601897693e-10
of O 0 2.2468409077713858e-10
morbidity O 0 1.007097623073605e-07
and O 0 1.6483929776711648e-09
mortality O 0 1.0916689063833473e-07
. O 0 3.53395108732002e-08

We O 0 5.043733608545153e-07
describe O 0 2.083580881162561e-07
the O 0 6.738275715179043e-08
outcome O 0 1.0151841678407436e-07
of O 0 5.429466654049975e-08
a O 0 1.1809921041106008e-08
5 O 0 4.600899661255653e-09
- O 0 2.5646187395977904e-09
year O 0 1.687509243453178e-09
- O 0 6.855428580365697e-08
old O 0 1.9802484985120827e-06
girl O 0 1.190180327625967e-07
with O 0 1.7894340231805472e-08
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 4.221676499582827e-05
was O 0 8.669925591675565e-06
first O 0 4.510707896088206e-08
seen O 0 1.418702311184461e-08
at O 0 3.215722133020904e-09
5 O 0 3.349641952699045e-10
months O 0 9.342140255830245e-11
of O 0 1.6162286786691737e-10
age O 0 2.633856743816665e-10
with O 0 1.418852396684045e-10
severe O 0 0.006421829108148813
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999995231628418
hepatomegaly B-Disease 1 1.0
, O 1 0.7130230665206909
encephalopathy B-Disease 1 0.9999998807907104
, O 0 6.500860649794049e-08
and O 0 4.727181931230007e-06
hypotonia B-Disease 1 0.9999986886978149
. O 0 0.00048485948354937136

Biochemical O 0 5.372607847675681e-05
studies O 0 9.695454536995385e-07
indicated O 0 0.0017014073673635721
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.15848222374916077
by O 0 6.4233929286672264e-09
a O 0 7.334111273848976e-08
stable O 0 6.516614234897133e-07
yet O 0 9.064764583399665e-08
inactive O 0 1.0525500329094939e-06
enzyme O 0 1.0570182666924666e-06
. O 0 8.961139030816412e-08

Molecular O 0 1.5240141237882199e-06
genetic O 0 9.019355218242708e-08
analysis O 0 1.0970077291005964e-08
of O 0 1.4461133446275198e-07
her O 0 3.3116812403477525e-08
VLCAD O 0 0.0024527208879590034
gene O 0 4.8743462599531995e-08
revealed O 0 1.4375110879427666e-07
a O 0 5.731531871333573e-08
T1372C O 0 6.803758765272505e-07
( O 0 2.5434476746966084e-09
F458L O 0 2.2932310628220876e-07
) O 0 1.2846221864037943e-09
missense O 0 1.3956027089534473e-07
mutation O 0 6.476167602187388e-09
and O 0 7.397285450849722e-09
a O 0 8.923259287030305e-08
1668 O 0 0.00011906149302376434
ACAG O 0 0.017149053514003754
1669 O 0 0.0002058491372736171
splice O 0 6.544416828546673e-05
site O 0 9.929419775289716e-07
mutation O 0 5.0553200736658255e-08
. O 0 2.5070940878890724e-08

After O 0 1.0058553243652568e-06
initial O 0 3.102389030118502e-07
treatment O 0 2.4611090339021757e-06
with O 0 2.964417378237272e-09
intravenous O 0 7.914966886346519e-07
glucose O 0 2.9735148928011768e-05
and O 0 3.517079605330764e-08
carnitine O 0 2.15915247281373e-06
, O 0 1.7597997503671081e-09
the O 0 3.7843538081006045e-08
patient O 0 9.140232464233122e-07
has O 0 3.0145597129660473e-09
thrived O 0 1.342053135289234e-08
on O 0 1.0942743600139693e-08
a O 0 3.925507918722815e-09
low O 0 2.9484391461664927e-07
- O 0 1.5380706486212148e-07
fat O 0 2.804464998007461e-07
diet O 0 3.7313434120278544e-08
supplemented O 0 1.4231246181495294e-09
with O 0 1.6595724794399302e-10
medium O 0 1.3684610848940792e-06
- O 0 1.0022453125202446e-06
chain O 0 2.6382093665233697e-07
triglyceride O 0 3.956479588396178e-07
oil O 0 9.372529063966795e-08
and O 0 1.1525869147988033e-09
carnitine O 0 4.710566869903232e-08
and O 0 6.059843737915571e-10
avoidance O 0 3.6418083482203656e-07
of O 0 1.5927466279208602e-07
fasting O 0 4.158014689892298e-06
. O 0 1.322983251839105e-07

Her O 0 3.173765435349196e-05
ventricular O 1 0.9999892711639404
hypertrophy O 1 0.9999555349349976
resolved O 0 0.00017811109137255698
significantly O 0 1.3597941688203719e-06
over O 0 4.9016723124850614e-08
1 O 0 2.002684063029392e-08
year O 0 2.6933100194526105e-10
, O 0 7.78945311030732e-11
and O 0 5.426023519383705e-10
cognitively O 0 7.747738095531531e-07
, O 0 7.197011320236868e-10
she O 0 2.717625291470682e-10
is O 0 1.3141068094801867e-11
in O 0 1.7017488113113544e-11
the O 0 1.9390380967543308e-10
superior O 0 9.255989397161102e-08
range O 0 3.110823243446248e-08
for O 0 4.510379181255075e-09
age O 0 1.3084019201414776e-07
. O 0 2.356150048399286e-07

Clinical O 0 1.3603606930701062e-05
recognition O 0 0.0037994515150785446
of O 1 1.0
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 3.2904210911510745e-06
important O 0 3.966709982705652e-08
because O 0 4.0169717552274165e-10
it O 0 3.971480783127035e-11
is O 0 1.8492259806768274e-11
one O 0 1.2233832870356398e-11
of O 0 3.519283753306013e-10
the O 0 2.54573850888562e-09
few O 0 1.5130977581989669e-09
directly O 0 6.455621814893675e-09
treatable O 0 0.0001914983004098758
causes O 0 4.056443003719323e-08
of O 0 1.4749630281585269e-06
cardiomyopathy B-Disease 1 1.0
in O 0 1.1809295585862856e-07
children O 0 4.685402732462762e-09
. O 0 4.19806989171434e-09
. O 0 6.746171976601545e-08

Cloning O 0 9.218685590894893e-06
of O 0 3.4974533491549664e-07
a O 0 3.4423365491420554e-08
novel O 0 3.0440052256608396e-08
member O 0 2.615450522824858e-09
of O 0 2.1711041853222923e-08
the O 0 6.048279033166182e-08
low O 0 9.886360885502654e-07
- O 0 8.185818956008006e-08
density O 0 7.833144799462843e-09
lipoprotein O 0 5.005962066206848e-06
receptor O 0 7.752319675091712e-07
family O 0 3.065651412725856e-07
. O 0 7.847833671803528e-08

A O 0 9.542178304400295e-06
gene O 0 7.367550125536582e-08
encoding O 0 3.861485993184033e-07
a O 0 1.28821056932793e-07
novel O 0 8.246607308137754e-08
transmembrane O 0 1.3576657131864067e-08
protein O 0 2.139845856063971e-09
was O 0 2.1965487206898615e-09
identified O 0 5.0135038481835537e-11
by O 0 5.530694392047453e-12
DNA O 0 6.742756908373337e-10
sequence O 0 8.101047610509227e-11
analysis O 0 3.655986277606438e-11
within O 0 6.112006734060316e-11
the O 0 1.0833046681923975e-09
insulin B-Disease 0 0.000856068276334554
- I-Disease 0 0.00011882626131409779
dependent I-Disease 1 0.6155851483345032
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 6.408966868320931e-08
IDDM B-Disease 0 1.432431599823758e-05
) O 0 9.45062583745937e-10
locus O 0 2.3445387853371358e-08
IDDM4 O 0 7.400088861686527e-07
on O 0 2.6593822255449595e-08
chromosome O 0 1.775721791830165e-08
11q13 O 0 5.521687853615731e-07
. O 0 7.330922358050884e-08

Based O 0 2.002544306378695e-06
on O 0 4.393345136577409e-07
its O 0 8.032940534974387e-09
chromosomal O 0 4.035861138618202e-07
position O 0 7.618895665473246e-07
, O 0 3.9643763272145804e-10
this O 0 2.1547774675667597e-10
gene O 0 4.315191259873785e-10
is O 0 3.953086122332472e-11
a O 0 1.462264753726572e-10
candidate O 0 5.996743102087976e-10
for O 0 7.049786449053741e-11
conferring O 0 5.98287925868135e-08
susceptibility O 0 8.372226147912443e-06
to O 0 4.752635902605107e-07
diabetes B-Disease 1 1.0
. O 0 2.990369284816552e-05

The O 0 2.787354560496169e-06
gene O 0 1.0021424401429613e-07
, O 0 2.1707842190465954e-09
termed O 0 1.783914171937795e-07
low O 0 3.058355787288747e-06
- O 0 1.4193767583492445e-07
density O 0 6.754138581754887e-09
lipoprotein O 0 3.1995631388781476e-07
receptor O 0 7.066675244971066e-09
related O 0 2.3699491258355465e-09
protein O 0 5.9973865873530485e-09
5 O 0 1.974806984605948e-09
( O 0 4.002698172911323e-11
LRP5 O 0 1.0419440599207519e-07
) O 0 5.597834348836095e-11
, O 0 2.0772697797988293e-11
encodes O 0 1.0763673979896637e-10
a O 0 4.908890516297504e-10
protein O 0 3.169274398473476e-09
of O 0 7.070261265340605e-09
1615 O 0 2.475847793448338e-07
amino O 0 1.1898915630581541e-08
acids O 0 4.33304103708565e-09
that O 0 2.0378933263121013e-10
contains O 0 2.9820657054813182e-09
conserved O 0 5.446079143212046e-09
modules O 0 9.273603218673543e-09
which O 0 3.435096998516407e-11
are O 0 5.677964608902242e-12
characteristic O 0 1.5085409310611197e-10
of O 0 3.246957369640313e-09
the O 0 6.897882709466785e-09
low O 0 7.706780991156847e-08
- O 0 3.5723071167836906e-09
density O 0 2.1928386884084716e-10
lipoprotein O 0 2.889701278263601e-08
( O 0 2.0348910056977587e-10
LDL O 0 6.882378045247606e-08
) O 0 3.227038081199396e-10
receptor O 0 2.7453443962599522e-08
family O 0 3.1577872761090475e-08
. O 0 2.157921841217103e-08

These O 0 2.2047920822387823e-07
modules O 0 7.351966928581533e-07
include O 0 1.1493910712090383e-08
a O 0 2.3666347104267516e-08
putative O 0 6.678700401607784e-07
signal O 0 8.575807441957295e-07
peptide O 0 1.0885953471984067e-08
for O 0 9.201518991197588e-10
protein O 0 2.810398580521678e-09
export O 0 1.214033762408917e-08
, O 0 2.99584329566116e-10
four O 0 1.9670891582279637e-09
epidermal O 0 9.266358347304049e-08
growth O 0 1.419751982645323e-09
factor O 0 3.4746643340355376e-09
( O 0 9.225436525817088e-10
EGF O 0 1.5095564265266148e-07
) O 0 1.828910356493907e-10
repeats O 0 2.1245707415573634e-09
with O 0 7.175816885141018e-11
associated O 0 1.0705496045204654e-08
spacer O 0 3.3991906889241363e-07
domains O 0 2.3062096232706608e-08
, O 0 5.162598681884845e-10
three O 0 2.169525892270485e-09
LDL O 0 5.977923365207971e-07
- O 0 4.271386444543168e-07
receptor O 0 4.80531632263137e-08
( O 0 7.22988058310392e-10
LDLR O 0 2.4415840016445145e-06
) O 0 5.200152530804303e-10
repeats O 0 4.931104857774926e-09
, O 0 1.407246957851882e-10
a O 0 2.3201283116947025e-09
single O 0 1.4703796402670832e-08
transmembrane O 0 1.3159499268056152e-08
spanning O 0 4.334148595575016e-09
domain O 0 2.4898418882202122e-09
, O 0 1.0222964141881619e-10
and O 0 1.468940108440009e-10
a O 0 6.073523906025002e-09
cytoplasmic O 0 7.694927717238897e-08
domain O 0 1.9102569126516755e-07
. O 0 9.41671700616098e-08

The O 0 6.339283117995365e-06
encoded O 0 2.3404309956731595e-07
protein O 0 1.5170465417213563e-07
has O 0 1.7616266223541288e-09
a O 0 5.78644743232104e-10
unique O 0 9.258894206887192e-10
organization O 0 9.022977920380981e-10
of O 0 4.7835339245239084e-08
EGF O 0 5.969696576357819e-05
and O 0 7.274413604818619e-08
LDLR O 0 0.0003317877999506891
repeats O 0 6.573878152948964e-08
; O 0 4.1505754388992955e-10
therefore O 0 2.2924113718403305e-09
, O 0 1.0174182607514126e-09
LRP5 O 0 8.68869847181486e-06
likely O 0 2.1712407871632422e-08
represents O 0 1.03788488914347e-09
a O 0 1.6476573438950481e-09
new O 0 9.062785522040429e-10
category O 0 1.3453944625041458e-09
of O 0 4.6024797306642995e-09
the O 0 2.7029157578795093e-08
LDLR O 0 0.0003890757216140628
family O 0 8.821501751299365e-07
. O 0 1.6187037488180067e-07

Both O 0 1.2765060546371387e-06
human O 0 1.8522682694310788e-06
and O 0 7.902250445113168e-07
mouse O 0 4.4692918891087174e-05
LRP5 O 0 0.058880049735307693
cDNAs O 0 3.606105747167021e-05
have O 0 1.3806301879526472e-08
been O 0 2.219036510098249e-08
isolated O 0 1.9647903570785274e-07
and O 0 4.5776862300783705e-09
the O 0 8.005515361730886e-09
encoded O 0 8.218805636062143e-10
mature O 0 8.583616040169773e-10
proteins O 0 2.5546178020197097e-11
are O 0 1.461742532571364e-11
95 O 0 3.549757154885924e-09
% O 0 1.7742236846363113e-10
identical O 0 1.208813382724827e-09
, O 0 6.737096991393798e-11
indicating O 0 1.0252161342094723e-09
a O 0 1.7779271388462803e-09
high O 0 9.492796770871337e-09
degree O 0 1.0353130797113863e-08
of O 0 1.2421216277758163e-09
evolutionary O 0 6.383174433466365e-09
conservation O 0 3.572429907450214e-09
. O 0 4.0741954254741586e-10
. O 0 6.5960437112266845e-09

The O 0 7.366526915575378e-06
APC B-Disease 0 1.8172602267441107e-06
variants O 0 4.707194420916494e-07
I1307K O 0 2.294697651450406e-06
and O 0 1.2185319420154883e-08
E1317Q O 0 1.5483786341974337e-07
are O 0 1.7555612519259967e-10
associated O 0 8.767379995333613e-07
with O 1 0.9981138706207275
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 6.3635357037128415e-06
but O 0 3.539960102827422e-09
not O 0 4.813769383105182e-10
always O 0 2.2217245820854714e-09
with O 0 1.2646088343171158e-10
a O 0 7.282156655463723e-09
family O 0 3.2619933421074165e-08
history O 0 2.5674490089500068e-08
. O 0 3.952631999482037e-08

Classical O 1 0.9758409857749939
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 9.805188892642036e-05
FAP B-Disease 0 0.00019481479830574244
) O 0 9.798427846874347e-09
is O 0 2.629496176353996e-09
a O 0 9.570775461043013e-08
high O 1 0.9999581575393677
- O 1 1.0
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
that O 0 6.469007551856976e-09
predisposes O 0 2.5378190002811607e-06
to O 0 1.368345259322723e-08
hundreds O 0 6.249858408580167e-09
or O 0 1.4173527240757267e-08
thousands O 0 1.4463526376573554e-08
of O 1 0.9997134804725647
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
and O 0 4.2349378759354295e-07
that O 0 3.2680805284179826e-10
results O 0 8.094719339268863e-10
from O 0 5.711231487737223e-09
truncating O 0 1.2544893479571328e-07
mutations O 0 8.370396042955974e-10
in O 0 5.221063026361605e-10
the O 0 1.0496511215762894e-08
APC B-Disease 0 9.523829902491343e-08
gene O 0 1.804098381796848e-08
. O 0 3.8231242172059865e-08

A O 0 1.0949894431178109e-06
variant O 0 3.537124939612113e-06
of O 0 1.0956589449051535e-06
FAP B-Disease 0 6.249677244341001e-05
is O 0 7.047590884212696e-07
attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
, O 0 1.1353672135783199e-07
which O 0 7.57114315685925e-10
results O 0 7.370832277864281e-10
from O 0 2.6692088539448378e-09
germ O 0 0.14536967873573303
- O 0 7.9499623097945e-06
line O 0 5.425982294582354e-07
mutations O 0 5.172040573597769e-10
in O 0 3.039105911373241e-10
the O 0 3.917519197926822e-09
5 O 0 3.244078783382065e-09
and O 0 2.9239899390631763e-10
3 O 0 3.77372710858026e-09
regions O 0 5.216981846523083e-10
of O 0 1.8162792159159835e-08
the O 0 7.096299015074692e-08
APC B-Disease 0 3.566638326901739e-07
gene O 0 5.313717466037815e-08
. O 0 5.6900645972746133e-08

Attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 1 0.9999916553497314
have O 0 3.023628494247532e-07
" O 0 5.585837925536907e-07
multiple O 0 0.004758389666676521
" O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 5.160399041415076e-08
typically O 0 2.6601671976322905e-09
fewer O 0 2.621672601232916e-10
than O 0 7.368410742669695e-11
100 O 0 1.302533775282555e-10
) O 0 8.30141597824019e-12
without O 0 1.2347629863018739e-10
the O 0 1.7063430668429191e-09
florid O 0 1.168925720662628e-07
phenotype O 0 2.2925306097931752e-08
of O 0 3.6577891826539144e-09
classical O 0 1.768654023237559e-08
FAP B-Disease 0 6.567918262589956e-07
. O 0 6.317239353847981e-08

Another O 0 3.77713604393648e-07
group O 0 5.1773327847115524e-09
of O 0 2.682106625684355e-08
patients O 0 5.3960786061679755e-08
with O 0 3.3429288226471954e-09
multiple O 0 8.209903171518818e-05
adenomas B-Disease 1 1.0
has O 0 1.8313980376660766e-07
no O 0 1.5050593660248524e-08
mutations O 0 1.3556232802969248e-09
in O 0 1.193463994297872e-09
the O 0 1.1023099766305222e-08
APC B-Disease 0 1.4575019413598511e-08
gene O 0 1.1340210992472066e-09
, O 0 1.04511718723721e-10
and O 0 1.5337532632830886e-10
their O 0 8.51993753325786e-10
phenotype O 0 2.963978040781967e-08
probably O 0 1.504249169670402e-09
results O 0 2.8656085837575063e-10
from O 0 8.737334189490298e-10
variation O 0 3.572520057559814e-08
at O 0 2.3520769332208147e-08
a O 0 3.6379039780598532e-09
locus O 0 9.077460561002226e-09
, O 0 8.031170173339319e-11
or O 0 3.971050988038627e-10
loci O 0 5.917867973437296e-09
, O 0 1.490983031482429e-10
elsewhere O 0 2.50225817843841e-09
in O 0 1.48656542631187e-09
the O 0 2.1410471617855364e-08
genome O 0 5.9045774492005876e-08
. O 0 8.816692798063741e-08

Recently O 0 3.7311556297936477e-06
, O 0 7.715263983243403e-09
however O 0 7.1447674443447795e-09
, O 0 7.407108260082396e-10
a O 0 3.789343061555428e-09
missense O 0 1.2537118720956641e-07
variant O 0 3.389461198821664e-06
of O 0 0.0004140095552429557
APC B-Disease 0 3.714746708283201e-05
( O 0 1.417642003787023e-08
I1307K O 0 2.754161698703683e-07
) O 0 8.36717140018095e-10
was O 0 1.3202892112929021e-08
described O 0 1.7626853310304114e-09
that O 0 2.462259215962881e-11
confers O 0 8.844019960818628e-10
an O 0 5.0084931861593684e-12
increased O 0 6.95122084892752e-11
risk O 0 8.584914112930164e-09
of O 1 0.9955388903617859
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 2.846239226528269e-07
including O 0 9.977553006024209e-09
multiple O 0 6.611982371396152e-06
adenomas B-Disease 1 0.9999977350234985
, O 0 3.116334568176171e-08
in O 0 5.076490765532071e-07
Ashkenazim O 1 0.9974364638328552
. O 0 1.0737953743955586e-05

We O 0 2.1610753719869535e-07
have O 0 2.3011335059663907e-09
studied O 0 1.388669357282879e-08
a O 0 1.6412589065595284e-09
set O 0 7.803093171609987e-10
of O 0 1.1330028026890204e-09
164 O 0 4.139161902116939e-09
patients O 0 3.286533267754521e-10
with O 0 6.697664090005162e-10
multiple O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
/ I-Disease 1 1.0
or I-Disease 1 1.0
carcinoma I-Disease 1 1.0
and O 0 7.150236456254788e-07
analyzed O 0 2.407216648236954e-08
codons O 0 1.2580086306002158e-08
1263 O 0 1.7093102542276029e-06
- O 0 2.021736094093285e-07
1377 O 0 2.4591804503870662e-06
( O 0 4.836835820754004e-09
exon O 0 6.253974760284109e-08
15G O 0 4.465594827252062e-08
) O 0 7.076703112396387e-11
of O 0 2.8231530446731767e-09
the O 0 2.057729275861675e-08
APC B-Disease 0 3.8639058175249374e-08
gene O 0 9.978556869683075e-10
for O 0 4.5241968504861063e-10
germ O 0 0.0001752509269863367
- O 0 4.477946276892908e-06
line O 0 2.3967813831404783e-06
variants O 0 2.2036811060388573e-06
. O 0 6.727572099407553e-07

Three O 0 1.2975333447684534e-06
patients O 0 1.2051931719270215e-07
with O 0 1.686711104120775e-09
the O 0 6.103673655388775e-08
I1307K O 0 4.243347007104603e-07
allele O 0 6.16516926399413e-09
were O 0 9.606888617952336e-10
detected O 0 7.2551222807248905e-09
, O 0 1.9183118635246466e-11
each O 0 5.203719399826667e-12
of O 0 2.1028367935826964e-09
Ashkenazi O 0 1.5424568573507713e-06
descent O 0 6.105961347202538e-06
. O 0 6.792549243073154e-07

Four O 0 1.2500253433245234e-05
patients O 0 1.0138602419829112e-06
had O 0 4.2506212594162207e-07
a O 0 1.1727880178113992e-07
germ O 0 0.001327247591689229
- O 0 2.763175689324271e-05
line O 0 1.2399369552440476e-05
E1317Q O 0 3.646795676104375e-06
missense O 0 5.262941158434842e-07
variant O 0 6.770437153136299e-07
of O 0 9.935984053299762e-07
APC O 0 1.9579871946007188e-07
that O 0 1.0422233076567977e-09
was O 0 2.5671944570149208e-08
not O 0 4.6377415796605703e-11
present O 0 4.93532770207139e-10
in O 0 2.673044008361103e-10
controls O 0 2.066238957709743e-09
; O 0 9.41165895218532e-11
one O 0 2.0971920033918678e-10
of O 0 1.8251684608117102e-09
these O 0 1.8299640969221542e-10
individuals O 0 6.20752338420516e-11
had O 0 1.6370794497788665e-08
an O 0 2.380031449700226e-10
unusually O 0 2.0411854428914467e-09
large O 0 4.2382061749002276e-10
number O 0 1.563848633923115e-10
of O 0 4.175942436290825e-08
metaplastic B-Disease 0 3.768195165321231e-05
polyps I-Disease 0 1.7540623957756907e-05
of I-Disease 0 8.38055075291777e-06
the I-Disease 0 2.026815309363883e-05
colorectum I-Disease 0 0.0013437937013804913
. O 0 4.079552581970347e-06

There O 0 4.014923717932106e-07
is O 0 2.975111712544276e-09
increasing O 0 5.79389092258964e-10
evidence O 0 5.336221686746967e-09
that O 0 1.0252332316440516e-10
there O 0 9.674588213881563e-11
exist O 0 4.800172481722598e-10
germ O 0 3.2253758490696782e-06
- O 0 7.028877746506623e-08
line O 0 2.455677972079684e-08
variants O 0 1.4749188537166447e-08
of O 0 5.402174707569429e-08
the O 0 3.110847046627896e-08
APC B-Disease 0 1.1451590786748511e-08
gene O 0 4.4059109138849806e-10
that O 0 8.400299900124253e-11
predispose O 0 1.683619998971153e-08
to O 0 4.0164815917620444e-10
the O 0 5.0760617931189245e-09
development O 0 1.7406257768470823e-08
of O 0 7.525625989046603e-08
multiple O 1 0.9999998807907104
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
, O 0 1.0294942676125629e-08
but O 0 6.203868530008094e-10
without O 0 6.8041008383090684e-09
the O 0 4.247630513987133e-08
florid O 0 5.547143473449978e-07
phenotype O 0 4.306167866729993e-08
of O 0 1.1984647940721516e-08
classical O 0 5.412571368879071e-08
FAP B-Disease 0 3.244189201723202e-07
, O 0 1.5359839788953167e-10
and O 0 7.275540586659801e-11
possibly O 0 4.94191187971893e-10
with O 0 4.4244018171379906e-11
importance O 0 2.937367469257879e-07
for O 0 0.006428352557122707
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 1.0703274710976984e-05
in O 0 4.601485859012655e-10
the O 0 1.3662661002555865e-09
general O 0 1.957817685749319e-09
population O 0 5.6778345046415435e-12
. O 0 1.0630444441384057e-10
. O 0 5.530386371077611e-09

Genomic O 0 8.661097581352806e-07
structure O 0 4.8744766445452115e-08
of O 0 4.8396895380165006e-08
the O 0 3.9581092181606436e-08
human O 0 0.0003254420589655638
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 0.13590526580810547
CLD B-Disease 1 1.0
) O 0 7.741845564623873e-08
gene O 0 1.9583308130677324e-07
. O 0 2.4264281250907516e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9993213415145874
CLD B-Disease 1 1.0
) O 0 2.469044524389119e-08
is O 0 6.842176270005496e-10
caused O 0 4.13598932880177e-09
by O 0 6.459309476181119e-11
mutations O 0 2.344791305564087e-10
in O 0 3.496655187618103e-10
a O 0 2.007203070419905e-09
gene O 0 3.054202724062094e-10
which O 0 1.2601063248407485e-10
encodes O 0 9.285670010683589e-10
an O 0 2.6310800760320774e-10
intestinal O 0 9.785056818145677e-07
anion O 0 8.084849696388119e-07
transporter O 0 2.7410482289269567e-05
. O 0 2.5770805223146453e-07

We O 0 3.2984155495796585e-07
report O 0 2.9486972863423944e-08
here O 0 3.735564746421005e-09
the O 0 3.4153964101335532e-09
complete O 0 3.677264048818074e-09
genomic O 0 2.5107022239012622e-08
organization O 0 1.6932126811752823e-09
of O 0 2.1995433030497225e-08
the O 0 4.046906454391319e-08
human O 0 1.2444633057384635e-07
CLD B-Disease 1 0.602555513381958
gene O 0 6.676166464103517e-08
which O 0 4.861241409415129e-10
spans O 0 1.989604703211967e-09
approximately O 0 4.6342221726725086e-11
39kb O 0 2.8750774205832386e-08
, O 0 5.6445369212010377e-11
and O 0 3.5993963365399395e-10
comprises O 0 1.3977407009591047e-09
21 O 0 5.6172446250002395e-08
exons O 0 1.4987805343480431e-06
. O 0 2.1292783003445948e-07

All O 0 4.995660219719866e-06
exon O 0 2.6389636332169175e-05
/ O 0 3.137153271381976e-06
intron O 0 2.5041774733836064e-06
boundaries O 0 1.6052103646302385e-08
conform O 0 2.3326691689362633e-08
to O 0 1.0629968905107035e-08
the O 0 1.6460883500712953e-07
GT O 0 4.715767863672227e-05
/ O 0 3.38122044922784e-05
AG O 0 0.00010102333180839196
rule O 0 1.3867895631847205e-06
. O 0 8.402361117987311e-07

An O 0 9.783692966891522e-09
analysis O 0 4.954428867165461e-09
of O 0 3.139650317507403e-08
the O 0 6.712415512311054e-08
putative O 0 1.4206068044586573e-05
promoter O 0 9.308522749051917e-06
region O 0 1.5616467408108292e-07
sequence O 0 4.940399378483562e-08
shows O 0 4.816097387561058e-08
a O 0 7.546295677229864e-08
putative O 0 1.3936830328020733e-05
TATA O 0 0.0009659454226493835
box O 0 1.5519104863415123e-06
and O 0 5.5615174687773106e-09
predicts O 0 5.843034944774672e-09
multiple O 0 5.561952232113754e-09
transcription O 0 1.094708963478297e-07
factor O 0 7.797428480671442e-09
binding O 0 1.9869853318255082e-08
sites O 0 1.7819603215230018e-07
. O 0 1.35558835268057e-07

The O 0 4.791336777998367e-06
genomic O 0 1.9724550384125905e-06
structure O 0 4.1752142010409443e-07
was O 0 1.566773875083527e-07
determined O 0 2.1222095192285906e-09
using O 0 1.9337897949611715e-10
DNA O 0 7.256534040323004e-09
from O 0 7.208084129572967e-10
several O 0 3.114358493316871e-10
sources O 0 3.7323379942222346e-09
including O 0 9.60846402442428e-10
multiple O 0 2.154512479535242e-08
large O 0 6.279086619542795e-07
- O 0 2.6672669264371507e-06
insert O 0 6.543292556671076e-07
libaries O 0 5.124170911585679e-06
and O 0 3.611191345953557e-09
genomic O 0 1.6889558196453436e-08
DNA O 0 3.78502491571453e-08
from O 0 1.1254327247911533e-08
Finnish O 0 0.0003646446275524795
CLD B-Disease 1 1.0
patients O 0 0.007079748902469873
and O 0 1.2846738854932482e-06
controls O 0 1.687146141193807e-05
. O 0 1.1772877996918396e-06

Exon O 0 7.135399937396869e-05
- O 0 1.4622740991399041e-06
specific O 0 2.8257456818892024e-08
primers O 0 3.545713127550698e-07
developed O 0 9.972649195333361e-08
in O 0 1.0942237116395859e-09
this O 0 1.1961935608706398e-10
study O 0 5.002003672371913e-11
will O 0 7.395369906737503e-12
facilitate O 0 9.184419197394433e-11
mutation O 0 4.810068315874716e-11
screening O 0 1.6049944706608699e-10
studies O 0 8.505607676512206e-12
of O 0 7.068299417989365e-11
patients O 0 9.401843886758243e-11
with O 0 7.002453478177628e-11
the O 0 9.583416726854921e-08
disease O 0 4.151284883846529e-05
. O 0 3.82778750918078e-07

Genomic O 0 1.9537806110747624e-06
sequencing O 0 6.250361366255675e-07
of O 0 9.535333447274752e-07
a O 0 1.3917605201640981e-06
BAC O 1 0.9938806295394897
clone O 1 0.9981786012649536
H O 1 1.0
_ O 0 5.953021968707617e-07
RG364P16 O 0 5.309988750923367e-07
revealed O 0 1.4009415849614015e-08
the O 0 1.789849601863125e-09
presence O 0 4.262632469220762e-10
of O 0 5.52781331819574e-09
another O 0 4.564320921218723e-09
, O 0 1.741201766103373e-10
highly O 0 7.705553417558519e-10
homologous O 0 4.477806569980203e-09
gene O 0 5.2316320164891295e-09
3 O 0 2.88495964895219e-08
of O 0 2.8012220099071783e-08
the O 0 3.2814918426993245e-07
CLD B-Disease 1 0.7153564095497131
gene O 0 4.7484448373324994e-08
, O 0 3.930240577432187e-10
with O 0 2.6800161048723403e-11
a O 0 9.533909217651626e-10
similar O 0 7.787110400947483e-10
genomic O 0 3.1746846929081585e-08
structure O 0 1.278097840895498e-07
, O 0 3.0865465738827425e-10
recently O 0 5.247519641038423e-10
identified O 0 1.0077769729832653e-09
as O 0 8.838033638269849e-10
the O 0 3.6402039427230193e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 8.431211284687379e-08
( O 0 1.588379650030447e-09
PDS B-Disease 0 3.717520485224668e-06
) O 0 5.630518273846974e-10
. O 0 4.017678634227195e-09
. O 0 1.5245622364545852e-07

The O 0 1.0061354259960353e-05
APCI1307K O 0 0.009037668816745281
allele O 0 3.660336005850695e-06
and O 0 1.5569536060411338e-07
cancer B-Disease 0 0.0035365261137485504
risk O 0 2.211794480899698e-07
in O 0 9.813502899191917e-09
a O 0 2.0970100322870167e-08
community O 0 3.1575448922183114e-09
- O 0 4.183561941317748e-09
based O 0 1.7041271171969186e-10
study O 0 8.240557541894233e-11
of O 0 1.7966697019033973e-09
Ashkenazi O 0 4.868892347076326e-07
Jews O 0 1.0825352347865191e-07
. O 0 2.0045111170929886e-07

Mutations O 0 7.229610332615266e-07
in O 0 3.0393639605108547e-08
APC O 0 1.2128283799484052e-07
are O 0 2.791389341894046e-10
classically O 0 9.062082426680718e-07
associated O 0 7.973180800036062e-07
with O 0 4.705664650828112e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 2.1618170649162494e-05
FAP B-Disease 0 6.616157406824641e-06
) O 0 8.810094875855157e-10
, O 0 1.3058720771397248e-10
a O 0 7.461363082938988e-09
highly O 1 0.9906002283096313
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9999737739562988
by O 0 1.78467985278985e-07
multiple O 0 0.28639814257621765
intestinal O 1 1.0
polyps B-Disease 0 0.0016164713306352496
and O 0 1.4222515609674247e-08
, O 0 1.3782239238757654e-10
without O 0 5.0617234848004955e-09
surgical O 1 0.7286723852157593
intervention O 0 4.1231112845707685e-05
, O 0 2.6784691131709337e-10
the O 0 1.4004626347485782e-09
development O 0 8.013233809833764e-08
of O 0 0.27110764384269714
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.0264849947816401e-07
CRC B-Disease 0 3.2402331271441653e-06
) O 0 1.2738158305936054e-09
. O 0 3.9685414066070734e-08

APC B-Disease 0 2.9956927392049693e-05
is O 0 3.7782237427563814e-07
a O 0 7.429498509736732e-07
tumour O 1 1.0
- O 0 9.58175064624811e-07
suppressor O 0 3.1548017886962043e-07
gene O 0 2.0584034476911484e-09
, O 0 7.949179509081361e-11
and O 0 6.364825888560688e-10
somatic O 0 4.806581728189485e-07
loss O 0 9.545052392923026e-08
occurs O 0 3.379917501433738e-08
in O 0 2.56554972821732e-08
tumours B-Disease 1 1.0
. O 0 1.9549306671251543e-06

The O 0 3.991633639088832e-05
germline O 0 1.784408414096106e-05
T O 0 2.3089442038326524e-06
- O 0 3.2312021858160733e-07
to O 0 1.3153150568712135e-08
- O 0 1.0735681144069531e-07
A O 0 2.7010688086193113e-07
transversion O 0 1.3596994676845497e-06
responsible O 0 1.757305057026315e-08
for O 0 1.3116341346375293e-09
the O 0 3.4723075970077844e-08
APC O 0 1.3930285547303356e-07
I1307K O 0 1.5752944193536678e-07
allele O 0 4.498497130356327e-09
converts O 0 1.1733782834255635e-08
the O 0 7.3725234805976925e-09
wild O 0 6.8945285036647874e-09
- O 0 1.7206939206815264e-09
type O 0 2.443193203305327e-09
sequence O 0 1.3718227664938354e-09
to O 0 3.2739717603647023e-09
a O 0 7.297371240611028e-08
homopolymer O 0 3.506727080093697e-05
tract O 0 9.860289537755307e-06
( O 0 3.5482004001607947e-09
A8 O 0 1.7066018642708514e-07
) O 0 5.645204789739289e-11
that O 0 2.8351350780941864e-11
is O 0 3.8835332172304504e-10
genetically O 0 1.1139817246430539e-07
unstable O 0 0.03722057864069939
and O 0 1.8074586023431038e-06
prone O 0 0.00012963206972926855
to O 0 3.1035045822136453e-07
somatic O 0 4.5069387851981446e-05
mutation O 0 3.1614158046977536e-07
. O 0 1.8614007046835468e-07

The O 0 3.142728928651195e-06
I1307K O 0 3.3057040127459913e-06
allele O 0 3.757052624564494e-08
was O 0 4.8974481359209676e-08
found O 0 1.0833998143056078e-09
in O 0 2.7642901301305756e-09
6 O 0 1.3775741081190063e-07
. O 0 1.0726041210773474e-07

1 O 0 6.168327672639862e-06
% O 0 4.211939241827167e-08
of O 0 7.649373401363846e-08
unselected O 0 0.00025229566381312907
Ashkenazi O 0 0.00018483195162843913
Jews O 0 1.5845184861973394e-06
and O 0 2.3715509556154757e-08
higher O 0 4.8763453719402605e-08
proportions O 0 2.0624686669634684e-07
of O 0 4.897472081211163e-07
Ashkenazim O 0 5.483679342432879e-05
with O 0 5.229657151772926e-09
family O 0 4.4877100435769535e-07
or O 0 1.5889076721009587e-08
personal O 0 7.110537580956588e-07
histories O 0 9.21000548714801e-07
of O 1 0.7691290974617004
CRC B-Disease 1 0.9999158382415771
( O 0 9.992202620878743e-08
ref O 0 0.000140465926961042
. O 0 1.378969471943492e-08
2 O 0 1.1561262169834663e-07
) O 0 2.0558765800871015e-09
. O 0 3.324883834920911e-08

To O 0 3.2165493735192285e-07
evaluate O 0 7.292708801287517e-07
the O 0 1.0251368820490825e-07
role O 0 4.3391139570303494e-08
of O 0 5.195418850689748e-08
I1307K O 0 4.423016548571468e-07
in O 0 3.1953315549060335e-09
cancer B-Disease 0 1.3994107348480611e-06
, O 0 1.1362294438654885e-09
we O 0 2.604240378900613e-09
genotyped O 0 2.3098805286281276e-06
5 O 0 1.3053983138888725e-07
, O 0 4.2381271825320255e-09
081 O 0 5.043877081334358e-06
Ashkenazi O 0 2.773518644971773e-06
volunteers O 0 2.2707757452167243e-08
in O 0 6.512337336062046e-09
a O 0 2.6521435714244035e-08
community O 0 1.1017425194381758e-08
survey O 0 1.984382436148735e-09
. O 0 1.1170153690898132e-08

Risk O 0 1.777982288331259e-05
of O 0 1.896639514598064e-05
developing O 1 1.0
colorectal B-Disease 1 1.0
, I-Disease 1 0.9998733997344971
breast I-Disease 1 1.0
and I-Disease 0 0.0028377086855471134
other I-Disease 0 2.9156195523682982e-05
cancers I-Disease 1 1.0
were O 0 8.671428872730758e-07
compared O 0 1.5584657830913784e-06
between O 0 3.0081973818596452e-06
genotyped O 0 0.0004903966910205781
I1307K O 0 6.445412168432085e-07
carriers O 0 9.841451209524621e-09
and O 0 2.826250788956486e-09
non O 0 1.6717546458266952e-08
- O 0 5.046357998139683e-09
carriers O 0 8.171194831874118e-10
and O 0 1.8588669492558552e-10
their O 0 2.5588614560589917e-10
first O 0 1.5393957220055654e-09
- O 0 2.717859715062332e-09
degree O 0 4.9701995408213406e-08
relatives O 0 9.952999846518651e-08
. O 0 2.766121731667681e-08

Sperm O 0 3.086205992985924e-07
DNA O 0 6.183496026324065e-08
analysis O 0 7.500431387086337e-09
in O 0 5.7067670589106e-09
a O 0 2.006186576863911e-07
Friedreich B-Disease 1 0.9998637437820435
ataxia I-Disease 1 1.0
premutation O 1 0.9999997615814209
carrier O 0 0.0017353045986965299
suggests O 0 1.2418744290698669e-06
both O 0 2.3607917398749123e-08
meiotic O 0 5.592533489107154e-05
and O 0 8.586244604202875e-08
mitotic O 0 4.851482913181826e-07
expansion O 0 1.6689341464370955e-07
in O 0 2.9311835181289325e-09
the O 0 2.2789501841202764e-08
FRDA B-Disease 0 1.2702331332548056e-05
gene O 0 7.376886657084469e-08
. O 0 6.075380554193544e-08

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 1.6846799553604797e-05
usually O 0 2.6450464929439477e-07
caused O 0 1.7374969729644363e-07
by O 0 2.3241976399024367e-10
an O 0 1.7478199443310416e-10
expansion O 0 8.160751718833126e-08
of O 0 4.368569364032737e-07
a O 0 1.001506802822405e-06
GAA O 0 5.3238658438203856e-05
trinucleotide O 0 6.994976865826175e-05
repeat O 0 2.516588040180068e-07
in O 0 1.3770691253967016e-08
intron O 0 7.471462595276535e-07
1 O 0 4.6693287458765553e-08
of O 0 1.4217905075497583e-08
the O 0 1.0057001276209121e-07
FRDA B-Disease 0 0.00011939119576709345
gene O 0 1.889561787038474e-07
. O 0 1.655433266023465e-07

Occasionally O 0 6.626039066759404e-06
, O 0 8.217293157031236e-08
a O 0 3.969964623706801e-08
fully O 0 6.044737688171153e-08
expanded O 0 6.482386538664286e-08
allele O 0 1.970251872762674e-08
has O 0 4.478385162709486e-10
been O 0 1.4649223500917685e-10
found O 0 1.293665036206093e-10
to O 0 1.296186907806529e-10
arise O 0 2.1417732032347203e-09
from O 0 2.560351708424946e-09
a O 0 9.677126655560642e-09
premutation O 0 6.843030178060872e-07
of O 0 8.096950665503755e-08
100 O 0 3.802106629535729e-09
or O 0 3.6227882915795817e-09
less O 0 2.2169636793023528e-08
triplet O 0 2.2228716716199415e-06
repeats O 0 5.530304179046652e-07
. O 0 1.4001220449699758e-07

We O 0 1.062875071511371e-06
have O 0 1.9956448937819005e-08
examined O 0 8.831571562950558e-08
the O 0 6.056680934563019e-09
sperm O 0 1.6182376549878086e-09
DNA O 0 5.635012012561447e-09
of O 0 6.016680931253404e-09
a O 0 1.6018613990809172e-08
premutation O 0 1.0404628483229317e-05
carrier O 0 2.289636995556066e-06
. O 0 9.97287429527205e-07

This O 0 8.801895887700084e-07
mans O 0 3.194711825926788e-05
leucocyte O 0 5.792322554043494e-06
DNA O 0 4.227746899232443e-07
showed O 0 1.863146081859668e-08
one O 0 6.904763427684202e-10
normal O 0 6.50473619412395e-10
allele O 0 5.481509135485396e-10
and O 0 1.8038522064944829e-10
one O 0 2.8011535799232767e-11
allele O 0 2.537021703830078e-10
of O 0 8.79469941317268e-10
approximately O 0 3.610872989501246e-10
100 O 0 3.946460491732751e-09
repeats O 0 1.674026606224288e-08
. O 0 3.033919426798093e-08

His O 0 6.71444604449789e-06
sperm O 0 5.853272000422294e-07
showed O 0 2.364658335807235e-08
an O 0 6.057925272529019e-10
expanded O 0 4.772258588303657e-09
allele O 0 1.7104593297290194e-08
in O 0 3.79046305454267e-09
a O 0 2.8786770300825992e-08
tight O 0 4.959943566973379e-07
range O 0 2.068007063371624e-07
centering O 0 6.718973963870667e-07
on O 0 5.9434579924300124e-08
a O 0 2.1938186822723083e-09
size O 0 3.860596287097451e-09
of O 0 5.919651435704054e-09
approximately O 0 1.2673621041514593e-09
320 O 0 1.7301134747071956e-08
trinucleotide O 0 1.0696722711145412e-05
repeats O 0 6.840159585408401e-07
. O 0 2.393436773218127e-07

His O 0 3.52673523593694e-05
affected O 0 3.019060841324972e-06
son O 0 0.20679119229316711
has O 0 1.090401102743499e-08
repeat O 0 5.313958162389554e-09
sizes O 0 2.955587552477823e-09
of O 0 3.4797860593016594e-08
1040 O 0 1.653489334785263e-06
and O 0 2.299761270307954e-08
540 O 0 7.629411413745402e-08
. O 0 7.750103492298877e-08

These O 0 9.936744049809931e-08
data O 0 6.882168435140557e-08
suggest O 0 5.831010785328772e-09
that O 0 3.350920096956145e-10
expansion O 0 1.2662465742607765e-08
occurs O 0 2.347929628498946e-09
in O 0 3.5602518155819496e-10
two O 0 1.105686445179721e-10
stages O 0 2.998960635380854e-09
, O 0 6.012453729331568e-11
the O 0 6.922063477965423e-10
first O 0 5.104681677359224e-10
during O 0 5.277229764288904e-10
meiosis O 0 2.3196990994733824e-09
followed O 0 1.1518704878810127e-09
by O 0 7.857138550892984e-11
a O 0 3.484194266434315e-09
second O 0 1.8599362050508716e-08
mitotic O 0 2.3183696384876384e-07
expansion O 0 2.0358963865874102e-06
. O 0 4.894982907899248e-07

We O 0 5.959479494777042e-06
also O 0 1.0536793126902921e-07
show O 0 2.2260213672353757e-09
that O 0 6.842042210575272e-11
in O 0 1.7928176998527334e-10
all O 0 4.2045082693231706e-11
informative O 0 1.4435262707390706e-10
carrier O 0 1.8065560158930793e-09
father O 0 1.9278477481066147e-08
to O 0 9.38953803597542e-10
affected O 0 1.9683952245941327e-09
child O 0 2.2351441586465626e-08
transmissions O 0 7.02359770343719e-08
, O 0 1.7729415158207473e-10
with O 0 3.312415619571851e-11
the O 0 2.924052555641765e-09
notable O 0 1.453886122604331e-09
exception O 0 4.255802821262478e-09
of O 0 4.93474878737743e-08
the O 0 5.748501763491731e-08
premutation O 0 1.2243443734405446e-06
carrier O 0 4.6897770999976274e-08
, O 0 4.941450026940686e-10
the O 0 4.27436663841263e-09
expansion O 0 2.1562350127624086e-08
size O 0 1.045375430663853e-08
decreases O 0 1.200066002127187e-08
. O 0 1.9562460540356597e-09
. O 0 2.6980430334333505e-08

The O 0 3.0717435492988443e-06
R496H O 0 5.090708327770699e-06
mutation O 0 1.100883793014873e-07
of O 0 1.4680095716812502e-07
arylsulfatase O 0 2.3772725398885086e-05
A O 0 8.737522989576973e-07
does O 0 4.900547967423563e-09
not O 0 2.3347779265492363e-09
cause O 0 2.535643034207169e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 4.807558070751838e-06

Deficiency B-Disease 1 0.9999754428863525
of I-Disease 0 0.0014743752544745803
arylsulfatase I-Disease 1 0.9911155700683594
A I-Disease 0 0.006272092927247286
( O 0 2.6222960514132865e-07
ARSA O 0 0.012776503339409828
) O 0 7.290620551714255e-09
enzyme O 0 1.354780607698558e-07
activity O 0 2.582556568597738e-08
causes O 0 1.0281960385327693e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 2.4244087626357214e-07
MLD B-Disease 1 1.0
) O 0 3.547200577713738e-08
. O 0 5.365453858985347e-08

A O 0 2.4680614387762034e-06
number O 0 1.4960438221578443e-08
of O 0 2.2918449360531667e-07
ARSA O 0 0.00025550046120770276
gene O 0 8.413748986413339e-08
mutations O 0 1.3172205548528382e-08
responsible O 0 9.45988265499409e-09
for O 0 2.5898767574972226e-08
MLD B-Disease 1 1.0
have O 0 9.943740053586225e-08
been O 0 3.581655860784849e-08
identified O 0 4.0156582059580614e-08
. O 0 2.5035197026568312e-08

Recently O 0 1.6431285985163413e-05
, O 0 4.595236902105171e-08
the O 0 6.206987279711029e-08
R496H O 0 1.000062752609665e-06
mutation O 0 1.620094636223257e-08
of O 0 7.192927853338915e-08
ARSA O 0 0.0002559098065830767
was O 0 2.4544235088796995e-07
proposed O 0 9.258492639219185e-09
to O 0 1.2632159762659967e-09
be O 0 6.639904737149038e-10
a O 0 5.708618022737255e-09
cause O 0 6.862244106287108e-08
of O 0 1.239400376107369e-06
MLD B-Disease 1 1.0
( O 0 8.549670837965095e-08
Draghia O 0 2.913321168307448e-06
et O 0 1.171708134961591e-07
al O 0 1.4411884308174194e-07
. O 0 3.138581339268143e-10
, O 0 6.05875419279478e-11
1997 O 0 6.052300882686268e-10
) O 0 5.530447211299361e-10
. O 0 3.58846641290711e-08

We O 0 7.721750421296747e-07
have O 0 1.4500485256974116e-08
investigated O 0 7.290178416496929e-08
the O 0 1.1955538781194264e-08
R496H O 0 8.392672867785222e-08
mutation O 0 1.1641753117075382e-09
and O 0 1.9783158444752758e-10
found O 0 1.0675430678341868e-10
this O 0 1.8572793303306412e-10
mutation O 0 2.4822266464497034e-09
at O 0 6.32096108788005e-09
a O 0 2.5110744594769585e-09
relatively O 0 8.693054276420753e-09
high O 0 9.027031211417125e-08
frequency O 0 1.9951881924384907e-08
in O 0 1.2899501466989705e-09
an O 0 8.805436935155342e-11
African O 0 2.0511597975669815e-10
American O 0 1.4106438239736008e-10
population O 0 1.149042449730131e-12
( O 0 1.2185068926084952e-11
f O 0 2.282759981042659e-09
= O 0 2.4344435356482563e-09
0 O 0 1.1319550852206817e-09
. O 0 9.006466406003e-11
09 O 0 2.9569182657951387e-09
, O 0 2.360537321166589e-10
n O 0 5.083008236539399e-09
= O 0 1.1523633602905647e-08
61 O 0 7.493424547533323e-09
subjects O 0 1.0526624905082826e-08
) O 0 1.5559590282876457e-09
. O 0 3.903394585336173e-08

The O 0 0.000985827879048884
ARSA O 0 0.12188486754894257
enzyme O 0 9.5666121069371e-07
activity O 0 1.324845033678912e-08
in O 0 4.0873568418753337e-10
subjects O 0 1.6609286168645099e-09
with O 0 8.88954188038582e-11
and O 0 5.726095153590904e-10
without O 0 3.1930715849171065e-09
the O 0 1.9975491483137375e-08
R496H O 0 7.188827311210844e-08
mutation O 0 8.193981604343037e-10
was O 0 2.879883664874683e-09
determined O 0 8.554262298510196e-10
and O 0 3.1327559990579346e-10
found O 0 2.8394767093153916e-10
to O 0 6.928271845119127e-10
be O 0 3.3299025758992684e-09
normal O 0 1.2708198937616544e-07
. O 0 1.1141560207761358e-07

It O 0 1.7998128498675214e-07
is O 0 3.587657060322158e-09
therefore O 0 3.41864869746189e-09
concluded O 0 1.1972494107226339e-08
that O 0 1.928647658244742e-10
the O 0 3.6904879152643844e-09
R496H O 0 9.86910535516472e-08
mutation O 0 6.960859888494042e-09
of O 0 1.6383233969463618e-07
ARSA O 0 0.003302130149677396
does O 0 8.289055664079115e-09
not O 0 1.284418793545683e-09
negatively O 0 7.1496750742028325e-09
influence O 0 2.740703664017019e-08
the O 0 1.770155755309588e-08
activity O 0 3.4151683703242952e-09
of O 0 1.804315097331255e-08
ARSA O 0 4.945178079651669e-05
and O 0 1.973432750546067e-09
is O 0 7.508739463535363e-11
not O 0 5.075611805849256e-11
a O 0 3.456163577553184e-09
cause O 0 2.5868905595416436e-07
of O 0 1.0316660336684436e-05
MLD B-Disease 1 1.0

Down O 0 0.00018178934988100082
- O 0 3.723406507560867e-06
regulation O 0 3.322656141335756e-07
of O 0 5.265531655140876e-08
transmembrane O 0 9.849134841033447e-08
carbonic O 0 3.916417699656449e-05
anhydrases O 0 0.0011719781905412674
in O 0 1.9222081846237415e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999995231628418
lines O 0 3.5028810430048907e-07
by O 0 3.3099876173281473e-09
wild O 0 1.7653719908139465e-07
- O 0 3.206316279147359e-08
type O 0 1.6865544239408337e-05
von B-Disease 1 1.0
Hippel I-Disease 1 1.0
- I-Disease 1 0.9850208759307861
Lindau I-Disease 1 0.5564634799957275
transgenes O 0 0.00039683294016867876
. O 0 1.4506509842249216e-06

To O 0 6.167235824250383e-07
discover O 0 5.693418714258769e-08
genes O 0 3.2493612245332315e-09
involved O 0 2.2596620130599376e-09
in O 0 7.87737430840707e-09
von B-Disease 1 0.9999313354492188
Hippel I-Disease 1 1.0
- I-Disease 1 0.9999994039535522
Lindau I-Disease 1 0.9999998807907104
( O 0 5.162717684470408e-07
VHL B-Disease 1 0.9999985694885254
) O 0 1.3464482151448465e-07
- O 0 6.986093012528727e-06
mediated O 1 0.771232008934021
carcinogenesis O 1 1.0
, O 0 5.597543761837187e-08
we O 0 6.79577416562438e-09
used O 0 3.3216499559785007e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999701976776123
lines O 0 3.0486530704365578e-06
stably O 0 1.2224122656334657e-06
transfected O 0 5.641950906465354e-07
with O 0 4.635694050847405e-09
wild O 0 1.9044361465603288e-07
- O 0 1.0929126403880218e-07
type O 0 1.6562920791329816e-05
VHL O 1 1.0
- O 0 0.0002447230217512697
expressing O 0 1.1403451480873628e-06
transgenes O 0 0.00014752006973139942
. O 0 6.548092983393872e-07

Large O 0 8.404648724535946e-06
- O 0 9.83491372608114e-06
scale O 0 1.2329152923484799e-05
RNA O 0 3.2936518437054474e-06
differential O 0 3.326454418584035e-07
display O 0 1.4287007132907092e-08
technology O 0 4.713280787882468e-08
applied O 0 8.109172888737248e-09
to O 0 4.89004170489693e-10
these O 0 1.3693177147722224e-10
cell O 0 2.237067775467949e-08
lines O 0 4.0655787070242866e-10
identified O 0 2.5455718088984725e-10
several O 0 1.4953262239547627e-10
differentially O 0 1.4319581076449595e-08
expressed O 0 6.142020780863788e-10
genes O 0 3.175056884074934e-10
, O 0 3.852427751804832e-11
including O 0 6.797504226163653e-11
an O 0 1.574113339675165e-10
alpha O 0 4.265125497227018e-08
carbonic O 0 1.318426711804932e-06
anhydrase O 0 2.0488863810896873e-05
gene O 0 5.114081602641818e-08
, O 0 2.117854558392196e-09
termed O 0 6.726551760039001e-07
CA12 O 0 0.0005188966752029955
. O 0 1.1259393204454682e-06

The O 0 3.4119002521038055e-06
deduced O 0 7.693707857470145e-07
protein O 0 1.9091382696956316e-08
sequence O 0 3.032379014555886e-09
was O 0 1.483889100484248e-08
classified O 0 1.9002330819972713e-09
as O 0 1.18480669719645e-09
a O 0 6.549483178019955e-09
one O 0 2.0230006114729804e-08
- O 0 7.997161333150871e-07
pass O 0 4.0572895159129985e-06
transmembrane O 0 1.8879887875300483e-06
CA O 0 1.144066231972829e-06
possessing O 0 1.0258840887900078e-07
an O 0 1.4351162036518872e-08
apparently O 0 1.0313515304005705e-06
intact O 0 3.351477971591521e-06
catalytic O 0 2.7618207809609885e-07
domain O 0 7.080359409883386e-08
in O 0 8.941979601218009e-09
the O 0 5.236207201164689e-08
extracellular O 0 6.456720029746066e-07
CA O 0 2.0853072783211246e-05
module O 0 0.00018258461204823107
. O 0 5.676313321600901e-07

Reintroduced O 0 8.49134085001424e-05
wild O 0 8.939081453718245e-06
- O 0 1.924189064084203e-06
type O 0 1.581981791787257e-06
VHL B-Disease 1 0.9999980926513672
strongly O 0 1.0062659612231073e-06
inhibited O 0 8.299791147692304e-07
the O 0 6.295936572087157e-08
overexpression O 0 1.1104813779638789e-07
of O 0 2.40402311391108e-08
the O 0 1.4053896713051017e-08
CA12 O 0 6.468547439908434e-07
gene O 0 4.407776643677863e-10
in O 0 3.4005333271469596e-11
the O 0 1.10735443037413e-09
parental O 0 7.906909331723e-07
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999974966049194
lines O 0 1.1335834642522968e-05
. O 0 1.2022582041026908e-06

Similar O 0 7.758149678238624e-08
results O 0 6.04429839512477e-09
were O 0 2.499062512484329e-09
obtained O 0 7.557685144377047e-09
with O 0 4.6008100107464145e-10
CA9 O 0 4.118093056604266e-05
, O 0 3.285218763693365e-09
encoding O 0 5.353728127488466e-08
another O 0 6.930101648094933e-08
transmembrane O 0 1.47873066680404e-07
CA O 0 1.485271496903806e-07
with O 0 5.677602277209814e-10
an O 0 1.1590550741402694e-09
intact O 0 3.3540698041178985e-07
catalytic O 0 3.0939827411202714e-07
domain O 0 4.2484447249080404e-07
. O 0 1.4191738273439114e-07

Although O 0 3.5548211485547654e-07
both O 0 4.497075423159913e-08
domains O 0 4.378053475306842e-08
of O 0 3.799513592639414e-07
the O 0 2.570257038314594e-07
VHL B-Disease 0 0.015541935339570045
protein O 0 1.575076709059431e-07
contribute O 0 2.681159072537298e-09
to O 0 3.731448483534905e-09
regulation O 0 1.8235867571547715e-07
of O 0 3.07309250047183e-07
CA12 O 0 0.22227320075035095
expression O 0 4.944217479874169e-08
, O 0 2.737091109317191e-10
the O 0 2.3372328517012875e-09
elongin O 0 5.6655139246686304e-08
binding O 0 7.3165447034284625e-09
domain O 0 1.5377032980268268e-08
alone O 0 4.674637565926787e-09
could O 0 5.781210177246976e-09
effectively O 0 3.316814556342251e-08
regulate O 0 8.211684132675146e-08
CA9 O 0 0.0002452172338962555
expression O 0 1.3433538015306112e-06
. O 0 4.538678695098497e-07

We O 0 9.483220310357865e-06
mapped O 0 2.228701487183571e-05
CA12 O 0 0.004375837743282318
and O 0 1.6574140317970887e-06
CA9 O 0 0.0018049293430522084
loci O 0 1.7634096138863242e-06
to O 0 6.852147294011957e-08
chromosome O 0 1.0512784598404323e-07
bands O 0 5.636250648421992e-07
15q22 O 0 2.460728637743159e-06
and O 0 4.612834914041741e-08
17q21 O 0 2.663138957359479e-06
. O 0 1.4503063994197873e-07

2 O 0 5.882056939299218e-06
respectively O 0 1.3559970568621793e-07
, O 0 4.751223858789899e-09
regions O 0 1.7978498689785738e-08
prone O 0 3.4093241083610337e-06
to O 0 2.3112473712672e-08
amplification O 0 0.00020964807481504977
in O 0 1.6796555257769796e-08
some O 0 1.8241175236966e-09
human O 0 4.898859060631366e-07
cancers B-Disease 0 0.041609026491642
. O 0 4.370677970655379e-07

Additional O 0 5.702700036636088e-07
experiments O 0 6.341879839055764e-07
are O 0 7.877309915471642e-10
needed O 0 2.8243233529678946e-08
to O 0 2.930903963971332e-09
define O 0 1.638250957114451e-08
the O 0 3.7964703381021536e-08
role O 0 7.805973467611693e-08
of O 0 9.162959599962051e-07
CA O 0 1.1358647498127539e-05
IX O 1 0.9999998807907104
and O 0 1.7970796761801466e-05
CA O 0 7.448963060596725e-06
XII O 0 0.0015910365618765354
enzymes O 0 3.209651211477649e-08
in O 0 1.726298770599044e-09
the O 0 2.658057329796293e-09
regulation O 0 4.300765077402957e-09
of O 0 2.52197018824063e-09
pH O 0 1.8562298009783262e-07
in O 0 3.78927778044158e-09
the O 0 1.919346637180297e-08
extracellular O 0 7.179838235060743e-08
microenvironment O 0 1.7679847132967552e-06
and O 0 4.892852345506071e-09
its O 0 7.38505923081334e-10
potential O 0 4.333884362495155e-09
impact O 0 2.6739337855019585e-08
on O 0 2.698911032439355e-07
cancer B-Disease 0 4.6663781176903285e-06
cell O 0 2.5785948309930973e-06
growth O 0 1.6941923419722116e-08
. O 0 1.0599482180850828e-07

A O 0 1.7536875702717225e-06
gene O 0 1.7221196912942105e-08
encoding O 0 8.625359271263733e-08
a O 0 5.7999120173235497e-08
transmembrane O 0 1.0929413818416833e-08
protein O 0 1.1339864602888383e-09
is O 0 2.1680924416900282e-11
mutated O 0 6.323658818807587e-10
in O 0 8.266043405313894e-11
patients O 0 2.3745008181919047e-09
with O 0 1.282544204173064e-08
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 0 2.0891926396870986e-05
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 1.7588936973567115e-09
. O 0 1.8132677581661483e-08

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.3293652955326252e-05
WFS B-Disease 1 0.9998263716697693
; O 0 3.8202020391508995e-07
OMIM O 0 0.02951057441532612
222300 O 0 3.6439173527469393e-06
) O 0 4.495209759980412e-10
is O 0 3.773653334260274e-10
an O 0 6.807164165678614e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 8.20457426016219e-05
by O 0 4.612694510797155e-07
young O 0 4.364506821730174e-06
- O 0 0.061241958290338516
onset O 1 1.0
non O 1 1.0
- O 1 1.0
immune O 1 1.0
insulin B-Disease 1 1.0
- I-Disease 1 0.9999814033508301
dependent I-Disease 1 0.9986070990562439
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.0022619962692260742
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 0 0.0854429304599762
. O 0 2.0895054149150383e-06

Linkage O 0 9.737607615534216e-05
to O 0 4.5968062067913706e-07
markers O 0 9.517735293229634e-07
on O 0 6.027785843798483e-07
chromosome O 0 3.044966945253691e-07
4p O 0 0.000698057992849499
was O 0 3.4179242902609985e-07
confirmed O 0 1.7335288760023104e-08
in O 0 6.483629744202801e-10
five O 0 2.8041391431088414e-09
families O 0 3.6446272666523782e-09
. O 0 6.293534937640288e-08

On O 0 2.422537363599986e-06
the O 0 1.952228956270119e-08
basis O 0 1.5970565314660234e-08
of O 0 5.740448472124626e-08
meiotic O 0 0.0003789567854255438
recombinants O 0 0.31763142347335815
and O 0 1.7794725692965585e-07
disease O 0 6.476583803305402e-05
- O 0 1.1978391967204516e-07
associated O 0 2.2448625713877846e-07
haplotypes O 0 1.1034080671379343e-06
, O 0 4.113190676946488e-09
the O 0 1.316736160106302e-07
WFS B-Disease 0 0.008045815862715244
gene O 0 1.2119750181227573e-07
was O 0 4.5226829570310656e-07
localized O 0 1.274103595960696e-07
to O 0 3.100658219068464e-08
a O 0 9.121928314925754e-07
BAC O 0 0.008331334218382835
/ O 0 1.165637240774231e-05
P1 O 0 5.88963985137525e-06
contig O 0 9.149224524662714e-07
of O 0 4.960915678253741e-09
less O 0 1.1900385121776935e-09
than O 0 3.306515339307481e-10
250 O 0 3.8137417668338e-09
kb O 0 8.27671897241089e-07
. O 0 1.8755616792986984e-07

Mutations O 0 2.482903482814436e-07
in O 0 1.676627547908538e-08
a O 0 2.60676635832624e-08
novel O 0 5.45630278736553e-08
gene O 0 7.3144241774514285e-09
( O 0 8.306365595345255e-10
WFS1 O 0 7.73931333242217e-06
) O 0 3.3749105732283624e-09
encoding O 0 1.094500134968257e-07
a O 0 5.25419011410122e-07
putative O 0 9.518900697003119e-06
transmembrane O 0 5.4370108415469076e-08
protein O 0 8.32019608765222e-09
were O 0 9.335714423741592e-10
found O 0 1.156572948524115e-09
in O 0 5.077830933508665e-10
all O 0 3.5465341774454373e-10
affected O 0 4.675312914592666e-10
individuals O 0 2.300933749088685e-11
in O 0 5.20606979748095e-09
six O 0 1.3253384167910554e-07
WFS B-Disease 1 0.9633713364601135
families O 0 1.349404410433408e-08
, O 0 1.509479208294806e-10
and O 0 4.3870913846166815e-11
these O 0 2.1928377516577946e-11
mutations O 0 1.0551620688303842e-10
were O 0 6.97768162694068e-11
associated O 0 5.997864427342847e-10
with O 0 4.0681230606409713e-10
the O 0 1.4427961048113502e-07
disease O 0 0.0003052563697565347
phenotype O 0 8.221326424973086e-06
. O 0 2.702138033328083e-07

WFS1 O 0 0.03412335366010666
appears O 0 2.3316431452258257e-06
to O 0 1.616301226192718e-08
function O 0 4.7832848792950244e-09
in O 0 1.5801543407079066e-09
survival O 0 7.254360752995126e-06
of O 0 5.488554961630143e-07
islet O 0 1.0781266610138118e-05
beta O 0 1.778197997737152e-06
- O 0 5.680846015820862e-07
cells O 0 1.507716973492279e-08
and O 0 4.42506431497236e-09
neurons O 0 2.473102433953045e-08
. O 0 5.288215199072965e-09
. O 0 2.7495573817759578e-08

Stable O 0 7.108988211257383e-05
interaction O 0 7.237710519802931e-08
between O 0 7.573602189836492e-09
the O 0 1.2745910993317011e-09
products O 0 3.645753476888558e-09
of O 0 1.9403053386213287e-08
the O 0 3.086956112952066e-08
BRCA1 O 0 1.0955231388720676e-08
and O 0 1.5984270573810022e-09
BRCA2 O 0 4.253400298637189e-09
tumor B-Disease 0 2.4742018212009498e-08
suppressor O 0 8.911913340625688e-08
genes O 0 4.949061715997516e-10
in O 0 1.4437052942017914e-10
mitotic O 0 3.770879786202386e-08
and O 0 9.40520727965577e-09
meiotic O 0 1.0807442777149845e-05
cells O 0 4.4050470933143515e-06
. O 0 3.324928741221811e-07

BRCA1 O 0 5.155103644938208e-05
and O 0 4.6118412910800544e-07
BRCA2 O 0 1.9151822527874174e-07
account O 0 8.334423706735095e-10
for O 0 2.8209715119409395e-10
most O 0 9.594395417034107e-11
cases O 0 3.2130717531053676e-10
of O 0 5.291625360115404e-09
familial O 0 2.9512289074773435e-06
, O 0 6.777751138109522e-10
early O 0 5.920241505918966e-07
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 0.9996237754821777
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.9192056650326776e-08
encode O 0 4.115393581471949e-10
products O 0 6.689241160984238e-09
that O 0 1.4189173447309855e-10
each O 0 1.302116470203174e-10
interact O 0 1.9205606549554943e-10
with O 0 3.5840985734836295e-10
hRAD51 O 0 7.658701406398905e-07
. O 0 8.577077892368834e-08

Results O 0 9.800166935747257e-07
presented O 0 2.0881450382148614e-06
here O 0 6.029986820976774e-08
show O 0 4.779363571572048e-09
that O 0 3.184081054374843e-10
BRCA1 O 0 2.5780384049767235e-08
and O 0 1.5024378186012655e-08
BRCA2 O 0 2.0756814933520218e-07
coexist O 0 7.636880638983712e-08
in O 0 2.5087383281885423e-09
a O 0 1.1552242717982608e-08
biochemical O 0 1.008894059850718e-06
complex O 0 1.3097133887640666e-05
and O 0 1.134387659362801e-07
colocalize O 0 2.7513799068401568e-05
in O 0 4.8645571126826326e-08
subnuclear O 0 1.308528590016067e-05
foci O 0 1.883205527519749e-06
in O 0 3.262377257229332e-09
somatic O 0 5.6731050079861234e-08
cells O 0 7.110047661740282e-09
and O 0 1.2709351349116105e-09
on O 0 3.4432867668243716e-09
the O 0 8.130370265924114e-10
axial O 0 3.709542228946816e-09
elements O 0 1.4211831711463674e-08
of O 0 4.820978105612994e-08
developing O 0 6.406876877917966e-07
synaptonemal O 0 1.489882924943231e-05
complexes O 0 7.772195544930582e-07
. O 0 1.2491148027038435e-07

Like O 0 5.101073838886805e-06
BRCA1 O 0 5.237718596617924e-06
and O 0 7.427415766869672e-07
RAD51 O 0 0.033217523247003555
, O 0 1.1691587076256837e-07
BRCA2 O 0 3.984055183536839e-07
relocates O 0 6.355708705996221e-07
to O 0 1.1141433020611657e-07
PCNA O 0 0.00014368411211762577
+ O 0 2.708272859308636e-07
replication O 0 8.937477424808549e-09
sites O 0 1.7585213285542522e-09
following O 0 1.0745587752936103e-09
exposure O 0 2.66418513916733e-08
of O 0 1.8127215284380327e-08
S O 0 7.452148906850198e-07
phase O 0 4.356034537522646e-07
cells O 0 4.49122055101725e-08
to O 0 7.938914414751252e-09
hydroxyurea O 0 5.388497470448783e-07
or O 0 2.0191228244925696e-08
UV O 0 0.0035177692770957947
irradiation O 0 5.0153812480857596e-05
. O 0 4.026868509754422e-07

Thus O 0 5.397351742431056e-06
, O 0 1.5670623554342455e-07
BRCA1 O 0 6.210397884842678e-08
and O 0 8.947984575513601e-09
BRCA2 O 0 6.40641006910414e-09
participate O 0 5.452166496056066e-10
, O 0 3.2605218525105784e-10
together O 0 5.842831773961166e-10
, O 0 2.220973543964888e-10
in O 0 1.6222799770204688e-09
a O 0 3.259057734794624e-08
pathway O 0 2.100168785545975e-07
( O 0 5.163858785017794e-10
s O 0 1.4408623627559791e-08
) O 0 1.007966765609325e-10
associated O 0 1.1785388220886261e-09
with O 0 5.411440184843741e-10
the O 0 5.09174391538636e-08
activation O 0 4.871994860877749e-07
of O 0 3.928180376533419e-07
double O 0 5.2965962282769397e-08
- O 0 3.239715340441762e-07
strand O 0 1.738317365607145e-07
break O 0 1.8995243067365664e-07
repair O 0 1.1567979527171701e-05
and O 0 8.559509723227166e-08
/ O 0 7.729199751338456e-07
or O 0 3.503855694475533e-08
homologous O 0 1.325272762642271e-07
recombination O 0 2.2173149716309126e-07
. O 0 1.8428070802656293e-07

Dysfunction O 1 0.9998424053192139
of O 0 0.00012412010983098298
this O 0 1.0747891820983568e-07
pathway O 0 2.067557034024503e-06
may O 0 5.7597588920543785e-09
be O 0 1.1058388649232143e-09
a O 0 3.8744647490318584e-09
general O 0 1.6862230722836102e-08
phenomenon O 0 1.2156998074885905e-08
in O 0 2.5550672688723353e-10
the O 0 5.404828806732098e-10
majority O 0 7.934724925717784e-12
of O 0 5.3617832396213316e-11
cases O 0 2.7088210147185876e-11
of O 0 4.24163726364668e-09
hereditary B-Disease 1 0.9999728202819824
breast I-Disease 1 0.9824514985084534
and I-Disease 0 0.0010884989751502872
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.548345486909966e-07
. O 0 3.422624672566599e-07

A O 0 2.1672354705515318e-05
novel O 0 2.203855501647922e-06
Arg362Ser O 0 9.485200280323625e-06
mutation O 0 5.066923236540788e-08
in O 0 4.900118089068428e-09
the O 0 3.0315536747593796e-08
sterol O 0 4.8485962906852365e-06
27 O 0 1.1899390983671765e-06
- O 0 2.592971668491373e-06
hydroxylase O 0 9.538170706946403e-05
gene O 0 1.4611154597332643e-07
( O 0 2.8670370522121402e-09
CYP27 O 0 6.885906623210758e-05
) O 0 1.6810938197053815e-09
: O 0 1.6052607854089018e-10
its O 0 1.1377127018263877e-09
effects O 0 1.132524118929723e-07
on O 0 6.619337256097424e-08
pre O 0 1.0613395033942652e-06
- O 0 3.95862258528723e-08
mRNA O 0 5.3226814067386385e-09
splicing O 0 1.0761385560442704e-08
and O 0 2.2079980899203377e-10
enzyme O 0 8.464089429338628e-10
activity O 0 9.86217219001162e-10
. O 0 1.0306279385474681e-08

A O 0 4.124272436456522e-06
novel O 0 4.5920478441985324e-07
C O 0 1.2061491361237131e-06
to O 0 6.73751499036257e-09
A O 0 4.6513378038071096e-08
mutation O 0 6.302971478078234e-10
in O 0 8.245545912721752e-10
the O 0 8.162849063353406e-09
sterol O 0 5.049707283433236e-07
27 O 0 5.659934458890348e-07
- O 0 6.237189609237248e-07
hydroxylase O 0 1.2100168532924727e-05
gene O 0 2.9959323910588864e-08
( O 0 1.100133539821968e-09
CYP27 O 0 3.6390554214449367e-06
) O 0 3.7059619262258536e-10
was O 0 4.282682208867072e-09
identified O 0 5.710084627352785e-10
by O 0 1.2094401868889548e-10
sequencing O 0 5.136516989523443e-08
amplified O 0 8.182322375205331e-08
CYP27 O 0 2.088848077619332e-06
gene O 0 1.3552846622744141e-09
products O 0 3.1272828771022887e-09
from O 0 3.3242990582493803e-09
a O 0 9.384922172728238e-09
patient O 0 1.2650519920498482e-07
with O 0 1.55876982432801e-08
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 6.408123454093584e-08
CTX B-Disease 0 0.0007034641457721591
) O 0 1.1886258199922395e-08
. O 0 7.86077762882087e-08

The O 0 2.3445174974767724e-06
mutation O 0 2.4664234388183104e-07
changed O 0 6.296128418625813e-08
the O 0 4.4316379899100866e-08
adrenodoxin O 0 7.167796525209269e-07
cofactor O 0 5.429601301898401e-08
binding O 0 1.901575430451885e-08
residue O 0 4.4685688749268593e-07
362Arg O 0 2.0125678190652252e-07
to O 0 4.873414116701724e-09
362Ser O 0 1.6677058738423511e-06
( O 0 1.7944412178394487e-08
CGT O 0 1.3695885172637645e-05
362Arg O 0 4.2463366298761684e-06
to O 0 1.333790606850016e-07
AGT O 0 0.0007337493007071316
362Ser O 0 8.9618032461658e-07
) O 0 3.665889536375033e-10
, O 0 5.3534648936093276e-11
and O 0 1.5277271114833013e-10
was O 0 1.8006295121608673e-08
responsible O 0 4.446223389464876e-09
for O 0 1.411322725353159e-09
deficiency O 0 1.6912235878407955e-05
in O 0 2.2462389281940887e-08
the O 0 1.0422635341456044e-06
sterol O 0 1.0215907423116732e-05
27 O 0 1.610032654753013e-06
- O 0 2.0573015717673115e-06
hydroxylase O 0 6.108768138801679e-05
activity O 0 2.2720842096646265e-08
, O 0 1.794507736851969e-10
as O 0 9.231945069521075e-11
confirmed O 0 3.061586817398876e-10
by O 0 1.2357266598872485e-10
expression O 0 4.5910382162617225e-09
of O 0 5.026514315886743e-08
mutant O 0 7.923079436977787e-08
cDNA O 0 5.434999295061971e-08
into O 0 1.2392403903049853e-07
COS O 0 5.5777163652237505e-06
- O 0 5.691844080502051e-07
1 O 0 9.966374392433863e-08
cells O 0 5.64632216537575e-08
. O 0 3.041649065949059e-08

Quantitative O 0 4.573691683162906e-07
analysis O 0 5.7887497462161264e-08
showed O 0 1.6285556014850044e-08
that O 0 2.975144575145805e-10
the O 0 4.021159405454e-09
expression O 0 3.378942459164591e-09
of O 0 2.3418257555363198e-08
CYP27 O 0 8.122486292450048e-07
gene O 0 6.667150720396364e-10
mRNA O 0 8.927199535158081e-10
in O 0 6.974780475399456e-11
the O 0 7.895872289331862e-10
patient O 0 8.57242987706286e-09
represented O 0 3.971523110379849e-09
52 O 0 2.357379429440698e-07
. O 0 1.9932984685056e-07

5 O 0 1.0412977644591592e-06
% O 0 5.76514480599144e-09
of O 0 1.4979510964963083e-08
the O 0 1.8700921700087747e-08
normal O 0 8.374300364266674e-08
level O 0 6.386404152181058e-07
. O 0 1.146145081065697e-07

As O 0 9.488045407124446e-07
the O 0 1.361001693567232e-07
mutation O 0 1.5538631714662188e-08
occurred O 0 7.298428528201839e-08
at O 0 8.424054342981435e-09
the O 0 2.678158805835551e-09
penultimate O 0 1.1902030649935114e-07
nucleotide O 0 1.4668781744830994e-08
of O 0 5.8909328970457864e-08
exon O 0 1.8808563595484884e-07
6 O 0 9.754814556117708e-08
( O 0 5.977193184847351e-10
- O 0 1.9487504943072054e-08
2 O 0 1.0292002627920738e-07
position O 0 1.940786944487627e-07
of O 0 3.980367750955338e-07
exon O 0 4.4729347337124636e-07
6 O 0 3.208580494629132e-07
- O 0 1.3462145886933286e-07
intron O 0 1.7643515093368478e-06
6 O 0 5.024377287554671e-07
splice O 0 1.68992801263812e-06
site O 0 3.92958519057629e-08
) O 0 3.851237384555617e-11
of O 0 8.380587890322033e-10
the O 0 7.390347001035025e-09
gene O 0 4.766400163447315e-09
, O 0 5.332698171933714e-10
we O 0 8.246977545312006e-10
hypothesized O 0 3.0983880350277104e-08
that O 0 9.532945544066251e-10
the O 0 2.705763080257384e-08
mutation O 0 6.82441525512445e-09
may O 0 8.068519186110734e-09
partially O 0 9.575943238360196e-08
affect O 0 5.179506157304559e-09
the O 0 9.20842424534385e-09
normal O 0 1.4086019461956312e-08
splicing O 0 5.590437979208218e-08
efficiency O 0 1.2918171421461011e-08
in O 0 9.183757643249635e-10
exon O 0 2.200495785587009e-08
6 O 0 8.391564776388805e-09
and O 0 4.4179529479215773e-10
cause O 0 5.893874721607517e-09
alternative O 0 6.875830393937576e-08
splicing O 0 8.552394348271264e-08
elsewhere O 0 3.5315503854604913e-09
, O 0 1.6723197479584506e-11
which O 0 3.0209673738262888e-12
resulted O 0 6.149369902175295e-10
in O 0 1.4304771256412607e-10
decreased O 0 1.9940535889162447e-09
transcript O 0 7.534559642863314e-08
in O 0 8.589577382700497e-10
the O 0 5.6235234247026256e-09
patient O 0 9.671115464016111e-08
. O 0 9.262259226261449e-08

Transfection O 0 0.00103005301207304
of O 0 2.5778532290132716e-05
constructed O 0 0.00010530056897550821
minigenes O 0 2.043557287834119e-05
, O 0 1.0193899058208444e-09
with O 0 3.710861826156098e-11
or O 0 1.9646819726659714e-09
without O 0 1.1290318013834622e-08
the O 0 1.3623452588262808e-08
mutation O 0 6.856415990519338e-10
, O 0 1.963062767895707e-10
into O 0 1.1107225361683959e-08
COS O 0 6.723615570081165e-06
- O 0 4.3022970430683927e-07
1 O 0 3.134384840564053e-08
cells O 0 1.4423794381102084e-09
confirmed O 0 2.3784081371047705e-09
that O 0 7.98327515205699e-11
the O 0 5.9238534078076555e-09
mutant O 0 1.5982449141915822e-08
minigene O 0 5.5907364071572374e-08
was O 0 3.964061079386738e-09
responsible O 0 4.842510281655166e-10
for O 0 8.296259512707849e-11
a O 0 6.62306876009211e-10
mRNA O 0 1.9129864359257454e-09
species O 0 1.6001434899326483e-10
alternatively O 0 2.464235038246443e-09
spliced O 0 3.563339845413793e-08
at O 0 2.605344917583352e-08
an O 0 6.198345170460584e-10
activated O 0 9.375261811328528e-07
cryptic O 0 2.1224632291705348e-06
5 O 0 2.224796418204278e-07
splice O 0 5.718205102311913e-06
site O 0 5.977244654786773e-07
88 O 0 1.5739234981992922e-07
bp O 0 1.1812223732476923e-07
upstream O 0 1.1851870596046865e-08
from O 0 1.125475046492852e-09
the O 0 5.2711159881368985e-09
3 O 0 7.4294677077091364e-09
end O 0 3.731507192128447e-08
of O 0 4.703169054209866e-08
exon O 0 7.673264121876855e-07
6 O 0 3.055540673813084e-07
. O 0 6.504742344759507e-08

Our O 0 8.220306881412398e-06
data O 0 1.0660143345830875e-07
suggest O 0 1.1742044669915686e-08
that O 0 3.952432270359907e-10
the O 0 4.871731906774812e-09
C O 0 9.9696059407961e-08
to O 0 3.0198312739315725e-09
A O 0 6.942869390513806e-08
mutation O 0 3.907743018061183e-09
at O 0 4.3524566173402945e-09
the O 0 1.3338200544055212e-09
penultimate O 0 4.4771084617423185e-08
nucleotide O 0 5.320164753186418e-09
of O 0 1.5321056423545087e-08
exon O 0 7.71872592508771e-08
6 O 0 2.5262513858592683e-08
of O 0 7.068724716674524e-09
the O 0 2.3115823921671108e-08
CYP27 O 0 4.18563031416852e-05
gene O 0 2.106804153356734e-08
not O 0 1.0936436201092192e-09
only O 0 4.919707419226427e-10
causes O 0 2.1588975940289856e-08
the O 0 2.2762048246249833e-08
deficiency B-Disease 0 1.569125561218243e-05
in I-Disease 0 1.493289936149722e-08
the I-Disease 0 1.4034159789844125e-07
sterol I-Disease 0 5.248488378128968e-06
27 I-Disease 0 7.231816994135443e-07
- I-Disease 0 8.157660431606928e-07
hydroxylase I-Disease 0 1.882079232018441e-05
activity I-Disease 0 2.493521655821951e-08
, O 0 2.93414098573308e-10
but O 0 3.1281047196962675e-10
also O 0 2.0545829482188083e-09
partially O 0 5.515441259262843e-08
leads O 0 5.731671137709782e-09
to O 0 4.780518758629171e-10
alternative O 0 3.923578262288174e-08
pre O 0 6.954730906727491e-07
- O 0 1.952765238399934e-08
mRNA O 0 5.228121047196055e-09
splicing O 0 1.0642708936359213e-08
of O 0 1.3421779243572018e-09
the O 0 3.2937390592735483e-09
gene O 0 6.458429790967557e-09
. O 0 1.1960670676103291e-08

To O 0 1.5788618838996626e-06
our O 0 8.1173442367799e-07
knowledge O 0 7.735910685369163e-07
, O 0 7.224518205894981e-10
this O 0 6.677940145305428e-11
is O 0 4.2950795697827004e-11
the O 0 2.9199215267894374e-10
first O 0 2.13419532046899e-10
report O 0 9.824205338127001e-11
regarding O 0 1.3085256211908813e-09
effects O 0 3.451323493663949e-08
on O 0 7.417647651664083e-08
pre O 0 6.280356501520146e-07
- O 0 2.1235427638544024e-08
mRNA O 0 7.959868320028818e-09
splicing O 0 1.5803843567141485e-08
of O 0 1.7628636328481662e-09
a O 0 2.96974722591159e-10
mutation O 0 7.878147439965844e-11
at O 0 6.915175654320649e-10
the O 0 1.1436479541160338e-09
- O 0 8.942047102777906e-09
2 O 0 1.3352690508838805e-08
position O 0 2.592704007042812e-08
of O 0 1.804504456970335e-08
a O 0 3.033063222801502e-08
5 O 0 1.4804577119775786e-07
splice O 0 3.905490757460939e-06
site O 0 6.969962100811244e-07
. O 0 8.998718215025292e-08

ATM O 0 0.0003242064267396927
germline O 0 4.478528717299923e-05
mutations O 0 1.9470010670374904e-07
in O 0 3.526255198949002e-08
classical O 1 0.8025378584861755
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 1.0
in O 0 8.479155439999886e-07
the O 0 1.7042676745404606e-06
Dutch O 0 8.158296623150818e-06
population O 0 6.707444044629085e-10
. O 0 1.2187713060995975e-08

Germline O 0 5.795681136078201e-05
mutations O 0 6.067054414415907e-08
in O 0 5.597818653058084e-09
the O 0 7.908687926772018e-09
ATM O 0 4.129779540562595e-08
gene O 0 2.379137442609647e-10
are O 0 1.9234548849500488e-12
responsible O 0 8.332257800391929e-11
for O 0 2.350823147256875e-10
the O 0 9.592625428922474e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9980030655860901
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 9.907853382173926e-06
. O 0 1.7530455806991085e-05

In O 0 1.4264904848459992e-06
our O 0 3.264318308993097e-07
study O 0 6.0590843453667276e-09
, O 0 4.687635279942981e-10
we O 0 7.570995219641219e-11
have O 0 2.5561140010177397e-11
determined O 0 9.908441844785898e-10
the O 0 1.1122955001496848e-08
ATM O 0 1.3272141075049149e-07
mutation O 0 2.0607604511724276e-09
spectrum O 0 6.665872120947824e-08
in O 0 1.2234545598843738e-09
19 O 0 9.08515129793841e-09
classical O 0 4.890895297648967e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 3.7865236208745046e-06
, O 0 2.3387880521141824e-10
including O 0 4.248077584145804e-11
some O 0 5.94907456630267e-11
immigrant O 0 1.0824702245670892e-09
populations O 0 5.8052156831633894e-11
, O 0 2.8305422242191902e-11
as O 0 2.0900839392545834e-10
well O 0 6.476337244265551e-10
as O 0 1.191826193291945e-09
12 O 0 1.7382494332807141e-09
of O 0 4.3703254348770315e-09
Dutch O 0 1.4240436030377168e-07
ethnic O 0 5.633977173680194e-10
origin O 0 9.901777175969073e-09
. O 0 1.2934177107126743e-07

Both O 0 7.357564868470945e-07
the O 0 2.962012501939171e-07
protein O 0 3.1911490339098236e-08
truncation O 0 8.903434149942768e-07
test O 0 1.8613918939536234e-07
( O 0 7.3021295676767295e-09
PTT O 0 1.8458200656823465e-07
) O 0 4.561069924524652e-11
and O 0 3.23964355342099e-10
the O 0 5.994001739395571e-09
restriction O 0 2.1749627876488375e-08
endonuclease O 0 4.466881478037976e-07
fingerprinting O 0 4.293087840778753e-08
( O 0 1.0300830188825216e-09
REF O 0 9.854168183665024e-07
) O 0 3.911915583132419e-11
method O 0 5.409572789716321e-10
were O 0 1.3047368740970455e-10
used O 0 5.609551156915416e-10
and O 0 1.2030555718300917e-10
compared O 0 3.835639306171146e-10
for O 0 9.70660149479663e-11
their O 0 5.20156084871104e-10
detection O 0 6.000936991767958e-07
efficiency O 0 2.2007601074847116e-08
, O 0 2.6960943894094314e-11
identifying O 0 2.7233534871662357e-10
76 O 0 5.970405947408608e-09
% O 0 1.684042211236303e-10
and O 0 1.7464436841141406e-10
60 O 0 3.662520564606808e-10
% O 0 8.635041987004044e-11
of O 0 9.59390566990237e-10
the O 0 5.745583120386755e-09
mutations O 0 8.925054584274505e-10
, O 0 4.3161790808099454e-10
respectively O 0 5.580591100340371e-09
. O 0 1.0336403022392915e-07

Most O 0 6.526814217977517e-07
patients O 0 1.3049663039055304e-07
were O 0 5.699946292736513e-09
found O 0 1.5589594060116951e-09
to O 0 6.960524379096e-10
be O 0 4.690579924471194e-09
compound O 0 5.70711290492909e-06
heterozygote O 0 7.988511060830206e-05
. O 0 7.219661597446247e-07

Seventeen O 0 7.481454304070212e-06
mutations O 0 2.5944649095777095e-08
were O 0 2.336894233678777e-09
distinct O 0 1.3728671532931003e-09
, O 0 1.8952985014752954e-10
of O 0 2.3940374127562336e-09
which O 0 2.3720100883473094e-10
10 O 0 7.891264863779668e-10
were O 0 2.8447458277902626e-10
not O 0 1.2995882148203464e-10
reported O 0 2.933806753091517e-09
previously O 0 1.6826954052362453e-08
. O 0 9.143931833932584e-08

Mutations O 0 1.2104368352083839e-06
are O 0 7.694234582800163e-09
small O 0 2.3980145869018088e-08
deletions O 0 4.100120349903591e-07
or O 0 2.354981774033149e-07
point O 0 3.091206735916785e-06
mutations O 0 2.6368251582198354e-08
frequently O 0 1.159962437213835e-08
affecting O 0 2.9555213387766344e-08
splice O 0 4.1812054405454546e-05
sites O 0 1.2063136409778963e-06
. O 0 4.2996597926503455e-07

Moreover O 0 2.0138513718848117e-06
, O 0 2.2044570613388714e-08
a O 0 6.642316918714641e-08
16 O 0 3.095213685355702e-07
. O 0 1.3548981314670527e-07

7 O 0 7.584578997921199e-05
- O 0 1.0448417924635578e-05
kb O 0 5.271478130453033e-06
genomic O 0 4.55157817214058e-07
deletion O 0 1.8089933462306362e-07
of O 0 1.3139890597813064e-07
the O 0 8.177220678362573e-08
3 O 0 2.7892474108170973e-08
end O 0 2.9731790363030086e-08
of O 0 1.2290192863417815e-08
the O 0 8.867079515084697e-09
gene O 0 1.1407635946980577e-09
, O 0 1.0154791590943901e-10
most O 0 1.1737084915086626e-10
likely O 0 1.338759547664381e-09
a O 0 7.64544261233624e-10
result O 0 1.2942554805661644e-09
of O 0 5.368491873269932e-09
recombination O 0 1.6511557676679445e-09
between O 0 8.062576717371428e-10
two O 0 8.301234144525438e-10
LINE O 0 2.2551708411810978e-07
elements O 0 7.072368646277027e-08
, O 0 7.36119443178751e-10
was O 0 2.6759543914067763e-08
identified O 0 2.0328950967041237e-08
. O 0 5.031271754774025e-08

The O 0 2.102510006807279e-05
most O 0 4.9501807097840356e-08
frequently O 0 5.2777355818989236e-09
found O 0 6.652758899328148e-10
mutation O 0 2.0831510127994335e-10
, O 0 2.9611708918242385e-11
identified O 0 3.142247018139699e-10
in O 0 6.057209178678136e-10
three O 0 2.531000742322931e-09
unrelated O 0 1.1428203805508019e-07
Turkish O 0 0.00020037233480252326
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
individuals O 0 2.244928332117979e-08
, O 0 6.513170003330515e-09
was O 0 1.4404726300654147e-07
previously O 0 2.6841369127339476e-09
described O 0 8.657342620566055e-10
to O 0 2.2997764803633913e-10
be O 0 4.232341421772645e-10
a O 0 9.858001526197313e-09
Turkish O 0 7.842369882382627e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
founder O 0 0.00014189166540745646
mutation O 0 3.393257088646351e-07
. O 0 1.1974782410106855e-07

The O 0 1.1959276662310003e-06
presence O 0 1.1658663368052657e-07
of O 0 1.0561878980297479e-06
a O 0 7.757615207992785e-07
founder O 0 4.2534913518466055e-05
mutation O 0 1.276945198469548e-07
among O 0 2.7615707498540587e-09
relatively O 0 1.9500779657732892e-08
small O 0 3.1340006145796906e-09
ethnic O 0 5.335839062259318e-11
population O 0 2.9872417473680857e-12
groups O 0 2.529592420946747e-12
in O 0 7.577452554308195e-11
Western O 0 3.064475961878088e-08
Europe O 0 5.976845329769276e-08
could O 0 3.1209606010662583e-09
indicate O 0 1.4881937904220877e-09
a O 0 2.3010413574553468e-09
high O 0 5.85151127552308e-09
carrier O 0 9.126864819464231e-10
frequency O 0 9.704681502853418e-10
in O 0 1.1607337313535027e-10
such O 0 3.892825506390807e-10
communities O 0 6.011519282367317e-09
. O 0 4.2021735424668805e-08

In O 0 4.0512475152354455e-07
patients O 0 2.977652115987439e-07
of O 0 1.6094404031719023e-07
Dutch O 0 2.5982640181609895e-06
ethnic O 0 1.3429999334846343e-09
origin O 0 5.877865305592422e-09
, O 0 2.6505531103282465e-10
however O 0 5.442618022932777e-10
, O 0 8.328730760620573e-11
no O 0 3.609330334608529e-10
significant O 0 4.093327010679104e-09
founder O 0 5.207086246628023e-07
effect O 0 1.1909451202996024e-08
could O 0 6.6995329284225136e-09
be O 0 5.657638801892517e-09
identified O 0 4.4056211123688627e-08
. O 0 4.291933208833143e-08

The O 0 3.020229996764101e-06
observed O 0 1.3485428951298672e-07
genetic O 0 7.149841252385158e-08
heterogeneity O 0 2.3270817450793402e-07
including O 0 6.100831839717102e-09
the O 0 3.9217459857354697e-07
relative O 0 0.0031722153071314096
high O 0 0.00043501058826223016
percentage O 0 1.1506023867013937e-07
of O 0 8.026251663295625e-08
splice O 0 1.5381514458567835e-05
- O 0 1.0512258086237125e-06
site O 0 1.056909866292699e-07
mutations O 0 8.118871686058071e-10
had O 0 1.923362358269287e-09
no O 0 5.819142390173226e-10
reflection O 0 8.425950603907495e-09
on O 0 3.3055350456834276e-08
the O 0 1.7930760876083696e-08
phenotype O 0 4.58133087022361e-07
. O 0 1.1055445980900913e-07

All O 0 2.2852755421354232e-07
patients O 0 4.41447838284148e-08
manifested O 0 1.0239604364414845e-07
classical O 0 6.107550689193886e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
and O 0 1.2841058882884226e-08
increased O 0 8.314929189623399e-09
cellular O 0 1.8927714506844495e-08
radioresistant O 0 2.1603188571361898e-08
DNA O 0 1.1564609714298513e-08
synthesis O 0 6.686476439199396e-08
. O 0 1.7525051632105715e-08

Determination O 0 1.850199441832956e-05
of O 0 2.820436748152133e-06
the O 0 5.472655573157681e-08
genomic O 0 3.204756993113733e-08
structure O 0 9.258369182418846e-09
of O 0 6.7369883005596876e-09
the O 0 2.762361006602987e-09
COL4A4 O 0 7.110117508091207e-07
gene O 0 3.9649963867738336e-10
and O 0 3.9130719498015054e-11
of O 0 1.151754136508032e-09
novel O 0 9.154053515203486e-08
mutations O 0 2.680966701973375e-07
causing O 0 2.8312945232755737e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0003026433987542987

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 5.004085778637091e-06
a O 0 2.3583948859595694e-05
progressive O 1 1.0
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 1 0.9999994039535522
by O 0 9.074415174836759e-06
glomerular B-Disease 1 1.0
basement I-Disease 1 1.0
membrane I-Disease 1 0.9992376565933228
abnormalities I-Disease 0 0.1441672295331955
and O 0 2.175218893896158e-09
associated O 0 2.6026926391864436e-08
with O 0 5.148323545256517e-09
mutations O 0 2.5707516115858198e-08
in O 0 8.947439233963905e-09
either O 0 1.9472163614864257e-07
the O 0 2.176163661715691e-06
COL4A3 O 0 0.000510627229232341
or O 0 1.1444538650096092e-08
the O 0 2.6360657656709918e-08
COL4A4 O 0 1.3384509429670288e-06
gene O 0 6.760154103169214e-10
, O 0 2.7205904196137e-11
which O 0 1.9548565891036596e-11
encode O 0 5.942250580481812e-10
the O 0 2.5336682085708162e-08
alpha3 O 0 3.679620704133413e-06
and O 0 1.495108215010532e-08
alpha4 O 0 4.7516252266177617e-07
type O 0 4.0089815911414917e-07
IV O 1 1.0
collagen O 0 0.05255511403083801
chains O 0 2.7465468974696705e-06
, O 0 4.004397702317419e-09
respectively O 0 1.0553925733347569e-08
. O 0 9.243145626669502e-08

To O 0 1.9365641890090046e-07
date O 0 1.0881987009270233e-06
, O 0 1.6858942020192558e-09
mutation O 0 2.0459631211444673e-10
screening O 0 2.9869726692055565e-09
in O 0 2.5742524778493703e-10
the O 0 6.9556307380480575e-09
two O 0 2.3837400942028353e-09
genes O 0 4.277400655894326e-09
has O 0 1.360176415943215e-09
been O 0 2.0503940767468976e-09
hampered O 0 2.3705799776507774e-06
by O 0 1.221719614363792e-09
the O 0 9.778506893098893e-09
lack O 0 6.084414394535997e-08
of O 0 5.660153679087898e-09
genomic O 0 8.020325736879386e-09
structure O 0 3.0915522586383304e-08
information O 0 1.007519934148604e-08
. O 0 8.536146367532638e-08

We O 0 5.278785124573915e-07
report O 0 1.3779282603820775e-08
here O 0 6.755504600164386e-09
the O 0 2.236848928305335e-09
complete O 0 1.96249483330746e-09
characterization O 0 4.558258837050744e-08
of O 0 2.3497408463413194e-08
the O 0 2.6229155736245957e-08
48 O 0 2.616469885197148e-08
exons O 0 1.0592933818998063e-07
of O 0 9.24534973023583e-08
the O 0 2.036135811067652e-07
COL4A4 O 0 6.127858068794012e-05
gene O 0 2.1810905082020327e-08
, O 0 4.88889428940098e-10
a O 0 1.3701101364560486e-09
comprehensive O 0 1.4595438635467417e-08
gene O 0 4.3789532000459985e-09
screen O 0 1.7001332253130386e-07
, O 0 3.5067540538058495e-10
and O 0 4.506524320380123e-10
the O 0 6.212714231956795e-10
subsequent O 0 2.1712314168809144e-09
detection O 0 4.695102617802149e-08
of O 0 1.0411305151336592e-09
10 O 0 8.170068788171392e-11
novel O 0 8.841637144652026e-11
mutations O 0 1.8877283416984802e-11
in O 0 1.559130255457397e-11
eight O 0 6.49457043699897e-10
patients O 0 2.7560982385210764e-09
diagnosed O 0 4.1495832192595117e-07
with O 0 8.041406118763916e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0006668675341643393

Furthermore O 0 3.0731471269973554e-06
, O 0 1.785169345680515e-08
we O 0 1.4740799691992379e-09
identified O 0 9.525062516502203e-09
a O 0 4.5809351867376336e-09
glycine O 0 1.5938125486059107e-08
to O 0 2.3689366024370884e-09
alanine O 0 4.6930971109304664e-08
substitution O 0 2.3316245290061488e-07
in O 0 3.693264005732999e-08
the O 0 2.3604276577771088e-07
collagenous O 0 5.0504522732808255e-06
domain O 0 5.1923549904131505e-09
that O 0 7.390114215022336e-11
is O 0 5.1359208552703706e-11
apparently O 0 1.6982194539494344e-09
silent O 0 8.632349945969509e-09
in O 0 2.094997092472184e-10
the O 0 1.5035206413216429e-09
heterozygous O 0 2.488938499745075e-10
carriers O 0 1.9339299606180305e-10
, O 0 1.1468496985411747e-10
in O 0 8.815658758543066e-10
11 O 0 7.119604106264887e-08
. O 0 1.1837732927233446e-07

5 O 0 1.8110215478372993e-06
% O 0 7.048785111152256e-09
of O 0 1.3020111211403673e-08
all O 0 4.3855374887158405e-10
control O 0 3.3192304460527566e-09
individuals O 0 1.2884341163421631e-11
, O 0 5.219965432123885e-11
and O 0 8.310640370323696e-11
in O 0 2.3751431377228016e-10
one O 0 1.3254250474936669e-10
control O 0 6.418441333977398e-10
individual O 0 1.5048158899522157e-11
homozygous O 0 6.252845463627921e-11
for O 0 2.831687141713335e-11
this O 0 4.7083861115515546e-11
glycine O 0 2.0115617616056625e-08
substitution O 0 2.6713451006799005e-07
. O 0 6.425527772080386e-07

There O 0 1.654787638472044e-06
has O 0 1.0022911389739875e-08
been O 0 1.6124024337926812e-09
no O 0 3.3398553367369743e-10
previous O 0 1.3742241788960996e-09
finding O 0 5.7963700506036275e-09
of O 0 4.387999741339854e-09
a O 0 1.702130325575979e-09
glycine O 0 3.282055738296208e-09
substitution O 0 3.3481359906772923e-09
that O 0 7.593643075454182e-11
is O 0 4.233097899986049e-11
not O 0 7.238386105778982e-12
associated O 0 1.4508381995792519e-10
with O 0 9.446400259238708e-12
any O 0 2.9769553488989686e-10
obvious O 0 1.1449493797499599e-08
phenotype O 0 1.6402957214722846e-08
in O 0 2.458267200911024e-10
homozygous O 0 1.4318536356583422e-09
individuals O 0 1.813909439318806e-10
. O 0 7.603045304449552e-08

Founder O 0 0.004097373224794865
BRCA1 O 0 5.136015715834219e-06
and O 0 7.882336916509303e-08
BRCA2 O 0 6.940076247019533e-08
mutations O 0 4.113031581987059e-10
in O 0 2.2994518789065665e-10
French O 0 9.496729802549453e-08
Canadian O 0 0.00025686706067062914
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.5582578473404283e-06
. O 0 5.370249596126087e-07

We O 0 3.2090363788483955e-07
have O 0 3.965527906046873e-09
identified O 0 1.6452149864676358e-08
four O 0 1.272434047017157e-09
mutations O 0 7.892555359267917e-11
in O 0 9.559469882347571e-11
each O 0 4.202191372648656e-11
of O 0 1.6377407519030385e-07
the O 0 0.00019626047287601978
breast B-Disease 1 0.9999983310699463
cancer I-Disease 1 0.9991851449012756
- O 0 6.000043413223466e-06
susceptibility O 0 1.464807382944855e-06
genes O 0 4.0878678220224174e-08
, O 0 3.2345821576740263e-09
BRCA1 O 0 5.936295011110815e-09
and O 0 1.0743911538213524e-08
BRCA2 O 0 9.655647836837034e-09
, O 0 6.430091181730546e-11
in O 0 1.2813325400706788e-10
French O 0 8.71809788804967e-08
Canadian O 0 6.4454643506905995e-06
breast B-Disease 1 0.5732836127281189
cancer I-Disease 0 0.16435912251472473
and O 0 7.489727431675419e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.486102925393425e-08
from O 0 1.1536437227732677e-07
Quebec O 0 3.5664791084855096e-06
. O 0 3.412114040202141e-07

To O 0 2.2294934751698747e-06
identify O 0 6.1989812820684165e-06
founder O 0 0.0003859488060697913
effects O 0 0.10845423489809036
, O 0 1.666453997017925e-08
we O 0 2.7855882045457747e-09
examined O 0 1.587120657120522e-08
independently O 0 1.8652537292496163e-09
ascertained O 0 5.1266113132442115e-08
French O 0 2.6839179767534915e-08
Canadian O 0 1.766751438481151e-07
cancer B-Disease 0 1.7058546291082166e-06
families O 0 3.5928185426747916e-10
for O 0 4.8496436033662604e-11
the O 0 2.874920856932306e-10
distribution O 0 1.2072851052202793e-10
of O 0 9.878702300625264e-10
these O 0 4.0029296544119575e-10
eight O 0 7.960020198538587e-09
mutations O 0 7.133738044728943e-09
. O 0 4.4448011493614104e-08

Mutations O 0 1.9188091471278312e-07
were O 0 1.3534074305709964e-08
found O 0 1.3865989467731765e-09
in O 0 1.0655397675307654e-09
41 O 0 2.2166338098372762e-08
of O 0 4.166983202935626e-08
97 O 0 1.9613376025517937e-06
families O 0 7.791827272285445e-08
. O 0 4.1884584334184183e-07

Six O 0 1.047998580361309e-06
of O 0 2.0446978510335612e-07
eight O 0 2.34994690373469e-08
mutations O 0 1.6286013648780795e-09
were O 0 1.890072098831297e-09
observed O 0 1.061141308156266e-08
at O 0 1.3589040115391526e-08
least O 0 7.963965042989685e-10
twice O 0 2.4771578566173957e-08
. O 0 6.010031228242951e-08

The O 0 4.595225982484408e-05
BRCA1 O 0 5.655123459291644e-06
C4446T O 0 1.9312833501317073e-06
mutation O 0 3.509233081899765e-08
was O 0 8.9917520540439e-08
the O 0 5.625948151788407e-09
most O 0 2.8785751560178596e-10
common O 0 8.476221946551732e-10
mutation O 0 2.923382091957194e-10
found O 0 1.701334212400596e-10
, O 0 1.0804930734853446e-11
followed O 0 7.19308293484211e-11
by O 0 4.439143844181537e-11
the O 0 4.79646118378696e-08
BRCA2 O 0 8.102450976821274e-08
8765delAG O 0 2.9849016414118523e-07
mutation O 0 3.078101684650392e-08
. O 0 4.171842604705489e-08

Together O 0 3.697768704569171e-07
, O 0 3.3717000302857514e-09
these O 0 2.5499552469554487e-10
mutations O 0 5.149754511712956e-10
were O 0 8.075135560225988e-10
found O 0 1.132531735059672e-09
in O 0 5.360293320322285e-10
28 O 0 5.996654728335216e-09
of O 0 3.956629868184791e-08
41 O 0 2.4470095283390947e-08
families O 0 4.447502088833488e-10
identified O 0 9.550289448156946e-10
to O 0 1.1314111869609178e-09
have O 0 4.4657291198291205e-09
a O 0 9.540502077243218e-08
mutation O 0 1.5499298910981452e-07
. O 0 1.3784335806121817e-07

The O 0 4.301974968257127e-06
odds O 0 2.051930778179667e-06
of O 0 5.0782237082103165e-08
detection O 0 4.335000539867906e-06
of O 0 3.025234462938897e-08
any O 0 5.060507568543926e-09
of O 0 5.747405751321821e-08
the O 0 3.374088208829562e-08
four O 0 1.9125121486496255e-09
BRCA1 O 0 1.7088868098369403e-09
mutations O 0 4.771363859568112e-10
was O 0 3.5189920311040623e-08
18 O 0 3.816348836949146e-08
. O 0 1.0711157472087507e-07

7x O 1 0.980006992816925
greater O 0 7.421931513817981e-06
if O 0 6.200041013926239e-08
one O 0 1.1179249748138886e-09
or O 0 7.602424939578967e-11
more O 0 1.9785742055161704e-12
cases O 0 1.897620671709177e-10
of O 0 8.165924555214588e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 3.936892056799479e-08
also O 0 1.7064658019982915e-10
present O 0 3.481588628506671e-10
in O 0 5.828117433104296e-10
the O 0 2.0306009318460383e-08
family O 0 6.33317682741108e-08
. O 0 1.6112226219888726e-08

The O 0 6.735359420417808e-06
odds O 0 4.443027592060389e-06
of O 0 1.3510943119854346e-07
detection O 0 5.52018946109456e-06
of O 0 3.078477561757609e-08
any O 0 5.847918149726183e-09
of O 0 2.7721904771738082e-08
the O 0 1.5297638711331274e-08
four O 0 2.372459118049619e-09
BRCA2 O 0 2.5835502626136986e-09
mutations O 0 6.392832929691394e-10
was O 0 7.916251831829868e-08
5 O 0 5.9004012342711576e-08
. O 0 7.683209446440742e-08

3x O 0 0.0002088964101858437
greater O 0 4.088098819465813e-07
if O 0 5.543947079189593e-09
there O 0 8.301234144525438e-10
were O 0 1.371422531093458e-09
at O 0 5.827583970940964e-10
least O 0 5.530873935927216e-12
five O 0 6.172642692120478e-12
cases O 0 2.1150066073505336e-11
of O 0 1.964250984087812e-09
breast B-Disease 0 1.57782433234388e-05
cancer I-Disease 0 1.6865194538695505e-06
in O 0 2.377500862849047e-09
the O 0 4.553558028419502e-07
family O 0 1.1348123507559649e-06
. O 0 9.674621281874352e-08

Interestingly O 0 2.5958740934584057e-06
, O 0 1.2220651157690554e-08
the O 0 8.32730862043718e-09
presence O 0 3.759588640406264e-09
of O 0 2.9767772957711713e-07
a O 0 4.3054208731518884e-07
breast B-Disease 0 0.00024300128279719502
cancer I-Disease 0 4.94174673804082e-06
case O 0 3.254337457292422e-07
< O 0 5.141677661413269e-07
36 O 0 2.360395612299726e-08
years O 0 1.5528549557330962e-09
of O 0 2.889247951998186e-09
age O 0 3.6531735414513378e-09
was O 0 8.655959504721977e-09
strongly O 0 3.025143677226616e-11
predictive O 0 2.5698912442528865e-10
of O 0 1.2539499438801727e-09
the O 0 6.350007741851016e-10
presence O 0 1.5807112563326342e-10
of O 0 5.220993637422566e-10
any O 0 4.685472010379499e-10
of O 0 3.1948745871090978e-09
the O 0 4.696282474014879e-09
eight O 0 3.055433683840647e-09
mutations O 0 2.013983202431291e-09
screened O 0 1.531933975229549e-07
. O 0 1.2285639172660012e-07

Carriers O 0 8.06392790764221e-07
of O 0 1.362888042422128e-06
the O 0 6.365912241790284e-08
same O 0 1.9716266397296067e-09
mutation O 0 5.477098774520073e-10
, O 0 1.0990920847053776e-11
from O 0 2.055937191325352e-11
different O 0 9.060154709805701e-11
families O 0 9.31531296544108e-10
, O 0 5.866860469661006e-11
shared O 0 5.451511464471537e-10
similar O 0 1.3881310545471592e-09
haplotypes O 0 5.6979274631885346e-08
, O 0 2.543931454379589e-10
indicating O 0 2.0922388266342296e-09
that O 0 1.422381101789938e-09
the O 0 6.665020180207648e-08
mutant O 0 2.9641137544444973e-08
alleles O 0 2.294247569700758e-10
were O 0 4.155677191253204e-10
likely O 0 1.5997690949731691e-09
to O 0 2.9357979935973333e-10
be O 0 2.386368047613274e-10
identical O 0 5.707613270899969e-10
by O 0 6.395269036563178e-11
descent O 0 9.040864057396902e-09
for O 0 2.347400329671956e-10
a O 0 9.084817342852602e-10
mutation O 0 3.3630084828040196e-10
in O 0 6.702341459607908e-10
the O 0 1.5132744835000267e-08
founder O 0 3.1223203222907614e-07
population O 0 1.40571262963185e-10
. O 0 9.201155393157023e-09

The O 0 8.938487638943116e-08
identification O 0 1.1238197039631359e-08
of O 0 5.489821930382277e-08
common O 0 2.4342302822333295e-06
BRCA1 O 0 8.403995934713748e-07
and O 0 5.909839373430259e-08
BRCA2 O 0 2.8273200669559628e-08
mutations O 0 8.425753983409834e-10
will O 0 1.8127403744738757e-10
facilitate O 0 1.3259566777890086e-09
carrier O 0 7.184561390261024e-09
detection O 0 1.9337308003741782e-06
in O 0 2.5195565633850947e-09
French O 0 1.7469760393851175e-07
Canadian O 0 6.368629783537472e-06
breast B-Disease 0 0.02177281491458416
cancer I-Disease 0 8.74646138981916e-05
and O 0 4.44751685790834e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.4926240510249045e-07
. O 0 1.3770211637620378e-07

Are O 0 8.517930893958692e-08
Dp71 O 0 0.0001224526495207101
and O 0 3.69642549458149e-07
Dp140 O 0 2.317618054803461e-05
brain O 0 5.444194175652228e-05
dystrophin O 0 5.708277967642061e-06
isoforms O 0 1.7763967719020002e-07
related O 0 2.6570752709176304e-08
to O 0 8.739737822338611e-09
cognitive B-Disease 0 0.00047218959662131965
impairment I-Disease 1 0.9985587000846863
in O 0 1.833372880355455e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9999792575836182

Molecular O 0 7.325321348616853e-06
study O 0 4.890643623411961e-08
and O 0 3.4500515777580176e-09
neuropsychological O 0 6.877168345909013e-08
analysis O 0 2.755767170015133e-09
were O 0 2.4043060875555966e-09
performed O 0 9.593484895376037e-10
concurrently O 0 6.152783837976017e-10
on O 0 9.957629387713496e-09
49 O 0 1.53447761164216e-08
patients O 0 6.10711836657174e-09
with O 0 6.22002360728402e-08
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.016572991386055946
DMD B-Disease 1 1.0
) O 0 2.2954917966444555e-09
in O 0 3.7125980067997943e-10
order O 0 2.4476525251060366e-09
to O 0 1.5145817933159833e-09
find O 0 3.61061980314048e-09
a O 0 7.148581171456669e-10
molecular O 0 3.9591343536926615e-09
explanation O 0 9.032964931598997e-10
for O 0 9.145226936846385e-11
the O 0 2.7410578251618745e-09
cognitive B-Disease 0 1.9559006148028857e-07
impairment I-Disease 0 2.452713374623272e-07
observed O 0 6.728705148617564e-09
in O 0 1.5882158921343148e-09
most O 0 3.8495613807754125e-08
DMD B-Disease 1 1.0
patients O 0 7.327782805077732e-05
. O 0 6.48570107841806e-07

Complete O 0 1.2507113069659681e-06
analysis O 0 2.650373609469625e-08
of O 0 6.289587162200405e-08
the O 0 4.524149588291948e-08
dystrophin O 0 1.2194943792565027e-06
gene O 0 7.633356347014342e-08
was O 0 4.5877757770540484e-07
performed O 0 3.577216300953978e-09
to O 0 1.1322272008840173e-09
define O 0 4.7568118333174425e-08
the O 0 1.1305191804922288e-07
localization O 0 1.8042441297438927e-05
of O 0 1.70536196719695e-07
deletions O 0 1.171893657669898e-07
and O 0 2.3514521441114766e-09
duplications O 0 3.6361441857479804e-08
in O 0 5.182053119945351e-10
relation O 0 2.896686002173965e-09
to O 0 1.0450000864636877e-09
the O 0 9.477364670829047e-09
different O 0 7.01518985124494e-08
DMD B-Disease 1 1.0
promoters O 0 7.291417568922043e-05
. O 0 5.601815473710303e-07

Qualitative O 0 3.937759174732491e-06
analysis O 0 1.5315308132812788e-07
of O 0 1.4138096275928547e-06
the O 0 3.7073095882078633e-07
Dp71 O 0 2.33280734391883e-05
transcript O 0 9.573439001542283e-07
and O 0 2.377047669810395e-09
testing O 0 9.497029829219628e-10
for O 0 5.950084869255079e-11
the O 0 3.160061379237078e-10
specific O 0 3.546622162620139e-10
first O 0 2.7489268639158126e-09
exon O 0 1.86387474343519e-08
of O 0 7.967615012205442e-09
Dp140 O 0 3.159450301382094e-08
were O 0 2.184332492660701e-09
also O 0 5.037028016907641e-10
carried O 0 1.4337611098369507e-09
out O 0 2.6415909459842624e-09
. O 0 2.5629574906815833e-08

Neuropsychological O 0 2.1162975826882757e-05
analysis O 0 2.2496654139558814e-07
assessed O 0 1.0300794883733033e-06
verbal O 0 9.9841986411775e-07
and O 0 2.1041442721525527e-07
visuospatial O 0 3.165784801240079e-05
intelligence O 0 9.688374120742083e-07
, O 0 1.573084551509396e-09
verbal O 0 1.2096379009562952e-07
memory O 1 1.0
, O 0 7.484970865334617e-08
and O 0 5.248646317568273e-08
reading O 0 1.4027244787939708e-06
skills O 0 7.722244845353998e-06
. O 0 6.396620051418722e-07

Comparison O 0 1.6277130043818033e-06
of O 0 1.3809508345730137e-06
molecular O 0 5.896356015000492e-06
and O 0 1.4638267487043777e-07
psychometric O 0 0.0001656066597206518
findings O 0 1.5799328423327097e-07
demonstrated O 0 8.898325631889747e-08
that O 0 3.4260705383815093e-09
deletions O 0 1.9409054630159517e-07
and O 0 6.198690893910452e-09
duplications O 0 6.568137678186758e-08
that O 0 3.760690925336263e-10
were O 0 1.5308139200698179e-09
localized O 0 4.545617926510204e-08
in O 0 1.727784360028295e-09
the O 0 1.6165357052955187e-08
distal O 0 8.758028684496821e-07
part O 0 2.3070807486647027e-08
of O 0 1.3425631095742574e-07
the O 0 9.235620268555067e-08
gene O 0 2.5671145209571478e-09
seemed O 0 6.886853309850949e-09
to O 0 8.038496257523065e-11
be O 0 4.756514279669055e-11
preferentially O 0 7.819720981849798e-10
associated O 0 2.125575937483859e-09
with O 0 1.1151968237754772e-09
cognitive B-Disease 0 0.0005669770180247724
impairment I-Disease 1 0.6426995396614075
. O 0 8.370334398932755e-06

Two O 0 5.436239916889463e-06
altered O 0 1.016783426166512e-05
Dp71 O 0 0.00012256106128916144
transcripts O 0 2.8919678243255476e-06
and O 0 5.6620894639536345e-08
two O 0 8.116491478915577e-09
deleted O 0 3.1481171447467204e-08
Dp140 O 0 3.19520516711691e-08
DNA O 0 2.5674966597222237e-09
sequences O 0 7.51566031631512e-11
were O 0 2.6273226649831116e-11
found O 0 2.002959777203106e-11
in O 0 2.2448990583123773e-11
four O 0 7.427703591078583e-11
patients O 0 5.477923670227369e-10
with O 0 1.726473297658515e-09
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 7.13421541149728e-05

These O 0 1.7524024542581174e-07
findings O 0 3.8395594259554855e-08
suggest O 0 3.593272568380712e-09
that O 0 1.1817299916394575e-10
some O 0 5.697875157806287e-11
sequences O 0 5.63565416555889e-10
located O 0 1.5524106444786412e-09
in O 0 1.1934565835591826e-10
the O 0 1.2294665285850215e-09
distal O 0 1.9695121977747476e-07
part O 0 7.190620987529428e-09
of O 0 2.0023325220108745e-08
the O 0 2.8309663502312787e-09
gene O 0 3.45359851827709e-10
and O 0 2.1033290387162396e-10
, O 0 1.4777210705085864e-11
in O 0 3.575153020851651e-11
particular O 0 4.853912272118066e-10
, O 0 8.615563124036996e-11
some O 0 1.4871998077481408e-10
DMD B-Disease 1 1.0
isoforms O 0 1.9632169312444603e-07
expressed O 0 1.3281848509905103e-08
in O 0 7.396975032492037e-09
the O 0 1.1268443955714247e-07
brain O 0 3.7170241284911754e-06
may O 0 1.1251380938048783e-09
be O 0 1.2258014048249777e-10
related O 0 1.8556653991197436e-09
to O 0 1.2730847487318897e-09
the O 0 8.483605995479593e-08
cognitive B-Disease 0 4.859014006797224e-05
impairment I-Disease 0 1.60888066602638e-05
associated O 0 2.0895593024761183e-06
with O 0 1.959855211453032e-07
DMD B-Disease 1 1.0
. O 0 1.6067749584181001e-06
. O 0 3.7053831647426705e-07

I1307K O 0 0.00023218465503305197
APC O 0 2.06696549867047e-05
and O 0 1.6976865424567222e-07
hMLH1 O 0 1.8889865032178932e-06
mutations O 0 2.560485157232506e-08
in O 0 1.98965399711426e-09
a O 0 2.0736031558499235e-08
non O 0 3.063176166051562e-07
- O 0 5.363510240385949e-07
Jewish O 0 1.9197683798211074e-07
family O 0 3.1176899284446336e-08
with O 0 2.1616478051988963e-10
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9998863935470581

We O 0 3.30118183455852e-07
describe O 0 1.558942983592715e-07
a O 0 6.27696721267057e-08
French O 0 3.584513024179614e-07
Canadian O 0 1.6785910474936827e-06
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.7700579166412354
HNPCC B-Disease 1 1.0
) O 0 3.144792515286099e-08
kindred O 0 3.3202792110387236e-05
which O 0 6.096992688497949e-09
carries O 0 1.0649835679998887e-08
a O 0 7.895755160802764e-09
novel O 0 1.5335908543079313e-08
truncating O 0 6.148355424784313e-08
mutation O 0 3.17018122863999e-09
in O 0 3.17329074128736e-09
hMLH1 O 0 1.251198114005092e-06
. O 0 2.328122832295776e-07

Interestingly O 0 9.105309800361283e-06
, O 0 8.558285458093451e-08
the O 0 1.475225985814177e-07
I1307K O 0 7.303552820303594e-07
APC O 0 8.040148458121621e-08
polymorphism O 0 5.2077211876166984e-08
, O 0 6.504907029691864e-11
associated O 0 1.6181997408715176e-10
with O 0 5.472164388287126e-12
an O 0 4.000483104504848e-12
increased O 0 8.513759836015211e-11
risk O 0 8.029129361375453e-08
of O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.5506389889073944e-08
is O 0 4.326075261906759e-11
also O 0 9.633264672070929e-12
present O 0 1.9129553843755254e-11
in O 0 1.3923305564045307e-10
this O 0 7.338764040909496e-10
family O 0 3.7708296929395146e-08
. O 0 1.4481385868236885e-08

The O 0 1.5925770640023984e-05
I1307K O 0 7.4582812885637395e-06
polymorphism O 0 9.777910463526496e-07
has O 0 6.745744851599511e-09
previously O 0 2.6947966080825836e-09
only O 0 3.941423923348175e-11
been O 0 8.176772453571957e-11
identified O 0 1.7100271199055328e-10
in O 0 5.974910843864478e-11
individuals O 0 6.618919821954616e-12
of O 0 1.0398966132640908e-08
self O 0 1.9384563643143338e-07
- O 0 3.855076329273288e-07
reported O 0 1.6930295387851402e-08
Ashkenazi O 0 7.734021778560418e-07
Jewish O 0 9.209340134930244e-08
origins O 0 4.5413889893097803e-07
. O 0 6.980926059441117e-08

In O 0 2.3321115349972388e-07
addition O 0 2.978986124446692e-08
, O 0 1.9230761427735388e-09
in O 0 4.291617616836163e-10
this O 0 3.885363142330789e-10
family O 0 1.0896360258527693e-08
, O 0 7.144296959582519e-11
there O 0 3.5916585677808754e-11
appears O 0 8.125595196695201e-10
to O 0 4.4259146347869205e-10
be O 0 2.8272859609046463e-09
no O 0 8.679816865253542e-09
relationship O 0 3.083517885471565e-09
between O 0 1.3633095541365492e-08
the O 0 2.919462005479545e-08
I1307K O 0 2.1158207630378456e-08
polymorphism O 0 3.2250768722263956e-09
and O 0 1.0337750100397614e-10
the O 0 1.832853036010107e-10
presence O 0 1.163675267257247e-10
or O 0 9.838724279731537e-10
absence O 0 4.532587993821835e-08
of O 0 9.956664825949701e-08
cancer B-Disease 0 2.5041892968147295e-06
. O 0 7.316238281873666e-09
. O 0 6.424154719297803e-08

Identification O 0 3.539949204878212e-07
of O 0 3.503542416183336e-07
a O 0 1.840790098128764e-08
novel O 0 1.3947612842457602e-08
mutation O 0 3.1312279435979917e-09
of O 0 2.9272236190536205e-08
the O 0 9.524212174483182e-08
CPO O 0 8.48697027322487e-07
gene O 0 2.8907363169849987e-09
in O 0 7.013497560492965e-10
a O 0 2.087922368332329e-08
Japanese O 0 4.365905624581501e-06
hereditary B-Disease 1 0.9999998807907104
coproporphyria I-Disease 1 0.9983919262886047
family O 0 1.0411218681838363e-05
. O 0 2.736695421390323e-07

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
( O 0 6.535598458867753e-06
HCP B-Disease 1 0.9999994039535522
) O 0 1.1638229047150617e-08
is O 0 3.2436271446556475e-09
an O 0 8.005011764566916e-09
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
characterized O 0 0.0804256796836853
by O 0 5.016725523887544e-08
a O 0 8.64734101924114e-06
deficiency B-Disease 1 0.9999998807907104
of I-Disease 1 0.9999998807907104
coproporphyrinogen I-Disease 1 0.9999866485595703
oxidase I-Disease 0 2.943173285530065e-06
( O 0 1.989293618720467e-09
CPO O 0 1.0339932998704171e-07
) O 0 3.30253012437165e-11
caused O 0 8.919557870079586e-10
by O 0 8.055317524124916e-11
a O 0 2.2255033371720856e-09
mutation O 0 2.9108129795396565e-10
in O 0 2.500176732311843e-10
the O 0 9.274700119021873e-09
CPO O 0 4.445047352419351e-07
gene O 0 1.6594094986999153e-08
. O 0 4.911611029001506e-08

Only O 0 1.4763773492632026e-07
11 O 0 4.803684916510065e-08
mutations O 0 2.8917728212007887e-09
of O 0 1.010502970189009e-08
the O 0 8.031025622301513e-09
gene O 0 1.263225635206311e-09
have O 0 2.2345793271316694e-10
been O 0 4.0120559652301324e-10
reported O 0 7.640529875452273e-10
in O 0 2.58914445439018e-09
HCP B-Disease 1 0.9999992847442627
patients O 0 8.08102049631998e-05
. O 0 3.9307055885728914e-06

We O 0 1.7754213388343487e-07
report O 0 3.871302833857726e-09
another O 0 1.1988849912825117e-09
mutation O 0 8.320938937877997e-10
in O 0 5.534266933615584e-10
a O 0 9.258651623156311e-09
Japanese O 0 1.2083665978934732e-06
family O 0 1.565798470437585e-06
. O 0 2.1901016111769422e-07

Polymerase O 0 4.88363548356574e-05
chain O 0 1.5791600844750064e-06
reaction O 0 1.2970195939487894e-07
- O 0 2.527712581468222e-07
single O 0 5.049066231777033e-08
strand O 0 3.460987585413022e-08
conformational O 0 4.675689613264922e-09
polymorphism O 0 4.192420632875837e-09
and O 0 4.118322627366666e-10
direct O 0 1.933779580909345e-09
sequence O 0 4.4689646427897856e-10
analyses O 0 8.456279565471903e-10
demonstrated O 0 1.2779259872530702e-09
a O 0 1.6294061655486303e-09
C O 0 2.482393668401528e-08
to O 0 2.1553705487065145e-09
T O 0 1.4740638043519994e-08
substitution O 0 1.1839602187535547e-08
in O 0 2.7818980452565256e-09
exon O 0 1.1468071825504467e-08
1 O 0 3.0139157836117647e-09
of O 0 4.882427240282539e-10
the O 0 1.7597292512050444e-09
CPO O 0 5.374467093588464e-08
gene O 0 1.0571609143639193e-09
at O 0 1.5978052214649097e-09
nucleotide O 0 2.772643892257065e-09
position O 0 3.4080446909001694e-08
85 O 0 2.8403677632127255e-08
, O 0 1.7718496114760285e-10
which O 0 1.9744406110078216e-10
lies O 0 2.7543025638010477e-08
in O 0 8.171163745629428e-10
the O 0 8.700784093207403e-09
putative O 0 2.7380841061130923e-07
presequence O 0 2.7990381568088196e-07
for O 0 6.007412900466136e-10
targeting O 0 8.211179292061388e-09
to O 0 1.081269918046246e-08
mitochondria O 0 2.7947542093897937e-06
. O 0 4.299901661397598e-07

This O 0 5.1374964726846883e-08
mutation O 0 2.3923680814164072e-08
changes O 0 4.9835815474352785e-09
the O 0 9.56307122379485e-09
codon O 0 1.4844913076572652e-09
for O 0 4.801051778358101e-10
glutamine O 0 6.9706382888057306e-09
to O 0 1.104692115561079e-09
a O 0 4.740307257833365e-09
termination O 0 1.2721537245852232e-07
codon O 0 9.67046620559131e-09
at O 0 5.360398347420414e-09
amino O 0 4.513629747737724e-10
acid O 0 1.2527880954849024e-09
position O 0 2.7137742719673952e-08
29 O 0 3.6599377040147374e-07
. O 0 1.7613258762594342e-07

MaeI O 0 0.0002567238116171211
restriction O 0 2.3295929452160635e-07
analysis O 0 1.1861278181868329e-08
showed O 0 5.741901620837098e-09
two O 0 4.3889600287450037e-10
other O 0 8.762947312224156e-11
carriers O 0 5.590347074146962e-10
in O 0 1.4754469868094588e-09
the O 0 8.487700853265778e-08
family O 0 2.4652567276461923e-07
. O 0 3.120092983976974e-08

The O 0 6.9952666308381595e-06
C O 0 8.737450843909755e-05
- O 0 3.3578726288396865e-05
T O 0 6.788857831452333e-07
mutation O 0 4.128233754840949e-09
is O 0 1.82357379197029e-10
located O 0 6.519940143334679e-10
within O 0 2.0600834926831624e-10
a O 0 5.020827087420798e-10
recently O 0 8.266946571744427e-10
proposed O 0 1.7606357483046509e-09
putative O 0 7.742804797317149e-08
alternative O 0 5.012804038528884e-08
translation O 0 1.5015439558396793e-08
initiation O 0 6.904043114985825e-09
codon O 0 3.2766564461716996e-10
( O 0 4.1415110924036824e-11
TIC O 0 2.0810551060179705e-09
- O 0 4.268744913105138e-09
1 O 0 7.649560096467667e-09
) O 0 1.0200332245524635e-10
, O 0 7.253786460381662e-11
supporting O 0 7.506752996988553e-10
that O 0 1.014550332634201e-09
TIC O 0 3.6790589774682303e-07
- O 0 6.728669177391566e-07
1 O 0 3.272151047895022e-07
is O 0 2.8822246811444074e-09
the O 0 1.907682367630059e-08
real O 0 9.843537895903864e-08
TIC O 0 1.435628718127191e-07
rather O 0 8.121446626319084e-09
than O 0 1.1018134182805284e-09
TIC O 0 5.1273936207962834e-08
- O 0 9.362416619751457e-08
2 O 0 3.504470313941965e-08
. O 0 2.567555501542529e-09
. O 0 3.0620338264952807e-08

Human B-Disease 0 1.741905180097092e-07
complement I-Disease 0 3.3568312574061565e-07
factor I-Disease 0 1.2186351341370028e-05
H I-Disease 1 1.0
deficiency I-Disease 1 0.9979498982429504
associated O 0 1.242970483872341e-06
with O 0 5.385936674429104e-06
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999998807907104

This O 0 2.4191514569338324e-08
study O 0 2.3533277548892784e-09
reports O 0 2.778467012021224e-09
on O 0 3.0387712346424678e-09
six O 0 1.016137868292688e-10
cases O 0 2.0215715212934526e-10
of O 0 1.9104239967759895e-08
deficiency B-Disease 1 0.9709156155586243
in I-Disease 0 6.335061186746316e-08
the I-Disease 0 5.363909281186352e-07
human I-Disease 0 1.2703831764326878e-08
complement I-Disease 0 2.484188676987742e-08
regulatory I-Disease 0 1.5703760709584458e-06
protein I-Disease 0 2.084058905893471e-06
Factor I-Disease 0 9.17276906875486e-07
H I-Disease 1 0.9999997615814209
( O 0 1.630575119371258e-09
FH O 0 2.6233808014808346e-08
) O 0 5.04631145897827e-12
in O 0 2.2161430676681526e-12
the O 0 8.968440573520198e-12
context O 0 6.196804874791795e-11
of O 0 8.887864055839856e-11
an O 0 5.89142901130657e-11
acute B-Disease 0 0.05152793973684311
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 8.616965715191327e-06

Five O 0 8.645120601613598e-07
of O 0 1.539557246132972e-07
the O 0 7.417800151898746e-09
cases O 0 5.696237370678148e-10
were O 0 1.641752706005306e-10
observed O 0 2.113181019058885e-10
in O 0 8.095993493661968e-12
children O 0 2.640131169240334e-12
presenting O 0 1.5540660425195085e-10
with O 0 2.0639978615122345e-09
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 0 1.9179076844011433e-05
. O 0 2.7987978683086112e-05

Two O 0 1.1035621838573206e-07
of O 0 1.4112647761521657e-07
the O 0 1.0733776889537694e-07
children O 0 3.5753611182798295e-09
exhibited O 0 1.1044334335963413e-08
a O 0 1.6044918993429746e-07
homozygous O 0 5.9418875935079996e-06
deficiency O 1 0.9993300437927246
characterized O 0 1.1716549579432467e-06
by O 0 5.297394167769198e-08
the O 0 4.970045483787544e-05
absence O 0 4.2228119127685204e-05
of O 0 3.068141813855618e-05
the O 0 3.938702661798743e-07
150 O 0 3.723364949692609e-09
- O 0 1.2798799797764104e-09
kD O 0 4.341562220844253e-09
form O 0 3.2903091362612713e-10
of O 0 3.108617008251713e-08
Factor O 0 2.3456820485989738e-07
H O 1 1.0
and O 0 7.585616579319776e-09
the O 0 4.057895353071217e-09
presence O 0 4.794206698299774e-10
, O 0 1.1729363313950358e-10
upon O 0 6.746336378427031e-09
immunoblotting O 0 2.059624648609315e-07
, O 0 4.420987465003634e-10
of O 0 3.2659261961498487e-09
the O 0 2.2998138504704002e-08
42 O 0 1.942741967297934e-08
- O 0 1.722589537678232e-08
kD O 0 1.6102724487154774e-07
Factor O 0 1.2377131497487426e-07
H O 1 0.9977306723594666
- O 0 1.3952197832622915e-06
like O 0 1.795338100407662e-08
protein O 0 4.563461075690611e-08
1 O 0 5.73109488755108e-08
( O 0 3.912200841060809e-10
FHL O 0 2.5001229460031027e-06
- O 0 3.1495622465627093e-07
1 O 0 7.696483095287476e-08
) O 0 1.8884928343343432e-10
and O 0 4.70189109869068e-10
other O 0 9.090589392357629e-10
FH O 0 2.8572620180966624e-07
- O 0 2.2884895756192236e-08
related O 0 1.5869391134515354e-08
protein O 0 1.1381453113301632e-08
( O 0 7.621360764709095e-10
FHR O 0 3.061618599531357e-06
) O 0 8.143655749748291e-10
bands O 0 2.0203522410611185e-07
. O 0 1.8744172791684832e-07

Southern O 0 4.786076897289604e-05
blot O 0 6.734248745488003e-05
and O 0 7.676277391510666e-09
PCR O 0 4.616390825162853e-08
analysis O 0 4.4265985321700896e-10
of O 0 8.430866560438233e-10
DNA O 0 6.550732400967263e-09
of O 0 9.881005347267546e-09
one O 0 9.484141250126754e-10
patient O 0 1.7803916563252642e-08
with O 0 1.5522420016012006e-09
homozygous O 0 8.470611874145106e-07
deficiency O 1 0.5270530581474304
ruled O 0 0.002152686705812812
out O 0 2.022195104700586e-07
the O 0 6.082162684606374e-08
presence O 0 2.752378991388582e-09
of O 0 3.063628639665694e-08
a O 0 3.998093855983598e-09
large O 0 1.8263385248573627e-09
deletion O 0 7.120457112819167e-09
of O 0 1.1254627452217392e-08
the O 0 2.8012753006123603e-08
FH O 0 3.240580781493918e-07
gene O 0 2.5353732446831145e-09
as O 0 9.747572748963762e-10
the O 0 4.2129011390557025e-09
underlying O 0 3.3115695714514004e-06
defect O 0 1.8959650333272293e-05
for O 0 4.206961179420432e-08
the O 0 2.9269804144860245e-05
deficiency O 1 0.9999997615814209
. O 0 1.0110995390277822e-05

The O 0 3.0338239866978256e-06
other O 0 1.9928378947042802e-08
four O 0 3.633743528297373e-09
children O 0 2.1521363857690545e-10
presented O 0 5.945360204151484e-09
with O 0 6.5261147597084346e-09
heterozygous O 0 4.4005699351146177e-07
deficiency O 1 0.9707272052764893
and O 0 2.2466508653451456e-07
exhibited O 0 1.7035479515925545e-07
a O 0 3.1332436378761486e-07
normal O 0 3.916715058949194e-07
immunoblotting O 0 2.669353591500112e-07
pattern O 0 3.670040049641443e-09
of O 0 2.7850091122161302e-09
proteins O 0 1.5807082032193165e-10
of O 0 7.0813279684500685e-09
the O 0 5.0443492938256895e-08
FH O 0 7.874687980802264e-06
family O 0 7.534861623526012e-08
. O 0 2.938512544403693e-08

Factor B-Disease 1 0.9997928738594055
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 8.414098751075016e-09
the O 0 7.929033429832089e-09
only O 0 1.4839873774263879e-09
complement B-Disease 1 0.999411940574646
deficiency I-Disease 1 1.0
associated O 0 6.546363238157937e-07
with O 0 2.5616037291342764e-08
HUS B-Disease 1 1.0
. O 0 2.8987689802306704e-05

These O 0 1.4562257888428576e-07
observations O 0 2.256885522911034e-07
suggest O 0 1.235225877138646e-08
a O 0 5.952758286298376e-09
role O 0 1.2067224552936295e-08
for O 0 1.236441504737229e-09
FH O 0 2.073717951134313e-06
and O 0 2.9777135424069456e-08
/ O 0 1.7777690572984284e-06
or O 0 3.007956195233419e-08
FH O 0 3.3601975246710936e-07
receptors O 0 1.0924428028857847e-09
in O 0 6.745325825674442e-11
the O 0 7.742059215942731e-10
pathogenesis O 0 2.052212494163541e-06
of O 0 1.0307915232488085e-07
idiopathic O 1 0.9994427561759949
HUS B-Disease 1 1.0
. O 0 5.234874151938129e-07
. O 0 2.169757209458112e-07

Further O 0 2.3196474074893558e-08
evidence O 0 2.0237726161553837e-08
for O 0 3.3505873076045134e-10
a O 0 1.0317150467287206e-09
major O 0 4.154228516739522e-09
ancient O 0 8.052516022871714e-07
mutation O 0 4.269934379408369e-06
underlying O 1 0.9999842643737793
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.0925413334916811e-05
linkage O 0 5.105473974253982e-06
disequilibrium O 0 7.593775421810278e-07
studies O 0 1.2543805993914248e-09
in O 0 2.2923053732970544e-10
the O 0 2.2124426735103953e-09
Japanese O 0 7.713825311839173e-08
population O 0 1.1282514505994712e-10
. O 0 7.948687930081633e-09

The O 0 0.00024413480423390865
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 4.406626976560801e-05
DM B-Disease 1 1.0
) O 0 2.8597529677654165e-08
mutation O 0 1.0104951542189156e-08
is O 0 1.3851662039598978e-09
an O 0 8.629926218084449e-10
unstable O 0 6.279228273342596e-06
( O 0 2.2172510938389678e-08
CTG O 0 1.4624562027165666e-05
) O 0 2.171972823816759e-09
n O 0 8.127429396154184e-09
repeat O 0 8.206153978562725e-09
, O 0 9.729363842359007e-11
present O 0 7.8346351628511e-10
at O 0 2.388254483065566e-09
a O 0 4.46894771188866e-10
copy O 0 1.2832948037555525e-09
number O 0 9.598458139414845e-11
of O 0 3.707943507791356e-09
5 O 0 1.1932643317891234e-08
- O 0 5.495845911696051e-08
37 O 0 3.828641226277796e-08
repeats O 0 3.243220447757267e-08
on O 0 4.8491887838508774e-08
normal O 0 6.287161902207572e-09
chromosomes O 0 4.315605206528517e-09
but O 0 1.578021935344509e-09
amplified O 0 2.709998270233882e-08
to O 0 4.048494872677111e-09
50 O 0 5.476997078091017e-09
- O 0 8.83321860101205e-09
3000 O 0 1.819836170646738e-09
copies O 0 9.757615826444521e-10
on O 0 6.650759587500943e-08
DM B-Disease 1 0.99996018409729
chromosomes O 0 1.5770319805596955e-07
. O 0 1.083483454067391e-07

Previous O 0 5.172744749870617e-06
findings O 0 1.7224817838723538e-07
in O 0 1.1653067844008547e-08
Caucasian O 0 2.294436427519031e-07
populations O 0 8.503739046261671e-09
of O 0 9.906484876864852e-08
a O 0 4.55317740488681e-06
DM B-Disease 1 1.0
founder O 1 0.9994598031044006
chromosome O 0 8.193408689294301e-07
raise O 0 1.4120639768577803e-08
a O 0 7.069345109300684e-09
question O 0 2.927802889018949e-09
about O 0 5.314357981456297e-11
the O 0 4.4220077599632646e-10
molecular O 0 1.4025397510053494e-09
events O 0 2.0342028408948387e-11
involved O 0 4.318680482673365e-11
in O 0 1.1410872247097359e-10
the O 0 1.4033610939989671e-09
expansion O 0 2.1823844065238518e-08
mutation O 0 1.0089583390993084e-08
. O 0 2.4881437354906666e-08

To O 0 3.3582915648366907e-07
investigate O 0 1.5325916535857687e-07
whether O 0 1.5566307354220044e-08
a O 0 5.889651788493211e-08
founder O 0 3.018059828718833e-07
chromosome O 0 5.121380208805704e-09
for O 0 1.2669367777107254e-09
the O 0 6.06276898906799e-07
DM B-Disease 1 1.0
mutation O 0 3.324855981645669e-07
exists O 0 3.289658101479631e-09
in O 0 4.937436570706666e-10
the O 0 9.854049798363462e-10
Japanese O 0 1.175275521347885e-08
population O 0 6.171595352821857e-12
, O 0 3.192726985568051e-11
we O 0 2.4970983614203135e-10
genotyped O 0 6.314697742482167e-08
families O 0 1.878788652431851e-10
using O 0 1.4402983250505486e-09
polymorphic O 0 8.602094681009476e-08
markers O 0 7.424059589311582e-08
near O 0 3.5267069051769795e-06
the O 0 3.438423163970583e-07
( O 0 8.60118909429275e-09
CTG O 0 2.630331209729775e-06
) O 0 1.8700341275490473e-09
n O 0 1.333342503073709e-08
repeat O 0 8.107796212186713e-09
region O 0 1.2372206370514505e-08
and O 0 6.776850192125039e-09
constructed O 0 3.8035775560274487e-06
haplotypes O 0 2.0326235699030804e-06
. O 0 1.3132097365087247e-07

Six O 0 3.492530140647432e-07
different O 0 4.748360815653996e-09
haplotypes O 0 1.6028003813062242e-07
were O 0 7.004076429950601e-09
found O 0 3.0698330544254304e-09
and O 0 1.0964722463313592e-08
DM B-Disease 1 1.0
alleles O 0 2.1528201443743455e-08
were O 0 2.137216092990002e-08
always O 0 4.274254905567432e-08
haplotype O 0 1.6966067732937518e-06
A O 0 1.9112569589196937e-06
. O 0 2.1775971958959417e-07

To O 0 6.676000339211896e-07
find O 0 9.715432014445469e-08
an O 0 5.570506833585398e-10
origin O 0 1.6712787820338804e-09
of O 0 4.5933617798255e-08
the O 0 5.754052523343489e-08
( O 0 4.150878307740413e-09
CTG O 0 5.42934412806062e-06
) O 0 3.5825287181268095e-09
n O 0 2.0327943772713297e-08
repeat O 0 1.3319419345236838e-08
mutation O 0 2.518835806597508e-09
and O 0 8.594428502206597e-10
to O 0 7.387045974915907e-10
investigate O 0 5.357454480048318e-09
the O 0 9.861989447301767e-09
mechanism O 0 2.5414607307538972e-08
of O 0 8.59597371061227e-09
the O 0 7.937369872479394e-09
expansion O 0 7.384386879749627e-09
mutation O 0 2.1591300969348026e-10
in O 0 6.525797263678967e-11
the O 0 5.60100910096395e-10
Japanese O 0 4.204808945473815e-09
population O 0 5.0595734199521125e-12
we O 0 4.808857478888484e-11
have O 0 1.9769342413100688e-11
studied O 0 2.5534023784246074e-09
90 O 0 3.8001344293547845e-09
Japanese O 0 2.160343939294762e-07
DM B-Disease 1 1.0
families O 0 1.489688372657838e-08
comprising O 0 2.0338239425932159e-10
190 O 0 7.026753068295477e-10
affected O 0 6.436585708868847e-10
and O 0 1.3952103916636815e-09
130 O 0 2.008897048710878e-08
unaffected O 0 2.1284945717070514e-07
members O 0 5.381664891501714e-09
. O 0 6.210883185531202e-08

The O 0 6.208654667716473e-06
results O 0 4.1356596369723775e-08
suggest O 0 1.2796877335574663e-08
that O 0 6.737383428934152e-10
a O 0 5.015632353888577e-09
few O 0 3.6816432125164056e-09
common O 0 4.6182755397694564e-08
ancestral O 0 2.3488098577217897e-06
mutations O 0 4.784562079862553e-09
in O 0 8.759393210766575e-10
both O 0 1.7415016095867486e-09
Caucasian O 0 4.34749779287813e-07
and O 0 1.7128041918113013e-07
Japanese O 0 1.610289837117307e-05
populations O 0 1.1029571700404972e-09
have O 0 1.7879958624789083e-10
originated O 0 5.825183668761724e-10
by O 0 2.4206662715964278e-11
expansion O 0 3.0791453831113813e-09
of O 0 2.6944417808039134e-09
an O 0 2.0616873486201115e-10
ancestral O 0 9.482336693622528e-09
n O 0 3.875425313992764e-09
= O 0 8.782982119370786e-10
5 O 0 8.504351667326659e-10
repeat O 0 8.364267056748531e-10
to O 0 1.496436863313022e-09
n O 0 8.699522879851429e-09
= O 0 1.41102205475363e-08
19 O 0 2.940598164968833e-08
- O 0 1.945404370928827e-08
37 O 0 9.885756213634522e-09
copies O 0 1.5471469438921304e-08
. O 0 9.147979085355473e-08

These O 0 1.7098665239245747e-07
data O 0 1.3160935452560807e-07
support O 0 7.090792308872551e-08
multistep O 0 5.085579687147401e-06
models O 0 2.84767821767673e-07
of O 0 2.9521240776375635e-06
triplet O 0 1.718852399790194e-05
repeat O 0 1.1646216790950348e-07
expansion O 0 7.72115598124401e-08
that O 0 5.929996771403268e-11
have O 0 1.62234010947504e-11
been O 0 8.42349627550032e-12
proposed O 0 3.2856727755214976e-11
for O 0 2.4728441516685962e-11
both O 0 5.114563772501413e-10
DM B-Disease 1 1.0
and O 0 2.97698193207907e-07
Friedreichs B-Disease 0 0.0006551053957082331
ataxia I-Disease 0 0.009332336485385895
. O 0 1.3355216310628748e-07
. O 0 3.213149000202975e-07

The O 0 3.2455693599331426e-07
molecular O 0 2.900525259974529e-07
basis O 0 1.5540638287347974e-07
of O 0 0.0006321423570625484
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 8.515234384276482e-08
the O 0 2.422707012783576e-08
western O 0 8.905337978148964e-08
Cape O 0 1.2460278639991884e-06
, O 0 6.383134576459781e-10
South O 0 4.6881920567898305e-09
Africa O 0 4.257604935276049e-09
. O 0 2.6588901747004456e-08

Deficiency B-Disease 1 0.9999920129776001
of I-Disease 0 0.12165556102991104
the I-Disease 0 0.00036299298517405987
sixth I-Disease 0 0.00038509926525875926
component I-Disease 0 3.8153884815983474e-06
of I-Disease 0 7.769564831505704e-07
human I-Disease 0 6.42796607053242e-08
complement I-Disease 0 4.888167381977837e-07
( O 0 1.2035140173338732e-07
C6 O 1 0.999523401260376
) O 0 1.4624412791874875e-09
has O 0 2.0030181679953074e-10
been O 0 2.3046727026798663e-10
reported O 0 1.7633602911182322e-10
in O 0 3.39138786498161e-11
a O 0 8.427823022794101e-11
number O 0 6.363581103036031e-12
of O 0 2.359736017698566e-10
families O 0 3.174123117122285e-11
from O 0 4.847925949569287e-10
the O 0 3.5733975778384774e-09
western O 0 5.238684863684284e-08
Cape O 0 1.2306317103139008e-06
, O 0 7.815411651179716e-10
South O 0 1.2861428366761629e-08
Africa O 0 1.0945290007668973e-08
. O 0 6.780847883192109e-08

Meningococcal B-Disease 1 1.0
disease I-Disease 1 1.0
is O 0 8.980508425793232e-08
endemic O 0 8.470105683500151e-08
in O 0 1.6257027946053881e-09
the O 0 3.191100361732424e-08
Cape O 0 3.192572648913483e-06
and O 0 3.5234231088310253e-09
almost O 0 3.6078920406801274e-10
all O 0 1.516810010926406e-10
pedigrees O 0 3.024190320388698e-08
of O 0 5.099325051105552e-08
total O 0 1.654445327403664e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.6953626058580085e-08
C6Q0 O 0 2.1907457266934216e-05
) O 0 1.0411042861147024e-10
have O 0 5.199703861924476e-11
been O 0 2.4228755113320233e-10
ascertained O 0 8.789823091603921e-09
because O 0 2.463857728951524e-10
of O 0 3.840040729841121e-09
recurrent O 0 1.902097210404463e-05
disease O 0 0.0005448911688290536
. O 0 3.3582753644623153e-07

We O 0 2.120390405480066e-07
have O 0 1.9461827704958523e-09
sequenced O 0 3.805140735835266e-08
the O 0 1.9286163777110232e-08
expressed O 0 1.4810699333622779e-08
exons O 0 1.1570863307497348e-06
of O 0 4.282182430870307e-07
the O 0 1.6990310314213275e-07
C6 O 0 1.315526787948329e-05
gene O 0 1.2275076510803729e-09
from O 0 1.7632796611710688e-10
selected O 0 5.884791959287483e-11
cases O 0 7.299309073838245e-11
and O 0 8.91831122840081e-11
have O 0 4.9850124028694154e-11
found O 0 4.344948290047057e-10
three O 0 1.0652023707535818e-09
molecular O 0 2.3301594410440885e-05
defects O 1 0.9999809265136719
leading O 0 1.1804935638792813e-05
to O 0 3.752061843442789e-07
total O 0 4.566282427731494e-07
deficiency O 1 1.0
879delG O 1 0.7777926325798035
, O 0 8.510895099789195e-09
which O 0 4.4421610834177727e-10
is O 0 2.60584887001869e-10
the O 0 3.613203070074178e-09
common O 0 1.52660931007631e-07
defect O 0 1.3878003528589034e-06
in O 0 1.0422735563508922e-08
the O 0 2.1657444904121803e-07
Cape O 0 5.224582764640218e-06
and O 0 1.0063311073338355e-08
hitherto O 0 3.386868030474943e-08
unreported O 0 1.2081387446016834e-08
, O 0 1.847555858303096e-10
and O 0 6.005671515652011e-10
1195delC O 0 1.1640121044820262e-07
and O 0 9.30950871946834e-09
1936delG O 0 2.900375761782925e-07
, O 0 6.595587409563564e-10
which O 0 1.1708932434739694e-10
have O 0 1.6017955017932906e-10
been O 0 1.1057545989956452e-09
previously O 0 2.9356819197801087e-09
reported O 0 4.2936482147482025e-10
in O 0 1.8150030089980618e-10
African O 0 1.5833765409922762e-09
- O 0 2.4016856059461134e-08
Americans O 0 4.472343384520627e-09
. O 0 2.0092423369533208e-07

We O 0 6.499919436464552e-06
also O 0 3.954690797058902e-08
show O 0 2.3050432673699106e-09
that O 0 3.9373365678940786e-11
the O 0 4.6324125091423696e-10
879delG O 0 2.1457527310531077e-08
and O 0 1.629486989784823e-09
1195delC O 0 8.814974989945767e-07
defects O 0 6.404362466128077e-06
are O 0 8.0903624077866e-11
associated O 0 4.307449330553936e-08
with O 0 3.576099416591205e-08
characteristic O 1 0.9999970197677612
C6 O 1 1.0
/ O 1 0.9999927282333374
C7 O 0 0.0002747576218098402
region O 0 4.640544659650914e-08
DNA O 0 2.741347486789891e-07
marker O 0 8.159864250956161e-08
haplotypes O 0 1.3842135437869274e-08
, O 0 5.2925285681793e-11
although O 0 1.4216398891431226e-10
small O 0 4.067316206057825e-10
variations O 0 4.32107416514782e-09
were O 0 1.0872756028845743e-08
observed O 0 6.184533418718274e-08
. O 0 8.864953571219303e-08

The O 0 3.234552787034772e-05
1936delG O 0 0.00020061759278178215
defect O 0 0.0005518768448382616
was O 0 3.351784698679694e-06
observed O 0 2.8634753235223798e-08
only O 0 8.078493429763967e-10
once O 0 9.72926184061862e-09
in O 0 6.076789071940425e-10
the O 0 5.288739668429798e-09
Cape O 0 2.5236707301701244e-07
, O 0 5.054367688273054e-11
but O 0 1.896215823249392e-11
its O 0 5.0662200129503177e-11
associated O 0 6.926187623434998e-09
haplotype O 0 3.8482627928715374e-07
could O 0 1.2113159364446346e-08
be O 0 1.6548233006119517e-08
deduced O 0 8.53757683216827e-07
. O 0 1.345840985322866e-07

The O 0 8.814507054921705e-06
data O 0 2.905597398239479e-07
from O 0 3.163291140140245e-08
the O 0 2.5411020843080223e-08
haplotypes O 0 2.712988305120234e-07
indicate O 0 4.297566746913617e-09
that O 0 1.168686675212527e-10
these O 0 7.915444411032979e-10
three O 0 1.1371096286794113e-09
molecular O 0 2.923748354533018e-07
defects O 0 1.1621568773989566e-06
account O 0 4.63671767647611e-10
for O 0 6.801946561552086e-09
the O 0 0.00029313209233805537
defects O 1 1.0
in O 0 1.2382244563013955e-07
all O 0 2.0460275251821258e-08
the O 0 1.808215444043526e-07
38 O 0 3.1809456402243086e-08
unrelated O 0 2.7831573490288974e-08
C6Q0 O 0 4.1174812395183835e-06
individuals O 0 8.159136560825786e-11
we O 0 1.0660297089515325e-09
have O 0 3.035016127306278e-10
studied O 0 6.0672027402119966e-09
from O 0 2.488000028222359e-09
the O 0 2.823321487710473e-08
Cape O 0 2.6006837288150564e-06
. O 0 5.587730456113604e-08

We O 0 1.41354689731088e-06
have O 0 2.176498270500815e-08
also O 0 3.242612622855745e-09
observed O 0 4.016820653873765e-09
the O 0 1.2670026805494672e-08
879delG O 0 2.5453471153014107e-07
defect O 0 3.2817172268551076e-07
in O 0 1.4731250885802183e-08
two O 0 2.6395909458187816e-07
Dutch O 1 0.9999995231628418
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 1 0.9998852014541626
, O 0 2.421459832646633e-08
but O 0 2.757991390822667e-09
the O 0 5.984807671666204e-08
879delG O 0 1.582239860908885e-06
defect O 0 1.023624099616427e-05
in O 0 3.441161666728476e-08
the O 0 2.1203450160101056e-06
Cape O 0 3.430393189773895e-05
probably O 0 1.5884886295225442e-07
did O 0 9.8767427569868e-10
not O 0 1.4905793266350997e-10
come O 0 2.541332144723185e-10
from O 0 8.434211662411428e-10
The O 0 8.421934261093611e-09
Netherlands O 0 2.407542609716984e-08
. O 0 3.740962206677523e-09
. O 0 8.355569036666566e-08

Complement B-Disease 1 0.9999997615814209
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 7.254391931610371e-08
seven O 0 1.089174794799419e-08
further O 0 2.675886623393353e-09
molecular O 0 6.784471224818844e-06
defects O 0 0.00020704833150375634
and O 0 1.6637886623982467e-09
their O 0 3.8744794039757835e-09
associated O 0 1.1761128462239867e-06
marker O 0 2.404294536972884e-05
haplotypes O 0 1.3228790521679912e-05
. O 0 1.8961375189974206e-06

Seven O 0 1.0545156925445553e-07
further O 0 2.8582900490903285e-09
molecular O 0 5.360748644989144e-08
bases O 0 2.3729997167265537e-07
of O 0 8.740500925341621e-05
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.6400208241739165e-08
described O 0 3.44652875128304e-07
. O 0 1.8483336816643714e-07

All O 0 1.6515147649442952e-07
these O 0 9.930582578476788e-09
new O 0 3.0964503849872926e-08
molecular O 0 3.968723660818796e-07
defects O 0 6.674141559415148e-07
involve O 0 3.6939877823272127e-09
single O 0 8.114828915495309e-07
- O 0 8.933985782277887e-07
nucleotide O 0 4.226819783070823e-07
events O 0 4.11869383043495e-09
, O 0 2.9387839384220626e-10
deletions O 0 8.989107236345717e-09
and O 0 2.0426342839385825e-09
substitutions O 0 8.45389713788336e-09
, O 0 1.2926193448947743e-10
some O 0 5.5860593928258595e-11
of O 0 3.600517439750206e-09
which O 0 4.636523109891044e-10
alter O 0 4.2453624615745866e-08
splice O 0 1.5483979041164275e-06
sites O 0 6.920931827636423e-09
, O 0 1.2992783238185979e-10
and O 0 5.54813306408164e-10
others O 0 7.395790202480157e-09
codons O 0 2.8663970397246885e-07
. O 0 7.536125394835835e-07

They O 0 1.1688599244052966e-07
are O 0 1.3489198646965406e-09
distributed O 0 1.0885241596980677e-09
along O 0 3.0731197586675307e-09
the O 0 2.0536202072207743e-08
C7 O 0 1.8002540400630096e-06
gene O 0 1.4352194988020983e-09
, O 0 3.606314552540013e-11
but O 0 1.4496149072784625e-11
predominantly O 0 1.8587915928680587e-11
towards O 0 2.1844739350740383e-09
the O 0 4.860705171694235e-09
3 O 0 1.7806836893896616e-08
end O 0 1.0894661528482175e-07
. O 0 8.428301612184441e-08

All O 0 6.699292498524301e-08
were O 0 1.020584861066709e-08
found O 0 1.8539602075762218e-09
in O 0 7.49820927570255e-10
compound O 0 3.3348877082062245e-07
heterozygous O 0 1.1057635695976842e-08
individuals O 0 4.383388096940166e-10
. O 0 1.273320151540247e-07

The O 0 0.00022796588018536568
C6 O 1 0.9999990463256836
/ O 0 0.1651563197374344
C7 O 0 0.0008100148988887668
marker O 0 2.3872366909927223e-06
haplotypes O 0 7.049648047541268e-07
associated O 0 8.813952234731914e-08
with O 0 1.817634220913078e-08
most O 0 2.361120277782902e-05
C7 B-Disease 1 1.0
defects I-Disease 1 1.0
are O 0 2.5983277751606693e-08
tabulated O 0 1.687781150394585e-07
. O 0 2.780928731738186e-08
. O 0 2.2238100427784957e-07

A O 0 3.618638947955333e-05
genome O 0 1.0204106501987553e-06
- O 0 4.836902576244029e-07
wide O 0 1.588205265079523e-07
search O 0 7.29109643771153e-08
for O 0 3.4718687924595315e-09
chromosomal O 0 3.030605284948251e-06
loci O 0 9.783824452824774e-07
linked O 0 4.7202262067003176e-05
to O 0 1.3326556427273317e-06
mental O 1 1.0
health O 1 0.9355623722076416
wellness O 0 2.8751417630701326e-05
in O 0 2.2935047194749814e-09
relatives O 0 3.464045406076366e-08
at O 0 1.1673572108961139e-09
high O 0 1.030708496330135e-08
risk O 0 1.58769584146512e-08
for O 0 1.9471310963581345e-07
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 0.012010174803435802
the O 1 0.994289755821228
Old O 1 0.9977649450302124
Order O 0 4.854383587371558e-05
Amish O 0 3.917127469321713e-05
. O 0 6.498480047412158e-07

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9999998807907104
BPAD B-Disease 1 1.0
; O 1 1.0
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 2.0990754023841873e-07
is O 0 2.5351991617128533e-09
characterized O 0 3.109967394721025e-09
by O 0 5.793559521016789e-10
episodes O 0 3.998393651727383e-07
of O 0 1.5787323945914977e-06
mania B-Disease 0 0.2979864776134491
and O 0 4.2116181475648773e-07
/ O 0 0.0003124299109913409
or O 0 1.8953731739657087e-07
hypomania B-Disease 0 0.00021629476395901293
interspersed O 0 6.149842413094575e-09
with O 0 6.39861219564608e-11
periods O 0 8.619274183274683e-08
of O 0 3.8962286907917587e-07
depression B-Disease 0 0.0012565413489937782
. O 0 2.605927136301034e-07

Compelling O 0 1.654762286307232e-06
evidence O 0 1.3877156561648007e-06
supports O 0 7.35753715730425e-08
a O 0 6.5711049934691346e-09
significant O 0 2.37906139233246e-09
genetic O 0 2.8846569577467562e-08
component O 0 4.794522467932438e-08
in O 0 1.5947909659530524e-09
the O 0 1.446656039405525e-08
susceptibility O 0 3.714525746545405e-06
to O 0 4.910786799428024e-08
develop O 0 0.01775931753218174
BPAD B-Disease 1 1.0
. O 0 0.0002725945087149739

To O 0 1.8776806598452822e-07
date O 0 7.765002010273747e-07
, O 0 1.7501794458141262e-09
however O 0 2.0189754312838204e-09
, O 0 1.5928325325376136e-10
linkage O 0 1.4965118921850262e-08
studies O 0 2.8741314883617974e-10
have O 0 2.36637043293797e-10
attempted O 0 1.952158079632227e-08
only O 0 3.7655575879647074e-10
to O 0 2.3765398537989313e-09
identify O 0 1.1969302704528673e-07
chromosomal O 0 2.4837661840138026e-05
loci O 0 1.1790687040047487e-06
that O 0 9.357592922754066e-09
cause O 0 3.6225078474672046e-06
or O 0 6.034092336903996e-09
increase O 0 5.349997111991911e-10
the O 0 1.0432282593342279e-08
risk O 0 5.800351310369933e-09
of O 0 5.30720427605047e-08
developing O 0 2.0150515410932712e-05
BPAD B-Disease 1 1.0
. O 0 6.4565751927148085e-06

To O 0 1.8123604377251468e-06
determine O 0 9.023533493746072e-07
whether O 0 1.881136313386378e-07
there O 0 2.0922717780536004e-08
could O 0 1.8620127661961305e-08
be O 0 1.7230978865967472e-09
protective O 0 9.054859901880263e-07
alleles O 0 2.3466042442521484e-09
that O 0 1.6552603732122861e-10
prevent O 0 6.660405560410254e-09
or O 0 4.597855873811341e-09
reduce O 0 2.4174772406126976e-08
the O 0 1.6992181883779267e-08
risk O 0 1.536354865550038e-08
of O 0 3.8213890718452603e-08
developing O 0 1.9765750039368868e-05
BPAD B-Disease 1 1.0
, O 0 4.4665104947938516e-10
similar O 0 2.333294391032581e-10
to O 0 1.656846188025085e-10
what O 0 1.3032146195524064e-10
is O 0 1.0849703947768408e-11
observed O 0 5.342713771394614e-11
in O 0 3.293120290348561e-11
other O 0 3.343114007847703e-09
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 3.863727116026894e-09
we O 0 2.632718043571458e-09
used O 0 4.014369915239513e-05
mental O 1 1.0
health O 0 0.3245713710784912
wellness O 0 1.594425157236401e-05
( O 0 2.5841503936696597e-10
absence O 0 1.4306968942889853e-08
of O 0 5.040959081270557e-07
any O 0 4.14143105444964e-05
psychiatric B-Disease 1 1.0
disorder I-Disease 0 0.25247547030448914
) O 0 8.28134005814718e-10
as O 0 4.112194584848794e-09
the O 0 6.147780595711083e-08
phenotype O 0 1.9456979316601064e-07
in O 0 7.616976382962548e-09
our O 0 1.8622725406203244e-07
genome O 0 7.619944142334134e-08
- O 0 1.5768667083193577e-07
wide O 0 1.8861841510897648e-07
linkage O 0 2.4888063876460365e-07
scan O 0 3.922224891539372e-07
of O 0 1.161723091058775e-07
several O 0 5.556502369330474e-09
large O 0 2.786950048516701e-08
multigeneration O 0 3.7903134852967924e-06
Old O 0 1.9683716345753055e-06
Order O 0 6.37852167528763e-07
Amish O 0 2.0086363292648457e-06
pedigrees O 0 1.3438364021567395e-07
exhibiting O 0 3.886884591963735e-09
an O 0 2.0147698787109647e-10
extremely O 0 3.91645826880449e-09
high O 0 1.007061101176987e-07
incidence O 0 2.210245611422579e-06
of O 0 2.2664398784399964e-05
BPAD B-Disease 1 1.0
. O 0 3.7317331589292735e-05

We O 0 8.498689680891403e-07
have O 0 7.556604231240271e-09
found O 0 1.8085279940294186e-09
strong O 0 6.587465573026918e-10
evidence O 0 9.36350197378033e-09
for O 0 1.21570609135091e-09
a O 0 1.2431343066054978e-08
locus O 0 1.0187260812699606e-07
on O 0 1.8256591260978894e-07
chromosome O 0 1.14454046240553e-07
4p O 0 0.001382094924338162
at O 0 1.5683659739806899e-06
D4S2949 O 0 4.2634746932890266e-07
( O 0 1.5168974965007465e-09
maximum O 0 1.0063602928767068e-07
GENEHUNTER O 0 2.7274709282210097e-05
- O 0 2.97367620305522e-07
PLUS O 0 2.1820189033405768e-07
nonparametric O 0 3.167865259001701e-07
linkage O 0 4.7367397115749554e-08
score O 0 6.271675179192471e-09
= O 0 3.1674614042742633e-09
4 O 0 2.3886825850638616e-09
. O 0 1.104173280586096e-10
05 O 0 6.62342856116993e-08
, O 0 6.891487380755734e-10
P O 0 9.610818807459509e-08
= O 0 7.380331901174486e-09
5 O 0 3.054856811957052e-09
. O 0 2.9874153151254745e-10
22 O 0 4.656706131811461e-09
x O 0 2.887139416429818e-08
10 O 0 7.281546032800179e-09
( O 0 7.811179481009844e-10
- O 0 1.1825474821591797e-08
4 O 0 4.462342673150488e-08
) O 0 3.206508947251052e-10
; O 0 8.665768103099936e-10
SIBPAL O 0 5.57036992177018e-06
Pempirical O 0 1.0608760021568742e-06
value O 0 2.018837719219846e-08
< O 0 5.830880667190286e-08
3 O 0 2.7793536361286897e-08
x O 0 4.340173376249368e-08
10 O 0 4.983248924617101e-09
( O 0 3.9222874947952846e-10
- O 0 9.05719144128625e-09
5 O 0 8.91561580118605e-09
) O 0 1.1615420431043688e-10
) O 0 7.04046057564689e-11
and O 0 9.695647756879922e-11
suggestive O 0 1.3126402187424446e-09
evidence O 0 1.5431151467737436e-08
for O 0 2.7355580023424864e-09
a O 0 1.7855235512342915e-08
locus O 0 1.5502462247241056e-07
on O 0 2.2311196801183542e-07
chromosome O 0 1.2666939142036426e-07
4q O 0 6.380970262398478e-06
at O 0 4.1490369540042593e-07
D4S397 O 0 9.090984463000495e-07
( O 0 4.639869377598416e-09
maximum O 0 1.2159182460891316e-07
GENEHUNTER O 0 1.8027358237304725e-05
- O 0 3.2535646710130095e-07
PLUS O 0 3.003571009685402e-07
nonparametric O 0 1.6980234818220197e-07
linkage O 0 6.47331788172778e-08
score O 0 9.2459462308625e-09
= O 0 2.2110673292274896e-09
3 O 0 1.2531824467032493e-09
. O 0 9.674441803220191e-11
29 O 0 4.957548149775448e-09
, O 0 1.6962567461753508e-10
P O 0 4.8091855830989516e-08
= O 0 4.59525217877399e-09
2 O 0 9.65168833744201e-09
. O 0 3.1858304883058963e-10
57 O 0 7.317089156799739e-09
x O 0 4.790098628859596e-08
10 O 0 8.427187836446137e-09
( O 0 3.474662502167547e-10
- O 0 9.804597134177584e-09
3 O 0 1.7373885441429593e-08
) O 0 3.8467759533311607e-10
; O 0 1.410951355751422e-09
SIBPAL O 0 4.096074007975403e-06
Pempirical O 0 1.3273942158775753e-06
value O 0 2.009732469332448e-08
< O 0 6.308955136091754e-08
1 O 0 1.8593652839626884e-08
x O 0 4.29106563615278e-08
10 O 0 2.2354755824238737e-09
( O 0 1.206684335786079e-10
- O 0 3.5736018588750085e-09
3 O 0 5.57567592096575e-09
) O 0 2.311332028548385e-11
) O 0 3.1579977348428212e-12
that O 0 2.0481318464132814e-12
are O 0 1.4433740661012884e-11
linked O 0 2.987133740361969e-08
to O 0 1.2448521324870399e-08
mental O 1 0.9897409677505493
health O 0 7.157542131608352e-05
wellness O 0 7.60813636588864e-05
. O 0 2.2439742508595373e-07

These O 0 1.6948105496794597e-07
findings O 0 4.6533966013839745e-08
are O 0 2.7682353631597323e-10
consistent O 0 2.428953216337959e-08
with O 0 3.279876648054625e-10
the O 0 4.762583660777864e-09
hypothesis O 0 1.4766246003716788e-08
that O 0 5.425275853565559e-11
certain O 0 1.160457507864976e-09
alleles O 0 2.1032096064743655e-09
could O 0 2.0947863443865344e-09
prevent O 0 1.18469669629917e-08
or O 0 8.908068949153858e-09
modify O 0 3.0449982091340644e-08
the O 0 8.49210124442834e-09
clinical O 0 1.8663577350253036e-08
manifestations O 0 7.00532154951361e-07
of O 0 6.793508191549336e-07
BPAD B-Disease 1 1.0
and O 0 4.25073221066441e-09
perhaps O 0 6.564975785217086e-10
other O 0 3.9728009770811923e-10
related O 0 8.305758456117474e-06
affective B-Disease 1 1.0
disorders I-Disease 1 1.0
. O 0 0.00123309763148427

Segregation O 0 7.630354957655072e-05
distortion O 0 8.740425255382434e-05
in O 0 6.61466003748501e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00011330781853757799

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.17899373173713684
DM B-Disease 1 1.0
) O 0 8.539583262745509e-08
is O 0 5.4480113753641035e-09
an O 0 9.704830272738718e-10
autosomal B-Disease 1 0.9576793313026428
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
which O 0 4.2200124283908735e-08
, O 0 6.530668783533145e-10
in O 0 9.04434360737838e-10
the O 0 2.5498801292656026e-08
typical O 0 2.4923951968958136e-07
pedigree O 0 1.1624124596210095e-07
, O 0 2.615060390454005e-10
shows O 0 5.041930206672873e-10
a O 0 2.0747930040698748e-09
three O 0 4.709540313285743e-09
generation O 0 1.817691781980102e-06
anticipation O 0 4.84956763102673e-06
cascade O 0 0.00017352229042444378
. O 0 7.616818606948073e-07

This O 0 8.370320436767997e-09
results O 0 4.948431886475646e-09
in O 0 1.4105699719380027e-08
infertility B-Disease 1 0.9241609573364258
and O 0 3.737117367563769e-05
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 7.722679583821446e-06
CDM B-Disease 0 2.837608553818427e-05
) O 0 1.5919213169901525e-10
with O 0 1.8959346592684057e-10
the O 0 2.149944151597083e-07
disappearance O 0 1.8317804233447532e-06
of O 0 3.077838846365921e-05
DM B-Disease 1 1.0
in O 0 2.3158371220688423e-07
that O 0 1.8947654112366763e-08
pedigree O 0 1.6779940779088065e-06
. O 0 7.958657732842767e-08

The O 0 1.99742703443917e-06
concept O 0 1.0190072998739197e-06
of O 0 6.663768203907239e-07
segregation O 0 1.2615608966370928e-06
distortion O 0 7.23396226476325e-07
, O 0 1.4203660470002433e-10
where O 0 9.278441903681767e-11
there O 0 1.4108799198386812e-11
is O 0 8.325644861029158e-12
preferential O 0 6.166553934150443e-10
transmission O 0 1.7734194113216972e-09
of O 0 1.044386355175675e-09
the O 0 1.443860142558151e-09
larger O 0 5.964964966409525e-09
allele O 0 5.128858227010369e-09
at O 0 1.641053160028605e-08
the O 0 4.1505636261263135e-08
DM B-Disease 1 0.9999998807907104
locus O 0 2.726714853906742e-07
, O 0 5.415250470264255e-10
has O 0 1.573665919796241e-10
been O 0 6.684493514264034e-10
put O 0 6.250871376067835e-09
forward O 0 2.4283002275637955e-08
to O 0 5.906726663340578e-09
explain O 0 9.849416215956808e-08
partially O 0 3.729376487626723e-07
the O 0 3.5689581068254483e-08
maintenance O 0 1.7126128568634158e-06
of O 0 3.918986806183966e-07
DM B-Disease 1 1.0
in O 0 2.665298204362898e-08
the O 0 4.123687347146188e-08
population O 0 3.151935101808334e-10
. O 0 9.21105858253668e-09

In O 0 5.862065108885872e-07
a O 0 7.367957266524172e-08
survey O 0 3.6847624951263924e-09
of O 0 1.7769009375001588e-08
DM B-Disease 1 1.0
in O 0 4.900793726392294e-08
Northern O 0 4.4953344513487536e-07
Ireland O 0 7.329398243882679e-08
, O 0 2.518095953973898e-09
59 O 0 1.3559161793352814e-08
pedigrees O 0 7.499690468648623e-08
were O 0 1.8970652604366478e-08
ascertained O 0 1.3629751265398227e-06
. O 0 1.329354830659213e-07

Sibships O 0 0.0018792428309097886
where O 0 5.864922059117816e-07
the O 0 6.773815641736292e-08
status O 0 4.493499972113568e-08
of O 0 7.365681398141533e-08
all O 0 1.6185217610598102e-09
the O 0 5.986735107654795e-09
members O 0 1.5351814264263908e-10
had O 0 1.2349943290246301e-09
been O 0 3.822026861666217e-10
identified O 0 5.943259218099683e-10
were O 0 6.254804452154872e-10
examined O 0 4.504515871417425e-09
to O 0 7.627642961693937e-10
determine O 0 3.3676958999251383e-09
the O 0 3.4975926155311754e-08
transmission O 0 1.2224899137436296e-07
of O 0 6.041072708740103e-08
the O 0 5.587190798905795e-07
DM B-Disease 1 1.0
expansion O 0 7.043034656817326e-06
from O 0 1.618436051842309e-08
affected O 0 7.808144353305124e-09
parents O 0 4.4078607430719785e-10
to O 0 4.948825793604783e-10
their O 0 5.5707007895478e-09
offspring O 0 1.9148315288930462e-07
. O 0 8.266434292636404e-08

Where O 0 4.073290824635478e-07
the O 0 2.6768051952785754e-07
transmitting O 0 2.3142792997532524e-06
parent O 0 4.9886725861369996e-08
was O 0 6.27090059879265e-08
male O 0 8.174659171800158e-09
, O 0 1.6132082336639542e-09
58 O 0 5.842558792323871e-08
. O 0 9.267206735330547e-08

3 O 0 2.4970827325887512e-06
% O 0 1.8158150538738482e-08
of O 0 2.560221368241855e-08
the O 0 2.8745839486532532e-08
offspring O 0 4.161852018569334e-08
were O 0 7.55000595376032e-09
affected O 0 2.200700288668145e-09
, O 0 1.5979598200210887e-10
and O 0 1.0340983624956834e-10
in O 0 7.05328295769192e-11
the O 0 6.986554113019849e-10
case O 0 1.770512736420926e-09
of O 0 2.0216497365055375e-09
a O 0 1.1596432702987158e-09
female O 0 7.961915016174714e-10
transmitting O 0 3.904377621211097e-08
parent O 0 9.83386971853406e-09
, O 0 2.571417301311385e-09
68 O 0 8.756324518799374e-07
. O 0 9.39018718781881e-07

7 O 0 1.199784401251236e-05
% O 0 5.831481431073371e-08
were O 0 4.4353164696531167e-08
affected O 0 1.308377051145726e-07
. O 0 3.1884241025181836e-07

Studies O 0 6.80171467593027e-07
on O 0 8.391822348130518e-07
meiotic O 0 1.544462975289207e-05
drive O 0 1.6005992620193865e-06
in O 0 1.2566829354909714e-07
DM B-Disease 1 1.0
have O 0 9.304821801947583e-09
shown O 0 1.070042832118645e-09
increased O 0 2.9461980077805094e-10
transmission O 0 1.987803033287605e-09
of O 0 4.0884093333026783e-10
the O 0 6.780001560180438e-10
larger O 0 1.8695562875592486e-09
allele O 0 1.4679522042371218e-09
at O 0 2.2717709935449193e-09
the O 0 1.2511696567685249e-08
DM B-Disease 1 0.9814414978027344
locus O 0 1.330084131723197e-07
in O 0 2.6226141258689495e-09
non O 0 1.7932441664925136e-07
- O 0 2.843243692041142e-06
DM O 1 1.0
heterozygotes O 0 4.618813818524359e-06
for O 0 9.735168760016677e-08
CTGn O 0 0.00014510472828987986
. O 0 4.963270043845114e-07

This O 0 8.884419600008187e-08
study O 0 1.1685651557513665e-08
provides O 0 6.560882392925294e-10
further O 0 5.331597316415859e-11
evidence O 0 1.261251547646225e-09
that O 0 2.7624230680700634e-10
the O 0 3.071638587925918e-08
DM B-Disease 1 1.0
expansion O 0 7.054355137370294e-06
tends O 0 1.3804094578517834e-07
to O 0 1.6071396435890506e-09
be O 0 1.8143115898539008e-09
transmitted O 0 2.8634753235223798e-08
preferentially O 0 2.125431031174685e-08
. O 0 3.387048863601194e-08

Diagnosis O 1 0.9999988079071045
of O 1 0.9992813467979431
hemochromatosis B-Disease 1 1.0
. O 0 0.0010587192373350263

If O 0 0.00020067498553544283
untreated O 1 1.0
, O 0 5.292130481393542e-06
hemochromatosis B-Disease 1 1.0
can O 0 0.00011248169175814837
cause O 1 0.999995231628418
serious O 1 0.9964110255241394
illness O 1 0.9999964237213135
and O 0 8.893604963589041e-09
early B-Disease 0 5.18496563017834e-07
death I-Disease 0 3.6388746593729593e-06
, O 0 1.8526373490868053e-10
but O 0 2.403213739121668e-10
the O 0 1.0999535504652158e-08
disease O 0 6.230561098163889e-07
is O 0 1.3907407170332675e-10
still O 0 2.7071125896505066e-10
substantially O 0 5.89185145116744e-09
under O 0 1.3963172023068182e-05
- O 0 0.46100321412086487
diagnosed O 0 0.0039192368276417255
. O 0 9.173346597890486e-07

The O 0 1.2368049283395521e-05
cornerstone O 0 0.0013416510773822665
of O 0 1.6437367094113142e-06
screening O 0 4.937318749398401e-07
and O 0 2.1484545253969145e-09
case O 0 4.584387980344218e-09
detection O 0 2.005646365432767e-06
is O 0 4.976142276014173e-10
the O 0 8.596297007557041e-10
measurement O 0 6.632277660401087e-08
of O 0 2.870277704403179e-08
serum O 0 9.182414828501351e-07
transferrin O 0 1.2082021385140251e-05
saturation O 0 1.9328557243625255e-07
and O 0 2.277450006360482e-09
the O 0 3.811327697889055e-09
serum O 0 2.7622002107818844e-07
ferritin O 0 7.755419574095868e-06
level O 0 1.7809665564527677e-07
. O 0 4.588913427028274e-08

Once O 0 2.1693258531740867e-05
the O 0 2.5617021037760423e-07
diagnosis O 0 0.0002670972316991538
is O 0 5.065007524507337e-09
suspected O 0 6.744949132553302e-07
, O 0 1.4728883668269077e-09
physicians O 0 1.1297297319856625e-08
must O 0 7.836940874028642e-09
use O 0 6.422611136258638e-07
serum O 0 0.06308234483003616
ferritin O 1 0.9896169900894165
levels O 0 6.029911219229689e-06
and O 0 4.532043647031969e-07
hepatic O 1 0.9999997615814209
iron O 1 1.0
stores O 0 2.172360836993903e-06
on O 0 8.488847811349842e-07
liver O 0 4.590288426697953e-06
biopsy O 0 3.665893189008784e-08
specimens O 0 6.075745462297277e-10
to O 0 2.9852967320387336e-10
assess O 0 3.779138779691493e-08
patients O 0 2.628183892738889e-08
for O 0 2.625947681522689e-09
the O 0 2.454760128500766e-08
presence O 0 8.261843653656342e-09
of O 0 1.398680979036726e-06
iron B-Disease 1 0.9999996423721313
overload I-Disease 0 0.0007755646365694702
. O 0 4.795427912540617e-07

Liver O 1 1.0
biopsy O 1 0.9946275353431702
is O 0 1.4832134809239506e-07
also O 0 2.4417490251948948e-09
used O 0 3.3641136543138828e-09
to O 0 2.456276293472115e-09
establish O 0 4.424644473033368e-08
the O 0 8.10824829500234e-08
presence O 0 7.688909064995642e-09
or O 0 3.1249410170630654e-08
absence O 0 1.0320343335479265e-06
of O 0 3.9177002690848894e-06
cirrhosis B-Disease 1 1.0
, O 0 3.976341478306722e-10
which O 0 3.7636095628901245e-11
can O 0 1.441449043459997e-10
affect O 0 5.908788569541912e-09
prognosis O 1 0.9990394711494446
and O 0 1.0659289984005227e-07
management O 0 1.3771173144050408e-06
. O 0 1.401511298126934e-07

A O 0 7.27978158465703e-06
DNA O 0 8.701176739123184e-07
- O 0 2.0620636576040852e-07
based O 0 1.21661365426462e-08
test O 0 2.2087164097683853e-08
for O 0 4.009350185185667e-09
the O 0 3.145968108242414e-08
HFE O 0 5.409948789747432e-05
gene O 0 2.8217762348958786e-08
is O 0 4.787152341201306e-10
commercially O 0 4.569800093889853e-09
available O 0 2.789914965717344e-10
, O 0 2.9612385460398016e-11
but O 0 2.4403779344539522e-11
its O 0 9.941602402419036e-11
place O 0 1.9590837840866016e-09
in O 0 5.668618352494548e-11
the O 0 1.8855594863254055e-10
diagnosis O 0 1.9805308681952738e-07
of O 0 2.3644786040222243e-07
hemochromatosis B-Disease 1 1.0
is O 0 8.321672240185762e-09
still O 0 8.088237857251102e-10
being O 0 4.42879644069194e-09
evaluated O 0 5.180793749559598e-08
. O 0 9.579925830394131e-08

Currently O 0 7.141745186345361e-07
, O 0 1.4674267134751062e-08
the O 0 1.638876057086236e-08
most O 0 5.122305357652124e-10
useful O 0 1.4440723061781569e-09
role O 0 2.051012026882404e-09
for O 0 4.852310775405044e-10
this O 0 1.2404755000972045e-10
test O 0 2.6504431982488086e-09
is O 0 1.6691595328133246e-10
in O 0 1.2609958910392294e-10
the O 0 9.780423138039396e-10
detection O 0 8.354232704732567e-06
of O 0 1.396605625814118e-06
hemochromatosis B-Disease 1 1.0
in O 0 7.539030377756717e-08
the O 0 1.0801736038956733e-07
family O 0 8.330867551364918e-09
members O 0 5.5617347533010175e-11
of O 0 1.2228759116439392e-09
patients O 0 5.151404858239061e-10
with O 0 1.2452261444195756e-10
a O 0 5.148539372612504e-09
proven O 0 3.0051523935981095e-07
case O 0 1.546433594512564e-07
of O 0 6.258288181015814e-07
the O 0 2.6364966743130935e-06
disease O 0 0.0005376078188419342
. O 0 2.1424365570510417e-07

It O 0 2.7990001427724565e-08
is O 0 4.439741019268695e-09
crucial O 0 9.656388755274747e-08
to O 0 4.716878265753621e-08
diagnose O 1 1.0
hemochromatosis B-Disease 1 1.0
before O 1 1.0
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 1 0.99996018409729
because O 0 4.8455081014253665e-06
phlebotomy O 1 0.9999979734420776
therapy O 1 0.93117755651474
can O 0 8.09619393749017e-08
avert O 1 0.997960090637207
serious O 1 0.9999996423721313
chronic O 1 1.0
disease O 1 1.0
and O 0 9.108595833140498e-08
can O 0 3.5576470658327253e-09
even O 0 2.373750440654021e-08
lead O 0 1.7554425468802037e-08
to O 0 4.736075420730401e-10
normal O 0 4.016968091491435e-08
life O 0 8.434215104102805e-09
expectancy O 0 1.4236513079524116e-09
. O 0 6.734274249353689e-10
. O 0 9.626134556128818e-09

Prevalence O 0 4.007767711300403e-05
of O 0 5.51507991986e-06
the O 0 1.1182793286934611e-06
I1307K O 0 1.7337524695903994e-06
APC B-Disease 0 8.027905096241739e-08
gene O 0 1.0872978073450668e-09
variant O 0 1.7050327372203355e-08
in O 0 8.005480722772518e-10
Israeli O 0 3.886293598043267e-08
Jews O 0 5.697870175680464e-09
of O 0 1.2752038314189917e-09
differing O 0 9.766213532325096e-11
ethnic O 0 1.109061193577121e-11
origin O 0 4.86336214355898e-11
and O 0 1.0994910537576175e-10
risk O 0 6.58169163614275e-09
for O 0 3.731973947651568e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0003832853981293738

BACKGROUND O 0 0.00012778598465956748
& O 0 1.8257238480146043e-05
AIMS O 0 1.7090088988425123e-07
Israeli O 0 5.216634235694073e-07
Jews O 0 2.2047289860438468e-07
of O 0 9.918849741552549e-08
European O 0 3.2318954623633545e-08
birth O 0 4.5226659040054074e-07
, O 0 1.7423721354603572e-09
i O 0 2.7482662812161607e-09
. O 0 2.70528544010773e-10
e O 0 4.4646705776862916e-10
. O 0 9.06802063993517e-11
, O 0 9.19279583011523e-11
Ashkenazim O 0 1.2576900587646378e-07
, O 0 1.0346034445829488e-10
have O 0 1.1159197177423863e-10
the O 0 1.809350003156851e-08
highest O 1 0.9998264908790588
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.0001492352457717061
of O 0 3.7138207176212745e-07
any O 0 4.376149931317741e-08
Israeli O 0 9.175601917377207e-06
ethnic O 0 5.2784226767244036e-08
group O 0 3.177665064413304e-08
. O 0 2.1429269736472634e-07

The O 0 9.359964678878896e-06
I1307K O 0 1.0880060472118203e-05
APC B-Disease 0 3.8110755440357025e-07
gene O 0 5.8862350549304665e-09
variant O 0 1.975867292003386e-07
was O 0 2.296012553415494e-07
found O 0 3.3343450223100035e-09
in O 0 3.857990371614051e-09
6 O 0 4.0699435999158595e-07
. O 0 1.4981374363287614e-07

1 O 0 2.303481096532778e-06
% O 0 4.985321488959471e-09
of O 0 3.949555349436196e-09
American O 0 2.2194501791972243e-09
Jews O 0 3.324762021250649e-09
, O 0 1.243706942988254e-10
28 O 0 8.243800642127042e-10
% O 0 6.20794943229086e-11
of O 0 1.0238268011164564e-09
their O 0 2.2611058625443547e-07
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 0.0005756537429988384
, O 0 1.3021270728330592e-09
but O 0 3.158326100649589e-10
not O 0 3.478800580936081e-10
in O 0 1.1852655523725275e-09
non O 0 3.7623593129865185e-08
- O 0 1.500805950627182e-07
Jews O 0 1.7312299860350322e-07
. O 0 2.1300135699675593e-07

We O 0 1.14152237529197e-06
assessed O 0 2.7620340006251354e-06
the O 0 1.1923161480353883e-07
I1307K O 0 6.029516725902795e-07
prevalence O 0 2.4161126432886704e-08
in O 0 2.424951350832316e-10
Israeli O 0 9.412170598466219e-09
Jews O 0 2.083915040529405e-09
of O 0 1.9149201668788862e-10
differing O 0 5.914341238977272e-11
ethnic O 0 1.3020513486838858e-11
origin O 0 6.330498625306547e-11
and O 0 1.1785471210057352e-10
risk O 0 4.923840002390989e-09
for O 0 3.6465868902268994e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0003688291471917182

METHODS O 0 5.665762728312984e-06
DNA O 0 9.194840799864323e-07
samples O 0 1.1047537107344851e-08
from O 0 7.542666047299917e-09
500 O 0 1.0187835020047942e-09
unrelated O 0 8.692491171302663e-09
Jews O 0 2.3686217431873047e-08
of O 0 1.9234994397265837e-07
European O 0 1.3372779505971266e-07
or O 0 7.249564504263617e-08
non O 0 3.354043442982402e-08
- O 0 3.626113631582939e-09
European O 0 5.224190524621974e-10
origin O 0 1.0819336537792879e-09
, O 0 3.112664639925988e-11
with O 0 1.0549764187239852e-11
or O 0 1.5997355662378254e-09
without O 0 1.3763811423928018e-08
a O 0 5.611077114053842e-08
personal O 0 3.983826900366694e-06
and O 0 1.5520080296482774e-06
/ O 1 0.5523109436035156
or O 0 2.9591201382572763e-06
family O 0 1.400591031597287e-06
history O 0 3.751567589915794e-08
of O 0 5.968506400222395e-08
neoplasia B-Disease 0 1.1086038284702227e-05
, O 0 2.5432052019880302e-09
were O 0 1.1481728456885776e-08
examined O 0 2.1767770874703274e-07
for O 0 5.675028003082616e-09
the O 0 1.0256923133056262e-07
I1307K O 0 1.2941518434672616e-07
variant O 0 4.871882808288319e-08
by O 0 1.4907706180622426e-09
the O 0 1.1448053172102846e-08
allele O 0 9.202132944530206e-10
- O 0 2.083179628797893e-09
specific O 0 1.6940752134431136e-09
oligonucleotide O 0 1.9060351519328833e-07
( O 0 7.31279170551602e-09
ASO O 0 3.390832034710911e-06
) O 0 3.382642221883003e-10
method O 0 3.7706282540739267e-08
. O 0 5.5164832701848354e-08

RESULTS O 0 1.5025832453829935e-06
In O 0 2.638671503518708e-08
persons O 0 3.165347539635377e-09
at O 0 2.2835613400218335e-09
average O 0 3.4573552354366655e-10
risk O 0 7.1327721506975195e-09
for O 0 5.297434881867957e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.5179524837094505e-07
I1307K O 0 6.450005685110227e-07
was O 0 9.648196197531433e-08
found O 0 1.4520266100603862e-09
in O 0 5.426489257942535e-10
5 O 0 3.330863052042332e-08
. O 0 3.7351604476043576e-08

0 O 0 1.5838960507608135e-06
% O 0 1.1016016543408114e-08
of O 0 1.2984423314321702e-08
120 O 0 7.816965741369586e-09
European O 0 1.102452973356094e-08
and O 0 1.7789897555076095e-08
1 O 0 7.102682957338402e-07
. O 0 1.2215063804887905e-07

6 O 0 1.2261168194527272e-05
% O 0 4.842940271032603e-08
of O 0 6.028457733009418e-08
188 O 0 3.2751852785395386e-08
non O 0 6.286756359941137e-08
- O 0 7.724469952563595e-08
European O 0 5.311346029657216e-08
Jews O 0 1.018051989376545e-07
( O 0 1.9230028680539135e-09
P O 0 2.0545297729768208e-07
= O 0 4.468744929653212e-09
0 O 0 8.045908939102731e-10
. O 0 9.498727499002158e-11
08 O 0 2.830663925479371e-09
) O 0 4.306442979995495e-10
. O 0 8.073414825560121e-09

It O 0 5.9013014919173656e-08
occurred O 0 1.9809878892829147e-07
in O 0 1.9003454365673633e-09
15 O 0 1.4943497106401082e-08
. O 0 3.317700603133744e-08

4 O 0 1.724791104606993e-06
% O 0 4.1723420274308864e-09
of O 0 1.0272268369249105e-08
52 O 0 1.709601527011273e-08
Ashkenazi O 0 2.907498810600373e-07
Israelis O 0 5.001973235607693e-08
with O 0 1.809708161104595e-09
familial O 0 1.5196041204035282e-05
cancer B-Disease 0 0.045369312167167664
( O 0 4.268614794966652e-09
P O 0 3.7475526823982364e-06
= O 0 3.2316613385319215e-08
0 O 0 5.0617234848004955e-09
. O 0 2.4123802955244855e-10
02 O 0 1.298363105917133e-08
) O 0 7.647655425602196e-11
and O 0 5.032159133833147e-10
was O 0 1.9462765621369726e-08
not O 0 2.4405372167635164e-10
detected O 0 2.5012381499323055e-08
in O 0 1.2356540235458624e-09
51 O 0 7.2371824089145775e-09
non O 0 1.1720340253873474e-08
- O 0 1.54430477294909e-08
European O 0 6.138966668345347e-09
Jews O 0 6.782257599979857e-08
at O 0 2.8276435415364176e-08
increased O 0 3.086094935156325e-09
cancer B-Disease 0 5.905163220631948e-07
risk O 0 6.435511323843457e-08
. O 0 2.010016686426752e-07

Colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999996423721313
occurred O 0 0.13270306587219238
personally O 0 1.4849359786239802e-06
or O 0 1.7204520474933815e-08
in O 0 1.1520857601254875e-09
the O 0 2.4504456241913886e-09
families O 0 2.371304264059404e-10
of O 0 4.947572573854586e-09
13 O 0 4.4218078087965296e-09
of O 0 2.8517893824187013e-08
20 O 0 1.6752689901977647e-08
Ashkenazi O 0 2.458741619193461e-07
I1307K O 0 1.0681290518732567e-07
carriers O 0 1.8293403458713442e-09
, O 0 3.4848304797385765e-10
8 O 0 5.25591659084057e-09
of O 0 2.1785874437796338e-08
whom O 0 3.9805195228836965e-07
also O 0 3.623688371590106e-08
had O 0 7.334698182148713e-08
a O 0 2.2109755803967346e-08
personal O 0 6.282657238898537e-08
or O 0 2.8996280931892215e-08
family O 0 1.688540329780608e-08
history O 0 6.69880417802915e-09
of O 0 2.315029092869736e-07
noncolonic O 0 8.460295794066042e-05
neoplasia B-Disease 1 0.5554770827293396
. O 0 4.5953001972520724e-05

CONCLUSIONS O 0 3.680826921481639e-05
The O 0 2.25387088903517e-06
I1307K O 0 7.032886060187593e-06
APC O 0 2.7936459900956834e-07
variant O 0 5.86207022479357e-07
may O 0 1.5668806696567117e-08
represent O 0 2.023910594672884e-09
a O 0 8.752984115290019e-09
susceptibility O 0 5.527799658011645e-07
gene O 0 4.429474387279697e-08
for O 0 5.900648503143202e-08
colorectal B-Disease 1 1.0
, I-Disease 0 3.420471557546989e-06
or I-Disease 0 0.0005048274761065841
other I-Disease 0 1.0630986253090668e-05
, I-Disease 0 1.0436182584783182e-08
cancers I-Disease 0 0.0035109457094222307
in O 0 2.4826385391918393e-09
Ashkenazi O 0 4.2127245251322165e-05
Jews O 0 5.778892386842926e-07
, O 0 2.923807196353323e-09
and O 0 8.933557893442412e-09
partially O 0 1.0703825381597198e-07
explains O 0 3.919163660270897e-09
the O 0 1.3538378196287226e-09
higher O 0 7.752658071069618e-09
incidence O 0 4.161289837156801e-07
of O 0 0.0004836369480472058
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.6265417457361764e-07
European O 0 1.399227613774201e-07
Israelis O 0 6.438322657231765e-07
. O 0 4.65761445411772e-07

Systematic O 0 1.0744530953843423e-07
analysis O 0 3.99723418809117e-08
of O 0 9.731956396308306e-08
coproporphyrinogen O 0 4.6361430577235296e-05
oxidase O 0 1.1006200111296494e-05
gene O 0 2.831397296176874e-06
defects O 0 0.0005456161452457309
in O 0 3.6456928143024925e-08
hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9996628761291504
and O 0 3.369098919847602e-07
mutation O 0 7.697335036027653e-08
update O 0 1.0583092944216332e-06
. O 0 8.503432695761148e-07

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.999995231628418
( O 0 5.677520675817505e-07
HC B-Disease 1 0.9999926090240479
) O 0 1.5511004036738996e-08
is O 0 2.4187487568383403e-09
an O 0 9.4175574005817e-09
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 1 1.0
autosomal O 1 1.0
dominant O 1 1.0
inheritance O 1 0.9999994039535522
caused O 0 0.0018817695090547204
by O 0 4.805231323956605e-09
deficient B-Disease 0 1.8825985534931533e-06
activity I-Disease 0 1.0480326828599118e-08
of I-Disease 0 1.495088781666709e-07
coproporphyrinogen I-Disease 0 9.179120752378367e-06
III I-Disease 1 1.0
oxidase I-Disease 0 9.30235671603441e-07
( O 0 1.943526672931739e-09
CPO O 0 1.8239796872876468e-07
) O 0 7.436353754997072e-10
. O 0 1.0092662705574185e-08

Clinical O 0 1.7728993043419905e-05
manifestations O 1 0.6172986030578613
of O 0 0.003990382421761751
the O 0 3.977384403697215e-05
disease O 1 0.9038697481155396
are O 0 2.545342582538357e-11
characterized O 0 9.460906502667399e-10
by O 0 5.952434378730942e-11
acute O 1 0.999913215637207
attacks O 0 0.0005927241290919483
of O 1 1.0
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 5.859924456785848e-08
precipitated O 0 1.406009602078484e-07
by O 0 1.2080153544147265e-10
drugs O 0 4.960700650258332e-08
, O 0 3.5022773570148047e-09
fasting O 0 0.00012719311052933335
, O 0 1.3677242449716687e-08
cyclical O 0 6.687128006888088e-06
hormonal O 0 1.8490634829504415e-05
changes O 0 4.8389882323363054e-08
, O 0 1.019644702004996e-09
or O 0 1.687464923350035e-08
infectious B-Disease 0 5.9133330069016665e-05
diseases I-Disease 0 0.025721024721860886
. O 0 5.620405545414542e-07

Skin O 1 1.0
photosensitivity O 1 1.0
may O 0 8.78190894582076e-06
also O 0 1.2585990916136325e-08
be O 0 1.2352275868821039e-09
present O 0 2.4511715324138095e-08
. O 0 1.728732001993194e-07

The O 0 9.714403859106824e-06
seven O 0 9.458457839173207e-07
exons O 0 2.4893622594390763e-06
, O 0 4.188496216528392e-09
the O 0 2.5033383366235284e-08
exon O 0 3.6922855883858574e-07
/ O 0 7.673016710896263e-08
intron O 0 1.275151504387395e-07
boundaries O 0 1.2753521572150817e-09
and O 0 8.660843708874211e-10
part O 0 3.2901539270824287e-09
of O 0 4.542012632668957e-08
3 O 0 5.2605123812554666e-08
noncoding O 0 1.7389807283052505e-07
sequence O 0 2.577009716731027e-09
of O 0 2.0862623628659094e-08
the O 0 4.498422256915546e-08
CPO O 0 2.105850569478207e-07
gene O 0 1.994856058118444e-09
were O 0 9.622164176548154e-10
systematically O 0 1.1097138763460634e-09
analyzed O 0 1.7876762292701187e-09
by O 0 3.727676500808741e-10
an O 0 3.5471700576827914e-10
exon O 0 1.6635798516517752e-08
- O 0 1.2098243296065903e-08
by O 0 3.076045862471233e-09
- O 0 5.464373202812567e-07
exon O 0 1.6601223933321307e-06
denaturing O 0 5.01054382766597e-05
gradient O 0 2.4869682420103345e-06
gel O 0 2.1242563263967895e-07
electrophoresis O 0 8.47990122565534e-08
( O 0 1.9544035279039917e-09
DGGE O 0 1.092497427634953e-06
) O 0 1.2660979209488943e-10
strategy O 0 1.5172100242821784e-09
followed O 0 2.5490118349402735e-10
by O 0 1.00039117614803e-11
direct O 0 3.66991909084291e-10
sequencing O 0 2.8429409937302808e-09
in O 0 6.035689170680314e-10
seven O 0 3.22054649615211e-09
unrelated O 0 3.453977726053381e-08
heterozygous O 0 6.5976788476973525e-09
HC B-Disease 0 1.5558711311314255e-05
patients O 0 8.028670350768152e-08
from O 0 3.272624482519859e-08
France O 0 1.6051798112926008e-08
, O 0 5.829440263838137e-10
Holland O 0 4.202325598612333e-08
, O 0 3.9382097583029463e-10
and O 0 1.436224472683989e-09
Czech O 0 1.983193214982748e-06
Republic O 0 3.7868478102609515e-05
. O 0 0.00044652409269474447

Seven O 0 2.4691019007150317e-06
novel O 0 2.824372700160893e-07
mutations O 0 5.472506892090223e-09
and O 0 3.0242408577407787e-09
two O 0 1.105741831430862e-09
new O 0 8.342777135794677e-09
polymorphisms O 0 2.152549569700568e-07
were O 0 1.6336632313596056e-07
detected O 0 4.8468859858985525e-06
. O 0 6.953391107344942e-07

Among O 0 1.5502416772505967e-07
these O 0 7.192116235898993e-09
mutations O 0 1.0779915626812908e-08
two O 0 2.8524518302930346e-09
are O 0 4.870094882925002e-10
missense O 0 2.060225767763768e-07
( O 0 2.90474155839604e-09
G197W O 0 4.5485234068110003e-07
, O 0 2.7389308598912976e-09
W427R O 0 9.607501283426245e-08
) O 0 2.3195122211827623e-10
, O 0 8.557472785941656e-11
two O 0 2.505963214716189e-10
are O 0 3.4017549888076815e-10
nonsense O 0 8.51914947475052e-08
( O 0 2.9291995495839274e-09
Q306X O 0 2.818125039993902e-07
, O 0 1.2228572598971255e-09
Q385X O 0 3.876624887766411e-08
) O 0 1.7932144658061588e-10
, O 0 1.0346448697795552e-10
two O 0 4.833098365963906e-10
are O 0 1.4013115667843579e-10
small O 0 3.355641764457573e-09
deletions O 0 4.262466291038436e-08
( O 0 1.2342878941140611e-09
662de14bp O 0 2.0284763024847052e-07
; O 0 1.1207671235524685e-08
1168del3bp O 0 2.061207624137751e-06
removing O 0 9.35195487272722e-07
a O 0 1.7994354095662857e-07
glycine O 0 9.629737007799122e-08
at O 0 5.502821665004376e-08
position O 0 1.6922223622373167e-08
390 O 0 4.38288871862369e-09
) O 0 3.656899782988887e-11
, O 0 3.1238636677421994e-11
and O 0 2.2582261061110387e-10
one O 0 9.022289026994201e-10
is O 0 5.244037981633198e-10
a O 0 5.641485945062641e-09
splicing O 0 4.247484497454934e-08
mutation O 0 2.6281024023688815e-09
( O 0 2.4535778964107635e-10
IVS1 O 0 1.1350006161592319e-06
- O 0 9.081793450604891e-08
15c O 0 1.842696178755432e-06
- O 0 1.5003708142558025e-07
- O 0 1.208496342997023e-07
> O 0 8.684308738793334e-08
g O 0 7.7373689677529e-09
) O 0 1.756933661056781e-11
which O 0 1.244622287177588e-11
creates O 0 4.3669901028664526e-10
a O 0 4.5227818712412216e-10
new O 0 1.3478860250160096e-09
acceptor O 0 8.109246052434571e-10
splice O 0 1.6292893860736513e-06
site O 0 1.647212712896362e-07
. O 0 3.795442182763509e-08

The O 0 2.4502821815985953e-06
pathological O 0 1.1127082871098537e-05
significance O 0 3.133914788122638e-06
of O 0 3.875049969792599e-06
the O 0 2.550965973568964e-06
point O 0 1.6751656630731304e-06
mutations O 0 1.0799507066394654e-08
G197W O 0 5.45929992767924e-07
, O 0 3.542101056908109e-09
W427R O 0 5.343894144971273e-07
, O 0 3.866823750087178e-09
and O 0 3.4001867987853984e-09
the O 0 4.572670775360166e-08
in O 0 1.7953517783553252e-08
- O 0 8.315868882391442e-08
frame O 0 7.172336609073682e-07
deletion O 0 2.4117255748024036e-07
390delGly O 0 5.228333321838363e-08
were O 0 1.2746348421188713e-09
assessed O 0 1.07659028358853e-08
by O 0 3.825717243000071e-10
their O 0 2.4353026262247113e-09
respective O 0 2.067044313491806e-08
expression O 0 6.741371016971698e-09
in O 0 1.492713841422244e-09
a O 0 1.7708842170449657e-09
prokaryotic O 0 9.436654124783672e-09
system O 0 2.0778117004738306e-08
using O 0 3.6962923832817296e-09
site O 0 4.613627169192114e-08
- O 0 2.7692575343962744e-08
directed O 0 2.3484368227855157e-08
mutagenesis O 0 3.028328592336038e-06
. O 0 8.197146428301494e-08

These O 0 3.9341369273415694e-08
mutations O 0 2.2098710417139955e-08
resulted O 0 1.8838717252833703e-08
in O 0 1.4038805673521892e-09
the O 0 9.77632552690011e-09
absence O 0 6.46489013433893e-08
or O 0 6.271580144101563e-09
a O 0 4.6163886047168035e-09
dramatic O 0 8.508314053301547e-09
decrease O 0 1.655053694094022e-08
of O 0 7.20064235792961e-07
CPO O 0 2.6464787879376672e-05
activity O 0 4.970967779627244e-07
. O 0 3.3202329063897196e-07

The O 0 2.030378027484403e-06
two O 0 3.461132891402485e-08
polymorphisms O 0 1.0315250875692072e-07
were O 0 2.0199546924004608e-08
localized O 0 7.845287655072752e-07
in O 0 1.645359404278679e-08
noncoding O 0 2.552085334173171e-06
part O 0 9.435540704316736e-08
of O 0 3.392881637864775e-07
the O 0 5.263373026309637e-08
gene O 0 7.765588727615125e-10
1 O 0 2.333179649482986e-09
) O 0 2.425805910311052e-11
a O 0 9.142789858529454e-10
C O 0 2.3115742919799231e-07
/ O 0 5.44349596509619e-08
G O 0 6.069172542311208e-08
polymorphism O 0 1.9356477309884212e-08
in O 0 9.313180782122288e-10
the O 0 5.960256732606695e-09
promotor O 0 8.870042051967175e-07
region O 0 1.7095526771981895e-08
, O 0 2.250328812181124e-09
142 O 0 2.3055498843405076e-08
bp O 0 2.1445583797685686e-07
upstream O 0 1.1830663559919685e-08
from O 0 1.6088326226793015e-09
the O 0 7.297590087773642e-09
transcriptional O 0 8.010101026911798e-08
initiation O 0 2.9285750713370362e-08
site O 0 3.268619863661115e-08
( O 0 1.3288802003241784e-10
- O 0 2.0536703448925664e-09
142C O 0 3.384956315244381e-08
/ O 0 7.660831968792081e-09
G O 0 2.041116253792552e-08
) O 0 1.3906187312784368e-10
, O 0 5.591730550813523e-11
and O 0 4.022062405351079e-10
2 O 0 2.5801933034586e-08
) O 0 3.1323016402851067e-10
a O 0 2.5338326992141447e-08
6 O 0 1.670241402962347e-07
bp O 0 1.7615947456306458e-07
deletion O 0 1.5719725965368525e-08
polymorphism O 0 2.0103534836835024e-08
in O 0 7.549153524522012e-10
the O 0 9.396600830768875e-09
3 O 0 3.3255307840818205e-08
noncoding O 0 2.02990065645281e-07
part O 0 1.5728543800719308e-08
of O 0 7.076578611986406e-08
the O 0 1.8443682847646414e-07
CPO O 0 1.1022237913493882e-06
gene O 0 1.5421560917161514e-08
, O 0 1.825290363299814e-09
574 O 0 1.3135429810517962e-07
bp O 0 6.421178113669157e-07
downstream O 0 9.356382690839382e-08
of O 0 1.5673082387479553e-08
the O 0 1.250582748468787e-08
last O 0 6.917157513441907e-09
base O 0 4.590331315057483e-08
of O 0 7.709335392291905e-09
the O 0 3.2474278821581493e-09
normal O 0 2.7868423124743913e-09
termination O 0 1.2139341087902267e-08
codon O 0 2.0603634354188216e-09
( O 0 5.022081639438625e-10
+ O 0 9.267592027129012e-09
574 O 0 5.6418869576191355e-08
delATTCTT O 0 1.9780242155320593e-07
) O 0 2.4764621464612446e-09
. O 0 2.599418280624377e-08

Five O 0 1.4645512237621006e-05
intragenic O 0 0.0005160715663805604
dimorphisms O 0 0.00028772398945875466
are O 0 1.3443178126237854e-08
now O 0 3.961944550212593e-09
well O 0 1.6183518969370425e-09
characterized O 0 1.51424170979908e-08
and O 0 1.9981654109102465e-09
the O 0 8.54467785416091e-09
high O 0 2.986814706673613e-08
degree O 0 6.258163409711415e-08
of O 0 3.4492046552259126e-08
allelic O 0 2.8538087804008683e-07
heterogeneity O 0 6.141499397926964e-07
in O 0 2.1324153109958388e-08
HC B-Disease 0 0.26120689511299133
is O 0 1.2324347764547383e-08
demonstrated O 0 1.1001612065797417e-08
with O 0 6.317944500899841e-10
seven O 0 2.291082656924459e-09
new O 0 5.253307788777306e-10
different O 0 6.343249536744366e-11
mutations O 0 3.1972868796970033e-10
making O 0 3.17470549848764e-10
a O 0 8.079541480299213e-10
total O 0 1.3814557831004493e-10
of O 0 8.032096765475671e-09
nineteen O 0 1.9375728754766897e-07
CPO O 0 4.57620535598835e-06
gene B-Disease 0 3.305983113932598e-07
defects I-Disease 0 3.999723048764281e-06
reported O 0 2.6533162333919336e-09
so O 0 9.18414289063918e-10
far O 0 5.977698336323556e-09
. O 0 2.1465171862189436e-09
. O 0 2.2205522753893092e-08

Coincidence O 0 4.437103598320391e-06
of O 0 8.944350611272966e-07
two O 0 2.9073701668380636e-08
novel O 0 4.693956512369368e-08
arylsulfatase O 0 5.480301297211554e-07
A O 0 5.466604946491316e-08
alleles O 0 1.354044321111303e-09
and O 0 1.1503205055163335e-09
mutation O 0 4.036328160594849e-09
459 O 0 2.56743923898739e-08
+ O 0 4.797330532824162e-08
1G O 0 2.1052271677035606e-06
> O 0 5.287612481197357e-08
A O 0 2.3725961639797788e-08
within O 0 2.0047046245252886e-09
a O 0 1.4147402138675602e-09
family O 0 2.1933166394205728e-09
with O 0 4.6267525921628305e-10
metachromatic B-Disease 1 0.9999697208404541
leukodystrophy I-Disease 1 0.9999997615814209
: O 0 4.548631471479325e-10
molecular O 0 3.908950940711975e-09
basis O 0 4.267417974546106e-09
of O 0 4.1179891496767596e-08
phenotypic O 0 2.381186277489178e-06
heterogeneity O 0 5.05460484419018e-05
. O 0 2.271262246722472e-06

In O 0 5.078364893051912e-07
a O 0 1.2566061968755093e-07
family O 0 2.3049958386422986e-08
with O 0 2.40231529113899e-10
three O 0 5.826519711149558e-09
siblings O 0 2.659567996943224e-07
, O 0 5.438726691231466e-10
one O 0 1.2504771662591452e-09
developed O 0 4.716954720151989e-07
classical O 0 3.292318433523178e-05
late O 1 0.9999995231628418
infantile O 1 1.0
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 1.2707229757324967e-07
MLD B-Disease 1 1.0
) O 0 2.5135951098320675e-09
, O 0 3.182368812915115e-10
fatal O 0 1.2799617365999438e-07
at O 0 1.0755845103460615e-08
age O 0 2.678567589953218e-09
5 O 0 7.278157632129023e-09
years O 0 2.2123920473404723e-09
, O 0 1.0249946724716352e-10
with O 0 7.581605343531805e-10
deficient O 0 0.000511806458234787
arylsulfatase O 0 0.001279217191040516
A O 0 0.0010740816360339522
( O 0 1.0900252078727135e-07
ARSA O 0 5.481169864651747e-05
) O 0 2.1686973050716318e-10
activity O 0 2.102775592538464e-10
and O 0 6.374930444641436e-11
increased O 0 4.5275377891229596e-10
galactosylsulfatide O 0 2.458410790495691e-07
( O 0 3.1467826122622e-09
GS O 0 0.026511309668421745
) O 0 5.162775762457272e-10
excretion O 0 1.2138461791266764e-08
. O 0 1.106560976182891e-08

The O 0 3.2614946121611865e-06
two O 0 6.570969901531498e-08
other O 0 1.232841562170961e-08
siblings O 0 1.6139774743351154e-06
, O 0 5.998027408082862e-09
apparently O 0 5.243803116172785e-07
healthy O 0 3.2615488976261986e-07
at O 0 2.942882701972849e-07
12 O 0 2.0235949804714437e-08
( O 0 6.81641132427302e-10
1 O 0 1.465325425442643e-07
/ O 0 1.2530711046565557e-07
2 O 0 9.482358365175969e-08
) O 0 2.309090418872728e-10
and O 0 8.181409993923694e-10
15 O 0 2.2751966977097027e-09
years O 0 1.5646370865596282e-09
, O 0 4.1428697278300675e-11
respectively O 0 1.8150375646897032e-10
, O 0 1.717878617135682e-11
and O 0 5.7077627346746596e-11
their O 0 4.976142276014173e-10
father O 0 3.9989276956475805e-07
, O 0 1.1103533648082475e-09
apparently O 0 5.5710433599642784e-08
healthy O 0 4.031695866046903e-09
as O 0 2.3521700143191993e-09
well O 0 3.732487652285954e-09
, O 0 1.164093155203716e-09
presented O 0 4.134595883442671e-07
ARSA O 1 0.9924331903457642
and O 0 9.302319085691124e-06
GS O 1 1.0
values O 0 1.8936669121671912e-08
within O 0 1.7947004993246196e-09
the O 0 1.0706919795211434e-09
range O 0 6.224174509128488e-09
of O 0 4.654035379303423e-08
MLD B-Disease 1 1.0
patients O 0 1.4541647033183835e-05
. O 0 5.372191367314372e-07

Mutation O 0 8.763593655203294e-07
screening O 0 3.4825490047296626e-07
and O 0 5.764221100434952e-09
sequence O 0 7.129762336077761e-10
analysis O 0 7.989373052019744e-10
disclosed O 0 2.1225060820029285e-08
the O 0 1.5858064861262733e-09
involvement O 0 8.998473965959874e-09
of O 0 1.2714109764999648e-08
three O 0 9.916041321389457e-10
different O 0 3.0012725638073334e-09
ARSA O 0 5.9216901718173176e-05
mutations O 0 2.697161827214245e-09
being O 0 1.1809599964607287e-09
the O 0 5.86118154011217e-10
molecular O 0 4.78794914826608e-09
basis O 0 2.665215381725261e-09
of O 0 2.7321073403641094e-08
intrafamilial O 0 3.6146570892015006e-06
phenotypic O 0 2.166063950426178e-06
heterogeneity O 0 1.825819708756171e-05
. O 0 1.6787545291663264e-06

The O 0 7.168998308770824e-06
late O 0 0.0009997173910960555
infantile O 0 0.00166682421695441
patient O 0 1.6950284589256626e-06
inherited O 0 3.754281351575628e-05
from O 0 3.683134366383456e-07
his O 0 8.007891665329225e-06
mother O 0 1.6817364212329267e-06
the O 0 4.2180573700534296e-07
frequent O 0 3.125573044826524e-08
0 O 0 2.6944329434286374e-08
- O 0 2.1238953706870234e-08
type O 0 8.353624991741526e-08
mutation O 0 4.799042230274608e-08
459 O 0 3.585654440030339e-08
+ O 0 2.6250878804034983e-08
1G O 0 3.85466108809851e-07
> O 0 7.73760522321254e-09
A O 0 8.015018870821677e-09
, O 0 3.8236872001995437e-11
and O 0 4.448959256553309e-11
from O 0 2.794100784075937e-10
his O 0 7.155050329998858e-09
father O 0 2.2563813928400123e-08
a O 0 1.8856898265084965e-09
novel O 0 2.439091373318547e-09
, O 0 5.596105176475241e-11
single O 0 7.012507796666512e-10
basepair O 0 2.1768185831660958e-07
microdeletion O 0 5.786248493677704e-07
of O 0 1.1727902915481536e-07
guanine O 0 4.5359871592154377e-07
at O 0 1.2343325295205432e-07
nucleotide O 0 2.390817144259927e-08
7 O 0 5.1625054453552366e-08
in O 0 2.9763720377218306e-09
exon O 0 8.114327698649504e-08
1 O 0 6.348996350880043e-08
( O 0 4.718906931877598e-10
7delG O 0 8.926271988229928e-08
) O 0 3.6017950844069446e-09
. O 0 3.431788542229697e-08

The O 0 3.2184561860049143e-06
two O 0 1.333892356569777e-07
clinically O 0 8.4191226051189e-05
unaffected O 0 3.371959610376507e-05
siblings O 0 6.676936550320534e-07
carried O 0 1.2299010698768598e-08
the O 0 1.6500546706765817e-08
maternal O 0 1.0386502680148624e-07
mutation O 0 6.761383009035171e-09
459 O 0 2.4366885398308114e-08
+ O 0 1.8143541780091255e-08
1G O 0 7.62788260999514e-07
> O 0 3.137626691795958e-08
A O 0 1.3165423418115552e-08
and O 0 3.4411645755128006e-10
, O 0 7.475729063566305e-11
on O 0 9.167201997506425e-10
their O 0 1.691533302317083e-10
paternal O 0 9.074414109022655e-09
allele O 0 1.8423206293860517e-09
, O 0 5.642674869021924e-11
a O 0 2.80599432578299e-10
novel O 0 1.6396599633594633e-09
cytosine O 0 1.5495922767172488e-08
to O 0 3.709160312226345e-09
thymidine O 0 3.5349466998013668e-06
transition O 0 3.3865565001178766e-06
at O 0 2.0584404580858973e-07
nucleotide O 0 1.1428716817363238e-07
2435 O 0 4.235335836710874e-06
in O 0 3.3228917395433655e-09
exon O 0 8.519068472878644e-08
8 O 0 9.9929806651744e-09
, O 0 1.6613578568414056e-11
resulting O 0 2.284300665289507e-10
in O 0 1.3532382159286982e-10
substitution O 0 7.881131303122402e-09
of O 0 2.332495796508738e-08
alanine O 0 6.211878655904002e-08
464 O 0 5.8478434539210866e-08
by O 0 5.003383041213283e-09
valine O 0 1.4919125987944426e-06
( O 0 5.0005972695998935e-09
A464V O 0 5.997727043904888e-07
) O 0 5.197735575279694e-09
. O 0 6.599519508654339e-08

The O 0 4.434320089785615e-06
fathers O 0 8.04674300525221e-07
genotype O 0 4.2173010683654866e-07
thus O 0 6.515681860719269e-08
was O 0 2.8556766551446344e-07
7delG O 0 2.2895321762916865e-06
/ O 0 1.0773111398520996e-06
A464V O 0 1.9267101833975175e-06
. O 0 7.660513290375093e-08

Mutation O 0 1.6290376834149356e-06
A464V O 0 3.1056235911819385e-06
was O 0 1.0365959468572328e-07
not O 0 1.5759217542044013e-10
found O 0 2.8872909618726794e-10
in O 0 1.0303300573832885e-10
18 O 0 3.6464209429709626e-09
unrelated O 0 9.123520499088045e-07
MLD B-Disease 1 1.0
patients O 0 0.14192111790180206
and O 0 5.943429073340667e-07
50 O 0 2.2953227585276181e-07
controls O 0 2.0377067357912892e-06
. O 0 1.4310455753729912e-06

A464V O 0 6.48454952170141e-05
, O 0 2.439497315265271e-08
although O 0 1.5630869043548046e-08
clearly O 0 3.379666324576647e-08
modifying O 0 2.903593895098311e-06
ARSA O 1 0.9999721050262451
and O 0 4.615062607626896e-06
GS O 1 1.0
levels O 0 6.851061584711715e-07
, O 0 5.491764265563859e-10
apparently O 0 4.166901934610223e-09
bears O 0 8.398130191267228e-09
little O 0 6.69852062706866e-10
significance O 0 1.6027408289431833e-09
for O 0 8.297795089928783e-11
clinical O 0 8.906233972538757e-09
manifestation O 0 4.962340972269885e-05
of O 0 0.003017031354829669
MLD B-Disease 1 1.0
, O 0 9.455718696926851e-08
mimicking O 0 3.766639338209643e-07
the O 0 1.659923043462186e-07
frequent O 0 5.953260142632644e-07
ARSA O 0 0.0002511034836061299
pseudodeficiency O 0 2.4726634364924394e-05
allele O 0 7.015416372269101e-07
. O 0 2.440549735638342e-07

Our O 0 2.6047440769616514e-05
results O 0 1.6399084756812954e-07
demonstrate O 0 3.840094109364145e-08
that O 0 5.129598967812399e-10
in O 0 6.462689827735346e-10
certain O 0 2.7466313667900977e-09
genetic O 0 1.3303872492542723e-07
conditions O 0 4.447338596946793e-06
MLD B-Disease 1 1.0
- O 1 0.9999997615814209
like O 0 5.459500607685186e-05
ARSA O 1 1.0
and O 0 3.985787043347955e-05
GS O 1 1.0
values O 0 3.597792064269356e-09
need O 0 1.7789270057022577e-10
not O 0 7.186277180964984e-12
be O 0 3.3101592213785613e-12
paralleled O 0 8.348340768682405e-11
by O 0 2.2354295064336283e-12
clinical O 0 9.308652182404842e-10
disease O 0 3.568399975506509e-08
, O 0 3.797101869040809e-11
a O 0 1.6994140816795067e-10
finding O 0 2.3847221974904187e-09
with O 0 7.241994504081362e-11
serious O 0 1.9841372989048978e-08
diagnostic O 0 1.881102980405558e-05
and O 0 4.0341910789720714e-07
prognostic O 1 0.9999996423721313
implications O 0 0.00037916924338787794
. O 0 3.2857318728929386e-05

Moreover O 0 4.428935881151119e-06
, O 0 6.103277883084957e-08
further O 0 1.3322943459570524e-07
ARSA O 0 0.0005401768139563501
alleles O 0 6.051844536614226e-08
functionally O 0 1.5734011071799614e-07
similar O 0 1.1458801019159637e-08
to O 0 1.0374420433834075e-08
A464V O 0 4.445123806817719e-07
might O 0 2.0741364181731115e-09
exist O 0 7.037510574292583e-10
which O 0 1.1629208707120142e-10
, O 0 1.717885035612543e-11
together O 0 1.2115543811253016e-11
with O 0 3.544355087203854e-11
0 O 0 5.5026929679513614e-09
- O 0 5.942684122572928e-09
type O 0 1.2251065584223397e-07
mutations O 0 2.4895012273873363e-08
, O 0 5.910070211001539e-10
may O 0 5.97135283442185e-08
cause O 0 0.008342896588146687
pathological O 1 0.9999659061431885
ARSA O 1 0.9999898672103882
and O 0 5.971353402856039e-07
GS O 1 1.0
levels O 0 6.01931233745745e-08
, O 0 3.985542104678608e-11
but O 0 7.712515522062535e-12
not O 0 4.88337235232672e-12
clinical O 0 3.6502884048772444e-10
outbreak O 0 1.1985831216421161e-09
of O 0 1.4786699642499457e-09
the O 0 7.746080221693319e-09
disease O 0 2.0253177979157044e-07
. O 0 2.7227837762211493e-09
. O 0 3.764483835766441e-08

Human O 1 0.9764408469200134
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 1 0.9995893836021423
to O 0 7.089330210874323e-06
hematological B-Disease 1 1.0
malignancy I-Disease 1 1.0
and O 0 3.2927458960330114e-05
neurofibromatosis B-Disease 1 0.9999998807907104
type I-Disease 1 0.9716897010803223
1 I-Disease 0 0.00045861181570217013
. O 0 6.061832209525164e-07

Heterozygous O 0 4.786518729815725e-06
germ O 0 0.0004119352379348129
- O 0 1.76305475179106e-05
line O 0 5.724774041482306e-07
mutations O 0 3.074626331311947e-09
in O 0 3.668085557517742e-10
the O 0 4.435255274159999e-09
DNA O 0 5.37864025318413e-07
mismatch O 0 0.00023453441099263728
repair O 0 0.05882895737886429
genes O 0 1.495915995519681e-07
lead O 0 6.660407336767094e-08
to O 0 3.9339795421255985e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.8982359170913696

The O 0 5.391980721469736e-06
disease O 0 3.90875393350143e-05
susceptibility O 0 9.355798283650074e-06
of O 0 2.9152749903005315e-06
individuals O 0 9.036709158749545e-09
who O 0 4.530813384917565e-06
constitutionally O 0 0.00016766424232628196
lack O 1 0.9964978694915771
both O 0 6.583301370710615e-08
wild O 0 3.608851883996067e-08
- O 0 3.874287557437128e-09
type O 0 5.470043973332395e-09
alleles O 0 6.768553495462015e-10
is O 0 2.392785414251364e-10
unknown O 0 1.7376802219359888e-08
. O 0 2.117940489654302e-08

We O 0 1.099870061693764e-07
have O 0 1.956470097042029e-09
identified O 0 4.656484087206536e-09
three O 0 3.253570468597644e-10
offspring O 0 7.342264018994626e-10
in O 0 1.6887125031672667e-10
a O 0 8.997993461434817e-09
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 1 1.0
who O 0 4.612017619365361e-06
developed O 1 0.9999651908874512
hematological B-Disease 1 1.0
malignancy I-Disease 1 1.0
at O 1 0.917736291885376
a O 0 3.4534710380285105e-07
very O 0 3.7795042651112e-09
early O 0 3.782145938657777e-07
age O 0 9.201119866020235e-09
, O 0 1.3611645144351314e-10
and O 0 1.7065471258348452e-10
at O 0 3.208282806088647e-10
least O 0 1.3432162500326417e-11
two O 0 1.31698740454822e-11
of O 0 1.7672055485640215e-10
them O 0 7.804384916099139e-11
displayed O 0 4.0856522609544754e-09
signs O 0 3.4905813350860626e-08
of O 0 5.298112455420778e-07
neurofibromatosis B-Disease 1 0.9558728337287903
type I-Disease 0 0.3787437677383423
1 I-Disease 0 7.784920308040455e-05
( O 0 3.4783045332886786e-09
NF1 B-Disease 0 5.859500015503727e-05
) O 0 9.413104962163743e-09
. O 0 8.268153095514208e-08

DNA O 0 8.969781220002915e-07
sequence O 0 1.5679180620509214e-08
analysis O 0 1.7396822871162954e-09
and O 0 6.802617913415077e-10
allele O 0 4.0394373956864627e-10
- O 0 3.6079814136336097e-10
specific O 0 2.4407467713594144e-10
amplification O 0 2.6338545566773064e-08
in O 0 1.856972020597425e-09
two O 0 5.1347801566237194e-09
siblings O 0 1.791317885135868e-07
revealed O 0 9.811709844598226e-08
a O 0 1.3187519698476535e-07
homozygous O 0 1.857292346585382e-07
MLH1 O 0 2.089770532620605e-05
mutation O 0 1.9386849459124278e-08
( O 0 1.4998543518274232e-09
C676T O 0 1.6983635475753545e-07
- O 0 3.506647772155702e-07
- O 0 1.0216715509159258e-06
> O 0 1.5099119536898797e-06
Arg226Stop O 0 3.1221045446727658e-06
) O 0 1.8056189876602957e-09
. O 0 2.1014384898876415e-08

Thus O 0 1.0203921192442067e-06
, O 0 3.1130849009741723e-08
a O 0 2.7179286377077005e-08
homozygous O 0 1.9312011545480345e-07
germ O 1 0.9794897437095642
- O 0 0.0015107414219528437
line O 0 0.000257723469985649
MLH1 O 1 0.9999827146530151
mutation O 0 5.972435701551149e-07
and O 0 2.2135409949441964e-08
consequent O 0 0.3075863718986511
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 1.0
results O 0 1.095613413326646e-07
in O 0 1.9457903732700288e-08
a O 0 1.0961798579955939e-07
mutator O 0 0.0007665075245313346
phenotype O 0 1.6306886152506195e-07
characterized O 0 1.200820998192853e-09
by O 0 5.768581792797711e-11
leukemia B-Disease 1 0.9999992847442627
and O 0 3.5534521884983405e-05
/ O 1 1.0
or O 1 0.9999778270721436
lymphoma B-Disease 1 1.0
associated O 0 0.0002817279892042279
with O 0 4.0883978869032944e-08
neurofibromatosis B-Disease 1 0.9697182774543762
type I-Disease 0 2.1119509256095625e-05
1 I-Disease 0 1.3907442735217046e-06
. O 0 7.822514191957453e-09
. O 0 3.4236684598454303e-08

Missense O 0 0.00047908388660289347
mutations O 0 1.2894141718788887e-06
in O 0 5.6453639984965776e-08
the O 0 4.6111285456618134e-08
most O 0 1.7140214803035292e-09
ancient O 0 1.4963083572183677e-07
residues O 0 3.8056999329683094e-08
of O 0 5.6468717701818605e-08
the O 0 1.2774250990332803e-07
PAX6 O 0 0.0009298384538851678
paired O 0 5.2730090516206474e-08
domain O 0 2.6988873358391174e-08
underlie O 0 7.816120017878347e-08
a O 0 6.445532996224301e-09
spectrum O 0 2.8402766361068643e-07
of O 0 8.030340126197189e-08
human O 1 0.981657862663269
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.41253358125686646

Mutations O 0 4.395306234528107e-07
of O 0 1.4126099756595067e-07
the O 0 4.928108054969016e-08
human O 0 1.811978762589206e-07
PAX6 O 1 0.9970253109931946
gene O 0 4.32358356192708e-05
underlie O 1 0.9999951124191284
aniridia B-Disease 1 1.0
( O 1 0.9965642094612122
congenital B-Disease 1 1.0
absence I-Disease 1 0.9985910058021545
of I-Disease 1 0.9999997615814209
the I-Disease 1 0.9997125267982483
iris I-Disease 1 0.9756177067756653
) O 0 1.7453323231109152e-09
, O 0 4.332212644175826e-10
a O 0 5.345310682969284e-08
rare O 0 0.06695560365915298
dominant O 1 1.0
malformation B-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 1 1.0
eye I-Disease 1 1.0
. O 0 0.00011908715532626957

The O 0 2.936226337624248e-06
spectrum O 0 1.3111105545249302e-05
of O 0 1.5388320662168553e-06
PAX6 O 1 0.9966017007827759
mutations O 0 3.93498839912354e-06
in O 0 8.337021313309378e-07
aniridia B-Disease 1 1.0
patients O 0 0.0004435992450453341
is O 0 5.115464052352081e-09
highly O 0 3.8973002602915585e-09
biased O 0 5.4651843051090054e-09
, O 0 5.596894822601506e-11
with O 0 1.4987662153020942e-11
92 O 0 3.659087033369701e-09
% O 0 4.4264189535958565e-11
of O 0 5.011565606949375e-10
all O 0 1.383966552470639e-10
reported O 0 1.1033148838990314e-09
mutations O 0 8.587972000206889e-10
leading O 0 5.6548659088662134e-09
to O 0 1.6443860717529901e-09
premature O 0 1.8335686036152765e-07
truncation O 0 7.053662102407543e-06
of O 0 2.355360447836574e-05
the O 0 9.901428938974277e-07
protein O 0 3.438845652681266e-08
( O 0 2.6187091384244354e-10
nonsense O 0 1.064908428105582e-08
, O 0 1.5334052083648686e-10
splicing O 0 8.667920603500079e-09
, O 0 1.3863470094133135e-10
insertions O 0 4.991563162803914e-09
and O 0 7.35478067337425e-10
deletions O 0 5.785854462203588e-09
) O 0 3.169683682191504e-10
and O 0 6.515356254510607e-09
just O 0 2.8858677225684914e-08
2 O 0 9.826617741737209e-08
% O 0 8.451732091963038e-10
leading O 0 9.238290132884686e-10
to O 0 6.464757895674467e-11
substitution O 0 5.37296784841601e-09
of O 0 7.723556194605408e-08
one O 0 9.150431523607949e-10
amino O 0 3.406507853576102e-10
acid O 0 3.460073338956704e-10
by O 0 4.4754540351465977e-11
another O 0 1.1783949371846347e-09
( O 0 6.994234080792694e-10
missense O 0 4.5237182888513416e-08
) O 0 1.1667294907979908e-09
. O 0 2.9601702422610288e-08

The O 0 2.137323690476478e-06
extraordinary O 0 3.51988234115197e-07
conservation O 0 1.1917613562673068e-07
of O 0 3.422167083044769e-08
the O 0 4.2077797246520277e-08
PAX6 O 0 4.492516745813191e-05
protein O 0 3.0050605914766493e-07
at O 0 1.9571650966554444e-08
the O 0 8.001881823815893e-09
amino O 0 4.528828867478296e-08
acid O 0 2.8111512051509635e-07
level O 0 6.552796776304604e-07
amongst O 0 1.8233224352570687e-07
vertebrates O 0 1.7520676465210272e-06
predicts O 0 6.987917355871787e-09
that O 0 1.8300340409727056e-10
pathological O 0 7.350495252467226e-07
missense O 0 3.106050883161515e-07
mutations O 0 1.7873831303916177e-09
should O 0 2.0138439527084273e-10
in O 0 1.3717932345613804e-10
fact O 0 2.2015136935671364e-10
be O 0 1.7682912079042268e-10
common O 0 2.6047222156933003e-09
even O 0 5.220674448302987e-10
though O 0 3.059841269248409e-10
they O 0 7.529808027095797e-11
are O 0 3.0926150529353436e-11
hardly O 0 1.2974322949332873e-08
ever O 0 6.642453698191275e-09
seen O 0 8.826245512238984e-09
in O 0 1.0020770879748397e-08
aniridia B-Disease 1 1.0
patients O 0 2.649730049597565e-06
. O 0 2.9092211661918554e-07

This O 0 6.984868150539114e-08
indicates O 0 4.7899337829448996e-08
that O 0 5.460679686208891e-10
there O 0 5.251865609068318e-10
is O 0 5.030614258494381e-10
a O 0 2.7446831474264854e-09
heavy O 0 1.7278995301239775e-06
ascertainment O 0 3.084429044974968e-05
bias O 0 1.7564313736784243e-07
in O 0 8.135210283199967e-10
the O 0 8.027621345441105e-10
selection O 0 5.678598702374416e-10
of O 0 8.804047491040023e-10
patients O 0 3.91023158297088e-10
for O 0 2.6431315469643835e-10
PAX6 O 0 2.425288130325498e-06
mutation O 0 9.855195548524875e-10
analysis O 0 4.571976963685387e-10
and O 0 1.6552384463075498e-10
that O 0 1.0675796358050604e-10
the O 0 4.38957528103856e-08
missing O 0 5.3298990678740665e-06
PAX6 O 1 0.9469800591468811
missense O 0 5.54527978238184e-05
mutations O 0 1.7254215833872877e-07
frequently O 0 4.680543508328583e-09
may O 0 1.672175642397633e-08
underlie O 0 6.3712536757520866e-06
phenotypes O 0 6.9384873313538264e-06
distinct O 0 1.2136661098338664e-07
from O 0 2.3812106064724503e-07
textbook O 0 3.629860657383688e-05
aniridia B-Disease 1 1.0
. O 0 6.900319476699224e-06

Here O 0 1.0540456969465595e-06
we O 0 1.286228634711506e-08
present O 0 7.195093409961828e-09
four O 0 4.807036990683855e-09
novel O 0 8.531556972002363e-08
PAX6 O 0 0.0002936070377472788
missense O 0 2.7551805032999255e-06
mutations O 0 2.7954364156812517e-08
, O 0 7.830511794537642e-10
two O 0 2.5891530586186207e-10
in O 0 6.208260017181999e-10
association O 0 4.5692397088181735e-10
with O 0 2.4143320676017765e-10
atypical O 0 8.512093700119294e-06
phenotypes O 0 0.0002274630533065647
ectopia B-Disease 0 0.0015604256186634302
pupillae I-Disease 0 0.00010480939818080515
( O 0 1.5023566835026259e-09
displaced B-Disease 0 5.490447652078956e-09
pupils I-Disease 0 4.680016818525701e-09
) O 0 2.2394275323023294e-09
and O 0 3.423218686293694e-07
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9929827451705933
( O 0 1.7744292790666805e-07
searching B-Disease 0 1.6721378415240906e-06
gaze I-Disease 0 2.4453938749502413e-06
) O 0 8.323684519417895e-10
, O 0 1.8871029738853906e-10
and O 0 3.650650337583272e-10
two O 0 1.0650987869453843e-09
in O 0 1.1319724046998658e-09
association O 0 1.218575573780356e-09
with O 0 5.686424109363486e-10
more O 0 2.6048365686648367e-09
recognizable O 0 4.077926860190928e-05
aniridia B-Disease 1 1.0
phenotypes O 0 0.00028481241315603256
. O 0 2.603547500257264e-06

Strikingly O 0 2.7175012291991152e-05
, O 0 3.23551603287342e-08
all O 0 1.6203873798303903e-09
four O 0 1.0207381606619492e-09
mutations O 0 4.3359987822455537e-10
are O 0 1.3860113057262424e-10
located O 0 1.2941846705416538e-08
within O 0 1.975674379650627e-08
the O 0 3.0289243113656994e-07
PAX6 O 0 0.0006836339016444981
paired O 0 1.251906525112645e-07
domain O 0 3.106056567503401e-08
and O 0 1.1730532101239532e-09
affect O 0 1.4803801517970783e-09
amino O 0 1.2754227673994478e-09
acids O 0 3.7497324689717004e-10
which O 0 5.0484037089626455e-11
are O 0 1.4838104703263078e-11
highly O 0 8.680656748971671e-10
conserved O 0 9.593045247058285e-10
in O 0 3.0039914999946404e-10
all O 0 5.181894913164342e-10
known O 0 2.475125659984201e-09
paired O 0 1.7985177791501883e-09
domain O 0 3.5142349030792275e-09
proteins O 0 6.19375939425737e-10
. O 0 8.874964763094795e-09

Our O 0 1.7934400602825917e-05
results O 0 1.028542797598675e-07
support O 0 1.6177330053324113e-07
the O 0 3.59079415090946e-08
hypothesis O 0 2.2156616097390724e-08
that O 0 2.977936300330164e-11
the O 0 4.4710793400959403e-10
under O 0 1.8552690494999524e-09
- O 0 3.26211613277394e-09
representation O 0 1.4776551093831358e-09
of O 0 1.47115946091958e-08
missense O 0 5.002812599741446e-07
mutations O 0 8.822745201086946e-09
is O 0 3.67941621615131e-10
caused O 0 9.859393301780983e-09
by O 0 1.9454924338191404e-09
ascertainment O 0 0.00032132380874827504
bias O 0 2.217812834715005e-06
and O 0 9.586009319662026e-09
suggest O 0 1.24245091992492e-09
that O 0 5.243204828642156e-11
a O 0 5.338499087237381e-10
substantial O 0 4.124943941974379e-09
burden O 0 2.982300770781876e-07
of O 0 9.83862719294848e-07
PAX6 B-Disease 1 0.9999998807907104
- I-Disease 0 0.00233576912432909
related I-Disease 0 1.3054822375124786e-05
disease I-Disease 1 0.993990421295166
remains O 0 4.4942882482246205e-07
to O 0 5.850370188298371e-10
be O 0 1.0356029367386554e-09
uncovered O 0 1.01385481343641e-07
. O 0 2.5638362544100346e-09
. O 0 1.3120025954549419e-08

The O 0 8.114797651614936e-07
chromosomal O 0 3.06961760543345e-06
order O 0 9.887305907341215e-08
of O 0 2.722256112974719e-06
genes O 0 2.67707292778141e-07
controlling O 0 1.1564233091121423e-06
the O 0 1.4498277778329793e-05
major O 0 0.19197985529899597
histocompatibility O 1 1.0
complex O 1 0.9999845027923584
, O 0 8.371709547816408e-09
properdin O 0 2.308335922407423e-07
factor O 0 8.07116684597986e-09
B O 0 2.2239987629291136e-07
, O 0 2.0978641046554003e-10
and O 0 4.824955990301305e-10
deficiency B-Disease 0 1.983401034522103e-06
of I-Disease 0 1.2488337233662605e-05
the I-Disease 0 1.2430961078280234e-06
second I-Disease 0 8.413299923404338e-08
component I-Disease 0 2.1203986477758008e-07
of I-Disease 0 1.7244377659153542e-07
complement I-Disease 0 6.844766176072881e-07
. O 0 1.6809956377983326e-06

The O 0 2.446168309688801e-06
relationship O 0 4.953028565068962e-07
of O 0 7.322578881030495e-07
the O 0 1.061728767126624e-07
genes O 0 4.782910956180331e-09
coding O 0 6.447022826705506e-08
for O 0 2.7381523715064304e-09
HLA O 0 1.9201566203719267e-07
to O 0 1.4296323014306722e-09
those O 0 2.0826276259100496e-09
coding O 0 1.4193592789979448e-07
for O 0 2.0736379280350548e-09
properdin O 0 3.1735953598399647e-07
Factor O 0 1.3662223352639558e-08
B O 0 1.4236579204407462e-07
allotypes O 0 1.3942924681487057e-07
and O 0 3.156001848747536e-10
for O 0 2.5485841215200367e-10
deficiency B-Disease 0 8.345835453837935e-07
of I-Disease 0 5.617433544102823e-06
the I-Disease 0 2.5420531528652646e-06
second I-Disease 0 9.241317684427486e-07
component I-Disease 0 4.024054476303718e-07
of I-Disease 0 2.6573522404760297e-07
complement I-Disease 0 7.924258227376413e-08
( O 0 3.884913279961211e-09
C2 O 0 5.811805081634702e-08
) O 0 4.7403206360208117e-11
was O 0 1.3758187922263687e-09
studied O 0 2.818024702477828e-10
in O 0 1.9429539574455923e-11
families O 0 1.2704635954374766e-11
of O 0 1.4044797269630038e-10
patients O 0 1.0481261414341247e-09
with O 0 9.81906378427766e-09
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 0.00016304828750435263

Patients O 0 2.267334821226541e-05
were O 0 1.8671343582354893e-07
selected O 0 7.9971211874863e-09
because O 0 2.0574142389762073e-09
they O 0 6.63613164419985e-10
were O 0 3.039605900312381e-09
heterozygous O 0 6.785240702633644e-10
or O 0 8.580555155290881e-10
homozygous O 0 2.9070154283772354e-08
for O 0 4.575235479364892e-08
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.2955739293829538e-05

12 O 0 2.0077820863662055e-06
families O 0 2.1370244240870306e-08
with O 0 1.8159318493360388e-09
15 O 0 3.093911615792422e-08
matings O 0 2.5088456823141314e-06
informative O 0 2.1808828876146436e-07
for O 0 1.433858187738224e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 2.356295993877211e-07
found O 0 5.0181132138504836e-08
. O 0 9.073863083131073e-08

Of O 0 4.989396620658226e-05
57 O 0 5.0707308218989056e-06
informative O 0 1.7597980672690028e-07
meioses O 0 9.480181688559242e-06
, O 0 4.9112713895738125e-09
two O 0 9.63827240241244e-10
crossovers O 0 1.3984881697126639e-08
were O 0 1.1335588467886737e-08
noted O 0 1.0384279214292746e-08
between O 0 1.0869649713640683e-07
the O 0 6.570323603227735e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 3.3118947584398484e-09
and O 0 1.2800458470962894e-09
the O 0 3.4412317440057905e-09
HLA O 0 1.701738305825984e-08
- O 0 1.3578675961412046e-08
B O 0 2.1481769252318372e-08
gene O 0 1.4599794984082592e-10
, O 0 4.263026563700034e-12
with O 0 2.7056336771719147e-12
a O 0 1.9977833276563217e-10
recombinant O 0 1.5424670429808884e-09
fraction O 0 2.7077493580662804e-09
of O 0 6.409932495898829e-08
0 O 0 1.6159813753802155e-07
. O 0 6.493820592368138e-08

035 O 0 0.021768271923065186
. O 0 4.1736089769983664e-05

A O 0 2.131010842276737e-05
lod O 0 0.00030212075216695666
score O 0 8.18979913219664e-07
of O 0 4.5659948000320583e-07
13 O 0 9.801384948104896e-08
was O 0 4.186261648442269e-08
calculated O 0 4.773041073491413e-09
for O 0 9.79276215673508e-10
linkage O 0 1.5177570276136976e-06
between O 0 2.7195419534109533e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 3.2520414805503606e-08
HLA O 0 6.156511034305368e-08
- O 0 2.2370549856987054e-08
B O 0 6.999712098831878e-08
at O 0 1.1490113305256955e-09
a O 0 6.70213329279079e-11
maximum O 0 1.5004145148544978e-10
likelihood O 0 3.029417827704606e-10
value O 0 1.0207688860841557e-10
of O 0 5.77606074081416e-10
the O 0 5.609433473274805e-10
recombinant O 0 8.257853845172747e-10
fraction O 0 1.937671134655261e-09
of O 0 9.580433335543148e-09
0 O 0 3.8118166401091e-08
. O 0 1.9744801349474983e-08

04 O 0 0.0035977486986666918
. O 0 4.0389069908997044e-05

18 O 0 2.4678122372279176e-06
families O 0 3.8708247274144014e-08
with O 0 3.381321667106363e-09
21 O 0 2.9911817023275944e-08
informative O 0 3.382147450992079e-09
matings O 0 1.4272141868332255e-07
for O 0 7.2229511260957224e-09
both O 0 6.682698838744727e-09
properdin O 0 3.007893155881902e-06
Factor O 0 8.800648032547542e-08
B O 0 2.6119255380763207e-07
allotype O 0 1.0369835479195899e-07
and O 0 1.2019966133536286e-09
HLA O 0 2.1752947887421215e-08
- O 0 1.591537390766007e-08
B O 0 7.330348950063126e-08
were O 0 3.7950638187567165e-09
found O 0 7.739124896488647e-09
. O 0 2.1229880076134577e-08

Of O 0 6.556328298756853e-05
72 O 0 7.078346243361011e-06
informative O 0 3.2898705626394076e-07
meioses O 0 1.2047124073433224e-05
, O 0 8.84464856909517e-09
three O 0 5.4696682738608615e-09
recombinants O 0 9.316250384472369e-07
were O 0 1.3096649098542912e-08
found O 0 3.7017815479600813e-09
, O 0 7.788785588713765e-11
giving O 0 8.32742833023481e-11
a O 0 7.109067223787235e-10
recombinant O 0 3.524384117881141e-09
fraction O 0 2.6948439924012746e-08
of O 0 5.705191483684757e-07
0 O 0 6.972501864765945e-07
. O 0 1.877279487416672e-07

042 O 0 0.0076183173805475235
. O 0 2.3021675588097423e-05

A O 0 2.4456516257487237e-05
lod O 0 0.00029196374816820025
score O 0 1.4640182826042292e-06
of O 0 1.0286570386597305e-06
16 O 0 7.321978756635872e-08
between O 0 6.145175479588261e-09
HLA O 0 1.1550418577144228e-07
- O 0 6.18079525338544e-08
B O 0 1.0194510480232566e-07
and O 0 8.440938503717632e-10
Factor O 0 4.526615970945613e-09
B O 0 6.196754753773348e-08
allotypes O 0 1.00060489671705e-07
was O 0 4.153729360467651e-09
calculated O 0 4.953434329380002e-10
at O 0 2.335734383684951e-10
a O 0 5.423124102565957e-11
maximum O 0 2.0096767305854968e-10
likelihood O 0 1.4136768144989986e-10
value O 0 5.734169389315369e-11
of O 0 2.397417542265856e-10
the O 0 2.2046693637367554e-10
recombinant O 0 6.441473465734759e-10
fraction O 0 1.147611783380853e-09
of O 0 8.853965560717825e-09
0 O 0 4.693938748800974e-08
. O 0 3.1832826152822236e-08

04 O 0 0.0028809108771383762
. O 0 3.615996683947742e-05

A O 0 1.8444123270455748e-05
crossover O 0 1.5386559653052245e-06
was O 0 3.6290978755459946e-07
shown O 0 2.6874102942997524e-09
to O 0 7.102290977556436e-10
have O 0 2.3261223502935024e-10
occurred O 0 1.0858372867517119e-08
between O 0 3.6547606607761907e-10
genes O 0 1.3506491758352723e-10
for O 0 9.886971796824184e-11
Factor O 0 1.5435738243141373e-09
B O 0 3.093964906497604e-08
and O 0 2.798400844383764e-09
HLA O 0 5.1170182757687144e-08
- O 0 1.399913855948398e-07
D O 0 3.9701393461655243e-07
, O 0 6.683728570600067e-10
in O 0 6.49541309627466e-10
which O 0 6.028395005408527e-10
HLA O 0 3.087332700602019e-08
- O 0 6.359334037142617e-08
D O 0 2.9802737344652996e-07
segregared O 0 8.044533501561091e-07
with O 0 2.2855308756675186e-09
HLA O 0 2.670927017334179e-07
- O 0 1.4517482327391917e-07
A O 0 5.219614536144945e-07
and O 0 6.351854864306006e-08
B O 0 4.70552504339139e-06
. O 0 1.3287984756971127e-07

These O 0 1.5375389850191823e-08
studies O 0 1.2158475337642471e-09
suggest O 0 8.071485702032533e-10
that O 0 3.2910858066559356e-11
the O 0 2.758747674747042e-10
genes O 0 1.581733632960436e-10
for O 0 1.3920331554118093e-10
Factor O 0 5.8528314639261225e-08
B O 1 0.9822472929954529
and O 0 0.00016620066890027374
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 4.999872516009418e-09
located O 0 9.834395520158523e-09
outside O 0 1.4887331367674506e-09
those O 0 1.48982326475533e-10
for O 0 1.285518635985028e-10
HLA O 0 4.5098307310809105e-08
, O 0 6.796337104209016e-11
that O 0 4.011793675040565e-11
the O 0 4.647610740704522e-09
order O 0 2.4579458468565463e-08
of O 0 7.354029918360538e-08
genese O 0 9.275744901060534e-07
is O 0 2.0859987071020214e-09
HLA O 0 1.1397723653772118e-08
- O 0 6.5267871107721476e-09
A O 0 7.702681159571512e-08
, O 0 5.082201326445102e-10
- O 0 1.3009776589356647e-09
B O 0 2.6355227333851872e-08
, O 0 6.628465554214813e-10
- O 0 1.816268913046315e-08
D O 0 1.537029561404779e-07
, O 0 1.647302294571773e-09
Factor O 0 8.408407126125894e-08
B O 0 5.481441621668637e-05
allotype O 0 0.001376634812913835
, O 0 2.5361782718391623e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 5.933439295446874e-10
that O 0 2.9293307363120746e-11
the O 0 1.498076107608881e-09
genes O 0 8.214422031471713e-09
coding O 0 7.468869398508104e-07
for O 0 1.7726314638366603e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 4.39628706772055e-07
Factor O 0 6.891428228072982e-08
B O 0 1.6141100900313177e-07
allotypes O 0 6.878270397692177e-08
are O 0 5.962012827875895e-11
approximately O 0 1.017526479740738e-10
3 O 0 1.4081928956244383e-09
- O 0 1.430887186515406e-09
- O 0 1.987462816543939e-08
5 O 0 1.4611286403010126e-08
centimorgans O 0 8.4410750389452e-08
from O 0 5.591245244573884e-09
the O 0 8.44951131284688e-09
HLA O 0 3.9820530872702875e-08
- O 0 2.058137660299053e-08
A O 0 1.3952767119462806e-07
and O 0 5.313795625738749e-09
HLA O 0 4.291655031352093e-08
- O 0 4.7028734684317897e-08
B O 0 2.155820340021819e-07
loci O 0 5.148657056253114e-09
, O 0 9.460252026194382e-11
and O 0 7.900688436812686e-11
that O 0 2.6133239669490216e-11
the O 0 1.7145872499568782e-09
apparent O 0 1.052407867518923e-07
lack O 0 1.8156598002860846e-07
of O 0 1.495319246203053e-08
recombinants O 0 6.788469875118608e-08
between O 0 5.763624577603821e-10
the O 0 4.355479532591744e-09
Factor O 0 2.6164300948039454e-08
B O 0 2.186110577895306e-06
gene O 0 2.5488449750810105e-07
and O 0 3.789601350945304e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 3.4293282880071274e-08
suggests O 0 7.461757878246544e-10
that O 0 6.7001612591433e-12
these O 0 4.4411588989712314e-11
two O 0 9.431102426793458e-11
genes O 0 1.332101318141099e-09
lie O 0 1.6457486040621916e-08
in O 0 2.0518338139652315e-09
close O 0 3.18516519826062e-08
proximity O 0 7.553061891485413e-07
to O 0 8.489445590953437e-09
one O 0 1.4390002078812358e-08
another O 0 5.043281348093842e-08
. O 0 2.2638785424078378e-07

Distribution O 0 1.5727201798654278e-06
of O 0 3.830485638900427e-06
emerin O 0 0.00020504834537860006
and O 0 1.281862296309555e-07
lamins O 0 0.0007359135779552162
in O 0 2.112280483856921e-08
the O 0 1.5546137888122757e-07
heart O 0 1.079668800230138e-05
and O 0 8.152890806911728e-09
implications O 0 2.1772704528189024e-08
for O 0 9.193471761648198e-09
Emery B-Disease 1 0.7729485630989075
- I-Disease 1 0.9999990463256836
Dreifuss I-Disease 1 0.9999998807907104
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0002879528619814664

Emerin O 0 0.002570842392742634
is O 0 4.901331180917623e-07
a O 0 2.619241854517895e-07
nuclear O 0 3.036009047718835e-06
membrane O 0 7.126016043912387e-08
protein O 0 1.5082605386851355e-08
which O 0 2.458370174096558e-10
is O 0 2.740978000126404e-10
missing O 0 1.3198762083277416e-08
or O 0 3.564623041185655e-09
defective O 0 4.176168204139685e-06
in O 0 2.0562548286306992e-07
Emery B-Disease 1 0.9999955892562866
- I-Disease 1 1.0
Dreifuss I-Disease 1 0.9999998807907104
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.1716845619957894e-05
EDMD B-Disease 1 1.0
) O 0 1.7611512248549843e-07
. O 0 4.0284086821884557e-07

It O 0 1.5123345065148897e-07
is O 0 8.862785172425447e-09
one O 0 1.7610353175712135e-09
member O 0 1.1264028598745313e-09
of O 0 9.128855005258174e-09
a O 0 1.4398924719216666e-08
family O 0 3.690095695674245e-08
of O 0 4.284228793949296e-08
lamina O 1 0.9792959690093994
- O 0 7.366323552560061e-05
associated O 0 4.4494328221844626e-07
proteins O 0 1.2533999393937734e-09
which O 0 4.057305602600536e-10
includes O 0 1.933853521762785e-09
LAP1 O 0 0.00018884985183831304
, O 0 1.1073464811772737e-08
LAP2 O 0 0.00038915115874260664
and O 0 1.1568976105991169e-06
lamin O 0 0.0001539237709948793
B O 0 2.241467336716596e-05
receptor O 0 8.374362323593232e-07
( O 0 4.248738250112183e-09
LBR O 0 6.504917564598145e-06
) O 0 7.904887411314121e-09
. O 0 9.747264329007521e-08

A O 0 5.388185672927648e-05
panel O 0 2.9670607091247803e-06
of O 0 3.188651760410721e-07
16 O 0 3.265255088535923e-08
monoclonal O 0 6.784367201362329e-08
antibodies O 0 6.411411845874682e-08
( O 0 7.852682060160987e-09
mAbs O 0 6.987692700022308e-07
) O 0 1.02694819315019e-09
has O 0 3.633741640918231e-10
been O 0 6.813967168284307e-10
mapped O 0 4.096341932324776e-09
to O 0 7.786487010719156e-10
six O 0 4.871831826847028e-10
specific O 0 2.7820504233666554e-10
sites O 0 3.5907925521883044e-09
throughout O 0 6.395711182882735e-10
the O 0 8.051239674955468e-09
emerin O 0 1.6338672992333159e-07
molecule O 0 3.0132261130688676e-09
using O 0 2.4452539992836364e-09
phage O 0 2.718913805210832e-08
- O 0 3.7186755008633554e-08
displayed O 0 8.707740306590495e-09
peptide O 0 3.811038951084811e-08
libraries O 0 4.46348069615965e-09
and O 0 1.2432427309860827e-09
has O 0 9.639977704978264e-11
been O 0 1.2545713079514798e-10
used O 0 1.3655183650485014e-09
to O 0 2.1532913230259965e-09
localize O 0 1.0843594964171643e-06
emerin O 0 2.680762236195733e-06
in O 0 1.6890741028063871e-09
human O 0 6.225884252586411e-09
and O 0 7.351404374134063e-09
rabbit O 0 1.75301047420362e-05
heart O 0 1.995250568143092e-05
. O 0 5.564357934417785e-07

Several O 0 1.267613811251067e-06
mAbs O 0 9.23393508855952e-06
against O 0 1.439264281088981e-07
different O 0 3.6601640829303506e-08
emerin O 0 1.7665994164417498e-05
epitopes O 0 5.800719009130262e-06
did O 0 7.125078127501183e-08
not O 0 4.362754602027508e-09
recognize O 0 1.023756990292668e-08
intercalated O 0 1.997088020289084e-06
discs O 0 1.742046038089029e-06
in O 0 7.4052755039133444e-09
the O 0 8.881640667368629e-08
heart O 0 4.185597845207667e-06
, O 0 1.907505542408927e-10
though O 0 1.68697417146646e-10
they O 0 2.929018971808972e-10
recognized O 0 3.3626894602178936e-09
cardiomyocyte O 0 2.560529708262038e-07
nuclei O 0 7.257802963067661e-07
strongly O 0 5.057325935808876e-08
, O 0 3.309716056776324e-09
both O 0 1.0579785048037138e-08
at O 0 2.0259901134522806e-07
the O 0 5.089423282811367e-08
rim O 0 6.781817774026422e-07
and O 0 4.462357150458729e-09
in O 0 4.279644638671698e-09
intranuclear O 0 2.4220776140282396e-06
spots O 0 9.271185064108067e-08
or O 0 4.876978110246455e-08
channels O 0 5.109801577418693e-07
. O 0 7.280646485696707e-08

A O 0 4.9369322368875146e-05
polyclonal O 0 0.0004598491359502077
rabbit O 0 0.00011054727656301111
antiserum O 0 3.37839410349261e-05
against O 0 1.9528081338648917e-06
emerin O 0 0.0011469093151390553
did O 0 2.402290988356981e-07
recognize O 0 1.0212318102276186e-07
both O 0 3.373689239083433e-08
nuclear O 0 8.980490747489966e-06
membrane O 0 1.2368317925393058e-07
and O 0 1.7636707649870687e-09
intercalated O 0 3.644420587534114e-08
discs O 0 2.0496678132531088e-08
but O 0 8.408174712037919e-10
, O 0 1.1740151906192153e-10
after O 0 1.870019916694332e-09
affinity O 0 4.1830992003610845e-09
purification O 0 1.1328243942898553e-07
against O 0 6.54256604448733e-09
a O 0 3.61314995700468e-08
pure O 0 1.2433391702870722e-06
- O 0 1.4710253992689104e-07
emerin O 0 9.9171256806585e-07
band O 0 1.297040626013768e-07
on O 0 4.389039887087165e-08
a O 0 5.507743594534986e-09
western O 0 4.992384816659978e-08
blot O 0 4.345141405792674e-06
, O 0 2.7926527756960695e-09
it O 0 5.267655756036049e-10
stained O 0 3.0065882583585335e-06
only O 0 8.226024306168256e-09
the O 0 2.9859659633757474e-08
nuclear O 0 9.204517255056999e-07
membrane O 0 5.3176813707978e-07
. O 0 8.34426145956968e-08

These O 0 2.407763588507805e-07
results O 0 5.981099349128272e-08
would O 0 4.859407987112263e-09
not O 0 5.938624592083386e-10
be O 0 5.838709515870733e-10
expected O 0 6.681514008732847e-09
if O 0 5.106388201170375e-09
immunostaining O 0 2.1702819594793255e-06
at O 0 3.408083770750636e-08
intercalated O 0 7.947917168849017e-08
discs O 0 1.0459682187047292e-07
were O 0 6.606947877685343e-09
due O 0 1.2765701740136137e-07
to O 0 4.664875596915863e-09
a O 0 5.777616607360869e-09
product O 0 6.021893650398624e-09
of O 0 5.48772831621136e-08
the O 0 5.392703883444483e-08
emerin O 0 2.443649691485916e-07
gene O 0 1.5071670578237217e-09
and O 0 4.797042207904667e-10
, O 0 3.262977735229988e-11
therefore O 0 8.789282635035534e-10
, O 0 2.152431982649361e-10
cast O 0 1.8243541122231477e-09
some O 0 5.8171641115212225e-11
doubt O 0 3.096247924716522e-09
upon O 0 3.602282916403965e-09
the O 0 6.393759410805444e-10
hypothesis O 0 3.678140902962923e-09
that O 0 2.321362269075422e-10
cardiac B-Disease 0 0.12170074135065079
defects I-Disease 1 0.7368698120117188
in O 0 6.623579906772648e-07
EDMD B-Disease 1 1.0
are O 0 2.5370823664161435e-08
caused O 0 1.9502829218254192e-07
by O 0 8.44332159743999e-10
absence O 0 1.3918121055667143e-07
of O 0 6.759501616215857e-07
emerin O 0 3.114881837973371e-05
from O 0 2.4360153361158154e-07
intercalated O 0 9.025701729115099e-06
discs O 0 4.356229692348279e-05
. O 0 3.0659632557217265e-06

Although O 0 2.677139491424896e-06
emerin O 0 0.0002462751290295273
was O 0 2.6861437163461233e-06
abundant O 0 2.7729552698474436e-07
in O 0 2.291633327544673e-09
the O 0 5.202913211377336e-09
membranes O 0 4.117698537697834e-08
of O 0 7.169998639255937e-08
cardiomyocyte O 0 1.4649065178673482e-06
nuclei O 0 2.40953772845387e-06
, O 0 2.2183412884402287e-09
it O 0 9.341449835886806e-10
was O 0 3.4372885693301214e-07
absent O 0 4.3822975470675374e-08
from O 0 3.6187068896964547e-09
many O 0 1.2017695727450928e-09
non O 0 7.368603860413714e-08
- O 0 2.2237104246869421e-07
myocyte O 0 1.8450383549861726e-06
cells O 0 8.836234854925351e-09
in O 0 6.675880404038992e-10
the O 0 2.7808436442455786e-08
heart O 0 6.460511031036731e-06
. O 0 2.7278125003249443e-07

This O 0 5.5865900350227093e-08
distribution O 0 3.820237992613329e-08
of O 0 7.60916734066086e-08
emerin O 0 2.379292936893762e-06
was O 0 2.826575773440254e-08
similar O 0 3.5111510920948774e-10
to O 0 3.7536754260436567e-10
that O 0 1.491583245805117e-10
of O 0 2.1155866392064127e-08
lamin O 0 1.6458606069136295e-06
A O 0 1.3596927317394147e-07
, O 0 2.085361189285706e-10
a O 0 5.328875118948417e-10
candidate O 0 8.273319251905775e-10
gene O 0 1.722620657229612e-10
for O 0 5.521653620443878e-11
an O 0 5.597834348836095e-11
autosomal O 0 1.2241267999257843e-09
form O 0 1.0934798666539791e-07
of O 1 0.9999995231628418
EDMD B-Disease 1 1.0
. O 0 0.026960447430610657

In O 0 9.292655818171625e-07
contrast O 0 1.4085032944421982e-06
, O 0 1.9105522142126574e-07
lamin O 0 0.0004483068478293717
B1 O 0 0.000650474859867245
was O 0 1.0543278222030494e-05
absent O 0 1.3796726534565096e-06
from O 0 4.575296941311535e-08
cardiomyocyte O 0 1.295441393267538e-06
nuclei O 0 1.527124709355121e-06
, O 0 4.124298680352467e-09
showing O 0 1.780490244129851e-08
that O 0 1.3630521600305201e-08
lamin O 0 0.002054924611002207
B1 O 0 2.5149563953164034e-05
is O 0 1.113504954908251e-09
not O 0 7.175707250617336e-11
essential O 0 1.220219814079826e-09
for O 0 1.442466562862066e-10
localization O 0 2.8417829867066757e-07
of O 0 3.728839104155668e-08
emerin O 0 9.191315939460765e-07
to O 0 6.0605982454831064e-09
the O 0 1.1460105753258176e-07
nuclear O 0 1.1043197446269915e-05
lamina O 1 0.5438308715820312
. O 0 3.962048140238039e-06

Lamin O 1 0.9994155168533325
B1 O 0 0.3849215507507324
is O 0 2.4684942445674096e-07
also O 0 8.134702689233109e-09
almost O 0 1.0638441239052554e-09
completely O 0 2.0866522731921577e-08
absent O 0 1.7662206630575383e-07
from O 0 3.522665537047942e-08
skeletal O 0 2.0410310753504746e-05
muscle O 0 3.4631484595593065e-06
nuclei O 0 0.019063809886574745
. O 0 1.1959291441598907e-05

In O 0 1.7387930711265653e-05
EDMD B-Disease 1 1.0
, O 0 3.153056482574357e-08
the O 0 1.0970203412341561e-08
additional O 0 4.196957004154456e-09
absence O 0 4.882124926552933e-07
of O 0 8.080679435806815e-06
lamin O 1 0.7025783061981201
B1 O 1 0.6659649610519409
from O 0 8.016679203137755e-06
heart O 1 1.0
and O 0 0.0006362760905176401
skeletal O 1 1.0
muscle O 1 0.9984050393104553
nuclei O 1 0.9999994039535522
which O 0 1.8430846466799267e-05
already O 0 1.7050967926479643e-06
lack O 0 0.0005451581091620028
emerin O 0 4.714289025287144e-05
may O 0 8.286209940422395e-09
offer O 0 1.9079868796012533e-09
an O 0 3.04101813175528e-11
alternative O 0 5.777206490975573e-10
explanation O 0 1.18203713483922e-09
of O 0 5.931413693538445e-10
why O 0 1.2341178079466886e-10
these O 0 6.034788641029465e-11
tissues O 0 1.3013283783891438e-08
are O 0 2.24311021146395e-11
particularly O 0 5.758054033577764e-10
affected O 0 9.530273237245979e-10
. O 0 2.9803028933628184e-09
. O 0 4.606671666351758e-08

Genetic O 0 3.112725153187057e-06
mapping O 0 7.177366683208675e-07
of O 0 1.3737894732912537e-06
the O 0 2.9437967441481305e-06
copper B-Disease 0 0.0019044044893234968
toxicosis I-Disease 1 0.9996090531349182
locus O 0 4.201133833703352e-06
in O 0 7.13085697157112e-08
Bedlington O 0 1.2711979252344463e-05
terriers O 0 1.675507633080997e-06
to O 0 1.9413047169791753e-08
dog O 0 4.811507210433774e-07
chromosome O 0 1.7019200271306545e-08
10 O 0 3.106836787836187e-09
, O 0 1.2090112244678153e-10
in O 0 7.338287755231931e-10
a O 0 2.496233975080031e-08
region O 0 1.0468024669307852e-07
syntenic O 0 1.2293037798372097e-05
to O 0 1.6214764642086266e-08
human O 0 3.1130550581792704e-08
chromosome O 0 7.244381095006247e-08
region O 0 6.081536696456169e-08
2p13 O 0 4.56723319075536e-06
- O 0 1.7239393628187827e-06
p16 O 0 6.139719062048243e-07
. O 0 9.743695272845798e-08

Abnormal O 1 0.9999948740005493
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9998717308044434
accumulation I-Disease 0 0.0009453468956053257
is O 0 6.273805031042912e-09
recognized O 0 3.063439946160429e-09
as O 0 4.067286951681126e-09
an O 0 2.4215554006445927e-09
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 0.00011336131865391508
man O 0 0.0002732397988438606
, O 0 8.66788774089855e-09
mouse O 0 1.8644259398570284e-06
, O 0 1.1465053795234326e-08
rat O 0 0.04712200537323952
and O 0 4.9416149749959e-07
dog O 0 0.008365717716515064
. O 0 2.371651817156817e-06

The O 0 3.5515447507350473e-06
major O 0 5.06025799040799e-06
cause O 0 4.958173303748481e-05
of O 0 0.00017465422570239753
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999953508377075
accumulation I-Disease 1 0.850752592086792
in O 0 7.2658617682463955e-06
man O 0 0.00022067387180868536
is O 0 1.1409926337080378e-08
a O 0 6.173678457344067e-08
dysfunctional O 0 1.4922696891517262e-06
ATP7B O 0 0.00036000352702103555
gene O 0 5.4459050602417847e-08
, O 0 2.889478101231191e-10
causing O 0 3.3697599377546794e-08
Wilson B-Disease 0 1.0296640766682685e-06
disease I-Disease 0 3.433247184148058e-05
( O 0 1.4450235674701162e-08
WD B-Disease 1 0.8805421590805054
) O 0 8.577683985322437e-08
. O 0 8.061014113991405e-07

Mutations O 0 1.8049333903036313e-06
in O 0 1.3443747093333513e-07
the O 0 5.924906645304873e-07
ATP7B O 0 0.0027985586784780025
genes O 0 3.683569715917656e-08
have O 0 1.788549308656684e-09
also O 0 1.3296010958896431e-09
been O 0 1.4885515042806219e-09
demonstrated O 0 1.4696787786760979e-08
in O 0 6.320298506778954e-09
mouse O 0 1.966169520528638e-06
and O 0 5.62063142695024e-08
rat O 0 0.00010763882892206311
. O 0 1.7251745987323375e-07

The O 0 5.0472932343836874e-05
ATP7B O 0 0.3778398036956787
gene O 0 5.368698339225375e-07
has O 0 5.530386371077611e-09
been O 0 1.0928721261294072e-09
excluded O 0 3.0221476432501504e-09
in O 0 1.5602019676208556e-10
the O 0 8.656417804786543e-10
much O 0 2.862179826479405e-09
rarer O 0 3.5325720091350377e-05
human O 0 1.9816766325675417e-06
copper B-Disease 1 0.9733281135559082
overload I-Disease 1 0.9997078776359558
disease O 1 0.999638557434082
non B-Disease 0 2.7814496206701733e-05
- I-Disease 0 9.537929145153612e-06
Indian I-Disease 0 1.7591548839845927e-06
childhood I-Disease 1 0.994799017906189
cirrhosis I-Disease 1 1.0
, O 0 2.398493847977079e-09
indicating O 0 1.9450220989369882e-08
genetic O 0 4.3161097096344747e-07
heterogeneity O 0 4.7066519073268864e-06
. O 0 7.042739866847114e-07

By O 0 2.0840113634790214e-08
investigating O 0 2.1489397283858125e-07
the O 0 1.4288198713074962e-07
common O 0 3.242155798943713e-05
autosomal O 1 0.9995608925819397
recessive O 1 0.9999951124191284
copper B-Disease 1 1.0
toxicosis I-Disease 1 1.0
( O 0 2.2794035885453923e-06
CT B-Disease 0 0.10979505628347397
) O 0 4.936214548223461e-09
in O 0 1.0699944041903109e-08
Bedlington O 0 0.0001284657628275454
terriers O 0 7.853597708162852e-06
, O 0 1.081007394709843e-09
we O 0 2.1618003220869042e-10
have O 0 2.770188245460048e-11
identified O 0 1.0389915316988407e-10
a O 0 8.49063527819105e-11
new O 0 8.674545109998988e-11
locus O 0 6.690527021291359e-10
involved O 0 8.147379992884396e-11
in O 0 2.5147555149374057e-09
progressive O 1 0.9999953508377075
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 8.087132300715894e-06

We O 0 6.694316994071414e-07
examined O 0 7.38858773274842e-07
whether O 0 4.050010460332487e-08
the O 0 1.8069279406063288e-07
WD B-Disease 0 7.400048343697563e-05
gene O 0 1.1612147687856123e-07
ATP7B O 0 8.330572018167004e-05
was O 0 3.598566706841666e-07
also O 0 1.3567511558676415e-09
causative O 0 1.7879498770412283e-08
for O 0 1.5547071408050783e-09
CT B-Disease 0 1.0124639629793819e-05
by O 0 4.071711412478862e-09
investigating O 0 1.2580260033701052e-07
the O 0 1.9069842949193117e-07
chromosomal O 0 3.2352741072827484e-06
co O 0 2.709928821786889e-06
- O 0 1.6752743476899923e-06
localization O 0 0.016662858426570892
of O 0 7.735354301985353e-05
ATP7B O 1 0.8934038877487183
and O 0 5.0137600737798493e-08
C04107 O 0 1.0542321149387135e-07
, O 0 5.395689797738079e-11
using O 0 3.526554326338527e-10
fluorescence O 0 4.235527484297563e-08
in O 0 2.4108819385304514e-09
situ O 0 1.6837233829392062e-07
hybridization O 0 1.2560043671783205e-08
( O 0 3.073762910865696e-10
FISH O 0 1.2742786736907874e-07
) O 0 8.019051533914023e-10
. O 0 1.0708171238604791e-08

C04107 O 0 4.307344352127984e-05
is O 0 4.387215213341733e-08
an O 0 1.4296268613378516e-09
anonymous O 0 2.1896854107694708e-08
microsatellite O 0 3.3767394143069396e-06
marker O 0 8.870752594702935e-07
closely O 0 3.191684427861219e-08
linked O 0 2.356914819756639e-06
to O 0 7.833937729628815e-07
CT B-Disease 1 1.0
. O 0 0.00010292804654454812

However O 0 6.89537228026893e-06
, O 0 3.0930712568988383e-07
BAC O 0 0.0003899544826708734
clones O 0 1.0091960575664416e-05
containing O 0 2.5076565179915633e-07
ATP7B O 0 0.0014297671150416136
and O 0 1.1059137250413187e-07
C04107 O 0 9.712779274195782e-07
mapped O 0 1.5869335356910597e-07
to O 0 2.38589716872184e-08
the O 0 2.1574574304850103e-07
canine O 0 6.71830866849632e-06
chromosome O 0 1.5804300801391946e-07
regions O 0 4.4316294633972575e-08
CFA22q11 O 0 2.954570845759008e-05
and O 0 1.4709497975218255e-07
CFA10q26 O 0 8.841742237564176e-05
, O 0 5.650596435202715e-09
respectively O 0 6.452224088349112e-09
, O 0 6.893131065943692e-10
demonstrating O 0 9.132268274925082e-09
that O 0 1.4212936383373176e-09
WD B-Disease 0 1.4702005501021631e-05
cannot O 0 2.3131613957616537e-08
be O 0 3.3559872658628365e-09
homologous O 0 1.3002366294756484e-08
to O 0 1.0489626944831798e-08
CT B-Disease 0 0.000260049564531073
. O 0 1.4532126897393027e-06

The O 0 1.736430021992419e-05
copper O 0 4.926312976749614e-05
transport O 0 2.4473838493577205e-06
genes O 0 2.48243225087208e-07
CTR1 O 0 0.0028661745600402355
and O 0 4.7020122906360484e-07
CTR2 O 1 0.981410801410675
were O 0 9.416049806532101e-07
also O 0 1.5488652138628822e-08
excluded O 0 1.4505934231578976e-08
as O 0 2.8260946915992236e-09
candidate O 0 1.893821321985456e-09
genes O 0 3.062416153998271e-10
for O 0 3.9801958950924643e-10
CT B-Disease 0 2.1063531676190905e-05
since O 0 3.675085125109945e-08
they O 0 1.6305066186106387e-09
both O 0 1.2106454727600635e-09
mapped O 0 5.7065523861865586e-08
to O 0 1.829522844332132e-08
canine O 0 1.6856205320436857e-06
chromosome O 0 3.6067194741917774e-07
region O 0 1.2485716638366284e-07
CFA11q22 O 0 0.00015039491700008512
. O 0 1.1760938605220872e-06

2 O 0 7.510469004046172e-05
- O 0 1.582032382430043e-05
22 O 0 2.3904603949631564e-06
. O 0 6.530008249683306e-07

5 O 0 4.630858529708348e-05
. O 0 3.719002506841207e-06

A O 0 1.3625132851302624e-05
transcribed O 0 3.2171811881198664e-07
sequence O 0 1.0780902393037195e-08
identified O 0 9.139777823463646e-09
from O 0 5.504036337811158e-09
the O 0 7.015471226168302e-08
C04107 O 0 1.0861676855711266e-06
- O 0 1.9124844641282834e-07
containing O 0 1.8195871476223147e-08
BAC O 0 0.00010723128798417747
was O 0 1.9460283340322349e-07
found O 0 1.136402860701935e-09
to O 0 2.5566856964864826e-10
be O 0 1.9909134063578193e-10
homologous O 0 8.040708099343874e-10
to O 0 1.5378198714444125e-09
a O 0 1.0121656401906876e-08
gene O 0 9.012181223511107e-09
expressed O 0 1.0753957724318752e-08
from O 0 2.1363071311952808e-08
human O 0 3.3550929146031194e-08
chromosome O 0 6.951986364356344e-08
2p13 O 0 2.791643396449217e-07
- O 0 8.258979278252809e-08
p16 O 0 1.0774674485958258e-08
, O 0 1.688519324360982e-10
a O 0 1.0857580390322141e-09
region O 0 4.092624905638331e-09
devoid O 0 9.616062612849419e-08
of O 0 3.1371343300889976e-09
any O 0 2.444517255284495e-09
positional O 0 1.4083448149904143e-06
candidate O 0 3.4668883586164156e-07
genes O 0 8.49085779464076e-08
. O 0 1.8148996616673685e-07

Molecular O 0 4.3712825004149636e-07
analysis O 0 4.219883820155701e-08
of O 0 1.600771781795629e-07
the O 0 8.439304366447686e-08
APC B-Disease 0 1.289791384806449e-07
gene O 0 5.001150604755367e-09
in O 0 2.0592478833236783e-09
205 O 0 4.113606344446907e-09
families O 0 2.055276837609199e-09
: O 0 3.3458616433001964e-10
extended O 0 1.109719178771229e-07
genotype O 0 6.937428679520963e-06
- O 0 1.189936824630422e-06
phenotype O 0 1.734148185050799e-07
correlations O 0 2.3575250196472552e-08
in O 0 5.459013796560441e-10
FAP B-Disease 0 5.4202473620534874e-08
and O 0 2.142973298813189e-10
evidence O 0 9.904285169781701e-10
for O 0 6.48261236357861e-11
the O 0 4.013479548703458e-10
role O 0 9.654759214328124e-10
of O 0 2.782518881971896e-09
APC B-Disease 0 6.590346934842728e-09
amino O 0 2.720925040833322e-09
acid O 0 8.085511815636437e-09
changes O 0 2.4922282904071835e-08
in O 0 0.009926019236445427
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9999990463256836
. O 0 1.054214226314798e-05

BACKGROUND O 0 8.221263851737604e-05
/ O 0 5.764169600297464e-06
AIMS O 0 6.786567041672242e-08
The O 0 6.741448732583422e-09
development O 0 4.5464503273251466e-08
of O 0 3.07679692923557e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.4359842204214601e-08
a O 0 6.706407651435597e-10
variable O 0 3.123639125135469e-10
range O 0 2.8880302593847773e-09
of O 0 2.894826067745271e-08
extracolonic O 0 3.1996444249671185e-06
manifestations O 0 2.7463653168524615e-05
in O 0 7.975942025950644e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 2.3891334421932697e-07
FAP B-Disease 0 7.535213057963119e-07
) O 0 1.937145305275223e-10
is O 0 6.176273381619524e-11
the O 0 3.137342330372661e-10
result O 0 7.313471495073998e-10
of O 0 1.289613837940351e-08
the O 0 1.376407432474025e-08
dominant O 0 2.2061486504298955e-07
inheritance O 0 5.34001173946308e-07
of O 0 4.654116310121026e-06
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 3.740478859981522e-08
APC B-Disease 0 2.3002533566796046e-07
) O 0 3.4784970459611486e-09
gene O 0 3.231044587437282e-08
mutations O 0 8.037235232905005e-08
. O 0 3.5642651141643e-07

In O 0 4.9514934374883524e-08
this O 0 1.1305397729088895e-09
study O 0 2.2812877975564305e-10
, O 0 7.2891631966443e-12
direct O 0 2.1509452205470403e-11
mutation O 0 1.5142019582636834e-11
analysis O 0 7.529879497703007e-11
of O 0 2.62806221229539e-09
the O 0 3.0050664179270825e-08
APC B-Disease 0 7.843688365483104e-08
gene O 0 1.238368074751861e-08
was O 0 1.0042165854429186e-07
performed O 0 3.1719471493829587e-09
to O 0 4.888148219528432e-10
determine O 0 9.944097101310945e-09
genotype O 0 5.464518721964851e-07
- O 0 1.1639932750995285e-07
phenotype O 0 2.7428109561355996e-08
correlations O 0 8.227656778103665e-09
for O 0 1.599631760385023e-09
nine O 0 2.4543854948433363e-08
extracolonic O 0 1.2792651205018046e-06
manifestations O 0 1.6027696574383299e-06
and O 0 1.2498436063879126e-08
to O 0 1.1458664017638398e-09
investigate O 0 3.4452183328426145e-09
the O 0 2.472124949193244e-09
incidence O 0 7.604074880873668e-08
of O 0 2.8832873866235786e-08
APC B-Disease 0 6.720486567246553e-08
mutations O 0 1.982706443470761e-09
in O 0 2.703177237606269e-09
non O 0 1.887014695967082e-05
- O 1 0.9999655485153198
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0003191570285707712

METHODS O 0 1.6566238628001884e-05
The O 0 3.0852074814902153e-06
APC B-Disease 0 9.04842920590454e-07
gene O 0 1.671059557395438e-08
was O 0 6.0041308813652e-08
analysed O 0 1.2459115517060582e-08
in O 0 1.2377157077025913e-09
190 O 0 2.7524105217224815e-09
unrelated O 0 1.3578184798745951e-08
FAP B-Disease 0 1.8122932488040533e-07
and O 0 5.35585042982234e-09
15 O 0 4.146385634840044e-08
non O 0 5.195335324970074e-05
- O 1 0.9999994039535522
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.00045538577251136303
using O 0 1.7554768305672042e-07
denaturing O 0 0.00011277511657681316
gradient O 0 1.717418172120233e-06
gel O 0 8.764749281908735e-08
electrophoresis O 0 4.1111533732873795e-08
, O 0 5.370526801051767e-10
the O 0 3.120627090069661e-09
protein O 0 2.1502706282205963e-09
truncation O 0 1.4215735255618256e-08
test O 0 1.9094577030642768e-09
, O 0 2.1417872683726635e-11
and O 0 2.5833309449940778e-11
direct O 0 1.1923150244896874e-09
sequencing O 0 8.433093512394407e-08
. O 0 5.136722336374078e-08

RESULTS O 0 7.120253485481953e-06
Chain O 0 2.6944362616632134e-06
terminating O 0 5.38076392331277e-07
signals O 0 2.860375616364763e-07
were O 0 3.0235371983877712e-09
only O 0 1.2436357499368e-10
identified O 0 9.209648599295406e-10
in O 0 2.089996231635638e-10
patients O 0 8.626782621590223e-10
belonging O 0 3.754672572853224e-09
to O 0 2.9088775832519786e-09
the O 0 1.8093609810421185e-07
FAP B-Disease 0 1.8279342839377932e-06
group O 0 1.7036665411751528e-09
( O 0 1.2027573381701018e-10
105 O 0 2.8375847449524372e-08
patients O 0 1.536354865550038e-08
) O 0 5.712342598940268e-09
. O 0 1.518708216963205e-07

Amino O 0 1.7699079535304918e-06
acid O 0 6.440865263357409e-08
changes O 0 7.790869060997352e-10
were O 0 1.4216975374736762e-09
identified O 0 1.7382760786333051e-09
in O 0 3.99883154367231e-10
four O 0 6.353666481828668e-10
patients O 0 5.538406400162899e-10
, O 0 9.4327747002243e-11
three O 0 3.041854546026457e-10
of O 0 3.505620682631161e-08
whom O 0 1.5123316643439466e-07
belonged O 0 3.8133002817630768e-06
to O 0 4.5211304922077034e-08
the O 0 5.402606575444224e-07
non O 0 5.056448344475939e-07
- O 0 1.4960302507915912e-07
FAP O 0 2.1166609087686084e-07
group O 0 3.608313425829124e-09
of O 0 0.015612911432981491
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9999821186065674
. O 0 6.267280696192756e-06

Genotype O 0 0.002111744834110141
- O 0 7.945843390189111e-05
phenotype O 0 2.005851001740666e-06
correlations O 0 2.52595327765448e-07
identified O 0 3.354235644792425e-08
significant O 0 1.7261974960547377e-08
differences O 0 1.3315491287357872e-06
in O 0 1.4342186993587802e-08
the O 0 4.195070246737487e-08
nature O 0 1.3563611567235512e-08
of O 0 9.965571479142454e-09
certain O 0 1.174898933697932e-08
extracolonic O 0 2.0210491129546426e-06
manifestations O 0 3.945887385725655e-07
in O 0 4.179988355446085e-09
FAP B-Disease 0 4.5043935870126006e-07
patients O 0 3.840443518754455e-09
belonging O 0 8.273764784405557e-09
to O 0 4.416464083334404e-09
three O 0 1.4506626122567923e-08
mutation O 0 4.421379884433918e-08
subgroups O 0 2.9528771960940503e-07
. O 0 1.9125866401736857e-07

CONCLUSIONS O 0 4.438469113665633e-05
Extended O 0 2.7534983018995263e-05
genotype O 0 4.036750760860741e-05
- O 0 3.422484951443039e-06
phenotype O 0 2.3483120514811162e-07
correlations O 0 8.576849097607919e-08
made O 0 8.186611388794063e-09
in O 0 7.869500606716429e-10
this O 0 1.3616216487655208e-10
study O 0 2.503670049058826e-10
may O 0 4.531071073898829e-10
have O 0 3.510233770320781e-10
the O 0 4.63496929725693e-09
potential O 0 5.29744204058602e-09
to O 0 6.983889577760749e-10
determine O 0 7.89549936541789e-09
the O 0 5.387272850043701e-09
most O 0 4.047473745050212e-10
appropriate O 0 2.4188040459449667e-09
surveillance O 0 5.402957725664237e-08
and O 0 6.168799915329259e-10
prophylactic O 0 1.8729269868345e-07
treatment O 0 3.8443303651547467e-07
regimens O 0 3.3715542713252944e-07
for O 0 3.1047500681502527e-10
those O 0 4.179699641948531e-10
patients O 0 5.11453435159126e-10
with O 0 3.6279777793080115e-11
mutations O 0 1.200756299946093e-10
associated O 0 1.0208783818299594e-09
with O 0 4.1963782448917186e-10
life O 0 6.202489544193668e-08
threatening O 0 5.292920377542032e-07
conditions O 0 8.731577690923586e-05
. O 0 2.795084810713888e-06

This O 0 6.626537185638881e-08
study O 0 9.433306580319822e-09
also O 0 5.588982054938185e-10
provided O 0 1.9003516815718768e-10
evidence O 0 5.332731589646755e-09
for O 0 1.0024933105867717e-09
the O 0 1.1021796808563522e-08
pathological O 0 1.000423367258918e-06
nature O 0 8.863478839771233e-09
of O 0 5.045186668439783e-08
amino O 0 1.3784987373810509e-08
acid O 0 2.9249410005149912e-08
changes O 0 4.727035207707786e-09
in O 0 5.912384359874068e-09
APC O 0 4.375315043603223e-08
associated O 0 8.162039932813059e-09
with O 0 1.1882801687068678e-10
both O 0 7.366137699804653e-10
FAP B-Disease 0 8.812725127427257e-08
and O 0 3.6254359514487078e-09
non O 0 9.398373549629468e-06
- O 1 0.9986914992332458
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 6.8440099312283564e-06
. O 0 8.919221805570032e-09
. O 0 4.559798227887768e-08

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 1 0.999985933303833
cancer B-Disease 1 1.0
risk O 0 1.3752124687016476e-05
of O 0 0.00514838146045804
the O 0 0.0412045493721962
APC O 0 0.0001916802575578913
I1307K O 0 8.738667020224966e-06
polymorphism O 0 3.550521796569228e-06
. O 0 3.4521735869930126e-07

Germ O 0 0.23261548578739166
- O 0 0.00013567996211349964
line O 0 3.3405135582142975e-06
and O 0 9.553026814046461e-09
somatic O 0 3.203605842827528e-07
truncating O 0 1.9011734764262656e-07
mutations O 0 1.9568506814948705e-09
of O 0 8.557138997389302e-09
the O 0 2.087703343534031e-08
APC B-Disease 0 1.0588081522655557e-08
gene O 0 1.7267029472911588e-10
are O 0 6.2380586807186944e-12
thought O 0 4.431836009288759e-10
to O 0 4.5041184670857604e-10
initiate O 0 1.5176281920048496e-07
colorectal B-Disease 1 1.0
tumor I-Disease 0 1.0065279639093205e-05
formation O 0 3.0777087545175164e-07
in O 0 1.5282364529412007e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 7.868496322771534e-05
sporadic O 1 0.9999707937240601
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 2.900398214933375e-07
respectively O 0 2.3485898736907984e-07
. O 0 1.0345235068598413e-06

Recently O 0 1.6902191418921575e-05
, O 0 4.8393022922255113e-08
an O 0 5.924711832250296e-09
isoleucine O 0 1.052100401466305e-06
- O 0 9.191000458486087e-07
- O 0 2.3443431018677074e-06
> O 0 2.010171328947763e-06
lysine O 0 6.162326826597564e-07
polymorphism O 0 3.628287714718681e-08
at O 0 4.967894096097325e-09
codon O 0 2.0209365292345183e-09
1307 O 0 5.11486689447338e-07
( O 0 8.452393229774202e-10
I1307K O 0 1.8285911451698666e-08
) O 0 1.81363257745204e-10
of O 0 9.491818886431247e-09
the O 0 3.4533844228690214e-08
APC B-Disease 0 6.309689126737794e-08
gene O 0 3.2996625431991333e-09
has O 0 5.235163413885857e-10
been O 0 2.0945856160636822e-10
identified O 0 7.581258953948122e-10
in O 0 1.0634423341926436e-09
6 O 0 9.63916058083214e-09
% O 0 1.1284821965773517e-09
- O 0 1.0668947503233994e-08
7 O 0 2.3107801894184377e-08
% O 0 4.509688456000305e-10
of O 0 4.428762689911991e-09
the O 0 2.4473736814911717e-08
Ashkenazi O 0 6.753297725481389e-07
Jewish O 0 3.004286597274586e-08
population O 0 1.7675425012519952e-10
. O 0 8.296346720726433e-09

To O 0 4.4895804762745684e-07
assess O 0 1.9881033495039446e-06
the O 0 1.1282896394959607e-07
risk O 0 3.305314422163974e-08
of O 0 3.814593085849083e-09
this O 0 1.8396791034991367e-10
common O 0 9.28409793488072e-09
APC B-Disease 0 4.412441256818056e-08
allelic O 0 1.2829117679302726e-07
variant O 0 1.0860177098948043e-05
in O 0 2.1296773411449976e-06
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 5.959565783086873e-07
we O 0 1.6206231023829787e-08
have O 0 2.0103294584572495e-09
analyzed O 0 4.575451573174405e-09
a O 0 7.533488832756063e-10
large O 0 1.8087349396012087e-09
cohort O 0 4.866607739018036e-08
of O 0 4.193094227389338e-08
unselected O 0 4.002870628028177e-05
Ashkenazi O 0 1.377940225211205e-05
Jewish O 0 3.1514338161287014e-07
subjects O 0 1.3381135488543805e-07
with O 0 2.4454964719922145e-09
adenomatous B-Disease 0 0.00026983857969753444
polyps I-Disease 0 0.0002572766097728163
and O 0 8.306214738240669e-08
. O 0 3.245900472848007e-07
or O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 2.9262189116252557e-08
for O 0 1.0775065284462926e-08
the O 0 3.01413001579931e-06
APC O 0 4.468685347092105e-06
I1307K O 0 2.164013494621031e-06
polymorphism O 0 1.3860834542356315e-06
. O 0 3.012084448528185e-07

The O 0 9.163387403532397e-06
APC O 0 2.6693305699154735e-06
I1307K O 0 1.463334342588496e-06
allele O 0 2.3326736098283618e-08
was O 0 3.110835322672756e-08
identified O 0 2.754742434163404e-09
in O 0 6.761534110388823e-10
48 O 0 4.144889320656375e-09
( O 0 1.4638526502075422e-10
10 O 0 4.412605281167714e-10
. O 0 7.712224608935614e-11
1 O 0 2.2079402750563304e-09
% O 0 5.275334682974808e-11
) O 0 1.3277420829460596e-11
of O 0 1.6563003191194525e-09
476 O 0 1.1059706395144531e-07
patients O 0 1.5804512543127203e-07
. O 0 2.890032817504107e-07

Compared O 0 6.823427725066722e-07
with O 0 4.9951442981921446e-09
the O 0 1.8250755573490096e-08
frequency O 0 1.72402270237626e-08
in O 0 4.43635267410869e-10
two O 0 9.613244228434681e-11
separate O 0 1.326856680083921e-10
population O 0 3.439540319227774e-12
control O 0 1.193509624464184e-09
groups O 0 2.91148355424653e-11
, O 0 2.429076106924555e-10
the O 0 1.3263874443225632e-08
APC O 0 2.0605166639597883e-07
I1307K O 0 4.068391490363865e-07
allele O 0 8.183239863512881e-09
is O 0 1.2025347384536644e-10
associated O 0 1.5325543611943715e-10
with O 0 8.68671020531897e-12
an O 0 8.363859951843189e-12
estimated O 0 9.518255975060619e-12
relative O 0 5.598053132160885e-09
risk O 0 1.1936786670219135e-08
of O 0 3.4054139064210176e-07
1 O 0 5.09061146658496e-06
. O 0 2.678081614249095e-07

5 O 0 1.4035464118933305e-05
- O 0 2.7032151592720766e-06
1 O 0 1.3388978459261125e-06
. O 0 1.7220745007762162e-07

7 O 0 4.766927668242715e-05
for O 0 2.2112806163931964e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999797344207764
( O 0 1.784005974059255e-07
both O 0 3.976709450626004e-08
P O 0 0.00010855477012228221
= O 0 7.626371001379084e-08
. O 0 1.9900638914549518e-09
01 O 0 2.7693367599113117e-08
) O 0 4.066742220754094e-10
. O 0 9.279690793562168e-09

Furthermore O 0 1.2346745279501192e-06
, O 0 9.903628139795728e-09
compared O 0 2.6486339788078794e-09
with O 0 7.954674141608109e-10
noncarriers O 0 8.472708032059018e-06
, O 0 1.0605079481251778e-08
APC O 0 1.7315106504156574e-07
I1307K O 0 1.70407759014779e-07
carriers O 0 4.030012323852361e-09
had O 0 1.8226219422601275e-09
increased O 0 1.7590873202522062e-10
numbers O 0 1.2994269549260196e-10
of O 0 1.9934764949880446e-08
adenomas B-Disease 1 0.9999712705612183
and O 0 0.16898471117019653
colorectal B-Disease 1 1.0
cancers I-Disease 1 1.0
per O 0 1.8104312005107204e-07
patient O 0 1.4404700777959079e-05
( O 0 9.657783905936412e-09
P O 0 2.75994852927397e-06
= O 0 8.171167742432317e-09
. O 0 1.9184444310926807e-10
03 O 0 3.0508566783993274e-09
) O 0 2.4197152961868973e-11
, O 0 1.0234859834645782e-11
as O 0 3.04334474288126e-11
well O 0 9.374286069618876e-11
as O 0 8.382182448141151e-11
a O 0 4.610226644885529e-10
younger O 0 4.842143574990132e-09
age O 0 1.874348010133531e-09
at O 0 3.769224043992381e-09
diagnosis O 0 1.9430964925959415e-07
. O 0 2.749201044593974e-08

We O 0 6.824546971984091e-07
conclude O 0 4.522178471688676e-07
that O 0 6.925712447980459e-09
the O 0 6.877746017153186e-08
APC O 0 2.948731889773626e-07
I1307K O 0 3.7138349284759897e-07
variant O 0 4.956490556651261e-06
leads O 0 1.9066588663463335e-07
to O 0 8.764778236525217e-09
increased O 0 2.546784401147306e-07
adenoma B-Disease 1 1.0
formation O 0 0.00044973217882215977
and O 0 2.42551408291547e-07
directly O 0 1.4009603255260572e-08
contributes O 0 3.0653263261015695e-10
to O 0 2.955980460406238e-10
3 O 0 2.8079714109452425e-09
% O 0 4.610769752111388e-11
- O 0 3.513006552324782e-10
4 O 0 6.75011713191509e-10
% O 0 1.7374553185067754e-11
of O 0 8.01632579761069e-11
all O 0 1.1705181268695242e-10
Ashkenazi O 0 1.7436084362998372e-06
Jewish O 0 0.00010451426351210102
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.9457497728581075e-06

The O 0 1.199999360324e-06
estimated O 0 1.2540175120534514e-08
relative O 0 2.563243981512642e-07
risk O 0 2.7088509213513134e-08
for O 0 5.758701848712633e-10
carriers O 0 1.0347203094340784e-09
may O 0 1.947096039955909e-09
justify O 0 1.65310414246278e-08
specific O 0 1.302010388393171e-09
clinical O 0 6.57840359963302e-09
screening O 0 5.0683994778921715e-09
for O 0 2.081093769534803e-10
the O 0 2.74418066048554e-09
360 O 0 1.2464178134052872e-08
, O 0 6.158334259209752e-11
000 O 0 3.360174638533664e-10
Americans O 0 5.915401501965789e-11
expected O 0 9.471216033674068e-10
to O 0 1.6557918369741742e-09
harbor O 0 2.536016609155922e-06
this O 0 2.410264487995306e-10
allele O 0 7.558561554432686e-10
, O 0 8.7720282426762e-11
and O 0 1.5832729571840787e-10
genetic O 0 2.2500155072435746e-09
testing O 0 1.7324042200783651e-09
in O 0 7.358049725070259e-10
the O 0 9.405153988950588e-09
setting O 0 9.373401610446308e-09
of O 0 2.190750691966059e-08
long O 0 1.8782889910085032e-08
- O 0 2.4427333045196065e-08
term O 0 1.960775080078747e-07
- O 0 7.843284777209192e-08
outcome O 0 8.009150676002719e-09
studies O 0 3.2997110599453094e-10
may O 0 1.179212699708998e-10
impact O 0 1.4758411159832008e-09
significantly O 0 1.437150558558642e-07
on O 1 0.9939042925834656
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.00010469221888342872
in O 0 1.9403255391292618e-10
this O 0 7.483903774474499e-11
population O 0 2.9152902314422136e-11
. O 0 3.830348482836143e-09

Localization O 0 0.0023503208067268133
of O 0 2.3484772100346163e-05
human O 0 1.9919200440199347e-06
BRCA1 O 0 6.127219194240752e-07
and O 0 1.142144423482705e-08
its O 0 4.6482844240358645e-09
loss O 0 3.617084018969763e-07
in O 0 1.9803790607397787e-08
high O 0 1.3799997759633698e-05
- O 0 2.2508413621835643e-07
grade O 0 1.0752676189440535e-06
, O 0 1.9430226316785593e-09
non B-Disease 0 1.0720882528403308e-06
- I-Disease 0 0.024666225537657738
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 6.456550636357861e-06

Although O 0 3.5883505233869073e-07
the O 0 8.68477201265705e-08
link O 0 6.206915514894717e-08
between O 0 2.1780556025419173e-08
the O 0 2.387796200764569e-07
BRCA1 O 0 5.884194251848385e-07
tumour B-Disease 1 1.0
- O 0 7.203897780527768e-07
suppressor O 0 6.341891776173725e-07
gene O 0 2.5447203455541967e-08
and O 0 1.969928575817903e-08
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 2.322409820010307e-08
established O 0 1.212235822833918e-08
, O 0 9.684281154775931e-11
the O 0 1.719289821622283e-09
role O 0 6.126275486906252e-09
, O 0 5.0647902538614176e-11
if O 0 2.4082782643097822e-11
any O 0 1.047602449233409e-09
, O 0 7.613162877895263e-11
of O 0 1.945277272596968e-09
BRCA1 O 0 2.9683611124653453e-09
in O 0 1.1528551446815527e-09
non B-Disease 0 1.8382485222900868e-06
- I-Disease 0 0.0004729768552351743
familial I-Disease 0 0.14444975554943085
cancers I-Disease 1 0.9999995231628418
is O 0 2.016021127815293e-08
unclear O 0 1.2420331358953263e-06
. O 0 5.696188054571394e-07

BRCA1 O 0 4.117637581657618e-05
mutations O 0 2.661780627022381e-07
are O 0 1.480572109358036e-09
rare O 0 8.398005491017102e-08
in O 0 1.12250431172356e-08
sporadic B-Disease 0 0.000856216240208596
cancers I-Disease 1 1.0
, O 0 3.781595037111174e-09
but O 0 3.003402859746984e-09
loss O 0 1.0207717195953592e-06
of O 0 7.618546806043014e-05
BRCA1 O 0 8.289912756254125e-08
resulting O 0 4.1983522436339626e-08
from O 0 8.569748466413785e-09
reduced O 0 6.878467218029982e-08
expression O 0 6.373575889284666e-09
or O 0 5.782456735659025e-09
incorrect O 0 1.2061240894922776e-08
subcellular O 0 3.660681215933437e-07
localization O 0 5.605588171420095e-07
is O 0 6.110680850213157e-10
postulated O 0 6.420306064569559e-09
to O 0 2.671657339803346e-10
be O 0 1.9366133696685495e-10
important O 0 1.7838615029575067e-09
in O 0 7.5076117544981e-10
non B-Disease 0 2.2624799100867676e-07
- I-Disease 0 6.728279004164506e-06
familial I-Disease 1 0.9998522996902466
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 0.00034797005355358124

Epigenetic O 1 0.5482011437416077
loss O 0 0.010072275064885616
, O 0 4.767366235114423e-08
however O 0 2.9452460026391236e-08
, O 0 5.70220537454702e-10
has O 0 4.602405262454923e-11
not O 0 7.727918131805733e-12
received O 0 8.655885730401991e-11
general O 0 1.229089052756649e-09
acceptance O 0 1.2765624113342255e-08
due O 0 1.0179297049717206e-07
to O 0 3.682106841651489e-09
controversy O 0 2.5807937120703173e-08
regarding O 0 8.899339931645045e-09
the O 0 9.885491536465452e-09
subcellular O 0 3.935485040074127e-07
localization O 0 4.7674166125943884e-06
of O 0 1.400334355139421e-07
BRCA1 O 0 1.0925766957825545e-08
proteins O 0 4.012201126890602e-10
, O 0 5.359963167750337e-11
reports O 0 2.2009595534999704e-10
of O 0 6.077000236359709e-09
which O 0 1.0160394747771306e-09
have O 0 1.2017031814082202e-09
ranged O 0 6.162008503451943e-08
from O 0 4.2212744411074254e-09
exclusively O 0 3.471577247893265e-09
nuclear O 0 1.9612576807048754e-07
, O 0 4.467839709310084e-10
to O 0 1.1272023314745638e-09
conditionally O 0 4.800772899216099e-07
nuclear O 0 5.7751026361074764e-06
, O 0 2.6068842640114553e-09
to O 0 2.8647082483956865e-09
the O 0 1.9989332145087246e-07
ER O 0 0.00019185176643077284
/ O 0 5.990112867948483e-07
golgi O 0 9.51312995312037e-06
, O 0 1.5887734461372816e-09
to O 0 1.4470141751488086e-09
cytoplasmic O 0 8.438370713292898e-08
invaginations O 0 6.872905942145735e-07
into O 0 5.964670890534762e-08
the O 0 3.8633309884517075e-08
nucleus O 0 3.216763957425428e-07
. O 0 1.3650534924636304e-07

In O 0 1.2758902130372007e-06
an O 0 1.2676166782910059e-08
attempt O 0 4.3943757077613554e-07
to O 0 3.228248246500698e-08
resolve O 0 4.2248251475029974e-07
this O 0 1.2078599453957395e-08
issue O 0 4.488634530730451e-08
, O 0 8.874723733676149e-10
we O 0 4.4721451541995805e-10
have O 0 4.3759118550923404e-10
comprehensively O 0 2.7329518204055603e-08
characterized O 0 2.5113823909350685e-08
19 O 0 4.204955672548749e-08
anti O 0 6.814883022343565e-07
- O 0 2.0004390535177663e-06
BRCA1 O 0 3.752784394350783e-08
antibodies O 0 3.2872637945047245e-08
. O 0 1.206445432444525e-07

These O 0 5.751549565502501e-07
reagents O 0 8.188759238692e-06
detect O 0 6.6374236666888464e-06
a O 0 4.7198753350130573e-07
220 O 0 2.498878473033983e-07
- O 0 2.0693448732345132e-07
kD O 0 1.4613846133215702e-06
protein O 0 3.959574002010413e-08
localized O 0 8.842830823141412e-08
in O 0 2.7903048760435922e-09
discrete O 0 1.2811193528250442e-07
nuclear O 0 3.86138981411932e-06
foci O 0 5.760689987255319e-07
in O 0 8.701361298157906e-10
all O 0 2.098916734860623e-10
epithelial O 0 3.0336067879943585e-08
cell O 0 7.334054430430115e-08
lines O 0 3.774733303707478e-10
, O 0 4.607479762303024e-12
including O 0 2.972991427693805e-12
those O 0 6.526718054900016e-11
derived O 0 5.049827223047032e-08
from O 0 7.935660732982797e-07
breast B-Disease 0 0.330967515707016
malignancies I-Disease 0 8.487988816341385e-05
. O 0 7.184639230217726e-07

Immunohistochemical O 0 0.00033050417550839484
staining O 0 0.00011471942707430571
of O 0 1.5790901670698076e-05
human O 0 6.526951210616971e-07
breast O 0 2.7536307243281044e-06
specimens O 0 7.661273571102356e-08
also O 0 2.4562307743281053e-08
revealed O 0 6.315390237432439e-07
BRCA1 O 0 5.265175104796072e-07
nuclear O 0 0.003723611356690526
foci O 0 0.0006437997217290103
in O 0 8.333865366694226e-07
benign O 1 1.0
breast O 1 1.0
, O 0 1.0128773283213377e-05
invasive B-Disease 1 1.0
lobular I-Disease 1 1.0
cancers I-Disease 1 1.0
and O 0 0.026662398129701614
low B-Disease 1 1.0
- I-Disease 1 1.0
grade I-Disease 1 1.0
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 5.9720878198277205e-06

Conversely O 0 5.7664074120111763e-05
, O 0 2.5376348844474705e-07
BRCA1 O 0 1.3805752985263098e-07
expression O 0 5.2353286150719214e-08
was O 0 1.196081171883634e-07
reduced O 0 2.22461356003123e-08
or O 0 2.676402210965989e-09
undetectable O 0 5.237865252638585e-08
in O 0 4.1449901844181625e-10
the O 0 2.8589333123107963e-09
majority O 0 2.1014724682633101e-10
of O 0 2.741304783171472e-08
high O 0 1.1954752153542358e-05
- O 0 1.3539414567276253e-06
grade O 0 9.627965482650325e-06
, O 0 6.033346267031447e-08
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 1.0382293913480112e-09
suggesting O 0 2.139209254181651e-09
that O 0 2.7497748522620213e-10
absence O 0 1.3346269724934245e-06
of O 0 0.00019524511299096048
BRCA1 O 0 1.541874468102833e-07
may O 0 1.3544887433880604e-09
contribute O 0 1.1223105084168239e-10
to O 0 4.2463624283506363e-10
the O 0 7.855677885970636e-09
pathogenesis O 0 0.00013843942724633962
of O 0 4.3230134139093934e-08
a O 0 2.9054452177490475e-09
significant O 0 4.3866776877621305e-09
percentage O 0 3.589019303973373e-09
of O 0 3.794689718006339e-08
sporadic B-Disease 0 0.0007661997224204242
breast I-Disease 1 1.0
cancers I-Disease 0 0.4948536157608032
. O 0 2.7848777506278566e-08
. O 0 1.8087432351876487e-07

